Cosmetic Dermatology: Products and Procedures - PDF Free Download (2024)

Cosmetic Dermatology Products and Procedures

Cosmetic Dermatology Products and Procedures E D I T E D BY

Zoe Diana Draelos MD Consulting Professor Department of Dermatology Duke University School of Medicine Durham, North Carolina USA

A John Wiley & Sons, Ltd., Publication

This edition first published 2010 © by Blackwell Publishing Ltd Blackwell Publishing was acquired by John Wiley & Sons in February 2007. Blackwell’s publishing program has been merged with Wiley’s global Scientific, Technical and Medical business to form Wiley-Blackwell. Registered office: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher. Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books. Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought. The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom. Library of Congress Cataloging-in-Publication Data Cosmetic dermatology : products and procedures / edited by Zoe Diana Draelos. p. ; cm. Includes bibliographical references and index. ISBN 978-1-4051-8635-3 (hardcover : alk. paper) 1. Skin–Care and hygiene. 2. Cosmetics. 3. Dermatology. I. Draelos, Zoe Kececioglu. [DNLM: 1. Cosmetics. 2. Dermatologic Agents. 3. Cosmetic Techniques. 4. Skin Care– methods. QV 60 C8346 2009] RL87.C68 2009 646.7′2–dc22 2009031482 ISBN: 9781405186353 A catalogue record for this book is available from the British Library. Set in 9 on 12 pt Meridien by Toppan Best-set Premedia Limited Printed and bound in Singapore 1



Contributors, viii

Section II Hygiene Products, 75

Foreword, xiv Jeffrey S. Dover

Part One Cleansers, 77

Introduction: Definition of Cosmetic Dermatology, xv Zoe D. Draelos

10 Bar cleansers, 77 Anthony W. Johnson and K.P. Ananthapadmanabhan

Section I Basic Concepts, 1 Part One Skin Physiology Pertinent to Cosmetic Dermatology, 3 1 Epidermal barrier, 3 Sreekumar Pillai, Marc Cornell, and Christian Oresajo 2 Photoaging, 13 Murad Alam and Jillian Havey 3 Self-perceived sensitive skin, 22 Olivier de Lacharrière 4 Pigmentation and skin of color, 27 Chesahna Kindred and Rebat M. Halder 5 Sensitive skin and the somatosensory system, 38 Francis McGlone and David Reilly 6 Novel, compelling non-invasive techniques for evaluating cosmetic products, 47 Thomas J. Stephens, Christian Oresajo, Robert Goodman, Margarita Yatskayer, and Paul Kavanaugh 7 Contact dermatitis and topical agents, 55 David E. Cohen and Aieska de Souza Part Two Delivery of Cosmetic Skin Actives, 62

11 Personal cleansers: body washes, 88 Keith Ertel and Heather Focht 12 Facial cleansers and cleansing cloths, 95 Erik Hasenoehrl 13 Non-foaming and low-foaming cleansers, 102 Duncan Aust 14 Liquid hand cleansers and sanitizers, 106 Duane Charbonneau 15 Shampoos for normal scalp hygiene and dandruff, 115 James R. Schwartz, Marcela Valenzuela, and Sanjeev Midha Part Two Moisturizers, 123 16 Facial moisturizers, 123 Yohini Appa 17 Hand and foot moisturizers, 130 Teresa M. Weber, Andrea M. Schoelermann, Ute Breitenbach, Ulrich Scherdin, and Alexandra Kowcz 18 Sunless tanning products, 139 Angelike Galdi, Peter Foltis, and Christian Oresajo 19 Sunscreens, 144 Dominique Moyal, Angelike Galdi, and Christian Oresajo Part Three Personal Care Products, 150

8 Percutaneous delivery of cosmetic actives to the skin, 62 Marc Cornell, Sreekumar Pillai, and Christian Oresajo

20 Antiperspirants and deodorants, 150 Eric S. Abrutyn

9 Creams, lotions, and ointments, 71 Irwin Palefsky

21 Blade shaving, 156 Keith Ertel and Gillian McFeat



Section III Adornment, 165 Part One Colored Facial Cosmetics, 167

38 Retinoids, 309 Olivier Sorg, Gürkan Kaya, Behrooz Kasraee, and Jean H. Saurat

22 Facial foundation, 167 Sylvie Guichard and Véronique Roulier

39 Topical vitamins, 319 Donald L. Bissett

23 Camouflage techniques, 176 Anne Bouloc

40 Clinical uses of hydroxyacids, 327 Barbara Green, Eugene J. Van Scott, and Ruey Yu

24 Lips and lipsticks, 184 Catherine Heusèle, Hervé Cantin, and Frédéric Bonté

41 The contribution of dietary nutrients and supplements to skin health, 335 Helen Knaggs, Steve Wood, Doug Burke, and Jan Lephart

25 Eye cosmetics, 190 Sarah A. Vickery, Peter Wyatt, and John Gilley Part Two Nail Cosmetics, 197 26 Nail physiology and grooming, 197 Phoebe Rich and Heh Shin R. Kwak 27 Colored nail cosmetics and hardeners, 206 Paul H. Bryson and Sunil J. Sirdesai 28 Cosmetic prostheses as artificial nail enhancements, 215 Douglas Schoon Part Three Hair Cosmetics, 222 29 Hair physiology and grooming, 222 Maria Hordinsky, Ana Paula Avancini Caramori, and Jeff D. Donovan

Part Two Injectable Antiaging Techniques, 342 42 Botulinum toxins, 342 Joel L. Cohen and Scott R. Freeman 43 Hyaluronic acid fillers, 352 Mark S. Nestor 44 Calcium hydroxylapatite for soft tissue augmentation, 356 Stephen Mandy 45 Skin fillers, 361 Neil Sadick, Misbah H. Khan, and Babar K. Rao 46 Polylactic acid fillers, 373 Kenneth R. Beer Part Three Resurfacing Techniques, 377

30 Hair dyes, 227 Frauke Neuser and Harald Schlatter

47 Superficial chemical peels, 377 M. Amanda Jacobs and Randall Roenigk

31 Permanent hair waving, 236 Annette Schwan-Jonczyk and Gerhard Sendelbach

48 Medium depth chemical peels, 384 Gary D. Monheit and Jens J. Thiele

32 Hair straightening, 248 Harold Bryant, Felicia Dixon, Angela Ellington, and Crystal Porter

49 CO2 laser resurfacing: confluent and fractionated, 393 Mitchel P. Goldman

33 Hair styling – technology and formulations, 256 Thomas Krause, Rene Rust, and Dianna C. Kenneally

Section IV Antiaging, 267

50 Non-ablative resurfacing, 409 David J. Goldberg and Katie Rossy 51 Microdermabrasion, 418 Pearl Grimes 52 Dermabrasion, 426 Christopher Harmon and Chad Prather

Part One Cosmeceuticals, 269 34 Botanicals, 269 Carl Thornfeldt 35 Antioxidants and anti-inflammatories, 281 Bryan B. Fuller 36 Peptides and proteins, 292 Karl Lintner 37 Cellular growth factors, 302 Richard E. Fitzpatrick and Rahul C. Mehta


Part Four Skin Modulation Techniques, 432 53 Laser-assisted hair removal, 432 Keyvan Nouri, Voraphol Vejjabhinanta, Nidhi Avashia, and Rawat Charoensawad 54 Radiofrequency devices, 439 Vic Narurkar 55 LED photomodulation for reversal of photoaging and reduction of inflammation, 444 Robert Weiss, Roy Geronemus, David McDaniel, and Corinne Granger

Contents Part Five Skin Contouring Techniques, 450 56 Liposuction: manual, mechanical, and laser assisted, 450 Emily Tierney and C. William Hanke 57 Liposuction of the neck, 463 Kimberly J. Butterwick 58 Hand recontouring with calcium hydroxylapatite, 473 Kenneth L. Edelson Part Six Implementation of Cosmetic Dermatology into Therapeutics, 480

60 Over-the-counter acne treatments, 488 Emmy M. Graber and Diane Thiboutot 61 Rosacea regimens, 495 Joseph Bikowski 62 Eczema regimens, 502 Zoe D. Draelos 63 Psoriasis regimens, 507 Steven R. Feldman and Lindsay C. Strowd Index, 514

59 Antiaging regimens, 480 Karen E. Burke



Eric S. Abrutyn

Donald L. Bissett

MS Founder TPC2 Advisors Ltd. Inc. Chiriqui, Republic of Panama

PhD Beth Jewell-Motz Procter & Gamble Co. Sharon Woods Technical Center Cincinnati, OH, USA

Murad Alam

MD, MSCI Associate Professor of Dermatology and Otolaryngology Chief of Cutaneous and Aesthetic Surgery Department of Dermatology Feinberg School of Medicine Northwestern University Chicago, IL, USA

K.P. Ananthapadmanabhan


Senior Principal Scientist Unilever HPC R&D Trumbull, CT, USA

Yohini Appa

PhD Senior Director of Scientific Affairs, Johnson & Johnson New Brunswick, NJ, USA

Duncan Aust

PhD Senior Vice President of Research and Development DFB Branded Pharmaceuticals Fort Worth, TX, USA

Nidhi Avashia

MD Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami, FL, USA

Kenneth R. Beer

MD, PA Palm Beach Esthetic, Dermatology & Laser Center West Palm Beach, FL, USA and Clinical Voluntary Assistant Professor of Dermatology University of Miami Miami, FL, USA

Frédéric Bonté

PhD Director of Scientific Communication LVMH Recherche Saint Jean de Braye, France

Anne Bouloc

MD, PhD Vichy International Medical Director Cosmetique Active International Asnières, France

Ute Breitenbach


Beiersdorf AG Hamburg, Germany

Harold Bryant

PhD Assistant Vice President L’Oréal Institute for Ethnic Hair and Skin Research Chicago, IL, USA

Paul H. Bryson

PhD Director of Research and Development OPI Products Inc. North Hollywood Los Angeles, CA, USA

Doug Burke

PhD Senior Scientist Phamanex Global Research and Development Provo, UT, USA

Karen E. Burke

MD, PhD Assistant Clinical Professor, Dermatology The Mount Sinai Medical Center Rivercourt New York, NY, USA

Joseph Bikowski

MD, FAAD Clinical Assistant Professor, Dermatology Ohio State University Columbus, OH, USA and Bikowski Skin Care Center Sewickley, PA, USA


Kimberly J. Butterwick

MD Dermatology/Cosmetic Laser Associates of La Jolla, Inc. San Diego, CA, USA


Hervé Cantin

Zoe D. Draelos

LVMH Recherche Saint Jean de Braye, France

Ana Paula Avancini Caramori

MD Department of Dermatology Complexo Hospitalar Santa Casa de Porto Alegre Porto Alegre, Brazil

Duane Charbonneau


Global Microbiology Procter & Gamble Co. Health Sciences Institute Mason, OH, USA

Rawat Charoensawad


Director, Rawat Clinic and Clinical Consultant, Biophile Training Center Bangkok, Thailand

David E. Cohen,

MD, MPH Vice Chairman for Clinical Affairs Director of Allergic, Occupational, and Environmental Dermatology New York University School of Medicine Department of Dermatology New York, NY, USA

Joel L. Cohen

MD About Skin Dermatology Englewood, CO, USA and Department of Dermatology University of Colorado Englewood, CO, USA

Marc Cornell Director L’Oréal Research Clark, NJ, USA

Felicia Dixon

PhD Manager L’Oréal Institute for Ethnic Hair and Skin Research Chicago, IL, USA

Jeff C. Donovan


Division of Dermatology University of Toronto Toronto, Canada

Jeffrey S. Dover

MD, FRCPC, FRCP (Glasgow) Associate Clinical Professor of Dermatology Yale University School of Medicine, Adjunct Professor of Dermatology Dartmouth Medical School, SkinCare Physicians Chestnut Hill, MA, USA

MD Consulting Professor Department of Dermatology Duke University School of Medicine Durham, NC, USA

Kenneth L. Edelson

MD, FAACS Clinical Instructor, Department of Dermatology Mount Sinai School of Medicine Attending Physician, Dermatology, The Mount Sinai Hospital New York, NY, USA and Private Practice Cosmetic, Dermatologic and Laser Surgery New York, NY, USA

Angela Ellington Assistant Vice President L’Oréal Institute for Ethnic Hair and Skin Research Chicago, IL, USA

Keith Ertel

MS, PhD Principal Scientist Procter & Gamble Co. Cincinnati, OH, USA

Steven R. Feldman

MD, PhD Center for Dermatology Research Departments of Dermatology, Pathology, and Public Health Sciences Wake Forest University School of Medicine Winston-Salem, NC, USA

Richard E. Fitzpatrick

MD Founder, Chair, Scientific Advisory Board SkinMedica, Inc. Carlsbad, CA, USA and Associate Clinical Professor Division of Dermatology UCSD School of Medicine San Diego, CA, USA

Heather Focht


Section Head Procter & Gamble Co. Cincinnati, OH, USA

Peter Foltis

MS Director of Scientific Affairs and Skin Care L’Oréal USA Clark, NJ, USA

Scott R. Freeman

MD Dermatology Resident University of Colorado at Denver and Health Sciences Center Denver, CO, USA



Bryan B. Fuller

PhD Founder, CEO Therametics and Adjunct Professor of Biochemistry and Molecular Biology University of Oklahoma Health Sciences Center Oklahoma City, OK, USA

Angelike Galdi


L’Oréal USA Clark, NJ, USA

Pearl Grimes

MD Director Vitiligo and Pigmentation Institute of Southern California Los Angeles, CA, USA and Clinical Professor Division of Dermatology David Geffen School of Medicine University of California–Los Angeles Los Angeles, CA, USA

Sylvie Guichard Roy Geronemus

MD Laser & Skin Surgery Center of New York New York, NY, USA and New York University Medical Center New York, NY, USA

John Gilley Principal Researcher Procter & Gamble Cosmetics Hunt Valley, MD, USA

David J. Goldberg

MD Clinical Professor and Director of Laser Research Department of Dermatology at the Mount Sinai School of Medicine New York, NY, USA and Director, Skin Laser & Surgery Specialists of New York and New Jersey New York, NY, USA

Mitchel P. Goldman

MD Volunteer Clinical Professor of Dermatology/Medicine University of California, San Diego and Dermatology/Cosmetic Dermatology Associates of La Jolla, Inc. San Diego, CA, USA

Robert Goodman Thomas J. Stephens & Associates Inc. Dallas Research Center Carrollton, TX, USA

Emmy M. Graber


SkinCare Physicians Chestnut Hill, MA, USA

Corinne Granger MD Director of Instrumental Cosmetics L’Oréal Research Asnières, France

Make Up Scientific Communication Director L’Oréal Recherche Chevilly-Larue, France

Rebat M. Halder

MD Professor and Chair Department of Dermatology Howard University College of Medicine Washington, DC, USA

C. William Hanke

MD, MPH, FACP Professor of Dermatology University of Iowa Carver College of Medicine Iowa City, IA, USA and Clinical Professor of Otolaryngology-Head and Neck Surgery Indiana University School of Medicine Indianapolis, IN, USA

Christopher Harmon

MD Total Skin and Beauty Dermatology Center Birmingham, AL, USA

Erik Hasenoehrl

PhD Procter & Gamble Co. Ivorydale Technical Center Cincinnati, OH, USA

Jillian Havey Department of Dermatology Feinberg School of Medicine Northwestern University Chicago, IL, USA

Catherine Heusèle LVMH Recherche Saint Jean de Braye, France

Maria Hordinsky Barbara A. Green

RPh, MS VP Clinical Affairs, NeoStrata Company, Inc. Princeton, NJ, USA

MD Professor and Chair Department of Dermatology University of Minnesota Minneapolis, MN, USA

M. Amanda Jacobs Senior Associate Consultant Department of Dermatology Mayo Clinic Rochester, MN, USA




Anthony W. Johnson


Jan Lephart

Director, Skin Clinical Science Unilever HPC R&D Trumbull, CT, USA

Senior Director Nu Skin Global Research & Development Provo, UT, USA

Behrooz Kasraee

Karl Lintner

MD Department of Dermatology Geneva University Hospital Geneva, Switzerland

MSc, PhD Technical Advisor Enterprise Technology/Sederma SAS Le Perray en Yvelines Cedex, France

Paul Kavanaugh

MS Thomas J. Stephens & Associates Inc. Dallas Research Center Carrollton, TX, USA

Gürkan Kaya

MD, PhD Department of Dermatology Geneva University Hospital Geneva, Switzerland

Stephen Mandy

MD Volunteer Professor of Dermatology University of Miami Miami, FL, USA and Private Practice Miami Beach, FL, USA

David McDaniel Dianna C. Kenneally


Principal Scientist Procter & Gamble Co. Mason, OH, USA

Misbah H. Khan

MD Fellow, Procedural Dermatology Northwestern University and Northwestern Memorial Hospital Chicago, IL, USA

Chesahna Kindred

MD Laser Skin & Vein Center of Virginia Virginia Beach, VA, USA and Eastern Virginia Medical School Virginia Beach, VA, USA

Gillian McFeat

PhD Gillette Reading Innovation Centre Procter & Gamble Co. Reading, UK


Clinical Research Fellow Department of Dermatology Howard University College of Medicine Washington, DC, USA

Francis McGlone

PhD Perception and Behaviour Group Unilever Research & Development Wirral, UK

Rahul C. Mehta Helen Knaggs


Vice President Nu Skin Global Research and Development Provo, UT, USA


Senior Scientific Director SkinMedica, Inc. Carlsbad, CA, USA

Sanjeev Midha Alexandra Kowcz


VP, US R&D Beiersdorf Inc. Wilton, CT, USA

PhD Principal Scientist Procter & Gamble Beauty Science Cincinnati, OH, USA

Gary D. Monheit Thomas Krause


Polymer Chemist Wella/Procter & Gamble Service GmbH Upstream Design Styling Darmstadt, Germany

Heh Shin R. Kwak

Dominique Moyal



L’Oréal Recherche Asnières, France

Knott Street Dermatology 301 NW Knott Street Portland, OR, USA

Olivier de Lacharrière

MD Total Skin & Beauty Dermatology Center, PC, and Clinical Associate Professor Departments of Dermatology and Ophthamology University of Alabama at Birmingham Birmingham, AL, USA


L’Oréal Recherche Clichy, France



Vic Narurkar

MD, FAAD Director Bay Area Laser Institute San Francisco, CA, USA and University of California Davis Medical School Sacramento, CA, USA

Babar K. Rao

MD Chair Department of Dermatology University of Medicine and Dentistry New Jersey Robert-Wood Johnson Medical School Somerset, NJ, USA

David Reilly Mark S. Nestor


Director Center for Cosmetic Enhancement Aventura, FL, USA and Voluntary Associate Professor of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami, FL, USA

Frauke Neuser


Principal Scientist Procter & Gamble Technical Centres Ltd Rusham Park, Whitehall Lane Egham Surrey, UK

Keyvan Nouri

MD Professor of Dermatology and Otolaryngology Director of Mohs, Dermatologic and Laser Surgery Director of Surgical Training Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami, FL, USA


One Discover Colworth Park Sharnbrook Bedford, UK

Phoebe Rich

MD Oregon Dermatology and Research Center Portland, OR, USA

Randall Roenigk

MD Robert H. Kieckhefer Professor, Chair Department of Dermatology Mayo Clinic Rochester, MN, USA

Katie Rossy

MD New York Medical College New York, NY, USA

Véronique Roulier Make Up Development Director L’Oréal Recherche Chevilly-Larue, France

Rene Rust

Assistant Vice President L’Oréal USA Clark, NJ, USA

PhD Senior Scientist, Hair and Scalp Care Wella/Procter & Gamble Service GmbH Darmstadt, Germany

Irwin Palefsky

Neil Sadick

Christian Oresajo


CEO Cosmetech Laboratories Inc. Fairfield, NJ, USA

Sreekumar Pillai

PhD Associate Principal Scientist L’Oréal Research Clark, NJ, USA

Crystal Porter

PhD Manager L’Oréal Institute for Ethnic Hair and Skin Research Chicago, IL, USA

Chad Prather

MD Total Skin and Beauty Dermatology Center Birmingham, AL, USA

MD, FAAD, FAACS, FACPh Clinical Professor Weill Cornell Medical College New York, NY, USA and Sadick Dermatology New York, NY, USA

Jean H. Saurat

MD Department of Dermatology Geneva University Hospital Geneva, Switzerland

Ulrich Scherdin


Beiersdorf AG Hamburg, Germany

Andrea M. Schoelermann


Beiersdorf AG Hamburg, Germany

Harald Schlatter

PhD Principal Toxicologist Procter & Gamble German Innovation Centre Darmstadt, Germany



Douglas Schoon

Emily Tierney

Schoon Scientific and Regulatory Consulting, LLC Dana Point, CA, USA

Annette Schwan-Jonczyk


Wella/Procter & Gamble Service GmbH Global Hair Methods Darmstadt, Germany

James R. Schwartz


Research Fellow Procter & Gamble Beauty Science Cincinnati, OH, USA

Gerhard Sendelbach

PhD Wella/Procter & Gamble Service GmbH Global Hair Methods Darmstadt, Germany

PhD Mohr Surgery and Procedural Dermatology Fellow Laser and Skin Surgery Center of Indiana Carmel, IN, USA and Department of Dermatology Boston University School of Medicine Boston, MA, USA

Marcela Valenzuela

PhD Senior Scientist Procter & Gamble Beauty Science Cincinnati, OH, USA

Eugene J. Van Scott


Private Practice Abington, PA, USA

Voraphol Vejjabhinanta Sunil J. Sirdesai

PhD Co-Director of Research and Development OPI Products Inc. North Hollywood Los Angeles, CA, USA

Olivier Sorg

PhD Department of Dermatology Geneva University Hospital Geneva, Switzerland

Aieska de Souza

MD, MSc New York University School of Medicine Department of Dermatology New York, NY, USA

Thomas J. Stephens

PhD Thomas J. Stephens & Associates Inc. Dallas Research Center Carrollton, TX, USA

Lindsay C. Strowd

MD Center for Dermatology Research Department of Dermatology Wake Forest University School of Medicine Medical Center Boulevard Winston-Salem, NC, USA

Diane Thiboutot

MD Pennsylvania State University College of Medicine Milton S. Hershey Medical Center Hershey, PA, USA

Jens J. Thiele

MD, PhD Dermatology Specialist, Inc. Oceanside, CA, USA

Carl Thornfeldt CTDerm, PC Fruitland, ID, USA and Episciences, Inc. Boise, ID, USA

MD Clinical instructor Suphannahong Dermatology Institute Bangkok, Thailand and Mohs, Dermatologic and Laser Surgery Fellow Department of Dermatology and Cutaneous Surgery University of Miami Miller School of Medicine Miami, FL, USA

Sarah A. Vickery

PhD Principal Scientist Procter & Gamble Cosmetics Hunt Valley, MD, USA

Teresa M. Weber

PhD Director, Clinical and Scientific Affairs Beiersdorf Inc. Wilton, CT, USA

Robert Weiss

MD Maryland Laser Skin & Vein Institute Hunt Valley, MD, USA and Johns Hopkins University School of Medicine Baltimore, MD, USA

Steve Wood

PhD Director Phamanex Global Research and Development Provo, UT, USA

Peter Wyatt Senior Engineer Procter & Gamble Cosmetics Hunt Valley, MD, USA

Margarita Yatskayer


L’Oréal Research USA Clark, NJ, USA


Ruey J. Yu

PhD, OMD Private Practice Chalfont, PA, USA



Dermatology began as a medical specialty but over the last half century it has evolved to combine medical and surgical aspects of skin care. Mohs skin cancer surgery was the catalyst that propelled dermatology to become a more procedurally based specialty. The combination of an aging population, economic prosperity, and technological breakthroughs have revolutionized cosmetic aspects of dermatology in the past few years. Recent minimally invasive approaches have enhanced our ability to prevent and reverse the signs of photoaging in our patients. Dermatologists have pioneered medications, technologies, and devices in the burgeoning field of cosmetic surgery. Cutaneous lasers, light, and energy sources, the use of botulinum exotoxin, soft tissue augmentation, minimally invasive leg vein treatments, chemical peels, hair transplants, and dilute anesthesia liposuction have all been either developed or improved by dermatologists. Many scientific papers, reviews and textbooks have been published to help disseminate this new knowledge. Recently it has become abundantly clear that unless photoaging is treated with effective skin care and photoprotection, cosmetic surgical procedures will not have their optimal outcome. Cosmeceuticals are integral to this process but, while some rigorous studies exist, much of the knowledge surrounding cosmeceuticals is hearsay and non-data based marketing information. Given increasing requests by our patients for guidance on the use of cosmeceuticals, understanding this body of information is essential to the practicing dermatologist. In Cosmetic Dermatology: Products and Procedures, Zoe Draelos has compiled a truly comprehensive book that addresses the broad nature of the subspecialty. Unlike prior texts on the


subject she has included all the essential topics of skin health. The concept is one that has been long awaited and will be embraced by our dermatologic colleagues and other health care professionals who participate in the diagnosis, and treatment of the skin. No one is better suited to edit a textbook of this scope than Dr. Zoe Draelos. She is an international authority on Cosmetic Dermatology and she has been instrumental in advancing the field of cosmeceuticals by her extensive research, writing, and teachings. This text brings together experts from industry, manufacturing, research, and dermatology and highlights the best from each of these fields. Doctor Draelos has divided the book into four different segments. The book opens with Basic Concepts, which includes physiology pertinent to cosmetic dermatology, and delivery of cosmetic skin actives. This section is followed by Hygiene Products, which include cleansers, moisturizers, and personal care products. The section on Adornment includes colored facial products, nail cosmetics, and hair cosmetics. The book concludes with a section on Antiaging, which includes cosmeceuticals, injectable antiaging techniques, resurfacing techniques, and skin modulation techniques. You will enjoy dipping into individual chapters or sections depending on your desires, but a full read of the book from start to finish will no doubt enhance your knowledge base and prepare you for the full spectrum of cosmetic dermatology patients. Enjoy. Jeffrey S. Dover August 2009

Introduction: Definition of Cosmetic Dermatology

This text is intended to function as a compendium on the field of cosmetic dermatology. Cosmetic dermatology knowledge draws on the insight of the bench researcher, the innovation of the manufacturer, the formulation expertise of the cosmetic chemist, the art of the dermatologic surgeon, and the experience of the clinical dermatologist. These knowledge bases heretofore have been presented in separate textbooks written for specific audiences. This approach to information archival does not provide for the synthesis of knowledge required to advance the science of cosmetic dermatology. The book begins with a discussion of basic concepts relating to skin physiology. The areas of skin physiology that are relevant to cosmetic dermatology include skin barrier, photoaging, sensitive skin, pigmentation issues, and sensory perceptions. All cosmetic products impact the skin barrier, it is to be hoped in a positive manner, to improve skin health. Failure of the skin to function optimally results in photoaging, sensitive skin, and pigmentation abnormalities. Damage to the skin is ultimately perceived as sensory anomalies. Skin damage can be accelerated by products that induce contact dermatitis. While the dermatologist can assess skin health visually, non-invasive methods are valuable to confirm observations or to detect slight changes in skin health that are imperceptible to the human eye. An important part of cosmetic dermatology products is the manner in which they are presented to the skin surface. Delivery systems are key to product efficacy and include creams, ointments, aerosols, powders, and nanoparticles. Once delivered to the skin surface, those substances designed to modify the skin must penetrate with aid of penetration enhancers to ensure percutaneous delivery. The most useful manner to evaluate products used in cosmetic dermatology is by category. The book is organized by product, based on the order in which they are used as part of a daily routine. The first daily activity is cleansing to ensure proper hygiene. A variety of cleansers are available to maintain the biofilm to include bars, liquids, nonfoaming, and antibacterial varieties. They can be applied with the hands or with the aid of an implement. Specialized products to cleanse the hair are shampoos, which may be useful in prevention of scalp disease. Following cleansing, the next step is typically moisturization. There are unique moisturizers for the face, hands, and feet. Extensions of moisturizers that contain other active

ingredients include sunscreens. Other products with a unique hygiene purpose include antiperspirants and shaving products. This completes the list of major products used to hygiene and skincare purposes. The book then turns to colored products for adorning the body. These include colored facial cosmetics, namely facial foundations, lipsticks, and eye cosmetics. It is the artistic use of these cosmetics that can provide camouflaging for skin abnormalities of contour and color. Adornment can also be applied to the nails, in the forms of nail cosmetics and prostheses, and to the hair, in the form of hair dyes, permanent waves, and hair straightening. From adornment, the book addresses the burgeoning category of cosmeceuticals. Cosmeceuticals can be divided into the broad categories of botanicals, antioxidants, antiinflammatories, peptides and proteins, cellular growth factors, retinoids, exfoliants, and nutraceuticals. These agents aim to improve the appearance of aging skin through topical applications, but injectable products for rejuvenation are an equally important category in cosmetic dermatology. Injectables can be categorized as neurotoxins and fillers (hyaluronic acid, hydroxyapatite, collagen, and polylactic acid). Finally, the surgical area of cosmetic dermatology must be address in terms of resurfacing techniques, skin modulation techniques, and skin contouring techniques. Resurfacing can be accomplished chemically with superficial and medium depth chemical peels or physically with microdermabrasion and dermabrasion. The newest area of resurfacing involves the use of lasers, both ablative and non-ablative. Other rejuvenative devices than collagen and pigmentation include intense pulsed light, radiofrequency, and diodes. These techniques can be combined with liposuction of the body and face to recontour the adipose tissue underlying the skin. The book closes with a discussion of how cosmetic dermatology can be implemented as part of a treatment regimen for aging skin, acne, rosacea, psoriasis, and eczema. In order to allow effective synthesis of the wide range of information included in this text, each chapter has been organized with a template to create a standardized presentation. The chapters open with basic concepts pertinent to each area. From these key points, the authors have developed their information to define the topic, discuss unique attributes, advantages and disadvantages, and indications.


Introduction It is my hope that this book will provide a standard textbook for the broad field of cosmetic dermatology. In the past, cosmetic dermatology has been considered a medical and surgical afterthought in dermatology residency programs and continuing medical education sessions. Perhaps this was in part because of the lack of a textbook defining the knowl-


edge base. This is no longer the case. Cosmetic dermatology has become a field unto itself. Zoe D. Draelos May 2009

Section I Basic Concepts

Part 1: Skin Physiology Pertinent to Cosmetic Dermatology Chapter 1: Epidermal barrier Sreekumar Pillai, Marc Cornell, and Christian Oresajo L’Oréal Research, Clark, NJ, USA

BAS I C CONCEPTS • The outer surface of the skin, the epidermis, along with its outermost layer, the stratum corneum, forms the epidermal barrier. • The stratum corneum is a structurally heterogeneous tissue composed of non-nucleated, flat, protein-enriched corneocytes and lipid-enriched intercellular domains. • The roles of the skin barrier include preventing microbes from entering the skin, protecting from environmental toxins, maintaining skin hydration, and diffusing oxidative stress. • Delivery technologies such as lipid systems, nanoparticles, microcapsules, polymers, and films can improve the barrier properties of the skin.

Introduction Skin is the interface between the body and the environment. There are three major compartments of the skin: the epidermis, the dermis, and the hypodermis. Epidermis is the outermost structure and it is a multilayered, epithelial tissue divided into several layers. The outermost structure of the epidermis is the stratum corneum (SC) which forms the epidermal permeability barrier that prevents the loss of water and electrolytes. Other protective or barrier roles for the epidermis include: immune defense, UV protection, and protection from oxidative damage. Changes in the epidermal barrier caused by environmental factors, age, or other conditions can alter the appearance as well as the functions of the skin. Understanding the structure and function of the SC and the epidermal barrier is vital because it is the key to healthy skin and its associated social ramifications.

Structural components of the epidermal barrier The outer surface of the skin, the epidermis, mostly consists of epidermal cells, known as keratinocytes, which are arranged in several stratified layers – the basal cell layer, the

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

spinous cell layer and the granular cell layer – whose differentiation eventually produces the SC. Unlike other layers, the SC is made of anucleated cells called corneocytes which are derived from keratinocytes. The SC forms the major protective barrier of the skin, the epidermal permeability barrier. Figure 1.1 shows the different layers of the epidermis and the components that form the epidermal barrier. The SC is a structurally heterogeneous tissue composed of non-nucleated, flat, protein-enriched corneocytes and lipidenriched intercellular domains [1]. The lipids for barrier function are synthesized in the keratinocytes of the nucleated epidermal layers, stored in the lamellar bodies, and extruded into the intercellular spaces during the transition from the stratum granulosum to the SC forming a system of continuous membrane bilayers [1,2]. In addition to the lipids, other components such as melanins, proteins of the SC and epidermis, free amino acids and other small molecules also have important roles in the protective barrier of the skin. A list of the different structural as well as functional components of the SC is shown in Table 1.1.

Corneocytes Corneocytes are formed by the terminal differentiation of the keratinocytes from the granular layer of the epidermis. The epidermis is comprised of 70% water, as are most tissues, yet the SC is comprised of only 15% water. Alongside this change in water content the keratinocyte nuclei and virtually all the subcellular organelles begin to disappear in the granular cell layer leaving a proteineous core containing keratins, other structural proteins, free amino acids and amino acid



Skin Physiology

Keratohyalin and lamellar granules of the stratum granulosum

Stratum corneum Stratum granulosum

Desmosomes Stratum spinosum

Melanocyte Langerhans cell

Stratum basale

Dermis Figure 1.1 Diagram of the epidermis indicating the different layers of the epidermis and other structural components of the epidermal barrier.

Table 1.1 Structural and functional components of the stratum corneum. Components





Topmost layer of epidermis


Resiliency of SC

Outer surface of the SC

Cornified envelope precursor proteins

Structural proteins that are cross-linked to form CE

Outer surface of SC


Permeability barrier of skin

Granular cells of epidermis

SC interfacial lipids

Permeability barrier of skin

Lipid bilayers between SC

Lipid–protein cross-links

Scaffold for corneocytes

Between SC and lipid bi-layers

Desmosomes and corneodesmosomes

Intercellular adhesion and provide shear resistance

Between keratinocytes and corneocytes

Keratohyalin granules

Formation of keratin “bundles” and NMF precursor proteins

Stratum granulosum


Water holding capacity of SC

Within SC

pH and calcium gradients

Provides differentiation signals and LG secretion signals

All through epidermis

Specialized enzymes (lipases, glycosidases, proteases)

Processing and maturation of SC lipids, desquamation

Within LG and all through epidermis

Melanin granules and “dust”

UV protection of skin

Produced by melanocytes of basal layer, melanin “dust” in SC

CE, cornified envelope; LG, lamellar granules; NMF, natural moisturizing factor; SC, stratum corneum.


1. Epidermal barrier derivatives, and melanin particles which persist throughout the SC. From an oval or polyhedral shape of the viable cells in the spinous layers, the keratinocyte starts to flatten off in the granular cell layer and then assumes a spindle shape and finally becomes a flat corneocyte. The corneocyte itself develops a tough, chemically resistant protein band at the periphery of the cell, called the cornified cell envelope, formed from cross-linked cytoskeletal proteins [3].

teins. The molecular structure of these components suggests that the glutamine and serine residues of CE envelope proteins such as loricrin and involucrin are covalently linked to the omega hydroxyl ceramides [8]. In addition, other free fatty acids (FFA) and ceramides (Cer), may also form protein cross-links on the extracellular side of the CE, providing the scaffold for the corneocytes to the lipid membrane of the SC.

Proteins of the cornified envelope

Desmosomes and corneodesmosomes

The cornified envelope (CE) contains highly cross-linked proteins formed from special precursor proteins synthesized in the granular cell layer, particularly involucrin, loricrin, and cornifin. In addition to these major protein components, several other minor unique proteins are also cross-linked to the cornified envelope. These include proteins with specific functions such as calcium binding proteins, antimicrobial and immune functional proteins, proteins that provide structural integrity to SC by binding to lipids and desmosomes, and protease inhibitors. The cross-linking is promoted by the enzyme transglutaminase which is detectable histochemically in the granular cell layer and lower segments of the stratum corneum. The γ-glutamyl link that results from transglutaminase activity is extremely chemically resistant and this provides the cohesivity and resiliency to the SC.

Desmosomes are specialized cell structures that provide cell– cell adhesion (Figure 1.1). They help to resist shearing forces and are present in simple and stratified squamous epithelia as in human epidermis. Desmosomes are molecular complexes of cell adhesion proteins and linking proteins that attach the cell surface adhesion proteins to intracellular keratin cytoskeletal filaments proteins. Some of the specialized proteins present in desmosomes are cadherins, calcium binding proteins, desmogleins, and desmocollins. Cross-linking of other additional proteins such as envoplakins and periplakins further stabilizes desmosomes. Corneodesmosomes are remnants of the desmosomal structures that provide the attachment sites between corneocytes and cohesiveness for the corneocytes in the SC. Corneodesmosomes have to be degraded by specialized proteases and glycosidases, mainly serine proteases, for the skin to shed in a process called desquamation [9].

Lamellar granules and inter-corneocyte lipids Lamellar granules or bodies (LG or LB) are specialized lipidcarrying vesicles formed in suprabasal keratinocytes, destined for delivery of the lipids in the interface between the corneocytes. These lipids form the essential component of the epidermal permeability barrier and provide the “mortar” into which the corneocyte “bricks” are laid for the permeability barrier formation. When the granular keratinocytes mature to the SC, specific enzymes within the LB process the lipids, releasing the non-polar epidermal permeability barrier lipids, namely, cholesterol, free fatty acids and ceramides, from their polar precursors – phospholipids, glucosyl ceramides, and cholesteryl sulfate, respectively. These enzymes include: lipases, phospholipases, sphingomyelinases, glucosyl ceramidases, and sterol sulfatases [4,5]. The lipids fuse together in the SC to form a continuous bi-layer. It is these lipids, along with the corneocytes, that constitute the bulk of the water barrier property of the SC [6,7].

Keratohyalin granules Keratohyalin granules are irregularly shaped granules present in the granular cells of the epidermis, thus providing these cells their granular appearance (Figure 1.1). These organelles contains abundant amount of keratins “bundled” together by a variety of other proteins, most important of which is filaggrin (filament aggregating protein). An important role of this protein, in addition to bundling of the major structural protein, keratin of the epidermis, is to provide the natural moisturizing factor (NMF) for the SC. Filaggrin contains all the amino acids that are present in the NMF. Filaggrin, under appropriate conditions, is dephosphorylated and proteolytically digested during the process when granular cells mature into corneocytes. The amino acids from filaggrin are further converted to the NMF components by enzymatic processing and are retained inside the corneocytes as components of NMF [4,9].

Lipid–protein cross-links at the cornified envelope LG are enriched in a specific lipid unique to the keratinizing epithelia such as the human epidermis. This lipid (a ceramide) has a very long chain omega-hydroxy fatty acid moiety with linoleic acid linked to the omega hydroxyl group in ester form. This lipid is processed within the SC to release the omega hydroxyl ceramide that becomes crosslinked to the amino groups of the cornified envelope pro-

Functions of epidermal barrier Water evaporation barrier (epidermal permeability barrier) Perhaps the most studied and the most important function of the SC is the formation of the epidermal permeability barrier [1,4,10]. The SC limits the transcutaneous movement



Skin Physiology

of water and electrolytes, a function that is essential for terrestrial survival. Lipids, particularly ceramides, cholesterol, and FFA, together form lamellar membranes in the extracellular spaces of the SC which limit the loss of water and electrolytes. Corneocytes are embedded in this lipid-enriched matrix, and the cornified envelope, which surrounds corneocytes, provides a scaffold necessary for the organization of the lamellar membranes. Extensive research, mainly by Peter Elias’ group has elucidated the structure, properties, and the regulation of the skin barrier by integrated mechanisms [5,7,11]. Barrier disruption triggers a cascade of biochemical processes leading to rapid repair of the epidermal barrier. These steps include increased keratinocyte proliferation and differentiation, increased production of corneocytes, and production, processing, and secretion of barrier lipids, ultimately leading to the repair of the epidermal permeability barrier. These events are described in more detail in the barrier homeostasis section below. A list of the different functions of human epidermis is shown in Table 1.2.

Mechanical barrier Cornified envelope provides mechanical strength and rigidity to the epidermis, thereby protecting the host from injury. Specialized protein precursors and their modified amino acid cross-links provide the mechanical strength to the SC. One such protein, trichohyalin, is a multifunctional crossbridging protein that forms intra- and inter-protein crosslinks between cell envelope structure and cytoplasmic keratin filament network [12]. Special enzymes called trans-

Table 1.2 Barrier functions of the epidermis. Function

Localization/components involved

Water and electrolyte permeability barrier

SC/corneocyte proteins and extracellular lipids

Mechanical barrier

SC/corneocytes, cornified envelope

Microbial barrier/immune function

SC/lipid components/viable epidermis



Protection from environmental toxins/drugs

SC/corneocytes, cornified envelope


SC, epidermis/proteases and glycosidases

UV barrier

SC/melanins of SC/epidermis

Oxidative stress barrier

SC, epidermis/antioxidants

NMF, natural moisturizing factor; SC, stratum corneum.


glutaminases, some present exclusively in the epidermis (transglutaminase 3), catalyze this cross-linking reaction. In addition, adjacent corneocytes are linked by corneodesmosomes, and many of the lipids of the SC barrier are also chemically cross-linked to the cornified envelope. All these chemical links provide the mechanical strength and rigidity to the SC.

Antimicrobial barrier and immune protection The epidermal barrier acts as a physical barrier to pathogenic organisms that attempt to penetrate the skin from the outside environment. Secretions such as sebum and sweat and their acid pH provide antimicrobial properties to skin. Innate immune function of keratinocytes and other immune cells of the epidermis such as Langerhans cells and phagocytes provide additional immune protection in skin. Epidermis also generates a spectrum of antimicrobial lipids, peptides, nucleic acids, proteases, and chemical signals that together forms the antimicrobial barrier (Table 1.3). The antimicrobial peptides are comprised of highly conserved, small, cysteine rich, cationic proteins that are expressed in large amounts in skin. Desquamation, which causes the outward movement of corneocytes and their sloughing off at the surface, also serves as a built-in mechanism inhibiting pathogens from colonizing the skin.

NMF and skin hydration and moisturization NMF is a collection of water-soluble compounds that are found in the stratum corneum (Table 1.4). These compounds compose approximately 20–30% of the dry weight of the

Table 1.3 Antimicrobial components of epidermis and stratum corneum. Component

Class of compound


Free fatty acids


Stratum corneum

Glucosyl ceramides


Stratum corneum



Stratum corneum



Stratum corneum










RNAse 7

Nucleic acid


Low pH


Stratum corneum

“Toll-like” receptors

Protein signaling molecules




Stratum corneum and epidermis

1. Epidermal barrier

Table 1.4 Approximate composition of skin natural moisturizing factor. Components

Percentage levels

Amino acids and their salts (over a dozen)


Pyrrolidine carboxylic acid sodium salt, urocanic acid, ornithine, citruline (derived from filaggrin hydrolysis products)






Glucosamine, creatinine, ammonia, uric acid


Cations (sodium, calcium, potassium) Anions (phosphates, chlorides)

10–11 6–7



Citrate, formate


corneocyte. Many of the components of NMF are derived from the hydrolysis of filaggrin, a histidine- and glutaminerich basic protein of the keratohyalin granule. The SC hydration level controls the protease that hydrolyzes filaggrin and histidase that converts histidine to urocanic acid. As NMF is water soluble and can easily be washed away from the SC, the lipid layer surrounding the corneocyte helps seal the corneocyte to prevent loss of NMF. In addition to preventing water loss from the organism, the SC also acts to provide hydration and moisturization to skin. NMF components absorb and hold water allowing the outermost layers of the SC to stay hydrated despite exposure to the harsh external environment. Glycerol, a major component of the NMF, is an important humectant present in skin which contributes skin hydration. Glycerol is produced locally within the SC by the hydrolysis of triglycerides by lipases, but also taken up into the epidermis from the circulation by specific receptors present in the epidermis called aquaporins [13]. Other humectants in the NMF include urea, sodium and potassium lactates, and pyrrolidine carboxylic acid (PCA) [9].

Protection from environmental toxins and topical drug penetration The SC also has the important task of preventing toxic substances and topically applied drugs from penetrating the skin. The SC acts as a protective wrap because of the highly resilient and cross-linked protein coat of the corneocytes and the lipid-enriched intercellular domains. Pharmacologists and topical or “transdermal” drug developers are interested in increasing SC permeation of drugs into the skin. The multiple route(s) of penetration of drugs into the skin can be via hair follicles, interfollicular sites, or by penetration

through corneocytes and lipid bilayer membranes of the SC [10]. The molecular weight, solubility, and molecular configuration of the toxins and drugs greatly influence the rate of penetration. Different chemical compounds adopt different pathways for skin penetration.

Desquamation and the role of proteolytic enzymes The process by which individual corneocytes are sloughed off from the top of the SC is called desquamation. Normal desquamation is required to maintain the homeostasis of the epidermis. Corneocyte to corneocyte cohesion is controlled by the intercellular lipids as well as the corneodesmosomes that bind the corneocytes together. The presence of specialized proteolytic enzymes and glycosidases in the SC help in cleavage of desmosomal bonds resulting in release of corneocytes [9]. In addition, the SC also contains protease inhibitors that keep these proteases in check and the balance of protease–protease inhibitors have a regulatory role in the control of the desquamatory process. The desquamatory process is also highly regulated by the epidermal barrier function. The SC contains three families of proteases (serine, cysteine, and aspartate proteases), including the epidermalspecific serine proteases (SP), kallikrein-5 (SC tryptic enzyme [SCTE]), and kallikrein-7 (SC chymotryptic enzyme), as well as at least two cysteine proteases, including the SC thiol protease (SCTP), and at least one aspartate protease, cathepsin D. All these proteases have specific roles in the desquamatory process at different layers of the epidermis.

Melanin and the UV barrier Although melanin is not typically considered a functional component of the epidermal barrier, its role in the protection of the skin from UV radiation is indisputable. Melanins are formed in specialized dendritic cells called melanocytes in the basal layers of the epidermis. The melanin produced is transferred into keratinocytes in the basal and spinous layers. There are two types of melanins, depending on the composition and the color. The darker eumelanin is most protective to UV than the lighter, high sulfur-containing pheomelanin. The keratinocytes carry the melanins through the granular layer and into the SC layer of the epidermis. The melanin “dust” present in the SC is structurally different from the organized melanin granules found in the viable deeper layers of the epidermis. The content and composition of melanins also change in SC depending on sun exposure and skin type of the individual. Solar UV radiation is very damaging to proteins, lipids, and nucleic acids and causes oxidative damage to these macromolecules. The SC absorbs some UV energy but it is the melanin particles inside the corneocytes that provide the most protection. Darker skin (higher eumelanin content) is significantly more resistant to the damaging effects of UV on DNA than lighter skin. In addition, UV-induced apoptosis



Skin Physiology

(cell death that results in removal of damaged cells) is significantly greater in darker skin. This combination of decreased DNA damage and more efficient removal of UVdamaged cells plays a critical part in the decreased photocarcinogenesis seen in individuals with darker skin [14]. In addition to melanin, trans-urocanic acid (tUCA), a product of histidine deamination produced in the SC, also acts as an endogenous sunscreen and protects skin from UV damage.

a controlled manner by degradation of desmosomal constituent proteins by the SC proteases. The protease activities are under the control of protease inhibitors which are colocalized with the proteases within the SC. In addition, the activation cascade of the SC proteases is also controlled by the barrier requirement. Lipids and lipid precursors such as cholesterol sulfate also regulate desquamation by controlling the activities of the SC proteases [21].

Corneocyte maturation Oxidative stress barrier The SC has been recognized as the main cutaneous oxidation target of UV and other atmospheric oxidants such as pollutants and cigarette smoke. UVA radiation, in addition to damaging the DNA of fibroblasts, also indirectly causes oxidative stress damage of epidermal keratinocytes. The oxidation of lipids and carbonylation of proteins of the SC lead to disruption of epidermal barrier and poor skin condition [15]. In addition to its effects on SC, UV also initiates and activates a complex cascade of biochemical reactions within the epidermis, causing depletion of cellular antioxidants and antioxidant enzymes such as superoxide dismutase (SOD) and catalase. Acute and chronic exposure to UV has been associated with depletion of SOD and catalase in the skin of hairless mice [16]. This lack of antioxidant protection further causes DNA damage, formation of thymine dimers, activation of proinflammatory cytokines and neuroendocrine mediators, leading to inflammation and free radical generation [17]. Skin naturally uses antioxidants to protect itself from photodamage. UV depletes antioxidants from outer SC. A gradient in the antioxidant levels (alfa-tocopherol, vitamin C, glutathione, and urate) with the lowest concentrations in the outer layers and a steep increase in the deeper layers of the SC protects it from oxidative stress [18]. Depletion of antioxidant protection leads to UV-induced barrier abnormalities. Topical application of antioxidants would support these physiologic mechanisms and restore a healthy skin barrier [19,20].

Regulation of barrier homeostasis The epidermal barrier is constantly challenged by environmental and physiologic factors. Because a fully functional epidermal barrier is required for terrestrial life to exist, barrier homeostasis is tightly regulated by a variety of mechanisms.

Desquamation Integral components of the barrier, corneocytes, and the intercellular lipid bilayers are constantly synthesized and secreted by the keratinocytes during the process of terminal differentiation. The continuous renewal process is balanced by desquamation which removes individual corneocytes in


Terminal differentiation of keratinocytes to mature corneocytes is controlled by calcium, hormonal factors, and by desquamation. High calcium levels in the outer nucleated layers of epidermis stimulate specific protein synthesis and activate the enzymes that induce the formation of corneocytes. A variety of hormones and cytokines control keratinocyte terminal differentiation, thereby regulating barrier formation. Many of the regulators of these hormones are lipids or lipid intermediates which are synthesized by the epidermal keratinocytes for the barrier function, thereby exerting control of barrier homeostasis by affecting the corneocyte maturation. For example, the activators and/or ligands for the nuclear hormone receptors (e.g. peroxisome proliferation activator receptor [PPAR] and vitamin D receptor) that influence keratinocyte terminal differentiation are endogenous lipids synthesized by keratinocytes.

Lipid synthesis Epidermal lipids, the integral components of the permeability barrier, are synthesized and secreted by the keratinocytes in the stratum granulosum after processing and packaging into the LB. Epidermis is a very active site of lipid synthesis under basal conditions and especially under conditions when the barrier is disrupted. Epidermis synthesizes ceramides, cholesterol, and FFA (a major component of phospholipids and ceramides). These three lipid classes are required in equimolar distribution for proper barrier function. The synthesis, processing, and secretion of these lipid classes are under strict control by the permeability barrier requirements. For example, under conditions of barrier disruption, rapid and immediate secretion by already packaged LB occurs as well as transcriptional and translational increases in key enzymes required for new synthesis of these lipids to take place. In addition, many of the hormonal regulators of corneocyte maturation are lipids or lipid intermediates synthesized by the epidermis. SC lipid synthesis and lipid content are also altered with various skin conditions such as inflammation and winter xerosis [22,23].

Environmental and physiologic factors Barrier homeostasis is under control of environmental factors such as humidity variations. High humidity (increased

1. Epidermal barrier SC hydration) downregulates barrier competence (as assessed by barrier recovery after disruption) whereas low humidity enhances barrier homeostasis. Physiologic factors can also have influence on barrier function. High stress (chronic as well as acute) increases corticosteroid levels and causes disruption of barrier homeostasis. Conditions that cause skin inflammation can stimulate the secretion of inflammatory cytokines such as interleukins, induce epidermal hyperplasia, cause impaired differentiation, and disrupt epidermal barrier functions.

Hormones Barrier homeostasis and SC integrity, lipid synthesis is all under the control of different hormones, cytokines, and calcium. Nuclear hormone receptors for both well-known ligands, such as thyroid hormones, retinoic acid, and vitamin D, and “liporeceptors” whose ligands are endogenous lipids control barrier homeostasis. These liporeceptors include peroxisome proliferator activator receptor (PPAR alfa, beta, and gamma) and liver X receptor (LXR). The activators for these receptors are endogenous lipids and lipid intermediates or metabolites such as certain FFA, leukotrienes, prostanoids, and oxygenated sterols. These hormones, mediated by their receptors, control barrier at the level of epidermal cell maturation (corneocyte formation), transcriptional regulation of terminal differentiation proteins and enzymes required for lipid processing, lipid transport, and secretion into LB [5].

pH and calcium Outermost SC pH is maintained in the acidic range, typically in the range 4.5–5.0, by a variety of different mechanisms. This acidity is maintained by formation of FFA from phospholipids; sodium proton exchangers in the SC and by the conversion of histidine of the NMF to urocanic acid by histidase enzyme in the SC. In addition, lactic acid, a major component of the NMF, has a major role in maintaining the acid pH of the SC. Maintenance of an acidic pH in the SC is important for the integrity and cohesion of the SC as well as the maintenance of the normal skin microflora. The growth of normal skin microflora is supported by acidic pH while a more neutral pH supports pathogenic microbes’ invasion of the skin. This acidic pH is optimal for processing of precursor lipids to mature barrier forming lipids and for initiating the desquamatory process. The desquamatory proteases present in the outer SC such as the thiol proteases and cathepsins are more active in the acidic pH, whereas the SCCE and SCTE present in the lower SC are more active at neutral pH. When the pH gradient is disrupted, desquamation is decreased resulting in dry scaly skin and disrupted barrier function. In the normal epidermis, there is a characteristic intraepidermal calcium gradient, with peak concentrations of

calcium in the granular layer and decreasing all the way up to the SC [24]. The calcium gradient regulates barrier properties by controlling the maturation of the corneocytes, regulating the enzymes that process lipids and by modulating the desquamatory process. Calcium stimulates a variety of processes including the formation and secretion of LB, differentiation of keratinocytes, formation of cornified envelope precursor proteins, and cross-linking of these proteins by the calcium inducible enzyme transglutaminase. Specifically, high levels of calcium stimulate the expression of proteins required for keratinocyte differentiation, including key structural proteins of the cornified envelope, such as loricrin, involucrin, and the enzyme, transglutaminase 1, which catalyzes the cross-linking of these proteins into a rigid structure.

Coordinated regulation of multiple barrier functions Co-localization of many of the barrier functions allows regulation of the functions of the epidermal barrier to be coordinated. For example, epidermal permeability barrier, antimicrobial barrier, mechanical protective barrier, and UV barrier are all co-localized in the SC. A disruption of one function can lead to multiple barrier disruptions, and therefore multiple barrier functions are coordinately regulated [5]. Disruption of the permeability barrier leads to activation of the cytokine cascade (increased levels of primary cytokines, interleukin-1, and tumor necrosis factor-alfa) which in turn activates the synthesis of antimicrobial peptides of the SC. Additionally, the cytokines and growth factors released during barrier disruption lead to corneocyte maturation, thereby strengthening the mechanical and protective barrier of the skin. Hydration of the skin itself controls barrier function by regulating the activities of the desquamatory proteases (high humidity decreases barrier function and stimulates desquamation). In addition, humidity levels control filaggrin hydrolysis which releases the free amino acids that form the NMF (histidine, glutamine arginine, and their by-products) and trans-urocanic acid (deamination of histidine) which serves as a UV barrier.

Methods for studying barrier structure and function Physical methods SC integrity and desquamation can be measured using tape stripping methods. Under dry skin conditions, when the barrier is compromised, corneocytes do not separate singly but as “clumps.” This can be quantified by using special tapes and visualizing the corneocytes removed by light microscopy. Another harsher tape-stripping method involves stripping of the SC using cyanoacrylate glue. These physical methods provide a clue to the binding forces that hold the



Skin Physiology

corneocyte together. The efficacy of treatment with skin moisturizers or emollients that improve skin hydration and reduce scaling can be quantitated using these methods.

Instrumental methods The flux of water vapor through the skin (transepidermal water loss [TEWL]) can be determined using an evaporimeter [25]. This instrument contains two water sensors mounted vertically in a chamber one above the other. When placed on the skin in a stable ambient environment the difference in water vapor values between the two sensors is a measure of the flow of water coming from the skin (TEWL). There are several commercially available evaporimeters (e.g. Tewameter® [Courage & Khazaka, Köln, Germany]), which are widely used in clinical practice as well as in investigative skin biology. Recovery of the epidermal barrier (TEWL) after disruption using physical methods (e.g. tape strips) or chemical methods (organic solvent washing) provides valuable information on epidermal barrier properties [26]. Skin hydration can be measured using the Corneometer® (Courage & Khazaka, Köln, Germany). The measurement is based on capacitance of a dielectric medium. Any change in the dielectric constant caused by skin surface hydration variation alters the capacitance of a precision measuring capacitor. The measurement can detect even the slightest changes in hydration level. Another important recent development in skin capacitance methodology is the SkinChip® (L’Oreal, Paris, France). Skin capacitance imaging of skin surface can be obtained using the SkinChip. This method provides information on skin microrelief, level of SC hydration, and sweat gland activity. SkinChip technology can be used to quantify regional variation in skin, skin changes with age, effects of hydrating formulations, surfactant effects on corneocytes, acne, and skin pore characteristics [27]. Several other recently developed methods for measuring epidermal thickness such as confocal microscopy, dermatoechography, and dermatoscopy can provide valuable information on skin morphology and barrier abnormalities [28]. Other more sophisticated (although not easily portable) instrumentation techniques such as ultrasound, optical coherence tomography, and magnetic resonance imaging (MRI) can provide useful information on internal structures of SC and/or epidermis and its improvements with treatment. MRI has been successfully used to evaluate skin hydration and water behavior in aging skin [29].

Biologic methods Ultrastructural details of SC and the intercellular spaces of the SC can be visualized using transmission electron microscopy of thin vertical sections and freeze–fracture replicas, field emission scanning electron microscopy, and immunofluorescence confocal laser scanning microscopy [30]. The ultrastructural details of the lipid bi-layers within the SC can


be visualized by electron microscopy after fixation using ruthenium tetroxide. The existence of corneodesmosomes in the SC, and their importance in desquamation, can be measured by scanning electron microscopy of skin surface replicas. The constituent cells of the SC, the corneocytes, can be visualized and quantitated by scraping the skin surface or by use of a detergent solution. The suspension so obtained can be analyzed by microscopy, biochemical or immunologic techniques. Punch or shaved biopsy techniques can be combined with immunohistochemistry using specific SC and/or epidermis specific antibodies to quantify the SC quality. Specific antibodies for keratinocyte differentiation specific proteins, desmosomal proteins, or specific proteases can provide information on skin barrier properties.

Relevance of skin barrier to cosmetic product development Topical products that influence barrier functions The human skin is constantly exposed to a hostile environment: changes in relative humidity, extremes of temperature, environmental toxins, and daily topically applied products. Daily exposure to soaps and other household chemicals can compromise skin barrier properties and cause unhealthy skin conditions. Prolonged exposure to surfactants removes the epidermal barrier lipids and enhances desquamation leading to impaired barrier properties [4,10]. Allergic reactions to topical products can result in allergic or irritant contact dermatitis, resulting in itchy and scaly skin and skin redness leading to barrier perturbations.

Cosmetics that restore skin barrier properties Water is the most important plasticizer of SC. Cracking and fissuring of skin develops as SC hydration declines below a critical threshold. Skin moisturization is a property of the outer SC (also known as stratum disjunctum) as corneocytes of the lower SC (stratum compactum) are hydrated by the body fluids. “Moisturizers” are substances that when applied to skin add water and/or retains water in the SC. The NMF components present in the outer SC act as humectants, absorb moisture from the atmosphere, and are sensitive to humidity of the atmosphere. The amino acids and their metabolites, along with other inorganic and organic osmolytes such as urea, lactic acid, taurine, and glycerol act as humectants within the outer SC. Secretions from sebaceous glands on the surface of the skin also act as emollients and contribute to skin hydration. A lack of any of these components can contribute to dry scaly skin. Topical application of all of the above components can act as humectants, and can relieve dry skin condition and improve skin moisturization

1. Epidermal barrier and barrier properties. Film-forming polysaccharide materials such as hyaluronic acid binds and retains water and helps to keep skin supple and soft. In addition to humectants, emollients such as petroleum jelly, hydrocarbon oils and waxes, mineral and silicone oils, and paraffin wax provide an occlusive barrier to the skin, preventing excessive moisture loss from the skin surface. Topically applied barrier compatible lipids also contribute to skin moisturization and improved skin conditions. Chronologically aged skin exhibits delayed recovery rates after defined barrier insults, with decreased epidermal lipid synthesis. Application of a mixture of cholesterol, ceramides, and essential/non-essential FFAs in an equimolar ratio was shown to lead to normal barrier recovery, and a 3 : 1 : 1 : 1 ratio of these four ingredients demonstrated accelerated barrier recovery [31]. Topical application of antioxidants and anti-inflammatory agents also protects skin from UV-induced skin damage by providing protection from oxidative damage to skin proteins and lipids [19,20].

Skin irritation from cosmetics Thousands of ingredients are used by the cosmetic industry. These include pure compounds, mixtures, plant extracts, oils and waxes, surfactants, detergents, preservatives, and polymers. Although all the ingredients used by the cosmetic industry are tested for safety, some consumers may still experience reactions to some of them. Most common reactions are irritant contact reactions while allergic contact reactions are less common. Irritant reactions tend to be more rapid and cause mild discomfort and redness and scaling of skin. Allergic reactions can be delayed, more persistent, and sometimes severe. Ingredients previously considered safe can be irritating in a different formulation because of increased penetration into skin. More than 50% of the general population perceives their skin as sensitive. It is believed that the perception of sensitive skin is, at least in part, related to skin barrier function. People with impaired barrier function may experience higher irritation to a particular ingredient because of its increased penetration into deeper layers of the skin.

Conclusions and future trends Major advances have been made in the last several decades in understanding the complexity and functions of the SC. Extensive research by several groups has elucidated the metabolically active role of SC and characterized the major components within it and their importance in providing protection from the external environment. New insights into the molecular control mechanisms of desquamation, lipid processing, barrier function, and antimicrobial protection have been elucidated in the last decade.

Knowledge of other less well-known epithelial organelles such as intercellular junctions, tight junctions, and gap junctions and their role in barrier function in the skin is being elucidated. Intermolecular links that connect intercellular lipids with the corneocytes of the SC and their crucial role for maintaining barrier function is an area being actively researched. New knowledge of the corneocyte envelope structure and the physical state of the intercellular lipid crystallinity and their interrelationship would lead to development of new lipid actives for improving SC moisturization and for treatment of skin barrier disorders. Further research in the cellular signaling events that control the communication between SC and the viable epidermis will shed more light on barrier homeostasis mechanisms. Novel delivery systems have an increasingly important role in the development of effective skin care products. Delivery technologies such as lipid systems, nanoparticles, microcapsules, polymers, and films are being pursued not only as vehicles for delivering cosmetic actives through skin, but also for improving barrier properties of the skin. Undoubtedly, skin care and cosmetic companies will exploit this new knowledge in developing novel and more efficacious products for strengthening the epidermal barrier and to improve and enhance the functional and aesthetic properties of the human skin.

References 1 Elias PM. (1983) Epidermal lipids, barrier function, and desquamation. J Invest Dermatol 80, 44s–9s. 2 Menon GK, Feingold KR, Elias PM. (1992) Lamellar body secretory response to barrier disruption. J Invest Dermatol 98, 279–89. 3 Downing DT. (1992) Lipid and protein structures in the permeability barrier of mammalian epidermis. J Lipid Res 33, 301–13. 4 Rawlings AV, Matts PJ. (2005) Stratum corneum moisturization at the molecular level: an update in relation to the dry skin cycle. J Invest Dermatol 124, 1099–11. 5 Elias PM. (2005) Stratum corneum defensive functions: an integrated view. J Invest Dermatol 125, 183–200. 6 Elias PM. (1996) Stratum corneum architecture, metabolic activity and interactivity with subjacent cell layers. Exp Dermatol 5, 191–201. 7 Elias PM, Feingold KR. (1992) Lipids and the epidermal water barrier: metabolism, regulation, and pathophysiology. Semin Dermatol 11, 176–82. 8 Uchida Y, Holleran WM. (2008) Omega-O-acylceramide, a lipid essential for mammalian survival. J Dermatol Sci 51, 77–87. 9 Harding CR, Watkinson A, Rawlings AV, Scott IR. (2000) Dry skin, moisturization and corneodesmolysis. Int J Cosmet Sci 22, 21–52. 10 Schaefer H, Redelmeier TE, eds. (1996) Skin Barrier: Principles of Percutaneous Absorption. Karger, Basel. 11 Elias PM, Menon GK. (1991) Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res 24, 1–26.



Skin Physiology

12 Steinert PM, Parry DA, Marekov LN. (2003) Trichohyalin mechanically strengthens the hair follicle: multiple crossbridging roles in the inner root shealth. J Biol Chem 278, 41409–19. 13 Choi EH, Man M-Q, Wang F, Zhang X, Brown BE, Feingold KR, et al. (2005) Is endogenous glycerol a determinant of stratum corneum hydration in humans? J Invest Dermatol 125, 288–93. 14 Yamaguchi Y, Takahashi K, Zmudzka BZ, Kornhauser A, Miller SA, Tadokoro T, et al. (2006) Human skin responses to UV radiation: pigment in the upper epidermis protects against DNA damage in the lower epidermis and facilitates apoptosis. FASEB J 20, 1486–8. 15 Sander CS, Chang H, Salzmann S, Muller CSL, EkanayakeMudiyanselage S, Elsner P, et al. (2002) Photoaging is associated with protein oxidation in human skin in vivo. J Invest Dermatol 118, 618–25. 16 Pence BC, Naylor MF. (1990) Effects of single-dose UV radiation on skin SOD, catalase and xanthine oxidase in hairless mice. J Invest Dermatol 95, 213–6. 17 Pillai S, Oresajo C, Hayward J. (2005) UV radiation and skin aging: roles of reactive oxygen species, inflammation and protease activation, and strategies for prevention of inflammationinduced matrix degradation. Int J Cosmet Sci 27, 17–34. 18 Weber SU, Thiele JJ, Cross CE, Packer L. (1999) Vitamin C, uric acid, and glutathione gradients in murine stratum corneum and their susceptibility to ozone exposure. J Invest Dermatol 113, 1128–32. 19 Lopez-Torres M, Thiele JJ, Shindo Y, Han D, Packer L. (1998) Topical application of alpha-tocopherol modulates the antioxidant network and diminishes UV-induced oxidative damage in murine skin. Br J Dermatol 138, 207–15. 20 Pinnell SR. (2003) Cutaneous photodamage, oxidative stress, and topical antioxidant protection. J Am Acad Dermatol 48, 1–19.


21 Madison KC. (2003) Barrier function of the skin: “la raison d’etre” of the epidermis. J Invest Dermatol 121, 231–41. 22 Chatenay F, Corcuff P, Saint-Leger D, Leveque JL. (1990) Alterations in the composition of human stratum corneum lipids induced by inflammation. Photodermatol Photoimmunol Photomed 7, 119–22. 23 Saint-Leger D, Francois AM, Leveque JL, Stoudemayer TJ, Kligman AM, Grove G. (1999) Stratum corneum lipids in skin xerosis. Dermatologica 178, 151–5. 24 Menon GK, Grayson S, Elias PM. (1985) Ionic calcium reservoirs in mammalian epidermis: ultrastructural localization by ioncapture cytochemistry. J Invest Dermatol 84, 508–12. 25 Nilsson GE. (1977) Measurement of water exchange through the skin. Med Biol Eng Comput 15, 209. 26 Pinnagoda J, Tupker RA. (1995) Measurement of the transepidermal water loss. In: Serup J, Jemec GBE, eds. Handbook of Non-Invasive Methods and the Skin. Boca Raton, FL: CRC Press, pp. 173–8. 27 Leveque JL, Querleux B. (2003) SkinChip, a new tool for investigating the skin surface in vivo. Skin Res Technol 9, 343–7. 28 Corcuff P, Gonnord G, Pierard GE, Leveque JL. (1996) In vivo confocal microsocopy of human skin: a new design for cosmetology and dermatology. Scanning 18, 351–5. 29 Richard S, Querleux B, Bittoun J, Jolivet O, Idy-Peretti I, de Lacharriere O, et al. (1993) Characterization of skin in vivo by high resolution magnetic resonance imaging: water behavior and age-related effects. J Invest Dermatol 100, 705–9. 30 Corcuff P, Fiat F, Minondo AM. (2001) Ultrastructure of human stratum coreum. Skin Pharmacol Appl Skin Physiol 1, 4–9. 31 Zettersten EM, Ghadially R, Feingold KR, Crumrine D, Elias PM. (1997) Optimal ratios of topical stratum corneum lipids improve barrier recovery in chronologically aged skin. J Am Acad Dermatol 37, 403–8.

Chapter 2: Photoaging Murad Alam and Jillian Havey Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

BAS I C CONCEPTS • UV radiation damages human skin connective tissue through several interdependent, but distinct, processes. • The normal dermal matrix is maintained through signaling transduction pathways, transcription factors, cell surface receptors, and enzymatic reactions. • UV radiation produces reactive oxygen species which inhibit procollagen production, degrade collagen, and damage fibroblasts.

Introduction Skin, the largest human organ, is chronically exposed to UV radiation from the sun. Thinning of the ozone layer, which increases UV transmittance to the Earth, has heightened awareness of the potential injurious skin effects of exposure to UV radiation: photoaging, sunburn, immunosuppression, and carcinogenesis. Photoaging, the most common form of skin damage caused by UV exposure, produces damage to connective tissue, melanocytes, and the microvasculture [1]. Recent advances in understanding photoaging in human skin have identified the physical manifestations, histologic characteristics, and molecular mechanisms of UV exposure.

Definition Photoaging is the leading form of skin damage caused by sun exposure, occurring more frequently than skin cancer. Chronic UV exposure results in premature skin aging, termed cutaneous photoaging, which is marked by fine and coarse wrinkling of the skin, dyspigmentation, sallow color, textural changes, loss of elasticity, and premalignant actinic keratoses. Most of these clinical signs are caused by dermal alterations. Pigmentary disorders such as seborrheic keratoses, lentigines, and diffuse hyperpigmentation are characteristic of epidermal changes [2]. These physical characteristics are confirmed histologically by epidermal thinning and disorganization of the dermal connective tissue (see p. 14). Loss of connective tissue inter-

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

stitial collagen fibrils and accumulation of disorganized connective tissue elastin leads to solar elastosis, a condition characteristic of photoaged skin [3]. Similar alterations in the cellular component and the extracellular matrix of the connective tissue of photoaged skin may affect superficial capillaries, causing surface telangiectasias [4].

Physiology Photoaged versus chronically aged skin Skin, like all other organs, ages over time. Aging can be defined as intrinsic and extrinsic. Intrinsic aging is a hallmark of human chronologic aging and occurs in both sunexposed and non-sun-exposed skin. Extrinsic aging, on the contrary, is affected by exposure to environmental factors such as UV radiation. While sun-protected chronically aged skin and photoaged chronically aged skin share common characteristics, many of the physical characteristics of skin that decline with age show an accelerated decline with photoaging [5]. Compared with photodamaged skin, sunprotected skin is characterized by dryness, fine wrinkles, skin atrophy, hom*ogeneous pigmentation, and seborrheic keratoses [6]. Extrinsically aged skin, on the contrary, is characterized by roughness, dryness, both fine and coarse wrinkles, atrophy, uneven pigmentation, and superficial vascular abnormalities (e.g. telangiectasias) [6]. It is important to note that these attributes are not absolute and can vary according to Fitzpatrick skin type classification and history of sun exposure. While the pathophysiology of photoaged and photoprotected skin differ, the histologic features of these two entities are distinct. In photo-protected skin, a thin epidermis is present with an intact stratum corneum, the dermoepidermal junction and the dermis are flattened, and dermal fibroblasts produce less collagen. In photoaged skin,



Skin Physiology

the thickness of the epidermis can either increase or decrease, corresponding to areas of keratinocyte atypia. The dermoepidermal junction is atrophied in appearance and the basal membrane thickness is increased, reflecting basal keratinocyte damage. Changes in the dermis of photoaged skin can vary based on the amount of acquired UV damage. Solar elastosis is the most prominent histologic feature of photoaged skin. The quantity of elastin in the dermis decreases in chronically aged skin, but in UV-exposed skin, elastin increases in proportion to the amount of UV exposure [7,8]. Accumulated elastic fibers occupy areas in the dermal compartment previously inhabited by collagen fibers [9]. This altered elastin deposition is manifest clinically as wrinkles and yellow discoloration of the skin. Another feature of photoaged skin is collagen fibril disorganization. Mature collagen fibers, which constitute the bulk of the skin’s connective tissue, are degenerated and replaced by collagen with a basophilic appearance, termed basophilic degeneration. Additional photoaged skin characteristics include an increase in the deposition of glycosaminoglycans and dermal extracellular matrix proteins [10,11]. In fact, the overall cell population in photodamaged skin increases, leading to hyperplastic fibroblast proliferation and infiltration of inflammatory substrates that cause chronic inflammation (heliodermatitis) [12]. Changes in the microvasculature also occur, as is clinically manifested in surface telangiectasias and other vascular abnormalities.


Photobiology In order to fully understand the molecular mechanisms responsible for photoaging in human skin, an awareness of the UV spectrum is crucial. The UV spectrum is divided into three main components: UVC (270–290 nm), UVB (290– 320 nm), and UVA (320–400 nm). While UVC radiation is filtered by ozone and atmospheric moisture, and consequently never reaches the Earth, UVA and UVB rays do reach the terrestrial surface. Although the ratio of UVA to UVB rays is 20 : 1 [13] and UVB is greatest during the summer months, both forms of radiation have acute and chronic effects on human skin. Photoaging is the superposition of UVA and UVB radiation on intrinsic aging. In order to exert biologic effects on human skin, both categories of UV rays must be absorbed by chromophores in the skin. Depending on the wavelength absorbed, UV light interacts with different skin cells at different depths (Figure 2.1). More specifically, energy from UVB rays is mostly absorbed by the epidermis and affects epidermal cells such as the keratinocytes, whereas energy from UVA rays affects both epidermal keratinocytes and the deeper dermal fibroblasts. The absorbed energy is converted into varying chemical reactions that cause histologic and clinical changes in the skin. UVA absorption by chromophores mostly acts indirectly by transferring energy to oxygen to generate reactive oxygen species (ROS), which subsequently causes several effects such as transcription factor activation, lipid peroxidation, and DNA-strand breaks. On the contrary, UVB has a more direct effect on the absorb-



Keratinocytes AP-1 NF-κB

ROS Dermis


MMP and mtDNA


Figure 2.1 Ultraviolet light interacts with different skin cells at different depths. More specifically, energy from UVB rays is mostly absorbed by the epidermis and affects epidermal cells such as the keratinocytes. Energy from UVA rays affects both epidermal keratinocytes and the deeper dermal fibroblasts. AP-1, activator protein 1; NF-κB, nuclear factor κB; MMP, matrix metalloproteinase; mtDNA, mitochondrial DNA; ROS, reactive oxygen species. (Reproduced by permission of: Blackwell Publishing. This figure was published in: Berneburg M, Plettenberg H, Krutmann J. (2000) Photoaging in human skin. Photodermatol Photoimmunol Photomed 16, figure 1, p. 240.)

2. Photoaging ing chromophores and causes cross-linking of adjacent DNA pyrimidines and other DNA-related damage [14]. Approximately 50% of UV-induced photodamage is from the formation of free radicals, while mechanisms such as direct cellular injury account for the remainder of UV effects [15].

Cutaneous microvasculature Intrinsically aged skin and photodamaged skin share similar cutaneous vasculature characteristics, such as decreased cutaneous temperature, pallor, decreased cutaneous vessel size, reduced erythema, reduced cutaneous nutritional supply, and reduced cutaneous vascular responsiveness [16– 18]. However, there are also significant differences in the microvasculature of chronologic sun-protected versus photoaged skin. Studies have reported that the blood vessels in photoaged skin are obliterated and the overall horizontal architecture of the vascular plexuses is disrupted [19]. In contrast to photodamaged skin, intrinsically aged skin does not display a greatly disturbed pattern of horizontal vasculature. Additionally, while cutaneous vessel size has been reported to decrease with age in both scenarios, only photoaged skin exhibits a large reduction in the number of dermal vessels. This reduction is especially highlighted in the upper dermal connective tissue, where it is hypothesized that chronic UV-induced degradation of elastic and collagen fibers is no longer able to provide the physical support required for normal cutaneous vessel maintenance [16]. Furthermore, preliminary studies have reported that the effects of exposure to acute UV radiation differ from chronic exposure. Recent studies have implied that a single exposure to UVB radiation induces skin angiogenesis in human skin in vivo [20,21]. The epidermis-derived vascular endothelial growth factor (VEGF) is an angiogenic factor that is significantly upregulated with UV exposure in keratinocytes in vitro and in human skin in vivo. Chung and Eun [16] have demonstrated that, compared to low VEGF expression in non-UV-irradiated control skin, epidermal VEGF expression increased significantly on days 2 and 3 post-UV-irradiation, consequently inducing cutaneous angiogenesis. Therefore, acute UV exposure has been shown to induce angiogenesis. However, chronic UV-exposed photodamaged skin exhibits a significant reduction in the number of cutaneous blood vessels. The reasons for this discrepancy between the effects of acute and chronic UV exposure on angiogenesis in vivo are still under investigation.

damages human skin by at least two interdependent mechanisms: 1 Photochemical generation of ROS; and 2 Activation of cutaneous signal transduction pathways. These molecular processes and their underlying components are described in detail below. Before these processes are highlighted, however, the structure and function of collagen must be understood.

Collagen Type I collagen accounts for greater than 90% of the protein in the human skin, with type III collagen accounting for a smaller fraction (10%). The unique physical characteristics of collagen fibers are essential for providing strength, structural integrity, and resilience to the skin. Dermal fibroblasts synthesize individual collagen polypeptide chains as precursor molecules called procollagen. These procollagen building blocks are assembled into larger collagen fibers through enzymatic cross-linking and form the three-dimensional dermal network mainly made of collagen types I and III. This intermolecular covalant cross-linking step is essential for maintenance and structural integrity of large collagen fibers, especially type I collagen. Natural breakdown of type I collagen is a slow process and occurs through enzymatic degradation [22]. Dermal collagen has a half-life of greater than 1 year [22], and this slow rate of type I collagen turnover allows for disorganization and fragmentation of collagen which impair its functions. In fact, fragmentation and dispersion of collagen fibers is a feature of photodamaged skin that is clinically manifest in the changes associated with photodamaged human skin. The regulation of collagen production is an important mechanism to understand before discussing how this process is impaired. In general, collagen gene expression is regulated by the cytokine, transforming growth factor β (TGF-β), and the transcription factor, activator protein (AP-1), in human skin fibroblasts. When TGF-βs bind to their cell surface receptors (TβRI and TβRII), transcription factors Smad2 and Smad3 are activated, combine with Smad4, and enter the nucleus, where they regulate type I procollagen production. AP-1 has an opposing effect and inhibits collagen gene transcription by either direct suppression of gene transcription or obstructing the Smad complex from binding to the TGF-β target gene (Figure 2.2) [23]. Therefore, in the absence of any inhibiting factors, the TGF-β/Smad signaling pathway results in a net increase in procollagen production.

How does UV irradiation stimulate photoaging?

Molecular mechanisms of photoaging During the last few years substantial progress has been made in exposing the molecular mechanisms accountable for photoaging in human skin. One major theoretical advance that has been elucidated by this work is that UV irradiation

UV irradiation stimulates photoaging through several molecular mechanisms, discussed in detail below.

Reactive oxygen species Approximately 50% of UV-induced photodamage is from the formation of free radicals, while mechanisms such as



Skin Physiology complex. This, in turn, reduces TGF-β target gene expression, such as expression of type I procollagen [27].


UV-induced matrix metalloproteinases stimulate collagen degradation

Smad 2,3 Smad 7 TβR I/II


Smad 2,3 Smad 4


Smad 2,3

Smad 4 AP-1


Smad 2,3

Smad 4

TGF-β target gene


Figure 2.2 The regulation of procollagen production: the TGF-β/Smad signaling pathway. AP-1, activator protein 1; TβR, TGF-β receptor; TGF-β, transforming growth factor β. (Reproduced by permission of: Elsevier Ltd. This figure was published in: Kang S, Fisher G, Voorhees JJ. (2001) Photoaging pathogenesis, prevention, and treatment. Clin Geriatric Med 17(4), figure 1, p. 645.)

direct cellular injury account for the remainder of UV effects [15]. Proposed in 1954, the free radical theory of aging suggests that aging is a result of reactions caused by excessive amounts of free radicals, which contain one or more unpaired electrons [24]. Generation of ROS occurs during normal chronologic aging and when human skin is exposed to UV light in photoaging [25]. ROS mediate deleterious post-translational effects on aging skin through direct chemical modifications to mitochondrial DNA (mtDNA), cell lipids, deoxyribonucleic acids (DNA), and dermal matrix proteins, including collagens. In fact, a 4977 base-pair deletion of mtDNA was recently found in dermal human fibroblast cells. This deletion is induced by UVA via ROS and is a marker of UVA photodamage [26].

UV radiation inhibits procollagen production: TGF-β/Smad signaling pathway UV light inhibits procollagen production through two signaling pathways: downregulation of TβRII and inhibition of target gene transcription by AP-1. UV radiation has been reported to disrupt the skin collagen matrix through the TGF-β/Smad pathway [1]. More specifically, UV radiation downregulates the TGF-β type II receptor (TβRII) and results in a 90% reduction of TGF-β cell surface binding, consequently reducing downstream activation of the Smad 2, 3, 4 complex and type I procollagen transcription. Additionally, UV radiation activates AP-1, which binds factors that are part of the procollagen type I transcriptional


It has been demonstrated that UV irradiation affects the post-translational modification of dermal matrix proteins (through ROS) and also downregulates the transcription of these same proteins (through the TGF-β/Smad signaling pathway). UVA and UVB light also induces a wide variety of matrix metalloproteinases (MMPs) [28]. As their name suggests, MMPs degrade dermal matrix proteins, specifically collagens, through enzymatic activity. UV-induced MMP-1 initiates cleavage of type I and III dermal collagen, followed by further degradation by MMP-3 and MMP-9. Recall that type I collagen fibrils are stabilized by covalent cross-links. When undergoing degradation by MMPs, collagen molecules can remain cross-linked within the dermal collagen matrix, thereby impairing the structural integrity of the dermis. In the absence of perfect repair mechanisms, MMP-mediated collagen damage can accrue with each UV exposure. This type of collective damage to the dermal matrix collagen is hypothesized to have a direct effect on the physical characteristics of photodamaged skin [14]. In addition to UV induction of MMPs, transcription factors may cause MMP activation. It has been reported that within hours of UV exposure, the transcription factors AP-1 and NF-κB are activated which, in turn, stimulate transcription of MMPs (Figure 2.3) [29].

Fibroblasts regulate their own collagen synthesis Fibroblasts have evolved to regulate their output of extracellular matrix proteins (including collagen) based on internal mechanical tension [30]. Type I collagen fibrils in the dermis serve as mechanical stabilizers and attachment sites for fibroblasts in sun-protected skin. Surface integrins on the fibroblasts attach to collagen and internal actin– myosin microfilaments provide mechanical resistance by pulling on the intact collagen. In response to this created tension, intracellular scaffolding composed of intermediate filaments and microtubules pushes outward to causing fibroblasts to stretch. This stretch is an essential cue for normal collagen and MMP production by fibroblasts (Figure 2.4) [30]. This mechanical tension model is different in photoaged human skin. Fibroblast–integrin attachments are lost, which prevents collagen fragments from binding to fibroblasts. Collagen–fibroblast binding is crucial for maintenance of normal mechanical stability. When mechanical tension is reduced, as in photoaged skin, fibroblasts collapse, which causes decreased procollagen production and increased collagenase (COLase) production [30]. Collagen is continually lost as this cycle repeats itself.

2. Photoaging




FB Figure 2.3 Model depicting the effects of UV irradiation on epidermal keratinocytes (KC) and dermal fibroblasts (FB). AP-1, activator protein 1; MMP, matrix metalloproteinase. (Reproduced by permission of: Fisher GJ, et al. Mechanisms of photoaging and chronological skin aging. Arch Dermatol 2002; 138: figure 1 p. 1463. Copyright 2002, American Medical Association. All Rights reserved.)

Growth factor Cytokine receptors

Growth factor Cytokine receptors

Signal transduction cascade

Signal transduction cascade



Procollagen MMP promoters promoters nucleus



AP-1 MMP promoters


Dermal matrix breakdown Imperfect repair



Intact collagen Cross-links

Photoprotected or young skin


Figure 2.4 Fibroblasts have evolved to regulate their output of collagen based on internal mechanical tension. Model depicting the effects of mechanical tension on procollagen production in (a) sun-protected human skin versus (b) photodamaged human skin. (Reproduced by permission of: Fisher GJ, Varani J, Voorhees, JJ. Looking older. Arch Dermatol 2008; 144(5), figure 2, p. 669. Copyright 2008, American Medical Association. All rights reserved.)

(a) Stretched fibroblast Collagen fragments

Photoaged or aged skin


(b) Collapsed fibroblast



Skin Physiology

Ethnic skin: photoaging All races are susceptible to photoaging. However, people with Fitzpatrick skin phototypes IV–VI are less susceptible to the deleterious effects of UV irradiation than people with a lower Fitzpatrick skin type classification. This phenomenon is most likely a result of the protective role of melanin [31]. Studies reporting ethnic skin photoaging are few and far between. However, for the purposes of this discussion, characteristics of photoaging in different ethnic skin categories are briefly highlighted. In one of the first studies comparing UV absorption amongst different skin types, Kaidbey et al. [32] compared the photoprotective properties of African-American skin with Caucasian skin exposed to UVB irradiation. It was known that only 10% of the total UVB rays penetrated the dermis. However, the mean UVB transmission into the dermis by African-American dermis (5.7%) was found to be significantly less than for Caucasian dermis (29.4%). Similar experiments were performed with UVA irradiation. Although only 50% of the total UVA exposure penetrates into the papillary dermis, UVA transmission into AfricanAmerican dermis was 17.5% compared to 55% for white epidermis [32]. The physiologic reason behind this difference in black and white skin lies at the site of UV filtration. The malpighian layer (basal cell layer) of African-American skin is the main site of UV filtration, while the stratum corneum absorbs most UV rays in white skin. The malpighian layer of African-American skin removes twice as much UVB radiation as the overlying statum corneum, thus mitigating the deleterious effects of UV rays in the underlying dermis [33]. In African-Americans, photoaging may not be clinically apparent until the fifth or sixth decade of life and is more common in individuals with a lighter complexion [34]. The features of photoaging in this ethnic skin group manifest as signs of laxity in the malar fat pads sagging toward the nasolabial folds [35]. In patients of Hispanic and European descent, photoaging occurs in the same frequency as Caucasians and clinical signs are primarily wrinkling rather than pigmentary alterations. The skin of East and South-East Asian patients, on the contrary, mainly exhibits pigmentary alterations (seborrheic keratoses, hyperpigmentation, actinic lentigines, sun-induced melasma) and minimal wrinkling as a result of photoaging [36,37]. Finally, very few studies have reported on the signs of photoaging in South Asian (Pakistanis, Indians) skin. UV-induced hyperpigmentation, dermatosis papulosa nigra, and seborrheic keratosis are noted [38]. Despite all of these differences, it is important to note that the number of melanocytes per unit area of skin does not vary across ethnicities. Instead, it is the relative amount of melanin packaged into melanocytes that accounts for the


physiologic differences between Caucasian skin and ethnic skin [39].

Prevention Although the effects of the sun’s rays appear daunting, there are some ways to avoid the deleterious effects of photoaging. Avoiding photoaging can often prove to be more costeffective than trying to reverse the signs of photoaging after they have manifested.

Primary prevention Sun protection UV rays are especially prevalent during the hours of 10AM– 4PM and sun protection should be encouraged during this time. Sun protection can be offered to patients in the form of sunscreens, sun-protective clothing, and/or sun avoidance. Sun-protective clothing includes any hats, sunglasses, or clothing that would help block the sun’s rays. Photoprotective clothing is given a UV protection factor (UPF) rating, which is a measurement of the amount of irradiation that can be transmitted through a specific type of fabric. A UPF of 40–50 is recommended by most dermatologists, as it transmits less than 2.6% of UV irradiation [5]. Traditionally, sunscreens contain one or more chemical filters – those that physically block, reflect, or scatter specific photons of UV irradiation and those that absorb specific UV photons. UVA sunblocks contain the inorganic particulates titanium dioxide or zinc oxide, while UVA-absorbing suncreens contain terephthalylidene dicamphor sulfonic acid or avobenzene. UVB-absorbing sunscreens can contain salicylates, cinnamates, p-aminobenzoic acid, or a combination of these [40]. The US Food and Drug Administration (FDA) recommended dose of sunscreen application is 2 mg/cm2 [41]. The sun protection factor (SPF) is an international laboratory measure used to assess the efficacy of sunscreens. The SPF can range from 1 to over 80 and indicates the time that a person can be exposed to UVB rays before getting sunburn with sunscreen application relative to the time a person can be exposed without sunscreen. SPF levels are determined by the minimal amount of UV irradiation that can cause UVBstimulated erythema and/or pain. The effectiveness of a particular sunscreen depends on several factors, including the initial amount applied, amount reapplied, skin type of the user, amount of sunscreen the skin has absorbed, and the activities of the user (e.g. swimming, sweating). The sun protection factor is an inadequate determination of skin damage because it does not account for UVA rays. Although UVA rays have an important role in photoaging, their effects are not physically evident as erythema or pain, as are UVB rays. Therefore, it has been suggested that SPF may be an imperfect guide to the ability of a particular sun-

2. Photoaging UV

Skin angiogenesis VEGF TSP

Acute effects

ECM degradation Collagen MMPs

Inflammation Figure 2.5 Model depicting the acute and chronic effects of UV irradiation on skin angiogenesis and extracellular matrix (ECM) degradation in human skin. MMP, matrix metalloproteinase; TSP, thrombospondin-1 (ECM protein; inhibitor of angiogenesis in epithelial tissues); VEGF, vascular endothelial growth factor. (Reproduced by permission of: Blackwell Publishing. This figure was published in: Chung JH, Eun HC. (2007) Angiogenesis in skin aging and photoaging. J Dermatol 34, figure 1, p. 596.)

Worse environment for normal vasculature Photoaged human skin ECM (collagen fibers, elastic fibers) Dermal vasculature

Chronic effects

screen to shield against photoaging [5]. As a result, combination UVA–UVB sunscreens have been developed and are recommended to protect the human skin from both types of irradiation.

Aged and photoaged human skin ECM (collagen fibers, elastic fibers) Dermal vasculature Retinoic acid

Secondary prevention Retinoids A large number of studies have reported that topical application of 0.025–0.1% all-trans retinoic acid (tRA) improves photoaging in human skin [42,43]. Results vary based on treatment duration and applied tRA dose. Although there have been a variety of clinical trials on the topic, the molecular mechanisms by which tRA acts are still waiting to be discovered. Retinoic acids have been used in an ex post facto manner to reverse the signs of photodamage and in a preventative fashion to avoid photoaging. More specifically, tRA has been shown to induce type I and III procollagen gene expression in photoaged skin [44]. It has been observed that topical tRA induces TGF-β in human skin [45], which stimulates the production of type I and III procollagen. In addition, tRA has been used in a preventive fashion to avert UV-induced angiogenesis. Kim et al. [20] demonstrated that topical application of retinoic acid before UV exposure inhibited UV-induced angiogenesis and increases in blood vessel density. In general, extracellular signal-related kinases (ERKs, or classic MAP kinases) positively regulate epidermally derived VEGF. VEGF stimulates angiogenesis upon UV induction. Retinoic acid inhibits ERKs, which can potentially lead to downregulation of VEGF expression, UV-induced angiogenesis, and angiogenesis-associated photoaging (Figures 2.5 and 2.6) [16]. Finally, tRA has been reported to prevent UV-stimulated MMP expression. The transcription factor, c-Jun, is a key

ECM degradation Collagen MMPs

Skin angiogenesis VEGF Vascularization

Better environment for normal vasculature

Improve skin aging Figure 2.6 Model depicting the effect of topical retinoids on photoaged human skin. ECM, extracellular matrix; MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor. (Reproduced by permission of: Blackwell Publishing. This figure was published in: Chung J, Eun HC. (2007) Angiogenesis in skin aging and photoaging. J Dermatol 34, figure 5, p. 599.)

component in forming the AP-1 complex. Recall that the AP-1 complex both inhibits types I and III procollagen and stimulates transcription of MMPs. Retinoic acid blocks the accumulation of c-Jun protein, consequently inhibiting the formation of the AP-1 complex and dermal matrixassociated degradation [46].

Antioxidants It is important to highlight briefly the role of antioxidants in the reduction of photoaging. In vitro studies have



Skin Physiology

discovered a large number of antioxidants that either forestall or reverse the clinical signs of photodamage caused by ROS. In vivo studies investigating these same antioxidants are ongoing. One such antioxidant, vitamin C, has been shown to mitigate photodamaged keratinocyte formation and erythema post-UV-irradiation [47].

Inherent defense mechanisms Although science has developed exogenous mechanisms to prevent and reverse the clinical signs of photoaging, the human skin possesses endogenous machinery built to protect the skin from UV-induced damage. These inherent defense mechanisms include, but are not limited to, increased epidermal thickness, melanin distribution, DNA repair mechanisms and apoptosis of sunburned keratinocytes, MMP tissue inhibitors, and antioxidants [5,32,48–50].

Failure of prevention: immunosuppression Although photoaging is the most prevalent form of skin damage, local and systemic immunosuppression, leading to skin carcinoma, can result from overexposure to the sun’s rays. This immunosuppression is mediated by a combination of DNA damage, epidermal Langerhans’ cell depletion, and altered cytokine expression [51,52].

Conclusions The pathophysiology of photoaging derives from the ability of UV irradiation to exploit established molecular mechanisms which have evolved to maintain the internal milieu of human skin connective tissue. Disruption of the normal skin architecture does not occur through one pathway, but rather is the culmination of several interdependent, but distinct, processes that have gone awry. The integrity of the normal dermal matrix is maintained through signaling transduction pathways, transcription factors, cell surface receptors, and enzymatic reactions that are intertangled and communicate with one another. When UV irradiation is introduced into this homeostatic picture, deleterious effects can be implemented. Production of ROS, inhibition of procollagen production, collagen degradation, and fibroblast collapse are only a few known processes amongst the medley of mechanisms still waiting to be discovered that contribute to photoaging. Although human skin is equipped with inherent mechanisms to protect against photoaging and methods of prevention and therapeutics are widely available, these alternatives are not absolute and do not necessarily guarantee a perfect escape from the sun’s UV irradiation. With each passing day, scientists continue to discover


novel cutaneous molecular mechanisms affected by UV irradiation and, consequently, search for new solutions to photodamage.

References 1 Quan T, He T, Kang S, Voorhees JJ, Fisher GJ. (2004) Solar ultraviolet irradiation reduces collagen in photoaged human skin by blocking transforming growth factor-beta type II receptor/Smad signaling. Am J Pathol 165, 741–51. 2 Gilchrest B, Rogers G. (1993) Photoaging. In: Lim H, Soter N, eds. Clinical Photomedicine. New York: Marcel Dekker, pp. 95–111. 3 Kang S, Fisher GJ, Voorhees JJ. (2001) Photoaging: pathogenesis, prevention, and treatment. Clin Geriatr Med 17, 643–59. 4 Weiss RA, Weiss MA, Beasley KL. (2002) Rejuvenation of photoaged skin: 5 years results with intense pulsed light of the face, neck, and chest. Dermatol Surg 28, 1115–9. 5 Rabe JH et al. (2006) Photoaging: mechanisms and repair. J Am Acad Dermatol 55, 1–19. 6 Rokhsar CK, Lee S, Fitzpatrick RE. (2005) Review of photorejuvenation: devices, cosmeceuticals, or both? Dermatol Surg 31, 1166–78; discussion 1178. 7 Bernstein E, Brown DB, Urbach F, Forbes D, Del Monaco M, Wu M, et al. (1995) Ultraviolet radiation activates the human elastin promoter in transgenic mice: a novel in vivo and in vitro model of cutaneous photoaging. J Invest Dermatol 105, 269–73. 8 Lewis KG, Bercovitch L, Dill SW, Robinson-Bostom L. (2004) Acquired disorders of elastic tissue: part I. Increased elastic tissue and solar elastotic syndromes. J Am Acad Dermatol 51, 1–21. 9 El-Domyati M, Attia S, Saleh F, Brown D, Birk DE, Gasparro F, et al. (2002) Intrinsic aging vs photoaging: a comparative histopathological, immunohistochemical, and ultrastructural study of skin. Exp Dermatol 11, 398–405. 10 Mitchell R. (1967) Chronic solar elastosis: a light and electron microscopic study of the dermis. J Invest Dermatol 48, 203–20. 11 Smith JG Jr, Davidson EA, Sams WM Jr, Clark RD. (1962) Alterations in human dermal connective tissue with age and chronic sun damage. J Invest Dermatol 39, 347–50. 12 Lavker R, Kligman A. (1988) Chronic heliodermatitis: a morphologic evaluation of chronic actinic damage with emphasis on the role of mast cells. J Invest Dermatol 90, 325–30. 13 Urbach F. (1992) Ultraviolet A transmission by modern sunscreens: Is there a real risk? Photodermatol Photoimmunol Photomed 9, 237–41. 14 Fisher G, Kang S, Varani J, Bata-Csorgo Z, Wan Y, Datta S, et al. (2002) Mechanisms of photoaging and chronological skin aging. Arch Dermatol 138, 1462–70. 15 Bernstein EF, Brown DB, Schwartz MD, Kaidbey K, Ksenzenko SM. (2004) The polyhydrxy acid gluconolactone protects against ultraviolet radiation in an in vitro model of cutaneous photoaging. Dermatol Surg 30, 189–96. 16 Chung JH, Eun HC. (2007) Angiogenesis in skin aging and photoaging. J Dermatol 34, 593–600. 17 Chung JH, Yano K, Lee MK, Youn CS, Seo JY, Kim KH, et al. (2002) Differential effects of photoaging vs intrinsic aging on the vascularization of human skin. Arch Dermatol 138, 1437–42. 18 Kelly RI, Pearse R, Bull RH, Leveque JL, de Riqal J, Mortimer PS. (1995) The effects of aging on the cutaneous microvasculature. J Am Acad Dermatol 33, 749–56.

2. Photoaging 19 Kligman AM. (1979) Perspectives and problems in cutaneous gerontology. J Invest Dermatol 73, 39–46. 20 Kim MS, Kim YK, Eun HC, Cho KH, Chung JH. (2006) All-trans retinoic acid antagonizes UV-induced VEGF production and angiogenesis via the inhibition of ERK activation in human skin keratinocytes. J Invest Dermatol 126, 2697–706. 21 Yano K, Kadova K, Kajiya K, Hong YK, Detmar M. (2005) Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol 152, 115–21. 22 Verzijl N, DeGroot J, Thorpe S. (2000) Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 275, 39027–31. 23 Massague J. (1998) TGF-β signal transduction. Annu Rev Biochem 67, 753–91. 24 Herman D. (1998) Expanding functional life span. Exp Geriatr Ontol 33, 95–112. 25 Sohal R, Weindruch R. (1996) Oxidative stress, caloric restriction and aging. Science 273, 59–63. 26 Berneburg M, Plettenberg H, Medve-Konig K, Pfahlberg A, Gers-Barlaq H, Gefeler O, et al. (2004) Induction of the photoaging-associated mitochondrial common deletion in vivo in normal human skin. J Invest Dermatol 122, 1277–83. 27 Karin M, Liu ZG, Zandi E. (1997) AP-1 function and regulation. Curr Opin Cell Biol 9, 240–6. 28 Berneburg M, Plettenberg H, Krutmann J. (2000) Photoaging of human skin. Photodermatol Photoimmunol Photomed 16, 239–44. 29 Fisher G, Wang ZQ, Datta SC, Varani J, Kang S, Voorhees JJ. (1997) Pathophysiology of premature skin aging induced by ultraviolet light. N Engl J Med 337, 1419–28. 30 Fisher GJ, Varani J, Voorhees JJ. (2008) Looking older: fibroblast collapse and therapeutic implications. Arch Dermatol 144, 666–72. 31 Pathak M. (1974) The role of natural photoprotective agents in human skin. In: Fitzpatrick T, Pathak M, eds. Sunlight and Man. Toyko: University of Toyko Press. 32 Kaidbey KH, Agin PP, Sayre RM, Kligman AM. (1979) Photoprotection by melanin: a comparison of black and Caucasian skin. J Am Acad Dermatol 1, 249–60. 33 Munavalli GS, Weiss RA, Halder RM. (2005) Photoaging and nonablative photorejuvenation in ethnic skin. Dermatol Surg 31, 1250–60; discussion 1261. 34 Taylor SC. (2002) Skin of color: biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol 46 (Suppl 2), S41–62. 35 Matory W. (1998) Skin care. In: Matory W, ed. Ethnic Considerations in Facial Aesthetic Surgery. Philadelphia: LippincottRaven, p. 100. 36 Chung JH, Lee SH, Youn CS, Park BJ, Kim KH, Park KC, et al. (2001) Cutaneous photodamage in Koreans: influence of sex, sun exposure, smoking, and skin color. Arch Dermatol 137, 1043–51. 37 Goh SH. (1990) The treatment of visible signs of senescence: the Asian experience. Br J Dermatol 122 (Suppl 35), 105–9. 38 Valia R, Ed. (1994) Textbook and Atlas of Dermatology. Bombay: Bhalani Publishing House.

39 Szabo G, Gerald AB, Pathak MA, Fitzpatrick TB. (1969) Racial differences in the fate of melanosomes in human epidermis. Nature 222, 1081–2. 40 Seite S, Colige A, Piquemal-Vivenot P, Montastier C, Fourtanier A, Lapiere C, et al. (2000) A full-UV spectrum absorbing daily use cream protects human skin against biological changes occurring in photoaging. Photodermatol Photoimmunol Photomed 16, 147–55. 41 Bowen D. (1998) Sep00/090600/c000573_10_Attachment_F.pdf. 42 Griffiths CE, Kang S, Ellis CN, Kim KJ, Finkel LJ, Ortiz-Ferrer LC, et al. (1995) Two concentrations of topical tretinoin (retinoic acid) cause similar improvement of photoaging but different degrees of irritation: a double-blind, vehicle-controlled comparison of 0.1% and 0.025% tretinoin creams. Arch Dermatol 131, 1037–44. 43 Kang S, Voorhees JJ. (1998) Photoaging therapy with topical tretinoin: an evidence-based analysis. J Am Acad Dermatol 39, S55–61. 44 Griffiths CE, Russman AN, Majmudar G, Singer RS, Hamilton TA, Voorhees JJ. (1993) Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). N Engl J Med 329, 530–5. 45 Kim HJ, Bogdan NJ, D’Agostaro LJ, Gold LI, Bryce GF. (1992) Effect of topical retinoic acids on the levels of collagen mRNA during the repair of UVB-induced dermal damage in the hairless mouse and the possible role of TGF-beta as a mediator. J Invest Dermatol 98, 359–63. 46 Fisher GJ, Talwar HS, Lin J, Lin P, McPhillips F, Wang Z, et al. (1998) Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo. J Clin Invest 101, 1432–40. 47 Lin JY, Selim MA, Shea CR, Grichnik JM, Omar MM, MonteiroRiviere NA, et al. (2003) UV photoprotection by combination topical antioxidants vitamin C and vitamin E. J Am Acad Dermatol 48, 866–74. 48 Huang LC, Clarkin KC, Wahl GM. (1996) Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci U S A 93, 4827–32. 49 Oh JH, Chung AS, Steinbrenner H, Sies H, Brenneisen P. (2004) Thioredoxin secreted upon ultraviolet A irradiation modulates activities of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in human dermal fibroblasts. Arch Biochem Biophys 423, 218–26. 50 Soter N. (1995) Sunburn and suntan: immediate manifestations of photodamage. In: Gilchrest B, ed. Photodamage. Cambridge, MA: Blackwell Science, pp. 12–25. 51 Vink AA, Moodycliffe AM, Shreedhar V, Ullrich SE, Roza L, Yarosh DB, et al. (1997) The inhibition of antigen-presenting activity of dendritic cells resulting from UV irradiation of murine skin is restored by in vitro photorepair of cyclobutane pyrimidine dimers. Proc Natl Acad Sci U S A 94, 5255–60. 52 Toews GB, Bergstresser PR, Streilein JW. (1980) Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB. J Immunol 124, 445–53.


Chapter 3: Self-perceived sensitive skin Olivier de Lacharrière L’Oréal Recherche, Clichy, France

BAS I C CONCE P T S • Sensitive skin is a term used by individuals who perceive their skin as being more intolerant or reactive than the general population. • Sensitive skin is clinically characterized by subjective, sensorial signs: facial discomfort with stinging, burning, and itching. • The clinical signs of sensitive skin appear in specific conditions, provoked by reactivity factors: environmental factors: wind, sun, cold weather, fast changes in temperature; topical factors: hard water, cosmetics; internal factors: life stress, menstruation, or spicy or hot foods.


Clinical features

Sensitive skin is a clinical syndrome, first described in the 1960s by Thiers [1]. A protocol for clinical evaluation of sensitive skin using lactic acid sting testing was first introduced in the 1970s by Frosch and Kligman [2]. Subsequent to that, interest in the field of sensitive skin exploded based on “subjective discomfort, namely, delayed stinging from topical agents applied to the skin.” In spite of the contrary opinion expressed by Maibach et al. [3] at the end of the 1980s, that “the plausibility of the concept of the sensitive skin evokes discussion and often amusem*nt because of the variance of the number of opinions compared with the amount of data, at least until recently,” significant progress has been made on sensitive skin research in recent years. Based on current opinion, sensitive skin is now well accepted as a clinical syndrome. Based on consumer complaints, it is clear that sensitive skin is a term used by individuals who perceive their skin as being more intolerant or reactive than the general population. Consequently, sensitive skin could be defined as a hyperreactive skin, characterized by exaggerated sensorial reaction to environmental or topical factors, including hard water and cosmetics. Consequently, instead of “sensitive skin,” it is better to call this syndrome “self-perceived sensitive skin” (SPSS). In the last decade, some new understanding on the mechanisms of sensitive skin, involving sensitive epidermal nerves has been emphasized [4].

Clinical signs and provocative factor

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


Sensitive skin is clinically characterized by subjective, sensorial signs: facial discomfort with stinging, burning, and itching. SPSS is more frequent in young women, and decreases with age. The clinical signs of sensitive skin appear in specific conditions, provoked by reactivity factors: • Environmental factors: wind, sun, cold weather, fast changes in temperature; • Topical factors: hard water, cosmetics; • Internal factors: life stress, menstruation, or spicy or hot foods.

Clinical subgroups Although the distribution of sensitive skin occurs throughout the population, multivariate analysis shows that several subgroups could be defined [4,5], according to the severity of sensitive skin and to the provocative factors: 1 Severe sensitive skin; 2 Sensitive skin to environment; 3 Sensitive skin to topical factors.

Severe sensitive skin Severe sensitive skin demonstrates very high facial skin reactivity to all kinds of factors: topical, environmental including atmospheric pollution and also internal factors such as stress and tiredness. Severe sensitive skin could present as “crisis phases” occurring for several days or weeks. During these phases, known as “status cosmeticus,” the skin becomes intolerant to all applied products, even products that are usually very well tolerated by the consumer [6].

3. Self-perceived sensitive skin

Sensitive skin to topical factors Around 25% of women have sensitive skin to topical factors. In this subgroup of sensitive skin, the provocative factor is the application of a product on the skin. It is important to underline that the intolerance observed appears immediately or in the minutes following application, sometimes from the first application.

Table 3.1 List of tested allergens on self-perceived sensitive skin and non-self-perceived sensitive skin subjects. (From [4] and [9].) Diazolidinyl urea





Ethylene diamine

Balsam of Peru


Sensitive skin to environmental factors Around 15–20% of women have sensitive skin to environmental factors such as heat, rapid changes in temperature, or wind.

Benzoic acid

Glyceryl monothioglycolate


Ammonium thioglycolate

Parabens mix


Diathesis factors

Ammonium persulfate


In most cases of sensitive skin, the skin hyperreactivity is constitutional. Thiers [1], who was the first to describe this syndrome, has suggested that diathesis features could exist. We also found that a familiar history of sensitive skin exists. Sensitive skin is more frequently found in subjects with fair complexion, and/or redness on the cheekbones [7,8]. Severe dry skin could be as affected as severe oily skin by skin hyperreactivity. Acquired skin hyperreactivity could mimic the signs observed during sensitive skin syndrome. This acquired “sensitive skin,” characterized by a temporary decrease of the threshold of sensorial reactivity of the skin, could be linked to topical irritants improperly applied such as retinoids or hydroxy-acids. In these cases, it is possible that skin that is usually “non-reactive” becomes “reactive” for a period of time. The presence of active facial dermatitis such as seborrheic dermatitis or rosacea could also lower the threshold of skin reactivity. However, although an outbreak of facial atopic dermatitis increases skin reactivity, it is incorrect to consider all sensitive skin as atopic skin.


Fragance mix

Sensitive skin and immuno-allergologic pattern An important point about sensitive skin comes from controversial opinions that exist regarding allergic status [5,7]. To explore this, skin patch test reactivity was studied in 152 female adult volunteers [9]. Eighty-eight declared themselves as having sensitive skin, and 64 as having nonsensitive skin. A series of 44 different topical ingredients known to be potential allergens were applied to the back under Finn Chambers (Table 3.1). The patches were removed after 47 hours and the reactions read after 1 hour and 2 days. For each ingredient, the incidence of positive reactions was compared between the two populations, using the χ2 test. Positive reactions were recorded for 19 out of the 44 tested compounds. No significant difference in the incidence of positive reactions was found between sensitive and non-sensitive skin subjects for any of the patch-tested ingredients. Currently, sensitive skin must not be considered as a syndrome linked to an immuno-allergologic pattern.

Wool alcohols

Diagnosis Provocative tests The diagnosis of SPSS must be based on clinical signs, which are neurosensorial (i.e. subjective). In fact, facial stinging, burning, and itching are clinical signs directly felt by the subject but not seen by the observer. It corresponds to the concept of “invisible dermatoses” [10], as is also the case for all sensorial signs encountered in dermatology (e.g. itching, pain). Pertinent clinical questionnaires are probably the best tools to diagnose this syndrome. Provocative tests could be of help. The lactic acid stinging test was first described by Frosch and Kligman [2,11]. A solution of 10% lactic acid is applied to a nasolabial fold and the provoked stinging feeling is quantified. Generally, the stinging is measured every minute for 5 minutes on a scale from 0 to 3. The lactic acid reaction is compared with the other nasolabial fold where a control solution (saline solution) is applied. The test discriminates between “stingers” and “non-stingers,” but does not affect the discrimination between sensitive skin and non-sensitive skin subjects [12]. In our opinion, the lactic acid stinging test is of interest to assess efficacy of products, but not for diagnostic purposes. Considering the clinical signs linked to SPSS (stinging, burning, itching), we have hypothesized that the main player is the sensitive epidermal nerve, C-fibers [13]. According to this physiologic hypothesis, we have proposed to test the skin reactivity by using capsaicin [14], an irritant compound extracted from red pepper which acts on vanilloid receptors of the nociceptive C-fibres and provokes the release of neuropeptides as substance P and calcitonin generelated peptide (CGRP) [15,16].



Skin Physiology

Capsaicin cream (0.075%) was applied at the angle of the jaw over an area of 4 cm2. The neurosensorial signs (stinging, burning, and itching [SBI]) were assessed at 3, 5, 10, 15 and 20 minutes according to a scale score (0, 1, 2, 3). The sum of the scores gives the global SBI score. The results we obtained on two groups of subjects clearly showed that the sensitive skin subjects’ (n = 64) reactions were significantly higher than the non-sensitive subjects (n = 88) (Figure 3.1). The capsaicin test allows one to discriminate quite well between SPSS subjects and non-SPSS subjects. On the same population sample, we compared the scores obtained with the capsaicin test with those from the lactic acid stinging test. The results are presented in Table 3.2. With capsaicin, the scores showed a better correlation to the SPSS than those recorded with lactic acid. Furthermore, there is a real relationship between the severity of the sensitive skin and the response to the capsaicin test. The higher the severity of SPSS, the higher the capsaicin score.

Sensitive skin and populations Epidemiologic data The prevalence of SPSS is estimated at 51–56% in Europe, USA, and Japan [8,17–20]. Willis et al. [8] published an epidemiologic study in the UK on sensitive skin where 2058 people (up to 18 years of age) were investigated. Of those who reposonded, 51% of the women and 38% of the men declared themselves to have sensitive skin. In the San Francisco area, the reported prevalence of SPSS in four ethnic groups (African-American, Asian, EuroAmerican, and Hispanic Central American) is 52% [19]. No significant difference of prevalence in each group was found: 52% of African-Americans had sensitive skin, 51% of Asians, 50% of Euro-Americans, and 54% of South Americans. Yang et al. [21] studied the sensitive skin in four cities of China: Beijing and Harbin (northern cities), Chengdu and Suzhou (southern cities). Two thousand Chinese women, aged 18–75 years, were included. The global prevalence of sensitive skin was 36%. The prevalence decreases with age (47% at 21–25 years; 20.8% at 51–55 years).

Global discomfort (stinging + burning + itching) 2.5

Clinical features

Mean score


Although the comparison of groups living in San Francisco (African-Americans, Asians, Euro-Americans, and Hispanics) gave the same prevalence of sensitive skin (52%), some differences (10) were observed for factors of skin reactivity and, to a lesser extent, its clinical symptoms. EuroAmericans were characterized by higher skin reactivity to the wind and tended to be less reactive to cosmetics. African-Americans presented less skin reactivity to most environmental factors and a lower frequency of recurring facial redness. Asians appeared to have greater skin reactivity to sudden changes in temperature, to the wind, and also to spicy foods. They tended to experience itching more frequently. In addition, the frequency of skin reactivity to alcoholic beverages was significantly lower in the African-

1.5 1.0 0.5 Sensitive skin (n = 88) Non-sensitive skin (n = 64)

0 0


10 5 Time (minutes)



Figure 3.1 Stinging, burning, and itching (SBI) score with capsaicin test on self-perceived sensitive skin and non-self-perceived sensitive skin subjects. Scores are significantly different at each experimental time (p < 0.01). (From [4] and [14].)

Table 3.2 (a) Stinging and itching scores with capsaicin test according to the different selfassessed level of self-perceived sensitive skin. (From [4].) Non-sensitive (n = 64)

Sensitive (n = 88)





(n = 42)

(n = 39)

(n = 7)


2.6 ± 0.6

3 ± 0.6

4.3 ± 0.6

5 ± 0.6

p < 0.02


0.6 ± 0.4

1.6 ± 0.4

2 ± 0.4

2.9 ± 0.4

p < 0.02


3. Self-perceived sensitive skin

Table 3.2 (b) Stinging scores during lactic acid stinging test according to the different self-assessed level of self-perceived sensitive skin. (From [4].)

skin, suggesting a direct involvement of epidermal sensitive nerves in skin reactivity.

Specific brain activation on sensitive skin subjects Non-sensitive (n = 64)

2 ± 0.3

Sensitive (n = 88)





(n = 42)

(n = 39)

(n = 7)

2 ± 0.2

3.3 ± 0.3

3 ± 0.3

p < 0.001

p < 0.001

p < 0.01

American and Hispanic sensitive groups and higher in the Asian group. In China, Yang et al. [21] have reported that sensitive skin was strongly reactive to environmental factors, but not to cosmetic use. A significantly higher prevalence (55.8%) of sensitive skin was found in Chengdu (Sichuan), where the food is very spicy. By studying the link between chili consumption and sensitive skin prevalence, it has been confirmed that sensitive skin was strongly linked to spicy food intake.

Physiologic mechanisms involved in selfperceived sensitive skin Barrier function and sensitive skin It is currently believed that sensitive skin is linked to the skin barrier alteration which could explain the increase in skin reactivity to physical or chemical factors. In fact, transepidermal water loss (TEWL) has been reported to be increased in subjects with sensitive skin [18]. In addition, an increase in TEWL has also been reported in the “lactic acid stingers” subjects [12]. The alteration of the skin barrier function is certainly involved in the physiology of some patterns of sensitive skin, but it is not unequivocal.

Epidermal sensitive nerves and sensitive skin In the last decade, additional evidence has been discovered implicating the key role for sensitive nerves in the physiologic mechanisms involved in sensitive skin. The neurosensorial signs of the pattern of capsaicin reactivity of sensitive skin suggest a neurogenic origin [14]. Recent data that emphasize the role of C-fibres in the itching process must also be considered [13]. It is observed that there is a decrease with age in the epidermal sensitive nerve density on the face [22]. It should also be noticed that there is a similar decrease in the facial skin reactivity to capsaicin and in the prevalence of sensitive

To investigate the possible involvement of the central nervous system (CNS) in SPSS patterns, we measured cerebral responses to cutaneous provocative tests in sensitive and in non-sensitive skin subjects using functional magnetic resonance imaging (fMRI) [23]. According to their responses to validated clinical questions about their skin reactivity, subjects were divided into two balanced groups: severe SPSS and non-SPSS subjects. Event-related fMRI was used to measure cerebral activation induced by split-face application of lactic acid and of its vehicle (control). In sensitive skin subjects, prefrontal and cingulate activity was significantly higher demonstrating a CNS involvement in sensitive skin physiologic pathways.

Conclusions Sensitive skin is a syndrome observed all over the world. The key clinical features of sensitive skin are neurosensorial signs, mainly provoked by climatic factors, or by topical applications usually well-tolerated on skin. The hypothesis of the neurogenic origin of sensitive skin is becoming more and more predominant. 1 Sensitive skin subjects demonstrate a significantly higher skin hyperreactivity to capsaicin which specifically stimulates the C-fibers. 2 With age, as sensitive skin is decreasing, facial sensitive epidermal nerve density is also decreasing. 3 Spicy food (rich in capsaicin) increases the prevalence of sensitive skin. 4 The results obtained with fMRI show that sensitive skin subjects demonstrate a specific pattern on cerebral activation, with a higher brain activity for sensitive skin subjects in prefrontal and cingulated areas.

References 1 Thiers H. (1986) Peau sensible. In: H. Thiers. Les Cosmétiques, 2nd edn. Paris: Masson, pp. 266–8. 2 Frosch PJ, Kligman AM. (1977) A method of appraising the stinging capacity of topically applied substances. J Soc Cosmet Chem 28, 197–209. 3 Maibach HI, Lammintausta K, Berardesca E, Freeman S. (1989) Tendancy to irritation: sensitive skin. J Am Acad Dermatol 21, 833–5. 4 De Lacharrière O. (2006) Sensitive skin: a neurological perspective. 24th IFSCC, Osaka, October 2006. 5 Francomano M, Bertoni L, Seidenari S. (2000) Sensitive skin as a subclinical expression of contact allergy to nickel sulfate. Contact Dermatitis 42, 169–70. 6 Fisher AA. (1990) Part I: “Status cosmeticus”: a cosmetic intolerance syndrome. Cutis 46, 109–11016.



Skin Physiology

7 De Lacharriere O, Jourdain R, Bastien P, Garrigue JL. (2001) Sensitive skin is not a subclinical expression of contact allergy. Contact Dermatitis 44, 131–2. 8 Willis CM, Shaw S, De Lacharriere O, Baverel M, Reiche L, Jourdain R, et al. (2001) Sensitive skin: an epidemiological study. Br J Dermatol 145, 258–63. 9 Jourdain R, De Lacharrière O, Shaw S, Reiche L, Willis C, Bastien P, et al. (2002) Does allergy to cosmetics explain sensitive skin? Ann Dermatol Venereol 129, 1S11–77. 10 Kligman AM. (1991) The invisible dermatoses. Arch Dermatol 127, 1375–82. 11 Frosch P, Kligman AM. (1996) An improved procedure for conducting lactic acid stinging test on facial skin. J Soc Cosmet Chem 47, 1–11. 12 Seidenari S, Francomano M, Mantovani L. (1998) Baseline biophysical parameters in subjects with sensitive skin. Contact Dermatitis 38, 311–5. 13 Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjörk HE. (1997) Specific C-receptors for itch in human skin. J Neurosci 17, 8003–8. 14 de Lacharrière O, Reiche L, Montastier C, et al. (1997) Skin reaction to capsaicin: a new way for the understanding of sensitive skin. Australas J Dermatol 38(Suppl 2), 288. 15 Magnusson BM, Koskinen LO. (1996) Effects of topical application of capsaicin to human skin: a comparison of effects evaluated by visual assessment, sensation registration, skin blood flow




18 19





and cutaneous impedance measurements. Acta Derm Venereol 76, 29–32. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389, 816–24. Johnson AW, Page DJ. (1995) Making sense of sensitive skin. Proceedings of the 18th IFSCC Congress, Yokohama, Japan 1995. Morizot F, Le Fur I, Tschachler E. (1998) Sensitive skin: definition, prevalence and possible causes. Cosm Toil 113, 59–66. Jourdain R, De Lacharriere O, Bastien P, Maibach HI. (2002) Ethnic variations in self-perceived sensitive skin: epidemiological survey. Contact Dermatitis 46, 162–9. Morizot F, Le Fur I, Numagami K, Guinot C, Lopez S, Tagami H, et al., eds. Self-reported sensitive skin: a study on 120 healthy Japanese women. 22nd IFSCC, Edinburgh, September 2002. Yang FZ, De Lacharriere O, Lian S, Yang ZL, Li L, Zhou W, et al. (2002) Sensitive skin: specific features in Chinese skin: a clinical study on 2,000 Chinese women. Ann Dermatol Venereol 129, 1S11–77. Besne I, Descombes C, Breton L. (2002) Effect of age and anatomical site on density innervation in human epidermis. Arch Dermatol 138, 1445–50. Querleux B, Dauchot K, Jourdain R, Bastien P, Bittoun J, Anton JL, et al. (2008) Neural basis of sensitive skin: an fRMI study. Skin Res Technol 1, 1–8.

Chapter 4: Pigmentation and skin of color Chesahna Kindred and Rebat M. Halder Howard University College of Medicine, Washington, DC, USA

BAS I C CONCEPTS • Differences in the structure, function, and physiology of the hair and skin in individuals of skin of color are important in understanding the structural and physiologic variations that exist and influence disease presentations. • Melanin, the major determinant of skin color, absorbs UV light and blocks free radical generation, protecting the skin from sun damage and aging. • UV irradiation of keratinocytes induces pigmentation by the upregulation of melanogenic enzymes, DNA damage that induces melanogenesis, increased melanosome transfer to keratinocytes, and increased melanocyte dendricity. • Racial differences in hair include the hair type, shape, and bulb.

Introduction The demographics of the USA reflect a dynamic mixture of people of various ethnic and racial groups. Currently, one in three residents in the USA is a person of skin of color [1]. Persons of skin of color include Africans, African-Americans, Afro-Caribbeans, Asians, Latinos (Hispanics), Native Americans, Middle Easterners, and Mediterraneans. The term “black” as in black skin refers to individuals with African ancestry, including Africans, African-Americans, and Afro-Caribbeans. Subgroups exist within each ethnoracial group. The differences in the structure, function, and physiology of the hair and skin in individuals of skin of color are important in understanding the structural and physiologic variations that exist and influence disease presentations. Pigmentation is especially important in patients of skin of color because pigmentary disorder is the most common reason for a visit to a dermatologist in this group [2].

Melanocytes Melanin, the major determinant of skin color, absorbs UV light and blocks free radical generation, protecting the skin from sun damage and aging. Melanocytes, the cells that produce melanin, synthesize melanin in special organelles, melanosomes. Melanin-filled melanosomes are transferred from one melanocyte to 30–35 adjacent keratinocytes in the basal layer [3]. The number of melanocytes also decreases with age. Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

There is more than one type of melanin: eumelanin, a dark brown–black pigment; and pheomelanin, a yellow– reddish pigment. Eumelanin is deposited in ellipsoidal melanosomes which contain a fibrillar internal structure. Synthesis of eumelanin increases after UV exposure (tanning). Pheomelanin has a higher sulfur content than eumelanin because of the sulfur-containing amino acid cysteine. Pheomelanin is synthesized in spherical melanosomes and is associated with microvesicles [4]. Although not obvious to the naked eye, most melanin pigments of the hair, skin and, eyes are combinations of eumelanin and pheomelanin [5]. It is generally believed that genetics determine the constitutive levels of pheomelanin and eumelanin. Eumelanin is more important in determining the degree of pigmentation than pheomelanin. Eumelanin, and not pheomelanin, increases with visual pigmentation [5]. Lighter melanocytes have higher pheomelanin content than dark melanocytes. In one study [5], white persons had the least amount of eumelanin, Asian Indians had more, and AfricanAmericans had the highest. Of note, adult melanocytes contain significantly more pheomelanin than cultured neonatal melanocytes. Melanosomes also differ among different races. In black persons they are mostly in the basal layer, but those of white persons are mostly in the stratum corneum. This is evident in the site of UV filtration: the basal and spinous layers in blacks and the stratum corneum in white persons. Of note, the epidermis of black skin rarely shows atrophied areas [6]. In black skin, melanocytes contain more than 200 melanosomes. The melanosomes are 0.5–0.8 mm in diameter, do not have a limiting membrane, are stuck closely together, and are individually distributed throughout the epidermis. In white skin, the melanocytes contain less than 20 melanosomes. The melanosomes are 0.3–0.5 mm in



Skin Physiology

diameter, associated with a limiting membrane, and distributed in clusters with spaces between them. The melanosomes of lighter skin degrade faster than that of dark skin. As a result, there is less melanin content in the upper layers of the stratum corneum. Thus, the melanocytes in black skin are larger, more active in making melanin, and the melanosomes are packaged, distributed, and broken down differently from in white skin. There is also a difference in melanosomes between individuals within the same race but with varying degrees of pigmentation. Despite greater melanin content in darker skins, there is no evidence of major differences in the number of melanocytes [7]. Also, dark Caucasian skin resembles the melanosome distribution observed in black skin [8]. Black persons with dark skin have large, nonaggregated melanosomes and those with lighter skin have a combination of large non-aggregated and smaller aggregated melanosomes [9]. White persons with darker skin have non-aggregated melanosomes when exposed to sunlight and white persons with lighter skin have aggregated melanosomes when not exposed to sunlight [7,8,10]. The steps of melanogenesis are as follows. The enzyme tyrosinase hydroxylates tyrosine to dihydroxyphenylalanin (DOPA) and oxidizes DOPA to dopaquinone. Dopaquinone then undergoes one of two pathways. If dopaquinone binds to cysteine, the oxidation of cysteinyldopa produces pheomelanin. In the absence of cysteine, dopaquinone spontaneously converts to dopachrome. Dopachrome is then decarboxylated or tautomerized to eventually yield eumelanin. Melanosomal P-protein is involved in the acidification of the melanosome in melanogenesis [11]. Finally, the tyrosinase activity (not simply the amount of the tyrosinase protein) and cysteine concentration determine the eumelanin–pheomelanin content [5]. Tyrosinase and tyrosinase-related proteins 1 and 2 (TRP-1 and TRP-2) are upregulated when α-melanocyte-stimulating hormone (α-MSH) or adrenocorticotropin binds to melanocortin-1 receptor (MC1R), a transmembrane receptor located on melanocytes [11–14]. The MC1R loss-offunction mutation increases sensitivity to UV-induced DNA damage. Gene expression of tyrosinase is similar between black and white persons, but other related genes are expressed differently. The MSH cell surface receptor gene for melanosomal P-protein is expressed differently between races. This gene may regulate tyrosinase, TRP-1, and TRP-2 [5]. In addition to the MC1R, protease-activated receptor 2 (PAR-2) is another important receptor that regulates epidermal cells and affect pigmentation [15]. PAR-2 is expressed on many cells and several different organs. Accordingly, the receptor is involved in several physiologic processes, including growth and development, mitogenesis, injury responses, and cutaneous pigmentation. In the skin, PAR-2 is expressed


in the keratinocytes of the basal, spinous, and granular layers of the epidermis, endothelial cells, hair follicles, myeoepithelial cells of sweat glands, and dermal dendritic-like cells [16,17]. PAR-2 is a seven transmembrane domain G-protein-coupled receptor which undergoes activation via proteolytic cleavage of the NH2 terminus which acts as a tethered ligand which then activates the receptor (autoactivation). PAR-2 activating protease (PAR-2-AP), endothelial cellreleased trypsin, mast cell-released trypsin and chymase, and SLIGKV all irreversibly activate PAR-2 while serine protease inhibitors interferes with the activation of the receptor [18–20]. SLIGKV and trypsin activate PAR-2 to use a Rhodependent signaling pathway to induce melanosomal phagocytosis by keratinocytes. The result is an increase in pigmentation to the same degree as UV radiation [17–21]. Serine proteases are regulatory proteins involved in tumor growth, inflammation, tissue repair, and apoptosis in various tissues [17]. In the skin, serine protease inhibitors prevent the keratinocytes from phagocytosing melanosomes from the presenting dendritic tip of the melanocyte. This leads to a dose-dependent depigmentation without irritation or adverse events. PAR-2 also has a proinflammatory affect in the skin [17]. The activation of PAR-2 expressed on endothelial cells by tryptase, trypsin, or PAR-2-AP leads to an increase in proinflammatory cytokines interleukin 6 (IL-6) and IL-8 and also stimulates NF-κB, an intracellular proinflammatory regulator [18]. Mast cells interact with endothelial cells to regulate inflammatory responses, angiogenesis, and wound healing, and PAR-2 has a regulatory role in this cell–cell interaction [17,18]. UV irradiation of keratinocytes induces pigmentation in several ways: upregulation of melanogenic enzymes, DNA damage that induces melanogenesis, increased melanosome transfer to keratinocytes and increased melanocyte dendricity. UV radiation (UVR) increases the secretion of proteases by keratinocytes in a dose-dependent manner. Specifically, UVR directly increases the expression of PAR-2 de novo, upregulates proteases that activate PAR-2, and activates dermal mast cell degranulation [21]. Data on whether PAR-2 is expressed differently in skin of color compared to white skin are needed. One study did find differences in skin phototypes I, II, and III [21]. UVR increases the expression of PAR-2 in the skin and activated PAR-2 stimulates pigmentation. This study found that the response of PAR-2 to UVR is an important determinant of one’s ability to tan. In the non-irradiated skin, PAR-2 expression was confined to the basal layer and just above the basal layer. Irradiated skin showed de novo PAR-2 expression in the entire epidermis or upper twothirds of the epidermis. Skin phototype I had a delayed upregulation of PAR-2 expression compared to phototypes II and III.

4. Pigmentation and skin of color

Dyspigmentation After cutaneous trauma or inflammation, melanocytes can react with normal, increased, or decreased melanin production; all of which are normal biologic responses. Increased and decreased production results in postinflammatory hyperpigmentation or hypopigmentation. Postinflammatory hyperpigmentation (PIH) is an increase in melanin production and/or an abnormal distribution of melanin resulting from inflammatory cutaneous disorders or irritation from topical medications [22,23]. Examples include acne, allergic contact dermatitis, lichen planus, bullous pemphigoid, herpes zoster, and treatment with topical retinoids. Often, the PIH resulting from acne is more distressing to darker skinned individuals than the initial acute lesion. The color of the hyperpigmentation in PIH depends on the location of the melanin. Melanin in the epidermis appears brown, while melanin in the dermis appears blue-gray. Wood’s lamp examination distinguishes the location of the melanin: the epidermal component is enhanced and the dermal component becomes unapparent [24]. Postinflammatory hypopigmentation shares the same triggers as PIH but instead results from decreased melanin production with clinically apparent light areas [23]. The Wood’s lamp examination does not accentuate hypopigmentation in postinflammatory hypopigmentation; it is useful for depigmented disorders such as vitiligo and piebaldism. The pathogenesis of PIH and postinflammatory hypopigmentation are unknown. It is likely that an inflammatory process in the skin stimulates keratinocytes, melanocytes, and inflammatory cells to release cytokines and inflammatory mediators that lead to the hyperpigmentation or hypopigmentation. The cytokines and inflammatory mediators include leukotriene (LT), prostaglandins (PG), and thromboxane (TXB) [25]. Specifically for PIH, in vitro studies revealed that LT-C4, LT-D4, PG-E2, and TXB-2 stimulate human melanocyte enlargement and dendrocyte proliferation. LT-C4 also increases tyrosinase activity and mitogenic activity of melanocytes. Transforming growth factor-α and LT-C4 stimulate movement of melanocytes. In postinflammatory hypopigmentation, the pathogenesis likely involves inflammatory mediators inducing melanocyte cell-surface expression of intercellular adhesion molecule 1 (ICAM-1) which may lead to leukocyte–melanocyte attachments that inadvertently destroy melanocytes. These inflammatory mediators include interferon-gamma, tumor necrosis factor α (TNF-α), TNF-β, IL-6, and IL-7.

Natural sun protective factor in skin of color It is clear that those who fall within Fitzpatrick skin phototypes IV–VI are less susceptible to photoaging; this is most

likely due to of the photoprotective role of melanin [26,27]. The epidermis of black skin has a protective factor (PF) for UVB of 13.4 and that of white skin is 3.4 [28]. The mean UVB transmission by black epidermis is 5.7% compared to 29.4% for white epidermis. The PF for UVA in black epidermis is 5.7 and in white epidermis is 1.8 [28]. The mean UVA transmission by black epidermis is 17.5% and 55.5% for white epidermis. Hence, 3–4 times more UVA reaches the upper dermis of white persons than that of black persons. The main site of UV filtration in white skin is the stratum corneum, whereas in black skin it is the basal layer [28]. The malphigian layer of black skin removes twice as much UVB radiation as the stratum corneum [29]. It is possible that even greater removal of UVA occurs in black skin basal layers [29]. While the above characteristics of natural sun protective factor were studied in black skin, they can probably be extrapolated to most persons of skin photoypes IV–VI.

Skin of color Epidermis The epidermal layer of skin is made up of five different layers: stratum basale, stratum spinosum, stratum granulosum, stratum lucidum, and stratum corneum. The stratum basale (also termed the basal layer) is the germinative layer of the epidermis. The time required for a cell to transition from the basal layer through the other epidermal layers to the stratum corneum is 24–40 days. The morphology and structure of the epidermis is very similar among different races, although a few differences do exist.

Stratum corneum The stratum corneum, the most superficial layer, is the layer responsible for preventing water loss and providing mechanical protection. The cells of the stratum corneum, the corneocytes, are flat cells measuring 50 μm across and 1 μm thick. The corneocytes are arranged in layers; the number of layers varies with anatomic site and race. There are no differences between races in corneocyte surface area, which has a mean size of 900 μm [2,30]. The stratum corneum of black skin is more compact than that of white skin. While the mean thickness of the stratum corneum is the same in black and white skin, black skin contains 20 cell layers while white skin contains 16. The answer to whether or not there are racial differences in spontaneous desquamation is inconclusive [29–31]. Parameters for skin barrier function (stratum corneum hydration, sebum secretion, erythema, and laser Doppler flowmetry) are similar, even after an objective epicutaneous test with sodium lauryl sulfate [32].



Skin Physiology

Transepidermal water loss Transepidermal water loss (TEWL) is the amount of water vapor loss from the skin, excluding sweat. TEWL increases with the temperature of the skin. Concrete evidence regarding the difference in TEWL between different races has yet to be established. Aside from TEWL, hydration is also a characteristic of skin. One of the ways to measure hydration, or water content, is conductance. Conductance, the opposite of resistance, is increased in hydrated skin because hydrated skin is more sensitive to the electrical field [33]. Skin conductance is higher in black persons and Hispanics than white persons [33]. Lipid content in black skin is higher than that of white skin [34]. However, black skin is more prone to dryness, suggesting that a difference in lipid content has a role. This includes the ratio of ceramide : cholesterol : fatty acids, the type of ceramides, and the type of sphingosine backbone. One study suggests that the degree of pigmentation influences lipid differences [35]. Pigmentation affects skin dryness. Skin dryness is greater on sun-exposed (dorsal arm) sites for lighter skin, such as Caucasian and Chinese skin, than sites that are primarily out of the sun (ventral arm) [36]. There is no difference in skin dryness between sites for darker skin, such as AfricanAmericans and Mexicans. For adults less than 51 years of age, skin dryness does not change as a function of ethnicity (African-American, Caucasian, Chinese, and Mexican) for sun-exposed sites and sites that are not primarily sunexposed. For those 51 years of age and older, skin dryness is higher for African-Americans and Caucasians than for Chinese and Mexicans. As a function of age, skin dryness in African-American skin increases 4% on the dorsal site and 3% on the ventral site; in Caucasian skin, it increases 11% on the dorsal site and 10% on the ventral site. All of the above findings suggest that sun exposure can dry the skin and that melanin provides protection.

Skin reactivity Mast cells Sueki et al. [37] studied the mast cells of four AfricanAmerican men and four white men (mean age 29 years) by evaluating punch biopsies of the buttocks with electron microscopy, with the following results. The mast cells of black skin contained larger granules (the authors attributed this to the fusion of granules). Black skin also had 15% more parallel-linear striations and 30% less curved lamellae in mast cells. Tryptase reactivity was localized preferentially over the parallel-linear striations and partially over the dark amorphous subregions within granules of mast cells from black skin, whereas it was confined to the peripheral area of granules, including curved lamellae, in white skin. Cathepsin G reactivity was more intense over the electrondense amorphous areas in both groups, while parallel-linear striations in black skin and curved lamellae in white skin were negative.


Patch test antigens Contact dermatit* Irritant contact dermatitis (ICD) is the most common form of dermatitis and loosely defined as non-specific damage to the skin after exposure to an irritant. The various clinical manifestations are influenced by the concentration of chemicals, duration of exposure, temperature, humidity, and anatomic location, and other factors. Acute contact dermatitis presents with the classic findings of localized superficial erythema, edema, and chemosis. Cumulative contact dermatitis presents with similar findings, but with repeated exposure of a less potent irritant [38]. The susceptibility to ICD differs between black and white skin [39]. The structural differences in stratum corneum of black skin (e.g. compact stratum corneum, low ceramide levels) are credited with decreasing the susceptibility to irritants. Reflectance confocal microscopy (RCM) is an imaging tool that permits real-time qualitative and quantitative study of human skin; when used with a near-infrared laser beam, one can create “virtual sections” of live tissue with high resolution, almost comparable with routine histology. Measuring skin reactivity to chemical irritants with RCM and TEWL reveal that white skin had more severe clinical reactions than black skin. The pigmentation in darker skin can make the assessment of erythema difficult and interfere with identification of subclinical degrees of irritancy. Even without clinical evidence of irritation, RCM and histology reveal parakeratosis, spongiosis, perivascular inflammatory infiltrate, and microvesicle formation. Mean TEWL after exposure to irritants is greater for white skin than for black skin. This supports the concept that the stratum corneum of black skin enhances barrier function and resistance to irritants. There are no differences between white persons and African-Americans in objective and subjective parameters of skin such as dryness, inflammation, overall irritation, burning, stinging, and itching [40]. Acute contact dermatitis with exudation, vesiculation, or frank bullae formation is a more common reaction in white skin whereas dyspigmentation and lichenification is more common in black skin [41]. The response to irritation in Caucasian and AfricanAmerican skin differs in the degree of severity. Caucasian skin has a lower threshold for cutaneous irritation than African-American skin [42]. Caucasian skin also has more severe stratum corneum disruption, parakeratosis, and detached corneocytes. Both groups have the same degree of intra-epidermal spongiosis epidermal (granular and spinous layer) vesicle formation. The variability in human skin irritation responses sometimes creates difficulty in assessing the differences in skin reactivity between human subpopulations. There are conflicting results in studies comparing the sensitivity to irritants in Asian skin with that in Caucasian skin [32,43–46].

4. Pigmentation and skin of color

Dermis The dermis lies deep to the epidermis and is divided into two layers: the papillary and reticular dermis. The papillary dermis is tightly connected to the epidermis via the basem*nt membrane at the dermoepidermal junction. The papillary dermis extends into the epidermis with finger-like projections, hence the name “papillary.” The reticular dermis is a relatively avascular, dense, collagenous structure that also contains elastic tissue and glycosaminoglycans. The dermis is made up of collagen fibers, elastic fibers, and an interfibrillar gel of glycosaminoglycans, salt, and water. Collagen makes up 77% of the fat-free dry weight of skin and provides tensile strength. Collagen types I, II, V, and VI are found in the dermis. The elastic fiber network is interwoven between the collagen bundles. There are differences between the dermis of white and black skin. The dermis of white skin is thinner and less compact than that of black skin [47]. In white skin, the papillary and reticular layers of the dermis are more distinct, contain larger collagen fiber bundles, and the fiber fragments are sparse. The dermis of black skin contains closely stacked, smaller collagen fiber bundles with a surrounding ground substance. The fiber fragments are more prominent in black skin than in white skin. While the quantity is similar in both black and white skin, the size of melanophages is larger in black skin. Also, the number of fibroblasts and lymphatic vessels are greater in black skin. The fibroblasts are larger, have more biosynthetic organelles, and are more multinucleated in black skin [6]. The lymphatic vessels are dilated and empty with surrounding elastic fibers [47]. No racial differences in the epidermal nerve fiber network have been observed using laser-scanning confocal microscopy, suggesting that there is no difference in sensory perception between races, as suggested by capsaicin response to C-fiber activation [48]. Skin extensibility is how stretchable the skin is. Elastic recovery is the time required for the skin to return to its

original state after releasing the stretched skin. Skin elasticity is elastic recovery divided by extensibility. Studies that investigated skin extensibility, elastic recovery, and skin elasticity between races yield conflicting results [31,49]. It is likely that elastic recovery and extensibility vary by anatomic site, race, and age.

Intrinsic skin aging in ethnic skin The majority of literature regarding facial aging features Caucasian patients. Facial aging is result of the combination of photodamage, fat atrophy, gravitational soft tissue redistribution, and bone remodeling. Figure 4.1 demonstrates the morphologic changes of the face caused by aging. The onset of morphologic aging appears in the upper face during the thirties and gradually progresses to the lower face and neck over the next several decades [50]. Early signs of facial aging occur in the periorbital region. In the late thirties, brow ptosis, upper eyelid skin laxity, and descent of the lateral portion of the eyebrow (“hooding”) lead to excess skin of the upper eyelids. During the midforties, “bags” under the eyes result from weakening of the inferior orbital septum and prolapse of the underlying intraorbital fat. Lower eyelid fat prolapse may occur as early as the second decade in those with a familial predisposition. Photodamage produces periocular and brow rhytides [50]. Brow ptosis in African-Americans appears to occur to a lesser degree and in the forties opposed to the thirties compared to that in whites [51]. Prolapse of the lacrimal gland may masquerade as lateral upper eyelid fullness in AfricanAmericans [52]. For Hispanics, the brow facial soft tissues sag at an earlier age [53]. In Asians, the descent of thick juxtabrow tissues in the lateral orbit coupled with the absences of a supratarsal fold may create a prematurely tired eye [50]. The midface show signs of aging during the forties. The malar soft tissue adjacent to the inferior orbital rim descends, accumulating as fullness along the nasolabial fold. The malar

Facial expression lines

Figure 4.1 Morphologic signs of aging. (Adapted from figure by Cindy Luu. From Harris MO. (2006) Intrinsic skin aging in pigmented races. In: Halder RM, ed. Dermatology and Dermatological Therapy of Pigmented Skins. Taylor & Francis Group, pp. 197–209.)

High brow

Low brow

Prominent upper eyelid crease

Excess upper eyelid skin

Full lips

Prominent fat pockets Lower lid hollowing ‘dark circles’ Low cheek Prominent nasolabial fold

Smooth jawline


High protuberant cheek Soft nasolabial fold

Fat accumulation



Skin Physiology

soft tissue atrophy and ptosis result in periorbital hollowing and tear trough deformity. Early aging is evident in individuals of African, Asian, and Hispanic origin in the midface region more so than the upper or lower regions. Signs include tear trough deformity, infraorbital hollowing, malar fat ptosis, nasojugal groove prominence, and deepening of the nasolabial fold. This predisposition to midface aging is likely the result of the relationship of the eyes to the infraorbital rim, basic midface skeletal morphology, and skin thickness [50]. The soft tissue of the lower face is supported in a youthful anatomic position by a series of retaining ligaments within the superficial musculo-aponeurotic system (SMAS) [54]. The SMAS is a discrete fascial layer that envolps the face and forms the basis for resuspending sagging facial tissues [14]. The SMAS fascia envelope maintains tension on facial muscles and offsets soft tissue sagging. In the late thirties, gradual ptosis of the SMAS and skin elastosis sets the stage for jowl formation. Accumulation of submandibular fat and a sagging submandibular gland may have a role in interrupting the smooth contour of a youthful jaw line. Changes in the lower face lead to changes in the neck because the SMAS is anatomically continuous with the platysma muscle. Sagging of the SMAS–platysma unit and submandibular fat redistribution gradually blunts the junction between the jaw and neck. A “double chin” appears at any age as a result of cervicomental laxity with excess submental fat deposits. During the fifties, diastasis and hypertrophy of the anterior edge of the platysma muscle may produce vertical banding in the cervicomental area. During the sixth, seventh, and eighth decades, progressive soft tissue atrophy and bony remodeling of the maxilla and mandible create a relative excess of sagging skin, further exaggerating facial aging. Jowling is a sign of lower facial aging in black persons [50]. In some cases, a bony chin underprojection make create excess localized submental fatty deposits despite a smoothly contoured jaw line. However, in Asians, jowl formation may result from fat accumulation in the buccal space [50]. The “double chin” is more common in Caucasians under 40 years of age than Asians of the same age group, but more common in Asians over 40 years of age because of redundant cervical skin [55].

Extrinsic aging (photoaging) of ethnic skin Sunlight is a major factor for the appearance of premature aging, independent of facial wrinkling, skin color, and skin elasticity. By the late forties, individuals with greater sun exposure appear older than those with less sun exposure. However, the perceived age of individuals in their late twenties is unaffected by sun exposure. Solar exposure greatly increases the total wrinkle length by the late forties. The extent of dermal degenerative change seen by the late forties correlates with premature aging. There is a high correlation between perceived age and facial wrinkles; perceived age


and elastosis; and perceived age and the quantity of collagen. The grenz zone is a subepidermal band of normal dermis consisting of normal collagen fibers and thought to be a site of continual dermal repair. The grenz zone becomes visually apparent only after there is sufficient elastotic damage. With progressive elastosis, the grenz zone beomces thinner [56].

Histopathology Epidermis The absolute number of Langerhans cells vary from person to person but chronic sun exposure decreases their number or depletes them [57]. The severely sun-damaged skin has many vacuolated cells in the spinous layer, excessively vacuolated basal keratinocytes and melnanocytes, cellular atypia, and loss of cellular polarity. Apoptosis in the basal layer is increased. A faulty stratum lucidum and horny layer result from intracellur vesicles in the cells of the basal and spinous layers (sunburn cells), apoptosis, and dyskeratosis. There is focal necrobiosis in the epidermis and dermis in sun-exposed skin. While histologic findings of photoaging in white sunexposed skin include a distorted, swollen, and distinctly cellular stratum lucidum, the stratum lucidum of AfricanAmerican sun-exposed skin remains compact and unaltered [6]. The stratum lucidum in black skin is not altered by sunlight exposure [6]. With age, the dermoepidermal junction becomes flattened with multiple zones of basal lamina and anchoring fibril reduplication. Microfibrils in the papillary dermis become more irregularly oriented. Compact elastic fibers show cystic changes and separation of skeleton fibers with age. The area occupied by the superficial vascular plexus in specimens of equal epidermal surface length decreases from the infant to young adult (21–29 years) to adult (39–52 years) age groups, then increased in the elderly adult (73–75 years) age group [58]. With the exception of the vascularity in the elderly adult group, the above features are similar to those seen in aging white skin, and suggest that chronologic aging in white and black skin is similar. Oxytalan fibers are found in the papillary dermis of sun-exposed skin of white individuals in their twenties and early thirties but disappear in the forties. In black skin, the oxytalan fibers are still found in the dermis of individuals in their fifties. No solar elastosis is seen in specimens of black sun-exposed skin. Older black subjects have an increased number and thickness of elastic fibers that separate the collagenous fiber layer in the reticular dermis. The single-stranded elastic fibers in individuals 50 years of age. Finally, the sun-exposed skin of a 45-year-old lightcomplexioned black female shared the same amount and distribution of elastic fibers as those in white sun-exposed skin [6]. The grenz zone consists of small fibers oriented horizontally and replaces the papillary dermis. When elastotic mate-

4. Pigmentation and skin of color rial accumulates in the dermis, it crowds out all the collagenous fibers, which are resorbed. As the elastic material is resorbed, wisps of collagenous fibers form in its place. Widely spaced, larger collagenous fiber bundles lie between the waning elastotic masses. The total volume of the dermis gradually diminishes as the spaces between the remaining collagenous and elastic fibers are reduced. When the epidermis rests directly on top of the horizontally oriented, medium-sized collagenous fiber bundles of the intermediate dermis, the dermis lacks a papillary and grenz zone and the dermis cannot sufficiently support the epidermis. As a result, the shrinking dermis crinkles and small wrinkles form. This may be the reason for the absence of a structural basis in secondary wrinkles and may explain why wrinkles flatten out when fluids are injected into the skin or when edema occurs [57]. Photoaging in skin of color has variable presentations. Wrinkling is not as common a manifestation of photoaging in black persons, South Asians, or darker complexioned Hispanics as in white persons because of the photoprotective effects of melanin. All racial groups are eventually subjected to photoaging. Within most racial groups, the lighter complexioned individuals show evidence of photodamaged skin. Caucasian skin has an earlier onset and greater skin wrinkling and sagging signs than darker skin types. Visual photoaging assessments reveal that white skin has more severe fine lines, rhytides, laxity, and overall photodamage than African-American skin [41]. Photoaging is uncommon in black persons but is more often seen in African-Americans than in Africans or AfroCaribbeans. The reason may be the heterogeneous mixture of African, Caucasian, and Native American ancestry often seen in African-Americans. In African-Americans, photoaging appears primarily in lighter complexioned individuals and may not be apparent until the late fifth or sixth decades of life [59]. Photoaging in this group appears as fine wrinkling and mottled pigmentation. In spite of the photoprotective effects of melanin, persons of skin of color are still prone to photoaging, but the reason is not completely known. Infrared radiation may also contribute to photodamage. There is evidence that chronic exposure to natural or artificial heat sources can lead to histologic changes resembling that of UV-induced changes, such as elastosis and carcinoma [60]. The pigmentary manifestations of photoaging common in skin of color include seborrheic keratoses, actinic lentigi-

nes, mottled hyperpigmentation, and solar-induced facial melasma [61]. However, African-American skin has greater dyspigmentation, with increased hyperpigmentation and uneveness of skin tone [40].

Hair There are two types of hair fibers: terminal and vellus. Terminal hair is found on the scalp and trunk. Vellus hair is fine and shorter and softer than terminal hair. The hair fiber grows from the epithelial follicle, which is an invagin*tion of the epidermis from which the hair shaft develops via mitotic activity and into which sebaceous glands open. The hair follicle is one of the most proliferative cell types in the body and undergoes growth cycles. The cycles include anagen (active growth), catagen (regression), and telogen (rest). Each follicle follows a growth pattern independent of the rest. The hair follicle is lined by a cellular inner and outer root sheath of epidermal origin and is invested with a fibrous sheath derived from the dermis. Each hair fiber is made up of an outer cortex and a central medulla. Enclosing the hair shaft is a layer of overlapping keratinized scales, the hair cuticle that serves as protective layers. Racial differences in hair include the hair type, shape, and bulb. There are four types of hair: helical, spiral, straight, and wavy. The spectrum of curliness is displayed in Figure 4.2. The vast majority of black persons have spiral hair [62]. The hair of black persons are naturally more brittle and more susceptible to breakage and spontaneous knotting than that of white persons. The kinky form of black hair, the weak intercellular cohesion between cortical cells, and the specific hair grooming practices among black persons account for the accentuation of these findings [62]. The shape of the hair is different between races: black hair has an elliptical shape, Asian hair is round-shaped straight hair, and Caucasian hair is intermediate [63,64]. The bulb determines the shape of the hair shaft, indicating a genetic difference in hair follicle structure [30]. The cross-section of black hair has a longer major axis, a flattened elliptical shape, and curved follicles. Asian hair has the largest cross-sectional area and Western European hair has the smallest [64,65]. Black persons have fewer elastic fibers anchoring the hair follicles to the dermis than white subjects. Melanosomes were in the outer root sheath and in the bulb of vellus hairs in black, but not in

Figure 4.2 The spectrum of curliness in human hair. (This figure was published in: Loussouarn G, Garcel A, Lozano I, Collaudin C, Porter Crystal, Panhard S, et al. (2007) Worldwide diversity of hair curliness: a new method of assessment. Int J Dermatol 46 (Suppl 1), 2–6.)



Skin Physiology is completely straight and the Caucasian hair form is intermediate [65]. Mesocortical, orthocortical, and paracortical cells are the three cell types in the hair cortex. In straight hair, mesocortical cells predominate [66]. In wavy hair, the orthocortical and mesocortical cells are interlaced around paracortical cells. In tightly curled hair, the mesocortex disappears, making orthocortical cells the majority. Distinct cortical cells express the acidic hair keratin hHa8. Figure 4.3 displays the distribution of hHa8 cells in straight, wavy, and tightly curled hair. Straight hair has a patchy but hom*oge-

white persons. Black hair also has more pigment and on microscopy has larger melanin granules than hair from light-skinned and Asian individuals. Similarities between white and black hair include: cuticle thickness, scale size and shape, and cortical cells [65]. While the curly nature of black hair is believed to result from the shape of the hair follicle [65], new research shows that the curliness of hair correlates with the distribution of cortical cells independent of ethnoracial origin [66]. Black hair follicles have a helical form, whereas the Asian follicle








Figure 4.3 hHa8 hair keratin distribution in hair follicles. hHa8 pattern in (a) straight, (b) wavy, and (c) curly hair longitudinal sections. hHa8 pattern in (d) straight and (e) curly hair cross-sections. (From Thibaut et al. (2007) Human hair keratin network and curvature. Int J Dermatol 46 (Suppl 1), 7–10.)


4. Pigmentation and skin of color nous pattern of positively charged hHa8 cells surrounding a core of negatively charged cells. As the degree of curl decreases, the hHa8 pattern becomes asymmetric, independent of ethnic origin. In tightly curled hair, hHa8 accumulates on the concave side of the hair fiber and the medulla compartment disappears. There are no differences in keratin types between hair from different races and no differences in amino acid composition of hair from different races [67]. Among Caucasian, Asian, and Africans, there are no differences in the intimate structures of fibers, whereas geometry, mechanical properties, and water swelling differed according to ethnic origin [68]. One study [69] in 1941 did find variation in the levels of some amino acids between black and white hair. Black subjects had significantly greater levels of tyrosine, phenylalanine, and ammonia in the hair, but were deficient in serine and threonine. The morphologic features of African hair were examined using the transmission and scanning electron microscopic (SEM) techniques in an unpublished study. The cuticle cells of African hair were compared with those of Caucasian hair. Two different electronic density layers were shown. The denser exocuticle is derived from the aggregation of protein granules that first appear when the scale cells leave the bulb region. The endocuticle is derived from the zone that contains the nucleus and cellular organites. The cuticle of Caucasian hair is usually 6–8 layers thick and constant in the hair perimeter, covering the entire length of each fiber. However, black hair has variable thickness; the ends of the minor axis of fibers are 6–8 layers thick, and the thickness diminishes to 1–2 layers at the ends of the major axis. The weakened endocuticle is subject to numerous fractures (Handjur C, Fiat, Huart M, Tang D, Leory F, unpublished data).

References 1 US Census Bureau. (2008) Older and More Diverse Nation by Midcentury. US Census Bureau News. August 14, 2008 online at: archives/population/010048.html. Accessed November 12, 2008. 2 Halder RM, Nandedkar MA, Neal KW. (2003) Pigmentary disorders in ethnic skin. Dermatol Clin 21, 617–28. 3 Fitzpatrick TB, Szabo G. (1959) The melanocytes: cytology and cytochemistry. J Invest Dermatol 32, 197–209. 4 Jimbow K, Oikawa O, Sugiyama S, Takeuchi T. (1979) Comparison of eumelanogenesis and pheomelanogenesis in retinal and follicular melanocytes: role of vesiculo-globular bodies in melanosome differentiation. J Invest Dermatol 73, 278–84. 5 Wakamatsu K, Kavanagh R, Kadekaro AL, Terzieva S, Sturm RA, Leachman S, et al. (2006) Diversity of pigmentation in cultured human melanocytes is due to differences in the type as well as quantity of melanin. Pigment Cell Res 19, 154–62.

6 Montagna W, Carlisle K. (1991) The architecture of black and white facial skin. J Am Acad Dermatol 24, 929–37. 7 Taylor SC. (2002) Skin of color; biology, structure, function, implications for dermatologic disease. J Am Acad Dermatol 46, S41–62. 8 Toda K, Fatnak MK, Parrish A, Fitzpatrick TB. (1972) Alteration of racial differences in melanosome distribution in human epidermis after exporsure to ultraviolet light. Nat New Biol 236, 143–4. 9 Olson RL, Gaylor J, Evertt MA. (1973) Skin color, melanin, and erythema. Arch Dermatol 108, 541–4. 10 Jimbow M, Jimbow K. (1989) Pigmentary disorders in Oriental skin. Clin Dermatol 7, 11–27. 11 Abdel-Malek Z, Swope VB, Suzuki I, Akcali C, Harriger MD, Boyce ST, et al. (1995) Mitogenic and melanogenic stimulation of normal human melanocytes by melanotropic peptides. Proc Natl Acad Sci U S A 92, 1789–93. 12 Sturm RA, Teasdale RD, Box NF. (2001) Human pigmentation genes: identification, structure and consequences of pylymorphic variation. Gene 277, 49–62. 13 Rees JL. (2003) Genetics of hair and skin color. Annu Rev Genet 37, 67–90. 14 Suzuki I, Cone RD, Im S, Nordlund J, Abdel-Malek ZA. (1996) Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology 137, 1627–33. 15 Hou L, Kapas S, Cruchley AT, Macey MG, Harriott P, Chinni C, et al. (1998) Immunolocalization of protease-activated receptor-2 in skin: receptor activation stimulates interleukin-8 secretion by keratinocytes in vitro. Immunology 94, 356–62. 16 Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer Gisela, Skov PS, et al. (2003) Proteinase-activated receptor-1 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 23, 6176–80. 17 Shpacovitch VM, Brzoska T, Buddenkotte J, Stroh C, Sommerhoff CP, Ansel JC, et al. (2002) Agonists of proteinase-activated receptor 2 induce cytokine release and activation of nuclear transcription factor κB in human dermal microvascular endothelial cells. J Invest Dermtol 118, 380–5. 18 Seiberg M, Paine C, Sharlow E, Andrade-Gordon P, Constanzo M, Eisinger M, et al. (2000) Inhibition of melanosome transfer results in skin lightening. J Invest Dermatol 115, 162–7. 19 Nystedt S, Ramakrishnan V, Sundelin J. (1996) The proteinaseactivated receptor 2 is induced by inflammatory mediators in human endothelial cells: comparison with the thrombin receptor. J Biol Chem 271, 14910–5. 20 Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, et al. (1996) Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J 314, 1009–16. 21 Scott G, Deng A, Rodriguez-Burford C, Seiberg M, Han R, Babiarz L, et al. (2001) Protease-activated receptor 2, a receptor involved in melanosome transfer, is upregulated in human skin by ultraviolet irradiation. J Invest Dermatol 117, 1412–20. 22 Gilchrest BA. (1977) Localization of melanin pigmentation in skin with Wood’s lamp. Br J Dermatol 96, 245–7. 23 Morelli JG, Norris DA. (1993) Influence of inflammatory mediators and cytokines on human melanocyte function (Review). J Invest Dermatol 100 (2 Suppl), 191S–5S.



Skin Physiology

24 Grover R, Morgan BDG. (1996) Management of hypopigmentation following burn injury. Burns 22, 727–30. 25 Johnston GA, Svukabd KS, McLelland J. (1998) Melasma of the arms associated with hormone replacement therapy (letter). Br J Dermatol 139, 932. 26 Pathak MA, Fitzpatrick TB. (1974) The role of natural photoprotective agents in human skin. In: Fitzpatrick TB, Pathak MA, Harber LC, Seiji M, Kukita A, eds. Sunlight and Man. Tokyo: University of Tokyo Press, pp. 725–50. 27 Kligman AM. (1974) Solar elastosis in relation to pigmentation. In: Fitzpatrick TB, Pathak MA, Harber LC, Seiji M, Kukita A, eds. Sunlight and Man. Tokyo: University of Tokyo Press, pp. 157–63. 28 Kaidbey KH, Agin PP, Sayre RM, Kligman AM. (1979) Photoprotection by melanin: a comparison of black and Caucasian skin. J Am Acad Dermatol 1, 249–60. 29 Manuskiatti W, Schwindt DA, Maibach HI. (1998) Influence of age, anatomic site and race on skin roughness and scaliness. Dermatology 196, 401–7. 30 Courcuff P, Lotte C, Rougier A, Maibach HI. (1991) Racial differences in corneocytes: a comparison between black, white, and Oriental skin. Acta Dermatol Venereol 71, 146–8. 31 Warrier AG, Kligman AM, Harper RA, Bowman J, Wickett RR. (1996) A comparison of black and white skin using noninvasive methods. J Soc Cosmet Chem 47, 229–40. 32 Aramaki J, Kawana S, Effendy I, Happle R, Löffler H. (2002) Differences of skin irritation between Japanse and European women. Br J Dermatol 146, 1052–6. 33 Triebskorn A, Gloor M. (1993) Noninvasive methods for the determination of skin hydration. In: Forsch PJ, Kligman AM, eds. Noninvasive Methods for the Quantification of Skin Functions. Berlin; New York (NY): Springer-Verlag, pp. 42–55. 34 La Ruche G, Cesarini JP. (1992) Histology and physiology of black skin. Ann Dermatovenereologica 119, 567–74. 35 Reed JT, Ghadially R, Elias MM. (1995) Skin type but neither race nor gender, influence epidermal permeability barrier function. Arch Dermatol 131, 1134–8. 36 Diridollou S, de Rigal J, Querleux B, Leroy F, Holloway Barbosa V. (2007) Comparative study of the hydration of the stratum corneum between four ethnic groups: influence of age. Int J Dermatol 46 (Suppl 1), 11–4. 37 Sueki H, Whitaker-Menezes D, Kligman AM. (2001) Structural diversity of mast cell granules in black and white skin. Br J Dermatol 144, 85–93. 38 Modjtahedi SP, Maibach HI. (2002) Ethnicity as a possible endogenous factor in irritant contact dermatitis: comparing the irritant response amoung Caucasians, blacks, and Asians. Contact Dermatitis 47, 272–8. 39 Hicks SP, Swindells KJ, Middelkamp-Hup MA, Sifakis MA, González E, González S. (2003) Confocal histopathology of irritant contact dermatitis in vivo and the impact of skin color (black vs white). J Am Acad Dermatol 48, 727–34. 40 Grimes P, Edison BL, Green BA, Wildnauer RH. (2004) Evaluation of inherent differences between african american and white skin surface properties using subjective and objective measures. Cutis 73, 392–6. 41 Berardesca F, Maibach H. (1996) Racial differences in skin pathophysiology. J Am Acad Dermatol 34, 667–72.


42 Galindo, GR, Mayer JA, Slymen D, Almaguer DD, Clapp E, et al. (2007) Sun sensitivity in 5 US ethnoracial groups. Cutis 80, 25–30. 43 Robinson MK. (2002) Population differences in acute skin irritation responses. Race, sex, age, sensitive skin and repeart subject comparisons. Contact Dermatitis 46, 86–93. 44 Foy V, Weinkauf R, Whittle E, Basketter DA. (2001) Ethnic variation in the skin irritation response. Contact Dermatitis 45, 346–9. 45 Robinson MK. (2000) Racial differences in acute and cumulative skin irritation responses between Caucasian and Asian populations. Contact Dermatitis 42, 134–43. 46 Tadaki T, Watanabe M, Kumasaka K, Tanita Y, Kato T, Tagami H, et al. (1993) The effect of tretinoin on the photodamaged skin of the Japanese. Tohoku J Exp Med 169, 131–9. 47 Montagna W, Giusseppe P, Kenney JA. (1993) The structure of black skin. In: Montagna W, Giusseppe P, Kenney JA, eds. Black Skin Structure and Function. Academic Press, pp. 37–49. 48 Reilly DM, Ferdinando D, Johnston C, Shaw C, Buchanan KD, Green MR. (1997) The epidermal nerve fiber network: characterization of nerve fibers in human skin by confocal microscopy and assessment of racial variations. Br J Dermatol 137, 163–70. 49 Berardesca E, Rigal J, Leveque JL, et al. (1991) In vivo biophysical characterization of skin physiological differences in races. Dermatologica 182, 89–93. 50 Harris MO. (2006) Intrinsic skin aging in pigmented races. In: Halder RM, ed. Dermatology and Dermatological Therapy of Pigmented Skins. Taylor & Francis Group, pp. 197–209. 51 Matory WE. (1998) Aging in people of color. In: Matory WE, ed. Ethnic Considerations in Facial Aesthetic Surgery. Philadelphia: Lippincott-Raven, 151–70. 52 Bosniak SL, Zillkha MC. (1999) Cosmetic Blepharoplasty and Facial Rejuvenation. New York: Lippincott-Raven. 53 Ramirez OM. (1998) Facial surgery in the Hispano-American patient. In: Matory WE, ed. Ethnic Considerations in Facial Aesthetic Surgery. Philadelphia: Lippincott-Raven, pp. 307–20. 54 Stuzin JM, Baker TJ, Gordon HL. (1992) The relationship of the superficial and deep facial fascias: relevance to rhytidectomy and aging. Plast Reconstr Surg 89, 441–9. 55 Shirakable Y. (1988) The Oriental aging face: an evaluation of adecade of experience with the triangular SMAS flap technique. Aesthetic Plast Surg 12, 25–32. 56 Warren R, Garstein V, Kligman AM, Montagna W, Allendorf RA, Ridder GM. (1991) Age, sunlight, and facial skin: a histologic and quantitative study. J Am Acad Dermatol 25, 751–60. 57 Montagna W, Kirchner S, Carlisle K. (1989) Histology of sundamaged human skin. J Am Acad Dermatol 12, 907–18. 58 Herzberg AJ, Dinehart SM. (1989) Chronologic aging in black skin. Am J Dermatopathol 11, 319–28. 59 Halder RM. (1998) The role of retinoids in the management of cutaneous conditions in blacks. J Am Acad Dermatol 39 (Part 3), S98–103. 60 Kligman LH. (1982) Intensification of ultraviolet-induced dermal damage by infrared radiation. Arch Dermatol 272, 229–38. 61 Halder RM, Richards GM. (2006) Photoaging in pigmented skins. In: Halder RM, ed. Dermatology and Dermatological Therapy of Pigmented Skins. Taylor & Francis Group, pp. 211–20.

4. Pigmentation and skin of color 62 Halder RM. (1983) Hair and scalp disorders in blacks. Cutis 32, 378–80. 63 Bernard BA. (2003) Hair shape of curly hair. J Am Acad Dermatol 48 (6 Suppl), S120–6. 64 Vernall DO. (1961) Study of the size and shape of hair from four races of men. Am J Phys Anthropol 19, 345. 65 Brooks O, Lewis A. (1983) Treatment regimens for “styled” black hair. Cosmet Toiletries 98, 59–68. 66 Thibaut S, Barbarat P, Leroy F, Bernard BA. (2007) Human hair keratin network and curvature. Int J Dermatol 46 (Suppl 1), 7–10.

67 Gold RJ, Scriver CG. (1971) The amino acid composition of hair from different racial origins. Clin Chim Acta 33, 465–6. 68 Franbourg A, Hallegot P, Baltenneck F, Toutain C, Leroy F. (2003) Current research on ethnic hair. J Am Acad Dermatol 48 (6 Suppl), S115–9. 69 Menkart J, Wolfram L, Mao I. (1966) Causacian hair, Negro hair and wool: similarities and differences. J Soc Cosmet Chem 17, 769–87.


Chapter 5: Sensitive skin and the somatosensory system Francis McGlone1 and David Reilly2 1 2

Perception and Behaviour Group, Unilever Research & Development, Wirral, UK One Discover, Colworth Park, Sharnbrook, Bedford, UK

BAS I C CONCE P T S • The primary sensory modality subserving the body senses is collectively described as the somatosensory system, and comprises all those peripheral afferent nerve fibers, and specialized receptors, subserving cutaneous, and proprioceptive sensitivity. • Individuals with sensitive skin demonstrate heightened reactivity of the somatosensory system. • A separate set of neurons mediates itch and pain. The afferent neurons responsible for histamine-induced itch in humans are unmyelinated C-fibers. • Low threshold mechanoreceptors are responsible for the sensation of touch, a wide range of receptor systems code for temperature, and as the skin’s integrity is critical for survival, there are an even larger number of sensory receptors and nerves that warn us of damage to the skin – the pain and itch systems.

Introduction The primary sensory modality subserving the body senses is collectively described as the somatosensory system, and comprises all those peripheral afferent nerve fibers, and specialized receptors, subserving cutaneous and proprioceptive sensitivity. The latter processes information about limb position and muscle forces which the central nervous system uses to monitor and control limb movements and, via elegant feedback and feedforward mechanisms, ensure that a planned action or movement is executed fluently. This chapter focuses on sensory inputs arising from the skin surface – cutaneous sensibility – and describes the neurobiologic processes that enable the skin to “sense.” Skin sensations are multimodal and are classically described as sensing the three submodalities of touch, temperature, and pain. We also consider the growing evidence for a fourth submodality, present only in hairy skin, which is preferentially activated by slowly moving, low force, mechanical stimuli. This brief introduction to somatosensation starts with the discriminative touch system. Sensation enters the periphery via sensory axons that have their cell bodies sitting just outside the spinal cord in the dorsal root ganglia, with one ganglion for each spinal nerve root. Neurons are the building blocks of the nervous system and somatosensory neurons are unique in that, unlike most neurons, the electrical signal does not pass through the cell body but the cell body sits off to one side, without dendrites. The signal passes directly

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


from the distal axon process to the proximal process which enters the dorsal half of the spinal cord, and immediately turns up the spinal cord forming a white matter column, the dorsal columns, which relay information to the first brain relay nucleus in the medulla. These axons are called the primary afferents, because they are the same axons that carry the signal into the spinal cord. Sensory input from the face does not enter the spinal cord, but instead enters the brainstem via the trigeminal nerve (one of the cranial nerves). Just as with inputs from the body, there are three modalities of touch, temperature, and pain, with each modality having different receptors traveling along different tracts projecting to different targets in the brainstem. Once the pathways synapse in the brainstem, they join the pathways from the body on their way up to the thalamus and higher cortical structures. Sensory information arising from the skin is represented in the brain in the primary and secondary somatosensory cortex, where the contralateral body surfaces are mapped in each hemisphere.

Peripheral nervous system The skin is the most extensive and versatile organ of the body and in a fully grown adult covers a surface area approaching 2 m2. This surface is far more than a just a passive barrier. It contains in excess of 2 million sweat glands and 5 million hairs that may be either fine vellous types covering all surfaces, apart from the soles of the feet and the palms of the hands (glabrous skin), or over 100 000 of the coarser type found on the scalp. Evidence is also emerging that non-glabrous skin contains a system of nerves that code specifically for the pleasant properties of touch. Skin consists

5. Sensitive skin of an outer, waterproof, stratified squamous epithelium of ectodermal origin – the epidermis – plus an inner, thicker, supporting layer of connective tissue of mesodermal origin – the dermis. The thickness of this layer varies from 0.5 mm over the eyelid to >5.0 mm over the palm and sole of the foot.

Touch Of the three “classic” submodalities of the somatosensory system, discriminative touch subserves the perception of pressure, vibration, and texture and relies upon four different receptors in the digit skin: 1 Meissner corpuscles; 2 Pacinian corpuscles; 3 Merkel disks; and 4 Ruffini endings. These are collectively known as low threshold mechanoreceptors (LTMs), a class of cutaneous receptors that are specialized to transduce mechanical forces impinging the skin into nerve impulses. The first two are classified as fast adapting (FA) as they only respond to the initial and final contact of a mechanical stimulus on the skin, and the second two are classified as slowly adapting (SA) as they continue firing during a constant mechanical stimulus. A further classification relates to the LTM’s receptive field (RF; i.e. the surface area of skin to which they are sensitive). The RF is determined by the LTM’s anatomic location within the skin, with those near the surface at the dermal– epidermal boundary, Meissner corpuscles and Merkel disks, having small RFs, and those lying deeper within the dermis, Pacinian corpuscles and Ruffini endings, having large RFs (Figure 5.1).

Psychophysical procedures have been traditionally employed to study the sense of touch where differing frequencies of vibrotactile stimulation are used to quantify the response properties of this sensory system. Von Bekesy [1] was the first to use vibratory stimuli as an extension of his research interests in audition. In a typical experiment participants were asked to respond with a simple button-press when they could just detect the presence of a vibration presented to a digit, within one of two time periods. This two alternative force choice paradigm (2-AFC) provides a threshold-tuning curve, the slopes of which provide information about a particular class of LTM’s response properties. Bolanowski et al. [2] proposed that there are four distinct psychophysical channels mediating tactile perception in the glabrous skin of the hand. Each psychophysically determined channel is represented by one of the four anatomic end organs and nerve fiber subtypes, with frequencies in the 40–500 Hz range providing a sense of “vibration,” transmitted by Pacinian corpuscles (PC channel or FAI); Meissner corpuscles being responsible for the sense of “flutter” in the 2–40 Hz range (NPI channel or FAII); the sense of “pressure” being mediated by Merkel disks in the 0.4–2.0 Hz range (NPIII or SAI); and Ruffini end organs producing a “buzzing” sensation in the 100–500 Hz range (NPII or SAII). Neurophysiologic studies have, by and large, supported this model, but there is still some way to go to link the anatomy with perception (Table 5.1). There have been relatively few studies of tactile sensitivity on hairy skin, the cat being the animal of choice for most of these studies. Mechanoreceptive afferents (Aβ fibers) have been described that are analogous to those found in human

Table 5.1 Main characteristics of primary sensory afferents innervating human skin. Class


Axonal diameter (μm)

Conduction velocity (m s−1)

Proprioceptors from muscles and tendons



Low threshold mechanoreceptors



Cold, noxious, thermal



Noxious, heat, thermal


retinoic acid.


Genomic effects The genomic effects of topical retinoids are the consequence of the modulation of gene expression following their binding to nuclear RAR or RXR receptors. These effects most probably explain the results obtained in reversing and preventing various hallmarks of skin aging such as the activation of

38. Retinoids


Figure 38.2 Structure of therapeutical (a) and cosmeceutical (b) retinoids. “R” in retinyl esters represents an acyl radical.





matrix metalloproteinase [31,32], oxidative stress, and the degradation of extracellular matrix [33]. In particular, retinoids are known to inhibit keratinocyte differentiation and to stimulate epidermal hyperplasia [10,34,35]. Heparin binding-epidermal growth factor (HB-EGF) activation of keratinocyte ErbB receptors via a RAR-dependent paracrine loop has been proposed to mediate retinoid-induced epidermal hyperplasia [36]. It has been shown that CD44v3, a heparan sulfate-bearing variant of CD44, which is a multifunctional polymorphic proteoglycan and principal cell surface receptor of hyaluronan (HA), recruits active matrix metalloproteinase 7, the precursor of HB-EGF (pro-HB-EGF) and one of its receptors, ErbB4, to form a complex on the surface of murine epithelial cells [37]. We have previously shown that topical application of retinaldehyde increases the expression of CD44 in mouse skin. The increased expression of CD44 accompanying epidermal hyperplasia induced by topical retinaldehyde is associated with an increase in epidermal and dermal HA and with increased expression of the HA synthases 1, 2, and 3 [38]. These observations indicate that the HA system is associated to the HB-EGF paracrine loop, with the transcriptional upregulation of CD44 and HA synthases. Thus, retinaldehyde-induced in vitro and in vivo proliferative response of keratinocytes is CD44-dependent and requires HB-EGF, its receptor ErbB1, and matrix metalloproteinases [39].

Non-genomic effects There is some evidence that retinoids might exert a biologic activity independently of their binding to nuclear receptors [10,40], thus confirming the concept of cosmeceutical retinoids. Such indirect effects have been well documented, and clinical manifestations have been observed.

Photobiology of topical retinoids Owing to their side chain containing multiple double bonds, retinoids strongly absorb UV light, with molar extinction coefficients of approximately 52 000 (M−1/cm−1) at wavelengths ranging from 325 nm for retinol to 385 nm for retinaldehyde. This property is crucial in the retina, where photoisomerization of 11-cis-retinaldehyde into all-transretinaldehyde is the first step in the biochemical cascade leading to the generation of nervous influx from the optic nerve to the visual cortex [41–43]. This property also enables retinoids to act as UV filters when applied topically: topical retinoids have been shown to load the skin with supraphysiologic epidermal concentrations [4,25]. For instance, topical retinyl palmitate 2% was as efficient as a commercial sunscreen with a sun protection factor of 20 to prevent UVB-induced erythema and DNA photodamage in the skin of healthy volunteers [44]. In mice, retinoic acid, retinaldehyde, retinol, and retinyl palmitate were efficient in preventing UVB-induced apoptosis and DNA photodamage [45]. The similar potencies of these retinoids


indicate a physical action mediated by their spectral properties rather than a biologic action mediated by the binding to nuclear receptors. This also implies that sun exposure induces significant vitamin A depletion in the epidermis, which significance in term of photoaging has not been fully analyzed. However, the biologic effects of photodegradation of vitamin A and other retinoids are less well understood and may be important for sun-exposed tissues, such as the skin. Exposure of retinol or its esters to UV light generates free radicals and reactive oxygen species that can damage a number of cellular targets, including proteins, lipids, and DNA [46,47]. The balance between positive, filter-like properties, and possible damage to biomolecules is difficult to assess, and might depend on several factors [48–50]. For this reason, it is still recommended to avoid UV exposure when using topical retinoids.

Antibacterial activity of retinaldehyde Aldehydes represent an intermediate state of oxidation between alcohols and carboxylic acids [51–54]. Retinaldehyde may thus exert a direct biologic activity by reacting nonenzymatically with many biomolecules on skin surface, as well as on bacterial flora, independently of its conversion to retinoic acid and subsequent activation of nuclear receptors [55]. The putative anti-infective property of vitamin A had already been observed in the 1920s, although its mechanism of action was not understood [56]. Retinoic acid has been shown to protect dendritic cells in mice [57] and topical retinaldehyde, because of its better tolerance profile than retinoic acid, was successfully applied to a long period of time to patients with inflammatory dermatoses [27,28]. Retinaldehyde has been successfully used against Grampositive bacteria of the cutaneous flora: 2 weeks’ treatment with topical retinaldehyde 0.05% displayed a significant decrease in counts of viable Propionibacterium acnes, Staphylococcus aureus, and Micrococcus spp. in healthy volunteers, whereas retinaldehyde showed to be more potent than retinol and retinoic acid when assessing the minimal inhibitory concentration on various bacterial strains [58,59]. Topical cosmeceutical retinoids as antioxidants Oxidative stress is considered to be the cornerstone of the biochemical pathways leading to both intrinsic (chronologic) and extrinsic aging (photoaging) [13,60–63]. The skin, which is exposed to environmental factors and pollutants, possesses an efficient antioxidant system able to counteract the deleterious effects of occasional oxidative stress of moderate magnitude [64,65]. However, in the case of chronic or severe oxidative stress, this endogenous antioxidant network reaches its limit and irremediable tissue damage is unavoidable [66–70]. According to the free radical theory of aging, oxidative stress increases with age, whereas during the same

38. Retinoids time the endogenous antioxidant systems become less efficient [71–74]. It thus seems logical to provide the skin with exogenous antioxidants in order to slow the natural process of skin aging. Retinoids have been shown to exert a free radical scavenging activity in vitro [75–79]. This property is most probably caused by the conjugated double bond structure of the side chain and their cyclohexenyl or aromatic moiety, rather than their ability to bind nuclear retinoid receptors, indicating that topical cosmeceutical retinoids should be as good candidates as therapeutical ones to prevent or improve skin aging. Because the endogenous antioxidants act together in a functional organized network, when supplying any organ with antioxidants, this concept should be followed; this means that if cosmeceutical retinoids have a role in the prevention or improvement of skin aging, they should be considered as partners of other topical antioxidants, rather than as a whole antioxidant system. In mice, the peroxidation of epidermal lipids induced by topical menadione (vitamin K3) was completely prevented by a pretreatment with either 0.25% topical α-tocopherol (vitamin E, a known efficient endogenous cutaneous antioxidant) or topical retinaldehyde 0.05% [78]. In human, topical retinol 0.075% provided a better protection of the stratum corneum against physical (UV) and chemical (sodium lauryl sulfate) threat than a cream containing αtocopherol 1.1% [80].

naldehyde was not solely a result of its bioconversion to retinoic acid, but also to a retinoid receptor-independent mechanism [87,88]. A clinical trial in which retinol 10% and lactic acid 7% replaced tretinoin 0.1% and dexamethasone 0.1% in the formula of Kligman and Willis was successfully applied to patients with hyperpigmented lesions on the face. This new formula was shown to be comparable to that of Kligman and Willis, with the advantage of preventing the steroid-induced skin atrophy [89]. Retinyl esters, in particular retinyl palmitate, are widely used in cosmetics. According to the proligand concept discussed above, in order to exert a retinoid-like activity, retinyl esters have first to be hydrolyzed to retinol, and then oxidized to retinoic acid, a process being less effective than retinol and retinaldehyde, because it requires more enzymatic steps [22,25]. If a non-genomic effect is expected, the total retinoid content of the skin would be determinant. However, very few studies aimed at assessing the penetration of retinyl esters through human skin have been reported. In hairless mice, we found that a 3-day treatment with topical retinyl palmitate 0.05% loaded the epidermis with more retinoids than topical retinol 0.05% (119 ± 4.5, 43.3 ± 6.6, and 1.5 ± 0.2 pmol/g for retinyl palmitate, retinol, and vehicle, respectively; unpublished data). Thus, retinyl esters seem to deliver the skin with more retinoids and have less genomic effects than retinol, suggesting that they should have similar depigmenting properties to retinol.

Effects of topical cosmeceutical retinoids on pigmentation It has long been observed that retinoic acid has a lightening property on human skin, and for this reason it has been used, alone or in combination with hydroquinone, to treat hyperpigmented lesions [81,82]. The mechanism of this effect is not clear. Depending on the cell culture model, retinoic acid inhibits tyrosinase activity – the rate-limiting step of melanogenesis – inhibits cell proliferation, decreases the melanin content, or has no effect on tyrosinase, melanin content, and cell growth; in particular, in monolayer cultures, there is few or no effect with retinoic acid [83–86]. This suggests that the observed in vivo depigmenting effect of retinoic acid, and retinoids in general, may be caused by the increased rate of epidermis “turnover” rather than to a direct effect on melanin content or melanocyte growth [86]. The best depigmenting product containing a retinoid is the formula developed by Kligman and Willis, consisting of 0.1% tretinoin (retinoic acid), 5.0% hydroquinone, and 0.1% dexamethasone, but none of its active ingredients can be used in cosmetic products. Amongst cosmeceutical retinoids, retinaldehyde, the direct precursor of retinoic acid, is well tolerated in human skin and has been shown to have several biologic effects identical to that of retinoic acid [27,28]. In the mouse tail model of depigmentation, topical retinaldehyde 0.05% showed a higher depigmenting effect than retinoic acid 0.05%, indicating that this effect of reti-

Hyaluronan as a partner for cosmeceutical retinoids HA is the major component of the extracellular matrix and is found in high quantities in the skin. HA is a high molecular weight, non-sulfated, linear glycosaminoglycan composed of repeating units of D-glucuronic acid and Nacetyl-D-glucosamine linked together via alternating β-1,4 and β-1,3 glycosidic bonds. HA chains can have as much as 25 000 disaccharide repeats, corresponding to a molecular mass of approximately 8 MDa. In normal skin, HA is synthesized essentially by dermal fibroblasts and epidermal keratinocytes. Because of its negatively charged residues, HA can accommodate many water molecules, which help to maintain the normal hydration and viscoelasticity of the skin [90–92]. With increasing lifespan, the chronic cutaneous insufficiency syndrome now called dermatoporosis is becoming an emerging clinical problem with significant morbidity, which sometimes results in prolonged hospital stays [17,18,93]. Dermatoporosis is principally caused by chronologic aging and long-term and unprotected sun exposure, but may also result from the chronic use of topical and systemic corticosteroids. Experimental evidence suggests that defective function of CD44, a transmembrane glycoprotein that acts as the main cell surface HA receptor, and the corresponding impaired HA metabolism, are implicated in the pathogenesis




of dermatoporosis, and may be a target for intervention [94]. Cleavage of the high molecular weight HA polymer during tissue remodeling gives rise to lower molecular weight fragments that elicit a variety of CD44-mediated cellular responses, including proliferation, migration, HA synhesis, and cytokine synthesis [91,92]. The cellular responses elicited by topical application of HA, and specifically HA synthesis by keratinocytes, depend on the size of the HA oligosaccharides [95,96]. Topical retinoids are known to stimulate epidermal hyperplasia through the activation of a RAR-dependent HB-EGF paracrine loop [36,97]. HA production is also selectively stimulated by retinoids in mouse and human skin [98,99]. In mouse skin, topical retinaldehyde increases HA content, the expression of CD44 and HA synthases [38], and prevents UV-induced depletion of HA and CD44, an effect also observed with topical retinol and retinoic acid, although to a lesser extent [100]. In humans, topical retinaldehyde has been shown to restore the epidermal thickness and CD44 expression in lichen sclerosus and atrophic lesions [101]. The proliferative response of keratinocytes elicited by either retinaldehyde or intermediate size HA fragments (HAFi) is dependent of CD44 and requires the presence of HB-EGF, its receptor ErbB1, as well as matrix metalloproteinase-7 (MMP-7) [39,102]. In particular, topical application of HAFi in combination with retinaldehyde caused epidermal hyperplasia by specifically stimulating the CD44 platform molecules in the keratinocytes and increased the HA content of epidermis and dermis [103]. Thus, topical retinoids, in particular retinaldehyde, can restore epidermal functions by stimulating HA synthesis and biologic functions.

Specific profiles of cosmeceutical retinoids Retinol and retinyl esters Retinol and retinyl esters (mostly retinyl palmitate) have been incorporated into many skin products. Theoretically, these topical endogenous retinoids, which are natural precursors of cutaneous retinaldehyde and retinoic acids [104– 106], could also be useful in treating skin conditions for which retinoic acid is active. However, although retinol is widely used in cosmetic formulations to improve photoaging, topical retinol has not been demonstrated to be effective to treat any skin condition, maybe because of its slow oxidation into retinaldehyde and retinoic acid [107]. It seems that the retinol concentrations required to induce a measurable biologic action similar to that of retinoic acid (0.05%) induce a similar irritant dermatitis [89]. Thus, to avoid high concentrations of retinol or retinyl esters in topical formulation, the best way would be to combine them at moderate concentrations with other topical agents such as tocopherols, ascorbate and derivatives, flavonoids, or other biologic antioxidants [108–110].


Another useful property of retinol is its absorption spectrum: it absorbs UV light in shorter wavelengths (325 nm) than retinaldehyde (385 nm) and retinoic acid (345 nm). Therefore, topical retinol could be useful as a filter partner of many cosmetic and cosmeceutical products in the most biologically active solar UV range (290–320 nm), while delivering small amounts of retinoic acid on a relatively long period of time [44,45]. This can be expanded to retinyl esters, which have the same UV spectrum as retinol, have the better tolerance profile among topical retinoids, while being the weaker retinoic acid precursors [22].

Retinaldehyde Retinaldehyde is much less irritant than retinoic acid, which explains its good compliance, and has been shown to be well tolerated and effective in treating photoaging for long periods of time: in particular, retinaldehyde produced significant improvement in fine and deep wrinkles [28,111]. Retinaldehyde does not bind to nuclear retinoid receptors and selectively delivers low concentrations of retinoic acid at the cellular level [27,97]; this prevents an excess of retinoic acid in the skin, a condition that contributes to cutaneous irritation [4,20] and confers to retinaldehyde the required properties for the intracrine concept discussed above [20]. The association of retinaldehyde and δ-tocopherylglucopyranoside, a vitamin E precursor, improved the protection against the generation of free radicals – a condition leading to aging – as well as the skin elasticity [112]. Retinaldehyde, which possesses an aldehyde functional group, exerts direct receptor-independent biologic actions not shared by other retinoids. This explains the usefulness of topical retinaldehyde 0.05% against P. acnes and Staphylococcus spp. [58,59]. Retinaldehyde shares with other retinoids a high absorption power in the UVA range, and may decrease the fluence received in this window significantly [45]. Compared with other retinoids, retinaldehyde loads the skin with natural retinoids very efficiently, probably because of its better penetration profile through the skin, and its ability to be reduced to retinol or oxidized to retinoic acid very rapidly [105,113–116]. Retinaldehyde has been shown to reduce the pigmentation when applied to the skin for a couple of weeks or longer; this could be due in part to a melanosomal dilution resulting from an increase of epidermal turnover, an effect attributable to its conversion to retinoic acid. The depigmenting property of retinaldehyde could also be due to its antioxidant power, because the production of small quantities of hydrogen peroxide has been considered to be an essential step of the melanogenesis [117]. Indeed, topical retinaldehyde 0.05% decreases the melanin content by 80% and the density of active melanocytes by 75% in mouse tail skin, whereas an application of retinaldehyde 0.01% to guinea pig ear skin decreases epidermal melanin by 50% and the density of active melanocytes by 40% (unpublished data). Owing to these properties,

38. Retinoids retinaldehyde should be considered as a key partner in topical depigmenting preparations.

4-Oxoretinoids According to Achkar et al. [7] and Blumberg et al. [8], 4-oxoretinol and 4-oxoretinaldehyde, the least known of endogenous retinoids, exert morphogenic properties and are able to bind and transactivate RARs in vitro. In a mouse model of retinoid activity, topical 4-oxoretinaldehyde 0.05% induced a moderate retinoid-like activity compared with topical retinoic acid 0.05%, as assessed by: 1 Epidermal hyperplasia and metaplasia; 2 Cutaneous inflammation (myeloperoxidase activity); and 3 Depigmentation of the tail. Topical 4-oxoretinol 0.05% was also active, albeit to a lesser extend. Parallel to the action of these 4-oxoretinoids, no retinoic acid could be detected in the skin, indicating that 4-oxoretinoids exerted a direct biologic activity, which was not due to their bioconversion to their non-oxo counterparts [10]. This confirms the in vitro studies mentioned above [7,8], which demonstrated a direct biologic action of 4-oxoretinol and 4-oxoretinal, and suggests a potential benefits for their use as cosmeceuticals. In another study, the 4-oxoderivatives of the biologically active all-trans-, 9-cis- and 13-cis-retinoic acids (although 13-cis-retinoic acid does not bind to retinoid receptors) have been shown to display strong and isomer-specific transcriptional regulatory activities in human keratinocytes and fibroblasts in vitro [118]. These data revive the interest for these oxidative metabolites of endogenous retinoids. Appropriate clinical trials should be performed to determine whether it is possible to use these the 4-oxoderivatives topically at high concentrations to obtain a better response than retinol and its esters, while retaining a good tolerance. Pilot studies in humans already indicate a good tolerance of 4-oxoretinaldehyde 0.5% (unpublished personal observations). Establishing the spectrum of potential activity of topical 4-oxoderivatives, especially on the pigmentary system also deserves specific clinical trials.

Association with topical hyaluronan fragments The molecular mechanisms underlying retinoid-induced epidermal hyperplasia are closely related to CD44-dependent pathways in keratinocytes. It is well demonstrated that retinoids synergize with the activities of HAFi on cell renewal and de novo HA synthesis [38,103,119]. Accordingly, the topical application of HAFi was found to have repairing action in dermatoporosis [102]. Therefore the combination of HAFi with a retinoid is highly promising as preventive treatment in early phases of dermatoporosis. High molecular weight HA, which do not show the topical activities of HAFi, has been widely used in cosmetic preparations [120]. Application of high molecular weight HAcontaining cosmetic products to the skin is reported to

moisturize and restore elasticity [121]. HA-based cosmetic formulations or sunscreens may also be capable of protecting the skin against UV irradiation due to the antioxidant properties of HA [122]. In almost all of these cosmetic formulations, the HA is associated with retinol. Scientific proof that the association of any topical retinoids with high molecular weight HA has some specific synergizing effect is currently lacking.

References 1 Castenmiller JJM, West CE. (1998) Bioavailability and bioconversion of carotenoids. Annu Rev Nutr 18, 19–38. 2 Roos TC, Jugert FK, Merk HF, Bickers DR. (1998) Retinoid metabolism in the skin. Pharmacol Rev 50, 315–33. 3 Sorg O, Antille C, Kaya G, Saurat JH. (2006) Retinoids in cosmeceuticals. Dermatol Ther 19, 289–96. 4 Saurat JH, Sorg O, Didierjean J. (1999) New concepts for delivery of topical retinoid activity to human skin. In: Nau H, Blaner WS, eds. Retinoids. The Biochemical and Molecular Basis of Vitamin A and Retinoid Action. Berlin: Springer-Verlag, pp. 521–38. 5 Sass JO, Forster A, Bock KW, Nau H. (1994) Glucuronidation and isomerization of all-trans- and 13-cis-retinoic acid by liver microsomes of phenobarbital- or 3-methylcholanthrenetreated rats. Biochem Pharmacol 47, 485–92. 6 Taimi M, Helvig C, Wisniewski J, Ramshaw H, White J, Amad M, et al. (2004) A novel human cytochrome P450, CYP26C1, involved in metabolism of 9-cis and all-trans isomers of retinoic acid. J Biol Chem 279, 77–85. 7 Achkar CC, Derguini F, Blumberg B, Levin AA, Speck J, Adams RM, et al. (1996) 4-Oxoretinol, a new natural ligand and transactivator of the retinoic acid receptors. Proc Natl Acad Sci U S A 93, 4879–84. 8 Blumberg B, Bolado J Jr, Derguini F, Craig AG, Moreno TA, Chakravarti D, et al. (1996) Novel retinoic acid receptor ligands in Xenopus embryos. Proc Natl Acad Sci U S A 93, 4873–8. 9 Ross SA, De Luca LM. (1996) A new metabolite of retinol: alltrans-4-oxo-retinol as a receptor activator and differentiation agent. Nutr Rev 54, 355–6. 10 Sorg O, Tran C, Carraux P, Grand D, Barraclough C, Arrighi JF, et al. (2008) Metabolism and biological activities of topical 4-oxoretinoids in mouse skin. J Invest Dermatol 128, 999–1008. 11 Fisher GJ, Voorhees JJ. (1996) Molecular mechanisms of retinoid actions in skin. FASEB J 10, 1002–13. 12 Napoli JL. (1996) Retinoic acid biosynthesis and metabolism. FASEB J 10, 993–1001. 13 Sorg O, Antille C, Saurat JH. (2004) Retinoids, other topical vitamins, and antioxidants. In: Rigel DS, Weiss RS, Lim HW, et al., eds. Photoaging. New York: Marcel Dekker, pp. 89–115. 14 Dawson MI. (2004) Synthetic retinoids and their nuclear receptors. Curr Med Chem Anticancer Agents 4, 199–230. 15 Sorg O, Kuenzli S, Saurat JH. (2007) Side effects and pitfalls in retinoid therapy. In: Vahlquist A, Duvic M, eds. Retinoids and Carotenoids in Dermatology. New York: Informa Healthcare, pp. 225–48. 16 Kuenzli S, Saurat JH. (2003) Retinoids. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology. London: Mosby, pp. 1991–2006.




17 Kaya G, Saurat JH. (2007) Dermatoporosis: a chronic cutaneous insufficiency/fragility syndrome: clinicopathological features, mechanisms, prevention and potential treatments. Dermatology 215, 284–94. 18 Saurat JH. (2007) Dermatoporosis: the functional side of skin aging. Dermatology 215, 271–2. 19 Stratigos AJ, Katsambas AD. (2005) The role of topical retinoids in the treatment of photoaging. Drugs 65, 1061–172. 20 Saurat JH, Sorg O. (1999) Topical natural retinoids: the “proligand-non-ligand” concept. Dermatology 199 (Suppl), 1–2. 21 Duell EA, Derguini F, Kang S, Elder JT, Voorhees JH. (1996) Extraction of human epidermis treated with retinol yields retro-retinoids in addition to free retinol and retinyl esters. J Invest Dermatol 107, 178–82. 22 Duell EA, Kang S, Voorhees JJ. (1997) Unoccluded retinol penetrates human skin in vivo more effectively than unoccluded retinyl palmitate or retinoic acid. J Invest Dermatol 109, 301–5. 23 Schaefer H. (1993) Penetration and percutaneous absorption of topical retinoids. Skin Pharmacol 6 (Suppl. 1), 17–23. 24 Tran C, Kasraee B, Grand D, Carraux P, Didierjean L, Sorg O, et al. (2005) Pharmacology of RALGA, a mixture of retinaldehyde and glycolic acid. Dermatology 210 (Suppl. 1), 6–13. 25 Tran C, Sorg O, Carraux P, Didierjean L, Seurat JH. (2001) Topical delivery of retinoids counteracts the UVB-induced epidermal vitamin A depletion in hairless mouse. Photochem Photobiol 73, 425–31. 26 Didierjean L, Sass JO, Carraux P, Grand D, Sorg O, Plum C, et al. (1999) Topical 9-cis-retinaldehyde for delivery of 9-cisretinoic acid in mouse skin. Exp Dermatol 8, 199–203. 27 Didierjean L, Tran C, Sorg O, Seurat JH. (1999) Biological activities of topical natural retinaldehyde. Dermatology 199 (Suppl), 19–24. 28 Saurat JH, Didierjean L, Masgrau E, Piletta PA, Jaconi S, Chatellard-Gruaz D, et al. (1994) Topical retinaldehyde on human skin: biological effects and tolerance. J Invest Dermatol 103, 770–4. 29 Kang S, Duell EA, Fisher GJ, Datta SC, Wang ZQ, Reddy AP, et al. (1995) Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristics of retinoic acid but without measurable retinoic acid levels or irritation. J Invest Dermatol 105, 549–56. 30 Kurlandsky SB, Xiao JH, Duell EA, Voorhees JJ, Fisher GJ. (1994) Biological activity of all-trans retinol requires metabolic conversion to all-trans retinoic acid and is mediated through activation of nuclear retinoid receptors in human keratinocytes. J Biol Chem 269, 32821–7. 31 Fisher GJ, Datta SC, Talwar HS, Wang ZQ, Varani J, Kang S, et al. (1996) Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature 379, 335–9. 32 Fisher GJ, Wang ZQ, Datta SC, Varani J, Wang S, Voorhees JJ. (1997) Pathophysiology of premature skin aging induced by ultraviolet light. N Engl J Med 337, 1419–28. 33 Griffiths CE, Russman AN, Majmudar G, Singer RS, Hamilton TA, Voorhees JJ. (1993) Restoration of collagen formation in photodamaged human skin by tretinoin (retinoic acid). N Engl J Med 329, 530–5. 34 Ponec M, Weerheim A, Havekes L, Boonstra J. (1987) Effects of retinoids on differentiation, lipid metabolism, epidermal









42 43





48 49

50 51

growth factor, and low-density lipoprotein binding in squamous carcinoma cells. Exp Cell Res 171, 426–35. Saurat JH. (1988) How do retinoids work on human epidermis? A breakthrough and its implications. Clin Exp Dermatol 13, 350–64. Xiao JH, Feng X, Di W, Peng ZH, Li LA, Chambon P, et al. (1999) Identification of heparin-binding EGF-like growth factor as a target in intercellular regulation of epidermal basal cell growth by suprabasal retinoic acid receptors. EMBO J 18, 1539–48. Yu WH, Woessner JF Jr, McNeish JD, Stamenkovic I. (2002) CD44 anchors the assembly of matrilysin/MMP-7 with heparinbinding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16, 307–23. Kaya G, Grand D, Hotz R, Augsburger E, Carraux P, Didierjean L, et al. (2005) Upregulation of CD44 and hyaluronate synthase by topical retinoids in mouse skin. J Invest Dermatol 124, 284–7. Kaya G, Tran C, Sorg O, et al. (2005) Retinaldehyde-induced epidermal hyperplasia via heparin binding epidermal growth factor is CD44-dependent. J Invest Dermatol 124, A32. Clifford JL, Menter DG, Wang M, Lotan R, Lippman SM. (1999) Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 59, 14–8. Nakanishi K. (2000) Recent bioorganic studies on rhodopsin and visual transduction. Chem Pharm Bull (Tokyo) 48, 1399–409. Blomhoff R, Blomhoff HK. (2006) Overview of retinoid metabolism and function. J Neurobiol 66, 606–30. Schoenlein RW, Peteanu LA, Mathies RA, Shank CV. (1991) The first step in vision: femtosecond isomerization of rhodopsin. Science 254, 412–5. Antille C, Tran C, Sorg O, Carraux P, Didierjean L, Saurat JH. (2003) Vitamin A exerts a photoprotective action in skin by absorbing UVB radiations. J Invest Dermatol 121, 1163–7. Sorg O, Tran C, Carraux P, Grand D, Hügin A, Didierjean L, et al. (2005) Spectral properties of topical retinoids prevent DNA damage and apoptosis after acute UVB exposure in hairless mice. Photochem Photobiol 81, 830–6. Fu PP, Xia Q, Yin JJ, Cherng SH, Yan J, Mei N, et al. (2007) Photodecomposition of vitamin A and photobiological implications for the skin. Photochem Photobiol 83, 409–24. Dillon J, Gaillard ER, Bilski P, Chignell CF, Reszka KJ. (1996) The photochemistry of the retinoids as studied by steady-state and pulsed methods. Photochem Photobiol 63, 680–5. Ferguson J, Johnson BE. (1989) Retinoid associated phototoxicity and photosensitivity. Pharmacol Ther 40, 123–35. Fu PP, Cheng SH, Coop L, Xia O, Culp SJ, Tolleson WH, et al. (2003) Photoreaction, phototoxicity, and photocarcinogenicity of retinoids. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev 21, 165–97. Kligman LH. (1987) Retinoic acid and photocarcinogenesis: a controversy. Photodermatol 4, 88–101. Becker TW, Krieger G, Witte I. (1996) DNA single and double strand breaks induced by aliphatic and aromatic aldehydes in combination with copper (II). Free Radic Res 24, 325–32.

38. Retinoids 52 Witz G. (1989) Biological interactions of alpha,beta-unsaturated aldehydes. Free Radic Biol Med 7, 333–49. 53 Esterbauer H, Schaur RJ, Zollner H. (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11, 81–128. 54 Feron VJ, Til HP, de Vrijer F, Wouterson RA, Cassee FR, van Bladeren PJ. (1991) Aldehydes: occurrence, carcinogenic potential, mechanism of action and risk assessment. Mutat Res 259, 363–85. 55 Ambroziak W, Izaguirre G, Pietruszko R. (1999) Metabolism of retinaldehyde and other aldehydes in soluble extracts of human liver and kidney. J Biol Chem 274, 33366–73. 56 Green HN, Mellanby E. (1928) Vitamin A as an anti-infective agent. Br Med J 2, 691–6. 57 Halliday GM, Ho KKL, Barnetson RSC. (1992) Regulation of the skin immune system by retinoids during carcinogenesis. J Invest Dermatol 99, 83S–6S. 58 Péchère M, Germanier L, Siegenthaler G, Péchère JC, Saurat JH. (2002) The antibacterial activity of topical retinoids: the case of retinaldehyde. Dermatology 205, 153–8. 59 Péchère M, Péchère JC, Siegenthaler G, Germanier L, Saurat JH. (1999) Antibacterial activity of retinaldehyde against Propionibacterium acnes. Dermatology 199 (Suppl 1), 29–31. 60 Wenk J, Brenneisen P, Meewes C, Wlaschek M, Peters T, Blauschun R, et al. (2001) UV-induced oxidative stress and photoaging. Curr Probl Dermatol 29, 83–94. 61 Yaar M, Gilchrest BA. (1998) Aging versus photoaging: postulated mechanisms and effectors. J Investig Dermatol Symp Proc 3, 47–51. 62 Pinnell SR. (2003) Cutaneous photodamage, oxidative stress, and topical antioxidant protection. J Am Acad Dermatol 48, 1– 19; quiz 20–2. 63 Nishigori C, Hattori Y, Arima Y, Miyachi Y. (2003) Photoaging and oxidative stress. Exp Dermatol 12, 18–21. 64 Sies H, Stahl W. (2004) Nutritional protection against skin damage from sunlight. Annu Rev Nutr 24, 173–200. 65 Thiele JJ, Schroeter C, Hsieh SN, Podda M, Packer L. (2001) The antioxidant network of the stratum corneum. Curr Probl Dermatol 29, 26–42. 66 Halliwell B. (1994) Free radicals and antioxidants: a personal view. Nutr Rev 52, 253–65. 67 Jacob RA, Burri BJ. (1996) Oxidative damage and defense. Am J Clin Nutr 63, 985S–90S. 68 Kohen R, Gati I. (2000) Skin low molecular weight antioxidants and their role in aging and in oxidative stress. Toxicology 148, 149–57. 69 Sorg O. (2004) Oxidative stress: a theoretical model or a biological reality? C R Biol 327, 649–62. 70 Halliwell B, Gutteridge JMC. (1999) Free Radicals in Biology and Medicine, 3th edn. Oxford: Oxford University Press. 71 Berr C. (2000) Cognitive impairment and oxidative stress in the elderly: results of epidemiological studies. Biofactors 13, 205–9. 72 Barja G. (2004) Free radicals and aging. Trends Neurosci 27, 595–600. 73 Harman D. (2001) Aging: overview. Ann N Y Acad Sci 928, 1–21. 74 Crastes de Paulet A. (1990) Free radicals and aging. Ann Biol Clin 48, 323–30.

75 Singh DK, Lippman SM. (1998) Cancer chemoprevention. Part 1: Retinoids and carotenoids and other classic antioxidants. Oncology (Williston Park) 12, 1643–53, 57–8; discussion 59–60. 76 Tsuchiya M, Scita G, Freisleben HJ, Kagan VE, Packer L. (1992) Antioxidant radical-scavenging activity of carotenoids and retinoids compared to alpha-tocopherol. Methods Enzymol 213, 460–72. 77 Tesoriere L, D’Arpa D, Re R, Livrea MA. (1997) Antioxidant reactions of all-trans retinol in phospholipid bilayers: effect of oxygen partial pressure, radical fluxes, and retinol concentration. Arch Biochem Biophys 343, 13–8. 78 Sorg O, Tran C, Saurat JH. (2001) Cutaneous vitamins A and E in the context of ultraviolet or chemically induced oxidative stress. Skin Pharmacol Appl Skin Physiol 14, 363–72. 79 Sorg O, Kuenzli S, Kaya G, Saurat JH. (2005) Proposed mechanisms of action for retinoid derivatives in the treatment of skin ageing. J Cosmet Dermatol 4, 237–44. 80 Goffin V, Henry F, Piérard-Franchimont C, Piérard GE. (1997) Topical retinol and the stratum corneum response to an environmental threat. Skin Pharmacol 10, 85–9. 81 Kligman AM, Willis I. (1975) A new formula for depigmenting human skin. Arch Dermatol 111, 40–8. 82 Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Voorhees JJ. (1993) Topical tretinoin (retinoic acid) improves melasma: a vehicle-controlled, clinical trial. Br J Dermatol 129, 415–21. 83 Hoal E, Wilson EL, Dowdle EB. (1982) Variable effects of retinoids on two pigmenting human melanoma cell lines. Cancer Res 42, 5191–5. 84 Edward M, Gold JA, MacKie RM. (1988) Different susceptibilities of melanoma cells to retinoic acid-induced changes in melanotic expression. Biochem Biophys Res Commun 155, 773–8. 85 Fligiel SE, Inman DR, Talwar HS, Fisher GJ, Voorhees JJ, Varani J. (1992) Modulation of growth in normal and malignant melanocytic cells by all-trans retinoic acid. J Cutan Pathol 19, 27–33. 86 Yoshimura K, Tsukamoto K, Okazaki M, Virador VM, Lei TC, Suzuki Y, et al. (2001) Effects of all-trans retinoic acid on melanogenesis in pigmented skin equivalents and monolayer culture of melanocytes. J Dermatol Sci 27 (Suppl 1), S68–75. 87 Kasraee B, Tran C, Sorg O, Saurat JH. (2005) The depigmenting effect of RALGA in C57BL/6 mice. Dermatology 210 (Suppl 1), 30–4. 88 Ortonne JP. (2006) Retinoid therapy of pigmentary disorders. Dermatol Ther 19, 280–8. 89 Yoshimura K, Momosawa A, Aiba E, Sato K, Matsumoto D, Mitoma Y, et al. (2003) Clinical trial of bleaching treatment with 10% all-trans retinol gel. Dermatol Surg 29, 155–60. 90 Fraser JR, Laurent TC. (1989) Turnover and metabolism of hyaluronan. Ciba Found Symp 143, 41–59. 91 Laurent TC. (1987) Biochemistry of hyaluronan. Acta Otolaryngol Suppl 442, 7–24. 92 Laurent TC, Fraser JR. (1992) Hyaluronan. FASEB J 6, 2397–404. 93 Kaya G, Jacobs F, Prins C, Viero D, Kaya A, Saurat JH. (2008) Deep dissecting hematoma: an emerging severe complication of dermatoporosis. Arch Dermatol 144, 1303–8.




94 Kaya G, Rodriguez I, Jorcano JL, Vassalli P, Stamenkovic I. (1997) Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissuespecific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Dev 11, 996–1007. 95 Forrester JV, Balazs EA. (1980) Inhibition of phagocytosis by high molecular weight hyaluronate. Immunology 40, 435–46. 96 West DC, Hampson IN, Arnold F, Kumar S. (1985) Angiogenesis induced by degradation products of hyaluronic acid. Science 228, 1324–6. 97 Didierjean L, Carraux P, Grand D, Sass JO, Nau S, Saurat JH. (1996) Topical retinaldehyde increases skin content of retinoic acid and exerts biological activity in mouse skin. J Invest Dermatol 107, 714–9. 98 Margelin D, Medaisko C, Lombard D, Picard J, Fourtanier A. (1996) Hyaluronic acid and dermatan sulfate are selectively stimulated by retinoic acid in irradiated and nonirradiated hairless mouse skin. J Invest Dermatol 106, 505–9. 99 Tammi R, Ripellino JA, Margolis RU, Maibach HI, Tammi M. (1989) Hyaluronate accumulation in human epidermis treated with retinoic acid in skin organ culture. J Invest Dermatol 92, 326–32. 100 Calikoglu E, Sorg O, Tran C, Grand D, Carraux P, Saurat JH, et al. (2006) UVA and UVB decrease the expression of CD44 and hyaluronate in mouse epidermis which is counteracted by topical retinoids. Photochem Photobiol 82, 1342–7. 101 Kaya G, Saurat JH. (2005) Restored epidermal CD44 expression in lichen sclerosus et atrophicus and clinical improvement with topical application of retinaldehyde. Br J Dermatol 152, 570–2. 102 Kaya G, Tran C, Sorg O, Hotz R, Grand D, Carraux P, et al. (2006) Hyaluronate fragments reverse skin atrophy by a CD44dependent mechanism. PLoS Med 3, e493. 103 Kaya G, Tran C, Sorg O, et al. (2006) Synergistic effect of retinaldehyde and hyaluronate fragments in skin hyperplasia. J Invest Dermatol 126, 33. 104 Bailly J, Crettaz M, Schifflers MH, Marty JP. (1998) In vitro metabolism by human skin and fibroblasts of retinol, retinal and retinoic acid. Exp Dermatol 7, 27–34. 105 Siegenthaler G, Saurat JH, Ponec M. (1990) Retinol and retinal metabolism: relationship to the state of differentiation of cultured human keratinocytes. Biochem J 268, 371–8. 106 Boehnlein J, Sakr A, Lichtin JL, Bronaugh RL. (1994) Characterization of esterase and alcohol dehydrogenase activity in skin: metabolism of retinyl palmitate to retinol (vitamin A) during percutaneous absorption. Pharm Res 11, 1155–9.


107 Connor MJ. (1988) Oxidation of retinol to retinoic acid as a requirement for biological activity in mouse epidermis. Cancer Res 48, 7038–40. 108 Bruce S. (2008) Cosmeceuticals for the attenuation of extrinsic and intrinsic dermal aging. J Drugs Dermatol 7, S17–22. 109 Burgess C. (2008) Topical vitamins. J Drugs Dermatol 7, S2–6. 110 Picardo M, Carrera M. (2007) New and experimental treatments of cloasma and other hypermelanoses. Dermatol Clin 25, 353–62. 111 Creidi P, Vienne MP, Ochonisky S, Lauze C, Turlier V, Lagarde JM, et al. (1998) Profilometric evaluation of photodamage after topical retinaldehyde and retinoic acid treatment. J Am Acad Dermatol 39, 960–5. 112 Boisnic S, Branchet-Gumila MC, Nocera T. (2005) Comparative study of the anti-aging effect of retinaldehyde alone or associated with pretocopheryl in a surviving human skin model submitted to ultraviolet A and B irradiation. Int J Tissue React 27, 91–9. 113 Kishore GS, Boutwell RK. (1980) Enzymatic oxidation and reduction of retinal by mouse epidermis. Biochem Biophys Res Commun 94, 1381–6. 114 Napoli JL, Race KR. (1988) Biogenesis of retinoic acid from beta-carotene. J Biol Chem 263, 17372–7. 115 Raner GM, Vaz AD, Coon MJ. (1996) Metabolism of all-trans, 9-cis, and 13-cis isomers of retinal by purified isozymes of microsomal cytochrome P450 and mechanism-based inhibition of retinoid oxidation by citral. Mol Pharmacol 49, 515–22. 116 Sorg O, Didierjean L, Saurat JH. (1999) Metabolism of topical natural retinoids. Dermatology 199 (Suppl), 13–7. 117 Kasraee B. (2002) Peroxidase-mediated mechanisms are involved in the melanocytotoxic and melanogenesis-inhibiting effects of chemical agents. Dermatology 205, 329–39. 118 Baron JM, Heise R, Blaner WS, Neis M, Joussen S, Dreuw A, et al. (2005) Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol 125, 143–53. 119 Tammi R, Pasonen-Seppanen S, Kolehmainen E, Tammi M. (2005) Hyaluronan synthase induction and hyaluronan accumulation in mouse epidermis following skin injury. J Invest Dermatol 124, 898–905. 120 Manuskiatti W, Maibach HI. (1996) Hyaluronic acid and skin: wound healing and aging. Int J Dermatol 35, 539–44. 121 Brown MB, Jones SA. (2005) Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin. J Eur Acad Dermatol Venereol 19, 308–18. 122 Trommer H, Wartewig S, Bottcher R, Pöppl J, Hoentsch J, Ozegowski JH, et al. (2003) The effects of hyaluronan and its fragments on lipid models exposed to UV irradiation. Int J Pharm 254, 223–34.

Chapter 39: Topical vitamins Donald L. Bissett Procter & Gamble Beauty Science, Cincinnati, OH, USA

BAS I C CONCEPTS • Vitamins are commonly used as active agents in skincare products designed to improve skin appearance. • The antioxidant vitamins A, C, and E can be safely applied topically. • Niacinamide (vitamin B3) and panthenol (vitamin B5) are of the vitamin B family used in moisturizers to improve skin appearance. • Careful formulation is required with vitamins to prevent loss of activity through photoinactivation or premature oxidation.

Introduction Vitamins are organic compounds required in small quantities for normal function and typically obtained from the diet. Many materials are described as vitamins [1]. Some of them have been used in topical cosmetic products, and certainly there is rationale for such use. Because they are essential nutrients, a few of them in a wide array of biochemical processes, they certainly have potential to have beneficial effects across a wide spectrum of skin problems. Also, because they are well studied because of their importance in nutrition, their mechanisms and toxicology are well understood. Additionally, with topical application and subsequent delivery into skin, they are more likely to have local meaningful effects vs. oral intake and the consequent limited delivery via the circulation to the skin site of interest (e.g. facial skin). Because there are so many vitamins, this review is necessarily selective, focusing on a few, with particular emphasis on those materials for which there is available well-controlled in vivo studies to illustrate skincare effects.

Vitamin A Forms Several forms of vitamin A are used cosmetically, the most widely utilized ones being retinol, retinyl esters (e.g. retinyl acetate, retinyl propionate, and retinyl palmitate), and retinaldehyde. Through endogenous enzymatic reactions, all are converted ultimately to trans-retinoic acid, the active form of vitamin A in skin. Specifically, retinyl esters are

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

converted to retinol via esterase activity. Retinol is then converted to retinaldehyde by retinol dehydrogenase. Finally, retinaldehyde is oxidized to retinoic acid by retinaldehyde oxidase (Figure 39.1).

Mechanisms Because trans-retinoic acid (RA) is the active form of vitamin A in skin, the abundant published literature on the former is applicable to this discussion. RA interacts with nuclear receptor proteins described as retinoic acid receptors (RAR) and retinoid X receptors (RXR), which can form heterodimer complexes. These complexes then interact with specific DNA sequences to affect transcription, to either increase or decrease expression of specific proteins and/or enzymes [2]. Using genomic methodology, work in our laboratories has found that the expression of over 1200 genes is significantly affected by topical retinoid treatment of photoaged human skin (unpublished observations). Many of these changes can be ascribed, at least on some level, as being normalization of the altered skin conditions that occur with aging (induced by both chronologic and environmental influences such as chronic sun exposure). Some specific changes induced by retinoid that are likely relevant to skin antiwrinkle appearance effects are those that result in thicker skin to diminish the appearance of fine lines and wrinkles; for example, increased epidermal proliferation and differentiation (increased epidermal thickness), increased production of epidermal ground substance (glycosaminoglycans [GAGs] which bind water, increasing epidermal hydration and thickness), and increased dermal production of extracellular matrix components such as collagen (increased dermal thickness). In addition to stimulation of events in skin, retinoids also have an inhibitory effect on other tissue components. For example, retinoids are reported to inhibit production of collagenase. Retinoid will stimulate production of ground









Retinyl palmitate


Retinol (vitamin A)

Alcohol dehydrogenase





Aldehyde dehydrogenase

COOH All- trans-retinoic acid

9-cis Retinoic acid C OOH 13-cis Retinoic acid COOH

substance (GAGs) in epidermis, but it will inhibit production of excess ground substance in photoaged dermis. While a low level of GAGs is required in the dermis for normal collagen structure and function, excess dermal GAGs are associated with altered dermal collagen structure and wrinkled skin appearance in the Shar Pei dog and in photoaged skin [3]. Because at least some of the epidermal effects of topical retinoid (e.g. epidermal thickening) occur relatively rapidly (days) after initiation of treatment, some skin effects (e.g. diminution of fine line appearance) can be realized quickly. The dermal effects likely occur on a much longer timeframe (weeks to months) such that reduction in skin problems via this mechanism likely require much longer timeframes (weeks to months).

Topical effects While much of the substantial literature on the improvement of skin wrinkles by topical retinoids is focused on


Figure 39.1 Conversion of retinyl ester into trans-retinoic acid in the skin.

trans-retinoic acid, there are also data available on the vitamin A compounds that are used cosmetically. Because retinoids are irritating to skin, defining skin-tolerated doses clinically is a key step in working effectively with these materials. Retinol is better tolerated by the skin than trans-retinoic acid. In our testing we noted that retinyl propionate is milder to skin than retinol and retinyl acetate (Table 39.1). Because retinoids in general tend to be fairly potent, topical doses of less than 1% are generally sufficient to obtain significant effects. At low doses, in double-blind, split-face, placebo-controlled facial testing (12 weeks’ duration), both retinol and retinyl propionate have both been shown to be significantly effective in reducing facial hyperpigmentation and wrinkles across the study (Figure 39.2). Determination of treatment effects was based on quantitative computer image analysis and blinded expert grading of high resolution digital images.

39. Topical vitamins

Table 39.1 Cumulative back irritation measures for retinol and its esters (double-blind, vehicle-controlled, randomized study; daily patching for 20 days, under semi-occluded patch, n = 45; 0–3 irritation grading). Equimolar doses and abbreviations used: 0.09% RP (retinyl propionate); 0.086% RA (retinyl acetate); and 0.075% ROH (retinol). RP and RA were significantly less irritating than ROH, and RP was directionally less irritating than RA. Topical treatment (oil-in-water emulsions) Emulsion control

Expert grader cumulative irritation scores 3.9

Significance of expert grader cumulative scores*

Chromameter “a” measure (day 21)

Significance of chromameter “a” measure*




0.09% RP





0.086% RA









0.075% ROH

* Treatments with the same letter codes are not significantly different from each other (p < 0.05).

Figure 39.2 Retinyl propionate (RP) reduces the appearance of fine lines and wrinkles. A 0.3% Retinyl propionate in a stable skincare emulsion system was applied twice daily for 8 weeks. (a) Baseline; (b) 8 weeks.



There are also clinical studies published on other retinoids. Retinyl palmitate has very low irritation potential and is effective if tested at a very high dose such as 2%. There are also several studies revealing the clinical efficacy of retinaldehyde, typically at a dose of 0.05%. However, retinaldehyde has irritation potential similar to retinol [4].

Formulation challenges There are two primary challenges in working with retinoids. One is their tendency to induce skin irritation (as noted above) which negatively affects skin barrier properties. While high doses will provide greater skin aging appearance improvement, the associated irritation tends to define an upper concentration limit where they can be used practically. While the skin may have some capacity to accommodate to retinoid treatment to yield less irritation, it is not completely eliminated even with long-term use, as demonstrated by evaluation of skin barrier function. Mitigation of the irritation may be managed to some extent with appropriate formulation to meter delivery into the skin, use of retinyl esters which are less irritating than retinol (as noted above),

or inclusion of other ingredients (e.g. those with antiirritancy or anti-inflammatory activity) to counter this issue. The second key issue is instability, especially to oxygen and light. Thus, to ensure stability of retinoid in finished product, formulation and packaging must be carried out in an environment that minimizes exposure to oxygen and light. The final product packaging also ideally needs to be opaque and oxygen impermeable, including use of a small package orifice to reduce oxygen exposure once the container is opened. In addition, a variety of other strategies can be employed (e.g. encapsulation of the retinoid and inclusion of stabilizing antioxidants).

Vitamin B3 Forms There are three primary forms of vitamin B3 that have found utility in skin care products: niacinamide (nicotinamide), nicotinic acid, and nicotinate esters (e.g. myristoyl nicotinate, benzyl nicotinate).




Family of co-factors:









•NADH (antioxidant) •NADPH (antioxidant)


P O-









‡‡‡‡ O


P O-


N Niacinamide (vitamin B3)







Mechanisms Vitamin B3 serves as a precursor to a family of endogenous enzyme co-factors (Figure 39.3), specifically nicotinamide adenine dinucleotide (NAD), its phosphorylated derivative (NADP), and their reduced forms (NADH, NADPH) which have antioxidant properties. These co-factors are involved in many enzymatic reactions in the skin, and thus have potential to influence many skin processes. This precursor role of vitamin B3 may thus be the mechanistic basis for the diversity of clinical effects observed for a material such as niacinamide. While precisely how the dinucleotide cofactors might contribute to all these effects has not been elucidated, several specific actions of niacinamide specifically have been described [5,6]. For example, topical niacinamide has the following effects: • Niacinamide inhibits sebum production, specifically affecting the content of triglycerides and fatty acids. This may contribute to the observed reduction in skin pore size and thus improved skin texture (a component of texture being enlarged pores). • Niacinamide increases epidermal production of skin barrier lipids (e.g. ceramides) and also skin barrier layer proteins and their precursors (keratin, involucrin, filaggrin), leading to the observed enhancement of barrier function as determined by reduced transepidermal water loss (TEWL). This improved barrier also increases skin resistance to environmental insult from damaging agents such as surfactant and solvent, leading to less irritation, inflammation, and skin redness (e.g. facial red blotchiness). Because inflammation is involved in development of skin aging problems, the barrier improvement may contribute to the antiaging effects




N Figure 39.3 Niacinamide as precursor to energy co-factors: nicotinamide adenine dinucleotide (NAD), nicotinamide adenine dinucleotide phosphate (NADP), and their reduced forms NADH and NADPH.

of topical niacinamide. The anti-inflammatory and sebum reduction effects of niacinamide likely contribute to the antiacne effect reported for this material. • Niacinamide has anti-inflammatory properties (e.g. inhibition of inflammatory cytokines). • Niacinamide increases production of collagen which may contribute to the observed reduction in the appearance of skin wrinkling. • Niacinamide reduces the production of excess dermal GAGs. In cell culture testing as noted above for retinyl propionate, 0.5 mmol niacinamide reduced excess GAG production by 15%. • Niacinamide inhibits melanosome transfer from melanocytes to keratinocytes, leading to reduction in skin hyperpigmentation (e.g. hyperpigmented spots). • Niacinamide inhibits skin yellowing. A contributing factor to yellowing is protein oxidation (glycation; Maillard reaction) which is a spontaneous oxidative reaction between protein and sugar, resulting in cross-linked proteins (Amedori products) that are yellow–brown in color. These products accumulate in matrix components such as collagen that have long biological half-lives [7]. Niacinamide has antiglycation effects, likely because of its conversion to the antioxidant NAD(P)H. Because nicotinic acid and its esters are also precursors to NAD(P), they would be expected to provide these same effects to skin. Nicotinic acid and many (if not all) of its esters (following in-skin hydrolysis to free nicotinic acid) also stimulate blood flow, leading to increased skin redness or a flush response. While in some situations this might be a desired effect (e.g. warming sensation for

39. Topical vitamins body skin), it is difficult to manage for the more sensitive facial skin.

Topical effects As representative for the vitamin B3 family of compounds, there are several published reports on the diversity of clinical effects of topical niacinamide. These data were obtained from double-blind, placebo-controlled, left–right randomized studies. For example, topical niacinamide has been shown to reduce skin fine lines and wrinkling. The effect increases over time and is significant after 8–12 weeks of treatment. Topical niacinamide also improves other aspects of aging skin, such as reduction in sebaceous lipids (oil control) and pore size, which likely contribute at least in part to improved skin texture. Additionally, niacinamide improves skin elastic properties as demonstrated for two parameters of skin elasticity. Beyond these effects, there is also improvement in appearance of skin color, in particular reduction in the appearance of hyperpigmented spots (Figure 39.4) and also skin yellowing. Fairly high doses (2–5%) of vitamin B3 have been used to achieve these effects. However, because there is very high tolerance of the skin to niacinamide even with chronic usage, high doses can be used acceptably. In fact, as noted above, because topical niacinamide improves skin barrier, it actually increases the skin’s resistance to environmental insult (e.g. from surfactant) and reduces red blotchiness. Some data on myristoyl-nicotinate have been presented to suggest that a similar broad array of effects occurs with this agent when used topically (1–5% doses). Clinical data for topical nicotinic acid and other esters are not available.

acid. Nicotinic acid, even at low doses, can induce an intense skin reddening (flushing) response. While a little skin redness (increased skin “pinkness”) may be a desired effect for the face, the flushing response among individuals is highly variable in terms of dose to induce it, time to onset of the response, and duration of response. Additionally, the flushing can also have associated issues such as facial burn, sting, and itch, particularly under cold and/or dry environmental conditions. To avoid hydrolysis, formulating in the pH range of 5–7 is preferred. This flushing issue also requires that the purity of the raw material (e.g. niacinamide) be very high to minimize any contaminating free acid. For the nicotinate esters, there are many commercial options. Many of them unfortunately are readily hydrolyzed to nicotinic acid on or in the skin such that flushing responses occur rapidly (within seconds to minutes) even at very low concentrations (15

Horizontal forehead lines




Glabellar complex

Procerus, depressor supercilii, orbicularis oculi




Crow’s feet

Orbicularis oculi

2–5 per side



Narrow palpebral aperture

Pretarsal fibers of orbicularis oculi

1 per side



Lateral brow lift

Superolateral fibers of orbicularis oculi

1–2 per side



Bunny lines


1 per side



Gummy smile

Levator labii superioris alaeque nasi

1 per side



Perioral lines

Orbicularis oris

4–6 per lip



Dimpled chin





Downturned smile

Depressor anguli oris




Platysmal bands


2–12 per band



Nerfertiti lift


7 per side



Masseter hypertrophy


5–6 per side



Mid face

Lower face

* BoNTA represents the type A botulinum toxin approved in the USA for cosmetics, Botox. All sites other than glabellar complex are “off-label” currently in the USA.


(a) Figure 42.2 Horizontal forehead lines before (a) and after (b) Botox injection.



Injectable Antiaging Techniques

low-set brows should be evaluated carefully prior to injection as they represent the population most at risk of significant eyebrow ptosis and/or complaints of “heaviness” after treatment. Patients with significant etched-in lines immediately superior to their lateral brows are also patients who may frequently be advised not to have BoNTA treatment as they depend on the baseline action of the lower frontalis fibers to hoist the brow upward and away from their eyelid.

Glabella The glabellar complex (Figure 42.1) represents the site most commonly treated with BoNTA. In the USA, it is the only cosmetic site for which Botox has FDA approval. It is one of the easiest sites to treat and a good place for novice injectors to begin. Both the corrugator supercilii and the depressor supercilii originate on the nose and insert into the midbrow. These muscles draw the brow medially and downward, and thus create vertical lines in the glabella. Treatment of these brow depressors leads to relaxation of these muscles, which usually results in a medial lift of the brow to some extent. The procerus muscle originates on the nasal bridge and inserts into skin of the mid-glabella. Contraction of the procerus also pulls the medial brow down, but with the pure vertical orientation of this muscle a horizontal line becomes etched in the skin with contraction over time. Glabellar doses of Botox typically range 10–30 U in women and 20–40 U in men. Injections are most commonly placed in five specific sites: one injection in the procerus, one in each of the medial corrugators, and one in each of the lateral corrugators (Figure 42.3). Sometimes, in patients who display significant medial recruitment above the mid-brow, 1–2 additional injection sites can be helpful to avoid this central pulling. Toxin should generally not be placed any closer than 1–1.5 cm above the bony orbital rim in the mid-

pupillary line in order to try to avoid lid ptosis. Lid ptosis can occur from migration of the toxin through the orbital septum to the levator palpebrae superioris muscle (which functions to elevate the lid upwards).

Periorbital The orbicularis oculi muscle is a circular, sphincter-like muscle that surrounds the eye and functions in eyelid closure. The circularity of this muscle creates an anatomical structure composed of fibers running in multiple directions. The muscular diversity of the orbicularis oculi creates functional diversity in animation of the periorbital area. For example, the lateral and superolateral fibers of the orbicularis oculi immediately below the brow function as brow depressors. Treatment of the lateral canthal rhytides (commonly described as crow’s feet) is often satisfying for the novice injector and the patient. Because of the presence of many small vessels in the lateral periocular area, it is often recommended to place BoNTA injections superficially (even intradermally) in this region, usually creating a wheal at the injection site. For treatment of lateral, canthal rhytides, the injector typically chooses 2–5 injection points per side, depending on the prominence of the musculature of the area. The reality is that orbicularis oculi muscle prominence varies between patients, making individual assessment of anatomy and patterns of dynamic muscular lines helpful prior to treatment of each patient [14]. Typically, 5–15 units of BoNTA are injected into each side (Figure 42.4). Care should be taken to inject no closer than 0.5–1 cm to the lateral orbital rim in order to avoid migration of toxin causing unintended paralysis of ocular muscles. In a small minority of patients, pretarsal bands of the orbicularis oculi muscle can be hypertrophic at the lower lid. A hyperfunctional, pretarsal orbicularis oculi muscle can cause unsightly bands around the lower eyelid and narrow-


(a) Figure 42.3 Glabellar frown lines before (a) and after (b) Botox injection.


42. Botulinum toxins


(b) Figure 42.4 “Crow’s feet” before (a) and after (b) Botox injection.

ing of the palpebral aperture. If treating this infraorbital, hyperfunctional musculature, it is recommended to first evaluate lower lid laxity with a “snap-test” to ensure lid competency after the muscle is weakened. Typically, 1–2 units of BoNTA are used in this pretarsal area for patients who complain of significant muscle prominence of this area, or those who desire changing the shape of their eye from an almond-type shape to that of a more rounded eye with a widened palpebral aperture. Injections are placed carefully from a lateral approach subdermally, about 3 mm below the ciliary margin in the mid-pupillary line [13]. A lateral approach in this area helps to ensure a superficial injection, and to allow the non-injecting hand to pull down the lower lid and protect the patient from movement.

Lateral brow lift In patients with downturned or ptotic lateral brows, either from dermatochalasis, overactive lateral orbicularis oculi activity pulling down on the tail of the brow, or inadvertent paralysis of the most inferior fibers of the frontalis after aggressive forehead BoNTA treatment, partial correction can sometimes be achieved with a BoNTA chemical brow lift. This lateral brow lift can be obtained by injection into the superolateral fibers of the orbicularis oculi muscle. This technique relaxes the specific aspect of the orbicularis oculi that is pulling the lateral brow downward, and carefully tries to avoid some of the adjacent inferolateral frontalis fibers just superior to the brow – as these frontalis fibers can be helpful to try to pull the lateral brow upward. To accomplish this effect the injector places 4–6 units of BoNTA in a specific spot just below the lateral infrabrow [15]. Identification of this injection site requires that the patient first elevate their brows to find the lateral margin of the frontalis muscle (known as the temporal fusion plane). Second, the patient must close their eyes forcefully in order to localize the area where the orbicularis oculi exerts maximal medial and

Figure 42.5 The lateral bow lift can be obtained by injection into the superolateral fibers of the orbicularis oculi muscle. This technique relaxes the specific aspect of the orbicularis oculi that is pulling the lateral brow downward. (Adapted from Sommer B, Sattler G, eds. (2001) Botulinum Toxin in Aesthetic Medicine. Blackwell Science, Boston, MA.)

downward pull on the lateral brow. The proper injection point is just inferior to the point of maximal pull downward on the brow, but making sure this site is at least 1–1.5 cm inferior to the most lateral fibers of the frontalis muscle (Figure 42.5). Avoiding these trailing lateral frontalis fibers allows for the preservation of the lift the lateral frontalis normally provides at baseline. Patients with more significant brow redundancy can sometimes be improved with a combination of BoNTA in conjunction with small volumes of fillers (e.g. 0.1–0.2 mL of a hyaluronic acid product) placed just below the lateral brow, but clearly those with more severe dermatochalasis can really only be effectively treated with surgical intervention.

Treatment of the mid-face Bunny lines Contraction of the nasalis muscle creates diagonal lines along the proximal nasal sidewall. This area is becoming a more common area of BoNTA treatment. Patients seeking



Injectable Antiaging Techniques

treatment of these lines often have experienced the benefits of BoNTA softening the forehead, glabella, and crow’s feet and are looking to extend a more relaxed look to the midface. Identification of the muscle is straightforward and accomplished by having the patient “scrunch” their nose. Some 3–5 units of BoNTA can be placed superficially into the muscle at the medial aspect of the proximal nasal sidewall on each side of the nose. Placement of BoNTA too far laterally can lead to unwanted paralysis of the adjacent levator labii superioris aleque nasi (LLSAN), resulting in elongation or drooping of the upper lip. The final cosmetic result can often be enhanced with concomitant treatment of the procerus in some patients with more significant bunny lines that seem to be most bulky on the proximal nasal dorsum.

Softening of the nasolabial fold or “gummy smile” An overactive LLSAN can be a component of an accentuated or prominent superior nasolabial fold. Treatment of the LLSAN can be an option for young patients looking to soften the superior aspect of the nasolabial fold without using fillers or at a lower cost than fillers. A total of 1–2 units of BoNTA can often achieve a softening of the top of the nasolabial fold, and a 1992 anatomic study by Pessa illustrated that the LLSAN is actually the more important muscle contributing to the prominence of the nasolabial fold. Higher doses (typically 3–5 units) of BoNTA are usually used at the same location for patients with significant gummy smiles. Injection of 3–5 units per side of BoNTA into the belly of LLSAN at the pyriform aperture can elongate the upper cutaneous lip and partially correct the excessive gingival display [16]. Doses of 5–7.5 units of BoNTA in patients with very severe gummy smiles have been reported [16]. In cases of a prominent nasolabial fold or a gummy smile, injection of the LLSAN is primarily a treatment for younger patients who can compensate for the resulting pronounced elongation of the cutaneous lip with other musculature. In addition to the LLSAN, the muscles responsible for the elevation of the upper lip particulary in younger individuals are the levator labii superioris, levator anguli oris, zygomaticus major and minor, and the depressor septi nasi. Older patients seem to be more reliant on primarily the levator labii muscles alone.

Treatment of the lower face Perioral lines The lips are the cosmetic focal point of the lower face and careful, conservative corrections can often dramatically improve aspects of an aging face. Vertical “etched in” lines of the perioral skin are common and are caused by years of contraction of the orbicularis oris muscle, a sphincter-like muscle that encircles the mouth. Etched in lines are preceded by years of vertical muscle columns in women, leading


eventually to imprinting of the perioral skin. The skin in this area is highly innervated and vascular, and therefore injections into this region are generally associated with more discomfort and can be associated with bruising or swelling. Topical anesthetics and the application of ice-packets can be very beneficial. Tenants of injecting BoNTA into the lips include: use of low doses with frequent follow-up for retreatment, preservation of symmetry utilizing photography and carefully placed injections, treatment of both upper and lower lips at the same time, and avoidance of midline injections to preserve the desirable Cupid’s bow. Injection technique varies depending on individual anatomy, but typical treatments include four superficial injection sites in the upper lip (two points on each side of the upper lip) just above the vermillion border. In patients with more significant vertical muscle columns (taller, bulkier, deeper) sometimes an additional site on each side of the upper lip (often 1 cm above the vermillion border) can be helpful. For the lower lip, usually four superficial injection sites are performed as well (two sites on each side of midline approximately 1.5 cm apart). It is important to inject superficially and use lower dosages, especially for a patient’s first treatment. Follow-up 2 weeks later will typically allow the injector to see if additional units may be helpful. Some have advocated doses for perioral injection to be in a range of 4–5 units [13], but the authors sometimes use a total of 10–12 units for patients with more significant perioral vertical muscle columns.

Dimpled chin The mentalis muscle originates in the incisive fossa and inserts into the skin of the chin. Contraction of this muscle can create a dimpled appearance of the chin that has been termed “pebbled chin,” “golfball chin,” “peau d’ orange chin,” and “apple dumpling chin.” A total of 4–8 U of BoNTA, placed as a single midline injection or in two points 0.5 cm lateral to midline at the bony part of the chin can be very effective. Product placed too far laterally risks paralysis of the depressor labii inferioris and can cause speech problems.

Downturned smile Descent of the lateral commisures of the mouth can result from gravity and volume loss and sometimes from hypertrophy of the depressor anguli oris (DAO) muscle. Injection of BoNTA (3–4 units per side) into the posterior aspect of the DAO in a single injection site can sometimes partially correct this appearance of a downturned smile (Figure 42.6). Complications associated with medial diffusion or injection of BoNTA into the depressor labii inferioris are discussed below. DAO prominence is often associated with volume loss of the lower face, and in our experience combination treatment with fillers and BoNTA is more consistently effective than BoNTA alone.

42. Botulinum toxins


Figure 42.6 Treatment of a downturned smile is accomplished by injection into the posterior fibers of the depressor anguli oris (DAO) muscles. (Adapted from Sommer B, Sattler G, eds. (2001) Botulinum Toxin in Aesthetic Medicine. Blackwell Science, Boston, MA.)

ment. Local adverse effects included masticatory difficulties (44% of patients) and speech disturbance (16% of patients). All side effects were transient. A study specifically measuring bite force in patients treated with 25 units of BoNTA per masseter (50 units total) reported significant bite-force reduction at 2, 4, and 8 weeks postinjection (p < 0.05) [20]. Difference in bite-force reduction was not statistically significant at the 12-week measurement, and while bite-force measurements trended upward, they still did not achieve preinjection values at the end of 12 weeks. So while injection can beneficially alter the shape of the masseter, it may alter mastication. Further study is needed to better define the duration and significance of the observed bite-force reduction.

Platysmal bands The platysma is a thin, superficial muscle that can create vertical bands in the neck which are displeasing to many patients. Patient selection is key to successful treatment of this condition, and the most appropriate candidates are those with prominent vertical bands at rest. A typical treatment session includes injection of 2–3 bands with 20–35 U of BoNTA total (2–12 injection points per band). Dysphagia is a rare complication that has been reported with cosmetic use of BoNTA for treatment of platysmal bands [17]. Conservative treatment, with low dosages and superficial injections, is recommended in order to avoid this very rare and disturbing complication that can persist for weeks. Marking injection points and pinching the band between the thumb and forefinger can aid in the precise superficial placement of BoNTA. In addition to the treatment of platysmal bands, placement of toxin along the inferior margin of the mandible and in the superior aspect of the posterior platysmal band may redefine the mandibular border. This procedure has been termed the “Nefertiti lift” and was described by Levy in a study of 130 patients [18]. Patients were treated with 2–3 units of BoNTA per injection site, with five sites being along the margin of the mandible and two sites being in the superior aspect of the posterior platysmal band. It was hypothesized that the resultant sharpening of the mandibular border was secondary to partial reversal of the chronic downward pull on the cheeks by the platysma.

Masseter hypertrophy Prominent masseter bulk over the posterior mandible can create a squared-off shape to the face which is not desirable to some people. A study of 45 patients with masseter hypertrophy were treated with BoNTA and followed for 10 months [19]. Twenty-five to 30 units of BoNTA were injected into each masseter in 5–6 injection points. The maximum reduction in masseter thickness as measured by ultrasound was seen at 1 month and CT scan found continued reduction of masseter muscle thickness up to 3 months after treatment. Eighty-two percent of patients were satisfied with the treat-

Combination of BoNTA with fillers While BoNTA treatment works well for dynamic rhytides, resting lines and volume loss are not corrected by neurotoxin placement alone. Combination treatment consisting of hyaluronic acid and BoNTA often yield impressive results and may double the duration of response compared with filler treatment alone in some areas [21]. Combination therapy can be useful in the glabella, periorbital area, perioral, mentalis, and sometimes the nasolabial creases. Placement of filler prior to BoNTA treatment may decrease untoward migration of toxin caused by massage of the filler and the common practice of confirming placement of the filler product after injection. Areas lending themselves to combination treatment as well as injection tips are presented in Table 42.4.

Complications and management Bruising, swelling, and mild asymmetry are commonly encountered issues. Less common is migration of toxin to adjacent but unintended musculature, which can result in significant asymmetry. Eyebrow ptosis can occur from toxin placement too close to the brow in the frontalis muscle, poor patient selection and use of higher dosages in the forehead. In fact, a recent consensus publication recommended using about half the frontalis dose of BoNTA previously suggested in an earlier statement by the same group [13]. Eyelid ptosis is also uncommon (less than 1% of patients in the hands of experienced injectors) and presumably occurs when injecting the lateral corrugator area, with migration of toxin through the orbital septum leading to the paralysis of the levator palpebrae superioris. This is a transient event (generally resolving by 2–3 weeks) and can be treated to some extent, but often not fully, by using ophthalmic drops such as Naphcon (Alcon, Fort Worth, TX, USA) (can be purchased over-the-counter) which exert mild



Injectable Antiaging Techniques

Table 42.4 Combination therapy with BoNTA and fillers. Treatment area

Filler tip


Prefer non-cross-linked collagen products* placed superficially and hyaluronic acid products with small particle size. Polymethylmethacrylate (Artefill), calcium hydroxylapatite (Radiesse), poly L lactic acid (Sculptra) and silicone should only be used by very experienced injectors in this area

Crow’s feet

Thin skin requires thin product such as non-cross-linked collagen agent* or a hyaluronic acid designed for superficial placement in small aliquots with 32-gauge needle

Perioral lines

Prefer collagen products (type depending on depth of wrinkle) or hyaluronic acid of small particle size. Polymethylmethacrylate (Artefill), calcium hydroxylapatite (Radiesse), poly L lactic acid (Sculptra) and silicone should only be used by very experienced injectors in this area and still should not be placed shallowly

Downturned smile/marionette lines

Correction of downturned smile with BoNTA can be enhanced with filler placement in the marionette lines. Useful agents in this area include collagens, hyaluronic acids, silicone, poly L lactic acid and calcium hydroxylapatite. Choice of filler depends on skill and experience of the injector


Choice of filler depends on skill and experience of the injector

* Zyderm I or II and Cosmoderm I or II.

adrenergic effects, or Iopidine (Alcon, Fort Worth, TX, USA) prescription drops [22]. The mechanism of both treatments is adrenergic stimulation and contraction of the adjacent Mueller’s muscle which can partially raise the eyelid. Iopidine may mask underlying glaucoma so this treatment should be reserved for short periods of treatment such as 3–5 weeks, as the eyelid ptosis is transient in nature [22]. In a double-blind, placebo-controlled, glabellar study, headache occurred in 20% of patients in the placebo group vs. 11.4% in the BoNTA treated group, leading authors to conclude that headache was likely related to trauma from the injection itself [23]. A non-blinded case series of 320 patients treated for cosmetic reasons with BoNTA reported the occurrence of severe, debilitating headaches in 1% of patients treated [24]. In this study, these headaches occurred within 2 days of injection with BoNTA and persisted at a high level for 2 weeks to 1 month after injection. As far as bruising and swelling, it is best to wipe off the patient’s make-up prior to injection (particularly in the lateral canthal area), to best identify little veins in the area


to better avoid them and to avoid the risk of introducing foreign make-up material into the skin. Ice prior to injection to facilitate vasoconstriction is also very helpful in helping to reduce the mild pain of the injections themselves. If patients are on medications or vitamins for preventive purposes that may have an anticoagulant type of effect, it is certainly helpful if they discontinue these agents a few days prior to injection. An example of such an agent would be the use of aspirin as a preventive measure in patients lacking a history of atherosclerotic disease, stroke, or clot. Immunogenicity to BoNTA has been reported in the literature but is very rare in patients treated with the newer (post-1997) formulation of BoNTA. The newer formulation of Botox has only 20% of the protein content that the older batch had (pre-1997) and presumably has made the product significantly less immunogenic. One case report, however, describes neutralizing antibody formation to the post-1997 formulation of Botox in a patient treated cosmetically for masseter hypertrophy [25]. Presence of neutralizing antibody was supported by two positive mouse protection assays and by ELISA testing [25]. Risks associated with immunogenicity are very large doses of toxin (more frequent in therapeutic uses of BoNTA) and short intervals (less than 3 months) between high-dose injections [1]. Generalized reactions have been reported related to toxicity and include headache, nausea, malaise, fatigue, flu-like symptoms, and rashes distant to injection sites from improper dosages and the use of “experimental strains of botulinum toxin” [26]. In studies measuring complications in patients treated with legitimate BoNTA, adverse events occurred in similar frequencies in both treatment and placebo groups. Most post-injection issues are transient in nature and resolve spontaneously, requiring no intervention other than reassurance.

Upper face Injection into the frontalis muscle can lead to brow ptosis, and patients can develop a quizzical look (raising of the lateral brow because of residual non-treated frontalis fibers pulling upward) if only medial fibers of the frontalis are treated. This “Mr. Spock” look can usually be easily treated with placement of 1–2 units in each side of the lateral functional frontalis. In addition, patients can rarely experience painful electric shock-like sensations if the supraorbital or supratrochlear sensory nerves are inadvertently hit with the injection needle.

Lower face Treatment of the orbicularis oris muscle for correction of vertical lip lines can very rarely lead to drooling or difficulty with phonation. Thus, when treating vertical muscle columns caused by a hyperfunctional orbicularis oris muscle, care should be taken to use lower dosages and avoid overtreatment. In addition, medial placement of these injections

42. Botulinum toxins can help avoid unintended musculature being affected, especially near the oral commissure. Correction of downturned smile is best accomplished with careful BoNTA placement in the posterior aspect of the depressor anguli oris muscle. This posterior placement helps avoid unintended medial migration and effect on the depressor labii inferioris, a complication that can cause slurred speech and drooling and lasts weeks to months [27]. As far as the neck, injection of BoNTA into the neck for softening of platysmal bands has in one report led to prolonged dysphagia secondary to paralysis of the deeper strap muscles requiring placement of nasogastric tube [17]. This event can be best avoided by following the recently revised recommendations presented in this chapter. Even the most experienced of injectors may observe asymmetric treatment effect, despite consistent technique. This unbalanced appearance is usually easily corrected with additional enhancement injections. Finally, temporary strabismus or diplopia are extremely rare and infrequently reported, and likely occur by either large diffusion or direct injection of toxin into the extraocular muscles.

11 12 13




17 18 19

References 1 Huang W, Foster JA, Rogachefsky AS. (2000) Pharmacology of botulinum toxin. J Am Acad Dermatol 43, 249–59. 2 Carruthers JDA, Carruthers JA. (1992) Treatment of glabellar frown lines with C. botulinum exotoxin. J Dermatol Surg Oncol 18, 17–21. 3 Sadick NS, Matarasso SL. (2004) Comparison of botulinum toxins A and B in the treatment of facial rhytides. Dermatol Clin 22, 221–6. 4 Ting PT, Freiman A. (2004) The story of Clostridium botulinum: from food poisoning to Botox®. Clin Med 4, 258–61. 5 Matarasso SL. (2003) Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 29, 7–13. 6 Lizarralde M, Gutierrez SH, Venegas A. (2007) Clinical efficacy of botulinum toxin type a reconstituted and refrigerated 1 week before its application in external canthus dynamic lines. Dermatol Surg 33, 1328–33. 7 Hexsel DM, Trindade de Almeida A, Rutowitsch M, et al. (2003) Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to 6 consecutive weeks before application. Dermatol Surg 29, 523–9. 8 Scott AB, Suzuki D. (1988) Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 3, 333–5. 9 Cote TR, Mohan AK, Polder JA, Walton MK, Braun MM. (2005) Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol 53, 407–15. 10 Cox SE, Finn JC, Stetler L, Mackowiak J, Kowalski JW. (2003) Development of the Facial Lines Treatment Satisfaction



22 23





Questionnaire and initial results for botulinum toxin type A-treated patients. Dermatol Surg 29, 444–9; discussion 449. Finn JC, Cox SE, Earl ML. (2003) Social implications of hyperfunctional facial lines. Dermatol Surg 29, 450–5. Review. Flynn TC. (2006) Update on botulinum toxin. Semin Cutan Med Surg 25, 115–121. Carruthers J, fa*gien S, Matarasso SL, and the Botox Consensus Group. (2008) Advances in facial rejuvenation: botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies: consensus recommendations. Plast Reconstr Surg 121 (Suppl), 5–30S. Kane MA. (2003) Classification of crow’s feet patterns among Caucasian women: the key to individualizing treatment. Plast Reconstr Surg 112(Suppl), 33–9S. Cohen JL, Dayan SH. (2006) Botulinum toxin type A in the treatment of dermatochalasis: an open-label, randomized, dosecomparison study. J Drugs Dermatol 5, 596–601. Kane MA. (2003) The effect of botulinum toxin injections on the nasolabial fold. Plast Reconstr Surg 112 (Suppl), 66–72S; discussion 73–4S. Carruthers J, Carruthers A. (1999) Practical cosmetic Botox techniques. J Cutan Med Surg 3 (Suppl 4), S49–52. Levy PM. (2007) The “Nefertiti lift”: a new technique for specific re-contouring of the jawline. J Cosmet Laser Ther 9, 249–52. Park MY, Ahn KY, Jung DS. (2003) Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg 29, 477–83. Ahn KY, Kim ST. (2007) The change of maximum bite force after botulinum toxin type a injection for treating masseteric hypertrophy. Plast Reconstr Surg 120, 1662–6. Carruthers J, Carruthers A. (2003) A prospective, randomized, parallel group study analyzing the effect of BTX-A (Botox) and nonanimal sourced hyaluronic acid (NASHA, Restylane) in combination compared with NASHA (Restylane) alone in severe glabellar rhytides in adult female subjects: treatment of severe glabellar rhytides with a hyaluronic acid derivative compared with the derivative and BTX-A. Dermatol Surg 29, 802–9. Klein AW. (2003) Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg 29, 549–56. Carruthers JD, Lowe NJ, Menter MA, Gibson J, Eadie N, Botox Glabellar Lines II Study Group. (2003) Double-blind, placebocontrolled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 112, 1089–98. Alam M, Arndt KA, Dover JS. (2002) Severe, intractable headache after injection with botulinum a exotoxin: report of 5 cases. J Am Acad Dermatol 46, 62–5. Lee S. (2007) Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg 33 (1 Spec No.), S105–10. Bootleg Botox sentences. New York Times January 27, 2006. Available at: B02EFDB113FF934A15752C0A9609C8B63. Accessed November 26, 2007. Cohen JL. (2007) Botulinum neurotoxin clinical update. Cosmet Dermatol 20, S3.


Chapter 43: Hyaluronic acid fillers Mark S. Nestor Center for Cosmetic Enhancement, Aventura, FL, and University of Miami Miller School of Medicine, Miami, FL, USA

BAS I C CONCE P T S • Hyaluronic acid fillers are used for 86% of the volume enhancing procedures performed in the USA. • Hyaluronic acid filler are popular because they are non-permanent but long-lasting, have few allergic aspects, minimal side effects, are relatively painless to inject, and can be reversible. • Hyaluronic acid is a polysaccharide, specifically a glycosaminoglycan, that is formed from repeating D-glucuronic acid and D-N-acetylglucosamine disaccharide units. The disaccharide units are linked together in a linear chain forming a large polymer with a total molecular weight of greater than 10 MDa. • The different hyaluronic acid fillers possess various hyaluronic acid concentrations, sizes of particles, gel consistencies, type of cross-linking, degree of cross-linking, and the degree of gel hardness. • Hyaluronic acids are injected in the deep dermis for optimal volume replacement.

Introduction The appearance of the aging face is a compilation of intrinsic aging; influenced by genetics causing the preprogrammed loss of fat, muscle, and bone as well skin elasticity changes, and extrinsic aging; primarily photodamage that affects collagen, elastin, and accelerates the intrinsic aging process [1]. One of the hallmarks of the aging face is the loss of tissue volume and as well as the accentuation of lines and folds [2]. While many procedures can be used to improve the appearance of the aging face, the use of soft tissue, dermal fillers has become one of the most popular ways of filling lines and wrinkles as well as replacing volume in the aging face [3]. According to recent statistics of the American Society of Aesthetic Plastic Surgeons, the use of dermal fillers is only second to Botox® (Allergan, Inc., Irvine, CA, USA) as one of the most popular non-surgical cosmetic procedures performed in 2007. Of all the dermal fillers used in the USA, hyaluronic acid fillers accounted for nearly 86% of fillers used [4]. While hyaluronic acid fillers might not be the “perfect” filler in all aspects, they come very close to what most patients and physicians look for in the ideal filler, namely non-permanent but long-lasting, having few if any allergic aspects, minimal side effects, relatively painless to inject, and safe because of the reversible nature of hyaluronic

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


acid fillers. This chapter outlines the science and use of hyaluronic acid fillers including: 1 The chemical composition and physical properties of hyaluronic acid fillers. 2 The indications for the variety of Food and Drug Administration (FDA) approved fillers. 3 Injection techniques, both beginner and advanced. 4 Complications of filler injections and their solutions. 5 Future uses and indications for hyaluronic acid fillers.

Chemical composition and properties of hyaluronic acid fillers At this time, there are nine FDA approved hyaluronic acid fillers used in the USA. These are listed in Table 43.1. All hyaluronic acid fillers are formed from either bacterial-based or animal-based hyaluronic acid. Hyaluronic acid is a polysaccharide, specifically a glycosaminoglycan, that is formed from repeating D-glucuronic acid and D-Nacetylglucosamine disaccharide units. The disaccharide units are linked together in a linear chain forming a large polymer with a total molecular weight of greater than 10 MDa. While both animal-based and bacterial-based hyaluronic acid fillers are on the market, the vast majority of utilized fillers are based on bacterial production. Native hyaluronic acid would break down very quickly if injected into the skin and needs to be altered and stabilized primarily by cross-linking to have a long resident life in the skin. Because the basis of all bacterial-based dermal fillers is the same, the difference of the fillers and their properties depend upon the type and

43. Hyaluronic acid fillers

Table 43.1 Food and Drug Administration (FDA) approved fillers. Allergan Juvéderm™ Ultra/Juvéderm™ Ultra Plus Captique/Hylaform/Hylaform Plus (phasing out) Anika Therapeutics Hydrelle™ Medicis Restylane® Perlane® Mentor Prevelle™ Silk

degree of cross-linking as well as the manufacturing process that forms the ultimate filler [5]. The important chemical and physical properties of the different filler substances include as noted, the type and degree of cross-linking, the total hyaluronic acid concentration, the size of the particle and/or the consistency of the gel, and the degree of gel hardness or G prime.

Cross-linking The most commonly used hyaluronic acid products in the USA use 1, 4-butanediol diglycidyl ether (BDDE) as crosslinking agents. This includes Juvéderm® (Allergan, Inc., Irvine, CA, USA), Perlane®, and Restylane® (Medicis Aesthetics, Inc., Scottsdale AZ, USA), which are the most commonly used hyaluronic acid products in the USA. Hydrelle™ (Anika Therapeutics, Bedford, MA, USA) uses a different cross-linking agent called biscarbodiimide (BCDI). The degree of cross-linking indicates the percentage of hyaluronic acid disaccharide monomer units that are bound to a cross-linking molecule. For hyaluronic acid fillers, some feel that when all factors are equal, a higher degree of a cross-linking agent may translate into a longer persistence of the filler. However, there are questions about the effect that the cross-linking has on biocompatibility, setting the filler as a foreign substance. Therefore there may be an optimal degree of cross-linking that may give the longest term residence in the skin without causing biocompatibility issues.

Hyaluronic acid concentration Total hyaluronic acid concentration refers to the amount of hyaluronic acid per milliliter in a product. It generally measures both cross-linked hyaluronic acid and free hyaluronic acid in a product. Free hyaluronic acid or uncross-linked

hyaluronic acid is generally added in varying amounts to some products to improve lubrication or product flow. The most widely used hyaluronic acid products are of similar concentration but may vary as to the degree of free or uncross-linked hyaluronic acid, gel hardness, and hyaluronic acid gel consistency. The two most popular hyaluronic acid products, Restylane and Juvéderm, are produced by different mechanical means. The Restylane product line is pressed through screens to split the molecules into different size particles. Juvéderm is manufactured in a way that hom*ogenizes the particles in a blender-type apparatus. The different formulations and production strategies yield different gel hardness or G prime to the variety of different products. Clinically, G prime can be thought of both as the amount of force that is necessary to inject a product through a specificsized needle, as well as the lifting capacity of the filler. In general, fillers that are thicker are more difficult to inject through smaller needles, but based on their properties can act to bring in more water and thus cause more tissue lifting in a given area.

Indications Virtually all fillers are FDA approved to fill “moderate to severe lines and folds” such as the nasolabial fold. Historically, fillers such as collagen were used to fill fine lines and wrinkles including those in the perioral and periorbital regions. Collagen fillers were injected in the mid-dermis and usually had a clinical life in the skin of approximately 3–6 months. Hyaluronic acid fillers are generally injected deeper in the skin, most often below the dermis in the superficial subcutaneous layer and traditionally have primarily been indicated for deeper lines and folds [6,7]. Hyaluronic acid fillers cannot be injected very superficially because of a complication known as the Tyndall effect; whereby the filler appears as a blue hue directly under the skin [8]. The majority of hyaluronic acid fillers used to date were initially used in the nasolabial fold, mesiolabial fold, as well as other similar lines and folds in the face. Over the last 3–4 years, the use of hyaluronic acid fillers has also eclipsed into volume replacement. Thicker hyaluronic acid fillers such as Perlane and Juvéderm Ultra Plus are indicated to replace volume in areas such as the midface and lower face to replace volume lost in both the intrinsic and photoaging process. Hyaluronic acid fillers may be used to augment areas such as the lips by both replacing lost volume with aging and enhancing lip volume. Additionally, fillers are used to replace volume in areas such as the hands and resculpt and act as reshaping agents in areas such as the nose and the chin [9,10]. Hyaluronic acid fillers have significant advantage for these indications because of their longevity and overall low incidence of inflammation and significant swelling.



Injectable Antiaging Techniques

Injection techniques Fillers in general are injected using three basic techniques: 1 Droplet injection; 2 Linear threading, either antegrade or retrograde; 3 Fanning. As noted, the majority of hyaluronic acid are injected either in the deep dermis or superficial subcutaneous layer and studies have shown that the vast majority of injections are in the subcutaneous layer [7]. Most injectors use a combination of injection techniques depending upon the specific area that is being injected. Studies have shown that slower injection techniques tend to decrease side effects and swelling as well as decrease patient discomfort [11]. Patients are usually prepared by cleansing the area either with alcohol or another anti-infective topical cleansing substance. A topical anesthethic is often used either in the form of topical lidocaine, or compounded topicals that may include lidocaine and benzocaine. Many injectors also use cooling methods to both decrease pain of injection, as well as decrease swelling and bruising. As the injector gets more comfortable, advanced injection techniques, specifically with regard to volume, may utilize the use of large volumes of hyaluronic acid filler to replace and sculpt volume in areas of loss and these injections may take place in the deeper subcutaneous tissue or under the muscle layer. Injection sites that may be under the muscle include the tear troughs and malar regions.

Complications Possible complications of hyaluronic acid fillers include unevenness of the filler substance, inflammation, swelling, and bruising, injection of the hyaluronic acid filler too superficially in the dermis, and, rarely, abscesses, both bacterial and sterile [12]. Swelling and bruising can be thought of by some as complications, but are usually normally associated with any filler injection. Depending upon the injection technique, swelling and bruising may be common but can often be mitigated by the use of ice as well as the use of a slow injection technique. Patients should be warned that they certainly can experience some swelling and bruising for at least the first 48 hours after injection. The most common type of complication is the unevenness of hyaluronic acid fillers. The clinician needs to evaluate a patient and understand very clearly the needs of that patient and proper injection technique to minimize unevenness. Patients are not symmetrical and they often may need differing amounts of hyaluronic acid on one aspect of the face versus the other. It is also very important that the filler is massaged and the clinician can feel whether the various


areas of the face are even upon completion of the injection of the filler. If a patient comes back in or is referred for unevenness, there are two methods of correcting this complication. The first is to simply inject more filler to correct the imbalance, and the second is the use of hyaluronidase to dissolve the uneven filler. Most unevenness can be adjusted by injecting small amounts of filler in the contralateral side to even; however, when bumps and areas are too apparent or uneven, hyaluronidase, usually in 25–50 units can be injected and within 48 hours the area of unevenness or of bulging can be dissolved. When a filler is injected too superficially and a Tyndall effect occurs, often it can be extruded by making a small puncture with a 25 gauge needle and massaging the filler through the opening. If this fails, hyaluronidase can be used to dissolve the filler. Finally, in those rare cases of sterile abscess or long-term inflammation, topical anti-inflammatories can be used; if they fail, the use of clarithromycin may also be effective.

Treatment optimization: persistance of dermal fillers and in vivo collagen stimulation Hyaluronic acid fillers injected as a single treatment in the nasolabial fold, with or without one touch-up 1–2 weeks later usually just for the initial treatment, persists in a subset of patients for up to 12 months or longer [13]. It has generally been hypothesized that the prolonged efficacy of stabilized hyaluronic acid fillers versus injectable substances such as collagen is attributed to the sustained persistence of the product in the skin because of the effect that cross-linking has on limiting breakdown from in vivo hyaluronidase. However, new data indicate that, in addition to residual product left at each reinjection which provides a base, hyaluronic acid fillers can stimulate collagen synthesis and inhibit collagen breakdown, which can contribute to their persistence and correlates with physician observations that patients require less overall filler over time to retain optimal correction. A landmark study by Narins et al. [14], which is the basis for a new FDA approval for Restylane for up to 18 months, may provide a key piece of evidence to show that full correction followed by a single optimizing treatment can not only optimize longevity and in turn patient satisfaction, but also may enhance the patient’s in vivo collagen stimulation. This paper is an 18-month interim analysis of a 30-month study to evaluate efficacy and persistence of nonanimalized, stabilized hyaluronic acid 100 000 gel particles/ mL filler based on different retreatment schedules. The results in this study seem to indicate initial full correction of the nasolabial folds, followed by an optimizing treatment at an interval between 4 and 9 months, causes improved

43. Hyaluronic acid fillers long-term persistence of the filler and may indicate that full correction followed by retreatment at optimum treatment intervals may enhance the patient’s own in vivo collagen stimulation. This hypothesis is supported by in vivo studies by Wang et al. [15] who demonstrated that NAHSA (non-animal stabilized hyaluronic acid) 100 000 gel particles/mL hyaluronic acid filler can induce synthesis of type I collagen probably by stretching fibroblasts. The effect of optimizing treatments intervals to enhance in vivo collagen stimulation is consistent with Wang et al.’s data and is further supported by data with other types of treatments that cause collagen stimulation in vivo, namely laser, light, and radiofrequency devices. The data by Narins et al., as well as Wang et al., leads to a new paradigm in the use of dermal hyaluronic acid fillers. Up until now, the standard for esthetic correction using hyaluronic acid dermal fillers has been to inject fillers to replace lost volume and to replace the fillers as they slowly degraded. These data may indeed indicate a new treatment approach. Optimizing initial treatment by achieving full correction and thereby stretching fibroblasts and maximally stimulating collagen synthesis, followed by a second optimizing treatment, perhaps at an interval of 4–9 months, may lead to long-term benefit and a continued enhancement effect by the hyaluronic acid filler. It is possible that with each touch-up injection set the product builds up on a base already there, the metabolism of filler degradation decreases, and collagen production is continually stimulated.

Conclusions The use of dermal fillers, and hyaluronic acid fillers specifically, has become a mainstay in the treatment of the aging face. Hyaluronic acid fillers can be used safely and effectively in treating a variety of aspects of the aging face including folds and wrinkles as well as replacing lost volume. Hyaluronic acid fillers can also be used to sculpt areas such as the chin, the nose, tear troughs, and the eyebrows to enhance features in a non-invasive, completely reversible procedure. Over the next 2 years, there will probably be another four or five hyaluronic acid fillers approved in the USA. The near future will bring the addition of lidocaine to fillers that are already approved in the USA to decrease discomfort both upon injection and tenderness in the injection sites post-injection. New hyaluronic acid products will also look to have characteristics that will increase their use and utilization and may also increase their effective time in the skin. Finally, new treatment paradigms such as initial treatment followed by an optimization treatment within 6

months may cause long-term improvements and optimize in vivo collagen synthesis. Hyaluronic acid fillers will continue to be the mainstay of treatment for static folds, lines, wrinkles, and volume replacement in the near future.

References 1 Chung J, Soyun C, Sewon K. (2004) Why does the skin age? Instrinsic aging, photoaging, and their pathophisiology. In: Rigel DS, Weis RA, Lim HW, Dover JS, eds. Photoaging. New York: Marcel Dekker, pp. 1–13. 2 Rohrich RJ, Pessa JE. (2008) The fat compartments of the face: anatomy and clinical implications for cosmetic surgery. Plast Reconstr Surg 121, 1061. 3 Brandt FS, Cazzaniga A. (2008) Hyaluronic acid gel fillers in the management of facial aging. Clin Interv Aging 3, 153–9. 4 American Society for Aesthetic Plastic Surgery. (2007) Statistics on Cosmetic Surgery. 5 Tezel A, Fredrickson GH. (2008) The science of hyaluronic acid dermal fillers. J Cosmet Laser Ther 10, 35–42. 6 Narins RS, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S. (2003) A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane® versus Zyplast® for the correction of nasolabial folds. Dermatol Surg 29, 588–95. 7 Arlette JP, Trotter MJ. (2008) Anatomic location of hyaluronic acid filler material injected into nasolabial fold: a histologic study. Dermatol Surg 34, S56–63. 8 Narins RS, Jewell M, Rubin M, Cohen J, Strobos J. (2006) Clinical conference. Management of rare events following dermal fillers: focal necrosis and angry red bumps. Dermatol Surg 32, 426–34. 9 Gold MH. (2007) Use of hyaluronic acid fillers for the treatment of the aging face. Clin Interv Aging 2, 369–76. 10 Beer KR. (2006) Nasal reconstruction using 20 mg/ml crosslinked hyaluronic acid. J Drugs Dermatol 5, 465–6. 11 Glogau RG, Kane MA. (2008) Effect of injection techniques on the rate of local adverse events in patients implanted with nonanimal hyaluronic acid gel dermal fillers. Dermatol Surg 34, S105–9. 12 Cohen JL. (2008) Understanding, avoiding, and managing dermal filler complications. Dermatol Surg 34, S92–9. 13 Lupo MP, Smith S, Thomas J, Murphy DK, Beddingfield FC 3rd. (2008) Effectiveness of Juvéderm Ultra Plus dermal filler in the treatment of severe nasolabial folds. Plast Recontr Surg 121, 289–97. 14 Narins RS, Dayan SH, Brandt FS, Baldwin EK. (2008) Persistence and improvement of nasolabial fold correction with nonanimalstabilized hyaluronic acid 100,000 gel particles/mL filler on two retreatment schedules: results up to 18 months on two retreatment schedules. Dermatol Surg 34, S2–8. 15 Wang F, Garza LA, Kang S, Varani J, Orringer JS, Fisher GJ, Voorhees JJ. (2007) In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol 134, 155–63.


Chapter 44: Calcium hydroxylapatite for soft tissue augmentation Stephen Mandy Volunteer Professor of Dermatology, University of Miami, Miami, FL, and Private Practice, Miami Beach, FL, USA

BAS I C CONCE P T S • Calcium hydroxylapatite is a fibroplastic filler in which volume correction is achieved in part through the biologic response of the host. • Calcium hydroxylapatite is approved for correction of moderate to severe wrinkles and folds, treatment of HIV-associated lipoatrophy, and vocal fold insufficiency. • The injectable filler is composed of microspheres of calcium hydroxylapatite suspended in an aqueous carrier gel. • Ideal areas for correction with calcium hydroxylapatite are the malar eminences, center of the cheek, nasolabial and nasojugal (tear trough) folds, prejowl sulcus/marionette, and chin and jawline regions. • Filler duration is documented for as long as 12 months, although some loss of correction may occur.

Introduction Facial volume loss leads to dramatic changes in appearance resulting from aging, disease, or hereditary conditions. The deflation from lipoatrophy causes skin redundancy, which is compounded by loss of elasticity and collagen degeneration from solar radiation and oxidative damage. Skeletal bone resorption further leads to deflation, enlargement of the ocular orbit, and shrinkage of the jaw. These visual signs of aging cannot be corrected by surgical tightening without volumization as this procedure alone leads to a skeletal, windswept appearance. Replacement of volume through soft tissue augmentation can often offer facial rejuvenation with or without surgery. A variety of suitable materials for soft tissue augmentation exists. Natural fillers, such as collagen, hyaluronic acid, and calcium hydroxylapatite (CaHA), are synthesized to mimic, or are derived from biologic materials. Synthetic fillers may be permanent, such as acrylates and silicone, or biodegradable, such as poly-L-lactic acid [1].

Physiology and pharmacology CaHA is a new type of fibroplastic filler in which volume correction is achieved in part through the biologic response of the host. Radiesse® (Bioform Medical, San Mateo, CA,

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


USA) is an injectable filler composed of microspheres of 30% CaHA suspended in an aqueous gel consisting of water, glycerin, and sodium carboxymethylcellulose. Once injected, the gel carrier is soon absorbed. The remaining microspheres are 25–45 μm in diameter, which facilitates injection but resists immediate phagocytosis. These bioceramic spheres have no antigenicity, foreign body or giant cell response, and cause a minimal inflammatory reaction. They do not stimulate ossification. Although visible on X-ray images and magnetic resonance imaging scans, they are radiolucent, appearing somewhat like frosted glass, and pose no impediment to radiologic analysis. The CaHA microspheres form a scaffold for the fibroplastic proliferation, which provides the natural tissue feel of the implant. The local fibroplastic response results in the fibrous encapsulation of the particles and their gradual dissolution into calcium and phosphate ions (Figures 44.1–44.3) [2].

Indications and techniques CaHA is a thick, white, clay-like, cohesive material intended for subdermal injection. The density of the material would make intradermal injection difficult because of poor tissue intrusion into the dermal stroma. It is not intended or suitable for fine lines, superficial injection, or injection into highly mobile areas such as the lip or above the orbital rim, where accumulation of material from movement might result in nodule formation. Because of its density the filler is most easily injected through a 27-g standard needle or a 28-g wide bore (Exel®) needle. It is most commonly injected in a linear retrograde fashion following penetration of the

44. CaHA for soft tissue augmentation

Figure 44.1 Calcium hydroxylapatite microspheres, 25–45 μm in diameter. (Illustration courtesy of BioForm Medical.)

Figure 44.2 Gradual dissolution of microspheres. (Illustration courtesy of BioForm Medical.)


(a) Figure 44.3 (a) Light microscopic section at 1 month post-injection showing microspherules at the dermal subcuticular junction and a slight increase in histiocytes (arrows). (Illustration courtesy of Drs. David J. Goldberg and Ellen Marmur.) (b) Electron microscopic section at 6 months showing both an intact microspherule and one undergoing a

histiocytic derived catabolic process into smaller particles of calcium (black particles). The phosphate ions are not seen because they are dissolved in the processing of tissue for electron microscopy analysis. (Illustration courtesy of Drs. David J. Goldberg and Ellen Marmur.)

dermis at a 45 ° angle and then fully inserting the needle in the subcutaneous plane parallel to the surface. The material is then extruded upon withdrawal of the needle in a threadlike manner. Multiple parallel or layered repeat injections may be utilized to achieve correction of a soft tissue contour. Fanning and cross-hatching are utilized to achieve greater volume by smooth even injections of 0.1–0.2 mL per pass, followed by massage to avoid lumps and irregularities. One of the advantages of CaHA is its immediate “moldability” by massaging the injected area firmly against underlying structures or bimanually between the injector’s fingers.

Supraperiosteal placement is used to correct bony deformity. Several comparative studies have demonstrated that lesser volumes of CaHA are required for full correction than with collagen or hyaluronic acid [3]. Ideal areas for correction are the malar eminences, center of the cheek, nasolabial and nasojugal (tear trough) folds, prejowl sulcus/marionette, and chin and jawline regions. Reinflation of the midface, including the malar, cheek, nasolabial, tear trough areas, yields a facelift-like effect and a far more dramatic rejuvenation than simple “line filling” (Figures 44.4 and 44.5) [4]. CaHA is a structural, volumetric filler analogous to the



Injectable Antiaging Techniques


Figure 44.4 Preinjection (a) and postinjection (b) of 2.6 mL CaHA.



(b) 358

Figure 44.5 Preinjection (a) and immediately post-injection (b) of 2.6 mL CaHA.

44. CaHA for soft tissue augmentation concrete foundation of facial restructuring. It is compatible with other more superficial fillers that can be overlaid for fine line smoothing, and with use in conjunction with radiofrequency and laser devices. Preinjection topical anesthesia, 20–30 minutes pretreatment, is very important to insure patient comfort. For large volume injections, injectable regional nerve blocks might be employed. A popular, non FDA-approved (off-label) means of achieving anesthesia is to mix CaHA with lidocaine via sterile syringe transfer [5]. CaHA is transferred via a female– female connector into a syringe containing 0.05–1.0 mL lidocaine and then the two are mixed by repeatedly passing the emulsion back and forth (Figure 44.6). Avoidance of aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), and other medications or supplements that promote bruising are advisable. Pre- and post-treatment viral prophylaxis is recommended in patients with a history of herpes simplex. The first indication for Radiesse was for vocal fold correction. In 2006, it was approved for correction of moderate to severe facial wrinkles and folds, and restoration or correc-

tion of signs of lipoatrophy in patients with HIV [4]. In comparative studies of nasolabial fold treatment with CaHa versus collagen or hyaluronic acid, implants with CaHA gave significantly greater and more persistent correction with lower volumes at all time points [3,6]. Duration is documented for as long as 12 months, although some loss of correction may occur prior to that. Off label, non-FDA approved applications include correction of nasal defects, chin augmentation, and filling of the hands. Injection of a full syringe (1.3 mL) into each dorsal hand is accomplished through several bolus deposits in the subcutaneous space and between veins and tendons, followed by massage evenly over the entire hand to provide a full, more youthful appearance (Figure 44.7) [5]. All injections are performed percutaneously. Although some authors suggest intraoral approach to the tear trough area, this approach needlessly creates the opportunity to introduce bacteria into the implant with potentially serious consequences [7]. Glabellar injections are probably illadvised because of the risk of vascular occlusion by embolization or compression, which has been reported with nearly all previous fillers.


Figure 44.6 Radiesse mixed with lidocaine, using a female–female connector.

Edema, erythema, pain, and ecchymosis are the most common complications, comparable to collagen and hyaluronic acid injections. Too superficial an injection can yield a visible white papule or plaque, which is slow to resolve. Too much material in one placement, or failure to massage, can result in palpable or visible nodules. Many of the complications, in the experience of this author, seem to be reduced when lidocaine is mixed with the CaHA prior to injection in the method described earlier.


(a) Figure 44.7 Preinjection (a) and post-injection (b) of CaHA into the hand.



Injectable Antiaging Techniques

Conclusions Substantial facial volume restoration with facelift-like effect can be achieved with the injection of CaHA. Large volume correction can be accomplished in a practical fashion because of the greater volumizing effect of CaHA in contrast to other filling agents. Success is technique-dependent; complications are infrequent and comparable to other agents. Durability of this fibroplastic filler may be up to 1 year.

References 1 Mandy SH. (2008) Fillers that work by fibroplasia: poly-L-lactic acid. In: Carruthers A, Caruthers J, eds. Soft Tissue Augmentation, 2nd edn. Saunders Elsevier, pp. 101–4.


2 Marmur ES, Phelps R, Goldberg D. (2004) Clinical histologic and electron microscopic findings after injection of calcium hydroxylapatite filler. J Cosmet Laser Ther 6, 223–6. 3 Moers-Carpi MM, Tufet JO. (2007) Calcium hydroxylapatite versus nonanimal stabilized hyaluronic acid for correction of nasolabial folds. Dermatol Surg 34, 210–5. 4 Graivier M, Bass L, Busso M, Jasin ME, Narins RS, Tzikas TL. (2007) Calcium hydroxylapatite for correction of mid and lower face. Plast Reconstr Surg 120:6, 55–66S. 5 Busso M, Applebaum D. (2007) Hand augmentation with Radiesse® (calcium hydroxylapatite). Dermatol Ther 20, 385–7. 6 Smith S, Busso M, McClaren M, Bass LS. (2007) A randomized, bilateral, prospective comparison of calcium hydroxylapatite microspheres versus human-based collagen for the correction of nasolabial folds. Dermatol Surg 33, S112–21. 7 Wolcott R, Ehrlich G. (2008) Biofilms and chronic infection. JAMA 299, 2682–4.

Chapter 45: Skin fillers Neil Sadick1, Misbah H. Khan2, and Babar K. Rao3 1

Weill Medical College of Cornell University, Department of Dermatology, New York, NY, USA Northwestern University and Northwestern Memorial Hospital, Chicago, IL, USA 3 University of Medicine and Dentistry New Jersey, Robert-Wood Johnson Medical School, Somerset, NJ, USA 2

BAS I C CONCEPTS • Collagen fillers were the first introduced into the marketplace to replace volume loss in the aging face. • Collagen fillers can be conveniently divided into: bioengineered human-derived, animal-derived, and bioengineered animal-derived. • Bovine, humanized, and porcine-based collagen fillers are presently in the marketplace. • Collagen may be combined with other fillers to produce the desired volumizing effect in the face and hands.


Historical perspectives

Facial beauty and attractiveness continue to appeal. The quest for and maintenance of a youthful visage are well established. Youth equates with vitality, fecundity, and attractiveness; disguising the passage of time etched in the face is not a new phenomenon, although the proportion of people living to old age is. Facial appearance is rapidly perceived and processed by the brain biasing subsequent cognitive processes [1]. Four characteristics emerge as the most important determinants of attractiveness: averageness, sexual dimorphism, youthfulness, and symmetry. As the population continues to age and cosmetic procedures gain more acceptance, adults from all age groups and socioeconomic backgrounds are seeking cosmetic enhancement. This demand is increasing in younger and older adults, in men as well as women. The demand for cosmetic procedures among people aged 50–65 years has doubled in the last 5 years, with 83% of the 11.5 million procedures performed in 2006 being non-surgical and with botulinum toxin and fillers leading the list [2]. The current understanding that volume loss contributes to the aging face appearance has driven the development of new filling products to replace lost subcutaneous fat. The search for the perfect filling material to eradicate rhytides, smooth scars, and fill traumatic defects continues. This chapter discusses those fillers based on collagen, the structural building block of the skin.

Soft tissue fillers have been used for more than a century to improve and enhance facial esthetic units. At present, a popular substance for soft tissue augmentation is injectable bovine collagen. Collagen was first extracted from fresh calf skin in 1958 by Gross and Kirk at Harvard Medical School [3]. They showed that, under physiologic conditions, a solid gel could be produced by gently warming a solution of collagen to body temperature. It was found in the 1960s that selective removal of the non-helical amino and carboxy terminal telopeptides significantly reduced the antigenicity of bovine collagen molecules. A team of investigators at Stanford University in the early 1970s, Perkins, Daniels, Luck, and Knapp, began work on the development of a clinically useful collagen implant material. In 1977, Knapp, Luck, and Daniels reported the successful injection of pepsin-solubilized, telopeptide-poor, purified human rabbit and rat collagen into the subcutaneous tissue of rats. They reported that the collagen implants remained stable and were progressively infiltrated by a matrix of viable host connective tissue. These same investigators later conducted a human trial of bovine collagen in 28 human subjects. Collagen was injected into the dermal and subcutaneous planes to correct depressed acne scars, subcutaneous atrophy, wrinkling, viral pock marks, and other contour defects, with 50–85% improvement that was maintained for 3–18 months. Subsequently, Zyderm collagen was developed by Collagen Corporation. In 1981, Zyderm I® (McGhan Medical, Santa Barbara, CA, USA) became the first Food and Drug Administratiom (FDA) approved xenogenic agent for soft tissue augmentation.

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.



Injectable Antiaging Techniques

Following this approval, two other formulations of bovine collagen, Zyderm II® and Zyplast®, were granted FDA approval.

The “potential face” for collagen implants Evaluation of aging face Although an aged face has several contributing factors, collagen implants are mainly used for tissue augmentation brought about by loss of dermal elasticity, volume, and subcutaneous fat [4]. A major component of esthetic disharmony in the aging face is the loss and/or redistribution of subcutaneous fat. The youthful face has an ample amount of volume evenly distributed, which displays a smooth transition from one area to another and confers a well-rounded, three-dimensional topography delineated by a series of arcs and convexities. Viewed frontally, the primary arc of the jaw line, convexities of the temples, and the smaller secondary arcs of the lips are evident [5]. In profile, the lateral cheek projection (the ogee curve) extending as an unbroken convex line from the lower eyelid to the cheek, the arc of the jaw line, and the arc of the forehead are the most definitive features of youth (Figure 45.1). Facial aging is associated with the loss of soft tissue fullness in the periorbital, forehead, glabellar, temporal, malar, and buccal cheek perioral areas, resulting in accumulation of fat in the infraorbital fat pouches, nasolabial and labiomental folds, jowls, and submental areas. The fat pockets become more discernable as separate entities, as do many of the underlying facial structures (i.e. submaxillary glands and bony protuberances). Malar fat slides forward and down to

Figure 45.1 Facial fat partitioned in discrete compartments in facial architecture.


bulge against the nasolabial crease, and preauricular and buccal fat slides down and forward to create the jowl, disrupting the defining arcs and convexities of a youthful face. This fat accumulates around the peripheral insertion of the orbicularis oris muscle into the overlying skin. Different compartments of facial architecture can age independently and malpositioning of one compartment may lead to a cascade of changes in others. For example, loss of volume in deep midface fat would decrease the support for the medial cheek compartment, resulting in a diminished midface projection and an unmasking of the nasolabial fold and malar mound. The resulting negative vector would then allow excess traction to be placed on the lower eyelid leading to scleral show. Consequently, medial cheek tissue enhancement will improve the lower lid laxity. Just as volume loss may lead to undesirable changes elsewhere, the replacement of volume in one area may possibly lead to desirable changes in another area.

Analysis of “potential face” correctable with collagen fillers Balance and proportions of the face have been measured over time in almost every conceivable way; however, some simple measurements are well-accepted standards (Figure 45.2). Compare changes in these areas between young and aged faces [6]. As the face ages, predictable changes occur in facial proportions. Looking at the face in vertical fifths and horizontal thirds, changes are visible from the so-called “triangle of youth” to the “pyramid of age.” The forehead narrows because of temporal atrophy and elongates because of loss of underlying support, causing the brows to droop as the hairline recedes. The lower face widens as jowls form and shortens as bone is remodeled in the maxilla and mandible. Focusing on the perioral area, the young face shows

Figure 45.2 Horizontal and vertical facial proportions in a youthful face.

45. Skin fillers triple helices contain three identical alfa-1 chains. Collagen molecules then assemble to form fibrils with other noncollageneous molecules. During the embryonic period, type III collagen, “fetal collagen,” outweighs type I collagen in human skin. However, after birth, the ratio changes favoring collagen type I, which remains the predominant type during childhood and early adulthood in non-sun-exposed skin. However, with aging, the proportion of collagen III will increase in human skin. The matrix metalloproteinases, including collagenase, are responsible for degrading collagen. UV radiation has been shown to increase the level of matrix metalloproteinases in vivo, therefore increasing collagen degradation and accounting for aging of the skin. In addition, decreased collagen formation and low levels of types I and III procollagen precursors have been demonstrated in photodamaged skin, correlating with the clinical severity of photoaged skin [7]. Figure 45.3 Potential sites for collagen fillers.

a one-third : two-thirds ratio of upper lip to chin, the socalled “golden mean.” With age this ratio approaches 1 : 1. Finally, most faces exhibit some bilateral asymmetry, which may reflect a developmental instability, accounting for its importance in the assessment of attractiveness. The changes in proportions in the aging face caused by bone loss and soft tissue repositioning cause speculation as to whether these changes could be improved with nonsurgical bony augmentation. Mild asymmetry caused by unequal volume loss can be addressed with collagen fillers. Specific areas of facial volume loss that are amenable to correction with collagen implants are distributed in a rather mask-shaped area (Figure 45.3).

Collagen-based filler materials, alone and in combination Collagen Collagen is the major structural component of the dermis and is responsible for providing strength and support to human skin. Dermal matrix in adult skin is composed of type I (80–85%) and type III collagen (10–15%), in addition to glycosaminoglycans and elastin fibers. Collagen types I and III are synthesized by dermal fibroblasts as alfa-procollagens. Hydroxylation of proline and lysyl residues is performed by prolyl and lysyl hydroxylase in the presence of copper and ascorbic acid (vitamin C). The alfa chains form the triple helix and are then secreted into the extracellular space, where the protocollagen N-proteinase and protocollagen C-proteinase cleave the amino and carboxy terminal domains of the propeptides. Collagen type I triple helices comprise two alfa-1 and one alfa-2 chains and collagen III

Filler materials A recent survey among plastic surgeons and dermatologists (Professional Education Panel Meeting, Berlin, Germany, 2005) revealed that the ideal filler material should be biodegradable but demonstrate longevity of at least 12 months and no more than 2 years. Although most collagen fillers do not satisfy the longevity criteria, these have been very popular as a dermal replacement filler since their inception. Collagen fillers can be conveniently divided into: bioengineered human-derived, animal-derived, and bioengineered animal-derived (Table 45.1).

Bioengineered human-derived collagen fillers Human-based collagen implants include Cosmo-Derm I, CosmoDerm II, and CosmoPlast (Inamed Corporation, Santa Barbara, CA, USA). These products, which were approved by the FDA in March 2003, contain types I and III human collagen. Dermal fibroblasts harvested from bioengineered human skin cells are placed into a three-dimensional mesh and cultured in a bioreactor simulating the human body. Dermal fibroblasts, supported nutritionally by the medium, produce collagen and extracellular matrix proteins. CosmoDerm I contains 35 mg/mL human-based collagen dispersed in a phosphate-based saline solution and 0.3% lidocaine. The collagen concentration in CosmoDerm II is about twice as much as that found in Cosmoderm I. CosmoPlast has the same ingredients as CosmoDerm I, but is cross-linked by glutaraldehyde, making it more resistant to degradation, allowing for deeper placement of the injectable implant. No skin testing is required for any of the human-derived collagen products, and adverse reactions are limited to bruising, erythema, and swelling. CosmoDerm is used in more superficial furrows, whereas CosmoPlast is ideal for deeper lines and the vermillion border of the lip. These products require refrigeration.



Injectable Antiaging Techniques

Table 45.1 Collagen filler products, their advantages and disadvantages. Product


Type and duration


Zyderm I and Zyderm II

Bovine collagen 0.3% lidocaine

Xenograft 3 months

Long history of use Commonly used Allergic reactions 1% Requires pretesting Requires refrigeration


Bovine collagen 0.3% lidocaine

Xenograft 3 months

Long history of use Commonly used Allergic reactions 1% Requires pretesting Requires refrigeration Possible vascular necrosis

Cosmoderm I and II

Human-derived collagen 0.3% lidocaine

hom*ograft 4 months

Commonly used Does not require pretesting No allergic reactions reported Requires refrigeration Shorter duration of action


Human-derived collagen 0.3% lidocaine

hom*ograft 4–7 months

Commonly used Does not require pretesting Lasts longer than cosmoderm No allergic reactions reported Requires refrigeration Possible vascular necrosis


Cadaveric human Dermal matrix

hom*ograft 4–18 months

Lasts longer Requires pretesting Allergic reactions reported Edema High cost

Artecoll and Artefill

Bovine collagen encapsulated in PMMA

Xenograft Semi-permanent

Semi-permanent Might cause allergic reaction Permanent granulomatous reactions Cannot be used for fine lines Requires refrigeration


Bovine collagen encapsulated in PMMA

Xenograft Semi-permanent

Semi-permanent Might cause allergic reaction Permanent granulomatous reactions Cannot be used for fine lines Requires refrigeration


Cultured autologous fibroblasts

3 mm punch of patient’s skin Cryo-preserved

Semi-permanent No allergic reactions Costly, effort to harvest skin


Autologous collagen, large piece of patient’s skin


Human-based collagen and elastin


No allergic reactions Cost of shipping and handling Not currently available Cadaveric skin

Stored at room temperature No longer available Allergic reactions

45. Skin fillers

Table 45.1 Continued Product


Type and duration



Porcine-collagen cross-linked in ribose sugar

Porcine 8–12 months

Skin pretesting not required Lasts up to 12 months Less edema Can be used for lip augmentation Requires refrigeration Can cause allergic reactions in porcine-sensitive patients Nodules Possible granulomatous reactions

PMMA, polymethyl methacrylate microspheres.

The cosmetic effects of CosmoDerm and CosmoPlast are immediate and last about 4–7 months, depending on the area of treatment, injection technique, and amount of collagen filler. It is believed that the collagen in the product contains platelet-aggregating effects that may decrease the risk of bruising [8]. Additionally, they contain lidocaine. CosmoPlast has a slightly stiffer consistency than hyaluronic acid-containing fillers, which make it ideal for use in the vermillion border of the lip, the bridge of the nose, and to elevate the corners of the mouth. It is often injected in medium to deep wrinkles alone or, in combination with hyaluronic acid. Contraindications to CosmoDerm and CosmoPlast include hypersensitivity to these products and allergy to lidocaine. Alloderm (LifeCell Corp., Branchburg, NJ, USA) is an acellular allograft human dermal matrix derived from cadaveric skin. The freeze–drying process eliminates the cellular component of human skin leaving behind collagen, laminin, elastin, and proteoglycans. Immunohistochemical staining has failed to show class I or II histocompatibility antigens. Alloderm has the capacity to incorporate into the surrounding tissue and support rapid revascularization, decreasing the risk of infection and rejection [9]. This product is manufactured as sheets and may be used for treating fullthickness burns, surgical defects, and acne scars. Cymetra (Lifecell Corp., Branchburg, NJ, USA), available since 2000, is the injectable form of Alloderm, containing micronized cadaveric-derived collagen. The product is prepared in powdered form and needs to be rehydrated and mixed with lidocaine. The mixing process needs to be carried out properly and takes about 10 minutes. Cymetra has been used for soft tissue augmentation and has been shown to have more durability than Zyderm in lip augmentation [10]. Alloderm and Cymetra are both provided by the American Association of Tissue Banks after appropriate screenings for infectious agents and teratogenicity have been performed. These products are contraindicated in patients with infection

of the treated site, allergy to gentamicin, and collagen vascular disease. Autologen (Collagenesis Corporation, Beverly, MA, USA) is an autologous collagen suspension, made of a patient’s own tissue, containing 3.5% collagen. The process, which takes 6–8 weeks, includes harvesting skin from the patient, usually from mammoplasty or abdominoplasty, which is then sent to the laboratory for culture and processing. About 2 inches of donor skin is needed to produce about 1 mL of Autologen. The advantages of this type of autologous injectable is that there is no risk of hypersensitivity to this product, and the correction may last up to 18 months – considerably longer than with other types of collagen. The disadvantages include the delays in harvesting and processing the skin as well as the need for a relatively large skin specimen and the cost of culture and processing. Autologen can be used for lip augmentation in addition to scars and furrows. However, it is no longer available in the USA. Isologen (Isologen Technologies Inc., Paramus, NJ, USA) is composed of cultured autologous fibroblasts. A 3-mm punch biopsy is obtained from the patient and sent to the laboratory as a frozen specimen. In about 6 weeks the living cultured fibroblasts with extracellular matrix are sent back to the physician for treatment. Injections should be placed within 24 hours of receiving the product. There is a minimal risk of hypersensitivity to this product and therefore a 2-week pretreatment skin allergy test is required prior to injection. It is of note that the fibroblast culture may be cryo-stored and used for additional injections. Disadvantages to this product are cost, processing time, and pain with injections. Also, because the fibroblasts require time to produce collagen, immediate correction is usually not observed with this product, making it dissatisfying to certain patients.

Animal-derived collagen fillers There are three types of bovine-derived collagen products: Zyderm I (Inamed Aesthetics, Santa Barbara, CA, USA),



Injectable Antiaging Techniques

Zyderm II, and Zyplast. Zyderm I, FDA-approved in 1981, is composed of 3.5% bovine dermal collagen, suspended in physiologic phosphate-buffered sodium chloride solution and 0.3% lidocaine. Zyderm II differs from Zyderm I by containing 6.5% bovine dermal collagen and was approved by the FDA in 1983. Zyplast, approved by the FDA in 1985, contains 3.5% bovine dermal collagen cross-linked with 0.0075% glutaraldehyde, which strengthens the collagen fibers and extends the duration of action. Each of these products contains 95% type I collagen and 5% type III collagen. All three products are manufactured in 0.5–1.5 mL preloaded syringes and must be kept refrigerated. Zyderm I and II are used for correction of the superficial lines of the skin including glabellar lines, horizontal forehead lines, crow’s feet, fine perioral lines, and scars [11]. Zyderm II has more collagen and therefore is more effective in moderate to deep wrinkles. Zyplast is more valuable in treating deeper lines such as nasolabial folds, deep acne scars, and the vermilion border of the lip. The cosmetic correction with bovine collagen products usually lasts about 3 months, as the product becomes degraded by collagenase. However, there are reports of bovine collagen lasting for up to 18 months. Zyplast tends to lasts longer than Zyderm. In addition, the amount of the filler, area of treatment, and injection techniques are important factors in the longevity of the correction. It is of note that because Zyderm and Zyplast contain lidocaine, the treatment area will be partially anesthetized; therefore additional numbing agents are usually not required. However, if a patient experiences pain, topical lidocaine, and, rarely, nerve blocks may be used to reduce the pain of injection. Patients treated with bovine collagen implants are at risk of developing allergic reaction to the foreign material. Therefore, two consecutive skin tests are recommended (6 and 2 weeks) prior to treatment. The skin test contains 0.3 mL of Zyplast I in a prefilled tuberculin syringe and is injected subcutaneously on the volar aspect of the forearm. About 3% of the general population is sensitive to bovine collagen [12]. It is generally safe to treat a patient with injectable bovine collagen if there is no reaction with the two skin tests. The risk of allergy remains 1.3–6.2% after one negative test, 0.5% after two negative tests, and rarely may occur after multiple treatments. The patient should then be instructed to check the site between 48 and 72 hours after placement and then again at 4 weeks by the treating physician. Patients with hypersensitivity reactions to bovine collagen may be reassured that it usually resolves within 4–24 months. However, if needed, topical, intralesional, or a brief course of systemic corticosteroids may be used to treat these reactions. It has been proposed that there may be a triggering effect of an autoimmune process, particularly dermatomyositis, in patients with the use of bovine collagen [13]. However, in


a study performed by Hanke et al. [14] the incidence rate of polymyositis and/or dermatomyositis in patients who received bovine collagen was not higher than the controlmatched population. Studies have indicated that the possibility of patients developing autoimmune disease is unlikely.

Bioengineered animal-derived collagen fillers Artecoll (Canderm Pharma Inc., St-Laurent, QC, Canada) is a solution that contains polymethyl methacrylate microspheres (PMMA) suspended in bovine collagen and lidocaine. PMMA is non-biodegradable; therefore it results in durable augmentation after the collagen is absorbed. This product is bovine-derived, a pretreatment skin test is required prior to injection. Artecoll has been used for facial furrows, lip, chin, and malar augmentation. Patients treated with Artecoll may have treatment effects lasting for up to 12 months [15]. Artefill is another form of bioengineered bovine collagen, encapsulated in PMMA microspheres, recently approved for use in the USA for nasolabial folds. Limited data are available in the USA regarding the safety and efficacy of this filler. However, it shares very similar chemical properties to Artecoll, with 80% by volume of bovine collagen in 0.3% lidocaine. Evolence® (ColBar LifeScience Ltd., Herzliya, Israel) is a new dermal filler manufactured specifically to closely resemble the composition of the collagen matrix found in human skin. Evolence is produced by means of a novel cross-linking process that uses a natural sugar ribose to cross-link porcine collagen, which mimics the natural cross-linking pathway of collagen in the body known as glycation. The safety and longevity of Evolence (30 mg/mL formulation) have initially been assessed in an appropriate animal model (rabbit ear assay), and the filler has been compared with two currently available bovine collagen treatments. Evolence has been shown to be safe with no significant degradation at 1, 6, 12, and up to 18 months after injection. It has demonstrated shape preservation and longevity superior to those of the bovine collagen filler, Zyplast [16]. In this study, both histologic and clinical findings supported the conclusion that there were no abnormal or hypersensitivity reactions in any of the study subjects. The immune response in humans to xenogeneic porcine dermal collagen is very reserved and of low frequency compared with bovine collagen because collagen has been well conserved during evolution with little change in basic amino acid composition among mammalian species.

Techniques for collagen filler injections Collagens are still used as the sole dermal-filling agent, but now even more often in a layering fashion with other

45. Skin fillers dermal and subcutaneous fillers. As with most dermal fillers, injection techniques will vary between injectors. When using any injectable, it is important to make the patient as comfortable as possible for the procedure. This will allow the injection process to be easier for both patient and physician. In most cases it is best to have the patient sitting upright in order to delineate the areas of wrinkling and/or dermal defects. In the reclined position, most of these defects will be minimized, resulting in undercorrection and patient dissatisfaction. Pain control is also important. As a result of the addition of lidocaine in the most commonly used, collagen-containing dermal fillers, most patients are able to tolerate injection of these agents without regional anesthesia. In the author’s practice, a topical anesthetic alone is typically used. When using collagen in combination with one of the other fillers, such as the hyaluronic acids, the collagen product is injected first, as this provides additional anesthesia, making the hyaluronic acid injection relatively painless. After visually delineating the areas to be corrected, the depth of the defect is determined in order to decide which agent to use. Very superficial epidermal and dermal defects are best corrected with either Cosmoderm or Zyderm. These agents are injected into the papillary dermis using a serial puncture or serial threading techniques (Figure 45.4). A slight, temporary blanching of the skin is noted at the time of injection, which represents accurate placement of the needle in papillary dermis. When using Zyderm, slight overcorrection is necessary as the product causes slight swelling which abates after 24 hours. Cosmoderm causes less swelling. Artecoll/Artefill, Evolence30, and, sometimes, Cosmoplast and Zyplast are used for deeper dermal defects when placed in mid–deep dermis. Injections should be placed at 45 ° angle with a 30-gauge needle using a linear threading technique (Figure 45.5). Other techniques such as fanning and cross-hatching can be used when combining collagen fillers with more fillers for deeper defects such as hyaluronic acid, fat, calcium hydroxylappatite, and poly-L-lactic acid. Collagen-based filler can be used after the placement of a deeper filler to fill in the more superficial defects such as for fine, perioral lines after lip augmentation with hyaluronic acid (Figure 45.6).

Facial augmentation Approach to the upper third of the face The primary objective in the management of aging in the upper third of the face is to attenuate wrinkles while maintaining patient facial animation. Collagen fillers are used for correction of fine lines, alone and in combination with botulinum toxin type A (Figure 45.6) [17]. Collagen fillers such

Figure 45.4 Various injection techniques.

as Cosmoderm or Zyderm can be used to correct rather superficial rhytids of the glabella and forehead. Linear threading technique is used for this purpose. Deeper injections of collagen fillers such as Cosmoplast and Zyplast, Artecoll/Artefill, and Evolence are generally avoided for the correction of deeper glabellar complex because of the seriousness of adverse effects (see below). Fine lines in the periorbital area can be corrected with more superficially placed fillers such as Cosmoderm I/II or Zyderm I/II. Serial threading or serial puncture techniques are best used. Pretreatment of the rhytids with botulinum toxin A significantly increases the longevity of soft tissue fillers.

Approach to the middle third of the face The middle third of the aging face is primarily treated with dermal fillers. Dermal fillers are useful for correction of the



Injectable Antiaging Techniques




(d) Figure 45.5 Techniques for injecting into the nasolabial folds and lower lip vermilion border (a–d).


(a) Figure 45.6 Correction of perioral rhytids and lip augmentation using a combination of dermal fillers and botulinum toxin type A. (a) Before. (b) After.


45. Skin fillers midface ptosis and volume loss, especially in patients who are considering non-surgical treatment modalities. The nasolabial folds are best treated with Zyplast or Cosmoplast, alone or in combination with hyaluronic acid fillers. The collagen fillers are placed using a 30-gauge needle at a 45 ° angle in a cross-hatching or fanning technique (Figure 45.5). As in the correction of the upper one-third of the face, synergism between filler and chemodenervation with botulinum toxin type A is still applicable. Bioengineered animal-derived collagens such as Artecoll/ Artefill and Evolence can also be used for correction of nasolabial folds. These fillers are ideal for patients who seek lasting results. The fillers are placed using cross-hatched or fanning techniques.

Approach to the lower third of the face Dermal fillers are widely used for lower face augmentation, most notably lips. Three aspects of lip augmentation are: 1 Definition of vermilion border; 2 Fullness; and 3 Poutiness. Non-cross-linked human collagen is usually used to highlight the vermilion border, injected by serial puncture technique. Fullness is achieved by creating tubercles (three sites for upper lip and two sites for lower lip). To achieve poutiness, collagen is injected above the gingivolabial sulcus to create eversion of the upper and lower lips. Perioral lines are optimally treated with specifically human-derived collagen for fine lines and bovine collagen for deeper rhytids (Figure 45.5d). Marionette lines are also amenable to collagen fillers. Zyplast or Cosmoplast can be used in a cross-hatched or linear threading technique. The irregular contours of the chin (i.e. “peau d’orange” or “cobblestoning”) may benefit from fillers, as these irregularities are a result of dermal and subcutaneous atrophy. Cross-linked bovine or human collagens are the fillers of choice. Additionally, the contraction of mentalis can exacerbate the “peau d’orange” appearance. This can be minimized by augmenting the lower third of the face with botulinum toxin type A.

Figure 45.7 Linear threading technique for injecting into the dorsal hand for hand rejuvenation using collagen dermal filler.

Although collagen fillers are better tolerated than hyaluronic acid fillers, their longevity has been of concern. Work carried out by Man et al. [18] clearly shows significantly higher patient satisfaction regarding longterm results for the hyaluronic acid treated sites versus collagen. Nonetheless, collagen fillers can be used for patients seeking temporary correction for volume loss and dermal atrophy.

Adverse reactions to collagen dermal fillers The occurrence of adverse reactions relates to both the inherent properties of the product and to inappropriate delivery or dilution of the filler, which may lead to harmful sequelae. Although injectable substances are subject to approval by the FDA, most are classified as class III devices. Thorough training of specialist physicians (dermsurgeons), including appropriate product selection, preparation, and injection techniques, is required to minimize avoidable adverse tissue responses.

Hand rejuvenation with collagen fillers

Evaluating adverse reactions

Resurgence in the examination of the aging hand is occurring, both in delineating the esthetics of the hand and in volumetric options for the intrinsic aging. The use of dermal fillers for hand rejuvenation is a new concept. Collagen fillers can be used to correct for volume loss and dermal atrophy of the dorsal hands and to “give it altitude.” Patients seem to tolerate collagen fillers better than the more popular hyaluronic acid derivatives [18] as far as pain is concerned. Collagen fillers can be injected using the linear threading technique followed by a gentle massage (Figure 45.7).

Most adverse reactions are mild and transient; however, responses of greater significance can occur, demanding anything from a short course of medication to surgery. By definition, patients undergo intervention to improve some aspect of their appearance; therefore, any risk of disfigurement from a filler is unacceptable. Some products may induce adverse events because of their inherent properties, such as their ability to elicit hypersensitivity reactions. Some reactions occur immediately after treatment, whereas some have a delayed onset [19], as summarized in Table 45.2.



Injectable Antiaging Techniques

Table 45.2 Adverse effects associated with collagen implants. Early adverse reactions (occurring up to several days post-treatment) Injections site reactions Erythema Edema Pain/tenderness Bruising Itching Infection Erythema Edema Pain/tenderness Acne papule formation Nodule Hypersensitivity Erythema Edema Pain/tenderness Non-fluctuant nodules Lumps Poor technique Discoloration Redness Whiteness Hyperpigmentation Local tissue necrosis Vascular occlusion Delayed adverse reactions occurring from weeks to years post-treatment Infection (atypical mycobacterial) Erythema Edema Pain/tenderness Nodule Systemic manifestations Granuloma formation Subclinical Large disfiguring nodules Hypersensitivity Sterile abcesses Persistent discoloration Scarring

Early injection-related events Temporary swelling and bruising With all injectable fillers, the injection itself can initiate tissue response. The intensity is proportional to the degree of tissue injury. With some injectable collagen fillers such as 370

Figure 45.8 Bovine collagen adverse effect. Ecchymosis after injecting Zyplast into the nasolabial folds in a patient on anticoagulants.

Zyderm/Zyplast, CosmoDerm/CosmoPlast, Artecoll, and Evolence this reaction manifests itself as a temporary swelling and/or erythema which resolves within a day. Bruising can occur in patients on anticoagulants. Temporary makeup can be used to camouflage the erythema (Figure 45.8). Newer, bioengineered collagen fillers have also been reported to cause temporary reactions. Acute post-injection swelling and bruising have been reported with the use of Artecoll. Evolence has been associated with lesser tissue swelling and post-procedure erythema.

Skin discoloration Skin discoloration of esthetic significance can occur at the site of treatment; such reactions typically occur immediately after injection and generally resolve within a few weeks. Redness occurs as a result of the inflammatory response, whereas whiteness at the injection site can be attributed to overcorrection and the color of the injected substance. Product-specific training and rigorous adherence to the manufacturer’s instructions should minimize the risk of discoloration occurring (e.g. correct depth of injection).

Hypersensitivity reactions Hypersensitivity reactions to fillers can be severe and cases of severe anaphylaxis have also been reported. Autologous collagen fillers such CosmoDerm and CosmoPlast do not cause a reaction. However, bovine-derived collagen fillers have been shown to cause reactions. Fortunately, potential allergenicity to injectable collagen is reliably determined by skin testing. A positive skin test (seen in 3.0–3.5% of patients), characterized by a change in the contour of the injected implant, erythema, edema, itching, and, occasionally, an indurated papule or inflamed dermal nodule, is a definite contraindication to treatment. Because 1–3% of patients with one negative skin test sub-

45. Skin fillers


(a) Figure 45.9 Bovine collagen adverse effect. (a,b) Formulation of nodules in the mucosal lip after lip augmentation.

sequently develop a reaction at the treatment site, double skin testing is advocated. Of note is the fact that allergy to bovine collagen does not contraindicate the use of humanderived collagen (CosmoDerm or CosmoPlast). Although Artecoll/Artefill has denatured bovine collagen encapsulated in microspheres of PMMA it also possesses an allergic risk. Skin testing prior to injection is therefore advised. Evolence however has not been shown to cause hypersensitivity reactions. This is partly because it is derived from porcine collagen which resembles very closely to human collagen and does not elicit an allergic reaction.

Vascular compromise with collagen dermal fillers There has been at least one case report of blindness from retinal artery thrombosis following an injection of Zyplast into the glabellar complex [20]. This is believed to be exceedingly rare and an idiosyncratic event. It is therefore recommended to inject glabellar complex rather superficially and with fillers such as Cosmoderm and Zyderm.

Late adverse reactions Nodule formation Nodules can arise from a number of causes and are not uncommon in soft tissue augmentation. Non-erythematous nodules can form immediately after injection as a result of the uneven distribution of product. Such nodules are distinct from the inflammatory responses that are to be expected early following injection, whether as a reaction to injury (which should disappear within days) or infection. Clinical presentation of infection can include single or multiple nodules with inflammatory signs. Nodules may present subcutaneously or in the dermis and may or may not be painful. Nodules may be transient inflammatory granulomatous reactions, although some have suggested that they are the result of the development of a fibrous reaction as a response to the presence of the implant.

Lip nodules are common with thicker collagen fillers such as Zyplast or Cosmoplast, especially when used for lip augmentation (Figure 45.9). If these fillers are injected into the superficial dermis a visible white, yellow, or blue discoloration may persist at the injection site [20].

Granuloma formation Foreign body reactions can occasionally precipitate the appearance of lumps and bumps by leading to granulomatous inflammation. However, without histologic examination, a definite diagnosis of granuloma is impossible. Patients with granulomas usually present with non-fluctuant lumps felt under the skin. Granulomas occur less frequently after injection of resorbable implants compared with more permanent products. The risk of granuloma is reduced following the implantation of products containing microspheres with smooth surfaces, such as PMMA containing filler (Artecoll/Artefill) and Evolence, compared with particles with irregular surfaces. Clinically significant granuloma can be treated successfully by the administration of local or systemic corticosteroids, although the therapeutic role of these agents in the treatment of cosmetic orofacial granulomas has yet to be extensively studied. For well-circ*mscribed nodular lesions, surgical excision is a very effective approach to eradication. However, where lesions are widespread, surgery may lead to scarring and fistulae [19].

Infections Recovered bacterial microorganisms associated with cosmetic procedures usually include common skin and soft tissue pathogens, such as Streptococcus aureus. Patients usually present with single or multiple erythematous and/or fluctuant nodules, which can be treated with a short course of appropriate antibiotics. However, presentation of a new lesion more than 2 weeks post-procedure strongly suggests atypical infection, with mycobacteria being a possible culprit [19]. As a response to infection, patients may also 371


Injectable Antiaging Techniques

experience systemic reactions, such as fever, leukocytosis, weight loss, and fatigue. In such cases, lesions should be aspirated or a biopsy should be performed, and the specimens should be sent for bacterial, fungal, and acid–fast stains and culture. Atypical or non-tuberculous mycobacterial organisms are commonly found in the soil and water. In normal healthy individuals, the organisms tend to be associated with low pathogenicity, the exceptions being Mycobacterium chelonae and Mycobacterium fortuitum, which represent more serious strains. Such infections are related to poor surgical technique and inadequate sterilization of the instruments and syringes used for injections. Such infections, if suspected, should be treated promptly with appropriate antibiotics.

Conclusions There are many causes for cutaneous defects, with a correspondingly wide range of techniques for addressing them. Dermal fillers are only one means to improve tissue and volume loss associated with aging. There is no single filler appropriate for all defects. That is partly because aging is a multifactorial process with a slowly progressive change in the three-dimensional facial anatomy, affecting essentially all components of the human face. Dermal fillers can provide temporary but adequate replacement for tissue volume, dermal elasticity, and support by enhancing subcutaneous fat. However, just like any other procedure, these have limitations. Additionally, serious side effects can occur if the practioner is not familiar with their use and potential adverse effects. Finally, regardless of the choice of dermal filler, it is the combination of clinical judgment, realistic expectations, meticulous preparation, and surgical skills that provide optimal results.

References 1 Olson IR, Marshuetz C. (2005) Facial attractiveness is appraised in a glance. Emotion 5, 498–502. 2 American Society for Aesthetic Plastic Surgery. (2007) 2005 Cosmetic Surgery National Data Bank Statistics. pp. 1–20. http:// 3 Klein AW, Elson ML. (2000) The history of substances for soft tissue augmentation. Dermatol Surg 26, 1096–105. 4 Glogau RG. (1994) Chemical peeling and aging skin. J Geriatr Dermatol 2, 30–5.


5 Donofrio LM. (2000) Fat distribution: a morphologic study of the aging face. Dermatol Surg 26, 1107–12. 6 Azizzedeh B, Murphy MR, Johnson CM. (2006) The aging face consultation. In: Master Techniques in Facial Rejuvenation. Elsevier, pp. 1–16. 7 Baumann L, Kaufman J, Saghari S. (2006) Collagen fillers. Dermatol Ther 19, 134–40. 8 Perret S, Eble JA, Siljander PR, Merle C, Farndale RW, Theisen M, et al. (2003) Prolyl hydroxylation of collagen type I is required for efficient binding to integrin alpha-1 and beta-1 and platelet glycoprotein VI but not to alpha-2 and beta-1. J Biol Chem 278, 29873–8. 9 Menon NG, Rodriguez ED, Byrnes CK, Girotto JA, Goldberg NH, Silverman RP. (2003) Revascularization of human acellular dermis in full-thickness abdominal wall reconstruction in the rabbit model. Ann Plast Surg 50, 523–7. 10 Sclafani AP, Romo T, Jacono AA III. (2002) Rejuvenation of the aging lip with an injectable acellular dermal graft (Cymetra). Arch Facial Plast Surg 4, 252–7. 11 Baumann L. (2002) Soft tissue augmentation. In: Baumann L, ed. Cosmetic Dermatology, Principals and Practice. New York: McGraw-Hill, pp. 155–72. 12 Stegman SJ, Chu S, Armstrong RC. (1988) Adverse reactions to bovine collagen implants: clinical and histological features. J Dermatol Surg Oncol 14, 39–48. 13 Cukier J, Beauchamp RA, Spindler JS, Spindler S, Lorenzo C, Trentham DE. (1993) Association between bovine collagen dermal implants and a dermatomyositis or a polymyositis-like syndrome. Ann Intern Med 118, 920–8. 14 Hanke CW, Thomas JA, Lee WT, Jolivette DM, Rosenberg MJ. (1996) Risk assessment of polymyositis and dermatomyositis after treatment with injectable collagen. J Am Acad Dermatol 34, 450–4. 15 Cohen SR, Holmes RE. (2004) Artecoll: a long-lasting injectable wrinkle filler material: report of a controlled, randomized, multicenter clinical trial of 251 subjects. Plast Reconstr Surg 114, 964–76. 16 Monstrey S, Pitaru S, Hamdi M, Van Landuyt K, Blondeel P, Shiri J, et al. (2007) A two-stage phase I trial of Evolence collagen for soft-tissue contour correction. Plast Reconstr Surg 120, 303–11. 17 Wise JB, Greco T. (2006) Injectable treatments for aging face. Facial Plast Surg 22, 140–6. 18 Man J, Rao J, Goldman M. (2008) A double-blind, comparative study of nonanimal-stabilized hyaluronic acid versus human collagen for tissue augmentation of dorsal hands. Dermatol Surg 34, 1026–31. 19 Lowe NJ, Maxwell A, Patnaik R. (2005) Adverse reactions to dermal fillers. Dermatol Surg 31, 1616–25. 20 Alam M, Gladstone H, Kramer EM, Murphy JP Jr, Nouri K, Neuhaus IM, et al. (2008) ASDS guidelines of care: injectable fillers. Dermatol Surg 34, S115–48.

Chapter 46: Polylactic acid fillers Kenneth R. Beer Clinical Volunteer Professor of Dermatology, University of Miami, Miami, FL, and Palm Beach Esthetic, West Palm Beach, FL, USA

BAS I C CONCEPTS • Polylactic acid fillers (PLLA) is a volume stimulator rather than a direct volume replacement. • PLLA is best suited for areas that are concave. • PLLA results are dependent on techniques such as dilution and injection. • Complications from PLLA are different from those from fillers and include subcutaneous papule formation. • PLLA results (both good and bad) may last for years.

Introduction Poly-L-lactic acid is the active ingredient found in Sculptra® (also known as New-Fill; Sanofi-Aventis, Paris, France). Each bottle of material also contains sodium carboxymethylcellulose (USP) and non-pyrogenic mannitol [1]. The sodium carboxymethylcellulose and mannitol act to stabilize the PLLA and have no biologic effect on the volume stimulation. The material comes as a freeze-dried powder that must be reconstituted with sterile water [2]. At the present time, Sculptra is the only product of its kind and as such is unique. Although the amount of PLLA in a bottle of Sculptra is fixed at 367.5 mg, the methods of reconstitution are variable. The ability to add different amounts of water and/or lidocaine is one opportunity for physicians to vary the use of this material and may contribute to varying reports of success and complications. Initial reports of product use in Europe utilized dilutions of 3 mL per bottle [3]. The duration of reconstitution for these early studies was 4 hours. The package insert for the product recommends a reconstitution time of 4 hours; however, many PLLA injectors advocate longer periods, with some recommending that water imbibe for at least 24 hours with longer periods of up to 3 weeks also touted. At the present time, there is no uniform consensus nor clinical trial to suggest what is the optimal dilution or reconstitution time. This author recommends using at least 4 mL water for at least 24 hours, with longer periods of time being preferable. In addition to the 4 mL water, various anesthetic agents are added to the mixture. The anesthetic added to the

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

product varies depending on injector preferences and experiences. Among the alternatives used, 1% lidocaine with 1 : 100 k epinephrine added is perhaps the most frequently used. Lidocaine without epinephrine (1%) and 2% lidocaine are also used. Volumes of anesthetic added to the reconstituted material also vary based on the location of each injection and the experience of the injector. At the present time, many skilled injectors utilize 4 mL water for at least 24 hours and immediately before injection add 3–4 mL of 1% lidocaine with epinephrine. When injecting areas such as the back of the hands or the tear trough under the eye, this dilution may require additional water and the total reconstitution volume for these areas is 9 mL for many injectors. For the 9-mL dilution, the author uses 4 mL water and 5 mL 1% lidocaine with 1 : 100 000 epinephrine. Once reconstituted, the bottle should be signed and dated and the material should be stored in a refrigerator. Before injection, it should be left out so that it can warm to room temperature. Whether or not gently heating it to body temperature before injecting to improve outcomes is another area of controversy. At the present time, it seems reasonable to inject material that is at room or body temperature but not to heat the product beyond these temperatures.

Advantages and disadvantages PLLA has many unique properties and strengths and weaknesses. Among the strengths of the product are its longlasting nature, ability to correct large volume losses, and ease of injection. Weaknesses of the product include the formation of subcutaneous papules, multiple injection visits, expense, and, most importantly, there is no way to predict the degree of improvement that will result from any given injection. This latter point means that unlike the hyalurons,



Injectable Antiaging Techniques

collagens, or calcium hydroxylapatite, there is no way for a physician to correct a given area with a 1 1 defect to product replacement ratio. Instead, the injector must wait to see the extent to which new collagen will form. One of the advantages of this product is its ability to produce collagen, providing a correction that lasts for more than 1 year [4]. Unlike any of the fillers, except for the permanent ones such as silicone or Artefill, once PLLA has attained a volume correction it will last for a prolonged amount of time. In addition, when the correction is diminishing, it can be enhanced with a touch up injection. Despite the initial high cost of injection, the degree and duration of the PLLA correction makes it cost effective. Volume replacement for moderate lipoatrophy costs $3000–4000. When compared with the cost of other fillers for the same time interval, PLLA correction is reasonably priced. PLLA is technically easy to inject. In fact, the difficulty associated with this product lies more with poor patient selection, inappropriate and inadequate volume reconstitution. The very nature of the product as it is injected (it is a suspension rather than a solution or gel) means that even with the best technique, particles of PLLA will migrate following injection. In addition, density differences both in the syringe and in the patient as the PLLA particles settle provide non-hom*ogeneous product dispersion even with the best technique.

Standard injection techniques Beginners should not have technical problems injecting this product as long as they select the right patients and locations to treat. The most common problem encountered by novice injectors is clogging of material in the needle, resulting in sporadic injections of product under high pressure and placement of the product at the wrong plane.

Rapid injection is the best technique for injecting PLLA. This avoids needle clogs producing high pressure injections and areas of high and low concentration product placement. Injection needles should be either 25 or 26 gauge and 0.5 inch in length. Smaller bore and longer needles may result in difficulty extruding the product into the tissue. Injections of PLLA require deep product placement. Thus, the needle should be at the level of the deep dermis or dermal–subcutaneous junction. Superficial placement will increase the probability of visible papule formation. Various methods of injecting including serial puncture, linear threading, and fanning have been described and espoused. Standard injection techniques should try to include aspects of each because the goal of the injection is to obtain a hom*ogeneous distribution of product at the plane where it will do the most good. Which technique predominates for a given individual depends on the area being injected and the amount of product being placed. Following any technique, it is essential to massage the product vigorously to distribute it. When massaging, deep pressure adequate to move product from discrete pearls into a contiguous plane is required. The most frequently injected areas are the cheeks, jawline, and temples. For the cheeks, it is helpful to inject half a bottle (3.5 mL) per session into each cheek. Each injection should be accomplished such that approximately 0.05 mL is inserted and the space between injections is about 0.5 cm. Serial puncture and fanning may be combined to produce a spoke-like network of injections (Figure 46.1). Typical injection schedules for the cheeks include three injections spaced at least 1 month apart. Patients with severe lipoatrophy may require more injections and it is acceptable to continue injections until full volume restoration is accomplished. However, it is not advisable to decrease the time interval between sessions. Correction of jawline volume loss may be required following loss of subcutaneous tissue and bone resorption. PLLA

1 3


5 4 7 9 6 8




Figure 46.1 Serial puncture and fanning techiques. (a) Fan technique. (b) Cross-hatching technique.

46. Polylactic acid fillers injections may be performed to stimulate collagen in this area with outstanding results. Standard injection techniques for this area are serial puncture and fanning. Needle insertion for this location should be at the level of the deep tissue (subcutaneous or just above the periosteum). As with other locations, deep massage is necessary to move the product into a hom*ogeneous plane. Needle orientation for the jawline is typically at 45 ° to the skin. Moderate volume loss may be treated with 2–3 mL of the 7-mL dilution of PLLA and can be completed in three visits for many patients. Severe volume loss may be treated with four or more injection sessions. Temporal wasting is one of the hallmarks of facial aging. Although other products may be used to treat this, PLLA is exceptionally well suited for this application. Injections in this location have several potential pitfalls that need to be avoided. The plethora of blood vessels in this area provides one potential pitfall for injection of any product and the particulate nature of PLLA is no exception. When injecting the temples with PLLA, it is important to aspirate prior to inserting product. Needle placement should be deep and at the level just superficial to the periosteum. Placement at this level will help avoid formation of visible subcutaneous papules. Average injection volume per side is 2–3.5 mL using the 7-mL volume dilution. The technique for injecting PLLA in this area is predominantly the fanning method but serial puncture is also used.

Advanced techniques Perhaps the most important consideration when performing advanced techniques is to change the dilution and volume to accommodate the different areas being treated. Advanced techniques for injecting PLLA may be utilized to treat areas such as the tear troughs and the dorsum of the hands. When treating these areas, it is worthwhile to dilute each bottle with 9 mL of total volume rather than with 7 mL. Tear troughs are one of the most difficult areas to treat with any injection and PLLA is no exception. There are some additional considerations for this material that warrant special consideration. Unlike standard techniques, this area is one that should be treated only by injectors with advanced skills and experience. Whereas half of the bottle is used for each side of each location treated with simple techniques, it is recommended that about 1–2 mL of the 9-mL diluted product be used for each side of the tear trough. When treating the tear trough, using the non-dominant hand to palpate the margin of the infraorbital rim will help to protect the eye and make certain that the injections remain outside of the globe. As with injections into the temple, aspiration of the syringe is essential prior to the injection. The multitude

of vessels in this area require caution when injecting and although blindness has not yet been reported with PLLA injections, it is a theoretical possibility that needs to be remembered when injecting. Placement of the needle for treatments of the tear trough are at the level immediately superficial to the periosteal plane. Orientation of the needle is either perpendicular to the skin or at 45 ° to the skin and directed medially. When injecting the tear troughs, never point the needle towards the globe as this may result in inadvertent punctures. Each injection should place a small amount of material (about 0.05 mL). Injections should be about 3–5 mm apart. Following placement, each should be massaged to avoid discrete nodule formation. Despite perfect technique, injections of PLLA may result in the delayed formation of nodules and patients should be aware of this possibility prior to treatment [5]. Dorsal hand lipoatrophy and photoaging are hallmarks of aging that are frequently left untreated because of the lack of effective modalities. The use of PLLA for this location is a technique utilized by advanced injectors with very good results. As with injections of the tear trough, the dorsal hands are covered with skin that is typically thin and translucent. Thus, dilution of each bottle of Sculptra with 9 mL liquid is appropriate. Longer needles such as 1 inch may be used to treat the dorsal hands. The needle may be inserted proximally and advanced parallel to the tendons and material inserted as the needle is withdrawn. Photoaged hands typically have prominent veins and care must be taken to avoid injections into these structures. Each hand will require about half a bottle per treatment session and approximately 9–10 injection sites to cover the entire hand.

Complications The most common complications related to injections of PLLA are injection site related [2]. These include bruising, erythema, and site-related discomfort. More serious complications include nodule formation known as subcutaneous papules. These nodules are typically foreign body type granulomas mixed in with collagen matrix [6]. The subcutaneous nodules may be treated with injections of intralesional cortisone and it is reasonable to begin treatments with 2.5– 5 mg/mL triamcinolone acetonide. Injections may be performed on a monthly basis until the nodule resolves. In the event that the nodule does not resolve after multiple injections it is possible to remove it surgically using a small incision. More serious complications are possible with injections of PLLA (or any material) and these include necrosis of the skin. This could result from intravascular injection of PLLA and it is wise to aspirate prior to injections near major



Injectable Antiaging Techniques

vascular structures. Inadvertent excursions of the needle into the globe may also occur with PLLA injections (or those of any product) when the periorbital area or tear troughs are injected. The injector should take care to use the non-dominant hand to palpate the infraorbital ridge and to orient the needle away from the eye so that if the patient makes a sudden movement, the needle will not jab them.

PLLA compared with other fillers With the advent of porcine collagen, calcium hydroxylapatite, and new forms of hyaluronic acid, one question asked by some physicians is when PLLA should be used and what patients should be treated with it. PLLA is not a direct volume replacement material and instead causes the body to replace collagen. Thus, it is not a substitute product for the various fillers. Many patients that need discrete line filling will have volume loss associated that can be treated with PLLA. Patients that only require volume replacement of the malar, temporal, or jaw areas may also obtain optimal results with PLLA. Deciding where PLLA fits into one’s practice is as much a patient selection issue as a technical one. Patients who have the temperament and budget to accept a gradual volume replacement should be treated with this product. Patients demanding a single visit correction should not. In addition, because there is no way to anticipate fully how any given individual will manufacture collagen, patients who will not tolerate a treatment program should be avoided.


Conclusions PLLA is a unique molecule capable of restoring significant amounts of subcutaneous volume for long periods of time. It causes the body to make collagen and other extracellular matrix proteins. Unlike other products used in cosmetic dermatology, PLLA cannot produce exactly predictable results and it requires multiple treatment sessions to achieve its planned correction. Used judiciously, it can correct deficits that would otherwise be difficult to correct. PLLA has some unique complications that should be understood before it is used and patient selection is perhaps more important with this product than any other. However, its unique properties offer cosmetic dermatologists unique opportunities and this product should be embraced by injectors who understand its strengths and weaknesses.

References 1 Beer K. (2007) Optimizing patient outcomes with collagenic stimulators. J Drugs Dermatol Suppl 6. 2 Sculptra Package Insert. Bridgewater, NJ: Sanofi-Aventis. 3 Vleggar D, Bauer U. (2004) Facial enhancement and the European experience with Sculptra. J Drugs Dermatol 3, 542–7. 4 Burgess C, Quiroga R. (2005) Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV associated facial lipoatrophy. J Am Acad Dermatol 52, 233–9. 5 Beer K. (2009) Delayed formation of nodules from PLLA injected in the periorbital area. Dermatol Surg 35 Suppl 1, 399–402. 6 Lombardi T, Samson J, Plantier F, Husson C, Küffer R. (2004) Orofacial granulomas after injection of cosmetic fillers: histopathologic and clinical study of 11 cases. J Oral Pathol Med 33, 115–20.

Part 3: Resurfacing Techniques Chapter 47: Superficial chemical peels M. Amanda Jacobs and Randall Roenigk Department of Dermatology, Mayo Clinic, Rochester, MN, USA

BAS I C CONCEPTS • Chemical exfoliating agent causes destruction of the epidermis (to varying degrees) with subsequent repair and rejuvenation. • Factors that influence the depth of a peel. • Specific peeling agents, chemical action, and results. • Standard and advanced techniques for superficial chemical peels. • Complications.

Depth of peel

Definition Superficial chemical peels involve the application of a chemical peeling agent to the skin, resulting in destruction of the epidermis. The peel may have effects anywhere from the stratum corneum to the basal cell layer. There are many factors that affect the depth of the peel including the peeling agent and the technique of application. Chemical peels create a controlled wound which the body then heals. Permanent histologic changes can be seen after a series of superficial peels.

Multiple factors influence the depth of a given peel, including chemical agent selection and technique of application (Table 47.1). Each of these factors should be considered when selecting a superficial peel for a patient.

Histologic changes Superficial chemical peels injure and rejuvenate the epidermis; however, histologic changes can also be seen in the dermis, including collagen formation in the papillary dermis. Repeated application of alfa-hydroxy acids to the skin surface resulted in a 25% increase in epidermal thickness as well as increased acid mucopolysaccharides and increased density of collagen in the papillary dermis [2].

Physiology Indications Superficial chemical peels are generally safe and can be used on all Fitzpatrick skin types. The peeling agent only affects the epidermis and so this procedure is only indicated for superficial processes such as mild photoaging, superficial dyschromias (melasma, lentigines, post-inflammatory hyperpigmentation [PIH]), acne, and actinic keratoses [1]. Typically, a series of peels is required for the best clinical response.

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

Formulation In a superficial peel, chemical agents are applied to the skin to create a wound by destroying the epidermis. There are multiple different chemicals that fall into this category (Table 47.2).

Alfa-hydroxy acids (glycolic, lactic, malic, oxalic, tartaric, and citric acid) These acids have been used on the skin for centuries. Ancient Egyptian women would bathe in sour milk (containing lactic acid) to smooth the skin [3,4]. They are naturally occurring in sugarcane, sour milk, and various fruits. When applied to the skin, they decrease corneocyte adhesion above the granular layer, reduce the number of desmosomes, and result in



Resurfacing Techniques

desquamation [2,4]. The application is typically painless, although some mild stinging may occur. These acids require neutralization with sodium bicarbonate or dilution with water. Prolonged contact with the skin may result in uneven penetration and deeper peel depths being achieved [1].

Pyruvic acid (alfa-keto acid) This product has keratolytic, antimicrobial, and sebostatic properties. It is a small molecule with a low pKa which

allows deep penetration in the skin. Typical formulations fall into the category of medium depth peels. This potent acid carries a high risk for scarring. Application is associated with an intense burning sensation and neutralization is required with a 10% sodium bicarbonate solution [1,3]. Berardesca et al. [3] describe the efficacy of a 50% pyruvic acid preparation with dimethyl sulfone. This buffered solution has a lower pH value. The overall result is a superficial peel with mild burning on application and mild erythema following the peel.

Jessner’s solution (resorcinol 14%, lactic acid 14%, and salicylic acid 14% in alcohol)

Table 47.1 Variables that affect the depth of a superficial peel.

The penetration of this solution is limited to the epidermis. The peel results in separation of the stratum corneum and upper epidermal edema [1]. Application is best with a sable hair brush. Wrung-out gauze pads may also be used. Typically, two to three coats are applied. The skin will first become erythematous and then a white, powdery appearance will emerge. This is caused by precipitation of the

Peeling agent and concentration Technique of application (number of coats and pressure of application) Duration of contact with the skin (prior to neutralization) Anatomic location Pretreatment regimen

Table 47.2 Characteristics of various chemical peeling agents. Peeling agent




Unique properties

Alfa-hydroxy acid

Diminishes corneocyte adhesion/desquamation


Pyruvic acid

Keratolytic, sebostatic, antimicrobial


Intense burning with application

Jessner’s solution

Stratum corneum separation, dermal edema


Intense burning with application 2–3 coats applied

TCA (10–25%)

Coagulation of epidermal proteins


True frost forms, intensity correlates with depth of injury

Burning with application Erythema for several days

Salicylic acid

Keratolytic, comedolytic, desquamation of upper SC Enhances other peeling agents


Burning with initial application, then acid becomes an anesthetic

Transient salicylism may occur


Not destructive Increases cell turnover

Painless Discolors skin (yellow) Must remain on skin for 6 hours Decomposed by UV light

Produces strong erythema Fine white flakes with peeling


Weakens hydrogen bonds of keratin

Daily application for 3 days Time consuming

Irritant or contact allergy possible Continued use associated with thyroid dysfunction

Solid carbon dioxide

Freezes and destroys epidermis

Block of dry ice dipped in acetone/ethanol solution Used to treat acne

Cold sensitivity

Deeper peel may be achieved with prolonged skin contact

* White precipitate can occur as vehicle evaporates, does not represent true frost.


Side effects

Newer formulation used for superficial peels

47. Superficial chemical peels chemical compounds onto the skin with vehicle evaporation. This is not equivalent to a “frost” which indicates depth of peeling in a trichloroacetic acid (TCA) peel. Complications are rare with this type of peel because of the limited penetration of the peeling solution.

Trichloroacetic acid TCA is a much stronger acid than alfa-hydroxy acid (AHA), and higher concentrations produce medium and deep peels. Superficial peels can be achieved using concentrations of 10–25%. TCA is an inorganic compound that occurs naturally in the crystalline form. It is dissolved in distilled water to form an aqueous solution of the desired concentration. It is stable for a long time (23 weeks) and is not heat or light sensitive. Use and storage may affect the concentration of the solution and care should be taken to handle appropriately [1]. Cotton tip applicators and debris can contaminate the solution. The mechanism of action for TCA is coagulation of epidermal proteins and necrosis of the cells. The skin gradually turns whitish gray, creating a “frost” as the epidermal proteins coagulate and precipitate (Figure 47.1) [5]. This is a self-neutralizing acid. Histologically, the epidermis and upper papillary dermis are destroyed along with new collagen deposition [1,4,6]. TCA must be applied in a controlled setting. Analgesia and/or sedation are typically required. Cotton-tipped applicators are dipped in a container with TCA solution and rolled on the edge to prevent dripping of solution. The acid is then painted on the skin, typically along cosmetic units until the desired level of frosting is achieved [6]. Multiple coats may be needed and depth of the peel correlates to the intensity of the frost. Cool compresses can be used to ease burning sensation, but do not neutralize the solution. Patients should expect several days of erythema followed by desquamation over 7 days.

Figure 47.1 White frost seen with a trichloroacetic acid (TCA) peel indicating epidermal protein coagulation. The intensity of the frost corresponds with the peel depth.

This peel is operator dependent and potential for error and complications are high. The greatest risk exists for peeling more deeply than originally intended.

Salicylic acid (ortho-hydroxybenzoic acid) This is a beta-hydroxyl acid. It is a lipophilic acid that allows desquamation of the upper layers of the stratum corneum without inflammation [1,6]. This peeling agent can be safely used on all skin types, even those prone to PIH. This agent also has keratolytic and comedolytic qualities making it ideal for acne patients. It also enhances the penetration of other acids and is often used in combination peels (such as Jessner’s solution). A mild–moderate burning sensation occurs on application. Typically, this is easily managed with a cool fan. The acid causes superficial anesthesia and so this quickly dissipates after a minute or more. The acid should be left on the skin for about 3–5 minutes. This is a self-neutralizing acid, but is typically washed off the skin after 5 minutes with plain water. A white precipitate will be seen on the skin after about 1 minute from evaporation of the vehicle (Figure 47.2). This is not a true frost and does not indicate depth of penetration. Desquamation will begin 2–3 days after the peel and continue for 7 days [1,4,6]. Salicylism is possible with this peel, although unlikely. Care should be taken to avoid peeling large areas at the same time. Patients may experience tinnitus, dizziness, and headache. The symptoms are transient and self-resolving [7]. Increased water intake may improve symptoms more quickly.

Figure 47.2 White discoloration of the skin seen during a salicylic acid peel caused by evaporation of the vehicle and precipitation of salicylate on the skin.



Resurfacing Techniques

Tretinoin peel Tretinoin applied in high concentration (1–5%) in propylene glycol is used for peeling. The solution is canary yellow and discolors skin on application. Tretinoin decomposes on UV exposure and should be applied late in the day. The application is painless and the peeling agent must be left on the skin at least 6 hours. This is a safe peel and the desquamation consists only of fine white flakes. It typically produces strong erythema and the risk for prolonged erythema is increased with this type of peel [6]. Tretinoin cream is typically used as part of a pre-peeling regimen to help improve penetration of peeling agent and improve healing time. Most practices advocate at least 2 weeks of pretreatment prior to the peel [7].

Resorcinol (m-hydroxybenzene) Resorcinol is structurally and chemically related to phenol and acts as a potent reducing agent. It disrupts the weak hydrogen bonds of keratin and is therefore a keratolytic. It remains stable in water, ethanol, and ether. Typically, the peeling agent is applied as a paste in concentrations of 10–50%. It is applied daily for 3 consecutive days and the skin contact time is slowly increased daily [1,7]. The paste is then wiped off the skin. Water and creams must be avoided for up to 1 week. Rescorcinol is not typically used as a peeling agent. The process is time-consuming and the results can be achieved by other methods. It also can cause a non-specific irritant reaction or contact allergy. Additionally, there are reports of thyroid dysfunction with continued use (over months to years) [7]. More recent reviews indicate no danger when used in the standard fashion (as described above) [8].

Solid carbon dioxide (dry ice) This modality has been used to treat acne for over 60 years. Brody describes a technique using a block of dry ice wrapped in a hand towel and dipped in a 3 : 1 solution of acetone and alcohol. Acetone dissolves sebum and lowers the temperature of the carbon dioxide. Individual lesions or segments of the face can be treated then using slow even strokes. The depth of injury is modified with pressure of application. Brody reports 5–8 seconds of moderate pressure as sufficient to freeze comedones. This is less destructive than liquid nitrogen which is more than twice as cold (−186 °C) compared to dry ice (−78 °C) [7].

Advantages and disadvantages Superficial chemical peels are generally very safe procedures with a minimal risk profile. They can safely be performed on all Fitzpatrick skin types [4]. Patient discomfort is typically minimal and local anesthesia is not typically needed.


Patients usually tolerate the erythema and desquamation following the peel quite well. Appropriate management of patient expectations is critical with superficial peels. Patients must be aware that a series of peels is required for maximum benefit. In addition, patients should be selected appropriately, based on the degree of skin disease to ensure a successful peel candidate.

Standard technique Initial consult The initial consult is essential. This allows the treating physician to determine if the patient is an appropriate candidate for a chemical peel. They should have a dermatologic condition that is amenable to this therapy. A history of recent isotretinoin use, hypertrophic scarring, facial radiation, or significant psychologic disorder may make the patient a less desirable candidate. Also, a history of oral contraceptive use or hormonal agents should be noted as this may increase the chance of PIH [4]. Photographs should be obtained at this visit. Perhaps the most important aspect of this consult is managing the patient’s expectations and preparing him or her for the procedure. The peel is superficial in nature and the need for serial treatments should be emphasized. Also, adherence to priming and post-treatment recommendations is essential to treatment success.

Priming Pretreatment is important for peeling. It allows for melanocyte suppression, uniform penetration of the peeling agent, and increased healing time. Ideally, priming occurs for 2–3 weeks prior to the peel procedure. The regimen can be customized to the patient but often includes glycolic acid products (around 10%), tretinoin, hydroquinone, and sunscreen on a regular basis. The regimen (except sunscreen) should be discontinued 3 days prior to the procedure [4,5].

Peel procedure The depth of the chemical peel is determined by multiple variables; however, the key factors are amount and concentration of peeling agent used, pressure used with application, and duration of contact with the skin. Basic peel protocol is similar for all types of superficial peels (Table 47.3). The procedure begins with cleansing and defatting the skin. Defatting is achieved by applying acetone or isopropyl alcohol to remove excess oil and sebum and allow for even penetration of the peeling agent. Occlusive ointment can be used to protect the lips and eyes; hair should be tied back away from face. Ideally, the office should be equipped with an eyewash station or have access to water for flushing [9].

47. Superficial chemical peels


(a) Figure 47.3 (a) Typical tray set-up for a salicylic acid peel. (b) Excess peel solution is removed from sponge prior to application.

Table 47.3 Standard procedure for a superficial peel. Initial consult Includes pre-peel photographs Priming 2–3 weeks prior to peel

Post-care Post-peel care includes gentle cleansing. Light moisturizing lotions can be used 24 hours after the peel procedure (Figure 47.5). Sun protection (avoidance or sunscreen) is essential for 1 month following the peel. It is critical in the first week after the peel.

Pre-treatment with glycolic acid, tretinoin, hydroquinone, sunscreen Peel Degreasing with acetone or alcohol

Advanced techniques

Application of peeling agent

Depth controlled TCA peel

Desired exposure to skin

Consistent results with TCA peels can be difficult to achieve and potential complications can occur more frequently depending on physician skill level and patient selection. A recent product, the TCA Blue Peel, offers a depth controlled TCA peel with more standardization in acid absorption [10]. The fixed concentration (15% or 20%) of TCA is mixed with the Blue Peel base (glycerin, saponins, and a non-ionic blue color). This base increases the surface tension of the solution and results in slower penetration of TCA into the skin. The blue color allows the physician to easily identify the areas that have been treated. Frosting occurs more slowly which allows the physician to control the depth of peel more consistently. Several coats may be applied depending on the desired depth of peeling.

Rinse skin or neutralize with appropriate material Application of sunscreen and possibly anti-inflammatory agent Post-peel Cool compresses Sunscreen/sun avoidance Creams/lotions as recommended

All of the materials needed should be gathered prior to beginning. This includes a neutralization solution if needed. Patients may be more comfortable with a fan blowing cool air during the peel. Applications with either cotton-tip applicators or gauze are typically used (Figures 47.3 and 47.4). There are inherent errors that can occur with peeling and care should be taken to avoid these situations. One error is incorrect formulation, either secondary to error in compounding or incorrect storage leading to evaporation of alcohol/water vehicle. The latter results in a stronger peeling solution than intended. Careful labeling and storage of peeling agents is essential. If greater than one strength is being used at a time, it is recommended that only one solution be on the tray at any given time and this should be clearly marked with concentration [8].

Fluor-hydroxy pulse peel This peel combines 5-flurorouracil with glycolic acid (70%) peels to treat actinically damaged skin. The two agents appear to have synergistic effects. One randomized study showed this combination cleared 91% of actinic keratoses, compared with 19% when treated with glycolic acid alone. The peel was repeated once weekly for 8 weeks [11].

Chemical reconstruction of skin scars Chemical reconstruction of skin scars (CROSS) is a technique to address acne scars while minimizing the risks of



Resurfacing Techniques





deeper peels (such as scarring and pigmentary changes). The CROSS technique involves focal application or high concentration TCA (65–100%) to atrophic acne scars. Each scar is pressed firmly with a sharpened wooden applicator. Variable improvement can be seen with this technique but typically it requires a series of treatments [12].

Complications Complications arising from superficial chemical peels are relatively rare (Table 47.4) [9]. Post-inflammatory hyperpig-


Figure 47.4 Standard peel procedure for a salicylic acid peel. (a) Face is degreased with acetone; (b) peel solution is applied; (c) erythema and white precipitate form on skin; (d) patient rinses face with water.

mentation can occur, particularly in darker skin types. Technical errors (dripping of acid in the eyes) or incorrect formulation must also be avoided.

Conclusions Superficial chemical peels wound the epidermis with destruction or desquamation. This leads to increased epidermal thickness and new collagen formation in the papillary dermis with repeated application. They are indicated for superficial processes such as superficial dyschromias, mild

47. Superficial chemical peels




Figure 47.5 (a) Pre-peel; (b) immediately post-peel; (c) 24 hours after a salicylic acid peel.

Table 47.4 Potential complications associated with superficial peels. Pigmentary changes Infection Reactivation of herpes Prolonged erythema/pruritus Contact dermatitis Lines of demarcation Transient textural changes (enlarged pores) Milia Cold sensitivity (CO2)

photoaging, acne, and actinic keratoses. They can safely be performed on all skin types and complications are rare. A series of peels is often required for the best clinical outcome.

References 1 Zakopoulou N, Kontochristopoulos G. (2006) Superficial chemical peels. J Cosmet Dermatol 5, 246–53. 2 Ditre CM, Griffin TD, Murphy GF, Sueki H, Telegan B, Johnson WC, et al. (1996) Effects of alpha-hydroxy acids on photoaged skin: a pilot clinical, histologic, and ultrastructural study. J Am Acad Dermatol 34, 187–95.

3 Berardesca E, Cameli N, Primavera G, Carrera M. (2006) Clinical and instrumental evaluation of skin improvement after treatment with a new 50% pyruvic acid peel. Dermatol Surg 32, 526–31. 4 Roberts WE. (2004) Chemical peeling in ethnic/dark skin. Dermatol Ther 17, 196–205. 5 Roenigk RK. (1998) Facial chemical peel. In: Baran R, Maibach HI, eds. Textbook of Cosmetic Dermatology, 2nd edn. Malden, MA: Blackwell Science, pp. 585–94. 6 Landau M. (2008) Chemical peels. Clin Dermatol 26, 200–8. 7 Brody HJ. (1992) Superficial peeling. In: Chemical Peeling. St. Louis, MO: Mosby Year Book, pp. 53–73. 8 Brody HJ. (2001) Complications of chemical resurfacing. Dermatol Clin 19 (3). 9 Drake LA, Dinehart SM, Goltz RW, Graham GF, Hordinsky MK, Lewis CW, et al. (1995) Guidelines of care for chemical peeling. Guidelines/Outcomes Committee: American Academy of Dermatology. J Am Acad Dermatol 33, 497–503. 10 Obagi ZE, Obagi S, Alaiti S, Stevens MB. (1999) TCA-based blue peel: a standard procedure with depth control. Dermatol Surg 25, 773–80. 11 Marrero GM, Katz BE. (1998) The new fluor-hydroxy pulse peel: a combination of 5-fluorouracil and glycolic acid. Dermatol Surg 24, 973–8. 12 Lee JB, Chung WG, Kwahck H, Lee KH. (2002) Focal treatment of acne scars with trichloroacetic acid: chemical reconstruction of skin scars method. Dermatologic Surgery 28, 1017–21.


Chapter 48: Medium depth chemical peels Gary D. Monheit1 and Jens J. Thiele2 1 Total Skin & Beauty Dermatology Center, PC, and Departments of Dermatology and Ophthamology, University of Alabama, Birmingham, AL, USA 2 Dermatology Specialists, Inc., Oceanside, CA, USA

BAS I C CONCE P T S • Indicated both for therapeutic field treatments of precancerous skin lesions and for various cosmetic indications. • Induce controlled chemical damage through the epidermis and variable portions of the dermis. • Pretreatments including even cleansing, degreasing, and subsequent application of Jessner’s solution will open the epidermal barrier for more even and deep penetration of trichloracetic acid. • Affords the patient a single procedure with healing time within 1 week to 10 days. • Are considered safe and effective when used by experienced dermatologists.

Introduction A number of acidic and basic chemical agents have been used to produce the varying effects of light, medium, or deep chemical peels, mediated by differences in their ability to penetrate and damage epidermal and dermal skin components. The level of penetration, destruction, and inflammation determines the level of peeling. The stimulation of epidermal growth through the removal of the stratum corneum without necrosis characterizes light superficial peels. Through exfoliation, it thickens the epidermis with qualitative regenerative changes. Destruction of the epidermis defines a full superficial chemical peel inducing the regeneration of the epidermis. Further destruction of the epidermis and induction of inflammation within the papillary and upper portions of the reticular dermis constitutes a medium depth peel. Further inflammatory response in the medium reticular dermis induces new collagen production and ground substances constituting a deep chemical peel [1].

Formulations Trichloracetic acid Trichloracetic acid (TCA) has become the gold standard of chemical peeling agents, based on its long history of usage, its versatility in peeling, and its chemical stability. Its first documented use for skin rejuvenation dates back as far as

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


1882, when German dermatologist Paul Gerson Unna described the properties of salicylic acic, resorcinol, phenol, and TCA [1]. TCA has since been used in many concentrations because it has no systemic toxicity and can be used to create superficial, medium, or even deep wounds in the skin. TCA is naturally found in crystalline form and is mixed weight-by-volume with distilled water. It is not light sensitive, does not need refrigeration, and is stable on the shelf for over 6 months. The standard concentrations of TCA should be mixed weight-by-volume to assess the concentration accurately. TCA crystals weight 30 g are mixed with 100 mL distilled water to give an accurate 30% weight-byvolume concentration. Any other dilutional system – volume dilutions and weight-by-weight – are inaccurate in that they do not reflect the accepted weight-by-volume measurements cited in the literature. Because TCA, at concentrations of 50% or above, has a high potential to be scarring, the use of higher concentrations has fallen out of favor [2]. Therefore, combined applications using an initial modifying treatment followed by a 35% TCA formula were developed to better control the level of damage and minimize the risk of side effects [3]. Brody [4] first developed the use of solid CO2 applied with acetone to the skin as a freezing technique prior to the application of 35% TCA. The preliminary freezing appears to break the epidermal barrier for a more even and complete penetration of the 35% TCA. Monheit [5] then introduced the use of Jessner’s solution prior to the application of 35% TCA (Table 48.1). The Jessner’s solution was found to be very effective in destroying the epidermal barrier by breaking up individual epidermal cells. This allows a deeper penetration of the 35% TCA and a more even application of the peel solution. Similarly, Coleman and Futrell [6] have demonstrated the use of 70% glycolic acid prior to the applica-

48. Medium depth chemical peels

Table 48.1 Jessner’s solution (Combes’ formula).

Table 48.3 Major indications for medium depth chemical peels.


14 g

Salicylic acid

14 g

85% Lactic acid

14 g

95% Ethanol (

100 mL

Destruction of premalignant epidermal lesions – actinic keratoses Resurfacing moderate to advanced photoaged skin (Glogau Levels II, III) Improving pigmentary dyschromias Improving mild acne scars Blending laser, dermabrasion, or deep chemical peeling in photoaged skin (transition from treated to non-treated area), a sufficient quantity up to.

Table 48.2 Agents used for medium depth chemical peeling. Agent


40–50% TCA

Not recommended

Combination 35% TCA + solid CO2 (Brody)

The most potent combination

Combination 35% TCA + Jessner’s solution (Monheit)

The most popular combination

Combination 35% TCA + 70% glycolic acid (Coleman)

An effective combination

88% phenol

Rarely used

tion of 35% TCA. Its effect has been very similar to that of Jessner’s solution. All three combinations have proven to be as effective as the use of 50% TCA; however, with a greater safety margin. The application of acid and resultant frosting are better controlled with the combination so that the “hot spots” with higher concentrations of TCA can be controlled, creating an even peel with less incidence of dyschromias and scarring (Table 48.2).

Advantages and disadvantages The advantages of chemical peeling compared with other modalities used to treat photoaging or precancerous lesions include the low cost, the ease of a single application, the ability to be performed in a routine treatment setting without the need for specialized equipment, and reliable efficacy. Additionally, chemical peeling may be performed in any office setting with routine dermatologic supplies such as 2 × 2 or 4 × 4 inch gauze pads and cotton-tipped applicators, and does not require special equipment (Figure 48.1). When performed properly on the correctly chosen patient, a medium depth peel will reliably improve the appearance of photoaged skin and produce sustained clearing of most precancerous skin lesions for a period of several months to several years.

Figure 48.1 Standard setup for Jessner’s and trichloracetic acid (TCA) combination peel. The standard setup includes a facial cleanser such as Septisol, acetone, Jessner’s solution, 35% TCA, cotton-tipped applicators, 2 × 2 inch and 4 × 4 inch gauze pads, and cool-water soaks for patient comfort.

Indications While very light and light peels may improve conditions such as acne and skin texture, and deep peels may help improve moderate rhytids and acne scarring, current indications for medium depth chemical peeling include Glogau type II photoaging, epidermal lesions such as actinic keratoses, pigmentary dyschromias, acne scarring, and also to blend the effect of deeper resurfacing procedures (Table 48.3) [7]. Several contraindications exist when choosing a medium depth chemical peel (Table 48.4). Because patient compliance during the recovery period is essential to avoiding permanent negative sequelae, a medium depth peel should not occur in the setting of a poor physician–patient relationship. Likewise, a frank discussion of what the peel can and cannot accomplish is necessary, and unrealistic expectations on the part of the patient must be recognized. Furthermore, poor general health and nutritional status will compromise wound healing and should dissuade a procedural approach.



Resurfacing Techniques

Table 48.4 Contraindications to medium-depth chemical peeling.

tion or hypopigmentation, types III–VI are at greater risk for these complications [8].

Absolute contraindications Poor physician–patient relationship Unrealistic expectations

Standard technique

Poor general health and nutritional status Isotretinoin therapy within the last 6 months Complete absence of intact pilosebaceous units on the face Active infection or open wounds (e.g. herpes, excoriations, or open acne cysts) Relative contraindications Medium depth or deep resurfacing procedure within the last 3–12 months Recent facial surgery involving extensive undermining, such as a rhytidectomy History of abnormal scar formation or delayed wound healing History of therapeutic radiation exposure

Jessner’s TCA peel procedure after Monheit: 1 The skin should be cleaned thoroughly with Septisol® (Vestal Laboratories, St. Louis, MO, USA) to remove oils. 2 Acetone or acetone alcohol is used to further débride oil and scale from the surface of the skin. 3 Jessner’s solution is applied. 4 35% TCA is applied until a light frost appears. 5 Cool saline compresses are applied to dilute the solution. 6 The peel will heal with 0.25% acetic acid soaks and a mild emollient cream.

History of certain skin diseases (e.g. rosacea, seborrheic dermatitis, atopic dermatitis, psoriasis, or vitiligo) or active retinoid dermatitis

Informed consent

Moreover, isotretinoin therapy within the previous 6 months has been associated with increased risk of scarring, and a medium depth chemical peel should be delayed until the patient is beyond 6 months of finishing a course of isotretinoin. Additionally, active infections or open wounds such as herpes simplex vesicles, excoriations, or open acne cysts should postpone the treatment until such conditions resolve. All patients with a history of herpes simplex virus I of the facial area should be premedicated with an antiviral agent such as acyclovir or valacyclovir and remain on prophylactic therapy for 1 week. While not absolute contraindications, patients with overly sensitive, hyperreactive, or koebnerizing skin disorders such as atopic dermatitis, seborrheic dermatitis, psoriasis, or contact dermatitis may find their underlying disease exacerbated by a chemical peel. In particular, patients with rosacea typically develop an exaggerated inflammatory response to the peeling agents, which serves as a trigger factor for symptoms. A history of keloid formation should be screened for prior to chemical peeling. Likewise, patients with a recent history of extensive or major facial surgery, or those who have recently had a medium depth peel in the preceding months should be evaluated closely with regard to risks and benefits. The collagen remodeling phase of wound healing due to prior treatments is still underway in such patients, and an altered wound healing response may occur. Another important relative contraindication is a history of radiation therapy to the proposed treatment area. An absence of pilosebaceous units should serve as a harbinger that the area does not have the reserve capacity of follicular epidermal cells with which to repopulate. While Fitzpatrick skin types I and II are at low risk for post-resurfacing hyperpigmenta-


A thorough pretreatment discussion is imperative. It allows the opportunity to discuss the risks and benefits, as well as to educate the patient on the expected timeframe and course of recovery. It also allows the surgeon to assess the patient’s goals and expectations so that the procedure is performed only on appropriate candidates. Those who are not willing to tolerate an acute event followed by 7–10 days of desquamation and 2–3 weeks of erythema are best served by other treatments. The patient must fully understand the potential benefits, limitations, and risks of the procedure, and an informed consent form must be signed. Pretreatment photographs are also highly recommended to allow for posttreatment comparison.

Setup All necessary reagents for a Jessner’s + 35% TCA medium depth peel may be obtained in bulk for multiapplication use from leading dermatologic suppliers. When ordering TCA, one must ensure that the strength of the acid is as intended by the physician. While both weight-to-weight and volumeto-volume methods of calculating acid concentration may be used, the authors prefer the more common method of weight-to-volume calculations. When changing vendors or ordering new products, the distributor’s method of calculation should be confirmed so as to avoid application of a more highly concentrated or less highly concentrated than intended product. The standard setup includes a facial cleanser such as Septisol, acetone, Jessner’s solution, TCA, cotton-tipped applicators, 2 × 2 inch and 4 × 4 inch gauze pads, and cool-water soaks for patient comfort (Figure 48.1).

48. Medium depth chemical peels

Patient preparation All patients with a history of oral or facial herpes simplex virus (HSV) infection should be pretreated with antiherpetic agents such as aciclovir or valcyclovir to prevent herpetic activation during the post-peel period. Because a negative history of HSV infection does not always correspond with actual prior exposure, and because antiviral medications are extremely safe, it is prudent to place all patients undergoing medium depth peels on a post-procedural course of medication. All antiherpetic agents act by inhibiting viral replication in the intact epidermal cell, such that the skin must be reepithelialized before the agent has its full effect. Thus, the antiviral agent must be continued after a medium depth peel for at least 10 days. Routine antiviral agents are not necessary in light or superficial chemical peeling, as the injury pattern usually is not enough to activate the HSV.

Analgesia and sedation Medium depth peels may be performed without anesthesia, with preceding topical anesthesia, with local nerve blocks, with mild preoperative sedation, or anxiolytic medications, or a combination of any of the above. For full-face peels in anxious patients, it is useful to give preoperative sedation (5–10 mg diazepam orally) along with mild analgesia in the form of 50 mg meperidine (Demerol, Winthrop, New York, USA) and a mild sedative such as 25 mg hydroxyzine hydrochloride intramuscularly (Vistaril, Lorec, New York, USA). The discomfort from this peel is not long-lasting, so shortacting anxiolytics and analgesics are all that are usually recommended [8].

Application technique Vigorous cleansing and degreasing of the skin prior to application of the active peeling agent represents a crucial and often overlooked step in the protocol. The removal of skin surface lipids deriving from sebum and epidermal lipids, scale and thickened stratum corneum is particularly important for even penetration of the solution. The face is first washed with an antibacterial cleanser in glycerin (Septisol) applied with 4 × 4 inch gauze pads, then rinsed with water. Acetone is then applied with 4 × 4 inch gauze pads to remove residual oils and debris. The skin is thus débrided of stratum corneum and excessive scale. The necessity for thorough degreasing in order to achieve reliable and even penetration cannot be overemphasized. Prior to application of the active peeling agent, one should assess the thoroughness of degreasing. If oil or scale is felt, the degreasing step should be repeated. Particular attention should be focused on the

hairline and nose. Thorough and uniform degreasing conditions the skin to ensure an even peel over the entire face. Next, Jessner’s solution is evenly applied, either with cotton-tip applicators or 2 × 2 inch gauze pads. Jessner’s solution alone constitutes a very light peel, and thus will open the epidermal barrier for a more even and more deeply penetrating TCA application. Only one coat of Jessner’s solution is usually necessary to achieve a light, even frosting with a background of erythema. The expected frosting is much lighter than that produced by the TCA. The face is treated in sequential segments progressing inferiorly from the hairline. Even strokes are used to apply the solution to the forehead first then each cheek, the nose, and the chin. The perioral area should follow, and the eyelids are treated last, creating the same erythema with blotchy frosting. As with the application of Jessner’s solution, cosmetic units of the face are then peeled sequentially with TCA from forehead to temple to cheeks, and finally to the cutaneous lips and eyelids. The 35% weight-to-volume TCA is applied evenly with 1–4 cotton-tipped applicators rolled over different areas with lighter or heavier doses of the acid. Four well-soaked cotton-tipped applicators are used with broad strokes over the forehead and the medial cheeks. Two mildly soaked cotton-tipped applicators can be used across the lips and chin, and one damp cotton-tipped applicator on the eyelids. The amount of acid delivered is thus dependent upon both the saturation of an individual cotton-tipped applicator and the number of cotton-tipped applicators used. In this manner the application is titrated according to the cutaneous thickness of the treated area. The white frost from the TCA application, which represents the keratocoagulated endpoint, should appear on the treated area within 30 seconds to 2 minutes after application (Figure 48.2). An even application should eliminate the need for a second or a third pass, but if frosting is incomplete or uneven, the solution should be reapplied. TCA takes longer to frost than a deep phenol peel, but less time than the superficial peeling agents. After a single application to an area, the surgeon should wait at least 3–4 minutes to ensure that frosting has reached its peak. The thoroughness of application can then be analyzed, and a touch up, or less commonly another pass, can be applied as needed. Areas of poor frosting should be retreated carefully with a thin application of TCA. The physician should seek to achieve a level II–III frosting. Level II frosting is defined as white-coated frosting with a background of erythema [9]. A level III frosting, which is associated with penetration to the reticular dermis, is solid white enamel frosting with no background of erythema. A deeper level III frosting should be restricted only to areas of heavy actinic damage and thicker skin. Although heavily damaged actinic skin may require a level III frosting, most medium depth chemical peels should strive to obtain no more than a level II frosting. This is especially true over



Resurfacing Techniques

Figure 48.2 Frosting observed immediately after combined Jessner’s and TCA peel. Typical opaque white frosting with mild erythema observed 2 minutes after TCA application.

tip against the rim of the bottle or onto a dry gauze pad before using it for application. The patient should be positioned with the head elevated at 30 ° and the eyelids closed. The applicator is then rolled gently on the lids and periorbital skin within 2–3 mm of the lid margin. Never leave excess peel solution on the lids, because the solution can roll into the eyes. Dry tears with a separate, dry cotton-tipped applicator during peeling because they may wick peel solution to the puncta and eyes by capillary attraction. The patient will experience an immediate burning sensation as the TCA is applied, but this subsides as frosting is completed. A circulating fan may be placed beside the patient for comfort. Cool saline or water compresses also offer symptomatic relief for a peeled area. The compresses are placed over the face for 5–6 minutes after the peel until the patient is comfortable. The burning subsides fully by the time the patient is ready to be discharged. At that time, most of the frosting has faded and a brawny desquamation is evident.

Post-procedure eyelids and areas of sensitive skin. Those areas with a greater tendency to scar formation, such as the zygomatic arch, the bony prominences of the jawline, and chin, should only receive up to a level II frosting. Overcoating TCA with multiple passes or highly saturated cotton-tipped applicators will increase its penetration, so that a second or third application will create further damage. One must be extremely careful to retreat only areas where the amount of solution taken up was not adequate or the skin is much thicker. One should never overcoat a fully frosted area. Certain facial features require special attention. Careful feathering of the solution into the hairline and around the rim of the jaw and brow conceals the line of demarcation between peeled and non-peeled areas. The perioral area has fine, radial rhytids that require a complete and even application of solution over the lip skin to the vermilion border. This is best accomplished with the help of an assistant who stretches and fixates the upper and lower lips as the peel solution is applied. Alternatively, the TCA may be applied along the rhytid to the vermilion border with the wooden end of a cotton-tipped applicator. It should be noted that deeper furrows such as expression lines will not be eradicated by a medium depth peel and thus should be treated like the remaining skin. Thickened keratoses should stand in contrast to the frosted background because they do not pick up peel solution evenly and thus do not frost evenly. Additional applications rubbed vigorously into these lesions may be needed for penetration. Eyelid skin must be treated delicately and carefully. A damp, rather than saturated, applicator should be used. This is accomplished by draining the excess TCA on the cotton


Postoperatively, edema, erythema, and desquamation are expected. With periorbital peels and even forehead peels, eyelid edema can be severe enough to close the lids. For the first 2–4 days, the patient is instructed to soak four times a day with a 0.25% acetic acid compresses made of 1 tablespoon white vinegar in 1 pint warm water. A bland emollient is applied to the desquamating areas after soaks. After 4 days, the patient can shower and clean gently with a mild facial cleanser. The erythema intensifies as desquamation becomes complete within 4–5 days. Thus, healing is completed within 7–10 days. At this time the bright red color has faded to pink and has the appearance of a sunburn (Figure 48.3). This erythema may be covered by cosmetics and will fade fully within 2–3 weeks.

Complications Many of the complications seen in peeling can be recognized early on during healing stages. The cosmetic surgeon should be well acquainted with the normal appearance of a healing wound in its timeframe for medium depth peeling. Prolongation of the granulation tissue phase beyond 1 week may indicate delayed wound healing. This could be the result of viral, bacterial, or fungal infection, contact irritants interfering with wound healing, or other systemic factors. A red flag should alert the physician that careful investigation and prompt treatment should be instituted to forestall potential irreparable damage that may result in scarring. Thus, it is critically important to understand the stages of wound healing in reference to medium depth peeling. The

48. Medium depth chemical peels









Figure 48.3 Sequential exfoliation, granulation, and re-epithelialization after Jessner’s and TCA combination medium depth peel. (a) Postoperative day 1: inflammation with edema, erythema; (b) day 2: early epidermal separation with hyperpigmentation; (c, d) day 3 morning; and (e, f) day 3 afternoon: dermal inflammation with granulation tissue and early re-epithelialization; (g, h) days 5 and 6, respectively: full desquamation with regeneration of new epidermis and beginning dermal remodeling. 389


Resurfacing Techniques



Figure 48.4 Jessner’s TCA peel performed for photoaging skin and actinic keratoses. (a) Preoperative; (b) 5 weeks postoperative; (c) 10 weeks postoperative.


physician then can avoid, recognize, and treat any and all complications early (Figure 48.4).

Long-term care Long-term care of peeled skin includes sunscreen protection for up to 6 months along with reinstitution of medical treatment such as low strength hydroxy acid lotions and topical tretinoin formulations. Repeeling areas should not be performed for 6 months from the previous peel. If any erythema or edema persists, the peel should not be performed as the reinjury may create complications. Medium depth peels should not be performed on undermined skin such as facelift or flap surgery performed up to 6 months prior to the peel [10].


Conclusions The evolution of medium depth chemical peeling has changed the face of cosmetic surgery. It has introduced new techniques into the armamentarium of the cosmetic surgeon to treat problems that previously have been approached with tools inadequate to obtain the results for moderate photoaging skin or with overly aggressive treatment using deep chemical peeling agents. The combination peels have provided some of the more popular tools needed to approach a burgeoning population with photoaging and photocarcinogenesis. The presented medium depth peel will produce excellent results for a variety of skin conditions, including actinic keratoses (Figure 48.5). A comparison study of the efficacy

48. Medium depth chemical peels

Figure 48.5 Jessner’s 35% TCA peel for actinic keratoses. (a & b) Preoperative diffuse actinic keratoses and seborrheic keratoses; (c & d) 9 months postoperative.





of Jessner’s solution plus 35% TCA with 5-fluorouracil documented superior effectiveness of this single procedure over 5-fluorouracil, with a significant reduction in morbidity [11]. Medium depth combination peels thus provide an effective, safe, and simple single procedure that can be used as both a therapeutic and cosmetic procedure to counteract cutaneous photodamage.

References 1 Brody HJ, Monheit GD, Resnik SS, Alt TH. (2000) A history of chemical peeling. Dermatol Surg 26, 405–9.

2 Brody HJ. (1989) Variations and comparisons in medium depth chemical peeling. J Dermatol Surg Oncol 15, 960–3. 3 Monheit GD. (2004) Chemical peels. Skin Ther Lett 9, 6–11. 4 Brody HJ. (1997) Chemical Peeling and Resurfacing. Mosby, p. 110. 5 Monheit GD. (1989) The Jessner’s + TCA peel: a medium depth chemical peel. J Dermatol Surg Oncol 15, 945. 6 Coleman WP, Futrell JM. (1994) The glycolic acid + trichloroacetic acid peel. J Dermatol Surg Oncol 20, 76–80. 7 Glogau RG. (1994) Chemical peeling and aging skin. J Geriatr Dermatol 2, 30–5. 8 Monheit GD. (1995) The Jessner’s trichloracetic acid peel. Dermatol Clin 13, 277–83.



Resurfacing Techniques

9 Rubin M. (1995) Manual of Chemical Peels. Philadelphia, PA: Lippincott, pp. 120–1. 10 Monheit GD. (1994) Advances in chemical peeling. Facial Plast Surg Clin North Am 2, 7–8.


11 Lawrence N, Cox SE, co*ckerell CJ, Freeman RG, Cruz PD Jr. (1995) A comparison of efficacy and safety of Jessner’s solution and 35% trichloracetic acid vs. 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 131, 176–81.

Chapter 49: CO2 laser resurfacing: Confluent and fractionated Mitchel P. Goldman Volunteer Clinical Professor of Dermatology/Medicine, University of California, San Diego and Dermatology/Cosmetic Laser Associates of La Jolla, Inc., San Diego, USA

BAS I C CONCEPTS • Fractionated laser resurfacing with ablative lasers gives better results than with non-invasive lasers. • Confluent ablative laser resurfacing gives better results than fractionated laser resurfacing. • More “down-time” correlates with better results. • Cold air cooling and advanced topical anesthesia provides optimal pain control. • Fractionated ablative resurfacing has minimal adverse effects.

Introduction Carbon dioxide (CO2) lasers are currently available in two forms: confluent and fractionated. The differences between the results, adverse effects, and down-time are compared and contrasted in this chapter.

CO2 laser resurfacing The modern era of CO2 laser resurfacing began in 1994 with the development of the UltraPulse CO2 laser by Coherent Medical (now Lumenis, Inc., Santa Clara, CA, USA). This laser delivers peak fluences above the ablation threshold of cutaneous tissue (5 J/cm2) with tissue dwell times shorter than the 1 ms thermal relaxation time of the epidermis. These new generation CO2 lasers limited tissue dwell time by either shortening the pulse duration (i.e. UltraPulse) or using scanning technology to rapidly sweep a continuous wave CO2 laser beam over the tissue such that the laser beam does not remain in contact with any particular spot on the tissue for longer than 1 ms (i.e. SilkTouch, Sharplan Laser Corporation, now Lumenis Inc., Santa Clara, CA, USA). These high peak-power, short-pulsed, and rapidly scanned CO2 laser systems allow laser surgeons to precisely and effectively ablate 20–30 μm of skin per pass while leaving in its wake a considerably smaller residual zone of thermal damage (up to 150 μm) than left behind by the

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

previous generation of continuous wave CO2 lasers (up to 600 μm). Clinically, this technologic advancement translates into superior clinical results and a much more favorable safety profile than seen previously with the continuous wave CO2 lasers. The thermal effect of the CO2 laser acts on dermal collagen stimulating neocollagenesis and tightening of facial skin. Successful ablation maximizes thermal stimulation of the dermis while limiting non-specific thermal damage. Another method used to decrease thermal damage is to follow a session of CO2 laser ablation with the erbium:yttrium aluminum garnet (Er:YAG) laser. With this technique, the residual non-specific thermal damage left from the CO2 laser is vaporized by subsequent passes with an Er:YAG laser which leaves little if any non-specific thermal damage. Given the impressive clinical results achieved with the high peak power, short pulsed, and rapidly scanned CO2 lasers, they quickly replaced chemical peels and dermabrasion as the treatment of choice for cutaneous resurfacing. However, the impressive results achieved with these new generation CO2 lasers were not without drawbacks. Reepithelialization can take 5–14 days and postoperative erythema and/or post-inflammatory hyperpigmentation can last 1–6 months depending on the depth of laser ablation, amount of residual non-specific thermal damage, and patient’s skin type. Finally, there is a risk of fungal, viral, and bacterial infections on the denuded skin as well as permanent hypopigmentation from destruction of melanocytes and resultant scarring. Minimizing these potential adverse effects requires excellent postoperative care and is timeconsuming for both the patient and physician. These side effects, as well as the significant “down-time” typically associated with CO2 laser resurfacing and extensive postoperative care, are unacceptable to many patients and



Resurfacing Techniques


(b) Figure 49.1 (a) Two passes of CO2 laser at 7 J/cm leaves approximately 70 μm of residual thermal necrosis. (b) Two passes of Er:YAG laser at 10 J/cm results in removal of approximately 50 μm of this necrotic tissue. (From Carcamo AS, Goldman MP. (2006) Skin resurfacing with ablative lasers. In: Goldman MP, ed. Cutaneous and Cosmetic Laser Surgery. London: Mosby-Elsevier, figure 7.44, p. 234.) 2

significantly dampened the initial enthusiasm associated with their use. Because the CO2 laser typically operates near its tissue ablation threshold (5 J/cm2) in most resurfacing applications, a large fraction of its energy is invested in heating rather than ablating tissue. Consequently, the CO2 laser produces relatively large residual thermal damage zones and causes significant desiccation of the target tissue after only a few passes. With each subsequent pass, the amount of vaporized tissue decreases while thermal damage increases and a “plateau” of ablation is typically reached after the fourth pass. Non-specific thermal damage has a negative impact, not only on the CO2 laser’s ablative capacity, but also on its side effect profile. Our research suggests that the relatively large thermally induced residual zone of necrosis (up to 150 μm) left behind by the CO2 laser is one of the main factors contributing to its adverse sequelae including prolonged erythema, postoperative pain, delayed healing, infection, hypopigmentation, and scarring. To minimize the issues resulting from a large residual thermal zone the Er:YAG laser was introduced for resurfacing. While it was successful in reducing thermal damage it was unable to penetrate beyond papillary dermis as a result of poor hemostatic properties. A multimode Er:YAG system, the Tunable Resurfacing Laser (TRL), was developed (Sciton, Inc., Palo Alto, CA, USA) which allows the user to blend a variety of ablation and thermal coagulation depths by extending the pulse duration of the Er:YAG laser which is typically less than 0.5 ms. Extending the pulse duration to 4–10 ms allowed for less flash vaporization and more prolonged thermal heating to occur. The TRL can be tuned for pure ablation or CO2-like thermal injury, or any point in between. Modifications of technical protocols have continued to improve clinical outcomes. Combination therapy with CO2 immediately followed by Er:YAG lasers allow cosmetic sur394


geons to capitalize on the unique benefits of each laser system and to minimize their disadvantages. Er:YAG laser treatment can be used to bypass the ablation “plateau” characteristic of CO2 resurfacing to ablate deeper into the dermis. Improved postoperative healing can also be attained when the short-pulsed Er:YAG laser is used to remove the residual zone of thermal necrosis left behind after CO2 resurfacing (Figures 49.1 and 49.2). Additionally, the ablative lasers have turned out to be extremely versatile therapeutic tools. Cosmetic surgeons now regularly combine ablative laser resurfacing with other problem-specific non-ablative technologies to address multiple cosmetic concerns for the patient in a single treatment session. The efficacy of Q-switched lasers in the treatment of pigmented lesions is enhanced when these lasers are used after ablative resurfacing. Treatment of vascular lesions with the pulsed dye laser or other vascular lasers has been shown to be extremely successful when performed prior to skin resurfacing with an ablative laser. Despite early reports advising against it, full-face laser resurfacing is now safely being combined with rhytidectomy and autologous fat transfer to achieve a more comprehensive approach to facial rejuvenation. Pretreatment and post-treatment protocols have also improved. Although some controversy remains surrounding the topic of antibiotic prophylaxis, a number of studies in the last decade have provided relevant information on common pathogens, effective antibiotic prophylaxis regimens, and clinical situations at increased risk for infection after cutaneous laser resurfacing. Improved laser wound care regimens have reduced recovery time and decreased morbidity after laser skin resurfacing. The benefits of occlusive dressings in accelerating laser wound healing have been well established in a number of studies. Timely institution of topical medications in the postoperative period is now allowing surgeons to effectively address a number of

49. CO2 laser resurfacing






Figure 49.2 Combination UltraPulse CO2 (UPCO2) and Er:YAG laser (patient’s right side) showing improvement equal to left side treated with UPCO2 alone. (a) Before treatment; (b) immediately after treatment; (c) 7 days after laser resurfacing; (d) 3 weeks after laser resurfacing; (e) 2 months after resurfacing. (From Carcamo AS, Goldman MP. (2006) Skin resurfacing with ablative lasers. In: Goldman MP, ed. Cutaneous and Cosmetic Laser Surgery. London: Mosby-Elsevier, figure 7.37 p. 225.)

expected postoperative symptoms and complications including postoperative erythema and edema, pruritus, and postinflammatory hyperpigmentation.

Fractionated CO2 laser resurfacing Because of the prolonged and meticulous postoperative care in addition to potential adverse effects, as well as the

advancement in minimally invasive procedures with rapid healing times, confluent CO2 and/or Er:YAG ablative resurfacing is rarely necessary. Physicians and patients find it easier to have minimally invasive procedures performed even at the expense of minimal results. The current consensus among patients is to embrace a treatment modality that delivers maximum results with minimal down-time. Unfortunately, the promises by most laser companies who have developed and are promoting these minimally 395


Resurfacing Techniques

invasive, non-ablative lasers have not lived up to their stated efficacy in improving photodamage. The development of fractionated lasers that treat a percentage of the skin while leaving the intervening areas untreated, allows for the more dramatic results of a variety of laser wavelengths including the 10 640 nm CO2 laser to be associated with quicker healing times and fewer postoperative sequelae. Initially, fractional lasers were introduced in a non-ablative format. This technology was developed to overcome the hom*ogeneous thermal damage typically created after treatment with standard CO2 and/or Er:YAG lasers and instead create microscopic thermal wounds which spares the tissue surrounding each wound. A 2.1% linear shrinkage of periorbital rhytids was noted at 3 months with this non-ablative fractionated laser which is much less than that achieved with standard ablative CO2 and/or Er:YAG laser resurfacing. It did not take long for fractional photothermolysis to be applied to ablative lasers, allowing for a more aggressive treatment option. My recommendation is that non-ablative fractionated lasers be reserved for patients who can not accept any “down-time” and are willing to wait at least 6 months and have 4–6 treatments to see definite improvement in wrinkles and/or scarring.

Interestingly, physicians have had the ability to perform fractionated CO2 laser resurfacing since the development of the scanning UltraPulse hand-piece in 1995. This scanner was developed to deliver precisely overlapped laser pulses that occurred in a Gaussian distribution uniformly to ablate and/or vaporize the epidermis. Recognition that one could use this scanner with a negative 10% overlap along with the development of smaller laser spot sizes (0.1 and 1.2 mm) produced the first fractionated CO2 laser. There are an ever-increasing variety of both fractionated CO2 and Er:YAG lasers to assist in facial rejuvenation. Table 49.1 summarizes the available lasers by company, wavelength, spot size, treatment area, density, speed, power, and maximal depth (if known). The remaining portion of this chapter discusses the available systems at the time of this writing (Fall 2008). Because I have not been able to test each system and very little if anything is currently available in the peer-reviewed medical literature, I am thankful to my friends and colleagues for sharing their experience.

Active and Deep FX Lumenis The Active and Deep FX fractionated CO2 laser delivers the equivalent of 240 W to the tissue compared to the other 30

Table 49.1 Summary of available lasers by company, wavelength, spot size, treatment area, density, speed, power, and maximal depth. Company


Wavelength (nm)


Deep FX

10 600




Active FX

10 600




Fraxel re:pair

10 600


15 × 15


Pixel CO2

10 600


Mixto SX Slim E30

10 600


20 × 20


MedArt FrX

10 600



SmartXide DOT/Affirm

10 600



Mosaic eCO2

10 600



2 940


Lux 2940

2 940



Fractionated Pearl

2 940




2 940


20 × 20




Profractional XC

2 940


20 × 20


5.5 or 11%



2 940

11 × 11

4 days, 1% incidence of herpes simplex in patients not prophylactically treated with an antiviral that cleared with antiviral treatment, and importantly no patient with either postoperative hyperpigmentation or hypopigmentation. A recent split-face study on Chinese patients confirms our adverse effects profile as well as the lack of post-laser pigmentary alterations. Of note is that unlike fully ablative, non-fractionated CO2 laser resurfacing, we have yet to see any patients with hypopigmentation. This could either be that we do not yet have long enough follow-up on a large enough patient group, or that fractionating epidermal and dermal ablation has a protective effect on epidermal melanocytes.

Conclusions In our clinic from 2004–2007, we performed on average 75 full-face CO2: Er:YAG laser resurfacing/year, 75 one pass Er:YAG laser resurfacings/year, and 150 Active/Deep FX



Resurfacing Techniques

fractionated CO2 laser resurfacings/year. In 2008 those numbers have changed with only 25 full-face CO2: Er:YAG laser resurfacings, 35 one pass Er:YAG laser resurfacings/ year, and 225 Active/Deep FX fractionated CO2 laser resurfacings. Our advice to patients is to choose the procedure based on how much time they can take off from work and/ or social events vs. the number of treatments that they are willing to undergo to achieve the expected results. Patients with severe acne scarring or those with extensive photodamage, actinic keratoses, and/or acne scarring do best with deeper, non-fractionated laser resurfacing and do not achieve satisfactory results with less invasive procedures. We have found that severe acne scarring may require 2–3 treatments every 6 months to achieve optimal results. Full face CO2: Er:YAG laser resurfacing usually gives excellent results for up to 10 years before patients request additional cosmetic procedures. Full-face Er:YAG laser resurfacing procedures have a more rapid healing and are best reserved for patients who need limited skin tightening but have extensive superficial photodamage. Full-face Er:YAG resurfacing can also be combined with spot Deep FX fractionated laser resurfacing over wrinkled areas or in areas that require skin tightening. Optimal results last approximately 5 years. Fractionated CO2 laser resurfacings are usually given twice within a year to achieve optimal results. At this time our limited experience over 3 years of use does not allow an accurate prediction for the longevity of this procedure, but 5 years seems like a reasonable estimate. Future advances in fractionated CO2 laser resurfacings will incorporate a variety of spot size and energy densities in one hand-piece to allow for more rapid treatment with variation of laser depths as well as differing widths and depths of both flash vaporization and non-specific thermal damage. Incorporation of different laser wavelengths including but not limited to 2940 nm Er:YAG, 1064, 1320, 1440, and 1550 nm separately or together may also increase efficacy.

Further reading Cassuto DA, Sadick NS, Scrimali L, Sirago P. (2008) An innovative device for fractional CO2 laser resurfacing: a preliminary clinical study. Am J Cosmet Surg 25, 97–101.


Christiansen K, Bjerring P. (2008) Low density, non-ablative fractional CO2 laser rejuvenation. Lasers Surg Med 40, 454–60. Fitzpatrick RE, Goldman MP, Satur NM, Type WD. (1996) Pulsed carbon dioxide laser resurfacing of photoaged skin. Arch Dermatol 132, 395–402. Goldman MP. (2006) Carbon dioxide and erbium:YAG laser ablation. Cutaneous and Cosmetic Laser Surgery. Mosby-Elsevier, p. 162. Goldman MP. (2006) Laser–tissue interactions. Cutaneous and Cosmetic Laser Surgery. Mosby-Elsevier. p. 5. Goldman MP, Manuskiatti W, Fitzpatrick RE. (2000) Combined laser resurfacing with the ultrapulse carbon dioxide and Er:Yag lasers. In: Fitzpatrick RE, Goldman MP, eds. Cosmetic Laser Surgery. St. Louis: Mosby. Goldman MP, Marchell N, Fitzpatrick RE, Tse Y. (2000) Laser resurfacing of the face with the combined CO2/Er:YAG laser. Dermatol Surg 26, 102–4. Greene D, Egbert BM, Utley DS, Koch RJ. (1999) The validity of ex vivo laser skin treatment for histological analysis. Arch Facial Plast Surg 1, 159–64. Hantash BM, Bedi VP, Chan KF, Zachery CB. (2007) Ex vivo histological characterization of a novel ablative fractional resurfacing device. Lasers Surg Med 39, 87–95. Hobbs ER, Bailin PC, Wheeland RG, Ratz JL. (1987) Superpulsed lasers: minimizing thermal damage with short duration, high irradiance pulses. J Dermatol Surg Oncol 13, 9. Lapidoth M, Odo MEY, Odo LM. (2008) Novel use of erbium (2,940-nm) laser for fractional ablative photothermolysis in the treatment of photodamaged facial skin: a pilot study. Dermatol Surg 34, 1048–53. Lowe NJ, Lask G, Griffin ME. (1995) Skin resurfacing with the UltraPulse carbon dioxide laser: observations in 100 patients. Dermatol Surg 21, 1025–9. Manstein, D, Herron GS, Sink, RK, Tanner, H, Anderson RR. (2000) Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med 320, 2026–38. Trelles MA, Velez M, Mordon S. (2008) Correlation of histological findings of single session Er:YAG skin fractional resurfacing with various passes and energies and the possible clinical implications. Lasers Surg Med (in press).

Chapter 50: Non-ablative resurfacing David J. Goldberg1 and Katie Rossy2 1

Mount Sinai School of Medicine, New York, and Skin Laser & Surgery Specialists of New York and New Jersey, New York, NY, USA 2 New York Medical College, New York, NY, USA

BAS I C CONCEPTS • Non-ablative resurfacing produces an injury requiring less recovery time than ablative resurfacing. • Non-ablative lasers have been used to successfully treat rhytides, dyspigmentation, vascular changes, skin texture, laxity, and scarring. • Non-ablative rejuvenation systems are composed of lasers, light sources, and radiofrequency devices. • Each non-ablative system targets a different chromophore in the skin to produce different clinical results.

Introduction In recent years there has been a progressive movement towards non-surgical interventions for facial rejuvenation. Ablative resurfacing with CO2 and erbium:yttrium aluminum garnet (Er:YAG) lasers were first used to treat photodamaged skin in the 1980s and remain the gold standard today [1–5]. Yet, despite their effectiveness in treating photoaging, there has been a recent push for non-ablative treatment modalities with less down-time and fewer side effects. Non-ablative lasers have been used to successfully treat rhytides, dyspigmentation, vascular changes, skin texture, laxity, and scarring [1,5,6]. The main goal of these systems is to selectively induce dermal damage, resulting in collagen remodeling and production while sparing the epidermis [1,3,6–8]. Many different systems have been used with this endpoint in mind (Table 50.1), and these are discussed in detail below.

Pathophysiology Non-ablative rejuvenation systems are composed of lasers, light sources, and radiofrequency devices. Laser systems use energy in the infrared or near-infrared spectrum to target specific dermal chromophores, such as water, melanin, and

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

hemoglobin. In contrast, radiofrequency devices produce heat in the dermis and subcutaneous tissue as a result of resistance to current flow through the tissue. Although the mechanisms of action are different, the end result is the same. Both the light sources and radiofrequency devices effectively heat the dermis eliciting a wound healing response without disturbing the integrity of the epidermis [1,5,9–11]. One of the main effects of photodamage and aging is a reduction in dermal collagen, and this is the target of nonablative rejuvenation. It has been proven that thermalinduced injury to the dermis causes local release of inflammatory cytokines leading to the proliferation of fibroblasts which results in collagen synthesis [7,12–15]. In vivo mouse studies have been performed to evaluate collagen composition after treatment with various lasers, and they have all demonstrated a significant change in collagen and extracellular matrix [7,13]. A study by Liu et al. [7] compared the dermal collagen composition after treatment with various laser systems. This study confirmed that collagen I production is predominantly increased after non-ablative treatment with the pulse dye laser (PDL), 1320 nm neodymium:yttrium aluminum garnet (Nd:YAG) laser, and the long pulsed 1064 nm Nd:YAG laser. However, collagen type III was more significantly increased in those treated with the Q-switched 1064 nm Nd:YAG laser. These results not only support the theory of neocollagenesis, but also provide specific data on collagen composition and differences in laser systems. This study suggests that because of the predominant increase in collagen type III after treatment with the Q-switched Nd:YAG laser, it may be more effective in increasing the elasticity of the skin and giving a more youthful appearance.



Resurfacing Techniques

Table 50.1 Lasers for facial rejuvenation. Laser type

System name

Pulsed KTP

Gemini (Laserscope) Aura (Laserscope) Versapulse (Coherent/Lumenis) Diolite (Iridex)

Pulsed dye 585 nm

Cbeam (Candela) SPTL-1B (Candela) Photogenica V (Cynosure)

595 nm

Cynosure V-star (Cynosure-585/595) V-beam (Candela)

Intense pulse light

Quantum SR (Lumenis) Palomar Starlux (Palomar) Vasculight (Lumenis) Estelux/Medilux (Palomar) Aurora DS/Aurora SR (Syneron)

1320 nm Nd : YAG

Cool Touch I, II, and III (Cooltouch)

1064 nm QS Nd : YAG

Medlite IV Continuum (Biomedical) VersaPulse VPC (Lumenis)

1450 nm diode

Smoothbeam (Candela)

Er:glass 1540 nm

Aramis-Quantel (Quantel Medical)

Infrared light (1100–1800 nm)

Titan (Cutera Inc.)

Radiofrequency devices Monopolar

Thermacool TC (Thermage)

Unipolar and bipolar

Accent (Alma Laser)

KTP, potassium titanyl phosphate.

Non-ablative modalities Many non-ablative systems have been evaluated for efficacy in facial rejuvenation. Results have been variable and often require multiple treatments in order to appreciate clinical improvement. The most effective treatment regimens are still being determined for facial rejuvenation, and the corresponding studies for each laser are discussed below. The most common lasers and parameter settings used today are outlined in Table 50.2.

Potassium titanyl phosphate 532 nm laser The 532 nm potassium titanyl phosphate (KTP) laser is one of the many modalities used in facial rejuvenation (Figure 50.1). It is absorbed more intensely by melanin and hemoglobin, and so it is thought that fewer treatments are needed


when targeting these components of photodamaged skin [2]. This laser has been shown to effectively target vascular and pigmentary change, skin texture, tightening, acne scars, and rhytides [5,15]. Lee [15] performed a 150 person study to compare the efficacy of the KTP laser alone, the long pulsed Nd:YAG alone, or the two modalities combined on collagen enhancement and photorejuvenation. After 3–6 treatments, all three groups showed statistically significant improvement in rhytides, skin toning and texture, reduction in redness, and improvement in dyschromia. Overall, the KTP laser-treated patients showed more improvement than the long pulsed Nd:YAG laser, but the combined treatment group was superior to either group alone. The combined group had a 70– 80% improvement in redness and pigmentation, 40–60% improvement in skin texture, tone, and tightening, and a 30–40% improvement in rhytides. In addition to these findings, it was also noted that collagen remodeling continues for up to 6–12 months post-treatment, with slow regression in benefit thereafter. Although further studies are necessary, these results suggest that combined modalities may be superior at targeting various factors involved in photodamage and more effectively stimulate collagen production.

Pulse dye laser 585 or 595 nm The PDL is a yellow light that targets oxyhemoglobin and melanin (Figure 50.2). It has been used to treat vascular changes and induce new collagen formation. It has been hypothesized that wavelengths targeting hemoglobin disrupt vascular endothelial cells resulting in cytokine release and subsequent collagen remodeling and production [5,16,17]. A group of 10 female patients, Fitzpatrick types I–IV, were treated in the periorbital area with the 595 nm flash lamp PDL [17]. One side of the face was treated with the following laser settings: 1.5 ms pulse, fluences of 5–6 J/cm2, and a spot size of 7 mm. The contralateral side was treated with a 40 ms pulse duration, fluences of 8–11 J/cm2, and a 7 mm spot size. Cryogen cooling was administered for 30 ms with a delay of 30 ms before treatment. Subjects were treated 1–2 times, and at their 6-month follow-up 70% treated had mild to moderate improvement overall. Sixty percent had equal improvement on both sides despite the different settings. Histologic and electron microscopic evaluation showed a significant increase in papillary dermal collagen, mainly type I. Another study performed by Bernstein [16] evaluated the effects of treatment of sun-damaged skin with a 595 nm long pulse duration PDL. Ten subjects were treated with 10 ms pulse duration, fluences of 8–10 J/cm2, and a 10 mm spot size. Improvements were evaluated 8 weeks after treatment with photograph comparison. Blinded physician evaluation of before and after treatment photographs rated improvement in wrinkles in 50%, facial veins improved in 82%,

50. Non-ablative resurfacing

Table 50.2 Non-ablative lasers. Laser type

Wavelength (nm)

Fluences (J/cm2)

Pulse duration

Spot sizes (mm)


KTP (pulsed)



20–50 ms

2, 4, 10

Hemoglobin, melanin


585 595

3–6.5 6–12

350, 450 μs 6–10 ms

5, 7, 10 7, 10

Hemoglobin, melanin




2.4, 4.0 ms




200 or 350 μs

6, 10





5 ns


Hemoglobin, melanin, water




160-260 ms

4, 6




Up to 126


4, 5


Infrared light



170–200 pulses

RF, monopolar

RF bipolar current

61.5–63.5 (adjusted for pain)

300–400 pulses

RF, unipolar

RF electromagnetic radiation


RF, bipolar

RF bipolar current


Hemoglobin, melanin, water (weak)

Radiofrequency 0.25, 1.0, 1.5, 3 cm

IPL, intense pulse light; KTP, potassium titanyl phosphate; RF, radiofrequency; QS, Q-switched; PDL, pulsed dye laser.

Figure 50.1 Potassium titanyl phosphate laser. Figure 50.2 Pulsed dye laser.

overall redness improved 80%, pigmentary change 61.4%, and a 25% improvement in pore size. A small clinical trial was performed on 10 patients comparing the efficacy of a long pulse PDL (LPDL) with an intense pulsed light (IPL) on photodamaged facial skin [18]. When compared with the IPL, the LPDL showed greater

improvement in lentigines (81% versus 62%), no significant difference in wrinkle reduction between the two groups, and fewer treatments were needed with the LPDL when compared with the IPL (three versus six). In addition to using the PDL laser as a single agent in photorejuvenation, recent trends have shown effective



Resurfacing Techniques

combination with aminolevulinic acid (ALA) in treatment of photodamaged skin. It is believed that PDL at 595 nm activates protoporphyrin IX, a photosensitizer, which accumulates in photodamaged cells, causing destruction of the cells, release of cytokines, and collagen repair [1]. This is a new and exciting area of research that offers another effective treatment modality for photorejuvenation.

Intense pulsed light The IPL system emits light, with wavelengths of 550– 1200 nm, which effectively targets melanin, hemoglobin, and water, to a lesser degree (Figure 50.3). The IPL device has been used in photorejuvenation to target vascular changes, pigmentary alteration, and mild rhytides [1,2,5,18,19]. Filters may be used with the IPL to target specific chromophores. Rapid improvement in overall appearance after IPL treatment is secondary to rapid and effective improvement of vascular and pigmentary change, rather than improvement in wrinkles [5]. As per Weiss et al. [2], shorter pulse duration and lower cutoff filters when using the IPL system result in significant improvement in pigmentary alteration. Although not thought to be the most effective treatment modality for rhytides, some studies using the IPL have shown improvement [1,3,4,18,19]. Goldberg [3] and Goldberg and Cutler [19] evaluated the treatment of facial rhytides with an IPL system using a 645 nm cutoff filter. Thirty patients, skin types I–III, were treated 1–4 times over a 10-week period. Treatments were delivered using fluences

Figure 50.3 Intense pulsed light.


of 40–50 J/cm2, through bracketed cooling device with triple 7 ms pulses, and interpulse delay of 50 ms. At 6 months’ follow-up, approximately 53% showed some improvement, 30% showed substantial improvement, and 17% showed no improvement. Hedelund et al. [4] performed a study looking at the efficacy of IPL treatment for perioral rhytides in comparison with CO2 ablative resurfacing. Twenty seven females, skin type II, with perioral rhytides were randomly treated with 3-monthly IPL sessions or one CO2 laser ablation. The results showed a higher degree of patient satisfaction and significant improvement in rhytides with CO2 laser resurfacing when compared with IPL rejuvenation. In addition to the more dramatic improvement seen with CO2 resurfacing, side effects were also found to be significantly higher in this group. Patients treated with the CO2 laser experienced milia, dyspigmentation, and persistent erythema, while the IPL group was not noted to have any side effects. Both groups showed long-term improvement in skin elasticity, although no significant improvement in wrinkles was seen in the IPL treatment group. Many physicians today advocate 3–6 treatments for significant improvement, which implies that the treatment course may not have been sufficient to produce notable results.

1320 nm Nd:YAG One of the first laser systems to be developed for nonablative rejuvenation was the Nd:YAG 1320 nm laser (Figure 50.4) [20]. At this wavelength, energy is able to penetrate into the papillary and mid-reticular dermis, and it is absorbed by water associated with dermal collagen. There is a high water absorption and strong scattering in the dermis which allows for extensive dermal wounding [20]. The surface

Figure 50.4 1320 nm neodymium:yttrium aluminum garnet (Nd:YAG) laser.

50. Non-ablative resurfacing cooling systems are present to protect the epidermis from involvement. The 1320 nm Nd:YAG laser has been used to target acne scarring, photoaging, and rhytides with variable results [1– 3,20,21]. As a result of its poor absorption by melanin, it can be used in all skin types without fear of pigmentary change [21]. When treating mild rhytides or acne scars, Weiss et al. [2] recommends using a fluence of 17–19 J/cm2, a total of 25 ms of cooling (pre and post cooling at 10 ms and midcooling at 5 ms), with a fixed pulse duration of 50 ms, and 2–3 passes. When treating acne scars with this regimen, 30–50% improvement has been observed in about four of five patients, while 20% show no significant response. According to a study performed by Rogachefsky et al. [21], the 1320 nm Nd:YAG laser is an effective modality to treat atrophic and mixed pattern facial acne scars. After treating 12 patients with 3-monthly sessions, optimal improvement was noted in atrophic acne scars; however, mixed acne scars also showed softening of sclerotic and shallow pitted scars. Sadick and Schecter [20] also confirm significant improvement in acne scars after treatment with the 1320 nm Nd:YAG, but they propose that six sessions is more effective than three laser sessions.

Q-switched Nd:YAG 1064 nm laser The Q-switched (QS) Nd:YAG 1064 nm laser has not only proven to be successful for treatment of tattoos, vascular, and pigmented lesions, but it has recently been used to treat rhytids, photodamage, and acne scars (Figure 50.5) [3,8,11,22]. This laser system is poorly absorbed by water, making deeper collagen damage more likely when compared with systems with other wavelengths [22]. It has been hypothesized that when compared with other non-ablative systems, the 1064 nm QS Nd:YAG laser is able to cause the most severe dermal damage and thus produce the greatest amount of collagen remodeling. This was confirmed in a mouse study which showed greatest improvement in skin elasticity after treatment with the QS Nd:YAG 1064 nm laser [13]. Another small study involving eight patients was performed to evaluate the effects of the QS 1064 nm Nd:YAG laser on facial wrinkles [22]. Treatments were performed monthly, for a total of 3 months, with a fluence of 7 J/cm2, a 3 mm spot size, and two passes, with petechiae as the desired endpoint. In the end, six of the eight subjects demonstrated clinical improvement in rhytides. The QS 1064 nm Nd:YAG laser has also been used to treat atrophic acne scars with notable success. In 11 patients who completed five treatment sessions with the QS 1064 nm Nd:YAG laser, significant improvement in facial acne scars was demonstrated [8]. After completing all five treatments, improvement was seen as early as 1 month, the greatest

Figure 50.5 1064 nm Q-switched Nd:YAG laser.

percentage improvement was noted at 3 months, and improvement had reached a plateau at 6 months. Another similar study used three-dimensional topography to quantify the efficacy of five QS 1064 nm Nd:YAG treatments on facial wrinkles and acne scars [11]. At 3 months post-treatment, a 61% improvement in surface topography was recorded, and it was maintained at the 6-month follow-up. These results, and others, have suggested that collagen remodeling and repair continues to occur for an extended period of time following the last treatment [1,3,8,11].

Erbium:glass 1540 nm The erbium:glass (Er:glass) 1540 nm laser has been used to treat perioral and periorbital rhytides with mild to moderate end results [1,3,12,23]. Fournier et al. [23] studied the effects of the Er:glass laser on 42 patients treated at 6-week intervals for a total of five sessions. Profilometry, ultrasound, and photography were used to rate clinical improvement after the final treatment. All patients reported improvement in quality and appearance of their skin at 6 months. Notable findings showed an increase in dermal thickness by 17%, a reduction of anisotropy by 44.8%, and an overall improvement in clinical appearance. An additional 35-month study was conducted to assess the long-term benefits of treatment with the Er:glass 1540 nm laser on facial rhytides [12]. Eleven patients with periorbital and perioral rhytides were treated with a series



Resurfacing Techniques

of five treatments at 6-week intervals. Approximately half of the patients also received two additional maintenance treatments at 14 and 20 months. Treatments were performed with settings of 8 J/cm2, three stacked pulses at 2 Hz repetition rates for periorbital and five stacked pulses for perioral sites, and a 4 mm spot size. It was demonstrated that for all 11 patients treated, the improvement in collagen anisotropy measurements showed a reduction in rhytides of 51.7% at 14 months, and 29.8% at 35 months. Overall patient satisfaction was 70% at approximately 2.5 years. Based on both of the aforementioned studies, the Er:glass 1540 nm laser appears to effectively stimulate collagen remodeling with long-term results.

In addition to wrinkles, the 1450 nm diode has been used to treat atrophic acne scars with minimal side effects. Tanzi et al. [24] performed a comparison study treating 20 patients with mild to moderate atrophic acne scars with the 1320 nm Nd:YAG on half of the face and the 1450 nm diode laser on the contralateral side. Three-monthly treatments were performed, and only modest improvement in facial scarring was seen among both groups at 6 months. Yet, greater overall clinical improvement and patient satisfaction was seen in the 1450 nm diode laser sites. Increase in dermal collagen and improvement in skin texture was found in both groups. Minimal side effects were reported.

Infrared light devices (1100–1800 nm) 1450 nm diode laser The 1450 nm diode laser targets water-containing tissue to stimulate collagen remodeling and production. It has been used to treat periorbital and perioral rhytides, and facial acne scars (Figure 50.6) [1–3,24,25]. A previous study was performed with the 1450 nm diode laser to assess the efficacy of treatment on facial rhytides and the associated side effects [25]. Twenty patients underwent 2–4 monthly treatment sessions focusing on perioral and periorbital wrinkles. Each session consisted of treatment of one side of the face with laser and cryogen and the other side with cryogen alone. The laser settings were: frequency of 0.5–1.0 Hz, pulse width of 160–260 ms, pre, post, and intermediate cryogen cooling of 40–80 ms total, and a 4 mm spot size. At 6 months after the final treatment, 13 of the 20 laser/cryogen treated sites showed some improvement, while none of the cryogen only sites showed any improvement. It also showed that periorbital wrinkles showed greater improvement when compared with the perioral sites.

Figure 50.6 1450 nm diode laser.


A new, non-ablative, broad spectrum infrared device, emitting wavelengths 1100–1800 nm, has been recently introduced for the treatment of photoaged skin. Improvement in skin laxity and rhytides is believed to result from volumetric heating of water in the dermis which leads to tissue contraction [1,26,27]. A large component of facial aging is the development of skin laxity. With this in mind, a study was conducted to evaluate the efficacy of a filtered infrared light device in the treatment of skin laxity with ptosis of the lower face and neck [27]. Thirteen females, with a mean age of 64 years, were treated from the nasolabial folds to the preauricular area, and from the malar prominence to the clavicle. The parameters used were fluences of 30–36 J/cm2, 230–440 pulses per session, pulse duration up to 11 s, a spot size of 1.5 × 1.0 cm, and cooling of the epidermis to 40 °C. Treatments were administered monthly for a total of two treatments. Improvement was seen clinically in 11 of 12 patients who completed the study. Significant improvement in submental and submandibular definition was noted. The most dramatic improvement was seen in those with loss of definition because of excess skin hanging separately from deeper soft tissue. Continued improvement was noted beyond the 1 month follow-up visit. Mild erythema was the only side effect seen, and it resolved within 30 minutes after treatment. A recent small study was performed on nine women, skin types III–IV, with variable photodamage [26]. Half of the subjects received a one time treatment to the face, while the other group had two monthly treatments. The laser parameters were: fluences of 30–40 J/cm2 and 170–200 pulses. Overall, both subjects’ and investigators’ assessments of preprocedural and post-procedural appearances found significant improvement in elasticity, pore size, dyschromia, wrinkles, and overall texture. Also, the improvement in elasticity, rhytides, and skin texture were more evident in the group treated twice. This study showed promising results but was limited to an 8-week timespan and small study

50. Non-ablative resurfacing

Table 50.3 Advanced non-ablative resurfacing. Laser/RF device

Treatment locations


Pulse duration/pulse number

Spot size

1320 nm Nd:YAG

Photodamaged dorsal hands

13–18 J/cm2

50 ms macropulse (stacked 350 μs micropulses)

10 mm

Infrared light device (1100–1800 nm)

Neck skin laxity

30–36 J/cm2 (adjusted for pain level)

11 s Total pulses 230–440

1.5 cm

Monopolar RF (Thermacool)

Upper arm skin laxity

Unipolar RF device (Accent XL)

Upper thigh, buttocks, abdominal cellulite

3 cm 150–170 W

30 s

RF, radiofrequency.

population. More studies will need to be performed to determine the role of new infrared light devices in the field of facial rejuvenation.

Table 50.4 Side effects of non-ablative laser resurfacing. Transient erythema and edema (most common) Pain/discomfort Purpura (KTP and PDL)

Radiofrequency devices

Temporary hyperpigmentation Petechiae/pinpoint bleeding (1064 nm QS Nd : YAG)

Radiofrequency (RF) devices have become another widely accepted method of non-ablative rejuvenation. The Food and Drug Administration (FDA) has approved the RF devices for the treatment of periorbital rhytides [9,10].

Burning and vesiculation (rare) Crusting Edematous papules, 1–7 days (1450 nm diode) KTP, potassium titanyl phosphate; PDL, pulse dye laser; QS, Q-switched.

Advanced approaches In addition to facial rejuvenation, several of these devices have also been evaluated for use in photoaging and tightening of other anatomic sites (Table 50.3) [26,28,29,31]. Early studies and preliminary results have suggested that nonablative resurfacing may play a significant part in non-facial rejuvenation and tightening. Yet, further results are necessary to determine how important they will be in this rapidly growing field. For example, a small case series was performed using the 1320 nm Nd:YAG laser to treat photoaging hands [29]. After six monthly treatments, four of the seven patients showed mild to moderate improvement in smoothness, reduced wrinkles, and more even pigmentation. Subjective improvement was reported by six of the seven patients at 6 months. Although this study was small, the results showed statistically significant, although mild, improvement in photoaged hands. RF and infrared light devices have also been used in an attempt to treat skin laxity in non-facial areas with variable findings [27,30,31]. Although non-ablative tightening results may not be as effective as surgical interventions, significant improvement has been found. A small trial using

an infrared light device showed improvement in neck contour and excess skin in 11 of the 12 patients who completed the study [27]. Early results from the use of a monopolar radiofrequency device on upper arm contouring have shown improvement in circumferential size of 36 of 70 patients treated at a 4-month follow-up [31]. Further longterm results are still expected to follow. Other trials are underway looking at the use of RF devices on tightening of thighs and enhancement of gluteal definition.

Complications One of the major benefits of all non-ablative rejuvenation modalities is the low risk of potential complications involved with treatments. The most common side effect found among all non-ablative lasers, light devices, and RF devices is mild transient erythema and edema which commonly resolves within hours to days [1–3,6,8–10, 12,16,17,20,23–25]. Although complications are rare, temporary side effects have been recorded and are listed in Table 50.4.



Resurfacing Techniques

Conclusions Non-ablative rejuvenation is a relatively new and exciting field in esthetic dermatology. Many different devices are currently being used to treat changes associated with photoaging, such as rhytides, skin laxity, vascular changes, and pigmentary alterations. Although ablative resurfacing and surgical intervention remain the gold standard, non-ablative systems offer an alternative option with less down-time and risk of complications. These devices selectively target the dermis, inciting a wound healing response locally, while sparing the epidermis from harm. Dermal collagen remodeling, production, and repair are upregulated as a result of this selective targeting. Multiple lasers, light sources, and RF devices have been used to induce significant neocollagenesis with measurable success. Yet despite the significant histologic changes noted, the clinical enhancement is often subtle with mild to moderate improvement over time. As a result, it is important to give patients realistic expectations when performing non-ablative rejuvenation. The most effective devices and treatment parameters for photorejuvenation have yet to be determined, but continued enthusiasm in this field gives hope for continued research and success.

References 1 Alexiades-Armenakas MR, Dover JS, Arndt KA. (2008) The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. J Am Acad Dermatol 58, 719–37. 2 Weiss RA, Weiss MA, Beasley KL, Munavalli G. (2005) Our approach to nonablative treatment of photoaging. Lasers Surg Med 37, 2–8. 3 Goldberg DJ. (2003) Lasers for facial rejuvenation. Am J Dermatol 4, 225–34. 4 Hedelund L, Bjerring P, Egekvist H, Haedersdal M. (2006) Ablative versus non-ablative treatment of perioral rhytides: a randomized controlled trial with long-term blinded clinical evaluations and non-invasive measurements. Lasers Surg Med 38, 129–36. 5 Sadick NS. (2003) Update on non-ablative light therapy for rejuvenation: a review. Lasers Surg Med 32, 120–8. 6 Bosniak S, Cantisano-Zilkha M, Purewal BK, Zdinak LA. (2006) Combination therapies in oculofacial rejuvenation. Orbit 25, 319–26. 7 Liu H, Dang Y, Wang Z, Chai X, Ren Q. (2008) Laser induced collagen remodeling: a comparative study in vivo on mouse model. Lasers Surg Med 40, 13–9. 8 Friedman PM, Jih MH, Skover GR, Payonk GS, Kimyai-Asadi A, Geronemus RG. (2004) Treatment of atrophic facial acne scars with the 1064 nm Q-switched Nd:YAG laser. Arch Dermatol 140, 1337–41. 9 Bogle MA, Ubelho*r N, Weiss RA, Mayoral F, Kaminer FS. (2007) Evaluation of the multiple pass, low fluence algorithm for radiofrequency tightening of the lower face. Laser Surg Med 39, 210–7. 10 Narins DJ, Narins RS. (2003) Non-surgical radiofrequency facelift. J Drug Dermatol 2, 495–500.


11 Friedman PM, Skover GR, Payonk G, Kauvar AN, Geronemus RG. (2002) 3D in vivo optical skin imaging for topographical quantitative assessment of non-ablative laser technology. Dermatol Surg 28, 199–204. 12 Fournier N, Lagarde JM, Turlier V, Courrech L, Mordon S. (2004) A 35-month profilometric and clinical evaluation of nonablative remodeling using a 1540 nm Er:glass laser. J Cosmet Laser Ther 6, 126–30. 13 Dang Y, Ren Q, Li W, Yang Q, Zhang J. (2006) Comparison of biophysical properties of skin measured by using non-invasive techniques in the KM mice following 595 nm pulsed dye, 1064 nm Q-switched Nd:YAG and 1320 nm Nd:YAG laser nonablative rejuvenation. Skin Res Technol 12, 119–25. 14 Keller R, Belda Junior W, Valente NY, Rodrigues CJ. (2007) Nonablative 1064 nm Nd:YAG laser for treating atrophic facial acne scars: histologic and clinical analysis. Dermatol Surg 33, 1470–6. 15 Lee MW. (2003) Combination 532-nm and 1064-nm lasers for noninvasive skin rejuvenation and toning. Arch Dermatol 139, 1265–76. 16 Bernstein EF. (2007) The new-generation, high-energy, 595 nm, long pulse-duration pulsed-dye laser improves the appearance of photodamaged skin. Lasers Surg Med 39, 157–63. 17 Goldberg DJ, Sarradet D, Hussain M, Krishtul A, Phelps R. (2004) Clinical, histologic, and ultrastructural changes after nonablative treatment with a 595-nm flashlamp-pumped pulsed dye laser: comparison of varying settings. Dermatol Surg 30, 979–82. 18 Kono T, Groff WF, Sakurai H, Takeuchi M, Yamaki T, Soejima K, et al. (2007) Comparison study of intense pulsed light versus a long-pulse pulsed dye laser in the treatment of facial skin rejuvenation. Ann Plast Surg 59, 479–83. 19 Goldberg DJ, Cutler KB. (2000) Nonablative treatment of rhytids with intense pulsed light. Lasers Surg Med 26, 196–9. 20 Sadick NS, Schecter AK. (2004) A preliminary study of utilization of the 1320-nm Nd:YAG laser for the treatment of acne scarring. Dermatol Surg 30, 995–1000. 21 Rogachefsky AS, Hussain M, Goldberg DJ. (2003) Atrophic and a mixed pattern of acne scars improved with a 1320-nm Nd:YAG laser. Dermatol Surg 29, 904–8. 22 Goldberg DJ, Silapunt S. (2000) Q-switched Nd:YAG laser: rhytid improvement by non-ablative dermal remodeling. J Cutan Laser Ther 2, 157–60. 23 Fournier N, Dahan S, Barneon G, Rouvrais C, Diridollou S, Lagarde JM, et al. (2002) Nonablative remodeling: a 14 month clinical ultrasound imaging and profilometric evaluation of a 1540 nm Er:glass laser. Dermatol Surg 28, 926–31. 24 Tanzi EL, Alster TS. (2004) Comparison of a 1450-nm diode laser and a 1320-nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. Dermatol Surg 30, 152–7. 25 Goldberg DJ, Rogachefsky AS, Silapunt S. (2002) Non-ablative laser treatment of facial rhytides: a comparison of 1450-nm diode laser treatment with dynamic cooling as opposed to treatment with dynamic cooling alone. Lasers Surg Med 30, 79–81. 26 Ahn JY, Han TY, Lee CK, Seo SJ, Hong CK. (2008) Effect of a new infrared light device (1100–1800 nm) on facial lifting. Photodermatol Photoimmunol Photomed 24, 49–51.

50. Non-ablative resurfacing 27 Goldberg DJ, Hussain M, Fazeli A, Berlin AL. (2007) Treatment of skin laxity of the lower face and neck in older individuals with a broad-spectrum infrared light device. J Cosmet Laser Ther 9, 35–40. 28 Sadick NS, Alexiades-Armenakas M, Bitter P Jr, Hruza G, Mulholland RS. (2005) Enhanced full-face skin rejuvenation using synchronous intense pulsed optical and conducted bipolar radiofrequency energy (ELOS): introducing selective radiophotothermolysis. J Drugs Dermatol 4, 181–6. 29 Sadick N, Schecter AK. (2004) Tilization of the 1320-nm Nd:YAG laser for the reduction of photoaging of the hands. Dermatol Surg 30, 1140–4.

30 Alexiades-Armenakas M. (2006) Rhytides, laxity, and photoaging treated with a combination of radiofrequency, diode laser, and pulsed light and assessed with a comprehensive grading scale. J Drugs Dermatol 5, 731–8. 31 Goldberg DJ, Hussain M, Fazeli A, et al. (2007) Monopolar radiofrequency tightening of upper arm skin laxity: a multicenter study. Laser Surg Med (Suppl 19), 19.


Chapter 51: Microdermabrasion Pearl Grimes Vitiligo and Pigmentation Institute of Southern California, and University of California – Los Angeles, Los Angeles, CA, USA

BAS I C CONCE P T S • Microdermabrasion is a superficial resurfacing procedure that utilizes a particulate to remove the stratum corneum. • Microdermabrasion has been used to improve acne, scarring, photodamage, textural changes, stretch marks, and hyperpigmentation. • All Fitzpatrick skin types can be treated with microdermabrasion. • The primary advantage of microdermabrasion is the minimal post-procedure down-time. • Contraindications to microdermabrasion include impetigo, herpes simplex, verruca plana, or other skin infections.

Introduction Microdermabrasion is a superficial skin resurfacing procedure, in which the stratum corneum is partially or completely removed by light abrasion, to correct or improve skin imperfections [1]. This non-invasive procedure is used to treat a variety of skin conditions including acne, acne scars, hyperpigmentation, striae, photodamage, and texturally rough skin (Table 51.1) [2–7]. Microdermabrasion can be used on young and mature skin and is safe for all Fitzpatrick skin types. It is used to treat a variety of anatomic skin sites including the face, neck, chest, back, arms, elbows, knees, and hands. It is sometimes used in combination with chemical peels, non-ablative resurfacing, or other skin rejuvenation procedures. First developed in Italy in 1985, it has become an extremely popular form of resurfacing. In 2007, it was one of the top five esthetic procedures performed in the USA; 829 658 microdermabrasion procedures were performed [8]. Despite the popularity of microdermabrasion there is a dearth of well-designed studies documenting the short-term and longterm efficacy of microdermabrasion.

Microdermabrasion units Multiple microdermabrasion units are available throughout Europe and the USA, with a wide range of features for physician-directed use. Despite the diversity of units, there are several common components to most systems: a pump, tubing, wand, vacuum, and crystals (Table 51.2).

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


Different methods of microdermabrasion include mechanical abrasion from jets of aluminum oxide or zinc oxide crystals, fine organic particles, or wands with a roughened surface. Some newer machines include more than one method. Aluminum oxide is the most commonly used abrasive in microdermabrasion. It is a relatively chemically inert abrasive that does not cause allergic skin reactions, such as eczema or itching. Other crystals can also be used for microdermabrasion and these include sodium chloride, sodium bicarbonate, and magnesium oxide crystals [9]. Generally, these alternative particles are not as abrasive as aluminum oxide. Instead of crystals, some newer techniques use diamond-tipped devices that abrade the skin. Such devices have tips made of diamond chips of varied size and coarseness for different types of skin and varied levels of resurfacing.

Procedure During the microdermabrasion procedure microcrystals are deposited on the skin via short, rapid strokes of the wand. A tube contained within the wand simultaneously aspirates the crystals and skin debris. Particle flow rate and vacuum pressure determine the volume of particles impacting the skin. The depth of the treatment is determined by several factors, including the strength of the flow of crystals, speed of movement of the wand, and the number of times the device passes over the treatment area [10]. Slower movement of the wand (allowing longer contact of the abrasive crystals with the skin) and more passes increase the depth of microdermabrasion. The treatment is typically performed in a series of 4–12 weekly or biweekly visits taking 20–30 minutes. The series can be significantly longer, particularly for acne scarring.

51. Microdermabrasion

Table 51.1 Indications for microdermabrasion. Acne Hyperpigmentation Melasma Post-inflammatory Oily skin Enlarged pores Photodamage Texturally rough skin Wrinkles

Table 51.2 Components of microdermabrasion units. Pump

To generate a high pressure stream of non-absorbable crystals


To deliver the crystals to the wand (hand-piece)


To contain the crystals


To remove the spent crystals


For exfoliating

microdermabrasion showed an increase in stratum corneum hydration after 24 hours, which increased significantly by day 7 on the sodium chloride-treated side. No difference was seen in pH or sebum production. The results suggested that changes in TEWL and hydration enhance lipid barrier function. Such barrier alterations may result in the improved texture and overall appearance of microdermabraded skin. Davari et al. [11] also demonstrated changes in skin barrier function. Their study evaluated the extent of skin barrier function changes in relation with the number of microdermabrasion passes. A series of six microdermabrasion treatments using aluminum oxide crystals were performed in 10 patients. One side of the face was treated with two passes of microdermabrasion and the other side was treated with three passes, randomly. Stratum corneum hydration, sebum secretion, and skin pH were measured before and after the procedure for all sessions, and also at 1 and 4 weeks after the last treatment. Significantly higher sebum content and stratum corneum hydration were observed on the side of the face treated with three passes, suggesting that the higher number of passes has a significant effect on lipid barrier restoration. In addition, significant increases in ceramide levels in the stratum corneum have been observed following the first and second microdermabrasion session. By the third or fourth treatment levels returned to normal [12]. The increase in activating protein 1 (AP-1) and NF-κB following microdermabrasion may also influence ceramide levels via cell signaling pathways [13].

Molecular effects

Skin physiology and histopathology Several studies have assessed the physiologic changes, barrier function, and histopathologic alterations induced by microdermbrasion. In general, most of these studies have been performed in small numbers of patients. In spite of the differences in methodologies, protocols, machines, pressures, number of passes, and biopsy sites, data suggest physiologic and histologic trends [1].

Epidermal barrier function Epidermal barrier changes induced by aluminum oxide and sodium chloride microdermabrasion were initially reported by Rajan and Grimes [9]. Eight patients were treated in a split-face study. One side of the face was treated with aluminum oxide and the other side with sodium chloride microdermabrasion. Transepidermal water loss (TEWL), stratum corneum hydration, skin pH, and sebum production were measured at baseline, 24 hours, and 7 days after treatment. At 24 hours, TEWL increased for both aluminum oxide and sodium chloride microdermabrasion. After 7 days, there was a decrease in TEWL values to less than baseline (p < 0.05), suggesting improved epidermal barrier function. In addition, both aluminum oxide and sodium chloride

It has been suggested that microdermabrasion activates dermal remodeling or the wound healing cascade. Karimipour et al. [13] assessed the molecular alterations following a single microdermabrasion treatment to buttock skin. They reported that transcription factors (AP-1 and NF-κB), primary cytokines (interleukin 1β [IL-1β] and tumor necrosis factor α [TNF-α]) and matrix metalloproteinases (interstitial collagenase, stromelysin-1, and gelatinase B) increase rapidly after a single microdermabrasion treatment. However, no significant alterations in stratum corneum structure were noted. The authors suggested that the increase in matrix metalloproteinases could: 1 Result in matrix remodeling and new collagen deposition; or 2 Remove damaged collagen and allow skin to regain its normal tension.

Histopathologic effects Histologic changes have been observed in both the epidermis and dermis (Table 51.3). The most significant change is an increase in the thickness of the epidermis. In a series of six microdermabrasion treatments in 10 patients, Freedman et al. [3] showed that after three passes, the epidermal thickness increased from 45 ± 4 μm to 62 ± 10 μm (p < 0.01), and



Resurfacing Techniques

to 65 ± 7 μm (p < 0.01) after an additional three passes. In the Hernandez-Perez and Ibiett [14] study, the epidermal thickness increased from 0.01 to 0.06 mm in some patients, and to 0.01 mm in one patient. Other studies also demonstrated an increase in the epidermal thickness [7,15]. Other epidermal alterations improved by microdermabrasion include polarity of cells, basal cell liquefaction, horny plugs, and atropic changes [14]. In addition, more regular distribution of melanosomes, less melanization, flattening of the rete pegs, and basal cell hyperplasia had been reported (Figure 51.1) [3,7]. Dermal changes include an increase in papillary dermal thickness, as demonstrated by Freedman et al., from 81 ± 8 μm to 108 ± 11 μm (p < 0.01) after three treatments and to 114 ± 9 μm after an additional three. The treated areas showed hyalinization of the collagen fibers in the papillary

dermis; the fibers were thicker, more tightly packed, and orientated horizontally. An increase in elastic fibers was seen at the junction of the reticular and papillary dermis after three treatments. After six treatments, the density of the elastic fibers in the reticular dermis increased. These new fibers were more vertically orientated and of normal caliber. After treatment, the blood vessels appeared ecstatic with the presence of a perivascular infiltrate. Fibroblasts were more conspicious, larger, and more densely distributed within the dermis, especially around the dermal capillaries. Recent interest in the impact of topical antioxidants on the skin has shown that the addition of a polyphenolic antioxidant serum to a facial microdermabrasion regimen also enhances clinical and histologic changes [16].

Contraindications Table 51.3 Histologic changes caused by microdermabrasion. Epidermal Increased thickness Decreased melanization

Relative contraindications to the use of microdermabrasion include rosacea and telangiectasia, which may be exacerbated. Absolute contraindications include active infections such as impetigo, flat warts, and herpes simplex [17–19]. The active use of isotretinoin is also contraindicated.

Alteration of rete ridges Variable epidermal changes Decreased liquefaction of basal cells Improved polarity Variable dermal changes Increased dermal thickness Increased collagen Increased elastin Mononuclear infiltrates Vascular ectasia

Indications for microdermabrasion Acne Microdermabrasion is most effective when treating superficial skin conditions such as acne (Figure 51.2). In a study by Lloyd [2], the role of microdermabrasion in the treatment of patients with acne was studied. Twenty five patients with grade II–III acne received eight microdermabrasion treatments (Parisian Peel microdermabrasion unit used at a pressure of 26.67 mmHg initially and then increased as tolerated)


(a) Figure 51.1 (a) Baseline biopsy. (b) Biopsy after a series of four microdermabrasion treatments performed at 1 week intervals. Note: No change in thickness of the stratum corneum; however, marked improvement in the polarity of epidermal cells, some increase in epidermal thickness and improvement in dermal collagen.


51. Microdermabrasion


(a) Figure 51.2 Patient with moderate acne treated with a series of five microdermabrasions in combination with oral antibiotics. Treatments at 2-week intervals.

at weekly intervals. Throughout the treatment, patients continued taking their oral antibiotics and topical acne treatment. Photographs were taken before and after treatment, and evaluated for clinical improvement. Twenty-four patients completed the study: 38% (9 of 24) achieved excellent results, 34% (8 of 24) had good results, 17% (4 of 24) had fair results, and 12% (3 of 24) had poor results. Ninetysix percent of patients were pleased with their results. The most prominent improvement was noted with postinflammatory acne changes and the overall skin quality. No adverse effects were noted during the procedure. The treatment was well tolerated. The only side effect was erythema, which resolved within 24 hours. No controls were included in this investigation.

Scars The effectiveness of this technique in the treatment of facial scarring was first demonstrated in 1995 by Tsai et al. [5]. They treated 41 patients with facial scarring with an average of 9.1 treatments. Facial scars included acne, burns, varicella, and post-traumatic scars. A Harvey 91 microdermabrasion unit with a pressure setting of 76 mmHg was used. All patients had “good to excellent” improvement. The study showed that patients with acne scars require longer treatment (mean, 15.19 times) than those with traumatic or surgical scars (mean, 4 times) to achieve clinical improvement (p < 0.001). Multiple passes and numerous treatments are often needed. This is probably because most

acne scars are depressed and surgical and traumatic scars are elevated – depressed lesions are more difficult to treat than elevated ones.

Hyperpigmentation Albeit commonly used to treat disorders of hyperpigmentation, only a few published reports describe the use of microdermabrasion in the treatment of hyperpigmentation [4,7,20]. Cotellessa et al. [4] evaluated the efficacy of microdermabrasion alone or in combination with 15% trichloroacetic acid (TCA) for treatment of patients with multiple hyperpigmented macules of the face. A total of 20 patients were treated. Eight (40%) had complete clearing of the pigmentation after four to eight treatments; 10 (50%) had partial clearance; and two patients (10%) had no improvement after eight treatments. When patients were treated with both TCA peels and microdermabrasion, fewer treatments (four to six) were required to clear or partially clear pigmentation, 50% and 40%, respectively. No serious side effects were observed. Other studies have also reported improvement in mottled and diffuse hyperpigmentation [1,7,21]. Data from the Vitiligo and Pigmentation Institute suggest that microdermabrasion is an effective and well-tolerated treatment for disorders of hyperpigmentation in all racial ethnic groups (Figure 51.3). Conditions treated included melasma, postinflammatory hyperpigmentation, and the dyschromias of photoaging.



Resurfacing Techniques



Photodamage Microdermabrasion is well suited for patients with early photodamage, especially those with Glogau photaging classes I and II. In a study to evaluate the effect of microdermabasion on photodamaged skin, 10 patients with Fitzpatrick skin types I–III and photodamage (Glogau scale II and III) were treated once a week for five to six treatments using a Parisian Peel [6]. The face was treated with four passes at a pressure of 30 mmHg, while the periorbital skin received two passes at a pressure of 15 mmHg. Clinical responses, skin surface roughness, topography, elasticity, stiffness, compliance, temperature, sebum content, and histology were analyzed. Nine patients completed at least five treatments. Clinical analysis showed mild improvement in the majority of patients. Immediately after treatment, skin temperature increased and sebum content decreased. There was a temporary increase in skin roughness. Dynamic skin analysis showed a decrease in skin stiffness and increase in skin compliance. The authors suggest that the observed changes in skin characteristics are consistent with increased blood flow and mild abrasion. Biopsies showed slight orthokeratosis and flattening of rete ridges and a perivascular mononuclear cell infiltrate, edema, and vascular ectasia in the upper reticular dermis. There was no change in collagen or elastin content. Other studies addressing photodamage have also shown improvements in skin roughness, mottled pigmentation, and


Figure 51.3 Patient with melasma and textural changes treated with four microdermabrasions and hydroquinone 4%. (a) Before. (b) After.

overall global improvement in the treated skin areas [7,21]. Hernandez-Perez and Ibiett [14] treated seven women, six with Glogau’s photoaging class II and one with Glogau’s photoaging class III. Five microdermabrasion treatments were carried out on each patient, at weekly intervals, three complete passes per treatment. Clinical parameters assessed were oily skin, dilated pores, fine wrinkles, thick skin, and general appearance. Skin biopsies were taken before and after treatment. All patients showed clinical and histopathologic improvements in all parameters assessed. Clinical improvement was considered ‘good to excellent.’ Patients also reported improved self-esteem.

Striae Microdermabrasion is occasionally used to treat striae. However, patients should be advised that this treatment is aggressive in order to reach the level of the papillary dermis and can cause erythema and hyperpigmentation.

Comparison of microdermabrasion and chemical peeling Chemical peeling and microdermabrasion are both popular resurfacing procedures that exfoliate the skin. While microdermabrasion works well on superficial skin imperfections, chemical peels may be more effective on skin defects such

51. Microdermabrasion as deeper scars and wrinkles. The aftercare and down-time are also longer with more aggressive peeling agents. Unlike microdermabrasion, the depth of wounding induced by chemical peeling is determined by the strength of the peeling agent. Superficial peels target the stratum corneum to the papillary dermis. They include glycolic acid, salicylic acid, Jessner’s solution, and trichloroacetic acid (TCA) 10–30%. Medium depth peels penetrate to the upper reticular dermis and the protype is TCA 35–50%, whereas deeper peels penetrate to the mid-reticular dermis (phenol). Glycolic acid peels were compared with microdermabrasion in a right–left controlled assessment [20]. Ten patients were enrolled in this split-face, unblinded, randomized trial. One side of the face was treated with a series of 20% glycolic acid peels on a weekly basis, and the opposite side was treated simultaneously with microdermabrasion. Patients’ self-analysis revealed that seven patients perceived greater improvement on the side treated with microdermabrasion. Physician investigator ratings found no differences between microdermabrasion or the side with glycolic acid. Furthermore, photographic comparisons by investigators did not reveal treatment-related differences. The investigators could not differentiate pre- and post-treatment photographs. However, both procedures were well tolerated. The efficacy and safety of microdermabrasion followed by a 5% retinoic acid peel was compared with the effects of a 5% retinoic acid peel alone in six patients with photodam-

Figure 51.4 Patient with mottled pigmentation, oily skin, and textural changes treated with a series of five microdermabrasions. (a) Before. (b) After.

age. The authors reported improvement in texture, pigmentation, and overall skin appearance. The combination group showed slightly greater improvement [22]. A recent study compared the immunohistologic and ultrastructural changes induced by chemical peeling and microdermabrasion [23]. Fifteen patients were treated by weekly microdermabrasion for 2 months while 15 were treated with weekly chemical peeling using either glycolic acid 70% or Jessner’s solution. Biopsies were pereformed 1 week before treatment and 1 week after treatment. Skin treated with both chemical peels and microdermabrasion showed an increase in epidermal thickness, dermal vascular ectasia, and densely arranged collagen fibers compared with untreated skin. Skin changes were very similar but milder in the group treated by microdermabrasion [23].

Advantages and disadvantages There are several microdermabrasion benefits. One of the most noteworthy is that there is no “down-time” after treatment, unlike chemical peels. Microdermabrasion is a relatively painless and safe procedure; the patient perceives immediate improvement in skin tone, texture, and pigmentation (Figure 51.4). Retinoids and other exfoliation therapies can be continued up to the day of the procedure without incurring significant irritation. However, the effectiveness of microdermabrasion is limited for deeper skin conditions,





Resurfacing Techniques

such as deep wrinkles and scars, which are currently best treated with other resurfacing techniques. Deeper injury increases complications and recovery time along with effectiveness. Microdermabrasion can be combined with other skin resurfacing procedures or chemical peels [4].

Complications and side effects Although microdermabrasion is considered a safe procedure with few reported side effects [2,5,6,7,14], complications can occur. The most common include mild erythema and increased sensitivity, but these are transient and resolve within a few hours [6,7]. Post-inflammatory hyperpigmentation and streaking can occur from intense pressure of the hand-piece. Petechia and purpura are also complications of aggressive treatment. Post-treatment hyperpigmentation has also been reported and is more likely with aggressive treatment on patients with higher Fitzpatrick skin types (IV–VI) [5]. Ocular complications can occur if microcrystals enter the eye. These include eye irritation, chemosis, photophobia, and punctate keratitis [24]. Patients must wear protective eyewear during the procedure. Cross-contamination can occur when using mircrodermabrasion equipment. Shelton reported that bloody material was present on the wand after performing microdermabrasion on a patient with acne scaring, indicating that it is not sufficient to sterilize the distal cap of the wand or to use disposable caps. The operator must therefore ensure that cross-contamination does not occur. An unusual case of a severe urticarial reaction immediately following aluminum oxide microdermabrasion has been reported [25].

Conclusions Microdermabrasion is considered a safe, non-invasive procedure for resurfacing the skin and is used to treat a variety of skin problems and is suitable for all skin types. However, despite its popularity by patients and physicians alike, there remains a dearth of robust scientific evidence about the efficacy and long-term safety of this procedure. However, the few studies published suggest that both patients and physicians have reported benefits from microdermabrasion: improved texture, pigmentation, improvement in acne scarring, photodamage, and appearance of treated skin as well as improved self-esteem. Most studies were performed on small patient groups where protocols and the variety of units used differed. Further, multicentered, randomized studies are needed to confirm the long-term benefits of this popular and widely used procedure for skin rejuvenation.


References 1 Grimes P. (2005) Microdermabrasion. Dermatol Surg 31, 1160–5. 2 Lloyd J. (2001) The use of microdermabrasion for acne: a pilot study. Dermatol Surg 27, 329–31. 3 Freedman BM, Rueda-Pedraza E, Waddell SP. (2001) The epidermal and dermal changes associated with microdermabrasion. Dermatol Surg 27, 1031–4. 4 Cotellessa C, Peris K, Fargnoli M, Mordenti C, Giacomello RS, Chimenti S. (2003) Microabrasion versus microabrasion followed by 15% trichloroacetic acid for treatment of cutaneous hyperpigmentations in adult females. Dermatol Surg 29, 352–6. 5 Tsai RY, Wang CN, Chan HL. (1995) Aluminum oxide crystal microdermabrasion. Dermatol Surg 21, 539–42. 6 Tan MH, Spencer JM, Pires LM, Ajmeri J, Skover G. (2001) The evaluation of aluminum oxide crystal microdermabrasion for photodamage. Dermatol Surg 27, 943–9. 7 Shim E, Barnette D, Hughes K, Greenway HT. (2001) Microdermabrasion: a clinical and histopathologic study. Dermatol Surg 27, 524–30. 8 American Society for Aesthetic Plastic Surgery. (2007) Procedure Survey, Dermasurgery Trends and Statistics. Available from 9 Rajan P, Grimes P. (2002) Skin barrier changes induced by aluminum oxide and sodium chloride microdermabrasion. Dermatol Surg 28, 390–3. 10 Grimes P. (2008) Aesthetics and Cosmetic Surgery for Darker Skin Types. Lippincott Williams and Wilkins. 11 Davari P, Gorouhi F, Jafarian S, Dowlati Y, Firooz A. (2008) A randomised investigator-blind trial of different passes of microdermabrasion therapy and their effects on skin biophysical characteristics. Int J Dermatol 47, 508–13. 12 Lew Bl, Cho Y, Lee MH. (2006) Effect of serial microdermabrasion on the ceramide level in the stratum corneum. Dermatol Surg 32, 376–9. 13 Kamimipour DJ, Kang S, Johnson T, Orringer JS, Hamilton T, Hammerberg C, et al. (2006) Microdermabrasion with and without aluminum oxide crystal abrasion: a comparative molecular analysis of dermal remodeling. J Am Acad Dermatol 54, 405–10. 14 Hernandez-Perez E, Ibiett EV. (2001) Gross and microscopic findings in patients undergoing microdermabrasion for facial rejuvenation. Dermatol Surg 27, 637–40. 15 Rubin M, Greenbaum S. (2000) Histological effects of aluminum oxide microdermbrasion on facial skin. J Aesthet Dermatol 1, 237–9. 16 Freedman B. (2009) Topical antioxidant application enhances the effects of facial microdermabrasion. J Dermatolog Treat 20, 82–7. 17 Clark C. (2001) New directions in skin care. Clin Plast Surg 28, 745–50. 18 Bernard R, Beran S, Rusin L. (2000) Microdermabrasion in clinical practice. Clin Plast Surg 27, 571–7. 19 Warmuth I, Bader R, et al. (1999) Herpes simplex infection after microdermabrasion. Cosmet Dermatol 12, 13. 20 Alam M, Omura N, Dover J, Arndt KA. (2002) Glycolic acid peels compared to microdermabrasion: a right–left controlled trial of efficacy and patient satisfaction. Dermatol Surg 28, 475–9.

51. Microdermabrasion 21 Hexsel D, Mazzuco R, Dal’Forno T, Zechmeister D. (2005) Microdermabrasion followed by a 5% retinoid acid chemical peel vs a 5% retinoid acid chemical peel for the treatment of photoaging: a pilot study. J Cosmet Dermatol 4, 111–6. 22 Hussein MR. (2008) Chemical peeling and microdermabrasion of the skin: comparative immunohistological and ultrastructural studies. J Dermatol Sci 52, 205–22.

23 Cotellessa C, Peris K, Onorati M. (1999) The use of chemical peelings in the treatment of different cutaneous hyperpigmentations. Dermatol Surg 25, 450–4. 24 Morgenstern K, Foster J. (2002) Advances in cosmetic oculoplastic surgery. Curr Opin Ophthalmol 13, 324–30. 25 Farris P, Rietschel R. (2002) An unusual acute urticarial response following microdermabrasion. Dermatol Surg 13, 324–30.


Chapter 52: Dermabrasion Christopher Harmon and Chad Prather Total Skin and Beauty Dermatology Center, Birmingham, AL, USA

BAS I C CONCE P T S • Dermabrasion involves mechanically removing the epidermis and papillary dermis, creating a newly contoured open wound to heal by second intention. • The most common indications for dermabrasion are for the improvement of cystic acne scarring, post-surgical scar revision, and enhanced contouring of partial thickness Mohs defects. • Patients must have realistic expectations of the anticipated improvement, possible side effects, and potential complications of dermabrasion prior to treatment. • Proper technique is paramount in order to avoid intraoperative complications. • Vigilance during the postoperative period is important in order to recognize complications at an early stage and prevent long-term sequelae.

Introduction Dermabrasion involves mechanically resurfacing the skin with an abrasive tip driven by a high-speed rotary hand engine. Either a wire brush or diamond fraise may be used as the abrading tip to create an open wound that will heal by second intention. An irregular or scarred cutaneous surface may be surgically abraded in order to achieve a more regular plane, or a more gradual transition between different planes, thereby improving skin contour. This chapter discusses the dermabrasion technique.

complex, wound healing response is triggered, involving transforming growth factor β (TGF-β) driven myofibroblastic deposition of new type I and III collagen and subsequent remodeling in the dermis [2]. Additionally, TGF-β, keratinocyte growth factor (KGF), and epidermal growth factor (EGF) stimulate re-epithelialization from both underlying skin appendages and adjacent epithelialized skin [2]. When properly performed, the irregularly contoured or actinically damaged epidermal and papillary dermal layers are removed, and second intention wound healing occurs. The clinical result is a smoother, more evenly contoured surface, with fewer irregularities in the form of acne scars, rhytides, keratoses, or step-off transitions.

Mechanism of action Indications Fundamentally, the skin can be subdivided into three layers: epidermis, dermis, and subcutaneous tissue. The dermis is further subdivided into the more superficial papillary dermis, containing both a finely woven meshwork of collagen interdigitating with the epidermal rete as well as the superficial vascular plexus, and the deeper reticular dermis, composed of thick bundles of predominantly type I collagen [1]. Resurfacing, by definition, involves iatrogenic removal of one or multiple layers of the skin to create a cutaneous wound. Dermabrasion mechanically removes the epidermis and papillary dermis, creating a partial thickness wound to heal by second intention. The well-characterized, yet

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


The most common indications for dermabrasion are desired improvement of acne scars, traumatic and surgical scars, rhinophyma, deep rhytides, and partial thickness Mohs defects [3]. However, dermabrasion is also indicated for improvement of actinic keratoses, seborrheic keratoses, angiofibromas, syringomas, solar elastosis, epidermal nevi, and tattoo removal [4]. With regard to acne scarring, even in the era of laser devices, fractionated delivery approaches, and non-invasive “tissue-tightening” procedures, dermabrasion remains an important tool in the combination approach to the improvement of cystic acne scarring. While the shallow and wide, undulating, or “rolling” type acne scars are better treated with subcision, dermal grafts, fillers, or fractionated laser devices, the slightly deeper and narrower “box-car” type

52. Dermabrasion acne scars that demonstrate step-off vertical borders respond best to mechanical dermabrasion. Additionally, the deepest and narrowest “ice-pick” type acne scars respond best to dermabrasion subsequent to punch excisions, punch grafts, or trichloroacetic acid (TCA) cross-destruction. For traumatic and surgical scars, the thickness, contour, and overall appearance is routinely improved with postoperative dermabrasion. Also known as “scar abrasion,” this procedure is best performed 6–8 weeks after the initial surgery or wounding event [5]. When performed during this 6–8 week window, the late proliferative and early remodeling phases of wound healing are interrupted and partially “reset,” resulting in an improved final cosmetic result. While several modalities, including wire loop electrosurgery and CO2 laser resurfacing, have been described for the treatment of rhinophyma, dermabrasion remains unmatched in the operator’s ability to re-establish the complex contour of the many cosmetic subunits of the nose. Furthermore, although CO2 resurfacing, erbium:yttrium aluminum garnet (Er:YAG) resurfacing, and deep chemical peels may improve facial rhytides, dermabrasion proves as efficacious or more efficacious at removal of both fine and moderate facial rhytides, with a slightly lower risk of permanent hypopigmentation. Finally, dermabrasion proves to be an incredibly useful technique in the armamentarium of the Mohs surgeon. Thin carcinomas in cosmetically sensitive or high-risk areas can often be completely removed with a shallow Mohs layer to the level of the superficial reticular dermis. After clearance, these partial thickness defects, particularly on the nose and scalp, may lend themselves to healing by second intention rather than primary closure, yet with slightly increased risk of an evident contour discrepancy or sharp pigmentary transition. Dermabrasion of the edges surrounding the partial thickness Mohs defect greatly improves the final contour by replacing the steeply beveled wound edge with a more gradual slope. Additionally, dermabrading the remainder of an involved cosmetic subunit of the nose results in a less obvious scar by placing the pigmentary demarcation lines at the less perceptible subunit boundaries.

Advantages and disadvantages Compared with fully ablative resurfacing with the CO2 and Er:YAG lasers, dermabrasion demonstrates similar or greater efficacy for the treatment of scars, rhytides, and precancerous lesions, with less postoperative erythema and more rapid re-epithelialization. While newer, fractionated delivery protocols result in even less erythema and quicker reepithelialization than dermabrasion, their efficacies for the improvement of scars, rhytides, and precancerous lesions do not currently match that seen with mechanical dermabrasion. Dermabrasion has also been shown to be more

efficacious than 5-fluorouracil for the treatment of actinic keratoses [6]. The major disadvantage of dermabrasion compared with the above modalities is that it is much more operatordependent. Unlike laser and light devices, the depth of penetration is not preprogrammed. Successful treatment relies not only on the physician’s knowledge of the modality and application settings, but also on his or her skilled execution. In the novice’s hands, dermabrasion exhibits a narrower window or buffer between effective treatment depth and inappropriate scarring depth. However, this is quickly overcome with experience.

Patient selection and preoperative consultation The most important components of the preoperative consultation are determining the patient’s specific motivation for resurfacing and establishing realistic expectations regarding the treatment outcome. The ultimate goal of any resurfacing treatment should be an improvement of the given defect rather than a complete eradication. Dermabrasion consistently achieves 30–50% improvement in the appearance of deep acne scars and rhytides, but the patient who seeks and expects the elimination of all scars and rhytides will rarely be satisfied. Reviewing before and after photographs with the patient during consultation, particularly when considering full cosmetic unit or full-face dermabrasion, may foster realistic expectations for improvement. The preoperative consult should also include a complete history addressing bleeding disorders, prior herpes simplex infection, impetigo, keloidal or hypertrophic scarring, koebnerizing conditions, prior isotretinoin therapy, and immunosuppression. The risk:benefit ratio of an iatrogenically induced wound is unfavorable in patients who are immunosuppressed, who have a history koebnerizing conditions such as lichen planus and psoriasis, or who demonstrate a propensity towards keloidal or hypertrophic scar formation. Because of an increased risk of scarring in patients on isotretinoin, dermabrasion should be delayed until 6 months after finishing an oral retinoid course [7]. Caution should also be exercised when planning to dermabrade patients who have recently undergone extensive procedures involving the area to be dermabraded, such as a facelift, as a robust blood supply is necessary for appropriate wound healing. Many surgeons prefer to wait 6 months after a facelift before subsequent dermabrasion. Antiviral prophylaxis should be instituted in those with a history of herpes simplex outbreak in the area to be spot dermabraded or in those who are undergoing full-face or multiple cosmetic unit dermabrasion. The antiviral agents acyclovir or valcyclovir may be used, and patients should remain on prophylactic therapy for 10 days after the



Resurfacing Techniques

procedure (50 mg valacyclovir b.i.d. for 10 days). Similarly, antibacterial prophylaxis with an antistaphylococcal agent should be instituted in those with a history of impetigo. Particular attention should also be paid to the Fitzpatrick skin type of the patient. Fitzpatrick skin types IV, V, and VI are much more prone to both postoperative hyperpigmentation and permanent, clinically significant hypopigmentation, the latter of which may not appear for several months following the procedure. Preoperative photographs are highly recommended, and should include a frontal view, 45 ° and 90 ° views from both sides, and a close-up view of the areas to be treated. Additionally, all preoperative and postoperative expectations should be discussed. The patient should particularly be made aware of the nature of the postoperative recovery routine, which includes extensive facial dressings with multiple changes over several days, and clinically apparent erythema for several weeks.

Instrumentation With mechanical dermabrasion, a diamond fraise or wire brush abrading tip is driven by a handheld engine at speeds of 15 000–30 000 rotations per minute. Current hand engines include the Osada, Ram, and Urawa Kohgyo Acrotorque hand-pieces. The classic Bell hand engine is no longer available from the manufacturer, but may occasionally be found as a refurbished item through select vendors. Diamond fraises come in a range of shapes and sizes, such as pears, cones, bullets, and wheels, and also vary in coarseness from fine to extra coarse. Alternatively, the wire brush is a 3.0–5.0 mm wide × 17.0 mm diameter wheel with steel bristles radiating from the center in a clockwise fashion when viewed from the shaft (Figure 52.1). The wire brush is the most aggressive type of end piece and can be more

Figure 52.1 Wire brush abrading wheel with steel bristles radiating from the center in a clockwise fashion.


technically difficult to master, yet it is considered more efficacious by those experienced with its use. The microlacerations created with the wire brush are the most efficient means of removing the nodules of rhinophyma, the thick plaques of hypertrophic scars, and deep acne scars.

Standard technique Treating surgical scars, rhinophyma, and partial thickness Mohs defects provides an excellent point of entry into the practice of dermabrasion prior to practicing advanced techniques such as full-face dermabrasion. If the treatment area is limited in size, local anesthesia (1% lidocaine with epinephrine 1 : 100 000) or tumescent technique is adequate. When treating the entire nose, a ring block may achieve an appropriate degree of anesthesia. Prior to abrasion, the area to be treated is cleansed with a 4% chlorhexidine solution. The body of the hand engine is grasped in the palm of the dominant hand with four fingers, allowing the thumb to project along the neck for stabilization (Figure 52.2). Finger position is similar to a “thumbs-up” sign or to that seen when gripping a golf club, yet the hand and instrument are pronated, with the palm facing downward. Freon 114 refrigerant spray (Frigiderm, Delasco, Council Bluffs, IA, USA) is applied to the treatment area in an amount necessary to achieve a 5–10 s thaw time, during which time abrasion is performed on the frozen area. Refrigerant spray accomplishes two important functions: decreasing pain by cryoan-

Figure 52.2 Dermabrasion of multiple cosmetic subunits of the nose showing operator hand position and three-point retraction by physician’s non-dominant hand and two hands of assistant.

52. Dermabrasion

Figure 52.3 Female patient after two stages of Mohs micrographic surgery for removal of basal cell carcinoma of the nasal tip. Tumor has been cleared and defect depth remains in the superficial reticular dermis. Surgical marking notes superior border of nasal supratip subunit.

Figure 52.4 Same patient as in Figure 52.3 after wire brush dermabrasion of the remaining nasal tip and surrounding cosmetic subunits. Area will now heal with improved contour and pigment match.

esthesia and a providing a firm substrate upon which to achieve recontouring. Immediately after freezing, three-point retraction is obtained by the two hands of the surgical assistant and the non-dominant hand of the surgeon. The frozen skin is thus stabilized by retraction, and the lesion is recontoured with the wire brush rotating in a counter-clockwise direction (with the angle of the radiating bristles) as determined from the point of view of the body of the hand engine. The wire brush is passed over the treatment area in an arciform motion with the long axis perpendicular to the rotating hand-piece (parallel to the body of the hand engine). Counter-clockwise rotation of the wire brush offers a less aggressive technique of wire brush surgery that is especially well suited for spot dermabrasion of Mohs defects or surgical scars without cryoanesthesia (Figures 52.3 and 52.4). With counter-clockwise rotation, the radiating bristles are less prone to gouge unfrozen skin. This counter-clockwise direction of rotation is also useful when dermabrading free margins of the face such as the lips and nasal alae, in order to prevent the inadvertent “grabbing” of tissue by the rotating wire brush when dermabrading from the right side with the dominant right hand. Regular pinpoints of bleeding signal abrasion to the level of the papillary dermis. As depth increases to the reticular dermis, the bleeding foci become larger, and frayed collagen bundles become apparent. Surgical scars will frequently disintegrate upon abrasion, which is a desirable endpoint. Contouring should often include “feathering” or graduating

zones of treatment around the central scar to provide a smooth transition between different planes and improved pigment transition. Alternatively, the treatment zone may be stopped at the border of a cosmetic unit or carried to an inconspicuous endpoint such as 1.0 cm beyond the mandible.

Advanced technique While local or tumescent anesthesia may be adequate for scar or spot dermabrasion, full-face abrasion of acne scarring or rhytides is best accomplished with a combination of oral (p.o.) or intramuscular (i.m.) light sedation, nerve blocks, and cryoanesthesia. A standard regimen consists of 50–75 mg meperidine i.m., 25 mg hydroxyzine i.m., and 5–10 mg diazepam p.o. or sublingual 30–60 minutes prior to the start of the procedure. After a chlorhexidine prep, nerve blocks to the supratrochlear, supraorbital, infraorbital, and mental nerves may also be performed. In contrast to the counter-clockwise rotation typically utilized for less aggressive dermabrasion, more experienced practitioners may opt to use a clockwise rotation of the abrasive wire brush. Rotation in a clockwise direction occurs against the angle of the radiating wire bristles and causes the tip to pull away from the thumb rather than driving toward it. Deeper planing and recontouring are possible with clockwise rotation, but this direction is much less forgiving. Additionally, clockwise rotation utilized by a



Resurfacing Techniques

dominant right hand increases the risk that free margins of the face, such as lips and nasal alae, will be “grabbed” by the rotating bristles rather than brushed away, resulting in unintentional, deeper abrasion in these areas. When performing full-face dermabrasion, beginning at the periphery of the cheek or mandible and working toward the center of the face allows the practitioner to avoid gravity dependent bleeding as the procedure progresses. A surgical towel, surgical cap, or petrolatum may also be used to help prevent entanglement of hair at the periphery of the treatment area. Surgical towels are also preferable to cotton gauze as sponges on the surgical field, as gauze becomes more easily entangled in the wire brush and hand engine.

Postoperative wound care Gauze soaked with 1% lidocaine with 1 : 100 000 epinephrine may be immediately applied to the post-abraded area for a period of 5–10 minutes to assist with hemostasis. A closed technique, layered bandage is then applied, composed of a semi-permeable hydrogel dressing (Vigilon, CR Bard, Inc., Covington, GA, USA, or Second Skin, Spenco Medical Corp., Waco, TX, USA) in contact with the wound, a nonadherent dressing (Telfa™, Covidien, Mansfield, MA, USA) above, and paper tape or surgical netting to secure the bandage in place. Semi-permeable hydrogel dressings provide two important advantages over other types of dressings: decreased patient discomfort in the postoperative period and decreased time to re-epithelialization by up to

40% [8]. The dressing should be changed daily for 3–5 days. If full-face dermabrasion has been performed, it is usually most convenient to have the patient return to the office for dressing changes during this period. For smaller areas, the patient may change the bandage at home. After 3–5 days, the patient begins an open wound care technique at home. 0.25% Acetic acid soaks (1 tablespoon white vinegar into 1 pint of warm water) are followed by topical petrolatum ointment until re-epithelialization is complete, usually 7–10 days after the procedure. Strict adherence to this regimen reduces the risk of both secondary infection and scarring. If full-face dermabrasion is performed, a short course of oral or intramuscular steroids may also be given immediately after the procedure to help reduce facial swelling. Swelling is an anticipated consequence of full-face dermabrasion and may be expected to resolve over several weeks to a few months. All previously prescribed antivirals and antibacterials should be instituted or continued, and patients should be given a prognosis and expected recovery timeframe. Once re-epithelialization has occurred, sunscreens and sun avoidance should be strictly adhered to for several weeks in order to minimize post-procedure pigment alteration. Makeup may be used to cover erythema after re-epithelialization.

Complications The most common complications encountered after dermabrasion are milia and acne flares (Table 52.1). These minor

Table 52.1 Complications of dermabrasion with suggested treatment. Complication



Milia and acne flare

Most common

Expression, topical retinoids, oral antibiotics

HSV “breakthrough” infection

Intensely painful erythematous lesions at 7–10 days

Increase antiviral dose (1 g valcyclovir t.i.d. for 7–10 more days)

Bacterial infection

Persistently painful erythematous lesions

Culture and begin empiric therapy with antistaphylococcal antibiotic

Fungal infection

Persistently painful erythematous lesions

Culture and begin empiric therapy with anticandidal agent


Usually transient

4–8% hydroquinone for 4–8 weeks


Delayed onset, usually permanent

Camouflaging makeup, possibly 308 nm excimer laser


Persistent erythema in the absence of infection

Treat early and repeatedly Topical steroids Intralesional steroids Pulsed dye laser


52. Dermabrasion side effects should be anticipated, and may be treated by comedone expression, topical tretinoin, and oral antibiotics. Infection, pigment alteration, and scarring are the more portentous complications that may be encountered after dermabrasion. Vigilance in the immediate postoperative period is necessary to identify these complications at an early stage and institute treatment. Herpes simplex infection may still occur while the patient is on a prophylactic antiviral dose, and clinically manifests as painful (out of proportion to healing phase), erythematous lesions 7–10 days postprocedure. Larger doses of antiviral medications are then necessary for treatment (1 g valcyclovir t.i.d. for 7–10 more days). Bacterial and fungal infections may likewise produce persistently painful, erythematous lesions. Lesions should be cultured and empiric therapy with an antistaphylococcal or anticandidal agent, or both, should be implemented as warranted by clinical suspicion. Transient, postoperative hyperpigmentation is a common complication, usually beginning 4–6 weeks after dermabrasion. 4–8% Hydroquinone, or formulations containing hydroquinone, tretinoin, and a mild steroid, should be implemented at the earliest signs of hyperpigmentation and continued for 4–8 weeks. A more difficult complication to treat is hypopigmentation. While not quite as common as with fully ablative CO2 laser resurfacing, nearly one-third of patients will develop permanent hypopigmentation after full-face wire brush dermabrasion. Furthermore, such hypopigmentation often does not develop until several months post-procedure. Female patients may camouflage such hypopigmentation with makeup, but male patients have fewer options for improvement. The 308 nm excimer laser has been shown to improve hypopigmented scars and vitiligo, and may be an option for improvement after dermabrasion [9]. True hypopigmentation should be differentiated from the pseudo-hypopigmentation seen when resurfaced skin without actinic damage simply appears lighter than the surrounding actinically damaged skin. Finally, persistent erythema in the absence of infection is the harbinger of scar formation. Scars should be treated early and proactively in order to minimize sequelae. Flat, erythematous scars may be managed by topical steroids, or steroid-impregnated tape (Cordran, Aqua Pharmaceuticals, LLC, West Chester, PA, USA) worn nightly. However, indurated scars also require intralesional corticosteroid injections and/or pulsed dye laser treatments on a regular basis. These may be repeated every few weeks until stabilization and improvement occur.

Conclusions With the armamentarium of resurfacing modalities increasing, mechanical dermabrasion remains an important dermasurgical procedure, particularly for the improvement of cystic acne, post-surgical scars, and partial thickness Mohs defects. Selecting appropriate patients and establishing realistic treatment goals are prerequisites. Small areas may be easily and safely treated with proper technique, and these demonstrate a rapid recovery. Although experience and skill are necessary in order to avoid serious complications with full-face dermabrasion, its efficacy for the treatment of acne scarring and deep rhytides currently remains unmatched for the patient who is willing to endure the resultant recovery period. Close follow-up during the postoperative period is important in order to recognize and treat the most serious potential complications of infection and scarring at the earliest stages. While new technologies continue to emerge, mechanical resurfacing will likely remain an essential and unmatched modality for scar improvement into the foreseeable future.

References 1 Murphy GF. (1997) Histology of the skin. In: Elder D, Elenitsas R, Jaworsky E, Johnson BL, eds. Lever’s Histopathology of the Skin, 8th edn. Philadelphia, PA: Lippincott, pp. 42–3. 2 Kirsner RS. (2008) Wound healing. In: Bolognia JL, Jorizzo JL, Rapini RP, eds. Dermatology, 2nd edn. Spain: Elsevier, pp. 2147–58. 3 Campbell RM, Harmon CB. (2008) Dermabrasion in our practice. J Drugs Dermatol 7, 124–8. 4 Roenigk HH Jr. (1977) Dermabrasion for miscellaneous cutaneous lesions (exclusive of scarring from acne). J Dermatol Surg Oncol 3, 322–8. 5 Yarborough JM Jr. (1988) Ablation of facial scars by programmed dermabrasion. J Dermatol Surg Oncol 14, 292–4. 6 Coleman WP 3rd, Yarborough JM, Mandy SH. (1996) Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg 22, 17–21. 7 Rubenstein R, Roenigk HH Jr, Stegman SJ, Hanke CW. (1986) Atypical keloids after dermabrasion of patients taking isotretinoin. J Am Acad Dermatol 5, 280–5. 8 Pinski JB. (1987) Dressings for dermabrasion: new aspects. J Dermatol Surg Oncol 13, 673. 9 Alexiades-Armenakas MR, Bernstein LJ, Friedman PM, Geronemus RG. (2004) The safety and efficacy of the 308-nm excimer laser for pigment correction of hypopigmented scars and striae alba. Arch Dermatol 140, 955–60.


Part 4: Skin Modulation Techniques Chapter 53: Laser-assisted hair removal Keyvan Nouri1, Voraphol Vejjabhinanta1,2, Nidhi Avashia1, and Rawat Charoensawad3 1

University of Miami Miller School of Medicine, Miami, FL, USA Suphannahong Dermatology Institute, Bangkok, Thailand 3 Rawat Clinic and Biophile Training Center, Bangkok, Thailand 2

BAS I C CONCE P T S Current options for hair removal include shaving, epilation, depilatories, electrolysis, and, more recently, lasers. • Lasers are fast, safe, and effective when used appropriately. • Selective photothermolysis is the key concept in laser hair removal. • By varying specific parameters such as wavelength, pulse duration, and fluence, certain specific chromophores may be targeted while protecting other tissues. • Melanin is the main endogenous chromophore in hair follicles. • In permanent hair reduction, heat from the laser must spread from the hair shaft to the bulb and the bulge of the hair. • Adverse effects reported after laser-assisted hair removal include erythema, perifollicular edema, crusting, vesiculation, hypopigmentation, and hyperpigmentation.

Introduction The use of lasers for hair removal, or photoepilation, is becoming increasingly popular. According to the American Society for Aesthetic Plastic Surgery (ASAPS), nearly 11.7 million cosmetic surgical and non-surgical procedures were performed in the USA in 2007. ASAPS, which has been collecting multispecialty procedural statistics since 1997, notes the number of cosmetic procedures has increased 457% [1]. Laser hair removal is one of the top, non-surgical, cosmetic procedures with 1 412 657 performed in 2007. Hair removal is of great interest because excess hair, especially in those with hypertrichosis or hirsutism, can be socially and psychologically troubling [2]. The psychosocial importance of hair is great, as noted by patient distress over both hair loss and excess hair [3]. Current options for hair removal include shaving, epilation, depilatories, electrolysis, and, more recently, lasers [4]. All of these hair removal methods possess side effects, yet lasers are fast, safe, and effective when used appropriately. The concept of laser hair removal was defined in 1998 by the US Food and Drug

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


Administration (FDA). Following this, manufacturers were given permission to use the term “permanent hair reduction” in their materials. The FDA definition of permanent hair reduction included “long-term, stable reduction in the number of hairs regrowing after a treatment regimen.” Thus, permanent hair removal does not imply the total elimination of hairs [5], but rather a significant reduction in growth rate. Complete hair loss is defined as a lack of regrowing hairs, which can be temporary or permanent. However, permanent hair loss is defined as lack of regrowing hair indefinitely. Hair removal with lasers produces complete but temporary hair loss for 1–3 months [6].

Biology of hair follicles Hair is a skin appendage, present on the entire body except for the palms and soles. There are approximately 5 million hair follicles on the adult body with a density of 40–800/ cm2. They are made of keratin fibers supported by specialized dermal structures. Hair is formed from the matrix epithelial cells at the base of the hair follicle. The hair matrix is contained in the hair bulb, which is the deep bulbous portion of the hair follicle that surrounds the dermal papilla. The bulge of the hair is the reservoir for hair stem cells. In permanent hair reduction, heat from the laser must spread

53. Laser-assisted hair removal

Table 53.1 Hair cycles for various body sites. Body site

Anagen (%)

Telogen (%)

Anagen duration (months)

Telogen duration (months)

Follicular depth (mm)







Upper lip
























Bikini area






from the hair shaft to the bulb and the bulge of the hair. Heating only the hair matrix is not sufficient for permanent hair reduction. There is no formation of new hair follicles throughout life, so, as the body expands, the density decreases. Hair changes throughout our lifetime. A single follicle can form several different types of hairs ranging from lanugo in preterm newborns to vellus hairs in children to terminal hairs in adults. Lanugo is fine, non-pigmented hairs present at birth. Vellus hairs are fine, short, non-pigmented hairs known as “peach fuzz.” Terminal hairs are the thick, usually pigmented, hairs of the scalp and secondary sexual areas. Terminal hairs are the targets of photoepilation. Hair does not grow continuously, but instead grows in three phases: anagen, catagen, and telogen. The anagen phase is known as the growth phase. Catagen is the transition phase. Telogen is the resting phase. The cycle for scalp hairs is not only asynchronous but lasts 3–5 years. The duration of the hair cycle varies depending on body location (Table 53.1). Photoepilation is most effective during certain phases of the hair growth cycle. The regulation of hair growth is influenced by genetic factors and hormones, particularly androgens. The function of hair, while primarily psychosocial, serves to protect from mechanical, thermal, and UV damage [3]. Thus, hair removal is important for appearance and not functional reasons. The basic concepts of laser-assisted hair removal are discussed next.

Basic concepts of laser-assisted hair removal Selective photothermolysis is the key concept in laser hair removal, known as photoepilation. Photoepilation causes thermal destruction of the hair follicle and its associated stem cells at the hair bulge. By varying specific parameters such as wavelength, pulse duration, and fluence, certain

specific cutaneous chromophores may be targeted while protecting other tissues [7]. Whether the hair is in telogen at the time of removal is important, because only anagen hairs are sensitive to photothermolysis. Because melanin is the main chromophore in hair follicles, the corresponding wavelength spectrum would range from UV to near-infrared light. Longer wavelengths are preferred, because the chromophore lies deep in the skin and the penetration of light increases with wavelength. The specific target in laser hair removal is melanin and the light emitted must be within the absorption spectrum of melanin, which is 250–1200 nm [8]. Melanin is an endogenous chromophore found in the hair bulb, bulge, and shaft. Thus, in the range of 600–1100 nm, deep dermal melanin absorption may be used for selective photothermolysis of hair follicles [9]. A drawback to the use of lasers for hair removal, especially in those with darker skin, is that melanin resides in the epidermis. This is problematic because epidermal melanin can interfere with photoepilation by distracting the laser energy, but can also lead to certain side effects, such as epidermal damage and pigmentation. Thus, proper preoperative management is essential to achieving superior results.

Preoperative management Discrepancy can exist between patient expectations for laser-assisted hair removal and the actual effects of such a treatment. Open communication must exist between the care provider and the patient. Preoperative management for laser hair removal consists of three main steps: history and physical examination, counseling, and preparatory instructions (Table 53.2). First, an accurate patient history must be taken focusing on patient’s expectations, current medications, scarring risk, and local infection including history of herpes virus infection in the area of treatment. Along with a complete history, a thorough physical examination is vital.



Skin Modulation Techniques

Table 53.2 Preoperative and postoperative procedures for hair removal. History

Preoperative care (4 weeks prior to treatment)

Preoperative care (day before treatment)

Day of treatment

Postoperative care

Conditions that may cause hypertrichosis: hormonal, familial, drug, tumor

Sunscreen application

Shave area to be treated

Clean and remove make-up from area to be treated

Ice packs

History of HSV perioral and genitalis

Bleaching cream (hydroquinone) to those with darker skin

When indicated, start prophylactic antiviral

Apply topical anesthetic cream to treatment area 1–2 h prior to treatment

Avoid sun exposure and trauma

History of keloids/hypertrophic scarring

No plucking, waxing, or electrolysis

When indicated, start prophylactic oral antibiotic

Previous treatment modalities

Shaving or depilatory creams may be used

Mild topical steroid creams (if necessary) Prophylactic antiobiotics/antivirals completed

Current medications HSV, herpes simplex virus infection.

Table 53.3 Step-by-step technique for hair removal. Skin preparation


Treatment fluence



Remove anesthetic cream, makeup

Treatment grid or Seymour light in order to prevent skipped areas and double treatment

Ideal treatment parameters individualized for each patient, increase fluence carefully while monitoring for adverse effects

Slightly overlapping laser pulses are delivered with a predetermined spot size and highest tolerable fluence to obtain best results

Cooling gel applied prior to pulses if device is not equipped with cooling feature

The physical examination should assess the aspects of the patient’s skin color, health condition, hair color, hair diameter, and hair density. Following the workup of the patient, a counseling session is necessary. The patient must be advised that 4–6 weeks prior to laser treatment no plucking or other hair removal methods can be used in the treatment areas. Shaving and depilatory creams may be used as these methods do not remove the hair root, which is targeted by the laser. In addition, sun exposure and tanning should be limited. Bleaching of the skin with retinoic acid or hydroquinone can lighten the skin prior to laser treatment. Topical anesthetic creams or cryogenic sprays may be applied to the treatment area to reduce discomfort during the procedure. Cold compresses are also effective in reducing discomfort, erythema, and edema at the treatment area. The skin surface must be thoroughly cleansed of all makeup, anesthetic creams, and other applicants immediately prior to laser treatment. This may be done with a gentle cleanser, followed by a cloth, and should be allowed to dry completely. 434

Laser systems are dangerous hazards to the eye. Because there are high concentrations of melanin in the iris and in the retina, these areas are highly susceptible to damage by laser light. Every person in the room during laser treatment should wear protective eyewear that is certified for the wavelength of the laser in use. Because the patient usually lies supine, he or she may require full occlusive eye protection to prevent laser light from entering underneath a sunglasses or goggle type of protective eyewear [6].

Description of techniques Long pulsed 694 nm ruby laser The long pulsed ruby laser was the first widely used laser for hair removal (Table 53.3). This laser has the shortest wavelength at 694 nm of all the available lasers for hair reduction. It is absorbed the best by melanin but has the shortest penetration depth. Thus, this would mean that the ruby laser is the most effective at hair removal, but has the greatest potential for epidermal injury. A cooling hand-

53. Laser-assisted hair removal piece is used concomitantly during treatment to reduce the risk of injury by lowering the skin’s temperature. This laser is ideal for those with light skin and dark hair, and penetrates the skin by only 1–2 mm. This laser is not recommended in darker skin types. In a study demonstrating the efficacy of the ruby laser, 48 areas of unwanted facial and body hair from 25 patients with blonde, brown, or black hair were treated with the long pulsed ruby laser at fluences of 10–40 J/cm2. Hair regrowth was measured at 4 weeks after the first treatment, 4 weeks after the second treatment, 4 weeks after the third treatment, and 16 weeks after the third treatment by counting the number of terminal hairs compared with baseline pretreatment values. The mean percent of regrowth after the first treatment was 65.5%, 41% after the second treatment, and 34% after the third treatment. Overall, regardless of skin type or targeted body region, patients who underwent three treatment sessions demonstrated an average 35% regrowth in terminal hair count [10].

neodymium:yttrium aluminum garnet (Nd:YAG) laser for treating patients with darker skin types. The diode laser is more effective for laser-assisted hair removal in patients with dark skin because of the higher absorption by melanin than is seen with the Nd:YAG laser. Still, temporary adverse effects have been reported with the use of the diode laser in the form of postinflammatory hyperpigmentation when used on individuals with dark skin. A retrospective study of 313 consecutive laser-assisted hair removal treatments was conducted on a total of 23 patients (22 women, 1 man) with 58 anatomic areas by means of an alexandrite laser. The long pulsed alexandrite system was used at a 755 nm wavelength to deliver fluences ranging 17–25 J/cm2 through a 10 mm spot size. The results showed that patients who undergo more treatment sessions achieve a higher rate of hair reduction; although this may be concomitant with an increase in the incidence of adverse effects. The benefit of more laser treatments should be balanced with the risk of occurrence of side effects in each patient [11].

Long pulsed 755 nm alexandrite laser The long pulsed alexandrite laser has a wavelength of 755 nm. This longer wavelength allows deeper penetration into the dermis with less absorption by epidermal melanin. This causes less adverse side effects such as pigmentation in darker skin patients. This laser is still typically used for patients with lighter skin types, but can also be used in those with darker skin. The adverse effects of this laser, when used on patients with darker skin types, can include blistering, crusting, and alterations of pigment, even when skin cooling devices are used. In patients classified as having the darkest skin, residual hypopigmentation or hyperpigmentation is the rule with the alexandrite laser.

Long pulsed 800 nm diode laser The 800 nm diode laser is comparable to the 755 nm alexandrite laser, and has become more popular along with the

1064 nm Nd:YAG laser The 1064 nm Nd:YAG has the longest wavelength and deepest penetration amongst the aforementioned laser systems available. It is not very well absorbed by melanin, but is sufficient in achieving selective photothermolysis and has superior penetration. This laser is able to penetrate the skin to 5–7 mm, a depth at which most of the target structures lay. Furthermore, the combination of a low melanin absorption and deep penetration leads to less collateral damage to the melanin-containing epidermis. These features make this particular laser the safest method to treat all skin types, especially darker skinned patients (Figure 53.1). Unfortunately, while this laser may be the safest, it is not the most effective. In a study by Bouzari et al. [12], hair reduction by the long pulsed Nd:YAG, alexandrite, and diode lasers were compared. They found


(a) Figure 53.1 (a) Pretreatment of the right axillary area with coarse hair. (b) Only fine hair exists after 3 months after five treatments with a 1064 nm Nd:YAG laser. 435


Skin Modulation Techniques


(a) Figure 53.2 (a) Pretreatment of the upper lip area. (b) Seven weeks after two treatments with intense pulsed light (IPL) system.

that after 3 months, the Nd:YAG was the least effective of the three.

Intense pulsed light The intense pulsed light (IPL) system is not a laser, but has recently entered the hair removal realm as a competent contender. It has been used for virtually all of the same indications as laser systems. IPL systems utilize a xenon bulb as a light source, which produces polychromatic light with wavelengths of 515–1200 nm. This is in contrast to laser light sources, which produce monochromatic light of a specific wavelength. Light emitted by the bulb passes through a filter that excludes shorter wavelengths which may severely damage skin. The ability to “tune” the wavelength of light emitted by these systems gives IPL systems the advantage of versatility. Using different filters, a pulsed light system could mimic any number of laser systems, allowing the operator to treat many different conditions amenable to light therapy, including, of course, the removal of unwanted hair (Figure 53.2).

Radiofrequency combinations Radiofrequency devices have been combined with both IPL and diode lasers to provide optimal hair removal treatments to a wider range of skin types. The combinations are considered safe for patients with darker skin types because the radiofrequency energy is not absorbed by melanin in the epidermis. This technology, termed electro-optical synergy (ELOS) has a dual mechanism of heating the hair follicle with electrical energy (radiofrequency) and heating the hair shaft with optical energy.

which is sprayed on, is selectively absorbed by the hair follicle and not the skin. This in turn gives the follicles a temporary boost of melanin to optimize laser hair removal treatments. Clinical studies in Europe have shown vast permanent hair reduction in patients who used meladine prior to treatment. However, other studies have found meladine to only offer a delay of hair growth as opposed to permanent hair reduction [6]. Another option for non-pigmented hair removal is photodynamic therapy. A photosensitizer such as 5-aminolevulinic acid (5-ALA) is used because non-pigmented hair lacks a natural chromophore. In a study conducted to compare the 6-month hair removal efficacy of a combined pulsed light bipolar radiofrequency device with and without pretreatment using topical 5-ALA, researchers found that an average terminal white hair removal of 35% was observed at 6 months after treatment with the combined pulsed light bipolar radiofrequency device. When pretreatment with topical 5-ALA was provided the average hair removal of terminal white hairs was found to be 48%. This finding can be explained by the fact that light exposure activates the 5-ALA, which leads to the formation of reactive oxygen elements and slows for hair follicle destruction [13].

Postoperative management Postoperative management consists of reducing pain and minimizing edema. This can be done using ice packs. Mild topical steroid creams can also be used to decrease redness. Antibiotics should be given if epidermal injuries occur during the procedure.

Complications Other removal methods for non-pigmented hair Meladine, a topical melanin pigment, has been studied in Europe with interesting results. The liposome solution dye,


Although there is no obvious advantage of one laser system over another in terms of treatment outcome (except the Nd:YAG laser, which is found to be less efficacious, but more suited to patients with darker colored skin), laser parameters

53. Laser-assisted hair removal or permanent unless the FDA determines that there are sufficient data to demonstrate such results. Several manufacturers received FDA permission to claim, “permanent reduction,” not “permanent removal” for their lasers. This means that although laser treatments with these devices will permanently reduce the total number of body hairs, they will not result in a permanent removal of all hair. There is a new laser hair removal device that the FDA has approved for at home use and over-the-counter sales. This new device is known as TRIA. SpectraGenics announced clearance from FDA for their patented hand-held laser hair removal device designed for at-home use. The TRIA is the first hair removal laser to enter the US home-based device market, an industry projected to grow exponentially over the next 3 years.

Conclusions Figure 53.3 Blister formation 3 days after treatment with IPL system.

may be important when choosing the ideal laser for a patient. Adverse effects reported after laser-assisted hair removal including erythema and perifollicular edema, which are common, and crusting and vesiculation of treatment site, hypopigmentation, and hyperpigmentation (depending on skin color and other factors) (Figure 53.3). Most complications are generally temporary. The occurrence of hypopigmentation after laser irradiation is thought to be related to the suppression of melanogenesis in the epidermis (which is reversible), rather than the destruction of melanocytes. Methods to reduce the incidence of adverse effects include lightening of the skin and sun avoidance prior to laser treatment, cooling of the skin during treatment, and sun avoidance and protection after treatment. Proper patient selection and tailoring of the fluence used to the patient’s skin type remain the most important factors in efficacious and well-tolerated laser treatment. While it is generally believed that hair follicles are more responsive to treatment while they are in the growing (anagen) phase, conflicting results have also been reported. There is also no consensus on the most favorable treatment sites [14]. In addition, patients should be cautious and not use numbing agents on large areas of their body for prolonged periods of time as this can lead to adverse reactions.

Future directions Laser hair removal is not FDA approved to be marketed as a permanent hair removal treatment. Further, manufacturers may not claim that laser hair removal is either painless

Up to 22% of women in North America have excessive or unwanted facial hair. Men also feel compelled to rid themselves of unwanted body hair, as dictated by popular culture and appearance anxieties. Excessive facial hair can negatively impact on one’s quality of life. Prior options to hair removal have been painful, tedious, resulted in frustrated clients, and caused short-term effects. With the advent of laser technology, laser and light systems have becomes some of the most popular procedures. While this is still not a permanent solution to hair removal, is a safe, fast, and effective method for hair reduction.

References 1 American Society for Aesthetic Plastic Surgery (ASAPS). (2007) ASAPS 2007 Cosmetic Surgery National Data Bank Statistics. Accessed 2008 Aug 20. 2 Nouri K, Trent JT. (2003) Lasers. In: Nouri K, Leal-Khouri S, eds. Techniques in Dermatologic Surgery. St. Louis: Mosby, pp. 245–58. 3 Rassner G. (2004) Atlas of Dermatology. Philadelphia, PA: Lea & Febiger, pp. 224–6. 4 Olsen EA. (1999) Methods of hair removal. J Am Acad Dermatol 40, 143–55. 5 Food and Drug Administration. (1998) FDA docket K980517. July 21. 6 Dierickx C, Crossman M. (2005) Laser hair removal. In: Golderg DJ, ed. Lasers and Lights, Vol. 2. China: Elsevier-Saunders, pp. 61–76. 7 Anderson RR, Parrish JA. (1983) Selective photothermolysis: precise microsurgery by selective abdorption of pulsed radiation. Science 220, 524–7. 8 Battle EF, Hobbs LM. (2003) Lasers in dermatology: four decades of progress. J Am Acad Dermatol 49, 1–31. 9 Mandt N, Troilius A, Drosner M. (2005) Epilation today: physiology of the hair follicle and clinical photoepilation. J Investig Dermatol Symp Proc 10, 271–4.



Skin Modulation Techniques

10 Williams R, Havoonjian H, Isagholian K, Menaker G, Moy G. (1998) Clinical study of hair removal using the long-pulsed ruby laser. Dermatol Surg 24, 837–42. 11 Bouzari N, Nouri K, Tabatabai H, Abbasi Z, Firooz A, Dowlati I. (2005) The role of number of treatments in laser-assisted hair removal using a 755-nm alexandrite laser. J Drugs Dermatol 4, 573–8. 12 Bouzari N, Tabatabai H, Abbasi Z, Firooz A, Dowlati Y. (2004) Laser hair-removal: comparison of long-pulsed Nd:YAG, long-


pulsed aleandrite, and long-pulsed diode alsers. Dermatol Surg 30, 498–502. 13 Goldberg DJ, Marmur ES, Hussain M. (2005) Treatment of terminal and vellus non-pigmented hairs with an optical/ bipolar radiofrequency energy source: with and without pretreatment using topical aminolevulinic acid. J Cosmet Laser Ther 7, 25–8. 14 Liew SH. (2002) Laser hair removal: guidelines for management. Am J Clin Dermatol 3, 107–15.

Chapter 54: Radiofrequency devices Vic Narurkar Bay Area Laser Institute, San Francisco, CA, and University of California Davis Medical School, Sacramento, CA, USA

BAS I C CONCEPTS • Radiofrequency devices have been introduced for non-surgical skin tightening of facial and non-facial skin. • The mechanism of action of these devices involves an initial immediate collagen contraction and a secondary wound healing response producing collagen deposition and remodeling with skin tightening over time. • Radiofrequency devices can be divided into monopolar and bipolar categories. • Monopolar radiofrequency utilizes an electrical current passed from the radiofrequency energy source through a monopolar electrode in the hand-piece and the current continues through the patient to the grounding pad, which completes the circuit. • Bipolar radiofrequency in conjunction with light and vacuum offer more superficial treatments, and, most recently, a combined unipolar and bipolar radiofrequency device has been introduced with control of depths of radiofrequency energies.

Introduction Radiofrequency devices have been introduced for nonsurgical skin tightening of facial and non-facial skin. The mechanism of action of these devices involves an initial immediate collagen contraction and a secondary wound healing response producing collagen deposition and remodeling with skin tightening over time. There has been a great deal of controversy surrounding the use of these devices when they were first introduced for non-surgical skin tightening. With the advent of newer protocols utilizing lower energies and multiple passes, the safety and efficacy of radiofrequency devices is increasing.

Radiofrequency devices Radiofrequency devices can be divided into monopolar and bipolar categories (Table 54.1). Monopolar radiofrequency utilizes an electrical current passed from the radiofrequency energy source through a monopolar electrode in the handpiece and the current continues through the patient to the grounding pad, which completes the circuit. The Thermage device is an example of monopolar radiofrequency. Bipolar radiofrequency devices employ a closed system and are usually combined with other sources. Examples include systems using bipolar radiofrequency and light (electrooptical synergy systems), bipolar radiofrequency and

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

vacuum, and a combination of unipolar and bipolar radiofrequency to deliver different depths of radiofrequency current to the skin.

Monopolar radiofrequency Monopolar capacitive radiofrequency was the first commercially available device to be introduced for non-surgical skin tightening and is the most widely studied. The generation of heat occurs because of natural tissue resistance to the movement of electrons within a radiofrequency field which creates heat relative to the amount of current and time. The different components of skin (dermis, fat, subcutaneous tissue, muscle, and fibrous tissue) have varying resistance to the movement of radiofrequency energy. For example, the fibrous septa are heated more than the surrounding subcutaneous tissue. Controlled radiofrequency pulses selectively heat zones of the dermis and deeper tissue with the use of cryogen delivery to protect and cool the epidermis. A pressure-sensitive tip prevents the non-uniform application of energy to the skin and the cryogen delivery minimizes epidermal compromise and assists in comfort of the procedure. The initial approach to utilize monopolar radiofrequency for skin tightening employed very high fluencies with one to two treatments. The discharge time was slow and the protocol was to utilize the highest tolerable fluence with a single pass over the entire treated area. With this protocol, the results were modest at best with significant pain. Moreover, the discharge time of the tip was slow at 5–6 seconds. In addition to significant discomfort and high variability in efficacy, infrequent reports of subcutaneous tissue



Skin Modulation Techniques

Table 54.1 Examples of radiofrequency devices. Device


Thermacool (Solta Medical)

Unipolar radiofrequency

Aluma (Lumenis)

Bipolar radiofrequency

ELOS devices (Syneron)

Bipolar radiofrequency

Accent (Alma lasters)

Unipolar and bipolar radiofrequency

Figure 54.1 Subcutaneous atrophy from unipolar radiofrequency using old protocol with high fluencies.

depressions were reported (Figure 54.1). As a result, the treatment received much skepticism and criticism. The Thermacool device utilizes monopolar radiofrequency energy with a maximal output of 225 J/cm2 with a peak temperature 2–3 mm beneath the surface. Upon activation of the device, a cooling system which uses a cryogen spray is activated and internally precools the electrode. The cryogen continues to be delivered during (parallel cooling) and after (post-cooling) the energy delivery. The initial treatment cycle consisted of 6 seconds but the newer protocol is about 2 seconds. A new protocol was developed to overcome these limitations based on observations and studies demonstrating that low fluence delivery with multiple passes of monopolar radiofrequency can produce a more reproducible clinical endpoint. Histologic correlations to these findings demonstrated greater collagen denaturation at multiple passes using lower energies. In addition, lower energies produced less discomfort and greater patient satisfaction. A consensus panel published these findings with the following criteria: 1 Use of patient feedback about heat sensation as a valid and preferred method for selecting the optimal amount of energy; 2 Use of multiple passes at moderate energy settings to yield consistent efficacy; and


3 Treatment to a clinical endpoint of visible tightening and contouring for maximizing predictability and long-term results. With the original treatment protocol (single pass and high fluence) 26% of patients showed immediate tightening and 54% showed delayed tightening. With the new protocol, 87% showed immediate tightening and 92% noted tightening after 6 months, with 94% of patients of the patients showing satisfaction. The largest studied areas for monopolar radiofrequency are the midface, lower face, and neck. The technique with the new protocol utilizes a tip that can deliver up to 900 pulses using multiple low fluence passes (typically 450 per each side of the face and neck). Treatments are administered without any topical anesthesia or intravenous sedation, as patient feedback is critical for outcomes. Up to 10 passes are performed using this algorithm. The greatest challenge in all skin tightening modalities is patient selection and setting expectations. Because threedimensional changes are often difficult to capture in twodimensional photography, it is imperative to have a detailed and thorough consultation to set realistic expectations. In our practice, we perform a detailed consultation to discuss the realistic goals of monopolar radiofrequency and emphasize the variability in results. Standardized photography is absolutely critical with standardized lighting and angles to capture subtle changes. Our criteria for patient selection include the following: 1 Patients who are absolutely averse to any surgical procedures for laxity such as rhytidectomy. 2 Patients who have had rhytidectomy and are showing signs of laxity. 3 Patients who are not surgical candidates because of risks associated with surgery. 4 Post-surgical patients who still show some laxity. 5 Off face loose skin, for which there are no other options. We also offer this procedure to candidates who seek subtle body contouring, with emphasis on the word subtle.

Complications Complications with monopolar radiofrequency are rare. With the old protocol, subcutaneous depressions were seen. Common transient side effects include mild erythema and edema. Slight tenderness post-treatments have been reported. Lack of proper contact with the skin can produce burns. With the new protocol, there have been no reports of permanent complications. All skin types can be treated, as radiofrequency is truly color blind and does not compete with melanin chromophores. There have been no reports of postinflammatory hyperpigmentation.

Future directions New directions for monopolar radiofrequency are the introduction of several new tips to address specific areas. These

54. Radiofrequency devices include tips for eyelid rejuvenation and large area body contouring. Eyelid rejuvenation has been one of the most exciting and innovative developments in monopolar radiofrequency tips. A shallow 0.25 cm2 tip is utilized which delivers heat more superficially than the medium depth tips utilized for facial and body areas. Plastic corneoscleral shields are placed prior to treatment. Ideal candidates for eyelid treatment include patients with mild to moderate dermatochalasis and good skin tone and patients who have previously had blepharoplasty and show signs of skin laxity. With low fluence and multiple pass protocol, upper eyelid tightening and reduction of hooding has been seen in over 80% of patients. The newest addition to the tip armamentarium is the large diameter deep tip for large body areas. One of the limitations of treating large body areas has been the amount of time required for treatments. Recently, a 16 cm2 deep tip was introduced which has shortened the treatment time by 50%. This allows for more efficient treatments of large body areas such as abdomen, buttocks, and flanks.

Summary Monopolar radiofrequency, in summary, is the most widely studied modality for non-surgical skin tightening. The initial protocol has been modified with a low energy multiple pass algorithm to reduce discomfort and achieve more predictable outcomes. While midface and lower neck were the initial areas for treatments, the advent of varying depth tips has expanded the use for the treatment of eyelids and off face areas such as the abdomen, buttocks, and flanks. The biggest challenge in treatment outcomes is predictability of results, which are variable. Therefore, a thorough consultation setting realistic patient expectations and “underpromising” results are key for optimal outcomes. It is imperative to emphasize that these procedures are not a subsititute for surgery and will not address severe laxity.

To further enhance outcomes of monopolar radiofrequency treatments, combination therapy approaches are being investigated. Most recently, we have initiated combining non-ablative fractional resurfacing, monopolar radiofrequency, and dermal fillers. Combination therapy is becoming the mainstay of treatments for a variety of non-surgical procedures. The combined non-ablative fractional resurfacing and monopolar radiofrequency procedure has been coined “Thermafrax,” with the fractional resurfacing addressing dyschromia, superficial rhytids, and the monopolar radiofrequency addressing laxity. The treatments can be performed on the same day or as staged procedures. The radiofrequency treatments are performed first, as patient feedback is necessary and anesthesia cannot be used. This is followed by non-ablative fractional resurfacing. Dermal fillers are performed last for any volume depletion. Facial and non-facial skin can be effectively treated with this approach. Hand rejuvenation with combination of monopolar radiofrequency, non-ablative fractional resurfacing, and dermal fillers is becoming increasingly popular, with each modality complementing the other – radiofrequency addressing laxity, fractional resurfacing addressing dyschromia and photodamage, and fillers addressing volume loss (Figure 54.2).

Bipolar radiofrequency and light The second commercially introduced modality for non-invasive skin tightening employed the combination of bipolar radiofrequency and light energy devices (900 nm diode laser in a single pulse or broadband light in the 700–2000 nm wavelength in a single pulse). The theory behind the use of two technologies is the safer delivery of radiofrequency energy, with the optical component enabling the bipolar


(a) Figure 54.2 (a) Pre-Thermage and Fraxel laser. (b) Post-Thermage and Fraxel laser.



Skin Modulation Techniques

radiofrequency energy to concentrate where the optical energy has selectively heated the target. Optical energy levels of 30–50 J/cm2 with radiofrequency levels of 80–100 J/ cm2 are utilized in this mode. Three to four passes are usually performed and, unlike monopolar radiofrequency, 3–5 treatment sessions are necessary, as opposed to a single treatment. The main indication for bipolar radiofrequency and light combination devices is diminution of superficial rhytids. There may be some subtle tissue tightening. There is much controversy regarding the synergistic effects of light and radiofrequency energies. The use of lower optical energies makes this a safe device in all skin types. However, because the radiofrequency energy does not penetrate very deep into the skin, tissue arcing can occur with improper technique, resulting in scar formation. The majority of published clinical studies using these devices have focused on the treatment of mild to moderate rhytids with modest improvement. The amount of energy penetration with these devices does not produce deep volumetric heating and subsequent tightening compared with monopolar radiofrequency.

Bipolar radiofrequency and vacuum Bipolar radiofrequency with vacuum was introduced to reduce discomfort associated with radiofrequency devices. The bipolar radiofrequency energy with an accompanying vacuum apparatus allows the tissue into the vacuum and targets the radiofrequency energy to the deep dermis. Less energy is necessary for treatment efficacy, as the vacuum brings the electrodes closer to the dermis, with the additional benefit of reducing pain. The main indications for this technology are subtle improvement of fine rhytids and tissue tightening.

Unipolar and bipolar radiofrequency device Different depths of radiofrequency energy can be delivered to the skin – bipolar for more superficial heating and unipolar for deeper heating. It is a closed system and does not require grounding, as monopolar radiofrequency. Published data are limited and there is some evidence in the reduction of the appearance of cellulite and subtle tissue tightening.

Conclusions Non-surgical tissue tightening has evolved considerably since its first introduction. Monopolar radiofrequency using


a new treatment algorithm remains the gold standard of radiofrequency, with the largest series of published papers, longest clinical experience, and modifications for optimal outcomes. Bipolar radiofrequency in conjunction with light and vacuum offers more superficial treatments, and, most recently, a combined unipolar and bipolar radiofrequency device has been introduced with control of depths of radiofrequency energies. The greatest challenge in all modalities of radiofrequency treatments is predictability of outcomes. Patient selection with a thorough consultation reviewing realistic expectations is key for successful outcomes. The development of newer algorithms with standardized protocols is allowing for more reproducible outcomes in using these devices for nonsurgical skin tightening.

Further reading Alster TS, Tanzi E. (2004) Improvement of neck and cheek laxity with a nonablative radiofrequency device: a lifting experience. Dermatol Surg 30, 503–7. Biesman B, Baker SS, Carruthers J, Silva JL, Holloman EL. (2006) Monopolar radiofrequency treatment of human eyelids: a prospective multicenter efficacy trial. Lasers Surg Med 38, 890–8. Doshi SN, Alster TS. (2005) Combination radiofrequency and diode laser for treatment of facial rhytids and skin laxity. J Cosmet Laser Ther 7, 11–5. Dover JS, Zelickson BD. (2007) 14 physician multispecialty consensus panel. Results of a survey of 5700 patient monopolar radiofrequency facial skin tightening treatments: assessment of a low energy multiple pass technique leading to a clinical endpoint algorithm. Dermatol Surg 33, 900–7. Emilia del Pino M, Rosado RH, Azuela A, Graciela Guzmán M, Arqüelles D, Rodríguez C, et al. (2006) Effect of controlled volumetric tissue heating with radiofrequency on cellulite and the subcutaneous tissue of the buttocks and thighs. J Drugs Dermatol 5, 714–22. Fitzpatrick R, Geronemus R, Goldberg D, Kaminer M, Kilmer S, Ruiz-Esparza J. (2003) Multicenter study of noninvasive radiofrequency for periorbital tissue tightening. Lasers Surg Med 33, 232–2. Fritz M, Counters JT, Zelickson BD. (2004) Radiofrequency treatment for middle and lower face laxity. Arch Facial Plast Surg 6, 370–3. Gold MH. (2007) Tissue tightening: a hot topic utilizing deep dermal heating. Drugs Dermatol 6, 1238–42. Gold MH, Goldman MD, Rao J, Carcamo JS, Ehrlich M. (2007) Treatment of wrinkles and elastosis using vacuum assisted bipolar radiofrequency heating of the dermis. Dermatol Surg 33, 303–9. Jacobson LG, Alexiades-Armenakis M, Bernstein L, Geronemus RG. (2003) Treatment of nasolabial folds and jowls with a noninvasive radiofrequency device. Arch Dermatol 139, 1371–2. Lack EB, Rachel JD, D’Andrea L, Corres J. (2005) Relationship of energy settings and impedance in different anatomic areas using a radiofrequency device. Dermatol Surg 31, 1668–70.

54. Radiofrequency devices Sadick NS. (2005) Combination radiofrequency and light energies: electro-optical synergy technology in esthetic medicine. Dermatol Surg 31, 1211–7. Weiss RA, Weiss MA, Munavalli G, Beasley KL. (2006) Monopolar radiofrequency facial tightening: a retrospective analysis of effi-

cacy and safety in over 600 treatments. J Drugs Dermatol 5, 707–12. Yu CS, Yeung CK, Skek SY, Tse RK, Kono T, Chan HH. (2007) Combined infrared light and bipolar radiofrequency for skin tightening in Asians. Lasers Surg Med 39, 471–5.


Chapter 55: LED photomodulation for reversal of photoaging and reduction of inflammation Robert Weiss1, Roy Geronemus2, David McDaniel3, and Corinne Granger4 1

Maryland Laser Skin & Vein Institute, Hunt Valley, MD, and Johns Hopkins University School of Medicine, Baltimore, MD, USA Laser & Skin Surgery Center of New York, NY, and New York University Medical Center, New York, NY, USA 3 Laser Skin & Vein Center of Virginia, and Eastern Virginia Medical School, Virginia Beach, VA, USA 4 L’Oréal Research, Asnières, France 2

BAS I C CONCE P T S • Photomodulation uses of non-thermal light treatments to regulate the activity of cells rather than to invoking thermal wound healing mechanisms. • Photomodulation stimulates cells to perform certain functions using light packets that are low energy and enhance cell metabolism. • LED arrays for photomodulation are useful for collagen stimulation, textural smoothing, and reduction of inflammation.

Introduction Photorejuvenation encompasses many procedures using light or laser-based technology to reverse the effects of photoaging. Photoaging, a huge component of which is dermal collagen degeneration, is compounded by environmental damage including smoking, pollutants, and other insults causing free radical formation. Non-ablative photorejuvenation refers to the controlled use of thermal energy to accomplish skin rejuvenation without disturbance of the overlying epidermis and with minimal to no down-time. Currently employed non-ablative modalities include primarily intense pulsed light (IPL), visible wavelengths including pulsed dye laser (PDL), and 532 nm green light (KTP laser) [1]. Various infrared wavelengths with water as the target are used for remodeling dermal collagen. Because absorption by melanin is negligible, these devices can be used for all skin types and these include 1064, 1320, 1450, and 1540 nm [2,3]. The primary mechanism of action is thermal injury either by heating the dermis to stimulate fibroblast proliferation or by heating blood vessels for photocoagulation [4–6]. The newest way to deliver these wavelengths is by fractionating the dose through microlenses that allow microthermal zones surrounded by normal skin [7]. A non-thermal mechanism, which represents a fundamental change in thinking, is the theory of photomodula-

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


tion. This concept involves the stimulation of cells to perform certain functions using light packets that are low energy and stimulate cell metabolism. This novel approach to photoaging uses non-thermal light treatments to regulate activity of cells rather than to invoke thermal wound healing mechanisms [8,9]. This incurs far less risk for patients than other light modalities. The first written report on using photomodulation to improve facial wrinkles was in 2002 [10]. Photomodulation was first discovered from use of LED and low energy light therapy (LILT) in stimulating growth of plant cells [11]. The belief that cell activity can be upregulated or downregulated by low energy light had been discussed in the past, but consistent or impressive results had been lacking [12,13]. Some promise had been shown with wound healing for oral mucositis [13]. Wavelengths previously examined included a 670 nm LED array [13], a 660 nm array [14], and higher infrared wavelengths [15]. Fluence and duration of exposure were variable in these studies with high energy required for modest results [13]. To investigate LED light for rejuvenation purposes, a fibroblast culture model was utilized in conjunction with clinical testing. Particular packets of energy with specific wavelengths combined with using a very specific propriety pulse sequencing “code” were found to upregulate collagen I synthesis in fibroblast culture using reverse transcription polymerase chain reaction (RT-PCR) to measure collagen I [10]. The upregulation of fibroblast collagen synthesis correlated with the clinical observation of increased dermal collagen on treated human skin biopsies [16]. Curiously, both in the fibroblast and clinical model, collagen synthesis was accompanied by reduction of matrix metalloproteinases

55. LED photomodulation (MMP). In particular, MMP-1 (collagenase) was greatly reduced with exposure to 590–870 nm low energy light. Use of very low energy, narrow band light with specific pulse code sequences and durations was termed LED photomodulation by McDaniel et al. [10]. A device that utilizes pulsed code sequences of LED light to induce photomodulation was termed Gentlewaves® (Gentlewaves, Inc., Charlotte, NC, USA) and patented by McDaniel.

Clinical applications LED photomodulation can be used both alone and in combination with a variety of common, non-ablative, rejuvenation procedures in an office setting. Several anti-inflammatory and wound healing applications are also possible. Treatments were delivered using the yellow/infrared light LED photomodulation unit with a full face panel. Energy density was set at 0.15 J/cm2 and 100 pulses were delivered with a pulse duration of 250 ms and an off interval of 100 ms. Treatment time was approximately 35 seconds.

Photorejuvenation This technique was evaluated on 6000+ patients over the last 6 years. Of these treatments, 10% were LED photomodulation alone and 90% were concomitant with a thermal-based photorejuvenation procedure. Using specific pulsing sequence parameters, which are the basis for the LED photomodulation “code,” the original multicenter clinical trial was conducted with 90 patients receiving a series of eight LED treatments over 4 weeks [17–20]. This study

showed positive results, with over 90% of patients improving by at least one Fitzpatrick photoaging category and 65% of the patients demonstrating global improvement in facial texture, fine lines, erythema, and pigmentation. Results peaked at 4–6 months following completion of a series of eight treatments [20]. Another retrospective study, using the same 590–870 nm LED array (Gentlewaves®), demonstrated similar results (Figure 55.1). These results were confirmed by digital microscopy [21]. Most recently, the 590 nm LED array was used in an independent clinical laboratory confirming the findings (data on file, L’Oréal Research, France). An additional clinical trial involving 65 subjects used silicone replica impressions of lateral canthal wrinkles (crow’s feet). These replicas, illuminated by reproducible lighting both parallel and perpendicular to each wrinkle, were analyzed with image-analyzing software (Quantirides, Monaderm, Monaco). The analysis showed a significant reduction in the number of wrinkles 2–4 months after treatment accompanied by a significant reduction in the length of wrinkles at 5 months post-treatment. Subject self-assessment showed significant improvement in skin wrinkles, texture, softness, and radiance. Others have confirmed that additional wavelengths of LED light, using red and infrared wavelengths, may be effective for skin texture improvement. Although these treatments were longer in duration, 36 patients receiving nine treatments over a 5-week period showed improvement in skin softness [22]. Each treatment was administered in continuous mode, without pulsing, with a treatment time of 20 minutes using 633 and 830 nm as an LED array (Omnilux™, Phototherapeutics, Altrincham, Cheshire, UK). Another


(a) Figure 55.1 Smoothing of the skin seen after eight treatments over 4 weeks of Gentlewaves® photomodulation (Gentlewaves, Inc., Charlotte, NC, USA) (a) Before treatments. (b) Eight weeks after baseline. Reduction in wrinkles, pigmentation and improvement of texture are noted.



Skin Modulation Techniques

recent report using this system studied 31 subjects with facial rhytids who received nine light therapy treatments using combined wavelengths of 633 and 830 nm. Fluences were relatively high utilizing 126 J/cm2 for 633 nm and 66 J/ cm2 for 830 nm. Improvements to the skin surface were reported at weeks 9 and 12 by profilometry performed on periorbital replicas. Results showed that 52% of subjects showed a 25–50% improvement in photoaging scores [23]. In the USA, the first Food and Drug Administration (FDA) cleared LED device to be used in the reduction of periocular wrinkles was in 2005 (Gentlewave; Figure 55.2). Other devices (Omnilux™, Photo Therapeutics Ltd., Altrincham, Cheshire, UK) then followed.

Figure 55.2 Gentlewaves LED photomodulation device. Array of LEDs.

Anti-inflammatory effects Photomodulation can also be used for the reduction of erythema from a variety of causes. Erythema may be induced from wide ranging skin injuries including but not limited to thermal laser treatments, UV burns, radiation therapy, blunt trauma, and skin disease. Treatment of atopic eczema in patients withdrawn from all topical medications led to resolution with 3–4 treatments over 1–2 weeks (Figure 55.3). Use of LED photomodulation in combination with other laser modalities may results in faster erythema resolution. The enhanced erythema resolution may be a result of the anti-inflammatory effects of LED photomodulation. The mechanism has not yet been elucidated but downregulation of inflammatory mediators from lymphocytes or macrophages is possible. Studies on human skin fibroblasts treated with LED photomodulation have shown a reduction in interleukins IL-1B1 and IL-6 [24]. A recent study looked at whether LED photomodulation therapy could accelerate resolution of post-intense pulsed light (IPL) erythema [25]. Fifteen subjects were randomized to receive LED treatment to one side of the face immediately following a single IPL treatment for photodamage. Results showed mean erythema scores on the first visit were statistically significantly lower on the LED-treated side. This led the authors to conclude that LED photomodulation treatment may accelerate resolution of erythema following IPL treatment [25]. A study on radiation dermatitis examined whether LED photomodulation could alter and improve the outcome of intensity-modulated radiation treatments (IMRT) on overlying breast skin. Nineteen patients with breast cancer were


(a) Figure 55.3 (a) Before shows flare of eczema following withdrawal of all therapy. (b) Atopic eczema after three treatments with Gentlewave LED photomodulation. The after image (b) shows effects of reduction of inflammation by LED photomodulation within 10 days.


55. LED photomodulation treated with LED photomodulation immediately after every radiation session. Treatments were administered to postlumpectomy patients receiving a full course of IMRT [26]. Skin reactions were monitored weekly using National Cancer Institute (NCI) criteria for grading. Age-matched controls (n = 28) received IMRT without LED photomodulation. The results of this study showed that LED treatment had a significantly positive effect. Of the LED treated patients, 94.7% (18) had grade 0 or 1 reaction and 5.3% (1) had a grade 2 reaction. Among controls, 4 (14.3%) had a grade 1 reaction and 24 (85.7%) had a grade 2 or 3 reaction. Of the non-LED treated group, 67.9% had to interrupt treatment because of side effects of skin breakdown with moist reactions but only 5% of the LED treated group had interrupted treatment. The authors concluded that not only did LED photomodulation treatments delivered immediately after each IMRT reduce the incidence of adverse NCI criteria skin reactions, but also allowed the full course of treatment and resulted in a final smoother skin texture with improved skin elasticity post-radiation treatment. Additional data indicates an anti-inflammatory effect for LED photomodulation following UV-induced erythema. Using a solar simulator, findings indicate a photoprotective effect when delivered after UV radiation [24]. This concept is a rescue from UV damage even after inadvertant UV radiation has occurred. We have observed a reduction in UV erythema when LED photomodulation was supplied within hours after UV exposure. The use of 590–870 nm LED photomodulation produced significant downregulation of dermal matrix degrading enzymes, which were stimulated by the UV exposure [24]. Additionally, a pilot study with precise CO2 laser epidermal destruction has shown promise with using this device for accelerated wound healing. Parallel to wound healing, use of photomodulation has been extended to a protective or preventative effect following several types of toxic injury. Experiments using LED light to protect the retina against the toxic actions of methanol-derived formic acid in a rodent model of methanol toxicity have been successful. In a recent study, LED treatment protected the retina from the histopathologic changes induced by methanol on mitochondrial oxidative metabolism in vitro and retinal protection in vivo [27]. Photomodulation may enhance recovery from retinal injury and other ocular diseases in which mitochondrial dysfunction is postulated to have a role. Human retinal pigment epithelial (RPE) cells were treated with LED photomodulation produced by acute injury from blue light wavelengths [28]. The results showed reduction of cell death at 24 hours from 94% to 10–20%. Another in vitro test on human RPE cells showed a sevenfold reduction in vascular endothelial growth factor (VEGF) expression at 24 hours post-LED exposure using LED photomodulation at 590–870 nm delivered at 0.1 J/cm2 [29].

Photodynamic therapy LED red light (630 nm) has been used in combination with a sensitizer (levulinic acid) for photodynamic therapy (PDT) [30]. When exposed to light with the proper wavelength, the sensitizer produces an activated oxygen species, singlet oxygen, that oxidizes the plasma membrane of targeted cells. As a result of a lower metabolic rate, there is less sensitizer in the adjacent normal tissue, thus less of a reaction. One of the absorption peaks of the metabolic product of levulinic acid, protoporphyrin, absorbs strongly at 630 nm red. A red LED panel emitting at 630 nm (Omnilux PDT™, Phototherapeutics, Altrincham, Cheshire, UK) has been used for this purpose in Europe and Asia [31]. A full panel 590 nm LED array has also been used for facilitating PDT. This therapy is delivered by application of levulinic acid (Levulan™, DUSA, Wilmington, MA, USA) for 45 minutes and exposure to continuous (non-pulsed) 590–870 nm LED for 15 minutes for a cumulative dose of over 70 J/cm2. The results show reduction in actinic damage including improvement of skin texture and reduction of actinic keratoses [32]. The primary means for photomodulated upregulation of cell activity for collagen synthesis by LED is the activation of energy switching mechanisms in mitochrondria, the energy source for cellular activity. Cytochrome molecules are believed to be responsible for the light absorption in mitochrondria. Cytochromes are synthesized from protoporphyrin IX and absorb wavelengths of light from 562 to 600 nm. It is believed that LED light absorption causes conformational changes in antenna molecules within the mitochrondrial membrane. Proton translocation initiates a pump, which ultimately leads to energy for conversion of adenosine diphosphate (ADP) to adenosing triphosphate (ATP). This essentially recharges the “cell battery” and provides more energy for cellular activity. Others have confirmed that mitochrondial ATP availability can influence cellular growth and reproduction, with lack of mitochrondrial ATP associated with oxidative stress [33]. Cellular aging may be associated with decreased mitochrondial DNA activity [34]. It has been concluded that LED light represents a novel, non-invasive, therapeutic intervention for the treatment of numerous diseases linked to mitochondrial dysfunction [35]. Previous work has also demonstrated rapid ATP production within mitochrondia of cultured fibroblasts exposed to 590–870 nm yellow/infrared LED light only with the proper pulsing sequence [9,36]. New ATP production occurs rapidly after LED photomodulation, triggering subsequent metabolic activity of fibroblasts [19]. There also appear to be receptor-like mechanisms, which result in modulation of the expression of gene activity producing upregulation or downregulation of gene activity as well as wide-ranging cell signaling pathway actions. The choice of photomodulation parameters has a vital role in determining the overall pattern



Skin Modulation Techniques

of gene upregulation and/or downregulation. In our experience, use of LED yellow/infrared light without the proper pulsing sequence leads to minimal or no consequences on mitochrondrial ATP production.

Conclusions LED arrays for photomodulation are useful for collagen stimulation, textural smoothing, and reduction of inflammation. Pilot wound healing studies show slightly accelerated wound resolution. Cellular rescue from UV damage and other toxic insults has been shown in small studies. Thermal, non-ablative photorejuvenation and non-thermal LED photomodulation have a synergistic effect. LED photomodulation is delivered immediately subsequent to the thermal-based treatment for its anti-inflammatory effects, which may reduce the thermally induced erythema and edema of nonablative treatments. Delivery of LED light immediately before and after thermal injury appears to increase antiinflammatory and protective effects.

References 1 Weiss RA, Weiss MA, Beasley KL, Munavalli G. (2005) Our approach to non-ablative treatment of photoaging. Lasers Surg Med 37, 2–8. 2 Munavalli GS, Weiss RA, Halder RM. (2005) Photoaging and nonablative photorejuvenation in ethnic skin. Dermatol Surg 31, 1250–60. 3 Weiss RA, McDaniel DH, Geronemus RG. (2003) Review of nonablative photorejuvenation: reversal of the aging effects of the sun and environmental damage using laser and light sources. Semin Cutan Med Surg 22, 93–106. 4 Weiss RA, Gold M, Bene N, Biron JA, Munavalli G, Weiss M, et al. (2006) Prospective clinical evaluation of 1440-nm laser delivered by microarray for treatment of photoaging and scars. J Drugs Dermatol 5, 740–4. 5 Weiss RA, Goldman MP, Weiss MA. (2000) Treatment of poikiloderma of Civatte with an intense pulsed light source. Dermatol Surg 26, 823–7. 6 Fatemi A, Weiss MA, Weiss RA. (2002) Short-term histologic effects of nonablative resurfacing: results with a dynamically cooled millisecond-domain 1320 nm Nd:YAG laser. Dermatol Surg 28, 172–6. 7 Bogle MA. (2008) Fractionated mid-infrared resurfacing. Semin Cutan Med Surg 27, 252–8. 8 Weiss RA, McDaniel DH, Geronemus RG. (2003) Review of nonablative photorejuvenation: reversal of the aging effects of the sun and environmental damage using laser and light sources. Semin Cutan Med Surg 22, 93–106. 9 McDaniel DH, Weiss RA, Geronemus R, Ginn L, Newman J. (2002) Light-tissue interactions I: photothermolysis vs photomodulation laboratory findings. Lasers Surg Med 14, 25. 10 McDaniel DH, Weiss RA, Geronemus R, Ginn L, Newman J. (2002) Light-tissue interactions II: photothermolysis vs photomodulation clinical applications. Lasers Surg Med 14, 25.


11 Whelan HT, Smits RL Jr, Buchman EV, Whelan NT, Turner SG, Margolis DA, et al. (2001) Effect of NASA light-emitting diode irradiation on wound healing. J Clin Laser Med Surg 19, 305–14. 12 Whelan HT, Buchmann EV, Dhokalia A, Kane MP, Whelan NT, Wong-Riley MT, et al. (2003) Effect of NASA light-emitting diode irradiation on molecular changes for wound healing in diabetic mice. J Clin Laser Med Surg 21, 67–74. 13 Whelan HT, Connelly JF, Hodgson BD, Barbeau L, Post AC, Bullard G, et al. (2002) NASA light-emitting diodes for the prevention of oral mucositis in pediatric bone marrow transplant patients. J Clin Laser Med Surg 20, 319–24. 14 Walker MD, Rumpf S, Baxter GD, Hirst DG, Lowe AS. (2000) Effect of low-intensity laser irradiation (660 nm) on a radiationimpaired wound-healing model in murine skin. Lasers Surg Med 26, 41–7. 15 Lowe AS, Walker MD, O’Byrne M, Baxter GD, Hirst DG. (1998) Effect of low intensity monochromatic light therapy (890 nm) on a radiation-impaired, wound-healing model in murine skin. Lasers Surg Med 23, 291–8. 16 Weiss RA, McDaniel DH, Geronemus RG, Weiss MA, Beasley KL, Munavalli GM, et al. (2005) Clinical experience with light-emitting diode (LED) photomodulation. Dermatol Surg 31, 1199–205. 17 Weiss RA, McDaniel DH, Geronemus RG, Weiss MA. (2005) Clinical trial of a novel non-thermal LED array for reversal of photoaging: clinical, histologic, and surface profilometric results. Lasers Surg Med 36, 85–91. 18 McDaniel DH, Newman J, Geronemus R, Weiss RA, Weiss MA. (2003) Non-ablative non-thermal LED photomodulation: a multicenter clinical photoaging trial. Lasers Surg Med 15, 22. 19 Geronemus R, Weiss RA, Weiss MA, McDaniel DH, Newman J. (2003) Non-ablative LED photomodulation: light activated fibroblast stimulation clinical trial. Lasers Surg Med 25, 22. 20 Weiss RA, McDaniel DH, Geronemus R, Weiss MA, Newman J. (2004) Non-ablative, non-thermal light emitting diode (LED) phototherapy of photoaged skin. Lasers Surg Med 16, 31. 21 Weiss RA, Weiss MA, Geronemus RG, McDaniel DH. (2004) A novel non-thermal non-ablative full panel led photomodulation device for reversal of photoaging: digital microscopic and clinical results in various skin types. J Drugs Dermatol 3, 605–10. 22 Goldberg DJ, Amin S, Russell BA, Phelps R, Kellett N, Reilly LA. (2006) Combined 633-nm and 830-nm led treatment of photoaging skin. J Drugs Dermatol 5, 748–53. 23 Russell BA, Kellett N, Reilly LR. (2005) A study to determine the efficacy of combination LED light therapy (633 nm and 830 nm) in facial skin rejuvenation. J Cosmet Laser Ther 7, 196–200. 24 Weiss RA, McDaniel DH, Geronemus RG, Weiss MA. (2005) Clinical trial of a novel non-thermal LED array for reversal of photoaging: clinical, histologic, and surface profilometric results. Lasers Surg Med 36, 85–91. 25 Khoury JG, Goldman MP. (2008) Use of light-emitting diode photomodulation to reduce erythema and discomfort after intense pulsed light treatment of photodamage. J Cosmet Dermatol 7, 30–4. 26 DeLand MM, Weiss RA, McDaniel DH, Geronemus RG. (2007) Treatment of radiation-induced dermatitis with light-emitting diode (LED) photomodulation. Lasers Surg Med 39, 164–8.

55. LED photomodulation 27 Eells JT, Henry MM, Summerfelt P, Wong-Riley MT, Buchmann EV, Kane M, et al. (2003) Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proc Natl Acad Sci U S A 100, 3439–44. 28 Eells JT, Henry MM, Summerfelt P, Wong-Riley MT, Buchmann EV, Kane M, et al. (2003) Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proc Natl Acad Sci U S A 100, 3439–44. 29 McDaniel DH, Weiss RA, Geronemus R, Weiss MA. (2006) LED photomodulation ‘reverses’ acute retinal injury. Annual meeting of the American Society for Laser Medicine and Surgery, Boston, MA, April 6, 2006. 30 Tarstedt M, Rosdahl I, Berne B, Svanberg K, Wennberg AM. (2005) A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 85, 424–8. 31 Chen HM, Yu CH, Tu PC, Yeh CY, Tsai T, Chiang CP. (2005) Successful treatment of oral verrucous hyperplasia and oral






leukoplakia with topical 5-aminolevulinic acid-mediated photodynamic therapy. Lasers Surg Med 37, 114–22. Weiss RA, McDaniel DH, Geronemus RG, Weiss MA, Beasley KL, Munavalli GM, et al. (2005) Clinical experience with light-emitting diode (LED) photomodulation. Dermatol Surg 31, 1199–205. Zhang X, Wu XQ, Lu S, Guo YL, Ma X. (2006) Deficit of mitochondria-derived ATP during oxidative stress impairs mouse MII oocyte spindles. Cell Res 16, 841–50. Sorensen M, Sanz A, Gomez J, Pamplona R, Portero-Otin M, Gredilla R, et al. (2006) Effects of fasting on oxidative stress in rat liver mitochondria. Free Radic Res 40, 339–47. Desmet KD, Paz DA, Corry JJ, Eells JT, Wong-Riley MT, Henry MM, et al. (2006) Clinical and experimental applications of NIRLED photobiomodulation. Photomed Laser Surg 24, 121–8. Weiss RA, Weiss MA, McDaniel DH, Newman J, Geronemus R. (2003) Comparison of non-ablative fibroblast photoactivation with and without application of topical cosmeceutical agents. Lasers Surg Med 15, 23.


Part 5: Skin Contouring Techniques Chapter 56: Liposuction: Manual, mechanical, and laser assisted Emily Tierney1,2 and C. William Hanke3 1

Laser and Skin Surgery Center of Indiana, Carmel, IN, USA Department of Dermatology, Boston University School of Medicine, Boston, MA, USA 3 University of Iowa, Carver College of Medicine, Iowa City, IA, and Indiana University School of Medicine, Indianapolis, IN, USA 2

BAS I C CONCE P T S • The safety profile for liposuction is significantly improved when tumescent local anesthesia technique is employed. • Tumescent local anesthesia utilizing lidocaine with epinephrine allows the removal of large volumes of fat with minimal associated blood loss and postoperative morbidity. • Liposuction is a procedure for patients who are either at or approaching their goal weight, to achieve a more esthetic figure, contour, and shape in conjunction with a diet and exercise regimen. • Preoperative consultation, setting realistic patient expectations for improvement, establishing patients’ overall health status and past medical history and discussion of risks and benefits of the procedure are critical to the success of the procedure. • Laser-assisted tumescent liposuction has been purported to result in mechanical cavitation of fat, resulting in greater ease of suction and greater skin retraction; however, additional studies are needed to confirm these results.

Introduction: history of liposuction with tumescent local anesthesia The early history of liposuction begins with Fischer’s description of hollow cannula liposuction in 1976 [1]. Shortly thereafter, Ilouz, a Frenchman trained in obstetrics and gynecology, and Fournier, a general surgeon, began practicing liposuction using the “wet technique,” involving injection of hypotonic saline and hyaluronic acid into the fat prior to suction [2]. Fournier pioneered the “criss-cross” technique and syringe liposuction and became a teacher of the technique [3]. Shortly thereafter, in 1977, an American dermatologist, Lawrence Field, visited Paris and learned about liposuction and published his experience with the technique in 1984. Jeffrey Klein, an American dermatologist, was the first to publish a report of liposuction using exclusively tumescent local anesthesia (TLA) in 1987 [4]. Prior to this point, the pain associated with liposuction had necessitated the procedure be performed under general anesthesia.

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


In 1988, Hanke and Bernstein published a report on the safety of the TLA technique for liposuction, reporting the results of 9478 patients treated by dermatologists [5]. Shortly after attending Fournier’s liposuction course in Paris, William Hanke, the editor-in-chief of the Journal of Dermatologic Surgery and Oncology, commissioned an issue of the dedicated to liposuction. Further innovations to the field evolved with the publication by Hanke and colleagues documenting the safety of TLA in 15 336 patients in 1995 [6]. Additionally, while initial reports by Klein established the safety of tumescent liposuction using a lidocaine dose of 35 mg/kg in 1990 [4], Ostad et al. [7] reported the safety at a total dose of 55 mg/kg. In 2000, Klein published a book entitled Tumescent Technique [8], highlighting many of his important contributions to the field including: TLA technique, the Klein microcannula, Klein infiltration pumps, multihole Klein Capistrano cannulas, and specific techniques for treating all body areas. Since Klein’s introduction of the technique of TLA for liposuction in 1987, it has revolutionized the technique among dermatologic surgeons and surgeons of all specialties performing the procedure. Liposuction with TLA facilitates the removal of large volumes of fat with minimal blood loss or postoperative morbidity, excellent esthetic results, and a remarkably superior safety profile to general anesthesia.

56. Liposuction

Table 56.1 Appropriate liposuction candidate selection. Does the patient have realistic expectations of the procedure? Is the patient at or near goal body weight? Is the patient in good health in the absence of anticoagulant therapy? Does the patient have localized fat deposits on the body that are diet and exercise resistant for which they are seeking treatment? Does the patient have good or adequate skin tone?

Physiology: what skin contour problem does the procedure address and how does this procedure alter the contour problem? Liposuction is a procedure that can assist patients to achieve a more idealized and balanced body contour (Table 56.1) [9–12]. It is designed for individuals at their ideal body weight who seek correction of a single or multiple anatomic sites with focal excess adiposity and laxity [9–12]. The ideal liposuction patient is a patient of ideal body weight with focal disproportionate adiposity, resulting in contour deformity [9–12]. Importantly, liposuction is not a weight loss procedure, and it should be emphasized that patients seeking the goal of weight loss are not good candidates for the procedure (Table 56.1) [9–12]. In initial patient consultations, it is important to set realistic patient expectations for the results of the procedure. The results of liposuction in all anatomic sites are limited by the existing bony structure, the texture and quality of the skin, the tone and build of muscle, and the pre-existing adiposity in areas not amenable to liposuction. Liposuction can help to achieve a more idealized and balanced body contour, and patients will largely vary in seeking correction of a single area or multiple anatomic sites to achieve their own personal optimal correction.

Advantages and disadvantages Liposuction with TLA allows the removal of large volumes of fat with minimal blood loss or postoperative morbidity, excellent cosmesis, and a remarkable safety profile. TLA techinique with the use of a dilute epinephrine and anesthetic achieves the aims of hemostasis and anesthesia at the surgical site [13–17]. The advantages of the technique include improved safety, precision, and patient convenience [13–17]. These advances have contributed to the enhanced safety profile and widespread growth in the popularity of the liposuction technique [13–17]. TLA can be utilized for any anatomic site treated with liposuction, from the neck to the ankles.

Figure 56.1 A 2-L liposuction cannula, filled with liposuction aspirate.

Advantages of the TLA technique include a significant reduction in blood loss attributed to the vasoconstrictive effects of epinephrine. This can be quantified by comparing the aspirate from TLA (containing 1–3% whole blood) with that from the procedure performed under general anesthesia (40% whole blood) [15]. Improved hemostasis results in both decreased blood loss as well as decreased bruising and discomfort for the patient in the postoperative phase [15]. In addition, the anesthetic and vasoconstrictive effects of the TLA are directed towards the sites being treated, resulting in prolonged anesthesia of several hours’ duration as a result of the reservoir effect of TLA [12–15]. This results in decreased reliance upon postoperative narcotics. The TLA solution also results in a hydrodissection effect, whereby the pressure of the solution allows easier and more uniform penetration and removal of adipose tissue by the cannula (Figures 56.1 and 56.2) [4–8, 12–15]. Tumescent fluid enlarges, magnifies, and lifts targeted fat, allowing for more precise removal of fat [4–8, 12–15]. With proper technique for infusion of the tumescent fluid, TLA can be performed without ancillary sedation and intravenous or general anesthesia [14,15]. With TLA, patient convenience is significantly enhanced during the perioperative recovery period where there is more rapid recovery [14–24]. In contrast, the recovery is much more prolonged after general anesthesia, both as a result of the after-effects of the anesthetic and from the increased bruising and discomfort associated with the procedure [14–24]. Complications with the TLA technique include discomfort, swelling, bruising, temporary loss of sensation, postinflammatory hyperpigmentation, and minimal scarring at the



Skin Contouring Techniques

incision sites but these are significantly less than those associated with the procedure performed under general anesthesia [14–24]. Potential risks of liposuction under general anesthesia are significantly greater and include deep venous thrombosis or pulmonary embolus, abdominal or other organ perforation, infection, and bleeding [21,23].

Figure 56.2 Blanching of skin visible after infusion of tumescent anesthesia with tumescent local anesthesia (TLA) technique.

Indications for tumescent liposuction, by anatomic site Abdomen Patient selection has a significant role in liposuction surgery of the abdomen. Patients should be within 10–25 lb (5– 12 kg) of their ideal body weight and should have good to excellent skin tone which will assist with skin contraction after the procedure [25]. The overall body shape of the patient should be examined during the preoperative physician examination [25]. The patient should be marked while standing to identify the larger areas of fatty deposition in the abdomen [25]. Incision sites are made in the following locations: two to three in the suprapubic region, one at the umbilicus, and two on the lateral portions of the umbilical fat depositions [25]. The patient should be lying on his or her back for the procedure; however, towards the end of the procedure, it is helpful if the patient lies in both lateral decubitus positions to identify pockets of fat as they fall away from the rectus muscle [25]. The goal of abdominal liposuction should be to reduce the deeper fatty layers while preserving a superficial, even layer of fat attached to the skin [25]. Oversuction can lead to dimpling of the skin, uneven fat deposits, and dermal necrosis [25]. Patients in group 1 (Table 56.2), lower abdomen only, are typically thin patients with a localized fatty deposition in the lower abdomen alone (Figure 56.3) [25]. These patients tend to respond very well to liposuction with high patient satisfaction.




Figure 56.3 Lower abdomen, anterior view: (a) pretreatment; (b) post-treatment.

56. Liposuction Patients in group 2 (Table 56.2), requiring liposuction of both the upper and lower abdomen, must be carefully evaluated (Figure 56.4) [25]. This group may also be relatively thin; however, if suction of the lower abdomen alone is performed, they may have a protuberant overhanging upper abdomen [25]. Therefore, it is important to perform liposuction on both segments of the abdomen to ensure a proportionate appearance. Patients requiring liposuction of the upper and lower abdomen in addition to the hips, waist, and back (group 3; Table 56.2; Figure 56.5) tend to be older postmenopausal women or those on hormone replacement therapy with a history of weight gain [25]. Men requesting liposuction of the abdomen may require more widespread liposuction to ensure a proportionate appearance as fat deposits in men in the abdomen are usually accompanied by excess fat on the chest, flanks, and back [25]. Many men are not good candidates for abdominal liposuction as much of the fat deposits are behind the rectus abdominus and thus are not accessible to suction during the liposuction procedure [25]. Table 56.2 Five groups of patients: abdominal liposuction. 1. Liposuction: lower abdomen 2. Liposuction: upper and lower abdomen 3. Liposuction: hourglass abdomen; upper and lower abdomen, hips, waist, and back 4. Liposuction and skin excision: mini-abdominoplasty with or without umbilical translocation 5. Complete abdominoplasty

Figure 56.4 Lower abdomen and hips liposuction, lateral view: (a) pretreatment; (b) post-treatment.

The fourth group of patients (Table 56.2) demonstrate atrophic, stretched skin from pregnancy, advancing age, and rapid fluctuations changes in weight [25]. More extensive liposuction is needed in these patients and liposuction alone is often not satisfactory. Waiting 3–4 months after the procedure will allow the physician to assess if liposuction alone is sufficient or if the patient will require abdominoplasty procedure to address skin redundancy [25].

Hips, outer thighs, and buttocks Evaluation of patients for liposuction in these anatomic sites requires a three-dimensional and universal approach to all anatomic site, otherwise a disproportionate appearance can result with more noticeable enlargement in the unsuctioned areas after suction of localized fat deposits. For the hips, outer thigh, and buttocks, it is important to observe review carefully with the patient all changes in underlying musculature, cellulite, and inelastic skin, none of which can be improved with liposuction. For the hips, the patient should be placed in the lateral decubitus position. For the thighs, the patient should also be in the lateral decubitus position with a pillow placed between the legs, which mimics the standing position and allows the femur to be directed anteriomedially [20]. The end result of suctioning should be that a region is flat, not concave [25]. Suctioning should also be equal on both sides and careful steps should be taken to monitor that relatively equivalent amounts of fat are removed from either side [25]. Liposuction of the buttocks must be performed carefully, with special consideration to the inferolateral gluteal crease, where a banana roll, comprised of a defined infragluteal fat





Skin Contouring Techniques



Figure 56.5 Lower abdomen, hips, and lateral thigh liposuction, lateral view: (a) pretreatment; (b) post-treatment.


(a) Figure 56.6 Arm, anterior view: (a) pretreatment; (b) post-treatment.

pocket, may worsen or lead to an atrophic buttock in the event of oversuction [25]. Physical examination must focus on bony and muscular prominences and asymmetry. Realistic expectations must be established with the patient as liposuction will not assist with underlying bony asymmetry, the presence of large or asymmetrical muscle masses, or skin laxity. Conservative buttock suction is recommended with removal of no more than 30–50% of fat from the middle and deep fat layers [25]. Superficial suctioning of the buttocks should be avoided as it is likely to result in undesirable dimpling.

Arms Liposuction of the arms is performed in women with laxity of the proximal arm musculature and who have a pendulous fatty protuberance of the posterior, lateral, or anterior upper arm (Figure 56.6). The fat distribution in the arms is best visualized when the arms are extended at 90 ° from the body. Avoiding oversuctioning is critical for the arms and


gentle liposuction should only be performed in the medial and posterior (extensor arms). As skin redundancy often contributes significantly to laxity of the arms, patients need to be advised that the goal is to decrease the convexity of the arms as opposed to complete removal of all redundancy of skin and soft tissue. Excessive tumescent solution should be avoided in the upper arm region as there is a small risk for creation of “compartment syndrome” whereby a functional tourniquet develops distal to the infused region, brought about by fluidinduced compression of neural, vascular, and lymphatic structures in the area. One position for the procedure is to lay the patient’s arms entirely flat with palms facing down over the hips with the body in a lateral decubitus position, which will serve to maximally expose the posterior portion of the arm. The other position that is helpful is for the patient to be in a supine or lateral decubitus position with a hand brought behind the head, forearm flexed, and elbow pointing out,

56. Liposuction which also exposes the posterior portion of the arm. Liposuction to the axilla should be avoided given the risks of damage to the branches of the brachial plexus in this area.

Neck and jowls The goal of liposuction of the neck and jowls is to give improved definition of the cervicomental angle and jawline [26–30]. Aging in this region can be caused by a multitude of factors, including ptosis of fatty tissue and decreased elastic tissue. These changes in the subcutaneous tissue of the neck allow the anterior margins of the platysma to slide forward and result in protrusion of the submental and submandibular fat [26–30]. Patients with excess laxity in this area may benefit from a spectrum of procedures, including facelifts, chin implants, platysmal plication, and CO2 laser resurfacing, and thus optimal selection of patients who will benefit from liposuction in this area is critical (Figure 56.7) [26–30]. Fullness in the neck and jowls can be attributed to a variety of factors, including redundant skin, muscle, or a low

or anteriorly positioned hyoid bone (creating an obtuse cervicomental angle) [26–30]. Patients with low set or anteriorly placed hyoid bones are unlikely to benefit form liposuction alone. The ideal candidate should have a hyoid positioned at the level of the C3–C4 vertebrae, excellent skin elasticity, and a palpable submental fat pad [26–30]. In order to mark the neck liposuction patient, the anatomic boundaries must be distinguished, including the mandibular border, the jowls, the submental fat pad, the anterior borders of the sternocleidomastoid, platsyma band, and the thyroid cartilage (Figure 56.8) [26–30]. The patient should be seated with the head gently extended posteriorly and the chin raised with the small supportive pillow for neck support [26–30]. For liposuction of the neck and jowls, entry points should be along the submental crease, just below or lateral to the jowls [26–30]. If extensive lateral neck fat is present, additional insertion sites can be made in a neck fold behind the earlobes [26–30]. The suctioning plane should begin just above the platysma muscle, with subsequent suction with


(a) Figure 56.7 Neck, lateral view: (a) pretreatment; (b) post-treatment.


(a) Figure 56.8 Neck liposuction markings: (a) anterior view; (b) lateral view.



Skin Contouring Techniques

small (1.5–2 mm) cannulae [26–30]. The cannula should be delicately applied in this area to suction above the platsyma in order to avoid placing the cannula through the platsyma [26–30]. In addition, the marginal mandibular branch of the facial nerve is located in this area (below the angle of the mandible at the anterior border of the masseter muscle), and care must be taken to avoid trauma to the nerve [26–30]. The nerve becomes increasingly superficial and more likely to be injured along or posterior (up to two fingerbreadths) to the posterior border of the sternocleidomastoid muscle [26–30]. The cannula can be used to elevate the subcutaneous fat away from the underlying structures in these areas to avoid injury to underlying structures [26–30]. Also, it is important to avoid oversuctioning cheeks and along the jowl–cheek margin, as an undesirable hollowed appearance results from oversuctioning in this area [26–30].

Female breast Traditional breast reduction in women, reduction mammoplastly, requires general anesthesia with significant associated risks, including, seroma, hematoma, scarring, skin loss, and fat necrosis [31,32]. The procedure involves making a T-shaped incision extending from the areola to the inframammary folds, which in the majority of cases leaves an unattractive scar [31,32]. Liposuction as a means to decrease breast size is a relatively new procedure and when utilized alone to decrease breast size has only been described in the literature in a handful of cases [31,32]. For women with moderate to severe breast enlargement, liposuction may not be sufficient given that it may not address issues of excess skin and soft tissue [31,32]. A preoperative breast weight should be taken to establish the optimal amount of fat reduction and then calculate the percentage fat reduction after the procedure [31,32]. The patient should be positioned supine with the ipsilateral arm behind the head or with the arm posteriorly displaced in order to bring the breast flat against the chest wall [31,32]. Two incisions for suctioning should be made, one in the lateral axillary line and one in the mid-inframammary crease [31,32]. Suctioning should focus in the mid to deep plane of the lateral and inferior quadrants of the breast [31,32]. It is less desirable for suction in the superior quadrant to preserve the natural contour of the breast, as the upper quadrants typically flatten with age [31,32]. The surgeon determines the amount of fat removed, calculated as a percentage of total fat, based upon preoperative measurement [31,32]. It is currently recommended that less than one-third of the measured total breast volume be removed in one session [31,32]. Breast reduction in female breasts by liposuction alone represents a promising new application of this technology and presents significant advantages relative to traditional reduction mammoplasties, including less risk


associated with general anesthesia, as well as benefits of decreased infection and scarring risks.

Male chest A careful history and physician examination should be performed in men before attempting liposuction in the male chest, with specific attention to the palpation of the gynecomastia and regional lymph nodes [31–33]. Several authors also recommend palpation of the testes to evaluate for testicular tumors [31,32]. While rare, breast tumors do occur in men and thus all masses with suspicion for malignancy (asymmetry, firm, or fixed) should undergo mammogram, ultrasound, and/or biopsy [31,32]. Etiologies for male breast enlargement include fatty deposition, glandular deposition, medications (estrogen, spironolactone, digitalis, diazepam, phenytoin and clomiphene), alcoholism, hypogonadism, and hormone-secreting tumors of the pituitary, adrenal gland, and testis [31,32]. As the male breast is one of the most vascular sites for TLA, care must be taken to ensure the vasoconstrictive effect of epinephrine has taken effect prior to the procedure and that the pectoralis muscle is not traumatized during the anesthesia infusion or liposuction [31,32]. The male breast is also one of the most fibrous sites in which liposuction is performed, with significant variability in the content of glandular and fatty tissue present [31,32]. Incision sites for the liposuction cannula are placed along the periphery of the breast and in the inframammary crease to allow for complete infiltration and criss-cross suction of adipose tissue [31,32]. Suction is started with microcannulae, allowing for easier tissue penetration, such as the 16gauge Capistrano cannula for initial tunneling with transition to a larger 14-gauge cannula [31,32]. The subareolar breast tissue can be gently suctioned with the use of a 16-gauge short (5 or 7 cm) Capistrano cannula [31,32].

Anesthesia technique Tumescent solution should be prepared on the day of the procedure utilizing 0.9% sodium chloride solution (normal saline) [4–9]. The anesthetic is lidocaine, available in 1% or 2% solution. Epinephrine and sodium bicarbonate are added to aid in vasoconstriction and buffering, respectively [4–9]. The range of doses utilized for TLA range from conservative doses of 30–35 mg/kg to as high as 55 mg/kg [4–9]. Doses at the lower end of the range can be utilized when patients are taking medications that inhibit cytochrome P450, specifically the CYP3A4 isoenzyme, responsible for the clearance of lidocaine [4–9]. In particularly smaller individuals, lidocaine concentrations should be limited to 0.05–0.075% as the total dose is limited by weight [4–9]. Higher concentrations are generally advised on more sensitive areas, such as the chest, waist, and periumibilical area [4–9]. Epinephrine

56. Liposuction is added to the solution at a concentration of 1 : 1 000 000 (1 mg 1 : 1000 epinephrine in 1 L solution of saline) [4–9]. Finally, bicarbonate is added in the amount of 10 mEq in 1 L [4–9]. Before mixing, the saline should be warmed to enhance the comfort of the patient during the infiltration process [4–9]. TLA should be administered once the patient has been comfortably positioned for the procedure. Insertion sites should be anesthetized with 1% lidocaine with epinephrine (usually at a dilution of 1 : 100 000) [4–9]. The incisions are created using a No. 11 blade through the dermis to allow entry of the blunt-tipped infiltration cannula into the subcutaneous tissue [4–9]. The infiltration cannula should be inserted and the infiltration rate should be appropriately adjusted for the anatomic site [4–9]. The infiltration rates should be less than 100 mL per minute to minimize patient discomfort [4–9]. Gentle advancement of the cannula should occur prior to infiltration of the tumescent solution [4–9]. Anesthesia should be performed using a fanned approach from the entry site with care taken not to put excessive strain on the entry site [4–9]. If the patient experiences excessive pain, slowing the rate of infiltration can improve patient comfort [4–9]. The infiltration endpoint is reached when the edges of the field become firm and indurated and the area of infiltration is blanched (secondary to vasoconstriction effect of epinephrine) [4–9].

Standard and advanced operating technique After infiltration of the TLA is complete and after allowing 15–20 minutes for full epinephrine effect to occur, fat suction can begin [4–9]. Suction can be performed through the same sites of insertion of the TLA [4–9]. More aggressive thinner cannulas should be used first to break up the fibrous setae and to create tunnels for subsequent removal of fat with larger (3 mm), less aggressive cannulae [4–9]. Suction movement should proceed in a linear and vertical fashion with little horizontal movement in the creation of subcutaneous tunnels [4–9]. The cannula should be directed so that the aperture is facing downwards or opposite the dermis [4–9]. Both deep and superficial tunneling should be performed so that the physician’s free or “smart hand” monitors the motion and position of the cannula tip [4–9]. Initially during the suctioning, the area is tense from the infiltration of TLA; however, as the suctioning proceeds, the area becomes more flaccid and techniques are needed to maintain the cannula in a uniform plane to ensure uniform suctioning [4–9]. One helpful technique is to have the assistant gently grasp the flaccid skin adjacent to the suction area and roll in such a way to flatten the suctioned area [4–9]. Another helpful technique is to have an assistant flatten the

region by placing counter traction of the skin while the surgeon continues suction guided by their “smart hand” [4–9]. The endpoint of fat suction is determined by a number of factors, such as the observation that the aspirate has become increasingly bloody and devoid of suctionable fat and palpation of the area revealing minimal persistence of fat pockets and even distribution of the remaining fat [4–9]. When this occurs, suctioning should stop in this area and the cannula should be repositioned. Localized pockets of fat should be sought out and removed by lacing the cannula (with the suction apparatus off) into tunnels and gently pulling back and up against the dermis. Pockets of fat may become more pronounced with this maneuver and further suctioning of these well-defined areas helps create a more even result. The total volume of fat removed in a single procedure should not exceed 4500 mL. This equates to 6000–8000 mL of total aspirate, assuming 50–60% of the aspirate of fat. If the patient possesses areas of fat where the estimated loss is greater than 4500 mL, treatments should be planned over multiple visits [4–9].

Equipment The fundamental equipment needed to perform liposuction includes an aspiration pump, liposuction cannulae, the infiltration pump, a sterile field, syringes with 1% lidocaine with or without epinephrine (to anesthetize the cannula insertion sites), a No. 11 blade, gauze, and clamps to secure tubing and drapes in place [34]. Various infiltration pumps for administration of the tumescent solution are available, the most optimal of which allow adjustment of the rate of administration of the TLA solution [34]. The infiltration pump is connected directly to the tumescent solution via intravenous tubing which is threaded through the power pump and connected directly to the tumescent solution through an infusion cannulae or needle [34]. The aspiration pump is an electrically powered device which is designed to create negative pressure and collect fatty tissue throughout the procedure [34]. There are a variety of machines available, the ideal of which are those with a closed collection system, overflow trap, and disposable air filter with efficient and uninterrupted suction [34]. The liposuction cannulae are comprised of stainless steel, aluminum, deldrin, or brass [34]. The shape, diameter, hole placement, and size determine the ease of fat removal as well as the relative injury to the tissue [34]. Easier fat removal is achieved with cannulae with several holes and a large-diameter tapered end (usually 3 mm), where the holes are located distally on the tip (e.g. Capistrano, Pinto, Cobra, Becker, and Eliminator cannulae; Wells Johnson Company,



Skin Contouring Techniques

Tucson, AZ, USA) [34]. Cannulae with smaller diameters (less than 3 mm), blunted ends, fewer holes, or holes placed more proximally relative to the tip are less aggressive and gentler to the tissue (e.g. Klein, Fournier, Standard cannulae; Wells Johnson Company, Tucson, AZ, USA) [34]. In fibrous tissue, it is best to begin with a cannula with an aggressive tip and a small diameter [34]. As the fibrous tissue is diminished, a less aggressive cannula with a larger diameter tip can be utilized [34]. In areas where the fat is soft, such as the inner thigh, smaller cannulae can be utilized to avoid oversuction. Per the guidelines of the American Academy of Dermatology regarding liposuction, the cannula diameter should be no greater than 4.5 mm in diameter [34]. As most liposuction cannula utilized are between 2 and 3 mm in size, they comply with this recommendation [34].

ing bleeding complications with prior deliveries or surgeries may elicit a history of bleeding which gives an indication for further work-up [16]. A review of medication intake, both prescription and over-the-counter, is essential to the safety and success of the TLA procedure [16]. Intake of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) is contraindicated before surgery, because of inhibition of platelet activity and subsequent increased perioperative bleeding [16]. Aspririn should be discontinued 7–10 days prior to surgery [16]. Ibuprofen and other NSAIDs should be discontinued 4–7 days prior to surgery [16]. The discontinuation of vitamins and herbal supplements, such as vitamin E, chondroitin, glucosamine, Ginkgo biloba, and ginseng is encouraged because of the anticoagulant effects of these agents [16].

Intraoperative phase

Complications Long-term experience has shown that the complications associated with liposuction under the TLA technique are minor and significantly less than those associated with complications with liposuction performed under intravenous or general anesthesia [18–24]. The most common complications of liposuction using TLA include bruising, swelling, soreness, inflamed incision sites, and postoperative fatigue [18–24].

Preoperative phase Obtaining informed consent from each patient prior to the procedure and reviewing the risks of the procedure, especially of skin contour abnormalities in areas of poor skin elasticity, will allow the patient to be more accepting of the final results [16]. It should be emphasized that there are limitations to the procedure. Safety dictates the amount of fat that can be removed [16]. Additionally, as a body contouring procedure, liposuction will not assist with pre-existing scars, pigmentary variation, cellulite, indentations, and skin textural changes [16]. Finally, it should be emphasized to the patient that his or she adopts and/or continues a regular exercise routine in order to assist with improved skin contraction and maintenance of results [16]. Preoperative assessment should also include assessment for possible abdominal wall hernias [16]. Blood tests should be performed to ensure the patient does not have an underlying bleeding tendency or liver transaminitis, which could also potentially affect clotting factor synthesis [16]. At a minimum, a full blood count with platelets, liver function tests, and a prothrombin time/partial thromboplastin time (PT/PTT) should be checked [16]. Additional studies to undergo with an underlying bleeding abnormality include: a bleeding time, von Willebrand’s factor, factor V Leiden level, or hemophilia screen [16]. Detailed questions regard-


The key to achieving a smooth end result with liposuction involves performing the suction from multiple angles and directions in a criss-cross motion. During the procedure, sterile technique must be emphasized, with the use of antiseptic washes to the area the night before and immediately prior to the surgery. Superficial infections, usually around incision sites, are typically culture positive for staphylococcus and streptococcus. However, deeper infections which occur in a delayed fashion several months after the procedure occur with atypical mycobacterial species (Mycobacterium abscessus, M. chelonae, M. fortuitum) and have been associated with improper cleaning and sterilization of surgical instruments. During liposuction, the surgeon should always use the non-dominant hand or “smart hand” to assess the position of the liposuction cannula at all times. Elevating the skin with the “smart hand” and then passing the cannula along the adipose tissue horizontally will preserve the integrity of the abdominal wall. Superficial placement of the cannula in this area is recommended to maximize the amount of fat removed, induce skin contraction, and allow a safe layered approach to fat removal. One of the significant advantages of liposuction using the TLA technique is that it minimizes blood loss. However, often surgeons will fail to wait long enough after infiltration of the TLA solution until the vasoconstrictive effects of epinephrine (15–20 minutes after infiltration of TLA solution) have taken effect. During the procedure, the surgeons should keep a close eye on the aspirate, directing the cannula away from areas where there are greater volumes of blood relative to fat in the aspirate. Selecting the appropriate cannula size (4 mm should be the largest utilized) and blunt tip style will have a significant role in the decreased tendency for bleeding and hematoma formation. To decrease the risk of bleeding and hematoma formation, larger procedures such as high volume abdominal liposuction, should be considered in two stages.

56. Liposuction During TLA, the maximum dosage of lidocaine used should be 55 mg/kg [4]. The lowest dose of lidocaine that provides complete local anesthesia should be utilized. The normal saline utilized should contain lidocaine in concentrations of 0.05–0.1% [4]. The peak plasma concentration of lidocaine occurs 12–18 hours postoperatively, given the slow systemic absorption of lidocaine from the adipose tissue [4]. Patients, family, and staff taking care of the patient should be aware of the symptoms and signs of lidocaine toxicity.

Postoperative phase Postoperative compression garments will both enhance skin contraction and assist with more rapid removal of local tumescent solution. The compression garment is also critical in order to minimize or eliminate bleeding, hematoma and seroma formation, and to speed wound healing. Patient comfort after the procedure is also greatly improved by wearing compression garments. In general, it is recommended that the garment be worn around the clock for the first week and be worn half-time for the subsequent 2–3 weeks. Any signs of infection should be evaluated and cultured as soon as possible. With atypical mycobacterial infections, it is important to obtain the culture medium requirements of the laboratory and to notify the laboratory that special processing of the specimen is needed. A rare case of necrotizing fasciitis has been reported with liposuction and thus any patient presenting with severe pain out of proportion to examination, surface blistering, and tenderness should be promptly evaluated for possible débridement and started immediately on broad-spectrum antibiotics and supportive care. Lidocaine, epinephrine, and bicarbonate utilized in the tumescent solution have all been proven to have antimicrobial effects on a diverse range of pathogens (bacteria, fungi, viruses) and thus the large dilute volume of anesthetic solution with the tumescent technique may further have a role in the low rates of infection associated with this procedure. In addition, using fine cannulas (4 mm or less) will assist with deep bruising and seroma formation and infection risk. Leaving the cannula sites open to drain leads to decreased hematoma and seroma formation. If significant hematomas form, they will usually spontaneously resolve or can be evacuated once they have liquefied. Large hematomas can be very uncomfortable for the patient and can prevent him or her from returning quickly to usual routines. Seromas need to be drained, sometimes repeatedly with recurrence, with subsequent compression applied to the area (Figure 56.9).

Figure 56.9 Adverse complication of liposuction: skin dimpling and scarring in medial thighs after overly aggressive liposuction procedure.

with a documented safety record, longevity of results, and high levels of patient satisfaction. Liposuction using TLA only in the office setting has a documented superior safety profile which has been documented in a number of studies in the dermatologic surgery literature by Bernstein, Hanke, Coleman and Housman (Table 56.3). Several of largest studies to date, the first by Hanke et al. in 1995 [6], reported data on 44 014 body areas treated with liposuction. There were no serious complications of death, emboli, hypovolemic shock, perforation of thorax or peritoneum, thrombophlebitis, seizures, or toxic reactions to drugs. Subsequently, in 2002, Housman et al. [24] reported data on 66 570 liposuction procedures. No deaths were reported and the serious adverse event ratio was low at 0.68 per 1000. In 2004, Hanke surveyed 39 tumescent liposuction centers and 688 patients treated with the tumescent technique to examine liposuction practice and safety [35]. The overall complication rate was 0.7%, with a minor complication rate of 0.57% and a major complication rate of 0.14% (1/688 patients). Patient satisfaction was very high among the surveyed population, where 91% of patients surveyed were positive about their decision to have liposuction. In contrast, in the plastic surgery literature (Table 56.3) the case fatality and complication rates were significantly higher for liposuction. In the largest study to date among plastic surgeons by Grazer and de Jong in 2000 [36] evaluating data on 496 245 procedures, the fatality rate was 19.1/100 000; where the most common causes of death included thromboembolism (23.1%), abdomen/viscus perforation (14.6%), anesthesia/sedation/medication (10%), fat embolism (8.5%), cardiorespiratory failure (5.4%), massive infection (5.4%), and hemmorhage (4.6%).

Conclusions and future directions Laser-assisted liposuction Liposuction with local TLA is a procedure that was designed and developed by dermatologic surgeons. It is a procedure

Current studies are undergoing evaluating the ability to liquefy or rupture fat cells using various lasers [37–43]. The



Skin Contouring Techniques

Table 56.3 Liposuction safety studies. Study/author


Number of procedures


Newman, Dolsky [45]


5 458

Cosmetic surgeons (derm, ENT, etc.)

1/38 426

Bernstein, Hanke [5]


9 478

Dermatologic surgeons

Temourian, Rogers [46]


112 756

Plastic surgeons


Dillerud [47]


3 511

Plastic surgeons

Hanke et al. [6]


15 336

Dermatologic surgeons

ASPRS Task Force on Liposuction [48]


24 295

Plastic surgeons


20.6/100 000

Jackson, Dolsky [49]


200 000

Cosmetic surgeons (derm, ENT, etc.)


2.4/100 000

Grazer, De Jong [36]


496 245

Plastic surgeons


19.1/100 000

Hughes [50]


94 159

Plastic surgeons

Not stated

1/47 415 (lipo only) 17 314 (lipo and other procedures) 1/3281 (lipo and abdominoplasty

Housman et al. [24]


66 570

Dermatologic surgeons

Hanke et al. [35]



Dermatologic surgeons

laser devices most widely utilized to assist with liposuction include a helium-neon laser (635 nm), a diode laser (600– 800 nm), and, most recently, a 1064 nm neodymium:yttrium aluminum garnet (Nd:YAG) laser [37–43]. The studies with a 635 nm diode laser utilized to release fat from adipocytes demonstrated changes in the adipose structure utilizing electron microscopy and magnetic resonance imaging (MRI) [37–44]. Six minutes of exposure to the 635 nm diode laser at 1.2 J/cm2 resulted in a transitory pore in the cell membrane with resultant release of the fat into the interstitial space [37–44]. Recent studies have evaluated both the clinical and histopathologic effects of the 1064 nm Nd:YAG laser and 980 nm diode laser in laser-assisted lipolysis [37–44]. A recent study by Mordon et al. [37] demonstrated both enhanced lipolysis and skin contraction with the laser-assisted devices. Using an optimal thermal modeling approach, the authors demonstrated that increased heat generated by the laser in the deep reticular dermis may result in collagen and elastin synthesis and resultant skin tightening which they observed clinically after laser lipolysis. Goldman demonstrated skin contraction and enhanced lipolysis with the use of the 1064 nm Nd:YAG laser for submental liposuction [39]. Clinical results of tissue tightening were correlated with histologic analysis confirming laser-induced rupture of the adipocyte membrane. Kim et al. [38] reported the results of 29 patients treated with


Number of fatalities

Fatality rate

12.7/100 000

laser lipolysis with the 1064 nm Nd:YAG device and demonstrated clinical improvement (at 3 months, average of 37%) as well as decreased adiposity as measured by MRI (average of 17% reduction in volume). Greater improvement was noted in smaller volume areas, such as the submentum, in both clinical outcome and dermal tightening. However, several other recent comparative trials evaluating laserassisted liposuction with the 1064 nm Nd:YAG laser have shown equivocal results with laser-assisted liposuction relative to liposuction alone [42–44]. Laser-assisted liposuction has been purported to result in both mechanical cavitation of fat resulting in greater ease of suction and greater skin retraction after the procedure resulting in enhanced tightening. However, further studies are highly needed to evaluate scientifically the benefits of pretreatment with lasers for ease of adipose removal and enhanced cosmesis [37–43].

References 1 Fischer G. (1990) Liposculpture: the correct history of liposuction, part I. J Dermatol Surg Oncol 16, 1087–9. 2 Ilouz Z. (1983) Body contouring by lipolysis: a 5 year experience with over 3000 cases. Plast Reconstr Surg 72, 591–7. 3 Fournier P. (1987) Body Sculpting Through Syringe Liposuction and Autologous Fat Re-injection. Corona del Mar: Samuel Rolf International.

56. Liposuction 4 Klein JA. (1990) Tumescent technique for regional anesthesia permits lidocaine doses of 35–55 mg/kg for liposuction. Peak plasma levels are diminished and delayed for 12 hours. J Dermatol Surg Oncol 16, 248–63. 5 Bernstein G, Hanke CW. (1988) Safety of liposuction: a review of 9478 cases performed by dermatologists. J Dermatol Surg Oncol 14(10), 1112–4. 6 Hanke CW, Bernstein G, Bullock S. (1995) Safety of tumescent liposuction in 15,336 patients: national survey results. Dermatol Surg 21, 459–62. 7 Ostad A, Kageyama N, Moy R. (1995) Tumescent anesthesia with a lidocaine dose of 55 mg/kg is safe for liposuction. Dermatol Surg 22, 921–7. 8 Klein JA. (2000) Tumescent Technique: TLA and Microcannular Liposuction. St. Louis, MO: Mosby. 9 Hanke CW. (1999) State-of-the-art liposculpture in the new millennium. J Cutan Med Surg 3 (Suppl 4), S36–42. 10 Pasman WJ, Saris WH, Westerterp-Plantenga MS. (1999) Predictors of weight maintenance. Obes Res 7, 43–50. 11 Brownell KD, Rodin J. (1994) Medical, metabolic and psychological effects of weight cycling. Arch Intern Med 154, 1325–30. 12 Ozgur F, Tuncali D, Guker Gursu K. (1998) Life satisfaction, self-esteem and body image: a psychosocial evluation of aesthetic and reconstructive surgery candidates. Aesthetic Plast Surg 22, 412–9. 13 Mann MW, Palm MD, Sengelmann RD. (2008) New advances in liposuction technology. Semin Cutan Med Surg 27, 72–82. 14 Hanke CW. (1989) Liposuction under local anesthesia. J Dermatol Surg Oncol 15, 12. 15 Lillis PJ. (1988) Liposuction surgery under local anesthesia. Limited blood loss and minimal lidocaine absorption. J Dermatol Surg Oncol 14, 1145–8. 16 Butterwick J. (2003) Liposuction consultation and preoperative considerations. In: Narins RS, ed. Safe Liposuction and Fat Transfer. New York: Marcel Dekker. 17 Jacob CI, Kaminer MS. (2003) Tumescent anesthesia. In: Narins RS, ed. Safe Liposuction and Fat Transfer. New York: Marcel Dekker. 18 Hanke CW, Coleman WP. (1999) Morbidity and mortality related to liposuction: questions and answers. Dermatol Clin 17, 899–902. 19 Coleman WP 3rd, Hanke CW, Lillis P, Bernstein G, Narins R. (1999) Does the location of the surgery or the specialty of the physician affect malpractice claims in liposuction? Dermatol Surg 25, 343–7. 20 Landry GL, Gomez JE. (1991) Management of soft tissue injuries. Adol Med 2, 125–40. 21 Klein JA. (2000) Miscellaneous complications. In: Klein JA, ed. Tumescent Technique, Tumescent Anesthesia and Microcannular Liposuction. St. Louis, MO: Mosby. 22 Narins RS, Coleman WP. (1997) Minimizing pain for liposuction anesthesia. Dermatol Surg 23, 1137–40. 23 Klein JA. (2000) Thrombosis and embolism. In: Klein JA, ed. Tumescent Technique, Tumescent Anesthesia and Microcannular Liposuction. St. Louis, MO: Mosby. 24 Housman TS, Lawrence N, Mellen BG, George MN, Filippo JS, Cerveny KA, et al. (2002) The safety of liposuction, results of a national survey. Dermatol Surg 39, 971–8.

25 Narins RS. (2003) Abdomen, hourglass abdomen, flanks and modified abdominoplasty. In: Narins RS, ed. Safe Liposuction and Fat Transfer. New York: Marcel Dekker. 26 Jacob CI, Kaminer MS. (2003) Surgical approaches to the aging neck. In: Narins RS, ed. Safe Liposuction and Fat Transfer. New York: Marcel Dekker. 27 Goddio AS. (1992) Suction lipectomy: the gold triangle at the neck. Aesth Plast Surg 16, 27–32. 28 Kamer FM, Minoli JJ. (1993) Postoperative platysmal band deformity: a pitfall of submental liposuction. Arch Otolaryngol Head Neck Surg 119, 193–6. 29 Key D. (2008) Efficacy of skin tightening and contour correction of the lower face and jowl using 1320 nm laser lipolysis: a comparison evaluation of lipolysis without aspiration, lipolysis with aspiration and aspiration without lipolysis. Abstract presented at American Society of Laser Medicine and Surgery Conference, Kissimmee, FL. 30 Goddio AS. (1992) Suction lipectomy. The gold triangle at the neck. Aesth Plast Surg 16 27–32. 31 Samdal F, Kleppe G, Amland PR, Abyholm F. (1994) Surgical treatment of gynecomastia. Scan J Plast Recontstru Hand Surg 28 123–30. 32 Matarasso A, Courtiss EH. (1991) Suction mammoplasty, the use of suction lipectomy to reduce large breasts. Plast Reconstr Surg 87, 709–10. 33 Gray LN. (1988) Liposuction breast reduction. Aesthetic Plast Surg 22, 159–62. 34 Bernstein G. (1999) Instrumentation for liposuction. Dermatol Clin 14, 735–49. 35 Hanke W, Cox SE, Kuznets N, Coleman WP 3rd. (2004) Tumescent liposuction report performance measurement initiative: national survey results. Dermatol Surg 30, 967–77. 36 Grazer FM, de Jong RH. (2000) Fatal outcomes from liposuction: census survey of cosmetic surgeons. Plast Reconstr Surg 105(1), 436–46. 37 Mordon SR, Wassmer B, Reynaud JP, Zemmouri J. (2008) Mathematical modeling of laser lipolysis. Biomed Eng Online 7, 10. 38 Kim KH, Geronemus RG. (2006) Laser lipolysis using a novel 1,064 nm Nd:YAG Laser. Dermatol Surg 32, 241–8. 39 Goldman A. (2006) Submental Nd:YAG laser-assisted liposuction. Lasers Surg Med 38, 181–4. 40 Ichikawa K, Miyasaka M, Tanaka R, Tanino R, Mizukami K, Wakaki M. (2005) Histologic evaluation of the pulsed Nd:YAG laser for laser lipolysis. Lasers Surg Med 36, 43–6. 41 Morton S, Wassmer B, Reynaud P, Zemmouri J. (2008) Mathematical modeling of laser lipolysis. Abstract presented at American Society of Laser Medicine and Surgery Conference, Kissimmee, FL. 42 Dressel T, Zelickson B. (2008) Laser liposuction a work in progress. Abstract presented at American Society of Laser Medicine and Surgery Conference, Kissimmee, FL. 43 Weiss R, Weiss M, Beasley K. (2008) Laser lipolysis: skin contraction effect of 1320 nm. Abstract presented at American Society of Laser Medicine and Surgery Conference, Kissimmee, FL. 44 DiBernardo B, Goldman M, Saluja R, Woodhall K, Reyes J. (2008) Mulicenter study evaluation of sequential emission of lasers for the treatment of fat with laser assisted lipolysis.



Skin Contouring Techniques

Abstract presented at American Society of Laser Medicine and Surgery Conference, Kissimmee, FL. 45 Dolsky RL, Newman J, Fetzek JR, Anderson RW. (1987) Liposuction. History, techniques, and complications. Dermatol Clin 5(2), 313–33. 46 Teimourian B, Rogers WB 3rd. (1989) A national survey of complications associated with suction lipectomy: a comparative study. Plast Reconstr Surg 84(4), 628–31. 47 Dillerud E, Håheim LL. (1993) Long-term results of blunt suction lipectomy assessed by a patient questionnaire survey. Plast Reconstr Surg 92(1), 35–42.


48 ASPRS Task Force on Liposuction, available at http://www. News_Bulletins/ASPS_urges_members_to_exercise_caution_in_ lipoplasty_procedures_Task_Force_report_calls_for_scrutiny_ of_training_large_volume_removals.html, accessed August 2, 2009. 49 Dolsky RL. (1997) State of the art in liposuction. Dermatol Surg 23(12), 1192–3. 50 Hughes CE 3rd. (1999) Patient selection, planning, and marking in ultrasound-assisted lipoplasty. Clin Plast Surg 26(2), 279–82; ix.

Chapter 57: Liposuction of the neck Kimberly J. Butterwick Dermatology/Cosmetic Laser Associates of La Jolla, San Diego, CA, USA

BAS I C CONCEPTS • Neck liposuction is used to remove excess fat from the neck area and minimize skin sagging. • Small cannulas and multiple entry sites are necessary to achieve even fat removal without ridging or deformity. • Tumescent anesthesia is key to reducing pain and bruising while facilitating fat removal. • Proper selection of patients with fat in front of the platysma muscle can ensure a successful outcome. • Overremoval of fat on the lower neck should be avoided.

Introduction One of the first signs of aging that prompts patients to seek cosmetic treatment is the sagging neck. Tumescent liposuction of this area often dramatically rejuvenates the neckline and is one of the most common body areas treated with this modality. Although this area may seem complicated to the novice surgeon, liposuction of the neck is relatively quick, safe, and readily learned. It is also well tolerated by patients with rapid healing in 3–4 days. With careful selection of patients and good technique, this is a very rewarding area for patients and surgeon alike.

Anatomy The primary goal of liposuction of the neck is restoration of the cervicomental angle (CMA). This is the angle formed by the horizontal plane of the submental region and the vertical plane of the neck (Figure 57.1) [1]. The ideal angle is generally considered to be 90–100 ° or more, up to 135 ° [1–3]. Other anatomic features of a youthful neck include definition of the inferior mandibular border, subthyroid depression, a thyroid notch visible as a gentle indentation, and a visible anterior border of the sternocleidomastoid muscle [1]. The face should be distinct from the neck such that a shadow should be cast on to the upper neck by the mandible. With aging and/or genetics, there may be accumulation of submental fat leading to blunting of the CMA or a “double chin.” Other anatomic factors may also contribute to an obtuse CMA such as a low-lying hyoid bone, microgenia, or

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

retrognathia. Ideally, the hyoid bone should be positioned at the C3–C4 level [4]. Lateral to the submental region, there may be loss of definition of the submandibular region leading to an unattractive continuum between the face and the neck. Further contributing to fullness in this area may be ptotic submandibular glands located along the inferior midportion of the mandibular ramus. Other stigmata of aging in the lower third of the face may need to be addressed such as the presence of jowls and the development of a depression just medial to the jowl called the prejowl sulcus [5]. The platysma muscle is the thin layer of muscle just deep to the submental fat pad arising from the cervicopectoral fascia inferiorly and attaching to the depressor anguli oris, risorius, and mentalis muscles superiorly with a varying degree of decussation at the midline [6]. Approximately 75% of the time, the fibers interlace 1–2 cm below the chin but separate in the suprahyoid region. Less often, the fibers decussate all the way down to the thyroid cartilage or not at all [7]. With aging, the medial fibers of the platysma muscle may hypertrophy into thick visible bands. Deep to the platysma, there may be a collection of fat that is midline and submental. While the preplatysmal fat pad is accessible to tumescent liposuction, the retroplatysmal fat pad is not and requires direct excision for removal. Having the patient clench his or her teeth tightens the platysma and aides in distinguishing pre- or retroplatysmal fat [3]. The amount of submental retroplatysmal fat has been estimated to vary between 30% and 57% of the total amount [8]. Also deep to the platysma is the marginal mandibular branch of the facial nerve, which is vulnerable to trauma during liposuction of this area. This motor nerve runs along the mandible, parallel to the ramus and is typically most superficial at the anterior border of the masseter muscle (Figure 57.2). However, the position of this nerve is variable, and it can be found 3–4 cm inferior to the ramus. Caution



Skin Contouring Techniques

must be exercised when suctioning this region because repeated pressure and rubbing from the cannula may result in temporary neuropraxis. While this typically lasts only 4–6 weeks, the distorted appearance is very distressing to the patient. To minimize injury to this nerve, patients should be asked to clench their teeth and the anterior edge of the massester should be marked where the nerve is likely to be found, at or just below the level of the ramus. Other techniques to minimize potential injury to this nerve are described below. Another structure less vulnerable to injury is the external jugular vein which passes over the sternocleidomastoid muscle. The vessel could be injured from inadvertent deep penetration by the cannula from a lateral position.

Esthetic considerations To the novice surgeon, liposuction of the neck entails simply removing fat in the submental area. However, there are

some esthetic principles and proportions that should be considered for optimal esthetic results (Figure 57.1) [9,10]. When evaluating the cervicomental angle, one should evaluate the entire profile of the head and neck. The ideal profile should be viewed with the head held in the Frankfurt horizontal plane. This is the horizontal plane, parallel to the floor, in which a horizontal line can be drawn through the highest point of the ear canal meatus and the lowest point of the orbital rim [10]. In this position, the chin is at the proper level for assessing the CMA and for uniformity of preoperative and postoperative photographs. It is said that in this position, the glabella, nasal root, lip projection, and mentum should ideally align in a vertical facial plane. Utilizing this proportion enables the surgeon to assess the relative strength of the chin and the adequacy of volume in the face. The face should be divisible by thirds from the midline frontal scalp to glabella, the glabella to the infranasal area, and the infranasal area to the mentum. Often, the lower third of the face is reduced in volume because of bone loss, aging, genetics, or other factors.

Patient selection

Frankfurt plane

CMA 105°

Facial plane Figure 57.1 The youthful neck with a cervicomental angle of 100 °. The facial and Frankfurt plane are shown with glabella, subnasale, and chin in alignment.

Potential candidates for submental liposuction fall into three groups: correction of genetic traits, rejuvenation for mild to moderate aging, and restoration of more advanced aging. The latter two groups may also have some pre-existing hereditary factors. All groups should be assessed systematically and all determinates to the aging neck evaluated (Table 57.1). The first group of patients tends to be relatively young, typically less than 30 years, and usually of normal weight, although this deposit makes them look heavier or older than they are. Although the skin quality is excellent, the profile is obscured by submental fat. There are often contributing factors to the obtuse CMA, such as microgenia or a low-lying

Facial artery and vein Parotid gland

Sternocleidomastoid muscle

Marginal mandibular branch of the facial nerve Submandibular gland

Platysma muscle


Figure 57.2 Marginal mandibular branch of the facial nerve and other relevant anatomy.

57. Liposuction of the neck

Table 57.1 Preoperative assessment. 1 Cervicomental angle 2 Degree of submental fat 3 Platysma banding 4 Degree of subplatysma fat 5 Hyoid position 6 Presence of jowls 7 Position of submandibular glands 8 Adequacy of chin profile 9 Skin thickness 10 Skin laxity

hyoid bone. These limitations should be addressed at the time of the consultation. Patients in this age group may also have quite full cheeks, but with age cheek hollows often become more marked. Removal of fat may then retrospectively be seen as inappropriate. The next group of patients is typically 35–50 years old with some skin laxity brought about by photoaging, facial volume loss, and a genetic tendency towards submental fat accumulation. They are often mildly overweight, but even at ideal weight, the problem persists. The last group is over 55 years old and has submental fat but in addition significant skin redundancy, bone and volume loss, platysma banding, and photoaging. Many in this group would fare better with reconstructive surgery, but at times the risk : benefit ratio – that is, the improvement offered by liposuction alone – will satisfy those wishing to avoid the risks of a more invasive surgical procedure. These patients should be carefully assessed, as liposuction alone could significantly worsen the appearance of the skin, platysma bands, or expose ptotic submandibular glands. In all three groups, males may show relatively less improvement than females. Their thickened, bearded skin retracts less readily than that of females. Even thinner females with little submental fat often show good benefit because of marked skin retraction after liposuction.

Consultation and physical examination The consultation is a key step in communicating expected risks and benefits. In our practice, patients initially voice their concerns to a practice consultant. The consultant reviews treatment options and helps patients develop and prioritize their beauty wish list. Patients often pull back the neck tightly and, in the same breath, state they would never want a facelift. If liposuction alone is being considered, it is helpful to grasp the submental fat and tuck it up under the chin. This maneuver essentially “removes” the fat from view

Figure 57.3 Grasping and tucking the submental fat to demonstrate expected results of submental liposuction without upward posterior retraction seen in rhytidectomy.

without pulling up on the jowls (Figure 57.3). If the patient has lax, photoaged skin, the surgeon should bunch it up a little and show the patient that it could look more wrinkled after the procedure. The surgeon should pull the skin back and demonstrate the probable result of a rhytidectomy to help the patient visualize the different results of different procedures. Any contributing factors to the blunted neck angle are reviewed with the patient at this point and additional corrective measures and alternative treatments are discussed. Platysma bands can be identified by having the patient grimace. An overview of the risks is also part of the consultation. At this point, the surgeon typically leaves the room, and the consultant answers additional questions, reviews the fee quote, and offers to schedule the procedure. Should the patient decide to proceed, he or she returns for a second visit for a preoperative examination. At this visit, the patient has a modified physical examination, reads and signs consents forms, and is given written preoperative and postoperative instructions. Preoperative laboratory studies and photographs are completed. Typical preoperative laboratory studies include: full blood count, chemistry panel, prothrombin time/partial thromboplastin time (PT/PTT), international normalized ratio, and viral titers. A prescription for preoperative antibiotics is given to start the night before surgery for a total of 10 days.



Skin Contouring Techniques

Procedure Markings The preoperative markings are summarized in Table 57.2. With the patient in an upright position, the edge of the mandible is outlined and a circle is drawn around the perimeter of the main accumulation of fat in the submental area (Figure 57.4). An “X” is then marked on the most visible mound within that circle. An additional circle may be drawn just inferior to the submental area if indicated, or concentric circles may be drawn around the main deposit of fat. The jowls are outlined as they extend both superior and inferior to the mandibular border. Again, the fullest aspects of the jowl are marked with an “X.” Laterally, fullness superior to the mandible is outlined. Inferior to the mandible, small “X’s” or a line should be drawn where maximum definition is desired. This is the area where a linear shadow should be cast. The patient is then instructed to clamp down on the back teeth. The edge of the masseter is then palpated and an “X”

is placed at the probable location of the marginal mandibular nerve, preferably in a different color. The platysma is assessed during this maneuver and the bands may be outlined in another color. Other landmarks that may be highlighted include the anterior border of the sternocleidomastoid muscle, the hyoid bone, and the inferior border of the neck. Parallel vertical lines are drawn from the immediate submental area down the remainder of the neck to the base of the neck. Fat is rarely removed from the lower two-thirds of the neck because the skin here is often so thin that it will look more aged and wrinkled if underlying fat is removed. The long vertical lines remind the surgeon not to remove fat but rather to tunnel through, without suction. Tunneling is thought to create tissue injury that will then stimulate some neocollagenesis and perhaps thicken or tighten the skin to some degree. On rare occasion if the patient has horizontal rhytids of the lower two-thirds of the neck and excessive fat, very conservative liposuction of the lower neck will significantly improve fat bulges and horizontal furrows.

Anesthesia and infiltration Table 57.2 Preoperative marking. 1 Mark border of mandible 2 Encircle submental fat and place “X” on apex 3 If present, outline jowl and excess fat in lower lateral cheek 4 Make a line or “X’s” where submandibular concavity desired 5 Mark likely position of marginal mandibular nerve 6 Dot in platysma bands if indicated 7 Draw parallel vertical lines to base of neck

Figure 57.4 Preoperative markings.


Patients undergoing liposuction of the neck do not require general anesthesia and many of them could undergo the procedure without any sedation at all. However, most patients prefer to have some anxiolysis and are typically given 1 mg lorazepam p.o. prior to the procedure. Alternatively, if a surgicenter is utilized, an intravenous line may be started and the patient given 1.0 mg midazolam IV along with 25 μg fentanyl IV as a one-time dose. Intravenous medications are often preferred because the patient will feel instantly relaxed and will be nearly fully awake when the procedure is over. One must be careful with intravenous medicationss to avoid excessive sedation and apnea; however, the low doses utilized above result in mild sedation with appropriate responsiveness. The patient is then positioned in a supine position with a neck roll partially under the shoulders so that the head rolls back comfortably in an extended position. After prepping with benzalkonium chloride antiseptic (Zephiran™, SanofiAventis, Bridgewater, NJ, USA), the patient is draped with sterile towels, including a sterile turban (Figure 57.5). A lap sponge is placed over the patient’s eyes for comfort and protection. Tumescent anesthesia of the neck is the next step. Superficial blebs of tumescent lidocaine are first made in five sites, corresponding to the entry sites for the cannula. Dilute lidocaine consisting of Klein’s standard formula with lidocaine 0.1% is infiltrated into the subcutaneous space with the aid of an infusion pump [11]. A 25-gauge spinal needle is used initially in a fan-like motion, introduced through five blebs, until the entire surgical field has been partially infused. The tumescent fluid is warmed, the infusion rate is low, and the needle gauge is small, assuring that there is minimal

57. Liposuction of the neck

Figure 57.5 Operative position with chin extended. Three of the five entry sites are denoted with circles and typical fanning pattern shown.

Table 57.3 Standard technique. 1 Debulk in midline submental region from three entry sites 2 Turn head laterally, suction lateral cheek/submandibular region 3 Avoid rasping mandible 4 Conservative suction of the jowl 5 Repeat steps 2 and 3 on contralateral side 6 Return head to central position. Tunnel inferiorly 7 Palpate all areas for smoothness 8 Apply French tape

discomfort for the patient. Approximately 50–100 mL is utilized at this point. The spinal needle is then changed to 20gauge, at a faster infusion rate, so that very quickly, within 5–15 minutes, the entire surgical field is tumesced. The patient may feel a bit anxious at this point because the neck will feel taut. Reassure patients that they can still breathe and swallow and that the tightness will loosen within a few minutes of starting the liposuction. It should be noted that it is not necessary to infiltrate the lower half of the neck. While the procedure is underway, the solution will drift inferiorly to the sternal notch, so that at the end of the procedure, when tunneling the lower neck may be desired, the lower neck will have adequate anesthesia. Typical volumes of infiltrated solution are 400–500 mL.

Liposuction: standard operative techniques The standard liposuction procedure utilizes five entry sites and a thorough suction with small cannulae (Table 57.3). The submental area is approached through three small stab incisions with an 11 blade. Although it may be tempting to perform the entire procedure through one site, the most thorough and smooth result requires criss-crossing through

multiple sites. In addition, one avoids a depression which is commonly seen under a single incision site. Only small cannulae are utilized, such as the Klein 14 and 16 gauge Finesse, to avoid ridges or troughs in thin-skinned patients. In patients with thicker skin, a slightly more aggressive cannula is sometimes needed such as a 12-gauge Klein Finesse or the multi-holed Klein Capistrano, gauge 14. These smaller cannulas also preserve connective tissue strands throughout the fat and are thought to maximize retraction of the skin. A thorough fanning technique is utilized through all three incisions with the cannula attached to the suction device. An assistant may anchor the skin at the entry site and elsewhere to minimize skin buckling, thereby facilitating long smooth strokes of the cannula. This is the area to be aggressive, from the submental crease to the superior edge of the thyroid cartilage, approximately 8–9 cm caudal to the submental crease. The end point in this area is a thin pinch of the skin. When lifting up a cannula under the skin, the overlying skin should be palpated and free of lumps. A thin layer of fat, approximately 3–5 mm in thickness should be left to prevent surface irregularities [12]. The cannula may be visible beneath the skin. The patient’s head is then turned to the side and a fourth incision site is made. If indicated by the preoperative examination, very conservative liposuction of the lower cheek is performed. Usually, less than 10 strokes of the cannula are needed in order to taper the face. One must be careful not to overressect this area and to feather (tunnel without suction) into the cheek immediately superior to the treated area in order to avoid a shelf or step-off. It is also important that fat is left behind. A strong, smooth, mandibular border is a youthful feature so it is rarely necessary to remove fat immediately overlying the mandible. The cannula is then directed approximately 3–4 cm below the ramus. This is a key area for removing fat to optimize definition between the head and the neck. Thorough removal is performed along this region. The surgeon must be mindful not to rasp against the ramus while performing liposuction with the head turned because of the proximity of the marginal mandibular nerve. In this position, the nerve may be located 3–4 cm below the mandible and become more superficial. Although it is deep to the platysma, this muscle is very thin and could be punctured by a small cannula [13]. If liposuction is needed near the ramus, one should pinch up the skin off the ramus and avoid deep fat. Special attention is then directed toward the jowl. If the jowl is large, a separate stab incision is made with an 18gauge No-Kor needle, at the most caudal extension of the jowl (Figure 57.6). A 16-gauge Klein Finesse cannula is then utilized to very conservatively remove less than 30% of the fat. Excessive removal in this area is not necessary as the skin will redrape nicely and overresection will result in deepening of the adjacent marionette fold. These same steps are then repeated on the contralateral side.



Skin Contouring Techniques

Figure 57.6 Liposuction of the jowl with a 16-gauge Klein Finesse cannula. The skin is pinched up by the non-dominant hand to avoid rasping the cannula against the mandible.

After liposuction of both sides, the head is then returned to a central position. A 14-gauge Klein Finesse cannula is passed through the three central incisions sites to check for remaining fat deposits. Sometimes there are stubborn deposits inferior to the lowermost extension of the jowls and this area is specifically checked. Tunneling or feathering without suction is then performed with the cannula passing through the entire surgical field, down to the sternal notch without suction. Some surgeons recommend “windshield wiping” at this point in order to gain maximal skin retraction. In the author’s opinion this is not necessary and may have a negative effect in the development of delayed and unattractive adherence of the skin to underlying fascia. If platysma bands were visible at the preoperative examination, it may be helpful to take a spatula-tipped cannula and tunnel underneath them to reduce cutaneous attachments. Others prefer a closed neck V-shaped neck dissector to release tethering fibrous bands [14]. At the end of the procedure, three pieces of French tape are applied as shown in Figure 57.7. This helps to minimize pooling of tumescent fluid and free floating adipocytes in the submental area and minimizes postoperative bruising. It is removed 23–48 hours after the procedure.

Figure 57.7 French tape with two shorter pieces applied with traction to the midline and a third piece across entire area. This helps to decrease central pooling.

and can be covered with clothing or scarves. During the first 2 weeks postoperatively, the submental area swells and patients will note increasing induration. There may be small focal areas of induration appearing as lumps or areas of stiff skin that crease unnaturally with movement. Patients should be advised ahead of time because induration always develops as an expected, temporary condition that resolves over a period of 4–8 weeks. Lymphatic massage may be helpful as the induration most likely represents a localized interstitial edema. Rarely, a larger nodule develops that is unsightly. Low doses of 2.5 mg/mL Kenalog (Bristol-Myers Squibb Princeton, NJ, USA) may be injected to reduce the edema more quickly. After the healing process, expected benefits of liposuction of the neck and jowls include reduction of adipocities, and skin retraction leading to elevation of the submental area, flattening of the jowls, and a reduced cervicomental angle (Figures 57.8 and 57.9). The capacity of the skin of the neck to retract and redrape in this area is outstanding and remarkable even compared to liposuction in other areas [15]. The very small incision sites (3 mm or less) heal readily and essentially ensure a scarless procedure. Avoiding both surgical scars and general anesthesia are key aspects of this procedure that factor into the patient’s choice over more invasive options.

Postoperative course In addition to French tape, patients wear a chin strap 24 hours a day for 3–4 days. The strap is then worn 2–4 hours per day for another 3 weeks. Immediately after the procedure, patients experience minimal to no discomfort. Mild discomfort may last 2–4 days. Patients may return to work after the initial few days at home. Purpura is typically minimal. If it develops, it tends to drift below the collar line


Complications Submental liposuction has a very low rate of complications with proper careful technique. Immediate potential complications include bleeding or hematoma. With tumescent liposuction and blunt-tipped cannulas the risk of significant

57. Liposuction of the neck


(a) Figure 57.8 Before (a) and 3 years after (b) removal of 50 mL of supranatant fat.


(a) Figure 57.9 Before (a) and 1 month after (b) removal of 100 mL of supranatant fat. CoolLipo laser applied at 15 W, 40 Hz for 625 pulses with simultaneous suction. After suction, skin tightening was performed at 5 W, 50 Hz for 93 pulses.

bleeding is very low. Postoperative compression further minimizes this risk. Temporary injury to the marginal mandibular nerve is probably the most common complication. It is important to be aware of the likely position of this nerve, anterior to the masseter muscle and at the level of the ramus or 3–4 cm inferior to the border. The nerve is most vulnerable when

the head is turned to the side. It is also prone to injury if one attempts to treat the jowl from a medial, submental incision site. Avoidance of brushing against the mandible in any position and avoidance of penetrating the thin platysma muscle is essential. In addition, approaching the jowl from the previously described inferior position should nearly eliminate this potential risk. If paresis develops, it presents



Skin Contouring Techniques


(a) Figure 57.10 Small platysma bands unmasked after submental liposuction (b).

not as ipsilateral weakness, but rather hyperkinesis of the contralateral side. This side effect is temporary, rarely lasting beyond a few weeks, but it may last for 2–3 months. If troublesome to the patient, a few units of botulinum toxin may be placed in the contralateral, hyperkinetic, depressor labii inferioris. Permanent injury to the marginal mandibular nerve has not been reported after tumescent liposuction because there is no sharp instrumentation. Sensory nerves may also be temporarily affected. Reassurance that the numb feeling will resolve within 4–6 weeks generally consoles the patient. Postoperative edema has been mentioned previously. One more troubling aspect of this is the development of a submental fold. This is most likely caused by the compression garment loosening in this area. Patients with larger necks, low hyoid bones, and who frequently flex their neck for work or hobbies (i.e. needlepoint) seem to be at risk for this complication, which presents as a ridge, just posterior to the submental crease. Careful taping with French tape and admonition to elevate the chin regularly will mitigate this risk. Overresection is an avoidable complication. Overressection in the submental area leads to a “cobra” neck in which there is an actual depression under the chin with flaring of the sides because of the relative overabundance of adjacent fat [16]. The jowls are another danger zone in which the surgeon may be overly aggressive and cause a depressed, aged appearance. If patients are thin-skinned and/or elderly, overresection will lead to increased wrinkling of the skin. Conservative liposuction, leaving a thin blanket of fat, is best in these patients.


Although it may not be a result of overresection, performing liposuction of the neck may unmask platysma bands and ptotic submandibular glands (Figure 57.10). A thorough preoperative examination should help to detect these patients. In one study of 301 patients, submental obesity and the anatomic pattern non-decussating platysma fibers were found to be significant correlates in the development of the postoperative platysmal banding [17]. The bands may be treated with botulinum toxin A (Allergan, Inc., Irvine, CA, USA) after surgery or adjuvant procedures such as platysmaplasty at the time of surgery. Excessive defatting in a patient with a round face, without tapering the lower face, can result in a “lollipop” appearance. Tapering of the lower face will prevent this appearance; however, care must be given to feather superiorly to avoid a shelf or step off. Infection is very rare with tumescent liposuction of any area. Patients are advised of this low risk, which is further reduced by preoperative antibiotics, and sterile procedures during surgery.

Advanced and ancillary operating techniques Submental liposuction is an excellent stand-alone procedure but it also lends itself to the addition of other procedures. At times, these procedures are essential for an acceptable outcome. Examples include platysmaplasty for thick, pronounced platysma bands that are present at rest or with mild animation [14,18]. A mini or full rhytidectomy may be added for excessively lax skin and jowls [11]. The use of

57. Liposuction of the neck

Figure 57.11 Before (a) and 6 months after (b) submental liposuction (25 mL) combined with fat augmentation to cheeks and chin (21 mL).



various lasers and devices to melt fat and/or tighten skin has been touted by some, but at this point, clinical data are lacking. At other times, procedures may be added to enhance an otherwise good outcome. With photoaged skin, for example, one may perform a resurfacing procedure to the face and neck immediately following the liposuction procedure. A typical procedure would add a fractionated laser versus a more invasive laser to avoid the oozing and discomfort from more aggressive laser procedures while wearing the chin strap. If the chin is recessed and/or the chin height short, chin implants may be inserted through a submental incision [19]. Alternatively, autologous fat transfer may be easily added to the procedure (Figure 57.11) [20]. Fat may be utilized from the neck, but it is usually difficult to obtain enough fat through a hand-held syringe, particularly if the fat is to be centrifuged as well. Another donor site may be necessary. Other areas of the face in which volume restoration will enhance the neckline include the prejowl sulcus, marionette fold, or mandibular border. Full-face volume restoration if indicated will elevate the cheeks and jowls and often lift the submental area.

Conclusions Liposuction of the neck is a procedure that is straightforward, takes 1 hour or less, and is rapidly healing with few complications. It is often a stand-alone procedure or it can be combined with other procedures that may be indicated in the aging patient or those with pre-existing anatomic factors. Proper patient selection and good technique that avoids overresection are key elements for achieving optimal results. Because aging of the neckline and drooping jowls

are often the first major complaint of the aging patient, it is incumbent of the dermasurgeon to achieve mastery of this technique as it is likely to become one of his or her favorite procedures to perform.

References 1 Prendiville S, Kohoska MS, Hollenbeak CS, et al. (2002) A comparative study of surgical techniques on the cervicomental angle in human cadavers. Arch Facial Plast Surg 4, 236–42. 2 Ellenbogen R, Karlin J. (1980) Visual criteria for success in restoring the youthful neck. Plast Reconstr Surg 66, 826. 3 Jacob CI, Berkes BJ, Kaminer MS. (2000) Liposuction and surgical recontouring of the neck: a retrospective analysis. Dermatol Surg 26, 635–2. 4 Moreno A, Bell WH, Zhi-Hao Y. (1994) Esthetic contour analysis of the submental cervical region. J Oral Maxillofac Surg 52, 704–13. 5 Mittelman H. (1994) The anatomy of the aging mandible and its importance to facelift surgery. Facial Plast Surg Clin N Am 2, 301–10. 6 de Castro CC. (1980) The anatomy of the platysma muscle. Plast Reconstr Surg 66, 680–3. 7 Hoefflin SM. (1998) Anatomy of the platysma and lip depressor muscles: a simplified mnemonic approach. Dermatol Surg 24, 1225–31. 8 Lambros V. (1992) Fat contouring in the face and neck. Clin Plast Surg 19, 401–14. 9 Powell N, Humphreys B. (1984) Proportions of the Aesthetic Face. New York: Thieme-Stratton. 10 Farkas LG, Sohm P, Kolar JC, Katic MJ, Munro IR. (1985) Inclination of the facial profile: art versus reality. Plast Reconstr Surg 75, 509–19. 11 Klein JA. (1990) Tumescent technique for regional anesthesia permits lidocaine doses of 35 mg/kg for liposuction. J Dermatol Surg Oncol 16, 248–63.



Skin Contouring Techniques

12 Watson D. (2005) Submentoplasty. Facial Plast Surg Clin N Am 13, 459–67. 13 Langdon RC. (2000) Liposuction of neck and jowls: five-incision method combining machine-assisted and syringe aspiration. Dermatol Surg 26, 388–91. 14 Jacob CI, Kaminer MS. (2002) The corset platysma repair: a technique revisited. Dermatol Surg 28, 257–62. 15 Goddio AS. (1992) Suction lipectomy: the gold triangle at the neck. Aesth Plast Surg 16, 27–32. 16 Fattahi TT. (2004) Management of isolated neck deformity. Atlas Oral Maxillofacial Surg Clin N Am 12, 261–70.


17 Kamer FM, Minoli JJ. (1993) Postoperative platysmal band deformity. Arch Otolaryngol Head Neck Surg 119, 193–6. 18 Knipper P, Mitz V, Maladry D, Saad G. (1997) Is it necessary to suture the platysma muscles on the midline to improve the cervical profile? An anatomic study using 20 cadavers. Ann Plast Surg 39, 566–71. 19 Newman J, Dolsky RL, Mai ST. (1984) Submental liposuction extraction with hard chin augmentation. Arch Otolaryngol 110, 445–57. 20 Butterwick KJ. (2003) Enhancement of the results of neck liposuction with the FAMI technique. J Drug Dermatol 2, 487–93.

Chapter 58: Hand recontouring with calcium hydroxylapatite Kenneth L. Edelson Mount Sinai School of Medicine and Private Practice, New York, NY, USA

BAS I C CONCEPTS • The aging hand is a common area of concern for patients. • Adequate treatment solutions were hampered by injection pain and the absence of treatment longevity. • The soft tissue filler calcium hydroxylapatite is effective for rejuvenating aging hands. • Calcium hydroxylapatite combined with lidocaine reduces pain of injection, improves product rheology of the procedure, and deposits the product in the correct metacarpal spaces. • The volume of injected calcium hydroxylapatite varies with physician preference.

Introduction This chapter begins with a description of the aging hand, then identifies various cosmetic hand treatment products used by physicians for the past 20 years. Calcium hydroxylapatite is then introduced as an alternative to past dermal fillers. A discussion of how to add anesthesia to the calcium hydroxylapatite follows. The author then leads the reader through a step-by-step instruction of injection of the product into the aging hand. The chapter closes with a summary and a discussion of the various volumes of product and possible durability effects that have been used by various physicians.

Physiology of the hand The great Irish playwright Oscar Wilde once said that “a woman who tells you her age will tell you anything.” Well, in his day she did not have to; one could just examine her hands. Today, with the technology of hand recontouring, her secret is safe. The hands have always been problem areas for physicians to rejuvenate and a myriad of applications and techniques have been used, both surgical and non-surgical with limited success. Until recently, no gratifying procedure has been

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

successful in producing the effect of Botox on wrinkles or intense pulsed light (IPL) and lasers on vessels. Signs of the aging hand include: a textural, crepe-like appearance, dryness, dyscromia, increased skin laxity, and volume loss giving the sunken appearance highlighting bones, tendons, and veins. A combination of both fractional non-ablative, or ablative laser resurfacing to address the epidermal defects, and the ideal subdermal filling agent to correct the loss of skin elasticity, volume, and wrinkling, is needed to address the aging hand. Both men and women can benefit from volume restoration and can attain a plumper, more youthful hand appearance with the proper technique and product. A panoply of dermal fillers exists in the esthetic marketplace. These have been well described in the 2008 American Society for Dermatologic Surgery (ASDS) guidelines publication [1]. Zyderm® collagen (Collagen Corp., Palo Alto, CA, USA), the original filler since 1982 and the gold standard for more than two decades, and Zyplast® (Collagen Corp., Palo Alto, CA, USA), followed by Cosmoderm® and Cosmoplast® (Allergan, Irvine, CA, USA) did not produce optimal results because of its consistency and flow characteristics, as well as lack of longevity. The filler was injected into the atrophic area, but did not cover objectionable structures. Collagen and hyaluronic acid fillers also did not flow well, yielding lumps and bumps. Harvested fat has also been used by some physicians. However, the large-bore needles required for injection often leave unsightly puncture marks. More importantly, the results were modest at best, and short-lived, requiring a second surgical procedure to harvest the fat.



Skin Contouring Techniques

Advantages of calcium hydroxylapatite for treatment of the aging hand

Technique of injection of CaHA into the hand

In 2007, Florida dermatologists Mariano Busso (Coconut Grove) and David Applebaum (Boca Raton) reported offlabel clinical experiences using calcium hydroxylapatite (CaHA; Radiesse, BioForm Medical, San Mateo, CA, USA) for hand recontouring [2]. Their idea involved addition of lidocaine to the existing Radiesse compound. (Radiesse was approved in later 2006 for treatment of severe lines and wrinkles of the face such as nasolabial folds as well as treatment for HIV-associated facial lipoatrophy.) As a result, pain of treatment was reduced to nearly none, with immediately pleasing results to patients in one treatment session. Radiesse consists of CaHA microspheres, 25 μm to 45 μm in diameter, in a carboxymethyl cellulose carrier gel. The CaHA is identical to the component found in human bone. The carrier gel disperses within weeks, leaving behind the calcium microspheres. It does not induce osteogenesis when placed in tissue but laboratory studies show neocollagenesis extending out to 72 weeks [3]. Hand recontouring required a substance that could not only fill atrophic areas of the dorsal hand, but could also conceal the vein and tendon color. Radiesse is white, opaque, possesses the proper viscosity, and flows smoothly with a low extrusion force (Table 58.1).

Contrary to the technique developed for collagen injection in 1982, CaHA hand recontouring requires a different injection technique : bolus injection, followed by vigorous massage, allowing the CaHA to fill where needed. It is a new technique, not predicated on line filling, but rather on steady vigorous massage to deliver the material to required atrophic areas (Table 58.2).

Preparing the Radiesse-lidocaine mixture Prior to injecting CaHA into the hands, it is hom*ogenized with 0.5 mL of 2% plain lidocaine. The 1.5 mL CaHA LuerLok syringe is attached via a Rapid Fill Luer-Lok to Luer-Lok connector (Baxa, Englewood, CO, USA) to a 3-mL Luer-Lok syringe containing 0.5 mL lidocaine (Figure 58.1) The use of a 3-mL Luer-Lok syringe is ideal for the hom*ogenization process, because a high extrusion pressure is generated to mix the two liquids. The Baxa connector should be filled with lidocaine prior to making the connection, otherwise the CaHA will not flow. Instead, the plunger will move down without product emerging from the needle tip, the result of air in the mixture. The CaHA is first injected into the syringe containing the lidocaine and mixed back and forth for 10 passes until the filler–lidocaine mixture is

Table 58.1 Representative treatment products for the aging hand. Product category

Duration of effect*†



Autologous fat

Widely variable, from 4 months to more than 12 months

Biocompatibility, potential neovascularization

Harvesting required, not amenable to patients with lipodystrophy, does not conceal structures

Calcium hydroxylapatite (Radiesse®)

Approximately 12–15 months

Biocompatibility, collagen proliferation, immediate correction, no overcorrection needed, minimal pain

Time required for mixing with lidocaine

Collagen [bovine] (Zyderm®, Zyplast®) CosmoDerm®, CosmoPlast® (human)

Approximately 2–3 months

Long history of use in US esthetics No testing required

Skin testing for hypersensitivity reactions, does not conceal structures

Hyaluronic acids (Juvederm™, Restylane®, Perlane®)

Approximately 6–9 months

Wide variety of products available

Visibility of papules, color not easily blended into skin of dorsum, tindall effect, does not conceal structures

Poly-L-lactic acid (Sculptra®)

Approximately 18–24 months

Sustained collagenesis after a few weeks post-injection

Multiple treatments often necessary, does not conceal structures

* Facial areas (scant literature on longevity in hand). ASDS Guidelines.


58. Hand recontouring

Table 58.2 Steps of in-office procedure for treatment of the aging hand. (Adapted from Busso M, Applebaum D. (2007) Hand augmentation with Radiesse® (calcium hydroxylapatite. Dermatol Ther 20, 315–17.) 1 Combine Radiesse with lidocaine, using a Luer-Lok connector for the Radiesse syringe and a 3-mL syringe containing 0.5 mL of 2% plain lidocaine 2 Identify the areas of treatment, usually between the second and fifth metacarpals, from the dorsal crease of the wrist to the metacarpophalangeal joints 3 Isolate the area of treatment with skin tenting between thumb and forenger of non-injecting hand, or forceps 4 Using a 27-gauge, 0.5-inch needle, inject the boluses of CaHAlidocaine mixture into the areolar plane between the subcutaneous layer and superficial fascia of the hand as needed 5 Have the patient make a fist of the injected hand, then firmly massage mixture to disperse 6 Schedule follow-up with patient in 2–4 weeks; repeat treatment for any areas missed during initial visit

Figure 58.2 Radiesse–lidocaine mixture with 1.5 mL Radiesse and 0.5 mL 2% plain lidocaine.

be modified depending on the injector’s judgment regarding the location of the defects to be filled.

How to inject

Figure 58.1 Radiesse with lidocaine using the Baxa connector.

smooth and without bubbles (Figure 58.2) [4]. The addition of the anesthetic changes the viscosity and filler extrusion force, delivering a more malleable mixture which is less viscous and therefore requires a smaller extrusion force.

Where to inject Careful injection site selection can considerably limit the amount of bruising. Before injecting, carefully examine the hand to ensure selection of an area devoid of veins or tendons. The imaginary line of bolus injection(s) is midway between the dorsal crease of the wrist and the metacarpophalangeal joints, bound laterally by the fifth metacarpal and medially by the second metacarpal. This boundary can

The patient should be comfortably seated on an examination table with the hands extended in front of them, preferably resting on a Mayo stand covered with a soft pillow, adjusted to the height of the patient’s knees, allowing gravity to have the desired effect on the defects to be corrected. The skin must be tented in order to separate it from the underlying veins and tendons (Figure 58.2). Entry is into the areolar plane, which is located between the superficial fascia and the subcutaneous fat. The thumb and forefinger of the noninjecting hand are used to lift the skin and create the entry point in the center of the tent (Figure 58.3). With a 27-gauge by 0.5 inch needle (or the new 28-gauge with 27-gauge inner lumen) attached to the prefilled CaHA syringe, inject 2–4 boluses of product across the previously described area of the dorsum of the hand, refilling the syringe when necessary. The average bolus amount is about 0.2–0.5 mL CaHA emulsion (Figures 58.4–58.6).

Post-injection hand massage At this point, massaging – the quintessential element of relocating the CaHA – is begun (Figure 58.7). Have the patient make a tight fist. To relieve friction and enhance the process, apply a liberal amount of Aquaphor (Beiersdorf Inc., Wilton, CT, USA) or white petrolatum to the dorsum. Begin pushing the boluses, one at a time, distally, laterally and medially, so that the bolus is flattened and spread as far as possible. Care should be taken not to encroach upon the metacarpophalangeal joints or the medial and lateral dorsopalmar junctions; product is not intended for these areas.



Skin Contouring Techniques

Figure 58.3 Tenting of the skin technique.

Figure 58.6 Injected bolus prior to closed-fist massage.

Figure 58.4 Injecting and forming bolus of Radiesse mixture (0.5 mL bolus) in the areolar plane.

Figure 58.7 Partial massage of bolus into the dorsum.

After completing treatment of the first hand, have the patient sit on that hand while you treat the other hand. It will help in the smoothing out process as well as add to hemostasis if needed. In the event of a hematoma, have the patient hold pressure firmly for 5–10 minutes, and proceed to begin treating the contralateral hand. When the other hand is completed, go back and complete the “bruised” hand. Each hand usually requires between one and two 1.5-mL syringes. CaHA is also available in 0.3 mL and 0.8 mL syringes, should a full 1.5-mL syringe not be needed for the second syringe.

Post-treatment care

Figure 58.5 Injected bolus prior to closed-fist massage.


After treatment is completed apply ice packs to the hands. The patient leaves the office with the disposable pack, using it for as long as it stays cool. Use of the ice pack will help reduce some of the possible swelling. The patient should be told to carry on with normal activities beginning the follow-

58. Hand recontouring ing day. Schedule the patient for follow-up in 2 weeks, and if at this time there are skip areas noticed, fill them in using the 0.3-mL CaHA syringe mixed with 0.12 mL of 2% lidocaine.

Adverse events Because it is a compound identical to that found in bone, CaHA has high biocompatibility and low adverse event risks. Adverse events in published studies have been few and of short duration [5–8]. They include ecchymosis, erythema, and occasional edema, when used in facial applications other than the lips. In general, the diluted product described for off-label use in the hands is even more forgiving. Clinical experiences with treatment of the aging hand suggest that adverse events in this area are infrequent and not severe. Anecdotal reports, however, have noted hand edema persist for 5–7 days post injection.

Figure 58.9 Same patient 2 weeks post-treatment with 1.5 mL mixture in each hand.

Results Figures 58.8–58.11 represent a 45-year-old female patient who received 1.5 mL CaHA mixture per hand during the initial visit, and did not have a touch-up performed. Figures 58.12–58.16 represent a 58-year-old female patient who also received 1.5 mL of CaHA mixture in each hand, and returned for a touch-up of the left hand only with 0.3 mL CaHA at week 8.

Discussion As with every new technique in surgery, refinements and modifications are the rule as time goes on. New approaches

Figure 58.10 Same patient 8 weeks post-treatment.

Figure 58.8 45-year-old female patient prior to treatment.

Figure 58.11 Same patient 12 weeks post-treatment.



Skin Contouring Techniques

Figure 58.12 58-year-old female patient pretreatment (pianist).

Figure 58.15 Same patient at 20 weeks after initial treatment.

Figure 58.13 Same patient 2 weeks post-treatment with 1.5 mL Radiesse mixture for each hand.

Figure 58.16 Same patient at 28 weeks after initial treatment.

Figure 58.14 Same patient 8 weeks post-treatment with a touch-up using 0.3 mL Radiesse mixture for only left hand performed at 4 weeks after initial treatment.


to the same technique give rise to slight revisions and adjustments leading to a better outcome. The original technique described by Busso was a single, voluminous bolus of an entire syringe of Radiesse and lidocaine, which was then spread out over the hand. Some physicians prefer the largevolume bolus approach; others believe it is less advantageous than the multiple, smaller-volume bolus approach. The volume of lidocaine remains an open question. The original volumes of lidocaine with the single bolus injection were much smaller (0.10 mL per 1.5 mL CaHA) than the volumes found in many clinical settings today (0.23–2.0 mL per syringe). In many personal communications, the author has determined that a larger volume of lidocaine is preferred for optimum results. These volumes have ranged 0.12– 2.0 mL lidocaine per 1.5-mL syringe of CaHA. A mixture of 0.5 mL of 2% lidocaine per 1.5-mL CaHA syringe and 0.12 mL for the 0.3-mL CaHA syringe appear optimal. There are several reasons why these two volumes are the volumes

58. Hand recontouring of choice. In the first place, considerably less hand swelling occurs when 0.5 mL lidocaine is used than using 2.0 mL. In addition, this volume enhances product flow and makes massage of injected mixture relatively easy. However, the most important reason is longevity and the convenience issue for the patient. Much less product is used with higher dilutions, and therefore the correction may not endure as long as with smaller dilutions. Busso’s recent paper states “physicians have reported that they see no significant decrease in durability for media diluted with lidocaine” [4]. At this point, controlled clinical trials are needed to determine that dilution with lidocaine does not negatively affect longevity of CaHA correction, not only in the hands, but for all applications. This issue of higher dilutions and possible decreased durability can easily be addressed, but it means more procedures at the 2-week follow-up than necessary. Follow-up sessions should address the missed areas that are inevitable, not retreating areas where the “excess” lidocaine has been absorbed. Another refinement that is helpful is the use of a smooth forceps to create the subsequent tents that might be needed. Once the emollient has been applied to the skin, a gloved hand on greasy skin will not be able to create the tent.

Conclusions Past experiences with products for treating the aging hand have met with limited success. These products – harvested fat, collagen, and hyaluronic acids – have disadvantages for placement in the hands for contouring enhancements. Foremost among these is the short duration, usually less than 3 months, and the inability of all of the other fillers to conceal the objectionable structures of the aging hand. CaHA appears well-suited for consideration as a product for recontouring of the hand, with a duration of effect of 6 months or longer. Unlike other areas, where there is not a

lot of muscle activity, the hand’s muscles and tendons are constantly moving, creating the friction that accelerates product breakdown. This is in contrast to more static treatment areas where there is greater longevity of correction. Perhaps the single most important and unique characteristic of CaHA that makes it ideal for hand recontouring is its opacity, the trait that enables the concealment of the undesirable structures of the aging hand. CaHA is also clinically unchanged by the addition of lidocaine, enabling painless treatment.

References 1 Alam M, Gladstone H, Kramer EM, Murphy JP, Nouri K, Neuhaus I, et al. Guidelines Task Force. (2008) American Society for Dermatologic Surgery (ASDS) Guidelines of Care: Injectable Fillers. Dermatol Surg 34, 115–48. 2 Busso M, Applebaum D. (2007) Hand augmentation with Radiesse® (calcium hydroxylapatite). Dermatol Ther 20, 315–7. 3 Berlin AL, Hussain M, Goldberg DJ. (2008) Calcium hydroxylapatite for facial filler rejuvenation: a histologic and immunohistochemical analysis. Dermatol Surg 34, 64–S67. 4 Busso M, Voigts R. (2008) An investigation of changes in physical properties of injectable calcium hydroxylapatite in a carrier gel when mixed with lidocaine and with lidocaine/epinephrine. Dermatol Surg 34, 16–24. 5 Tzikas TL. (2008) A 52-month summary of results using calcium hydroxylapatite for facial soft tissue augmentation. Dermatol Surg 34, 9–15. 6 Carruthers A, Liebeskind M, Carruthers J, Forster BB. (2008) Radiographic and computed tomographic studies of calcium hydroxylapatite for treatment of HIV-associated facial lipoatrophy and correction of nasolabial folds. Dermatol Surg 34, 78–84. 7 Moers-Carpi M, Vogt S, Martinez Santos B, Planas J, Rovira Vallve S, Howell DJ. (2007) A multicenter, randomized trial comparing calcium hydroxyalaptite to two hyaluronic acids for treatment of nasolabial folds. Dermatol Surg 33, 144–51. 8 Sadick NS, Katz BE, Roy D. (2007) A multicenter, 47-month study of safety and efficacy of calcium hydroxylapatite for soft tissue augmentation of nasolabial folds and other areas of the face. Dermatol Surg 33, 122–7.


Part 6: Implementation of Cosmetic Dermatology into Therapeutics Chapter 59: Antiaging regimens Karen E. Burke The Mount Sinai Medical Center, New York, NY, USA

BAS I C CONCE P T S • The appearance of aging skin can indeed be reversed without invasive treatments by daily skin care using scientifically proven techniques and products. • Proper cleansing and exfoliation smooth the skin’s surface to decrease pore size and wrinkles within days. • Sun protection by application of ample amounts of high-SPF, UVA-protective, highly water-resistant sunscreen is essential to protect from photoaging and to enhance natural repair. • Topical retinoids as well as topical antioxidants such as vitamins C and E, selenium, genestein, and coenzyme Q10 not only protect from but also reverse photoaging if the correct molecular forms and concentrations are applied.

Introduction In her book, Survival of the Prettiest, Etcoff [1] synthesizes literature and research from anthropology, biology, psychology, and archeology to show that indeed appreciation of one’s own and others’ beauty is hard-wired in human brains. Etcoff concludes, “Flawless skin is the most universally desired feature of beauty.” This chapter presents a basic skin regimen to protect from photodamage and reverse the appearance of aging. The four necessary steps are cleansing, exfoliation, protection, and treatment. Helpful techniques and scientific research proving efficacy of specific ingredients are presented.

Cleansing Proper cleansing is an essential component of skincare. The face accumulates endogenous and exogenous soils.

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


Sebaceous gland size and density are greatest on the face, upper back, and chest. The natural oils, sweat, and sebum secretions create a hydrolipid film on the skin surface that, in addition to applied cosmetics, traps and accumulates environmental pollutants such as dust, airborne irritants, and compounds from cigarette smoke. Care must be taken to accomplish thorough cleansing without irritation or drying. Therefore, a gentle, effective cleanser is of utmost importance. Surfactants are the ingredients that bind to dirt and oil for removal. These surfactants are classified by their charge on the surface-active moiety as anionic (negatively charged, for good foaming and lathering), cationic (positively charged), amphoteric (both positive and negative, considered to “condition” skin while helping to foam), and non-ionic (which are used in baby products to suppress foam) [2]. Components of surfactants can bind to the stratum corneum proteins, decreasing the skin’s ability to bind and hold water. With continued, frequent use, surfactants can damage the skin barrier. New synthetic surfactants improve cleansing with less irritation. Other components of cleansers include polypeptides and synthetic polymers to make the product smooth and to soften skin, polymers to moisturize, preservatives, opacify-

59. Antiaging regimens

Figure 59.1 To treat wrinkles while washing, gently rub upward horizontally across the upper lip and “up and out” on the rest of the face – perpendicular to the direction of wrinkles.

ing agents, and fragrance. With frequent washing, these ingredients can cause sensitivities or contact allergy in certain individuals. Because cleansers are rinsed off, their contact time with the skin is reduced causing less contact allergy. Newer cleansers are less alkaline than older formulations, so they are less drying. In recent years, antibacterial agents (e.g. triclosan and triclocarban) have been added to hand cleansers. Surprisingly, these agents are rarely skin irritants. However, some physicians voice concern, fearing development of bacterial resistance to these antibiotics with frequent use. Originally, triclosan was thought to kill bacteria by a “broad-based” mechanism, similar to alcohol and peroxide. However, recent research demonstrated that triclosan acts at a specific gene site in Escherichia coli to inhibit replication, so resistant strains could evolve [3]. Thorough washing with gentle cleansers removes dirt and has been shown to be as effective as using these antibacterial compounds. Cleansing the face should be accomplished with lukewarm water and the fingertips. The face and neck should be washed with upward, outward motions. On the face, one should always rub perpendicular to the direction of those wrinkles that could develop later. On the forehead, cheeks, chin and neck, rub up and out; above the upper lip and under the eyes, the strokes should be first horizontal, then upward at the edges, as illustrated in Figure 59.1. Sunscreen, moisturizer, or other treatments should be applied immediately after gently towel-drying.

Exfoliation Exfoliation is the rejuvenation treatment providing the most immediate improvement in appearance. Exfoliation removes

the outer layers of stratum corenum, and thus treats the hyperkeratosis of dry skin. Exfoliative rubbing perpendicular to the direction of wrinkles minimizes small wrinkles because the surface is smoothed (Figure 59.1). Exfoliation can be chemical or mechanical. Chemical exfoliants such as hydroxyacids and retinoic acid remove dead surface cells by keratolysis. Mechanical exfoliants include cleansing grains, waxy creams that adhere to the surface cells, as well as slightly abrasive terry washcloths, non-woven polyester polishing pads, brushes, or loofas which physically “sand” the skin surface by rubbing. Grainy exfoliants with aluminum oxide crystals can be effective, but the user must be careful not to get the grains into the eyes. Exfoliants to be avoided are those with apricot or almond kernels, walnut shells, and pumice – all of which have irregularly shaped particles with sharp edges which can be too rough on delicate skin and dangerous if they get into the eyes. The immediate improvement in small wrinkles by gentle exfoliation can be appreciated in Figure 59.2. Masks are among the oldest face mechanical exfoliants. Masks can “wash off” or “peel off.” Some “wash off” masks are made of clay, which harden and are removed with water rinsing. “Peel-off” masks contain synthetic polymers that are quite safe and effective. Some masks may irritate the skin; it is advisable to test on the inner wrist before treating the face.

Protection The single most effective therapy for aging skin is sun protection [4]. Avoid sun exposure between 10AM and 4PM, and beware of “hidden sun”: UVA is not filtered by glass and neither UVA or UVB are filtered by clouds. People get their worst burns on cloudy days, especially when skiing or when on the beach or in the water. Sunscreen should be applied often and generously. Sunscreens are classified as organic filters (which absorb photons of UV light) or inorganic filters (which reflect or scatter UV radiation) [5]. As shown in Figure 59.3, some organic sunscreen agents block only UVB (p-aminobenzoic acid [PABA] and its esters padamate A and O, the cinnamates, and salicylates); others absorb primarily UVB and some low wavelength UVA (octocrylene, benzophenones, anthranalides). Mexoryl XL or SL blocks UVB as well as most UVA. The UVA absorbing sunscreen avobenzone (Parsol 1789) can degrade with exposure to UV [6], but stabilizing compounds (benzylidene camphor and diphenyl cyanoecrylate derivatives, both UVB filters) can be effectively added [7]. The inorganic filters with microfine titanium dioxide and zinc oxide are total UVB blocks, blocking low wavelength UVA and almost all UVA, respectively. Thus, zinc oxide provides better protection than titanium dioxide [8]. The new technology with microfine particles makes them



Implementation of Cosmetic Dermatology into Therapeutics





Padimate-O Sunscreen ingredients

Octyl methoxycinnamate Octyl salicylate Octocrylene Benzophenone Titanium dioxide Avobenzone Mexoryl Zinc oxide


320 UVB


400 UVAI

Ultraviolet spectral coverage Figure 59.3 Ultraviolet spectral coverage of sunscreen ingredients.


Figure 59.2 Tiny wrinkles and crepy skin can be treated immediately at home by exfoliation. Improvement is seen in this 60-year-old woman’s face after she simply washed with a non-woven polyester polishing pad and used a waxy exfoliant that mechanically “sticks” and removes surface cells. (a) and (c), pre-exfolitaion; (b) and (d), post-exfoliation.

non-opaque and cosmetically appealing. The concentration and the size of the microparticles determine SPF efficacy [5]. The ability of a sunscreen to prevent UVB-mediated erythema is measured by the internationally accepted standard sun protection factor (SPF), the ratio of equivalent exposure by UVB in sunscreen-protected compared with unprotected skin. (An SPF of 30 means that the amount of UB exposure in 10 minutes without sunscreen is equivalent to 10 minutes × 30 = 5 hours of exposure with sunscreen.) The SPF should be at least 25–30. After SPF, the second important criterion for a sunscreen is that it be “highly water resistant,” meaning it is effective for about 90 minutes. Many prefer a different sunscreen for the face than for the body. These criteria are summarized in Table 59.1. Further protection with topical antioxidants and sun protective clothing, hats, and sunglasses are indicated. Sun pro-

59. Antiaging regimens

Table 59.1 Criteria of a good sunscreen. 1. 2. 3. 4. 5.

High SPF (SPF 25 or higher) Protection against UVA and UVB Highly water resistant Non-comedogenic Excellent esthetics

SPF, sun protection factor.

tective clothing is rated using UV protective factor (UPF), measured by the amount of UV radiation transmitted through the fabric. A fabric with a UPF of 40–50 transmits only 2.6% of biologically effective radiation, in contrast with normal summer clothing that typically has a UPF of only 4–10, providing a maximum SPF of 30% but often only an SPF of about 2 if wet [9]. New products (such as SunGuard (2,2 ′ - (1,2 - ethenediyl)bis[5 - [[4 - (methylamino) - 6[[4 (methylamino)catonyl]-phenyl]amino]-1,3,5-triazin-2-yl] amino]-, disodium salt)) have recently become available to be added when washing clothes to give a UPF of 30 that lasts 20 washes.

Treatment There are several medical treatments for antiaging purposes. These include retinoic acid, hydroxy acids, and topical antioxidants. Many products are advertised, but their efficacy may not have been demonstrated by rigorous placebocontrolled, double-blind clinical trials.

Hydroxyacids Hydroxyacids (HAs) have been used for centuries. Cleopatra routinely applied HAs and Marie Antoinette washed with red wine, benefitting from tartaric acid. Hydroxyacids were reintroduced to dermatology in 1974 when Van Scott and Yu [10] reported improvement of severe hyperkeratosis and icthyosis. Hydroxyacids are classified by the position of the hydroxyl group attached to the acid moiety: α-hydroxyacids (AHAs) (glycolic acid, lactic acid, and citric acid), β-hydroxyacids (BHAs) (tropic acid, salicylic acid [SA] – called a BHA but actually an αhydroxybenzoic acid), and the “new generation” polyhydroxy acids (PHAs) (gluconolactone or lactobionic acid – a naturally occurring component of skin). AHAs act rapidly (within 2 weeks) to smooth the surface skin by reducing epidermal cornecyte adhesion, first at the innermost level of the stratum corneum (just above the stratum granulosum) [11]. Epidermal damage of photoaging is corrected in 14–16 weeks, resulting in a thinned stratum corneum, epidermal acanthosis, and decreased melanogenesis [12]. An increase

in epidermal intercellular hyaluronic acid improves surface moisturization by water retention. An elegant study demonstrated that epidermal keratolysis is followed by dermal penetration which increases synthesis of glycosaminoglycans and increases fibroblast proliferation and production of collagen and elastin [13]. A 25% increase in skin thickness was measured after 6 months’ treatment with 25% AHAs with no inflammation. SA is unique among the hydroxyacids in that it is lipophilic and is particularly attracted to sebaceous orifices, thereby exhibiting its keratolytic properties not only to smooth surface wrinkles, but also to decrease pore size and prevent acne. As an excellent keratolytic agent, SA solubilizes intercellular cement by disrupting corneocyte adhesion layer by layer, from the surface downward. SA may also be directly bacteriostatic. The PHAs have several advantages. They have larger molecules, so they penetrate the skin gradually and are therefore less irritating than AHAs or SA. PHAs are recommended for patients with sensitive skin, rosacea, or atopic dermatitis [12]. They can even be used in conjunction with retinoic acid without irritation. PHAs also give improved moisturization of the stratum corneum when compared with AHAs. PHAs have anti-inflammatory and antioxidant activity, further enhancing repair of cutaneous photoaging [14]. Three key factors determine HA efficacy: 1 Type of hydroxyacid (described above). 2 Concentration: the higher the concentration, the more effective but the more possible irritation. Concentrations of 8–12% glycolic and lactic acids are available by prescription, as are concentrations of SA greater than 3%. High concentrations are used for medical chemical peels. 3 pH (acidity): the amount of biologically free acid determines the clinical strength [15]. To be effective, the hydroxyacid must be acidic. There is a delicate balance in attaining efficacy without irritation. For each type of hydroxyacid or mixture thereof, the concentration and pH determines the strength and the clinical benefits [15].

Retinoids Retinoids are the “gold standard” for reversing photoaging of the skin. Retinoic acid (tretinoin) has been used for more than 35 years for the treatment of acne. In the late 1980s, the remarkable clinical improvement of wrinkles and solar lentigos after treatment with topical tretinoin was documented [15–17]. UV exposure leads to decreased expression of retinoic acid receptors (RAR) and retinoic X receptors (RXR) (in particular, RAR-α and RXR-γ, the two major nuclear receptors in keratinocytes) with subsequent activation of transcription factors (AP-1 and NF-IF) which increase proliferation and inflammation and activate the matrix metaloproteinases (MMPs) which break down extracellular



Implementation of Cosmetic Dermatology into Therapeutics

matrix proteins [18]. By binding to these receptors, topical retinoids restore expression, thereby reversing UV-induced damage at all levels of the epidermis and dermis [19,20]. Retinoids increase epidermal proliferation causing epidermal thickening with compaction of the stratum corneum and deposition of glycosaminoglycans intercellularly; with epidermal proliferation, inhibition of excess melanogenesis and shedding of melanin-laden keratinocytes resolves mottled hyperpigmentation; and retinoids directly induce collagen synthesis and reduce collagen breakdown by inhibiting the UV-induced MMPs [21,22], thereby correcting wrinkles. Topical tretinoin also reverses intrinsic aging, perhaps even more significantly in non-sun-exposed than in photoaged skin. A marked increase in epidermal thickness (with a more undulating dermoepidermal junction), in anchoring fibrils, and in dermal angiogenesis with new elastic fibers and glycosaminoglycans was observed [23]. Previously, topical tretinoin was postulated to make the skin more sensitive to UV exposure. Indeed, resolution of unattractive hyperkeratosis may allow more UV to penetrate deeper, but the inhibition of the UV-induced MMPs that break down collagen results in less UV damage with tretinoin treatment. Occasionally, irritation (retinoid dermatitis) can occur, especially when beginning treatment. This can usually be avoided by starting with lower concentrations (0.025% cream instead of 0.05% cream or 0.01% gel), other formulations (microsphere gels, new generic formulations, or different retinoids as described below), and less frequent application. Patients with sensitive skin should begin with a mild formulation, applying initially each 3 days and increasing to daily over several weeks or months. Most of the improvement occurs within the first year, improvement is maintained with continued use, as proven by up to 4-year histologic studies [22]. Other “second generation” retinoids have been proven effective in treating photodamage [22]. Retinaldehyde cream (0.05%) and retinol cream (up to 1.6%) are comparable to tretinoin in efficacy, but are more irritating. Tazarotene (0.5% and 0.1%) may give faster improvement but is also more irritating. Adapalene (0.1% cream and gel) is less irritating but probably less effective than tretinoin.

Antioxidants The skin naturally uses nutritional antioxidants to protect itself from photodamage and topical application has been investigated. The challenge is to make topical antioxidant formulations that are stable and that give percutaneous absorption to deliver high concentrations of the active forms to the dermis as well as the epidermis.

Vitamin C If the retinoids are the “gold standard,” topical vitamin C is the “silver standard” for reversing photoaging of the skin. Vitamin C (L-ascorbic acid) is the body’s major aqueous-


phase antioxidant. Dietary vitamin C is absolutely required for life. Environmental free-radical stress depletes vitamin C levels in the skin. UV exposure of 1.6 minimal erythema dose (MED) decreases vitamin C to 70% normal, and 10 MED to 54% [20]. Although vitamin C is itself not a sunscreen, topical vitamin C protects against solar damage. As an antioxidant, vitamin C deactivates the UV-induced free radicals, decreasing erythema and sunburn. This protection has been confirmed by histologically: treatment with topical 10% vitamin C decreases the number of abnormal “sunburn cells” by 40–60% and reduces the UV damage to DNA by 62% [24]. The main function of vitamin C is as the essential co-factor for collagen synthesis. When 10% vitamin C was added to in vitro elderly fibroblasts, collagen proliferation and synthesis increased by factors of 6 and 2, respectively [25]. Vitamin C also inhibits tyrosinase, thereby lightening solar lentigos. Formulation is key to optimizing percutaneous absorption of vitamin C. Because L-ascorbic acid is inherently unstable – making it an excellent antioxidant – an effective topical delivery system is crucial. Many products contain stable derivatives, which are not metabolized by the skin (such as ascorbyl-6-palmitate or magnesium ascorbyl phosphate) and therefore have no appreciable cutaneous activity [26]. Other formulations do not result in measurable absorption of vitamin C because they are not at the correct pH. Topical absorption of 10% vitamin C cream was proven by radioactive labeling studies in pigs. After treatment, 8.2% was found in the dermis, and 0.7% was in the blood [27]. The most effective concentration for topical delivery is 20%, giving maximal skin levels after 3 days.

Vitamin E (d-α-tocopherol) Natural vitamin E is the most important lipid-soluble, membrane-bound antioxidant in the body. Natural dietary vitamin E can exist in four methylated forms (α, β, χ, δ); synthetic vitamin E is a mixture of eight (d,l) stereoisomers. The d-α-tocopherol isomer has the greatest biologic efficacy. In order to attain activity through cutaneous application, the natural non-esterified form must be applied in concentrations greater than 2% (5% is optimal) [28]. Most commercial products containing “vitamin E” contain a mixture of 32 synthetic isomers, esterified, and in quite low concentrations. Allergic contact dermatitis has been reported from such formulations, although no adverse reaction has ever been reported with the natural d-α-tocopherol. In a mouse model, topical d-α-tocopherol has been shown to be impressively effective in protecting against all acute and chronic UV-induced damage, and far more effective than the esterified topical d-α-tocopherol succinate [29]. Vitamin E has also been demonstrated to reverse photoaging dramatically. Figure 59.4 shows the dramatic decrease in periorbital rhytides after 4 months of daily application of

59. Antiaging regimens


(a) Figure 59.4 Correction of periorbital wrinkles after 4 months of once-daily treatment with 0.05% d-α-tocopherol cream. (a) Before. (b) After.

d-α-tocopherol (5%). Histology confirmed this improvement in a mouse model. The UV-induced epidermal hypertrophy and hyperkeratosis, the increased incidence of damaged “sunburn cells” in the basal layer, and the disruption of dermal collagen and elastin were all corrected after 8 weeks of topical treatment (KE Burke, L Riciotti, EG Gross, unpublished observations).

Vitamin C with vitamin E In cells, vitamins C and E interact synergistically to provide antioxidant protection. In membranes, vitamin E is oxidized as it quenches peroxyl free radicals and intracellular vitamin C regenerates the vitamin E activity [30]. Oral vitamin C with E in high doses protects against UV-induced erythema in humans, whereas either vitamin alone is ineffective [27]. Compared to twofold protection for either vitamin alone, topical L-ascorbic acid (15%) with α-tocoperol (1%) gives fourfold protection against UV-induced erythema, decreasing the number of damaged “sunburn cells” seen histologically and decreasing thiamine dimer formation in porcine skin [29]. Fortunately, mixing these hydrophilic and lipophilic antioxidants in a topical formulation stabilizes each.

Vitamin C with vitamin E and ferulic acid Ferulic acid is a potent antioxidant present in the cell walls of grains, fruits, and vegetables. Ferulic acid alone absorbs some UV and therefore is itself a weak sunscreen. When mixed with vitamins C and E, it further stabilizes the formulation and acts synergistically to double the photoprotection from fourfold to eightfold [31]. This triple antioxidant combination has been made into the SkinCeuticals product

C E Ferulic (15% vitamin C, 1% vitamin E, and 0.5% ferulic acid).

Other antioxidants Coenzyme Q10 Coenzyme Q10 (ubiquinone or CoQ10) is a component of the mitochondrial electron transport chain in all plant and animal cells, including human cells, especially in organs with high rates of metabolism such as the heart, liver, and kidney. In the skin, CoQ10 acts as an antioxidant, although the level is naturally relatively low, with 10 times more in the epidermis than the dermis [32]. CoQ10 has been shown to reverse natural intrinsic aging by increasing rates of cell division and increasing natural hyaluronic acid [33]. Decreased wrinkle depth was documented by optical profilometry using 0.3% ubiquinol cream for 6 months [34]. CoQ10 also suppresses UVA destruction of collagen [33].

α-Lipoic acid α-Lipoic acid (αLA), made in cells of all plants and animals, has many impressive antioxidant properties and has been shown to retard aging in heart and brain cells in laboratory studies. However, the evidence for reversal of photoaging in the skin is scant: 33 women applied 5% αLA to half of their faces for 12 weeks and noted some decrease in wrinkles, skin roughness, and fading of dark spots [35]. αLA provides little or no protection against sun damage [33]. Selenium Selenium is a trace mineral essential to human life because it is the required co-factor for the intracellular antioxidant



Implementation of Cosmetic Dermatology into Therapeutics

Table 59.2 Photoprotection and reversal of photoaging. Treatment agent



Treatment of wrinkles

Treatment of solar lentigos

α-Hydroxy acids

Sugar cane, milk, fruits*



β-Hydroxy acids

Willow or sweet birch bark, wintergreen leaves*



Retinoic acid

Vitamin A*

Dermis only



Vitamin C

Citrus fruits, red peppers




Vitamin E (d-α)

Sunflower oil




Ferulic acid

Cell wall of fruits, grains, vegetables




Coenzyme Q10 (ubiquinone)

Fish, shellfish, spinach, nuts

Dermis only



α-Lipoic acid

All plant and animal cells (including humans)*




Grains, saltwater fish









+, Minimal effect noted in good studies; ++++, maximal effect (a “gold standard”) ?, not studied. * Produced synthetically for cosmetic products.

enzymes glutathione peroxidase and thiodoxin reductase. Topical L-selenomethionine (0.02–0.05%) has been shown to protect the skin from both acute and chronic UV damage (erythema, pigmentation, and skin cancer) [36]. Application increases MED [37] and delays the onset and decreases the incidence of skin cancer [38]. Furthermore, when applied to sun-damaged skin, topical L-selenomethionine was shown clinically and histologically to reverse photoaging as effectively as retinoic acid – with a decrease in hyperkeratosis and regeneration of collagen and repair of elastic tissue.

Genistein Genistein is a potent antioxidant isolated from soy, which has been proven to protect against UV-induced erythema and skin cancer [38]. As a phytoestrogen, genistein confers the additional benefit of stimulating collagen synthesis, and thus may prove to be an excellent treatment for wrinkles. In Table 59.2, this author has summarized her personal impressions of the clinical efficacy of well-researched topicals for photoprotection and reversal of photoaging. Others include niacinamide (smoothing texture, improving red blotchiness, and dark spots, decreasing yellowing, and improving fine lines, wrinkles, and elasticity – but is only about one-third to one-fifth as effective as retinoic acid), and kinetin (a synthetic plant growth hormone that retards senescence in plants, shown to reverse aging of skin cells in


the laboratory, but in the author’s experience only minimally helpful in correcting wrinkles).

Conclusions The appearance of aging skin can be treated non-invasively. Strategies include primary prevention (with changes in lifestyle by not smoking, avoiding excessive sun exposure, and assiduous protection when in the sun) and treatment. Some treatments improve the appearance immediately and others act physiologically to inhibit further photodamage and to reverse previous damage at a molecular level. New therapies for photoaging are promoted, but many have not been subjected to large, placebo-controlled, double-blind, clinical trials.

References 1 Etcoff N. (1999) Survival of the Prettiest: The Science of Beauty. New York: Anchor Books, Random House. 2 Rieger MM. (2000) Skin cleansing products. In: Rieger MM, ed. Harry’s Cosmeticology. New York: Chemical Publishing Company, Inc., pp. 485–500. 3 Levy CW, Roujeinikova A, Sedelnikova S, Baker PJ, Stuitje AR, Slabas AR, et al. (1999) Molecular basis of triclosan activity. Nature 308, 383–4. 4 Glaser DA. (2003) Anti-aging products and cosmeceuticals. Facial Plast Surg Clin North Am 11, 219–27.

59. Antiaging regimens 5 Forestier S. (2008) Rationale for sunscreen development. J Am Acad Dermatol 58, S133–8. 6 Roscher NM, Lindeman MKO, Kong SB, et al. (1994) Photodecomposition of several compounds commonly used as sunscreen agents. J Photochm Photobiol A 80, 417–21. 7 Deflandre A, Forestier S, Lang G, et al., inventors; L’Oreal, assignee. (1997) Photostable cosmetic composition containing a UV-A screen and a UV-B screen and a process for stabilizing the UV-A screen with the UV-B screen. US patent US 5605680. February 25. 8 Pinnell SR, Fairhurst D, Gillies R, Mitchnick MA, Kollias N. (2000) Microfine zinc oxide is a superior sunscreen ingredient to microfine titanium dioxide. Dermatol Surg 26, 309–14. 9 Diffey BL. (2001) Sun protection with clothing. Br J Dermatol 144, 449–51. 10 Van Scott EJ, Yu RJ. (1974) Control of keratinization with the alpha hydroxy acids and related compounds. Arch Dermatol 110, 586–90. 11 Van Scott EJ, Ditre CM, Yu RJ. (1996) Alpha-hydroxyacids in the treatment of signs of photoaging. Clin Dermatol 14, 217–26. 12 Grimes PE, Green BA, Wildnauer RH, Edison BL. (2004) The use of polyhydroxy acids (PHAs) in photoaged skin. Cutis 73, 3–13. 13 Ditre CM, Griffin TD, Murphy GF, Sueki H, Telegan B, Johnson WC, et al. (1996) Effects of AHAs on photoaged skin: a pilot clinical, histological and ultra-structural study. J Am Acad Dermatol 34, 187–95. 14 Green B, Briden ME. (2009) PHAs and bionic acids: next generation hydroxy acids. In: Draelos ZD, Dover JS, Alan M, eds. Philadelphia, PA: Elsevier Saunders, In press. 15 Weiss JS, Ellis CN, Headington JT, Tincoff T, Hamilton TA, Voorhees JJ. (1988) Topical tretinoin improves photodamaged skin: a double-blind, vehicle-controlled study. JAMA 259, 527–32. 16 Kligman AM, Grove GL, Hirose R, Leyden JJ. (1986) Topical tretinoin for photoaged skin. J Am Acad Dermatol 15, 836–59. 17 Burke KE, Graham GF. (1988) Tretinoin for photoaging skin: North Carolina vs. New York. JAMA 260, 3130. 18 Fisher GJ, Wang ZQ, Datta SE. (1997) Pathophysiology of premature skin aging induced by ultraviolet radiation. N Engl J Med 337, 1419–28. 19 Stratigos AJ, Katsambas AD. (2005) The role of topical retinoids in the treatment of photoaging. Drugs 65, 1061–72. 20 Shindo Y, Wit E, Han D, Packer L. (1994) Dose–response effects of acute ultraviolet irradiation on antioxidants and molecular markers of oxidation in murine epidermis and dermis. J Invest Dermatol 23, 470–5. 21 Wang Z, Boudjelal M, Kang S, Voorhees JJ, Fisher GJ. (1999) Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pretreatment. Nat Med 5, 418–22. 22 Bhawan J, Olsen E, Lufrano L, Thorne EG, Schwab B, Gilchrest BA. (1996) Histologic evaluation of the long-term effects of tretinoin on photoaged skin. J Dermatol Sci 11, 177–82.

23 Kligman AM, Dogadkina D, Lauker RM. (1993) Effects of topical tretinoin on non-sun-exposed protected skin of the elderly. J Am Acad Dermatol 39, 25–33. 24 Darr D, Combs S, Dunston S, Manning T, Pinnell S. (1992) Topical vitamin C protects porcine skin from ultraviolet radiation-induced damage. Br J Dermatol 127, 247–53. 25 Phillips CL, Combs SB, Pinnell SR. (1994) Effects of ascorbic acid on proliferation and collagen synthesis in relation to donor age of human dermal fibroblasts. J Invest Derm 103, 228–32. 26 Pinnell SR, Yang HS, Omar M, Monteiro-Riviere N, DeBuys HV, Walker LC, et al. (2001) Topical L-ascorbic acid: percutaneous absorption studies. Dermatol Surg 27, 137–42. 27 Fuchs J, Kern H. (1998) Modulation of UV-light-induced skin inflammation by d-α-tocopherol and L-ascorbic acid: a clinical study using solar simulated radiation. Free Radic Biol Med 25, 1006–12. 28 Burke KE, Clive J, Combs GF Jr, Commisso J, Keen CL, Nakamura RM. (2001) The effects of topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh:2 hairless mice. J Nutr Cancer 38, 87–97. 29 Lin JY, Selim MA, Shea CR, Grichnik JM, Omar MM, MonteiroRiviere NA, et al. (2003) UV photoprotection by combination topical antioxidants vitamin C and E. J Am Acad Dermatol 48, 866–74. 30 Chan AC. (1993) Partners in defense, vitamin E and vitamin C. Can J Physiol Pharmacol 71, 725–31. 31 Lin FH, Lin JY, Gupta RD, Tournas JA, Burch JA, Selim MA, et al. (2005) Ferulic acid dstabilizes a solution of vitamins C and E and doubles its photoprotection of skin. J Invest Dermatol 125, 826–32. 32 Hoppe U, Bergemann J, Diembeck W, Ennen J, Gohla S, Harris I, et al. (1999) Coenzyme Q10, a cutaneous antioxidant and energizer. BioFactors 9, 371–8. 33 Pinnell SR, Lin J-Y, Lin F-H, et al. (2004) Alpha lipoic acid is ineffective as a topical photoprotectant of skin. Poster presentation, 62nd Annual Meeting of the American Academy of Dermatology, Washington, DC. 34 Eucerin Q10 Anti-Wrinkle Sensitive Skin Crème. (2003) From Wrinkle Reduction Study 2003. In: Eucerin Q10 Product Compendium. Wilton, CT: Beiersdorf Inc., p. 11. 35 Beitner H. (2003) Randomized, placebo-controlled, double blind study on the clinical efficacy of a cream containing 5% alphalipoic acid related to photoaging of facial skin. Br J Dermatol 149, 841–9. 36 Burke KE, Combs GF, Gross EG, Bhuyan KC, Abu-Libdeh H. (1992) The effects of topical and oral L-selenomethionine on pigmentation and skin cancer induced by ultraviolet irradiation. Nutr Cancer 17, 123–37. 37 Burke KE, Burford RG, Combs GR Jr, French IW, Skeffington GR. (1992) The effect of topical L-selenomethionine on minimal erythema dose of ultraviolet irradiation in humans. Photodermatol Photoimmun Photomed 9, 52–7. 38 Wei H, Saladi R, Lu Y, Wang Y, Palep SR, Moore J, et al. (2003) Isoflavone genistein: photoprotection and clinical implications in dermatology. J Nutrition 133, 3811S–9S.


Chapter 60: Over-the-counter acne treatments Emmy M. Graber1 and Diane Thiboutot2 1 2

SkinCare Physicians, Chestnut Hill, MA, USA Pennsylvania State University College of Medicine, Hershey, PA, USA

BAS I C CONCE P T S • Over-the-counter cosmeceutical products are frequently used in the treatment of acne. • Topical benzoyl peroxide is one of the most effective over-the-counter acne treatments. • Other active agents in acne products include hydroxy acids, salicylic acid, sulfur, and retinol. • Leave-on products have a more profound effect on acne than cleansers. • Cleansing cloths and scrubs may be used for their sebum removal and keratolytic activity.

Introduction Although acne is one of the most common conditions that a general dermatologist treats [1], most people with acne will first try to self-treat before seeking the assistance of a healthcare professional. A survey carried out in 2000 demonstrated that 75% of acne sufferers waited about 1 year prior to seeking the help of a healthcare professional [2]. Another study estimated that one-third of those battling acne will ever consult a physician regarding their condition [3]. Without the assistance of a physician, patients will often turn to the drugstore shelves to treat their acne. A plethora of over-the-counter (OTC) modalities exists for treating acne. These modalities include topical cleansers, creams, lotions, gels, and masks as well as mechanical treatments, essential oils, and oral vitamins. The non-prescription acne market is one of the fastest growing segments of the dermatologic industry. This OTC market worldwide is estimated to be 2–4 times the size of the prescription market [4]. Estimates from 2001 revealed that consumers spend approximately $100 million per year on OTC antiacne products [5]. The Food and Drug Administration (FDA) is the regulatory agency that presides over the marketing of nonprescription acne products. In the Final Acne Monograph, the FDA states that any product labeled as an “acne drug product” is defined as: “A drug product used to reduce the number of acne blemishes, acne pimples, blackheads and whiteheads.” The FDA defines OTC products that fit this description to include: salicylic acid, sulfur, sulfur combined

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


with resorcinol, and benzoyl peroxide [6]. Although products cannot be sold bearing an antiacne label unless they contain one of the above approved ingredients, many other products are marketed towards the acne-prone consumer claiming to “heal,” “purify,” or “cleanse,” the skin and pores. In this chapter we address OTC products that are marketed for the treatment of acne, not just those products that the FDA defines as an “acne drug product.” There are a multitude of OTC products with labeling that implies an acne efficacy. Some of these washes and leave-on products contain benzoyl peroxide, salicylic acid, alfa-hydroxy acids, polyhydroxy acids, retinol, or sulfur. Mechanical treatments exist as well and come in the form of cleansing brushs, adhesive pads, heating devices, and scrubs. Some patients may turn to homeopathic remedies such as tea tree oil or chamomile. Oral vitamins, such as vitamin A, zinc, or nicotinamide are also tried as an OTC acne fix.

Soaps and syndets Studies show that over half of those with acne believe that their condition is caused by poor hygiene and dirt on the skin [7]. This belief often leads patients to alter both how they wash their face and their face washing frequency. While washing the face twice daily is more optimal then washing once or four times daily, the quantity of cleansings probably does not matter as much as the substance that is used to wash the face [8]. A multitude of cleansers exist and can be categorized as either soaps or syndets. Traditional soaps are made of fats and an alkali and have a basic pH of 9–10. This pH, which is higher than the skin’s pH, disrupts the intercellular lipids that hold the stratum corneum together. The disintegration of the intercellular “cement” causes skin irritation. Syndets are made of synthetic deter-

60. Acne treatments 3.0 2.5

Log cm2

2.0 1.5 1.0 Figure 60.1 Reduction in Propionibacterium acnes with topical therapy. Clin-BP, clindamycin and benzoyl peroxide; Ery-BP, erythromycin and benzoyl peroxide. (From Leden JJ. (2001) The evolving role of Propionibacterium acnes in acne. Semin Cutan Med Surg 20, 139–43.)

0.5 0

gents and have a pH of 5.5–7, similar to the skin’s natural pH. Because syndets only contain less than 10% soap, they are much less damaging to the stratum corneum [9]. The benefit of syndet cleansers specifically for acne patients has been demonstrated in studies. One study, looking at 25 patients undergoing acne treatment, were randomized to cleanse with either a soap or a syndet. After 4 weeks, those using the syndet cleanser reported having significantly less acne and less oil. Both patients and dermatologists reported less irritation in those using the syndet cleanser [10]. Although not all-inclusive, some brands of syndet cleansers include Cetaphil, Aveeno, Purpose, Basis, Oil of Olay, and Dove. There are additional cleansers that are marketed specifically for acne use that contain an active antiacne ingredient (e.g. benzoyl peroxide or salicylic acid).

Benzoyl peroxide Benzoyl peroxide is commonly found in OTC antiacne washes, creams, and lotions. In fact, 23% of people aged 13–27 have used an OTC benzoyl peroxide product [11]. Benzoyl peroxide was first utilized in 1917 to bleach flour. In the 1960s, benzoyl peroxide began to have medical applications for treating leg and decubitus ulcers. Several years later, in 1979, it was first used for treating acne. Benzoyl peroxide has antibacterial, anti-inflammatory, and comedolytic properties, which makes it effective in acne treatment. It has antimicrobial properties against Propionibacterium acnes and Staphylococcal aureus. One study demonstrated an almost 2-log10 decrease in P. acnes concentration just after 2 days of 5% benzoyl peroxide use [12]. Another study confirmed this fast-acting effect showing that P. acnes counts reduced by a mean of 2-log10 after applying 10% benzoyl peroxide cream for 3 days. After 7 days, there was no further decline in P. acnes levels [13]. Benzoyl peroxide has greater antimicrobial properties against P. acnes than any of the topical antibiotics alone. However, unlike the antibiotics, benzoyl peroxide will not induce bacterial resistance. Using a topical



Benzoyl peroxide



Azelaic acid

antibiotic with the addition of benzoyl peroxide will increase the bactericidal effect of the antibiotic (Figure 60.1) [14]. Furthermore, it will also prevent the development of P. acnes resistance when used in combination with a topical or oral antibiotic [15]. Benzoyl peroxide also acts as an anti-inflammatory agent by reducing oxygen free radicals and also by lessening P. acnes density. The reduction of P. acnes has a profound antiinflammatory effect because the bacteria induce monocytes to produce tumor necrosis factor α (TNF-α), interleukin-1β, and interleukin-8 [16,17]. The strong anti-inflammatory and antibacterial effects of benzoyl peroxide can be parlayed into good clinical results, as shown in a large UK study. This study looked at five antimicrobial acne treatments over an 18-week period. Subjects used either oral oxytetracycline, oral minocycline, benzoyl peroxide, separate administration of topical erythromycin and benzoyl peroxide, or a combination product with containing both topical erythromycin and benzoyl peroxide. The 5% benzoyl peroxide used twice daily had similar efficacy to 100 mg minocycline once daily. This study also carried out a cost-effectiveness analysis and found that the least expensive treatment (benzoyl peroxide) was 12 times more cost-effective than minocycline [18]. Besides being an anti-inflammatory, benzoyl peroxide is also comedolytic. One study utilizing the rabbit ear comedogenicity assay showed a 10% reduction of comedones [19]. Another study compared 5% benzoyl peroxide twice daily with 0.05% tretinoin once daily for 8 weeks. Both treatments were “extremely effective” for all acneiform lesions but significantly reduced both open and closed comedones after only 2 weeks [20]. Benzoyl peroxide is available OTC in 2.5–10% strengths and as either washes or leave-on products (e.g. cream, lotion, gel). Leave-on products reduce P. acnes counts more than the washes, although both significantly reduce P. acnes on the skin [14]. There is some indication that gel formulations may be more stable and release benzoyl peroxide more consistently than creams and lotions [21]. Equal reductions of acneiform lesions are seen with benzoyl peroxide strengths of 2.5, 5, and 10%. Increasing the strength of benzoyl



Implementation of Cosmetic Dermatology into Therapeutics

peroxide seems only to intensify the irritation [22]. Skin irritation to benzoyl peroxide is one of its greatest barriers to use. Redness, stinging, and dryness may be manifestations of irritation. Many patients describe this as an “allergy” to benzoyl peroxide. However, true allergic contact dermatitis to benzoyl peroxide is estimated at only 1–2.5% of patients with acne [23,24]. Patients should be warned about irritation that may result and should also be told of the propensity for benzoyl peroxide to bleach fabrics and hair. In addition to being available OTC, benzoyl peroxide is also available as a prescription. These prescription products may contain different formulations that may enhance penetration and decrease irritation, although no head-to-head trials exist comparing prescription with OTC benzoyl peroxide. Since mouse studies have shown that benzoyl peroxide can produce DNA strand breaks, there has been some question to its carcinogenic potential. However, two case–control studies showed no correlation between benzoyl peroxide use and skin cancer. Additionally, 23 carcinogenicity studies in rodents produced negative results [11]. Epidemiologic evaluations have shown no association between benzoyl peroxide and malignant melanoma [25].

Alfa-hydroxy acids The hydroxy acids are another common OTC antiacne ingredient found in washes and leave-on products. There are two main classes of hydroxy acids that are used for treating acne: alfa-hydroxy acids and beta-hydroxy acids (Table 60.1). The alfa-hydroxy acids are water-soluble, penetrate the epidermis and even into the dermis at higher concentrations. They act by desquamating the stratum corneum (i.e. exfoliation). Specifically, alfa-hydroxy acids disrupt corneocyte adhesion in the upper stratum corneum, possible by chelating calcium [26]. This results clinically in a smoother appearance to the skin, and may also give the illusion of reducing pore size

[27]. Alfa-hydroxy acids also promote epidermolysis, disperse basal layer melanin, and when strong enough to penetrate the dermis they may increase collagen synthesis [28]. These effects may make alfa-hydroxy acids helpful for acne prevention and treatment of postinflammatory hyperpigmentation. The most common OTC alfa-hydroxy acids are glycolic acid (derived from sugar cane) and lactic acid (from sour milk) and are found in less than 10% concentration.

Salicylic acid The only beta-hydroxy acid used in dermatology is salicylic acid. Unlike the alfa-hydroxy acids, it is lipid-soluble allowing it to penetrate not only the epidermis but also the pilosebaceous unit. This added penetration makes it comedolytic, thus giving it superiority over the alfa-hydroxy acids in treating acne [29]. Salicylic acid also exerts anti-inflammatory effects by inhibiting arachidonic acid. Multiple studies exist demonstrating the superiority of salicylic acid to placebo or to benzoyl peroxide. One study examined 49 patients who applied either 0.5% salicylic acid or placebo twice daily for 12 weeks. Those who applied the salicylic acid had significantly reduced inflammatory papules and open comedones, but closed comedones were not diminished [30]. One of the two studies submitted to the FDA during the OTC approval phase was a 12-week, doubleblind investigation of 180 subjects. It compared the efficacy of 2% salicylic acid solution with a vehicle solution and 5% benzoyl peroxide. Of the subjects treated with the salicylic acid, 40% showed a good or excellent response versus 5% in the vehicle group and only 2% in the benzoyl peroxide group. Salicylic acid was better than either vehicle or benzoyl peroxide in improving total lesions, inflammatory lesions, and open comedones, but not closed comedones. The second study submitted to the FDA involved 187 subjects and compared 0.5% and 2% salicylic acid solution with the vehicle solution. Both 0.5% and 2% salicylic acid

Table 60.1 Hydroxy acids. Hydroxy acid


Alfa-hydroxy acids

Water soluble


Glycolic acid

Sugar cane

Lactic acid

Sour milk

Beta-hydroxy acid Salicylic acid


Lipid soluble

Willow bark, wintergreen, sweet birch



Over-the-counter strength

Dermis (at high concentrations)


Less than 10%

Epidermis and pilosebaceous unit

Exfoliative, comedolytic, anti-inflammatory


60. Acne treatments were superior to the vehicle in reducing inflammatory lesions, open and closed comedones, and total lesions [31]. There are also several studies that demonstrate the efficacy of salicylic acid formulations other than solution. A cross-over study evaluating a 2% salicylic acid cleanser and a 10% benzoyl peroxide lotion in 30 patients found the salicylic acid cleanser to be superior at improving comedones [32]. Another study demonstrated the efficacy of a 2% salicylic acid scrub in reducing open comedones [33]. Based on these studies, many consider salicylic acid more effective than benzoyl peroxide in treating comedonal acne, but less effective than benzoyl peroxide in treating inflammatory acne [31]. Unlike benzoyl peroxide, salicylic acid does not have the ability to prevent resistance when used in combination with oral or topical antibiotics.

to be comedogenic [39], further studies have not validated this claim [40]. Sulfur is available OTC in concentrations of 3–8% and is often found in combination with resorcinol or resorcinol monoacetate. The malodor and messiness of sulfur limits its use.

Triclosan and triclocarban Triclosan and triclocarban are two antimicrobials that are found in cleansers marketed for acne treatment and are often labeled as “antibacterial” cleansers. Including having effects against P. acnes, both of these antimicrobials are effective against Gram-positive bacteria and triclocarban also is effective against Gram-negative bacteria. Studies are scant, but there is some evidence that these antimicrobials improve acne [41,42].

Polyhydroxy acids A third class of hydroxy acids, polyhydroxy acids, is becoming more popular in OTC dermatologic formulations. Polyhydroxy acids have been shown to be less irritating than alfa-hydroxy acids, but their larger particle size may limit penetration [34]. Lactobionic acid and gluconolactone are polyhydroxy acids most often found in topicals marketed for antiaging purposes but may someday also be found in OTC acne treatments. Although very little of either the topical benzoyl peroxide or hydroxy acids is absorbed systemically, both of these OTC products are pregnancy category C. Like benzoyl peroxide, the hydroxy acids can cause skin irritation marked by dryness, erythema, and flaking. Use of the hydroxy acids can also lead to greater sun sensitivity. Although generally safe, toxic levels of salicylic acid (known as salicylism) can occur if salicylic acid is used on a large body surface area in patients with icthyosis or excoriations. Use of salicylic acid is contraindicated in any patient with an aspirin allergy [35].

Retinols Retinols are a group of vitamin A derivatives that are available topically OTC in various forms such as retinol, retinyl propionate, and retinyl palmitate. Both retinol and retinyl propionate are absorbed by keratinocytes where they are reversibly oxidized into retinaldehyde, wherease retinyl palmitate is inactive. Retinaldehyde is irreversibly converted into all-trans retinoic acid (i.e. tretinoin). Tretinoin is transported into the keratinocyte nucleus where it acts by binding to the hormone response elements. There are no large multicenter trials that evaluate the efficacy of the retinols. In general, the retinols are 20 times less potent than topical tretinoin but exhibit greater penetration than tretinoin [43]. 0.25% Topical retinol induces cellular and molecular changes similar to that observed with 0.025% tretinoin without causing the irritation typical of tretinoin. However, it should be noted that most OTC formulations of retinol come in only 0.04–0.07% [44].


Cleansing cloths

Sulfur is a yellow, non-metallic element that has been used for centuries to treat various dermatologic conditions. A physician in Ancient Rome, Aulus Cornelius Celsus (ca 25 BC – ca 50 BC), wrote De Medicina, a medical text which includes the use of sulfur in mineral baths to treat acne [36]. Sulfur continues to be used today for a variety of conditions because of its antifungal and bacteriostatic properties [37]. It is believed by some to also have a keratolytic effect. Although the precise mechanism of action is not known, sulfur is thought to interact with cysteine in the stratum corneum causing a reduction in sulfur to hydrogen sulfide. Hydrogen sulfide in turn degrades keratin, producing the keratolytic effect of sulfur [38]. Although one study has shown sulfur

Cleansing cloths are disposable, dry towlettes that are impregnated with a cleanser and possibly an antiacne ingredient. Just prior to use, most of them need to be moistened with water. They are manufactured by combining polyester, rayon, cotton, and cellulose fibers through a thermal process. Many cloths are impregnated with triclosan or a hydroxy acid. Their effect on the skin is determined in part by their ingredients but also by the type of weave. The cloths may be either open or closed weave. Cloths with an open weave have 2–3 mm between fibers. This relatively large spacing between the fibers decreases the cloth’s contact area with the skin and in turn lessens irritancy. The closed weave cloths have less space between each individual fiber and



Implementation of Cosmetic Dermatology into Therapeutics

are more irritating to the skin [45]. There are no known published trials evaluating the efficacy of cleansing cloths against acne.

Mechanical treatments In addition to the above-described antiacne ingredients, there are several OTC treatments designed to mechanically rid the skin of acne. Some of these treatments, such as scrubs and cleansing brushes, physically abrade the skin in an attempt to control acne. There are many abrasive scrubs available OTC that patients will often try to combat acne. Scrubs are topical agents that incorporate particles that mechanically abrade the skin and thin the stratum corneum. In general, three classes of scrubs exist. The most abrasive scrubs are made of aluminum oxide particles and ground fruit pits. These particles are the harshest on the skin, in part because of their irregular shape. The second, and milder, class of scrubs is made of polyethylene beads that are smooth and round particles. The mildest class of scrubs is composed of sodium tetraborate decahydrate granules, which soften and dissolve soon after application [45]. To our knowledge, there is only one published study looking at the effect of scrubs on acne. This study showed that scrubs did not improve comedones, but in fact worsened them. The abrasives also caused peeling and erythema. However, resorption of inflammatory lesions was somewhat augmented by the abrasives [46]. Some scrubs also include benzoyl peroxide or a hydroxy acid in order to target the consumer with acne. In addition to scrubs, another cleansing method designed to thin the stratum corneum is the cleansing brush. Some cleansing brushes (e.g. Sonic™ Skin Care Brush [Pacific Bioscience Labs, Bellevue, MA, USA]) are handheld, battery operator devices with an oscillating brush head while others are simply handheld, coarse pads (Clean and Clear™ Blackhead Eraser [Johnson and Johnson, New Brunswick, NJ, USA]). There are no published trials evaluating the efficacy of either of these devices for removing acne. However, there is a small internally performed study by the makers of the Sonic™ Skin Care Brush demonstrating the brush to remove 2.34 times more foundation than traditional cleansing methods. There are also adhesive pads (Biore™ [Kao Brands Co., Cincinnati, OH, USA]) on the market that are purported “to get rid of pore clogging buildup and blackheads” [47]. These disposable pads are applied to wet skin and left in place for 10 minutes, over which time the pad will stiffen. The active agent of these pads is polyquaternium 37, a cationic hydrocolloid substance that binds to the anionic component of comedonal plugs [48]. Although no studies exist evaluating the pads’ efficacy in treating acne, there is a report of its success in treating trichostasis spinulosa [48]. Besides mechanical agents such as brushes and pads, there is a handheld, electronic heating device (Zeno™ [Zeno 492

Corp., Houston, TX, USA]) designed to speed the resolution of existing acne lesions. The user is directed to apply the device to individual acne lesions for 2.5 minutes, for 2–3 times a day. The device heats to 121°Fahrenheit, killing P. acnes. The exact mechanism by which the delivered heat kills this bacterium is unknown. Data from the manufacturer demonstrates that lesions treated with the Zeno device clear on average 1.3 days faster than those treated with a placebo [49].

Essential oils Patients who are seeking a homeopathic approach to treating acne may seek out essential oils and oral vitamins. Two topical essential oils that can be used are tea tree oil and chamomile. Tea tree oil is derived from the Australian tree Melaleuca alternifolia. The oil contains several antimicrobial substances including terpinen-4-ol, alfa-terpineol, and alfapinene [50]. A comparative study of 5% tea tree oil versus 5% benzoyl peroxide showed that both substances significantly reduce acne. The tea tree oil had a slower onset but was less irritating than the benzoyl peroxide [51]. It should be noted that the majority of tea tree oil available OTC is no more than 1% concentratioon. Chamomile is derived from the German chamomile plant Matricaria recutita. The active ingredient is alfa bisabolol. One study demonstrated that alfa bisabolol has an anti-inflammatory effect in the skin equal to that of 0.25% hydrocortisone [52]. Because of this anti-inflammatory effect, some will try this homeopathic approach to treat their acne.

Oral vitamins Oral vitamins that have been tried for the treatment of acne include zinc, nicotinamide, and vitamin A. Zinc sulfonate was first used as an acne treatment in 1970. Later, in the 1980s, a different formulation of zinc was developed – zinc gluconate. In patients with acne, zinc inhibits chemotaxis, is bacteriostatic against P. acnes, and reduces TNF-α production. In vitro, zinc inhibits type I 5-alpha reductase, a key enzyme in the hormonal impact on acne [53]. A randomized, double-blind study of 332 patients compared 30 mg/ day zinc gluconate with 100 mg/day minocycline. At 90 days, patients treated with either medication had significant reductions of papules and pustules. However, minocyclinetreated subjects had a 17% greater reduction in inflammatory lesions than those treated with zinc [54]. It should be noted that the recommended daily allowance of zinc is 15 mg, half the dose than is often used to treat acne. The most common side effect of zinc supplementation is gastrointestinal upset. Although generally safe at common doses (even safe in pregnancy), side effects can ensue when higher doses are used. In an anecdotal report, a desperate

60. Acne treatments teenage boy with acne self-medicated with 300 mg/day zinc for 2 years. As a result, he developed severe anemia, leucopenia, and neutropenia, which improved upon cessation of the zinc [55]. Another oral vitamin often utilized for acne treatment is nicotinamide (also known as niacinamide), a water-soluble B vitamin. Nicotinamide can improve acne by both inhibiting white blood cell chemotaxis and by inhibiting the release of lysosomal enzymes by white blood cells which damage the follicular wall [56]. Although the recommended daily allowance of nicotinamide is 20 mg, studies showing its beneficial effect for acne have used 750–1000 mg/day [57]. Supplementation is safe up to 3000 mg/day, at which point it may induce reversible elevations of liver function tests. Oral nicotinamide is also available as a prescription in combination with zinc, copper, and folic acid in a product known as Nicomide (DUSA Pharmaceuticals, Inc., Wilmington, MA, USA) and has shown success in treating acne [58]. Topical nicotinamide has not shown benefit in treating acne [59]. Vitamin A is a fat-soluble vitamin that can be used in high doses to treat acne. Interestingly, those with acne tend to have lower plasma levels of vitamin A than controls [60,61]. Vitamin A binds to some of the same nuclear receptors as isotretinoin (13-cis retinoic acid). The recommended daily allowance of vitamin A is 50 000–100 000 IU. It is effective for acne at 300 000 IU/day in females and 400 000–500 000 IU/ day in males [62]. At these high doses most patients experience similar side effects to those who are on isotretinoin (e.g. xerosis and cheilitis). High doses of vitamin A also have the potential to induce liver and kidney damage and to cause pseudotumor cerebri.

Conclusions Because many patients will turn to OTC remedies to treat their acne, it is important that the physician understand what is available to patients. The ability of the physician to speak knowledgeably on OTC remedies instills patient confidence in the physician. Many of these OTC treatments may be used beneficially; however, it is helpful for the physician to advise the patient on both their advantages and shortcomings. Some OTC treatments may enhance the use of prescription medications while others may only cause further irritation. Ultimately, the physician should be educated on merging OTC and prescription acne medications to best help the patient with acne.

References 1 Feldman SR, Fleischer AB Jr. (2000) Role of the dermatologist in the delivery of dermatologic care. Dermatol Clin 18, 223–7. 2 Woodard I. (2002) Adolescent acne: a stepwise approach to management. Top Adv Nurs Pract eJournal 2(2). 3 Malus M, LaChance PA, Lamy L, Macaculay A, Vanasse M. (1987) Priorities in adolescent health care: the teenager’s viewpoint. J Fam Pract 25, 159–62.

4 Bowe WP, Shalita A. (2008) Effective over-the-counter acne treatments. Semin Cutan Med Surg 27, 170–6. 5 Agency for Healthcare Research and Quality. (2001) Management of Acne. March 2001, Contract No. 01-E018. 6 21 CFR Part 333.350(b)(2), 21 CFR (1991). 7 Clearihan L. (2001) Acne: myths and management issues. Aust Fam Physician 30, 1039–44. 8 Choi JM, Lew VK, Kimball AB. (2006) A single-blinded, randomized, controlled clinical trial evaluating the effect of face washing on acne vulgaris. Pediatr Dermatol 23, 421–7. 9 Abbas S, Goldberg JW, Massaro M. (2004) Personal cleanser technology and clinical performance. Dermatol Ther 17 (Suppl 1), 35–42. 10 Subramanyan K. (2004) Role of mild cleansing in the management of patient skin. Dermatol Ther 17, 26–34. 11 Kraus AL, Munro IC, Orr JC, Binder RL, LeBoeuf RA, Williams GM. (1995) Benzoyl peroxide: an integrated human safety assessment for carcinogenicity. Regul Toxicol Pharmacol 21, 87–107. 12 Bojar RA, Cunliffe WJ, Holland KT. (1995) Short-term treatment of acne vulgaris with benzoyl peroxide: effects on the surface and follicular cutaneous microflora. Br J Dermatol 132, 204–8. 13 Pagnoni A, Kligman AM, Kollias N, Goldberg S, Stoudemayer T. (1999) Digital fluorescence photography can assess the suppressive effect of benzoyl peroxide on Propionibacterium acnes. J Am Acad Dermatol 41, 710–6. 14 Leyden JJ. (2001) Current issues in antimicrobial therapy for the treatment of acne. J Eur Acad Dermatol Venereol 15 (Suppl 3), 51–5. 15 Berson DS, Shalita AR. (1995) The treatment of acne: the role of combination therapies. J Am Acad Dermatol 32, 31–41. 16 Kim J, Ochoa M, Krutzik S, Takeuchi O, Uematsu S, Legaspi A, et al. (2002) Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 169, 1535–41. 17 Vowels B, Yang S, Leyden J. (1995) Induction of proinflammatory cytokines by a soluble factor of Propionibactreium acnes: implications for chronic inflammatory acne. Infect Immun 63, 3158–65. 18 Ozolins M, Eady EA, Avery AJ, Cunliffe WJ, Po ALW, O’Neill C, et al. (2004) Comparison of five antimicrobial regimens for treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomised controlled trial. Lancet 364, 2188–95. 19 Tucker SB, Flannigan SA, Dunbar M Jr, Drotman RB. (1986) Development of an objective comedogenicity assay. Arch Dermatol 122, 660–5. 20 Belknap BS. (1979) Treatment of acne with 5% benzoyl peroxide gel or 0.05% retinoic acid cream. Cutis 23, 856–9. 21 Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, et al. (2003) Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 49 (Suppl), S1–37. 22 Mills OH Jr, Kligman AM, Pochi P, Comite H. (1986) Comparing 2.5%, 5%, and 10% benzoyl peroxide on inflammatory acne vulgaris. Int J Dermatol 25, 664–7. 23 Balato N, Lembo G, Cuccurullo FM, Patruno C, Nappa P, Ayala F. (1996) Acne and allergic contact dermatitis. Contact Derm 34, 68–9. 24 Morelli R, Lanzarini M, Vincenzi C. (1989) Contact dermatitis due to benzoyl peroxide. Contact Derm 20, 238–9. 493


Implementation of Cosmetic Dermatology into Therapeutics

25 Cartwright RA, Hughes BR, Cunliffe WJ. (1988) Malignant melanoma, benzoyl peroxide and acne: a pilot epidemiological case–control investigation. Br J Dermatol 118, 239–42. 26 Berardesca E, Distante F, Vignoli GP, Oresajo C, Green B. (1997) Alpha hydroxyacids modulate stratum corneum barrier function. Br J Dermatol 137, 934–8. 27 Bergfeld W, Tung R, Vidimos A, Vellanki L, Remzi B, StantonHicks U. (1997) Improving the cosmetic appearance of photoaged skin with glycolic acid. J Am Acad Dermatol 36, 1011–3. 28 Tung RC, Bergfeld WF, Vidimos AT, Remzi BK. (2000) Alphahydroxy acid-based cosmetic procedures: guidelines for patient management. Am J Clin Dermatol 1, 81–8. 29 Kligman AM. (1997) A comparative evaluation of a novel lowstrength salicylic acid cream and glycolic acid products on human skin. Cosmet Dermatol 11 (Suppl). 30 Shalita AR. (1981) Treatment of mild and moderate acne vulgaris with salicylic acid in an alcohol-detergent vehicle. Cutis 28, 556–8. 31 Chen T, Appa Y. (2006) Over-the-counter acne medications. In: Draelos ZD, Thaman LA, eds. Cosmetic Formulations of Skin Care Products. New York: Taylor & Francis, pp. 251–71. 32 Shalita AR. (1989) Comparison of a salicylic acid cleanser and a benzoyl peroxide wash in the treatment of acne vulgaris. Clin Ther 11, 264–7. 33 Pagnoni A, Chen T, Duong H, Wu IT, Appa Y. (2004) Clinical evaluation of a salicylic acid containing scrub, toner, mask and regimen in reducing blackheads. 61st meeting, American Academy of Dermatology, February 2004, Poster 61. 34 Grimes PE, Green BA, Wildnauer RH, Edison BL. (2004) The use of polyhydroxy acids (PHAs) in photoaged skin. Cutis 73 (Suppl), 3–13. 35 Brubacher JR, Hoffman RS. (1996) Salicylism from topical salicylates: review of the literature. J Toxicol Clin Toxicol 34, 431–6. 36 Thayer B. (2006) Celsus: De Medicina. Available from: http:// html. 37 Gupta AK, Nicol K, Gupta AK, Nicol K. (2004) The use of sulfur in dermatology. J Drugs Dermatol 3, 427–31. 38 Lin AN, Reimer RJ, Carter DM. (1988) Sulfur revisited [see comment]. J Am Acad Dermatol 18, 553–8. 39 Mills OH Jr, Kligman AM. (1972) Is sulphur helpful or harmful in acne vulgaris? Br J Dermatol 86, 620–7. 40 Fulton JE Jr, Pay SR, Fulton JE 3rd. (1984) Comedogenicity of current therapeutic products, cosmetics, and ingredients in the rabbit ear. J Am Acad Dermatol 10, 96–105. 41 Franz E, Weidner-Strahl S. (1978) The effectiveness of topical antibacterials in acne: a double-blind clinical study. J Intern Med Res 6, 72–7. 42 Lee TW, Kim JC, Hwang SJ. (2003) Hydrogel patches containing triclosan for acne treatment. Eur J Pharm Biopharm 56, 407–12. 43 Duell EA, Kang S, Voorhees JJ. (1997) Unoccluded retinol penetrates human skin in vivo more effectively than unoccluded retinyl palmitate or retinoic acid. J Invest Dermatol 109, 301–5. 44 Kang S, Leyden JJ, Lowe NJ, Ortonne JP, Phillips TJ, Weinstein GD, et al. (2001) Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized,


45 46 47 48 49







56 57






vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks [see comment]. Arch Dermatol 137, 1597–604. Draelos Z. (2005) Reexamining methods of facial cleansing. Cosmet Dermatol 18, 173–5. Mills OH Jr, Kligman AM. (1979) Evaluation of abrasives in acne therapy. Cutis 23, 704–5. Available from: Elston DM. (2000) Treatment of trichostasis spinulosa with a hydroactive adhesive pad. Cutis 66, 77–8. Bruce S, Conrad C, Peterson RD, Conrad R, Arambide LS, Thompson J, et al. Significant efficacy and safety of low level intermittent heat in patients with mild to moderate acne. http:// Raman A. (1995) Antimicrobial effects of tea-tree oil and its major components on Staphylococcus aureus, Staph. epidermidis and Propionibacterium acnes. Lett Appl Microbiol 21, 242–5. Bassett IB. (1990) A comparative study of tea-tree oil versus benzoyl peroxide in the treatment of acne. Med J Aust 153, 455–8. Brown DJ, Dattner AM. (1998) Phytotherapeutic approaches to common dermatological conditions. Arch Dermatol 134, 1401–4. Dreno B, Trossaert M, Boiteau HL, Litoux P. (1992) Zinc salts effects on granulocyte zinc concentration and chemotaxis in acne patients. Acta Derm Venereol 72, 250–2. Dreno B, Moyse D, Alirezai M, Amblard P, Auffret N, Beylot C, et al. (2001) Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris. Dermatology 203, 135–40. Porea TJ, Belmont JW, Mahoney DH Jr. (2000) Zinc-induced anemia and neutropenia in an adolescent. J Pediatr 136, 688–90. Fivenson DP. (2006) The mechanisms of action of nicotinamide and zinc in inflammatory skin disease. Cutis 77 (Suppl), 5–10. Niren NM. (2006) Pharmacologic doses of nicotinamide in the treatment of inflammatory skin conditions: a review. Cutis 77 (Suppl), 11–6. Niren NM, Torok HM. (2006) The Nicomide Improvement in Clinical Outcomes Study (NICOS): results of an 8-week trial. Cutis 77 (Suppl), 17–28. Shalita AR, Smith JG, Parish LC, Sofman MS, Chalker DK. (1995) Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int J Dermatol 34, 434–7. Vahlquist A, Michaelsson G, Juhlin L. (1978) Acne treatment with oral zinc and vitamin A: effects on the serum levels of zinc and retinol binding protein (RBP). Acta Derm Venereol 58, 437–42. El-Akawi Z, Abdel-Latif N, Abdul-Razzak K. (2006) Does the plasma level of vitamins A and E affect acne condition? Clin Exp Dermatol 31, 430–4. Kligman AM, Mills OH Jr, Leyden JJ, Gross PR, Allen HB, Rudolph RI. (1981) Oral vitamin A in acne vulgaris. Preliminary report. Int J Dermatol 20, 278–85.

Chapter 61: Rosacea regimens Joseph Bikowski Ohio State University, Columbus, OH, and Bikowski Skin Care Center, Sewickley, PA, USA

BAS I C CONCEPTS • Rosacea is a chronic vascular disorder characterized by flushing, redness, telangiectasias, and inflammatory skin lesions. • Skincare products and cosmetics can improve the skin barrier and also camouflage the underlying erythema. • Cleansers, moisturizers, and sunscreens can impact the appearance of rosacea. • Skincare products can be used in conjunction with prescription medications for optimal redness reduction.

Introduction Rosacea is a chronic vascular disorder affecting the facial skin and eyes which often is characterized by a chronic cycle of remission and flare. Regardless of disease severity (Figure 61.1a–c), there are cosmetic consequences for the patient including flushing, redness, telangiectasia, papules, and/or pustules. Estimates of disease prevalence vary, but it is likely that 14 million people in the USA have rosacea [1]. Because there is no cure for the disease, management consists of the avoidance of disease triggers and the use of both prescription and over-the-counter (OTC) products that work in concert to achieve remission, prevent flare, and camouflage disease manifestations such as flushing and redness.

Physiology of rosacea Rosacea is found most frequently in fair-skinned individuals with Fitzpatrick type I skin who tend to burn rather than tan. UV radiation damages blood vessels and supporting tissue, and sun exposure may be a causative factor in the disease [2]. Rosacea is most often diagnosed in patients between the ages of 30 and 60 years [2] but it also can begin in adolescence, when it is often mistaken for acne vulgaris, or in persons older than 60 years. The etiology and pathogenesis of rosacea have not been established, nor are there any known histologic or serologic markers of the disease. However, rosacea is diagnosed by the presence of one or more primary disease features including flushing (transient erythema), non-transient erythema, tel-

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

angiectasia, papules, and pustules. Secondary diagnostic features include burning/stinging, plaque formation, dryness, edema, ocular manifestations, peripheral location, and/or phymatous changes [3]. Although these disease features often occur in various combinations, four rosacea subtypes have been classified and agreed upon to assist in the diagnosis and selection of appropriate treatment [4] (Figure 61.2a–d). Subtype 1 is erythematotelangiectatic rosacea (Figure 61.2a), which is characterized by flushing episodes lasting more than 10 minutes and persistent erythema of the central face. Telangiectasia is often present. These patients may also complain of central facial edema, stinging and burning, roughness or scaling, and a history of flushing alone is common. Subtype 2 is papulopustular rosacea (Figure 61.2b), which is characterized by persistent erythema, with transient papules and/or pustules on the central face. Subtype 2 resembles acne, but without comedones; however, acne and papulopustular rosacea can occur simultaneously. Papules and pustules also can occur around the mouth, nose, or eyes, and some patients report burning and stinging. Subtype 3 is phymatous rosacea (Figure 61.2c), which includes thickening skin and nodularities. Rhinophyma, nose involvement, is the most common presentation; however, ears, chin, and forehead may be involved. Patients may also have telangiectasias and/or patulous follicles in the phymatous area. Subtype 4 is ocular rosacea (Figure 61.2d), which should be considered if the patient has one or more of the following ocular signs: watery or bloodshot eyes, foreign body sensation, burning or stinging, dryness, itching, light sensitivity, blurred vision, telangiectasia of the conjunctiva and lid margin, or lid and periocular erythema. Blepharitis and conjunctivitis are also found commonly in rosacea patients with ocular manifestations. Ocular rosacea can precede cutaneous signs by years, but it is found most frequently along with cutaneous disease.



Implementation of Cosmetic Dermatology into Therapeutics



(b) Figure 61.1 Mild (a), moderate (b), and severe (c) rosacea.

Rosacea flare Beyond these recognized disease stages and presentation, rosacea is characterized by a chronic cycle of remission and flare. Sun avoidance is crucial in avoiding recurrence, but there are numerous other disease triggers. Table 61.1 is only a partial list of flare factors, but it is sufficient to illustrate how challenging flare avoidance is for patients and next to impossible for them to adhere to completely. Because rosacea pathophysiology has not yet been fully described, treatment targets the signs and symptoms of the disease without a full understanding of disease mechanisms. Disease manifestations and treatment-related cosmetic sequelae necessitate the use of OTC and prescription products for long-term treatment and for camouflaging skin redness, flushing, and blemishes.

Rosacea skincare: available OTC products Rosacea patients should be counseled to avoid astringents, soaps, fresheners, toners, facial scrubs, masks, and OTC skin-


Table 61.1 Potential rosacea flare factors. (Adapted from ‘Factors that may trigger rosacea flare-ups’. National Rosacea Society website, National Rosacea Society. triggers.php. Accessed July 3, 2008.) Heat Hot baths, saunas, excessively warm environments, overdressing

Food Spicy and thermally hot foods Foods high in histamine

Exertion Exercise, lifting

Alcohol Red wine, liquor, beer

Emotions Anxiety, stress, embarrassment

Drugs Vasodilatators, topical steroids

Medical conditions Chronic cough, menopause

Topical products Some cosmetics and hair sprays, especially those containing alcohol; witchhazel or fragrances; hydro-alcoholic or acetone substances

Weather Sun, hot, cold, strong winds, humidity

61. Rosacea regimens




(d) Figure 61.2 Rosacea clinical subtypes: (a) subtype 1; (b) subtype 2; (c) subtype 3; (d) subtype 4.

care programs. However, even though the list of verboten agents is long, there are numerous safe and effective cleansers, moisturizers, sunscreens, and cosmetics available for rosacea patients. Disease management is aimed at achieving synergy between prescription and OTC products to ensure maximum efficacy of active drugs, extend remission, and conceal redness and blemishes. People with rosacea have skin that is extremely sensitive to chemical irritants, so it is important that patients try to avoid all sources of irritation. Furthermore, the skin care regimen of a rosacea patient needs to be simple because the more the skin is specifically manipulated the more opportunity there is for unnecessary irritation.

Cleansing and moisturizing A proper cleansing and moisturizing routine is an important part of rosacea management. Patients should be counseled that daily cleansing is important to rid the skin of surface dirt, makeup, dead skin, and excess oil, but they should

wash with only cool or lukewarm water. The ideal cleanser for rosacea skin is a product that leaves minimal residue, is non-comedogenic and lipid free, and contains non-ionic surfactants with a neutral or slightly acidic pH [4]. Table 61.2 lists some recommended cleansers for rosacea patients. Moisturizing is important in order to maintain the softness and elasticity of the skin, and therapeutic moisturizers devoid of irritants are important adjunctive therapy in rosacea management [5]. A large proportion of rosacea patients have dry skin, and some topical rosacea medications (e.g. topical metronidazole) can cause further drying and irritation. Moisturizers formulated with a combination of emollients and humectants are recommended to help keep the stratum corneum intact to either repair or prevent skin barrier dysfunction. Furthermore, moisturizing dry skin lessens the itchiness and irritation that rosacea patients often experience as a part of their condition. Table 61.3 lists some moisturizers that can be used as part of a rosacea skin care regimen.



Implementation of Cosmetic Dermatology into Therapeutics

Table 61.2 Recommended over-the-counter cleansers for rosacea skincare.

Table 61.3 Recommended over-the-counter moisturizers for rosacea skincare.





Cetaphil® Gentle Skin Cleanser

Lipid-free, neutral pH, soap-free, non-comedogenic, fragrance-free, leaves no residue, non-irritating

Cetaphil® Moisturizing Cream

Eucerin® Gentle Hydrating Cleanser

Lipid-free, soap-free, non-comedogenic, fragrance-free, leaves no residue, non-irritating

Non-greasy, cosmetically appealing, fragrance-free and non-comedogenic. Contains sweet almond oil, which is a source of essential fatty acids

L’Oréal® Plénitude Gentle Foaming Cleanser

Lipid-free, soap-free, non-comedogenic, leaves no residue, non-irritating

Eucerin® Redness Relief Soothing Moisture Lotion SPF 15 or Daily Protecting Lotion SPF 16

Contains licochalcone A; protects from UVA/UVB; fragrance-free, oil-free, non-irritating, noncomedogenic; Daily Protecting Lotion contains green color neutralizers

Purpose® Gentle Cleansing Wash

Lipid-free, soap-free, non-comedogenic, soap-free, non-irritating

Olay® Complete UV Protective Moisture Lotion

Eucerin® Redness Relief Soothing Cleanser

Soap-free gel, non-irritating, non-drying, fragrance-free, non-comedogenic, contains licochalcone A

Color and fragrance-free; contains vitamin E; SPF 15, protects against UVA and UVB

Rosaliac® Anti-Redness Moisturizer

Contains vitamin C to reduce redness and green tint to conceal redness; expensive

All trademarks are property of their respective owner.

All trademarks are property of their respective owner.



Cosmetics Cosmetics are used to camouflage disease signs and symptoms, which is an important part of disease management. Rosacea patients should be counseled to avoid products containing menthol, camphor, or sodium lauryl sulfate, as these can be irritating. It is also recommended that rosacea patients avoid the use of waterproof cosmetics and heavy foundations because they are mechanically harder to apply, and their removal often requires the use of irritating solvents.


Figure 61.3 The effect of green-tinted makeup on reddened skin. (a) Patient with rosacea. (b) Camouflage of patient’s rosacea using green-tinted makeup.

Pigmentation irregularities can be camouflaged by applying foundations of complementary colors [6]. For example, red skin can be camouflaged by applying a green foundation, which is the complementary color to red; the combination of green and red creates a brown tone, and this can be covered further, if desired, by a light foundation that spreads easily. Furthermore, a yellow skin tone will turn brown when complemented with purple foundation. Figure 61.3 (a & b) shows how effective green-tinted makeup can be in camouflaging redness. Fortunately, there are an increasing

61. Rosacea regimens

Table 61.4 Recommended over-the-counter cosmetics for rosacea skincare.

Table 61.5 Recommended over-the-counter sunscreens for rosacea skincare.





Eucerin® Redness Relief Concealer

Smooth formula blends easily into the skin. Fragrance-free, oil-free, non-irritating, non-comedogenic, contains licochalcone A and has green color neutralizers

L’Oréal® Anthelios SX®

Contains ecamsule; expensive

Neutrogena Helioplex™

Contains avobenzone; protects from UVA/UVB

Active Photo Barrier Complex™

Contains avobenzone; protects from UVA


Contains avobenzone; protects from UVA

Titanium dioxide/zinc oxide formulations

Effective options for UVA protection. Older formulations made patients look pale, but newer manufacturing techniques have made these effective products cosmetically elegant


Cellex-C Eye Contour Cream with a 5% L-ascorbic acid

Contains L-ascorbic acid and zinc; lightweight; expensive

All trademarks are property of their respective owner.

number of tinted cosmetics and skincare products available to help camouflage rosacea redness, some of which are listed in Table 61.4.

All trademarks are property of their respective owner.

Sunscreens The daily uninterrupted use of sunscreen is a cornerstone in the long-term management of rosacea. Sun exposure is the leading cause of rosacea flares, and patients should be advised to use a sunscreen daily, irrespective of cloud coverage, with a sun protection factor (SPF) of at least 15. However, patients should be advised that a good sunscreen contains both UVB blockers (e.g. octyl methoxycinnamate, hom*osalate), as well as UVA blockers (e.g. avobenzone, ecamsule, titanium dioxide, oxybenzone, sulisobenzone, and zinc oxide) [6]. It is also important that the sunscreen be non-irritating, and patients with rosacea may have better tolerance of products containing dimethicone or cyclomethicone [7]. Furthermore, green-tinted sunscreens have the additional benefit of camouflaging erythema. Examples of some recommended sunscreens for rosacea can be found in Table 61.5. Cleansing, moisturizing, camouflaging, and using sunscreen are the primary features of a rosacea skincare regimen. OTC products that have a green tint or that are cosmetically elegant can be applied during the day, and prescription products used to treat erythema and redness that are less cosmetically elegant can be applied at night. Patients with long-term rosacea often have sensitive skin and can be the most difficult to treat.

Available prescription agents Oral and topical prescription agents are fundamental in the management of rosacea. Mild to moderate rosacea can be treated with topical monotherapy or topical combination therapy with or without an oral antibiotic. Moderate to

severe rosacea necessitates the use of oral antibiotic therapy until remission is achieved, usually for 3–4 months. Remission can often be maintained by continuing the topical therapy alone or in combination with a low-dose oral antibiotic [1]. Because rosacea pathogenesis is so poorly understood, management is focused on treating disease endpoints rather than the underlying disease. In general, inflammation is treated with an anti-inflammatory agent, papules and pustules are treated with antibiotics (with no target organism), flushing is treated with vasoconstrictors, and telangiectasias are treated with light-based therapies.

Oral antibiotic therapy Papular-pustular rosacea responds well to oral antibiotics, although their efficacy likely is brought about bytheir antiinflammatory effects more than their antimicrobial effects [2]. Standard antibiotic agents include tetracyclines (tetracycline, doxycycline, and minocycline), erythromycin, and co-trimoxazole, although the latter is usually reserved for use in Gram-negative rosacea or for patients who have not responded to other therapies [8]. These agents have been used for decades and are associated with a relatively good safety profile [8]. Tetracyclines are the most commonly prescribed oral antibiotics for rosacea, but there is apprehension about antibiotic resistance with the long-term use of these and other antibiotic agents. In response to this concern, an anti-inflammatory dose doxycycline (40 mg delayed-release formulation) has been formulated for the treatment of rosacea. Long-term use of this agent did not alter bacterial susceptibility to antibiotics during a 9-month period [9]. Furthermore, a 16week comparison study showed that both the 40-mg



Implementation of Cosmetic Dermatology into Therapeutics

delayed-release and the 100-mg formulations in combination with 1% metronidazole topical gel are equally effective for the treatment of moderate to severe rosacea with a similar onset of action, and the delayed-release group had a superior side effect profile including fewer gastrointestinal effects [10].

Topical therapy Topical therapy for rosacea reduces inflammatory lesions (papules and pustules), decreases erythema, improves pruritus, burning and stinging, and reduces the incidence and intensity of flares [1]. Standard topical therapies include sulfacetamide 10%/sulfur 5%, metronidazole, and azelaic acid (AzA), which is the first new therapeutic class of topical agents approved for rosacea in more than a decade. Topical antibiotics erythromycin and clindamycin are second-line agents, but data regarding their efficacy in rosacea treatment are limited [1]. Sulfacetamide-sulfur has anti-inflammatory properties, and the gel comes in a green-tinted formulation, which has the advantage of simultaneously treating inflammation and toning down redness. Sulfacetamide-sulfur also has been combined with avobenzone (UVA filter) and octinoxate (UVB filter) in an SPF 18 formulation, which has shown superior efficacy than topical metronidazole in investigator global severity, percent reductions in inflammatory lesions, and improvement in erythema [11]. Overall, these leave-on products have demonstrated favorable safety and tolerability profiles [1]. Furthermore, sulfacetamide-sulfur cleansers also have demonstrated efficacy as adjunctive therapy in combination with other topical and/or systemic agents [1].

Other treatment modalities Flushing is a challenging treatment aspect of rosacea management and a source of frustration for most patients. Although there are few data supporting the use of vasoconstrictor agents for flushing, anecdotal reports support the use of low-dose beta-blockers, selective serotonin reuptake inhibitors, and clonidine [12].

Light-based therapies Many patients also are frustrated with the poor efficacy of oral and topical therapies in resolving telangiectasia and persistent erythema. However, efficacy has been demonstrated in the improvement of vascular disease features from light-based and laser therapies. Pulsed dye laser can be highly effective in reducing telangiectasia, flushing, and erythema by eliminating hemoglobin within increased dilated vessels in rosacea skin. However, efficacy is inconsistent, and treatment can be limited by the frequent occurrence of purpura, which can be long-lasting and difficult to conceal [13].


More recently, intense pulsed light (IPL) therapy has been used with success to treat vascular symptoms of rosacea. IPL utilizes selective photothermolysis with a broad spectrum of light to destroy targeted vessels by coagulation while sparing surrounding tissue [1]. IPL is advantageous because it can penetrate the skin more effectively than lasers. Furthermore, variable light durations can target vessels of different sizes at multiple depths, IPL’s increased spot size allows a larger treatment area, and sequential pulsing provides for epidermal cooling between pulses [13].

Natural actives Cosmetic products with natural actives can be useful to soothe irritation associated with rosacea. Vitamin C is an antioxidant with numerous positive effects on the skin including collagen repair, normalization of photodamage, and anti-inflammatory properties. The use of a 5.0% vitamin C preparation demonstrated efficacy in objective and subjective improvement in erythema, which might be because of its anti-inflammatory effects [2]. There are currently three or four anti-redness products available, and the anti-redness moisturizer listed in Table 61.3 also has a green tint, which heals and conceals redness simultaneously. Licochalcone A is a major phenolic constituent of the licorice species Glycyrrhiza inflata which exhibits anti-inflammatory and antimicrobial effects, and improves redness and irritation [14]. The Eucerin® Redness Relief line has an SPF lotion and spot concealer containing licochalcone A with a green-tinted base, which provides both an anti-inflammatory component and redness camouflage. A study assessing the efficacy of this product line in reducing irritation in patients with mild to moderate facial redness showed that a regimen of cleanser, SPF lotion, spot concealer, and night cream containing licochalcone A improved redness and was compatible with daily metronidazole treatment [15]. Chrysanthellum indicum is a plant-based extract containing phenylpropanoic acids, flavonoids, and saponosids with documented effects on vascular wall permeability and on the increase of the mechanical resistance of capillaries [16]. A cream containing C. indicum was recently evaluated in 246 patients with moderate rosacea. Results showed that 12week, twice daily treatment with the C. indicum extractbased cream was significantly more effective than placebo in reducing erythema. Furthermore, this cream has vitamin P properties, which may be responsible for reducing or preventing microcirculation disorders involved in the erythema of rosacea [16]. Alfa-hydroxy acid-based cosmetic peels and at-home regimens also have shown promise for rosacea treatment. A regimen of a daytime cream containing SPF 15 and gluconolactone 8%, and an evening cream with gluconolactone 8% demonstrated significant improvement in texture, fine lines, photodamage, dryness, and erythema, and 80% of patients rated the cosmetic acceptability of these products as

61. Rosacea regimens good to excellent [17]. A polyhydroxy acid skin care regimen (cleanser and moisturizer) also demonstrated good tolerability and efficacy in combination with AzA 15% in patients with sensitive skin conditions [18]. This regimen significantly added to the reduction of facial erythema, did not interfere with the efficacy of AzA 15%, and smoothed the skin, which could further enhance patient satisfaction with the products. Glycolic acid peels and topical glycolic acid products added to an antibacterial regimen also have demonstrated dramatic improvement in skin texture and follicular pores, and in the resolution of comedones, papules, and pustules [17]. An additional benefit of these products and procedures is that they provide a treatment option for pregnant women because glycolic acid products, as well as AzA 15%, are not contraindicated in pregnancy.

Conclusions Management of rosacea includes avoidance of disease triggers and use of oral and topical prescription agents and OTC products to achieve remission, maximize time to flare, and conceal redness. A non-irritating skincare regimen is essential for long-term disease management. A variety of OTC cleansers, moisturizers, sunscreens, and cosmetics are available to keep skin healthy, and an increasing number of OTC products are tinted and/or contain natural anti-redness actives such as vitamin C and licochalcone A, which can be used in combination with prescription agents to maximize response. Although the pathogenesis of rosacea still has not been elucidated, there is hope that future rosacea therapies will target the disease at the genetic level, which is now common for other inflammatory skin disorders such as atopic dermatitis. There is ongoing research on vascular endothelial growth factor (VEGF) antagonists. It would appear that retinoids can modulate VEGF expression in the skin, and topical retinoic acid has demonstrated beneficial effects on vascular components of rosacea, specifically erythema and telangiectasia. Natural actives and botanicals will continue to be evaluated for their positive effects on the skin, and work remains to be done in optimizing light-based therapy in terms of clarifying treatment parameters, optimal treatment frequency, and the utility of adjuvant light-based therapies.

References 1 Del Rosso JQ. (2004) Medical treatment of rosacea with emphasis on topical therapies. Expert Opin Pharmacother 5, 5–13. 2 Cohen AF, Tiemstra JD. (2002) Diagnosis and treatment of rosacea. J Am Board Fam Pract 15, 214–7.

3 Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. (2002) Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol 46, 584–7. 4 Bikowski J. (2001) The use of cleansers as therapeutic concomitants in various dermatologic disorders. Cutis 68 (Suppl), 12–9. 5 Bikowski J. (2001) The use of therapeutic moisturizers in various dermatologic disorders. Cutis 68 (Suppl), 3–11. 6 Draelos ZD. (2007) Cosmetics. Emedicine online journal. Available at: Accessed June 4, 2008. 7 Nichols K, Desai N, Lebwohl MG. (1998) Effective sunscreen ingredients and cutaneous irritation in patients with rosacea. Cutis 61, 344–6. 8 Del Rosso JQ. (2000) Systemic therapy for rosacea: focus on oral antibiotic therapy and safety. Cutis 66 (Suppl), 7–13. 9 Walker C, Webster G. (2007) The effect of anti-inflammatory dose doxycycline 40 mg once-daily for 9 months on bacterial flora: Subset analysis from a multicenter, double-blind, randomized trial. Poster presented at 26th Anniversary Fall Clinical Dermatology Conference; October 18–27, 2007, Las Vegas, Nevada. 10 Del Rosso JQ. (2008) Comparison of anti-inflammatory dose doxycycline (40 mg delayed-release) vs doxycycline 100 mg in the treatment of rosacea. Poster presented at 8th Annual Caribbean Dermatology Symposium, January 15–19, 2008; St. Thomas, US Virgin Islands. Shalita AR, Dosik JS, Neumaier GJ, et al. (2003) A comparative efficacy study of Rosac® cream with sunscreens (sodium sulfacetamide 10% and sulfur 5%) and MetroCream® (metronidazole 0.75%) in the twice daily treatment of rosacea. Skin Aging Oct (Suppl), 17–22. 11 Baldwin HE. (2007) Systemic therapy for rosacea. Skin Ther Lett 12, 1–5; 9. 12 Bikowski JB, Goldman MP. (2004) Rosacea: where are we now? J Drugs Dermatol 3, 251–61. 13 Kolbe L, Immeyer J, Batzer J, Wensorra U, tom Dieke K, Mundt C, et al. (2006) Anti-inflammatory efficacy of licochalcone A: correlation of clinical potency and in vitro effects. Arch Dermatol Res 298, 23–30. 14 Weber TM, Ceilley RI, Buerger A, Kolbe L, Trookman NS, Rizer RL, et al. (2006) Skin tolerance, efficacy, and quality of life of patients with red facial skin using a skin care regimen containing licochalcone A. J Cosmet Dermatol 5, 227–32. 15 Rigopoulos D, Kalogeromitros D, Gregoriou S, Pacouret JM, Koch C, Fisher N, et al. (2005) Randomized placebo-controlled trial of a flavonoid-rich plant extract-based cream in the treatment of rosacea. J Eur Acad Dermatol Venereol 19, 564–8. 16 Tung RC, Bergfeld WF, Vidimos AT, Remzi BK. (2000) Alphahydroxy acid-based cosmetic procedures: guidelines for patient management. Am J Clin Dermatol 1, 81–8. 17 Draelos ZD, Green BA, Edison BL. (2006) An evaluation of a polyhydroxy acid skin care regimen in combination with azelaic acid 15% gel in rosacea patients. J Cosmet Dermatol 5, 23–9.


Chapter 62: Eczema regimens Zoe D. Draelos Consulting Professor, Department of Dermatology, Duke University School of Medicine Durham, NC, USA

BAS I C CONCE P T S • Dry skin affected by eczema is characterized by loss of intercellular lipids which results in barrier deficits. • Moisturizers are an important part of eczema treatment as they provide an environment optimal for barrier repair. • Moisturizers function by impeding transepidermal water loss with oily occlusive substances, such as petrolatum, mineral oil, vegetable oils, and dimethicone, and by attracting water to the dehydrated stratum corneum and epidermis with humectants, such as glycerin, sodium PCA, propylene glycol, lactic acid, and urea. • Moisturizing ingredients can be delivered to the skin surface by emulsions, liposomes, and niosomes. • Careful moisturizer selection is key to the treatment and prevention of eczematous skin disease.

Introduction Eczematous skin disease is one of the most commonly treated dermatologic conditions. While topical prescription corticosteroids and calcineurin inhibitors are the mainstay of therapy, cosmeceutical moisturizers are key to the treatment and prevention of disease. Moisturizers enhance the skin barrier, decreasing stinging and burning from a sensory standpoint and improving the look and feel of the skin. Moisturizers can also smooth desquamating corneocytes and fill corneocytes gaps to create the impression of tactile smoothness. This effect is temporary, of course, until the moisturizer is removed from the skin surface by wiping or cleansing. From a functional standpoint, moisturizers can create an optimal environment for healing and minimize the appearance of lines of dehydration by decreasing transepidermal water loss. Transepidermal water loss increases when the “brick and mortar” organization of the protein-rich corneocytes held together by intercellular lipids is damaged. A well-formulated cosmeceutical moisturizer can decrease the water loss until healing occurs.

the use of abrasive substances that induce stratum corneum exfoliation. In some cases, the barrier may be defective because of insufficient sebum production, inadequate intercellular lipids, or abnormal keratinocyte organization. The end result is the induction of the inflammatory cascade accompanied by erythema, desquamation, itching, stinging, burning, and possibly pain. The immediate goal of treatment is to stop the inflammation through the use of topical, oral, or injectable corticosteroids, depending on the severity of the eczema and the percent body surface area involved. In dermatology, topical corticosteroids are most frequently employed with low potency corticosteroids (desonide) used on the face and intertrigenous areas, medium potency corticosteroids (triamcinolone) on the upper chest and arms, high potency corticosteroids (fluocinonide) on the legs and back, and ultra high potency corticosteroids (clobetasol) used on the hands and feet. Newer topical options for the treatment of eczema-induced sensitive skin include the calcineurin inhibitors, pimecrolimus, and tracrolimus. However, the resolution of the inflammation is not sufficient for the treatment of eczema. Proper skin care must also be instituted to minimize the return of the conditions that led to the onset of eczema.

Etiology Moisturizer mechanism of action Eczema is characterized by barrier disruption, which is the most common cause of sensitive skin. The barrier can be disrupted chemically through the use of cleansers and cosmetics that remove intercellular lipids or physically through

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.


Moisturizers are incorporated into eczema treatment regimens to reduce transepidermal water loss. There are three cosmeceutical ingredient categories that can reduce transepidermal water loss: occlusives, humectants, and hydrophilic matrices [1]. The most common method for reducing transepidermal water loss is the application of an occlusive ingredient to the skin surface. These are oily sub-

62. Eczema regimens

Table 62.1 Occlusive moisturizing ingredients to inhibit transepidermal water loss. 1. Hydrocarbon oils and waxes: petrolatum, mineral oil, paraffin, squalene 2. Silicone oils 3. Vegetable and animal fats 4. Fatty acids: lanolin acid, stearic acid 5. Fatty alcohol: lanolin alcohol, cetyl alcohol 6. Polyhydric alcohols: propylene glycol 7. Wax esters: lanolin, beeswax, stearyl stearate 8. Vegetable waxes: carnauba, candelilla 9. Phospholipids: lecithin 10. Sterols: cholesterol

stances that create a barrier to water evaporation. The more commonly used occlusive ingredients in current formulations and their chemical category are listed in Table 62.1 [2]. The most popular and effective occlusive ingredient is time-tested petrolatum, which blocks 99% of water loss from the skin surface [3]. This remaining 1% transepidermal water loss is necessary to provide the cellular message for barrier repair initiation. If the transepidermal water loss is completely halted, the removal of the occlusion results in failure to repair the barrier and water loss quickly resumes at its preapplication level. Thus, the occlusion does not initiate barrier repair [4]. Petrolatum does not function as an impermeable barrier, rather it permeates throughout the interstices of the stratum corneum allowing barrier function to be re-established [5]. Moisturizers for eczematous disease must contain several occlusive moisturizing ingredients. In addition to occlusive ingredients, a therapeutic moisturizer for eczema must contain humectants. Humectants are substances that attract water to the viable epidermis and stratum corneum from the dermis. They function as a sponge to hold and release water as necessary. Examples of humectants include glycerin, honey, sodium lactate, urea, propylene glycol, sorbitol, pyrrolidone carboxylic acid, gelatin, hyaluronic acid, vitamins, and some proteins [2,6]. Humectants only draw water from the environment when the ambient humidity exceeds 70%. In environmentally controlled spaces, this does not occur, thus humectants pull water from the deeper epidermal and dermal tissues to rehydrate the stratum corneum. A therapeutic moisturizer for eczema must trap the water in the skin with an occlusive film placed on top of the stratum corneum [7]. Humectants also allow the skin to feel smoother by filling holes in the stratum corneum through swelling [8,9]. Therefore, a moisturizer recommended for eczema must combine both occlusive and humectant ingredients for optimal efficacy and patient esthetics. Occlusive and humectant moisturizers are the formulations most beneficial in the treatment of eczema and include the majority of those found in the dermatologic

sample closet (Eucerin Cream and Lotion, Beiersdorf; Norwegian Formula Moisturizers, Neutrogena; Aveeno Cream and Lotion, Johnson & Johnson; Olay Daily Facial Moisturizer, Procter & Gamble, Plentitude, L’Oréal; Cetaphil Cream and Lotion, Galderma; CeraVe Cream and Lotion, Coria). A third type of moisturizing formulation is known as the hydrophilic matrix. Hydrophilic matrices are large molecular weight substances that create a film over the skin surface thereby retarding water evaporation. The first hydrophilic matrix developed was an oatmeal bath (Aveeno Oatmeal Bath, Johnson & Johnson). The colloidal oatmeal created a film that prevented water from leaving the skin to enter the bath water. Newer hydrophilic matrices include peptides and proteins, but they do not provide meaningful skin moisturization in the eczema patient.

Moisturizer goals in eczema The goal of all moisturizing emulsions is to accomplish skin remoisturization, which occurs in four steps: initiation of barrier repair, alteration of surface cutaneous moisture partition coefficient, onset of dermal–epidermal moisture diffusion, and synthesis of intercellular lipids [10]. These steps must occur sequentially in order for proper skin barrier repair. Once the barrier has repaired, there must be some substance that holds and regulates the skin water content. This substance has been termed the natural moisturizing factor (NMF). The constituents of the NMF have been theorized to consist of a mixture of amino acids, derivatives of amino acids, and salts. Artificially synthesized NMF has been constructed from amino acids, pyrrolidone carboxylic acid, lactate, urea, ammonia, uric acid, glucosamine, creatinine, citrate, sodium, potassium, calcium, magnesium, phosphate, chlorine, sugar, organic acids, and peptides [11]. Ten percent of the dry weight of the stratum corneum cells is composed of NMF in well-hydrated skin [12]. Cosmeceutical moisturizing emulsions try to duplicate the effect of the NMF.

Moisturizer delivery systems Another method for optimizing the ability of moisturizers to create an environment for healing in eczema patients is through novel delivery of the ingredients. This has led to the development of delivery systems that can time release substances onto the skin surface and improve product esthetics. For example, petrolatum is the most effective ingredient for skin healing, yet it leaves an easily removed, sticky, greasy film on the skin surface. A delivery system could allow small amounts of petrolatum to be released onto the skin surface avoiding the esthetic drawbacks. Examples of delivery systems relevant to eczema treatment include emulsions,



Implementation of Cosmetic Dermatology into Therapeutics

serums, liposomes, niosomes, multivesicular emulsions, and nanoemulsions.

Moisturizing emulsions Most moisturizers developed for the treatment of eczema are emulsions [13]. An emulsion is formed from oil and water mixed and held in solution by an emulsifier. Most emulsifiers are surfactants, or soaps, which dissolve the two nonmiscible ingredients. The most common emulsions are oil-in-water, where the oil is dissolved in the water [14]. This emulsion is the most popular among patients because the water evaporates leaving behind a thin film of oily ingredients. If the emulsion can be poured from a bottle, it is considered a lotion. These moisturizing products are popular for eczema treatment, but may make the eczema worse as the repeated wetting and drying of the skin results in further maceration. Cream oil-in-water emulsions are preferred because the environment created for barrier repair is far superior. Water-in-oil emulsions, where the water-soluble substances are dissolved in the oil-soluble substances, are less popular because of their greasy esthetics. Most ointments are water-in-oil emulsions, but they leave the skin feeling warm and sticky. Ointments deliver higher levels of moisturization because the water phase is small, leaving behind a proportionately larger concentration of ingredients capable of retarding transepidermal water loss. Even though their efficacy is greater, most eczema patients prefer more esthetic formulations.

Moisturizing serums A specialized form of emulsion is a serum. Serums are usually low viscosity, oil-in-water emulsions that deliver of

thin film of active ingredients to the skin surface. For example, a high concentration glycerin serum can be placed under a high concentration petrolatum oil-in-water emulsion to provide robust skin moisturization. Sometimes a serum will contain cosmeceutical barrier enhancing ingredients, such as ceramides, cholesterol, and free fatty acids.

Moisturizing liposomes and niosomes Moisturizing ingredients can be incorporated into structures with unique physical properties on the skin, such as liposomes and niosomes (Table 62.2). Liposomes are spherical vesicles with a diameter 25–5000 nm formed from membranes consisting of bilayer amphiphilic molecules, which possess both polar and non-polar ends. The polar heads are directed toward the inside of the vesicle and toward its outer surface while the non-polar, or lipophilic tails, are directed toward the middle of the bilayer. Liposomes are based on the natural structure of the cell membrane, which has been highly conserved through evolutionary change. The name is derived from the Greek word “lipid” meaning fat, and “soma” meaning body. Liposomes are primarily formed from phospholipids, such as phosphatidylcholine, but may also be composed of surfactants, such as dioleoylphosphatidylethanolamine. Their functionality may be influenced by chemical composition, vesicle size, shape, surface charge, lamellarity, and hom*ogeneity. The liposome is an extremely versatile structure. It can contain aqueous substances in its core, or nothing at all. Hydrophobic substances can dissolve in the phospholipid bilayer shell, which allows liposomes to deliver both oilsoluble and water-soluble substances without need for an emulsifier. Thus, the internal moisturizer payload plus the phospholipid membrane can both function as moisturizers.

Table 62.2 Special moisturizer delivery systems. Delivery system


Advantages vs. disadvantages


Spherical vesicles consisting of bilayer amphiphilic molecules with polar and non-polar ends

Can deliver hydrophilic and hydrophobic substances to the skin surface without an emulsifier

Multivesicular emulsion (MVE)

Liposome within a liposome within a liposome to form concentric liposomes

Deliver multiple moisturizing ingredients (glycerin, dimethicone, sphingolipids, ceramides) simultaneously


Liposome composed of non-ionic surfactants, such as ethoxylated fatty alcohols and synthetic polyglycerol ethers

Non-ionic surfactants do not moisturize the skin surface


Emulsions with 20–300 nm droplets

Allow enhanced skin penetration due to small droplet size


62. Eczema regimens It is unlikely that liposomes diffuse across the stratum corneum barrier intact. The corneocytes are embedded in intercellular lipids, composed of ceramides, glycosylceramides, cholesterol, and fatty acids, which are structurally different from the phospholipids of the liposome. It is postulated that liposomes penetrate through the appendageal structures. They may also fuse with other bilayers, such as cell membranes, to release their ingredients. This is the mechanism by which liposomes can function as moisturizers, supplementing deficient intercellular lipids. Niosomes are a specialized form of liposome composed of non-ionic surfactants. These are detergents, such as ethoxylated fatty alcohols and synthetic polyglycerol ethers (polyoxyethylene alkylester, polyoxyethylene alkylether). These liposomes do not deliver the moisturizing phospholipids to the skin surface.

droplets of 70 nm are transparent. Nanoemulsions offer the ability to deliver highly hydrophobic or lipophilic substances into the skin, which could not otherwise penetrate. The stratum corneum is an excellent barrier to lipophilic ingredients. For example, new nanoemulsions of ubiquinone have been developed. Ubiquinone, also known as coenzyme Q10, is an important antioxidant manufactured by the body and found in all skin cells. It is found in both hydrophilic and hydrophobic cellular compartments, but topical delivery has been challenging. Nanoemulsions have successfully delivered higher concentrations of ubiquinone into the skin with the goal of enhancing the skin’s natural antioxidant capabilities, while leaving beyond a moisturizing film from the other ingredients in the emulsion.

Multivesicular emulsions

Developing a moisturizer regimen

Another variant of the liposome is a multivesicular emulsion (MVE) (Figure 62.1). The MVE is created through a physical mixing technique, which makes them more stable, but also less expensive to produce. An MVE can be thought of as a liposome within a liposome within a liposome. Thus, with the release of each liposome, additional moisturizing ingredients can be deposited on the skin surface. MVEs can deliver glycerin, dimethicone, sphingolipids, and ceramides to the skin surface simultaneously.

Moisturizing nanoemulsions Nanoemulsions are similar to regular emulsions with an oilloving hydrophobic phase and a water-loving hydrophilic, except droplets in these emulsions are on the nano scale of 20–300 nm [15]. If the nano droplets are larger than 100 nm, the emulsion appears white, while nanoemulsions with

This chapter has discussed the goals of moisturization, the various types of moisturizers, and some of the unique moisturizer delivery systems. The biggest challenge for the clinician is adding moisturizers or combining moisturizers as part of a treatment regimen. Patients with eczema require basic hygiene. The face and body must be cleansed. There is no doubt that the synthetic detergent cleansers, also known as syndets, provide the best skin cleansing while minimizing barrier damage. Bars based on sodium cocyl isethionate appear to perform the best (Dove, Unilever; Olay, Procter & Gamble). There are some patients, however, who only require the use of a facial syndet cleanser occasionally, because sebum production and physical activity are minimal. For these patients, a lipid-free cleanser is preferable because it can be used without water


Hyaluronic acid




Oil Figure 62.1 A multivesicular emulsion can dissolve many ingredients in the concentric lipsomes.




Implementation of Cosmetic Dermatology into Therapeutics

and wiped away (Cetaphil, Galderma; CerVe, Coria). These products may contain water, glycerin, cetyl alcohol, stearyl alcohol, sodium laurel sulfate, and occasionally propylene glycol. They leave behind a thin moisturizing film and can be used effectively in persons with excessively dry, sensitive, or dermatitic skin. They do not have strong antibacterial properties, however, and may not remove odor from the armpit or groin. Lipid-free cleansers are best used where minimal cleansing is desired. After completing cleansing, the eczema patient requires moisturization. The moisturizer should create an optimal environment for barrier repair, while not inducing any type of skin reaction. For example, the product should not contain any mild irritants that may present as an acneiform eruption in the eczema patient because of the presence of follicular irritant contact dermatitis. The best moisturizers are simple oil-in-water emulsions. The morning moisturizer should provide SPF 30 photoprotection. A variety of sunscreen-containing moisturizers are on the market for this purpose (Olay Complete Defense SPF 30, Procter & Gamble; Neutrogena Daily Defense SPF 30, Johnson & Johnson). If additional hydration is required, a moisturizer can be applied to the face followed by a second sunscreen-containing moisturizer on top. It is possible to layer moisturizers for additive benefit. The sunscreen-containing moisturizer should be applied last, as it does not need to touch the skin to provide optimal photoprotection. The evening moisturizer provides the best opportunity for barrier repair, because the body is at rest. The best ingredient for barrier repair is white petrolatum, but dimethicone and cyclomethicone are commonly added to decrease the greasiness of a simple petrolatum and water formulation. Basic night creams containing these ingredients, in addition to glycerin, are the mainstay of therapeutic eczema moisturizers. It is important to remember that fewer ingredients are preferred, because more ingredient exposure creates added opportunities for sensitization or an adverse event.

Conclusions Eczema treatment requires the use of prescription medications in conjunction with skincare products. Both must be


judiciously selected to insure optimal results. Thorough resolution of eczema requires alleviation of the disease, the treatment phase, and prevention of recurrence, the maintenance phase. This chapter has discussed those concepts that are key to designing a maintenance phase regimen for eczema patients.

References 1 Baker CG. (1987) Moisturization: new methods to support time proven ingredients. Cosmet Toilet 102, 99–102. 2 De Groot AC, Weyland JW, Nater JP. (1994) Unwanted Effects of Cosmetics and Drugs Used in Dermatology, 3rd edn. Amsterdam: Elsevier, pp. 498–500. 3 Friberg SE, Ma Z. (1993) Stratum corneum lipids, petrolatum and white oils. Cosmet Toilet 107, 55–9. 4 Grubauer G, Feingold KR, Elias PM. (1987) Relationship of epidermal lipogenesis to cutaneous barrier function. J Lipid Res 28, 746–52. 5 Ghadially R, Halkier-Sorensen L, Elias PM. (1992) Effects of petrolatum on stratum corneum structure and function. J Am Acad Dermatol 26, 387–96. 6 Spencer TS. (1988) Dry skin and skin moisturizers. Clin Dermatol 6, 24–8. 7 Rieger MM, Deem DE. (1974) Skin moisturizers II .The effects of cosmetic ingredients on human stratum corneum. J Soc Cosmet Chem 25, 253–62. 8 Robbins CR, Fernee KM. (1983) Some observations on the swelling of human epidermal membrane. J Sos Cosmet Chem 37, 21–34. 9 Idson B. (1992) Dry skin: moisturizing and emolliency. Cosmet Toilet 107, 69–78. 10 Jackson EM. (1992) Moisturizers: What’s in them? How do they work? Am J Contact Derm 3, 162–8. 11 Wehr RF, Krochmal L. (1987) Considerations in selecting a moisturizer. Cutis 39, 512–5. 12 Rawlings AV, Scott IR, Harding CR, Bowser PA. (1994) Stratum corneum moisturization at the molecular level. Prog Dermatol 28, 1–12. 13 Chanchal D, Swarnlata S. (2008) Novel approaches in herbal cosmetics. J Cosmet Dermatol 7, 89–95. 14 Carlotti ME, Gallarate M, Rossatto V. (2003) O/W microemulsions as a vehicle for sunscreen. J Cosmet Sci 54, 451–62. 15 Kaur IP, Agrawal R. (2007) Nanotechnology: a new paradigm in cosmeceuticals. Recent Pat Drug Deliv Formul 1, 171–82.

Chapter 63: Psoriasis regimens Steven R. Feldman1,2,3 and Lindsay C. Strowd1 Center for Dermatology Research, Departments of Dermatology,1Pathology,2and Public Health Sciences,3 Wake Forest University School of Medicine, Winston-Salem, NC, USA

BAS I C CONCEPTS • Psoriasis is a common condition that can be treated with a variety of over-the-counter skincare products. • Over-the-counter skincare products helpful for the treatment of psoriasis include moisturizers, keratolytics, tar, hydrocortisone, salicylic acid, and tanning booth radiation exposure. • Compliance is key in psoriasis therapy, which may be encouraged by over-the-counter skincare products. • Over-the-counter skincare products can be combined with prescription medications for optimal treatment.

Introduction Psoriasis affects an estimated 7.5 million people in the USA and 125 million worldwide. Men and women are affected equally. The disease may occur at any age, most frequently starts in the late teens and early twenties, and is most prevalent in the third through fifth decades of life. Caucasians are twice as likely as African-Americans to be diagnosed with psoriasis [1]. The etiology of psoriasis is not yet fully characterized. There is tremendous variation in individual’s disease presentation and response to treatment, adding to the complexity of psoriasis treatment. Most patients with psoriasis have limited, or so-called “mild,” disease, covering less than 3% of total body surface area [2]. However, the disease burden does not correlate closely with the extent of disease, and even patients with limited areas of psoriasis can experience significant psychosocial stress and depression [3,4]. Only about 1 in 6 people with psoriasis sees a doctor for their disease in any given year. The remaining patients with psoriasis do not seek treatment by a dermatologist. They may be untreated, or they may self-treat with a variety of over-the-counter (OTC) medications. The poor quality of life seen in patients with psoriasis is in part brought about by the cutaneous manifestations of the disease and the treatment regimens. Patients claim physical appearance to be a large negative factor in quality of life. The concern over physical appearance increases as the extent of disease spreads. The treatment regimens can also negatively impact quality of life, as they often require mul-

Cosmetic Dermatology: Products and Procedures. Edited by Z.D. Draelos. ©2010 Blackwell Publishing.

tiple daily applications, come in messy, greasy vehicles, and can be very expensive. This chapter focuses on the role of OTC medications in psoriasis and describes strengths and weaknesses of different OTC products. We briefly discuss the role of OTC medications as part of a combination treatment regimen. Patient compliance is a major factor affecting the effectiveness of psoriasis treatments, and we discuss the future development of OTC medications.

Physiology Psoriasis is a multifactorial, inherited condition, involving genetics, immune system alterations, and environmental factors. Normal keratinocytes remain in the epidermis for 300 hours, but psoriasis keratinocytes only remain in the epidermis for 36 hours. This shortening of the keratinocyte life cycle is associated with an increased proliferation of keratinocytes and subsequent plaque formation [5]. The pathophysiology behind the shortened keratinocyte life cycle is brought about, at least in part, by a complex immune reaction. This cascade is largely driven by helper T cells and their release of cytokines and tumor necrosis factor α (TNFα) into the dermis. The presence of cytokines in the dermis triggers infiltration and activation of both polymorphonuclear and mononuclear leukocytes [6]. Many different cytokines have been found in the dermis and epidermis of psoriatic skin, including interleukins IL-4, IL-6, IL-12, IL-23, and transforming growth factor β (TGF-β) [5]. The roles of each of these cytokines have yet to be fully understood. Genetics impacts psoriasis, as up to 70% of identical twins both develop this disease [7]. Psoriasis has been associated with certain HLA genotypes, and recently researchers have identified a psoriasis risk allele PSORS1 that codes for HLA-



Implementation of Cosmetic Dermatology into Therapeutics

Cw6 genotype [8]. However, no single allele can be called the “psoriasis gene” because there are multiple alleles that contribute to the inheritance and risk of developing psoriasis. There are at least seven other genetic loci that have also been identified as psoriasis risk alleles [7]. Complex inherited diseases such as psoriasis require large studies of many affected families in order to begin to identify all the possible genetic loci, a task that has been difficult to achieve. While there is still much debate about the affect of stress on psoriasis, many retrospective studies have found a correlation between stress and psoriasis flares [9,10]. At baseline, patients with psoriasis have high stress levels and poor quality of life [11]. Up to 80% of patients with psoriasis report that a stressful event triggered a flare during the course of their disease. Most of these stress-related flares occur within 2 weeks of the stressful event [12]. Obesity is a risk factor both for developing psoriasis and for increased severity of psoriasis [13]. Streptococcal type A infections have also been reported to cause psoriasis outbreaks. The link between streptococcal infections and psoriasis has been extensively researched, but no single hypothesis has emerged. Some theories posit there exists molecular mimicry between streptococcal antigens and keratinocytes, while other theories blame bacterial superantigens [5]. These genetic, biologic, and environmental factors combine to create the “perfect storm” of psoriasis. The shortened keratinocyte life cycle results in thick scales that accumulate on the surface of the skin. The inflammatory infiltrates cause dysfunction of the skin’s natural barrier. Inflammatory cytokines cause vascular capillary dilatation which results in skin erythema and helps perpetuate the inflammatory process [14]. The end result is dry, cracked, inflamed plaques that can be both painful and pruritic.

Role of OTC medications Psoriasis education The first step in any psoriasis treatment regimen is education. Empowering patients with knowledge about their disease allows them to make informed decisions about their care and creates realistic expectations for treatment outcomes. The National Psoriasis Foundation is a great resource for patients. Foundation members feel more satisfied with their treatment and have less disease burden. The Foundation’s website has an OTC treatment guide that provides information on many products commonly used for psoriasis. The site also provides information to help patients screen out non-prescription remedies that are touted for their efficacy but which are at best unproven.

Role in self-treating vs. dermatology patients Patients who self-treat their psoriasis tend to have mild disease and can achieve a measure of control with OTC


medications alone. For these patients OTC medications provide symptom relief (reduced pruritus) or improve the skin’s cosmetic appearance [15]. Based on their experiences, some dermatologists may feel OTC medications have little efficacy; such an impression may be based on seeing only the patients who have failed to adequately control their disease with OTC medications. People who do achieve adequate control with OTCs alone would be less likely to feel the need to visit a dermatologist. For those patients who do visit a dermatologist for prescription treatment, OTC medications may still have an important role in reducing symptoms and improving appearance. Additionally, OTC medications such as moisturizers and keratolytics can serve to increase the efficacy of prescription topical corticosteroids and phototherapy.

OTC products recommended by physicians The National Ambulatory Care Survey (NAMCS) provides a representative snapshopt of psoriasis treatment in the USA. Through this survey, prescription and OTC medications prescribed by dermatologists and non-dermatologists are tabulated each year. OTC treatment options for psoriasis are estimated to cost $500 million and to account for 40% of all psoriasis-related expenditures [16]. The NAMCS provides data on the OTC psoriasis treatments most commonly prescribed by physicians. We looked at NAMCS data from 1986 to 2005 and identified the most common OTC prescriptions for psoriasis in each of four 5-year periods. The most popular classes of OTC medications were hydrocortisone and keratolytics. These were followed by moisturizers and tar (Figure 63.1). When the keratolytics were broken down into individual types, salicylic acid, lactic acid, and urea were the three most commonly prescribed keratolytics (Figure 63.2). Urea was the least commonly prescribed keratolytic. While the prescription frequency of tar, urea, and lactic acid have remained relatively constant over time, salicylic acid and moisturizers show a recent increase in prescription. In contrast, OTC hydrocortisone has dropped in prescription frequency in recent years.

Compliance in psoriasis treatment Psoriasis patients are among the worst in terms of compliance with treatment regimens [17]. They have levels of depression and anxiety that are higher than other patients with dermatologic disease [3]. Depression and disease burden can negatively affect the patients’ ability to adhere to treatment. Adherence to topical medications is worse than adherence to oral medications, with the number of daily applications, the chronicity of treatment, and the complexity of the treatment regimen affecting overall compliance [18]. Topicals have traditionally been messy, greasy, and generally unappealing from a cosmetic perspective. When choosing a topical preparation for a patient, that particular patient’s

63. Psoriasis regimens

Figure 63.1 Over-the-counter (OTC) psoriasis medications prescribed by physicians 1986–2005. National Ambulatory Care Survey (NAMCS) data was used to find the prescription frequency of OTC medications prescribed by both dermatologists and non-dermatologists. Yearly data was then grouped in four 5-year time periods. OTC medications were grouped in hydrocortisone, keratolytics, moisturizers, and tar preparations.

Prescription frequency (000)

700 000 600 000 500 000 Hydrocortisone Keratolytics Moisturizers Tar

400 000 300 000 200 000 100 000 0 1986–1990 1991–1995 1996–2000 2001–2005 Time period

Figure 63.2 Over-the-counter (OTC) psoriasis medications prescribed by physicians 1986–2005. National Ambulatory Care Survey (NAMCS) data was used to find the prescription frequency of OTC medications prescribed by both dermatologists and non-dermatologists. Yearly data was then grouped in four 5-year time periods. OTC medications analyzed included hydrocortisone, salicylic acid, lactic acid, urea, moisturizers, and tar preparations.

Prescription frequency (000)

600 000 500 000 400 000

Hydrocortisone Salicylic acid Urea Lactic acid Moisturizer Tar

300 000 200 000 100 000

preferences are critical to consider. While ointments may be said to be more efficacious for psoriasis, they will not be efficacious for patients who find them too messy to use. OTC medications allow patients access to a wide variety of treatment options at relatively low cost. Patients can try out different vehicles and different combinations of products to achieve the best improvement. OTC products give patients the independence to experiment with products until they find one they prefer, rather than having to go through a dermatologist every time they want to switch products or try something new.

Moisturizers and keratolytics Dry skin is often a sign of poor barrier function, as is the case in psoriasis. Symptoms of psoriasis include scaling, itching, and increased sensitivity. Moisturizers can improve the skin’s hydration in two ways. First, the hydrophobic emollients such as petrolatum provide occlusive benefits, meaning they create a physical layer of protection on the surface of the skin which acts to slow epidermal water loss. Second, hydrophilic emollients such as glycerine provide humectant benefits, meaning they attract moisture from the

0 1986–1990 1991–1995 1996–2000 2001–2005 Time period

air and help skin preserve its water content. Some moisturizers only contain either hydrophobic or hydrophilic elements, but most contain both compounds. The net effect of this increase in moisture on psoriatic skin is a decrease in appearance of scale. Factors such as number of applications and thickness of the applied layer impact success. Moisturizers can often make scale completely invisible by changing the refractive index of scale so less light is reflected. Keratolytics differ from moisturizers in that they actually dissolve the scales on the skin’s surface. Keratolytics help decrease the thickness of the hyperkeratotic plaque from the top surface inward by softening the scaly layers allowing for easy removal [19]. Salicylic acid comes in a wide variety of vehicles from shampoo to gels to creams. OTC concentrations approved for psoriasis use range 1–3%. OTC concentrations exist up to 6%, but concentrations above 3% have not been FDA approved for psoriasis [20]. OTC lactic acid products come in 5–12% concentrations. Other OTC keratolytics include phenol (which is often used in scalp preparations) and urea products. OTC urea preparations range 10–25% in concentration and typically are sold as lotions or creams [20]. Keratolytics such as these can be found OTC in single preparations or in OTC combinations with a moisturizer. Combination products allow the scale to be camou-



Implementation of Cosmetic Dermatology into Therapeutics

flaged by moisturizer as the keratolytics gradually thin the psoriatic plaques. Keratolytics can cause irritant contact dermatitis secondary to their acidic nature. Therefore it is important for patients to find a keratolytic product with a potency that is effective but minimizes irritation.

Tar Tar is one of the oldest treatments for psoriasis, but its exact mechanism of action remains unknown. Tar is believed to exert anti-inflammatory and antimitotic effects on psoriasis skin. It also has antipruritic effects that can provide a great deal of symptom relief [21]. Tar is developed from coal or wood and can be sold as crude or refined tar products. Most tar products for psoriasis treatment are coal tar products, and are available OTC in concentrations of 0.5–5%. OTC formulations are varied and include shampoos, soaps, lotions, creams, and ointments [20]. Tar shampoos and ointments can be very helpful in the treatment of scalp psoriasis [22]. There are several disadvantages to tar products that prevent them from being used more commonly to treat psoriasis. Traditional tar preparations have been messy, malodorous, and stain skin and clothing. This is especially true of crude tar products. Newer products that use refined tar have tried to minimize these unwanted side effects, increasing the esthetic appeal of tar topicals while maintaining the desired efficacy [22,23]. Despite improvements in the vehicle and odor, patient compliance with tar products may be poor. Tar can also cause unwanted skin reactions such as contact irritation and folliculitis, further decreasing patient compliance. Another component of tar therapy that affects patient use is the fear of its carcinogenic properties. While there is no clear evidence showing an increased risk of cancer in humans, several animal studies have demonstrated an increased risk of cancer with topical tar application [24]. All OTC tar products are covered by an FDA monograph that permits marketing and sales of tar products of certain concentrations for an indication of psoriasis [25]. Other ingredients that are generally regarded as safe may also be in the product. Thus, companies can create and market many different products and claim they are effective for psoriasis as long as the product contains the appropriate concentration of tar. Companies can create all manners of fruit and vegetable extracts and claim their product is FDA approved for the treatment of psoriasis by incorporating tar into the product.

Hydrocortisone Topical hydrocortisone cream is available OTC in 0.5% and 1% concentrations and is a low-potency corticosteroid with


anti-inflammatory and anti-itch properties. In a survey conducted by the National Psoriasis Foundation, psoriasis patients named “scaling,” “itching,” and “skin redness” as their most common symptoms [26]. Topical corticosteroids help relieve these symptoms. Despite their low potency, OTC hydrocortisone treatments can have an important role in psoriasis management. A benefit of low-potency OTC hydrocortisone is that psoriasis patients can use this corticosteroid to self-treat more sensitive areas of their skin, such as the face, axilla, and genital area.

UV light therapy Phototherapy has been a mainstay treatment for psoriasis for millenia. Up until the 1990s, broad-spectrum UVB was the treatment of choice. More recently, narrowband (300– 313 nm) UVB boxes were introduced, as well as devices designed to provide localized therapy to individual lesions [27]. The addition of PUVA (psoralen and UVA) therapy for severe psoriasis in the 1990s further expanded the use of phototherapy for psoriasis [28]. Many patients with psoriasis realize the benefit of UV exposure before any prescription phototherapy is used, through the seasonal variation in their psoriasis and the beneficial effect of outdoor (and sometimes indoor) tanning on their disease. Benefits of non-prescription phototherapy over prescription phototherapy include greater convenience and lower cost, albeit at the expense of less control over dosimetry. Prescription phototherapy requires patients to travel to the dermatologist’s office anywhere from three to five times a week to receive UV treatments. This can be costly and inconvenient to patients, which compromises the overall benefit and accessibility of the treatment. Sun exposure is the least costly way to obtain phototherapy for psoriasis, although it may be inconvenient or inaccessible (depending on geography). Dosimetry is difficult to control. Commercial tanning beds provide another phototherapy option. Although these devices radiate mostly UVA light, the most widely used commercial tanning bulbs have about 5% of the output that is in the UVB range and this may contribute to tanning bed efficacy. Some dermatologists discourage use of tanning beds for treating psoriasis because of the potential and poorly defined risk of skin cancer and premature aging. However, tanning beds can be an option for psoriasis patients who cannot afford or who do not have access to home or dermatologist-administered UVB therapies. Some dermatologists may not think tanning beds are effective based on their experiences with patients who have tried tanning and seen no benefit. Dermatologists should keep in mind that the people who tried tanning and did find it to be effective for clearing their psoriasis may not come to the dermatologist.

63. Psoriasis regimens If tanning bed use is recommended by a dermatologist for a particular patient, guidance for use should be provided and realistic expectations about length of time until improvement should be set. Most patients will require multiple tanning sessions over several weeks before seeing improvement in their skin. To help control the dosimetry, patients should use the same tanning bed for each exposure (not switching between tanning establishments or between beds within a single establishment). Tanning bed operators are familiar with their equipment and will likely recommend a safe starting dose, but starting with half that dose may provide a greater degree of safety, particularly if the tanning bed is used in conjunction with oral retinoid treatment (tanning beds should not be used in conjunction with psoralen as life-threatening burns may result). Sunscreen or protective clothing can be recommended to protect unaffected skin, and eye protection should be worn. These measures help patients avoid burning their skin and minimize the risk of developing skin cancer or cataracts [1]. Psoriasis patients may inquire if OTC tanning is safe to use with other psoriasis medications. Topical corticosteroids are safe to use with phototherapy and may even enhance the UV light’s effect by thinning the psoriatic plaques, although there is concern that corticosteroids reduce the remission periods associated with phototherapy. Systemic retinoids are not only safe to use with phototherapy, they are frequently prescribed in combination with phototherapy because they can improve the efficacy of phototherapy [29]. While methotrexate is safe to use with phototherapy, cyclosporine should not be used with UVB therapy [30]. UV therapy may inactivate topical calcipotriol, so it is recommended for patients to apply calcipotriol after, rather than before, phototherapy sessions [30,31].

Combination regimens Most psoriasis treatment regimens do not rely on only one drug to treat psoriasis effectively. Specific combinations of therapies often produce the best results with the least side effects. The caution with combination treatment regimens is that overly complex regimens can confuse and discourage patients and negatively affect treatment adherence. The goal of a dermatologist should be to develop a streamlined regimen that focuses on the individual patient’s treatment goals and lifestyle. OTC medications have a large role in combination psoriasis therapies. Keratolytics are used to enhance the ability of topical corticosteroids to penetrate the epidermis and target dermal inflammation. Topical corticosteroids can penetrate skin two to three times better with keratolytics than without. This results in better relief of symptoms such as scaling and pruritus [19]. Keratolytics have similar effects with tar prod-

ucts and UV phototherapy. Moisturizers can also enhance the efficacy of topical corticosteroids [32]. When prescribing such combination regimens, however, it is essential to consider that complicating the regimen may reduce treatment adherence, resulting in the loss of any potential gains expected from increased penetration. The classic psoriasis combination therapy is the Goeckerman treatment, which combines topical coal tar and UVB phototherapy. This combination’s success was first described by Dr. Goeckerman in 1925, and continues to be one of the most effective psoriasis treatments in use today. The Goeckerman treatment can induce remission even when the most technologically advanced regimens such as biologics fail [33]. Goeckerman treatment is typically administered by a dermatologist in the inpatient or specialized outpatient psoriasis treatment center. Patients can attempt to mimic the effects of Goeckerman by using outdoor or indoor UV therapy followed by prolonged OTC tar ointment used under plastic wrap or sauna suit occlusion.

Conclusions OTC medications play a large part in the treatment regimen of self-treating patients and those managed by a dermatologist. For the vast majority of people with psoriasis who choose to self-treat their disease, OTC medications provide relief of symptoms such as pruritus, erythema, and dry skin as well as effectively controlling plaque formation. For the minority of patients who require a dermatologist, OTC medications still provide a degree of symptom relief, and are commonly used in combination with prescription medications. The NAMCS data show that dermatologists prescribe OTC hydrocortisone, keratolytics, and moisturizers to supplement prescription psoriasis therapies. The large percentage of psoriasis patients who rely on OTC medications continues to drive the production of new and improved OTC products. New moisturizers are constantly being developed to increase skin’s hydration, and new keratolytics seek to improve the appearance of hyperkeratotic plaques while minimizing skin irritation. Improved vehicles such as foams and sprays for OTC corticosteroids are being developed to increase efficacy and make them more attractive to patients. New tar extracts and derivatives are designed to be less messy and smelly than their older counterparts; by increasing patient adherence such treatments may offer improved efficacy outcomes. Future trends in OTC psoriasis medications can be considered in two different populations. In those people who entirely self-treat and do not see a dermatologist, there will probably be a continued increase in the use of products such as moisturizers, keratolytics, and tar as the products continue to improve. In patients who see a dermatologist, there



Implementation of Cosmetic Dermatology into Therapeutics

may be a decrease in some OTC use of medications such as keratolytics as more and more topical prescriptions are switching to combination topical products that contain a prescription drug along with an OTC drug. An example of this would be a high-potency topical corticosteroid ointment that also contains salicylic acid. Prescription topicals are now available in new vehicles such as foams and sprays that reduce the messy application process. This movement towards multiple therapies in one product and improved prescription vehicles may result in a decrease in the prescription of OTC topical medications. Biologic agents have revolutionized treatment in a small population of psoriasis patients, inducing rapid and complete remission and thereby reducing their need for complicated combination regimens.

Funding/conflicts of interest The Center for Dermatology Research is supported by an educational grant from Galderma Laboratories, L.P. Dr. Feldman has received research, speaking, and/or consulting support from Galderma, Abbott Labs, Warner Chilcott, Aventis Pharmaceuticals, 3M, Connetics, Roche, Amgen, Biogen, and Genentech. Dr. Strowd has no conflicts of interest to disclose.

References 1 National Psoriasis Foundation. Accessed July 18, 2008. 2 Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. (2004) Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9, 136–9. 3 Evers AWM, Lu Y, Duller P, van der Valk PJ, Kraaimaat FW, van de Kerkhof PC. (2005) Common burden of chronic skin diseases? Contributors to psychological distress in adults with psoriasis and atopic dermatitis. Br J Dermatol 152, 1275–81. 4 Gupta MA, Gupta AK. (1998) Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 139, 846–50. 5 Nickoloff BJ, Qin JZ, Nestle FO. (2007) Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 33, 45–56. 6 Linden KG, Weinstein GD. (1999) Psoriasis: current perspectives with an emphasis on treatment. Am J Med 107, 595–605. 7 Valdimarsson H. (2007) The genetic basis of psoriasis. Clin Dermatol 25, 563–7. 8 Nair RP, Stuart PE, Nister I, Hiremagalore R, Chia NV, Jenisch J, et al. (2006) Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78, 827–51. 9 Buske-Kirschbaum A, Kern S, Ebrecht M, Hellhammer DH. (2007) Altered distribution of leukocyte subsets and cytokine production in response to acute psychosocial stress in patients with psoriasis vulgaris. Brain Behav Immun 21, 92–9.


10 Berg M, Svensson M, Brandberg M, Nordlind K. (2008) Psoriasis and stress: a prospective study. J Eur Acad Dermatol Venereol 22, 670–4. 11 Misery L, Thomas L, Jullien D, Cambazard F, Humbert P, Dehen L, et al. (2008) Comparative study of stress and quality of life in outpatients consulting for different dermatoses in five academic departments of dermatology. Eur J Dermatol 18, 412–5. 12 Kimyai-Asadi A, Usman A. (2001) The role of psychological stress in skin disease. J Cutan Med Surg 5, 140–5. 13 Azfar RS, Gelfand JM. (2008) Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 20, 416–22. 14 Joshi R. (2004) Immunopathogenesis of psoriasis. Indian J Dermatol Venereol Leprol 70, 10–2. 15 Proksch E. (2008) The role of emollients in the management of diseases with chronic dry skin. Skin Pharmacol Physiol 21, 75–80. 16 Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, et al. (2004) Burden of skin diseases. Available at Diseases%202004.pdf. 17 Storm A, Andersen SE, Benfeldt E, Serup J. (2008) One in three prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol 59, 27–33. 18 Carroll CL, Feldman SR, Camacho FT, Manuel JC, Balkrishnan R. (2004) Adherence to topical therapy decreases during the course of an 8-week psoriasis clinical trial: commonly used methods of measuring adherence to topical therapy overestimate actual use. J Am Acad Dermatol 51, 212–6. 19 Koo J, Cuffie CA, Tanner DJ, Bressinck R, Cornell RC, DeVillez RL, et al. (1998) Mometasone furoate 0.1%-salicylic acid 5% ointment versus mometasone furoate 0.1% ointment in the treatment of moderate-to-severe psoriasis: a multicenter study. Clin Ther 20, 283–91. 20 National Psoriasis Foundation Treatment Guide. http://psoriasis. org/treatment/guide/otc/. Accessed July 26, 2008. 21 Roelofzen JH, Aben KK, van der Valk PG, van Houtum JL, van de Kerkhof PC, Kiemeney LA. (2007) Coal tar in dermatology. J Dermatolog Treat 18, 329–34. 22 Dodd WA. (1993) Tars: their role in the treatment of psoriasis. Dermatol Clin 11, 131–5. 23 Mefford L. (2008) NeoStrata® announces the launch of Psorent™ Psoriasis Topical Treatment. article/pressRelease/idUS169492+04-Feb-2008+PRN20080204. Accessed August 10, 2008. 24 van Schooten FJ, Godschalk R. (1996) Coal tar therapy. Is it carcinogenic? Drug Saf 15, 374–7. 25 Kessler DA. (1991) Food and Drug Administration. Dandruff, seborrheic dermatitis, and psoriasis drug products for over-the-counter human use: final monograph. Federal Register 56, 63554–63569. Available at otcmonographs/Dandruff&Seborrheic_Dermatitis&Psoriasis/ dandruff_seborrheic_dermatitis_psoriasis_FR_19911204.pdf. 26 Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. (2001) The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137, 280–4. 27 Stein KR, Pearce DJ, Feldman SR. (2008) Targeted UV therapy in the treatment of psoriasis. J Dermatolog Treat 19, 141–5.

63. Psoriasis regimens 28 Kostovic´ K, Pasic´ A. (2004) Phototherapy of psoriasis: review and update. Acta Dermatovenerol Croat 12, 42–50. 29 Carlin CS, Callis KP, Krueger GG. (2003) Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol 139, 436–42. 30 Zanolli MM. (2004) Phototherapy arsenal in the treatment of psoriasis. Dermatol Clin 22, 397–406. 31 Adachi Y, Uchida N, Matsuo T, Horio T. (2008) Clinical effect of vitamin D3 analogues is not inactivated by

subsequent UV exposure. Photodermatol Photoimmunol Photomed 24, 16–8. 32 Ghali FE. (2005) Improved clinical outcomes with moisturization in dermatologic disease. Cutis 76 (Suppl), 13–8. 33 Soares TF, Davis MD. (2007) Success of Goeckerman treatment in two patients with psoriasis not responding to biological drugs. Arch Dermatol 143, 950–1.



Note: page numbers in italics refer to figures, those in bold refer to tables

Aα fibers 39, 41 Aβ fibers 39, 41 trigeminal nerve sensory nucleus 44 Aδ fibers 39, 41 dorsal horn entry 44 nociception 42 abdomen, liposuction indications 452–3 Ablative Affirm Carbon Dioxide resurfacing 396, 402 ABS nail tips 216, 217 acetaminophen 287 acetone artificial nail removal 219 nail polish remover 213 acids, strong 56–7 acne adhesive pads 492 alpha-hydroxyacids 490 antimicrobials 491 benzoyl peroxide 489–90, 491 beta-hydroxyacids 490–1 cleansing 488–9 cleansing brushes 492 cleansing cloths 491–2 electronic heating device 492 essential oils 492 gluconolactone 491 isotretinoin 493 lactobionic acid 491 mechanical treatments 492 microdermabrasion 420–1 mild cleansing 84–5, 86 nicotinamide 493 oral vitamins 492–3 over-the-counter treatments 488–93 polyhydroxyacids 491 retinoids 491 salicylic acid 490–1 scarring 426–7 scrubs 492 soaps 488–9 sulfur 491 syndet treatment 488–9 triclosan/triclocarban 491 vitamin A 493


acneiform eruptions 57 acrylates 217 actinic keratoses, chemical peel 390, 391 activator protein 1 (AP-1) 16, 17, 19 activation by phenolic compounds 283 by retinoic acid receptors 483 corticosteroid mechanism of action 286, 287 MAP kinase signaling pathway 302 microdermabrasion effects 419 Active and Deep FX Lumenis fractionated carbon dioxide laser 396–8, 399, 400 procedures/technique 407 adhesive pads 492 advanced glycation endproducts (AGEs) 339 adverse reactions antiperspirants 154–5 artificial nails 219–20 calcium hydroxylapatite hand recontouring 477 collagen fillers 369–72 cosmetics 55 deodorants 154–5 hair permanent waving 245, 245, 246 nail cosmetic prostheses 219–20 nail grooming 203–4 aerosol sprays, sunscreen vehicles 147 afferent nerves, synapses 43–4 African hair 35, 264 pseudofolliculitis barbae 162 styling aids 263–4 African–American skin aging 31–2 ashy skin 92 self-perceived sensitive skin 24–5 UV irradiation 18 aging African-American skin 31–2 Asian skin 31–2 brow ptosis 31 Caucasian skin 31–2 chronic 13–14 cytokines 304–5 ethnic skin 31–2 face evaluation 362 facial tissue sagging 32

free radical theory 312–13 growth factors 304–5 hair 237–8 hands 473–9 Hispanic skin 32 inflammatory process 286 pathophysiology 409 physiology 302–5 reversal 304–6 see also antiaging products; photoaging; wrinkles alcohol hand sanitizers 108, 111 waterless cleansers 104 aldobionic acids 328 alexandrite laser, long pulsed 435 alkalis, strong 57 alkaloids, plant 272 allergens 56–60 IgE antibodies 60 self-perceived sensitive skin 23 allergic contact dermatitis 55–6 irritant contact dermatitis differential diagnosis 56 allergy/allergic reactions 58–60 antibacterials 111 bovine collagen 366 collagen fillers 60, 370–1 fragrances 111 hair dyes 59, 234 nail cosmetics 203, 204 sensitive skin 23 UV cured nail lacquer 212 Alloderm 364, 365 aloe 275–6 alpha-hydroxyacids (AHA) 327, 328, 329 acne treatment 490 antiaging 483, 486 antioxidant 329 chemical peels 377–8 peels 332–3, 500–1 rosacea 500–1 water binding 329 aluminium compounds, antiperspirants 152, 153 aluminium oxide, microdermabrasion 418 Alzheimer’s disease 154

Index amino acids definition 292 hair 238 protein chain 293 side chains 292, 293 5-aminolevulinic acid (5-ALA) 436 ammonium thioglycolate 250–1 anaesthetics, injectable 59 anagen phase of hair growth 157, 236, 433 anesthesia dermabrasion 428, 429 fractionated carbon dioxide laser resurfacing pretreatment 407 liposuction 450 neck 466–7 polylactic acid fillers 373 angiogenesis 19 antiaging products antioxidants 484–6 botanicals 274 coenzyme Q10 485, 486 cytokines 304–5, 307 ferulic acid with vitamins C and E 485, 486 genistein 486 hyaluronic acid fillers 352–5, 474 hydroxyacids 332, 483, 486 alpha-lipoic acid 485, 486 retinoic acid 483, 486 retinoids 483–4 selenium 485, 486 vitamin C 484, 486 with vitamin E 484–5 vitamin E 484, 486 see also botulinum entries; calcium hydroxylapatite; fillers; growth factors antiaging regimen 480–6 cleansing 480–1 exfoliation 481, 482 protection 481–3 sunscreens/UV light protection 481–3 treatments 483–6 vitamin C 325 see also photoaging antibacterials allergy 111 cleansers 480–1, 491 soap bars 79 antibiotics, rosacea treatment 499–500 antidandruff materials 117 antifungal agents, nail lacquer 209 anti-inflammatory agents 284–90 botanicals 289 cosmeceutical actives 289 topically applied 11 anti-inflammatory techniques, LED photomodulation 446–8

antimicrobial agents acne treatment 491 resistance 111–12 antioxidants 8, 281–4 antiaging 484–6 body washes 90 cell signaling pathways 282 enzymes 8 free radical damage protection 282 hydroxyacids 329–30 lipsticks 188 oral 281 partition coefficient value 284 peptides 294 photoaging prevention 19–20 potency assessment 282 retinoids 312–13 skin health 336 skin penetration 284 topical 11, 281 formulation 283–4 sun protection 482–3 topical formulation protection 52–3, 54 UV damage protection 337 combinations 338 product 53 vitamin C 281, 282, 283, 324 vitamin E 281, 282, 283, 325 topical formulation 284 antiperspirants 150–5 actives 152 adverse effects 154–5 aluminium compounds 152, 153 breast cancer 154–5 chemistry 153 crystal products 153 definition 152 delivery systems 153–4 formulation 153 sweating control 155 Wetness Inhibiting Performance 153 antiwrinkle performance, facial foundation effect measurement 173 apocrine glands 150, 151, 152 apoptosis photoaging 32 UV-induced 7–8 aquaporins 135–6, 137 arbutin 272 arms, liposuction indications 454–5 aromatic hydroxyacids 328–9 arrector pili muscle 157 Artecoll 366, 367 Artefill 366, 367 ascorbic acid see vitamin C ascorbyl phosphates 325 ashy skin, African–Americans 92 Asian hair 33–5, 264

Asian skin 18 aging 31–2 self-perceived sensitive skin 24, 25 aspartate proteases 7 aspirin 287 astaxanthin 338 atopic dermatitis body washes 92, 94 facial 128 mild cleansing 84, 85 moisturizer use 128 topical corticosteroids 128 Autologen 364, 365 avobenzone 147, 148 sunscreen 481, 482 azelaic acid 500, 501 B cells, corticosteroid prolonged use 287 bar cleansers 77–87, 104 barrier function microdermabrasion 418 panthenol effects 323 repair 506 see also epidermal barrier behenyl alcohol 126 benzoyl peroxide 489–90, 491 beta-hydroxyacids (BHA) 327–8, 329 acne treatment 490–1 antiaging 483, 486 antioxidant 329 water binding 329 betaines, facial cleansers 97 bionic acids 328, 329 biotin, brittle nails 203 black henna tattoos 234 black skin dermis 31 dyspigmentation 33 hyperpigmentation 33 irritant contact dermatitis 30 photoaging 33 transepidermal water loss 30 UVA protective factor 29 UVB protective factor 29 see also African–American skin blade shaving see shaving, blade bleaches allergic reactions 59 see also hair bleaches blepharopigmentation 194 body washes 88–94 antioxidants 90 ashy skin 92 atopic dermatitis 92, 94 chelating agents 90 cleansing ability 90 color 90 components 89–90 consumer understanding 90–1


Index exfoliation aids 90 fragrances 90 in-use performance 90–2 moisturization from 91–2, 93 moisturizing 88–91 people benefitting 92, 93, 94 regular 88 skin benefit agents 89–90 specialty 89 surfactants 89 syndets 89 types 88–9 water content 89 bombesin 295 botanicals 269–79 antiaging 274 anti-inflammatory 289 emollients 274 lighteners 276 photoprotection 276 studied 273 tighteners 276 Botox 342 advantages 343 complications 350–1 contraindications 344 disadvantages 343 indications 343–4 injection techniques 344, 345, 346–9 lower face treatment 348–9 side-effects 350–1 midface treatment 347 precautions 344 product stability 343 treatment sites 344, 345, 346–9 upper face treatment 344, 345, 346–7 side-effects 350 botulinum neurotoxin type A (BoNTA) 342–3 filler combination 349, 350 immunogenicity 350 upper face treatment 344, 345, 346–7 botulinum neurotoxin type B (BoNTB) 342 botulinum toxin 299, 342–51 allergic reactions 60 fractionated carbon dioxide laser resurfacing pretreatment 407 marginal mandibular branch of facial nerve damage 470 mechanism of action 343 physical characteristics 343 brain activation with self-perceived sensitive skin 25 thalamocortical afferents 44, 45 breast cancer, antiperspirants 154–5 breasts, liposuction 456 brighteners 276


bromelain 276 brow lift, lateral 347 brow ptosis 31 bruising Botox 349–50 collagen fillers 370 buffer salts, hair permanent waving 242 bunny lines 347–8 buttocks, liposuction indications 453–4 butyl methoxy dibenzoyl methane (BMDM) 147, 148 caffeine 276–7 calcineurin inhibitors 288 eczema treatment 502 calcitonin gene-related peptide (CGRP) 294–5 calcium gradient, stratum corneum 9 calcium hydroxylapatite 356–60 anaesthesia 359 areas for correction 357 complications 359 hand recontouring 473–9 adverse events 477 injection technique 474–7 lidocaine 474–5, 478–9 post-injection hand massage 475–6 post-treatment care 476–7 results 477, 478 indications 356–7, 358, 359 microspheres 356, 357, 474 pharmacology 356 physical properties 356 techniques 356–7, 358, 359 camouflage makeup 176–83 application 176–8 color matching 177 definition 176 goals 176 indications for 179 melasma 180 neutralizers 177 periorbital hyperpigmentation 179 postsurgical scars 179 quality of life 182–3 removal 178 skin matching 177 telangiectasia 182 texture abnormalities 177 vascular malformation 181 vitiligo 179, 180 camouflage therapists 181–2 camphor 208 cancer risk growth factors 306 hair dyes 234 capsaicin test 23–4 carbomers 73 carbon dioxide, solid 378, 380

carbon dioxide laser resurfacing 393–408 fractionated 394–8, 399, 400–3, 404, 405–7 thermal necrosis 394 carnosine 294, 296 beta-carotene 337, 339 carotenoids antioxidant 281 skin appearance improvement 338 UV damage protection 337 castor oil, lipsticks 187 catagen phase of hair growth 157–8, 433 catalase 8 cationic polymers, shampoo conditioning aids 116 Caucasian hair 33–5, 264 Caucasian skin aging 31–2 self-perceived sensitive skin 24 UV irradiation 18, 29 cell signaling pathways, antioxidants 282 central nervous system (CNS), self-perceived sensitive skin 25 central projections 43–4 ceramides microdermabrasion effects 419 skin barrier building 103 cervicomental angle (CMA) 463, 464 reduced after liposuction 468 C-fibers 23, 39, 41 dorsal horn entry 44 itch 42–3 nociception 42 pleasure sensation 43 self-perceived sensitive skin 25 chamomile, German 277, 492 cheilitis 186 chelating agents, body washes 90 chemical peel, microdermabrasion comparison 422–3 chemical peels advantages 380, 385 combination 384–5 complications 382 contraindications 385, 386 depth 377, 378 disadvantages 380, 385 fluor-hydroxy pulse peel 381 formulation 377–80, 384–5 frosting 388 histologic changes 377 indications 377, 385–6 long-term skin care 390 medium-depth 384–91 analgesia 387 complications 388, 390 granulation 388, 389 long-term skin care 390 patient preparation 387

Index post-procedure 388 sedation 387 set-up 386 technique 386, 387–8 wound healing 388, 389 post-care 381 priming 380 procedure 380–1 scar chemical reconstruction 381–2 superficial 377–83 techniques 380–2, 386, 387–8 chemical reconstruction of skin scars (CROSS) 381–2 chemokines 285 chest liposuction, male 456 chin Botox treatment of dimple 348 implants 471 Chinese herbal medicines, toxicity 271 chromophores 146 UV absorption 14 Chrysanthellum indicum 500 ciclosporin 288 citric acid 483 clays, hair styling aids 262 cleansers allergic reactions 58 antiaging 480–1 antibacterials 480–1, 491 bar 77–87, 104 exfoliants 481 foaming liquid 104 formulation 480–1 fragrances 104 lipid-free 104 low-foam 102–5 mechanisms 104–5 mildness 103–4 production 103 types 102–4 non-foam 102–5 mechanisms 104–5 types 102–4 personal 88–94 preservatives 104 rosacea 497, 498 skin barrier building ingredients 103 skin disease 84–5, 86 types 104 waterless 104 see also body washes; facial cleansers; hand sanitizers; hand washes; shampoos cleansing acne 488–9 antiaging regimen 480–1 body wash ability 90 mechanisms 104–5

procedure 481 skin barrier damage 105 see also facial cleansing cleansing bars 77–87 formulation 77–8 manufacturing processes 78 non-soap detergent 79 preservatives 79 skin structure/function impact 79–81 soap 78–9 see also syndets/syndet bars cleansing brushes 492 cleansing cloths 98–9 acne treatment 491–2 dry lathering 99 wet 99 cleansing milks 98 climbazole 117, 118 Clostridium botulinum 342 C-mechano-heat (CMH) nociceptors 42 coacervate 116 coal tar 118 coenzyme Q10 (CoQ10) 284 antiaging 485, 486 nanoemulsions 505 skin appearance 339 wound healing 340 coffee 276–7 coffeeberry extract 277 cold-sensitive fibers 41, 42 collagen bovine 366 degradation stimulation 16 dermis 31 laser treatment 409 photoaging 15, 409 skin fibroblast 297 stimulation by hyaluronic acid fillers 354–5 synthesis by fibroblasts 16, 17 collagen fibers, photoaging 14 collagen fillers 361–72 adverse reactions 369–72 allergic reactions 60, 370–1 anaesthesia 367 animal-derived 365–6 bioengineered animal-derived 366 cross-hatching 367 facial augmentation 367–9 fanning 367 granuloma formation 371 hand rejuvenation 369 infections 371–2 injection techniques 366–7 injection-related events 370–1 materials 363, 364–5, 365–6 nodule formation 371 ‘potential face’ 362–3 vascular compromise 371

color additives in sunless tanning products 141 appraisal of facial foundation 173, 174 body washes 90 coordinates 177 matching 177 color charts 49 Color Index (CI) number 209 color stabilizers, nail lacquer 209 color standard chips 49 coloration, sunless tanning products 141–2 colored cosmetics camouflage techniques 176–83 facial foundation 167–74 coloring agents lipsticks 187, 188 nail polish 208–9 combination gels, allergic reactions 60 comedones 57 benzoyl peroxide treatment 489 salicylic acid treatment 491 compartment syndrome, risk with liposuction 454 complexion 167 history of makeup 167–9 Complexion Analysis Software 49–50 conditioners (hair) 225 after hair relaxing 253 allergic reactions 58–9 colored hair 234 rinse-off 121 conditioning polymers, hair permanent waving 242 confocal Raman microspectroscopy (CRS) 68–9 consumers facial moisturizer testing 128 understanding of body washes 90–1 contact dermatitis 55–61 diagnosis 60 skin of color 30 treatment 60 see also allergic contact dermatitis; irritant contact dermatitis contact urticaria 56, 57–8 contouring see skin contouring techniques copper, UV damage protection 338 corneocytes 3, 5, 6 cohesion 7 desquamation 8 dry lips 186 lip labial epidermis 185 maturation 8 melanin particles 7–8 visualization 10 corneodesmosomes 5, 7 desquamation 10 Corneometer® 10


Index corneometry 127 cornified envelope (CE) 5, 6 lipid–protein cross-links 5 cortex 44, 45 corticosteroids anti-inflammatory action 286–7 eczema treatment 502 mode of action 286 psoriasis 508, 509, 510 topical allergic reactions 59 atopic dermatitis 128 contact dermatitis treatment 60 cosmeceuticals anti-inflammatory actives 289 botanicals 269–79 growth factors 302–8 nutrients 335–40 peptides 296–7, 298, 299 polylactic acid fillers 373–6, 474 product development 273–4 proteins 293, 299–300 see also anti-inflammatory agents; antioxidants; hydroxyacids; retinoids; vitamin(s) cosmetic(s) adverse skin reactions 55 allergic contact reactions 11 hypersensitivity reactions 55–6 product development 10–11 rosacea 498–9 skin irritation 11 cosmetic actives composition 62–3 delivery assessment 68–9 emulsions 63 formulation 63–4 molecular weight 62–3 natural 500–1 occlusion of skin 64 patch formulations 67 penetration enhancement 64–8 percutaneous delivery 62–9 rosacea 500–1 skin barrier 62 skin partition coefficient 64 transepidermal delivery 62 vehicle effect 63–5 cosmetic intolerance syndrome 57 cosmetic product evaluation bio-instrumentation 47–8 non-invasive 47–54 digital photography 48–51 methods 48 cosmetic surgery, lips 186 CosmoDerm 364, 365, 367 hands 473 CosmoPlast 364, 365, 367, 369 hands 473


creams 71–4 active ingredients 73 composition 72–3 definition 71 elevated temperature testing 74 oil-in-water 72–3 stability 74 sunless tanning product delivery 140–1 water-in-oil 73 critical wavelength method, UVA radiation 148 cross-linking agents 353 crystal products, antiperspirants 153 C-tactile afferents 43 curcumin 282–3, 284, 289 curl, degree of 248 cuticle remover 200 irritant reactions 203–4 cyanoacrylate monomers 217, 218, 219 cyclomethicone 506 cyclo-oxygenase (COX) 287 cyclo-oxygenase 2 (COX-2) inhibitors 287–8 Cymetra 364, 365 cysteine proteases 7 cytokeratins, lip labial epidermis 184–5 cytokines 285 aging reversal 304–5 anti-aging 307 skin function 304–5 dandruff 115, 116 therapeutic shampoos 117, 120–1 year-round treatment 121 deodorants 150–5 adverse effects 154–5 delivery systems 153–4 odor control 153 soap bars 79 depigmentation niacinamide 323 retinaldehyde 314–15 retinoids 313 vitamin B3 323 dermabrasion 426–31 advanced technique 429–30 advantages 427 complications 430–1 disadvantages 427 Fitzpatrick skin types 428 full-face 429–30 indications 426–7 instrumentation 428 mechanism of action 426 patient selection 427 postoperative wound care 430 preoperative consultation 427–8 preoperative photographs 428 technique 428–30

dermatomyositis, bovine collagen 366 dermis 4 collagen 31 grenz zone 32–3 hydroxyacids effects 329 microdermabrasion effects 420 photoaging 14 skin of color 31 desmosomes 4, 5 desquamation 7, 8, 124 assessment 9–10 corneodesmosomes 10 pathogen protection mechanism 6 detergent bars non-soap 79 stratum corneum interactions 80–2 detergents, synthetic see syndets/syndet bars diathesis factors, sensitive skin 23 dibutyl phthalate 208 diclofenac 287, 288 diet 335–40 deficiency 335 digital photography cosmetic product evaluation 48–50 terminology 50–1 dihydroxyacetone (DHA) mechanism of action 139–40 moisturizers 142 processing 140 stability checks 140 storage 140 structure 140 sunscreen addition 140 sunless tanning products 139 vitiligo camouflage 179 dimethicone 506 dimethyl urea, nail hardening 211 diode laser, long pulsed 435 diode laser 1450 nm 410, 411, 414 dirt, facial cleansing 101 DNA, UV damage 7, 8 dorsal horn 44 double-chin formation 32 Dove bar 79 dry ice peel 378, 380 dry skin cleanser mildness 101 facial 123–4 flaking 124 hydroxyacids use 330, 332 lactic acid treatment 133 lips 186 moisturizer use 91 urea treatment 133 dryness of skin 30 assessment 127 D-squames 127 dyes see hair dyes

Index dyspigmentation 29 black skin 33 hydroxyacids 332 see also hyperpigmentation; hypopigmentation East Asian skin, UV irradiation 18 eccrine glands 150, 151, 152 eczema etiology 502 facial moisturizers 128 hygiene 505–6 moisturizer use 128, 502–6 occupational 60 regimens 502–6 syndet use 505–6 elastic fibers, photoaging 32 elastic recovery time 31 elasticity of skin 31 nutrient effects 339 elastosis 32 elevated temperature testing 74 emollients 11, 73 botanicals 274 cleansers 97 facial moisturizers 125, 126–7 hair styling aids 259, 260 moisturizers 125 emulsification, emollient/lathering cleansers 97 emulsifiers/emulsifying agents 71 cationic 72 creams 72 facial foundation 169 moisturizers 131 facial 125 emulsions 71, 72 cosmetic actives 63 fluid facial foundation 169 hair 261–2, 263 styling aids 259 moisturizers 504, 505 multivesicular 504, 505 oil-in-water 73, 104, 131 sunscreen vehicles 147 water-in-oil 73, 131 enhanced glycerol derivatives 136–7 enkephalin 295 environmental factors irritants 57 sensitive skin 23 environmental toxins, stratum corneum protective function 7 epidermal barrier 3–11 antimicrobial 6 building ingredients in cleansers 103 cosmetic product development 10–11 damage in cleansing 105 disruption 6

functions 5–8, 124 regulation 9 herbal product penetration 271–2 homeostasis 7, 8–9 immune protection 6 mechanical 6 microdermabrasion 418 oxidative stress 8 permeability 5–6 restoration by cosmetics 10–11 self-perceived sensitive skin 25 structural components 3, 4, 5 study methods 9–10 topical products 10 UV barrier 7–8 water evaporation 5–6 epidermal nerves 25 epidermis hydroxyacids effects 329 photoaging 32–3 skin of color 29 thickening with retinoids 483–4 thickness measurement 10 erbium:glass 1540 nm laser 410, 411, 413–14 Er:YAG lasers 394 fractionated 396 erythema intense pulsed light laser 446 laser-assisted hair removal complication 437 UV-induced 447 essential oils, acne treatment 492 ethnic skin see skin of color ethyl acetate, nail polish remover 213 etodolac 287 eumelanin 27, 229 eutectic blends 64 Evolence® filler 365, 366, 367 exfoliants/exfoliation aids body washes 90 chemical 481 mechanical 481 exfoliation antiaging 481, 482 facial cleansers 95, 96, 101 extensibility of skin 31 extracellular matrix (ECM), degradation effects of UV irradiation 19 extremozymes 300 eye(s) microdermabrasion side-effects 424 protection against laser beams 434 eye cosmetics 190–6 history 190–1 microbiological contamination protection 195 safety/regulatory consideration 195

virtual modeling 196 see also mascara eyebrow ptosis with Botox treatment 349 eyelashes ailments 191 curling 195 digital simulation 196 extensions 194 false 193 growth stimulation 194, 196 perming 194 physiology 191 tinting 193–4 transplantation 194 see also mascara eyelids nail cosmetic allergic reactions 204 ptosis with Botox treatment 349–50 rejuvenation 441 tattooing 194 eyeliners 194–5 eyeshadow 194, 195 face ageing evaluation 362 full-face volume restoration 471 tapering of lower 470 facial augmentation, collagen fillers 367–9 facial cleansers 95–101 exfoliation 95, 96, 101 function 96–7 makeup removal 98, 101 mildness 101 pH 96 scrubs 98 selection 99–101 solvents 97 surfactants 96, 97 types 97–9 facial cleansing chemistry 96–7 dirt 101 form 100 friction 97 history 95–6 physical 97 ritual 100 skin problems 100–1 surfactants 96, 97 facial foundation 167–74 antiwrinkle performance measurement 173 application 171–2 color appraisal 173, 174 color creation 170 compact 169–70 coverage 170–1 design 172 fillers 171, 172


Index fluid 169 formulation 169–71, 172 history 167–9 iron oxides 170 manufacturing development 169 moisturizing effect measurement 173 performance 172–3 pigments 170–1 powders 170 product categories 171 silicone oils 169 facial moisturizers 123–8 dihydroxyacetone content 142 formulation 125 inflammatory dermatoses 128 ingredients 126–7 testing 127–8 facial nerve, marginal mandibular branch 463–4 damage during liposuction 469–70 facial skin cell differentiation/maturation 124 dry 123–4 water content 124 facial tissue sagging 32 fast adapting (FA) receptors 39 fat transfer, autologous 471 hand recontouring 473, 474 fern, golden 277 ferulic acid with vitamins C and E 485, 486 feverfew 277 fibroblasts collagen I 297 collagen synthesis 16, 17 growth factor source 307 inflammatory mediator release 285 microdermabrasion 420 UV radiation effects 17 fillers allergic reactions 60 botulinum neurotoxin type A combination 349, 350 calcium hydroxylapatite 356–7, 358, 359–60 collagen 60, 361–72 facial foundation 171, 172 following radiofrequency treatment 441 hand 473 hyaluronic acid 352–5 persistence 354–5 polylactic acid 373–6 fish oils, skin health 336 Fitzpatrick skin types, dermabrasion 428 flaking, dry skin 124 flavonoids 272 skin health 336 topical 325–6 UV damage protection 338


fluor-hydroxy pulse peel 381 flushing response to vitamin B3 323 rosacea 500 foaming liquid cleansers 104 follicular inflammation 121 follicular plugging 57 foot, moisturization of skin 130–1 foot moisturizers 130–8 commercially available 132 lactate efficacy 133–4, 135 urea efficacy 133–4, 135 forearm controlled application test (FCAT), soap and syndet bars 83, 84 forehead Botox treatment 344, 345, 346 brow ptosis 31 lateral brow lift 347 foreign body reactions 56 formaldehyde 211–12 allergy 58, 211 formalin 211 fractionated carbon dioxide laser resurfacing 394–8, 399, 400–3, 404, 405–7 Ablative Affirm Carbon Dioxide resurfacing 396, 402 Active and Deep FX Lumenis 396–8, 399, 400 anaesthetic 407 botulinum toxin neuromodulator 407 complications 407 Fractionated Pearl 396, 406–7 Fraxil Re:Pair 396, 398, 400 Lux 2940 396, 406 MedArt FrX 396, 401–2 Mixto SX Slim Evolution 396, 400–1 Mosaic Lutronic eCO2 396, 402–3 Paxel 396, 406 Pixel 2940 396, 405–6 Pixel Carbon Dioxide 396, 401 postoperative treatment 407 preoperative treatment 407 procedures 407 Sciton ProFractional resurfacing 396, 403, 404, 405 SmartXide DOT resurfacing 396, 402 technique 407 Fractionated Pearl (Cutera) resurfacing 396, 406–7 fragrances allergic reactions 58 allergy 111 body washes 90 cleansers 104 facial moisturizers 127 lipsticks 188 Frankfurt plane 464 Franz cell 68, 284

Fraxil Re:Pair (Reliant) 396, 398, 400 free radical scavengers retinoids 313 see also antioxidants free radicals 281–2 aging theory 312–13 antioxidant protection against damage 282 friction, facial cleansing 97 gallic acid 328–9 gel fillers 56 gels/gelees hair 258–9, 261, 263 sunless tanning products 141 genistein 486 Gentlewaves® photomodulation 445, 446 German chamomile 277, 492 Ginseng, delivery 271 glabella, Botox treatment 342, 344, 345, 346 glabrous skin 38, 39 low threshold mechanoreceptors 41 structure 40 gluconolactone 483, 491 glutathione 294 glycation 339 glycerin cleanser humectant 103 keratinocyte maturation 128 moisturizer humectant 125, 126 glycerol 7 glycerol monothioglycolate 242 glycolic acid acne treatment 490 antiaging 483 medium depth peel 384–5 microdermabrasion comparison 423 rosacea 501 glycols 73 glycosaminoglycans (GAGs) 319–20, 331 glyoxal, nail hardening 211 Goeckerman treatment for psoriasis 511 golden fern 277 golden mean 363 granulation medium depth chemical peel 388, 389 nail 204, 204 wound healing 303 granuloma formation, collagen fillers 371 grape products 277 green tea, skin appearance 339 grenz zone 32–3 growth factors 302–8 aging reversal 304–5 delivery methods 307–8

Index natural 306–7 product quality 308 risks 306 skincare 304–5 stem cell 307 synthetic 307 wound healing 303–4 hair 33–5, 222–5 African 263, 264 aging 237–8 biology 157–9 bonds 248 care of colored 233 chemical structure 238–9 color 224, 227 natural 229–30 cortex 224 curl 244 degree of 248 retention 258 curliness spectrum 33, 34–5 cuticle 223, 236, 237 ethnic types 264 eyelashes 191 fiber 222–4, 236 water hydrophilicity 237 geometry 236–7 graying 229 grooming 224–5 growth 236, 433 anagen phase 157, 236, 433 catagen phase 157–8, 433 telogen phase 158, 433 hydration 158, 161 keratin 34, 35, 224 loss 121 medulla 224 melanin 224, 229, 230 peptide application 297, 298, 299 physiology 222–4, 236, 256 pigmentation 229–30 properties 158–9 racial differences 33–4 shaft 157 shape 33 stabilization 257 shedding 236 split ends 238 structure 33–4, 248 stabilization 257 terminal 33, 433 thermal behavior 237 water interaction 237 waving 239, 240 weathering 238 wet setting 258 hair bleaches 229, 232 allergic reactions 59

chemistry 230 growth cycle 157–8 hair cosmetics 222 see also conditioners (hair); hair dyes; shampoos hair creams 261–2 hair dyes 227–35 advantages 231–2 allergic reactions 59, 234 application 232–3 cancer risk 234 care of colored hair 233 chemistry 229–31 couplers 231 definition 227 demi-permanent 228, 229, 232 disadvantages 232 fiber damage 233 formulation 231, 232, 233 hair structure 233–4 occupational safety 234 oxidative dye formation 230–1 permanent 59, 228–9, 232 chemistry 230–1 precursors 230 product types 227–9 regulation 234 safety 234 semi-permanent 228 sensitization 233, 234 skin sensitivity test 233, 234 temporary 228 hair emulsions 261–2, 263 hair follicles 157, 222, 223–4 biology 432–3 innervation 158 keratins 222, 223–4 melanocytes 229 peptide application 298 hair gels 258–9, 261, 263 hair mousses 258–9, 261, 263 hair permanent waving 236–46 acidic 243 adverse reactions 245, 245, 246 alkaline perms 243 alkalizing additives 242 buffer salts 242 carriers 242 complexing agents 242 conditioning polymers 242 disulfide cleaving 239, 240 ingredients 240–3 neutral 243 neutralizers 243 opacifiers 243 practise 243–4 products 240–3 reducing agents 240–1 regulatory aspects 243

safety 244–5 solubilizing agents 243 solutions 239 steps 241 sulfite 243 surfactants 242 thermal waves 243 thickeners 243 types 240–3 hair pomades 261–2 hair relaxers 251–5 application 253 effects 253–4 hair removal 156 laser-assisted 432–7 see also shaving hair setting lotions 258–9, 261 hair spray gels 261, 263 hair straightening 248–55 hydroxides 251–2 reducing agents 250–1 relaxers 251–5 sulfites 251 terminology 252 thermal processing 249–50 thiol with heat 255 hair styling 256–65 consultations 264–5 hair styling aids 258 African hair 263–4 applications 259–64 clays 262 curl retention 258 definition 256 emollients 259, 260 emulsions 259 film-forming active ingredients 259 formulations 258–9 polymer formulations 258–9 product forms 259–64 silicone 262–3 silicone pump sprays 262–3 silicone serums 262–3 smoothness improvement 257 technologic developments 265 uses 259–64 volume improvement 257 wax formulations 259 waxes 260, 262, 263 hairdressers, occupational hand eczema 60 hairsprays 258–9, 259–61, 263 aerosol 259–60, 261 formulation 260–1 propellants 260–1 pump 260 spot welds 260 hairy skin 38, 39, 41 structure 40


Index hand(s) aging 473–9 microbiota 106–7, 110 moisturization of skin 130–1 pH 108 physiology 473 polylactic acid fillers 375 rejuvenation with collagen fillers 369 skin damage 108 volume restoration 473 washing 108 hand flora 107 resident 110 hand hygiene 107–8 compliance 108 effectiveness in community 110–11 guidelines 107–8 hospital epidemiology nosocomial studies 111 nail cosmetics 206 hand moisturizers 130–8 commercially available 132 lactate efficacy 133, 134 urea efficacy 133, 134 hand recontouring autologous fat 473, 474 calcium hydroxylapatite 473–9 adverse events 477 injection technique 474–7 lidocaine 474–5, 478–9 post-injection hand massage 475–6 post-treatment care 476–7 results 477, 478 hand sanitizers 106–12 alcohol-based 108 safety 111 efficacy 108–10 formulations 112 safety 111–12 skin irritation 111 hand washes 106–12 efficacy 108–10 formulations 112 safety 111–12 skin irritation 111 in vitro measurement 108–9 in vivo models 109 headache, Botox treatment side-effect 350 heating device, electronic 492 heliodermatitis 14 henna, allergic reaction 59 herbal extracts 270 herb-based products 269–79 active ingredients 270 cross-reactivity with other herbs 271 delivery of therapeutic concentration 271 effectiveness 271–2


extraction methods 270 mechanism of action 272 quality control 270–1 regulation 269 safety 271 secondary metabolites 272, 273 variability 270 herbs esthetic utility 273–9 wildcrafting 270 herpes simplex virus (HSV) antiviral prophylaxis 427–8 dermabrasion 427–8, 431 pretreatment for medium-depth chemical peel 387 hips, liposuction indications 453–4 Hispanic skin aging 32 self-perceived sensitive skin 24, 25 homeostasis, epidermal barrier 7, 8–9 hom*ogenous gels, allergic reactions 60 humectants 73 cleansers 103 facial moisturizers 125, 126 moisturizers 125, 131, 132 hyaluronic acid fillers 352–5, 474 chemical composition 352–3 collagen stimulation 354–5 complications 354 concentration 353 cross-linking 353 indications 353 injection techniques 354 persistence 354–5 properties 352–3 hyaluronan 313–14, 315 hydration of hair 158, 161 hydration of skin 6–7, 9, 124 measurement 10 microdermabrasion 418 panthenol effects 323 surface 124 hydrocortisone, psoriasis 508, 509, 510 hydrogen peroxide 230, 231 allergic reaction 59 hair structure alteration 232 regulatory aspects 243 hydrophilic substances, delivery through sweat glands 62 hydroquinone, allergic reactions 58 hydroxide hair straighteners 251–2 hydroxyacids 327–33 antiaging 483, 486 antioxidant 329–30 biological properties 329–30 chemical peels 377–8 clinical uses 330, 331, 332–3 efficacy 483 gel matrix formation 329

groups 327–9 matrix metalloproteinase inhibition 330 natural occurrence 327–9 physicochemical properties 329–30 sensory responses 330 skin effects 330, 331 sun sensitivity 330 topical drug synergy 333 water binding 329 wrinkle treatment 332, 333 hyperhidrosis 155 Botox use for palmar 342 hyperkeratinization, hydroxyacids use 330, 332 hyperpigmentation black skin 33 dermabrasion postoperative 431 laser-assisted hair removal complication 437 microdermabrasion 421 side-effects 424 periorbital 179 postinflammatory 29 hypersensitivity reactions 55–6 collagen fillers 370–1 diagnosis 60 immediate (type I) 56, 58 hyponychium 198–9 hypopigmentation dermabrasion postoperative 431 laser-assisted hair removal complication 437 postinflammatory 29 ibuprofen 287 immune protection, epidermal barrier 6 immuno-allergologic pattern of sensitive skin 23 immunoglobulin E (IgE) antibodies, allergens 60 immunomodulators 288–9 immunosuppressants 60 immunosuppression 20 indomethacin 287 nano-encapsulated 66 induration, neck liposuction 468 infections/infectious diseases artificial nails 220 collagen fillers 371–2 epidemiology 106 epidermal barrier for pathogens 6 hand hygiene efficacy 111 nails 204–5, 205 staining 220 transmission 106 inflammation acute 284, 285 chronic 284, 285–6

Index follicular 121 foreign body reactions 56 photoaging 14 pigmentation effects 29 prescription medicines 286–90 process 284–6 proteolytic enzyme release 302 reactive oxygen species release 302 inflammatory mediators 285 inflammatory responses, immune cell-mediated 285 informed consent Jessner’s solution medium depth peel 386 liposuction 458 infrared light devices 410, 411, 414–15 injectables, allergic reactions 60 integrins 16 intense pulsed light (IPL), rosacea treatment 500 intense pulsed light (IPL) laser 410, 411, 412 erythema 446 hair removal 436, 437 intensity-modulation radiation treatments (IMRT) 446–7 intercellular adhesion molecules (ICAM) 285 inter-corneocyte lipids 5 interleukins, skin damage 302 iontophoresis 68 iron oxides, facial foundation 170 irritant contact dermatitis 55 allergic contact dermatitis differential diagnosis 56 keratolytics 510 skin of color 30 irritants 56–7 environmental factors 57 skin barrier function assessment 127–8 irritation antiperspirants 154 benzoyl peroxide-induced 490 cosmetics 11 deodorants 154 hand washes/sanitizers 111 keratolytics 510 nail cosmetics 203–4 panthenol protective effects 323 retinoid induction 310, 321 shaving 158 subjective 57 vitamin A 321 Isologen 364, 365 isopropyl alcohol, waterless cleansers 104 isotretinoin 493 itch 42–3

Jessner’s solution 378–9 medium depth peel 384, 385, 389, 390, 391 informed consent 386 microdermabrasion comparison 423 technique 386 jowling 32 jowls 463 liposuction 467, 468 indications 455–6 jugular vein, external 464 Juvéderm filler 353 keratin hair 34, 35, 224 hair cuticle 223 hair follicles 222, 223–4 nail granulations 204, 204 nail plate 199 keratin chain interactions 257 keratinocytes 3, 5 differentiation 8 epidermal barrier disruption 6 facial skin 123 glycerin in maturation 128 growth factor source 307 immune function 6 inflammatory mediator release 285 psoriasis 507, 508 UV radiation effects 17 pigmentation induction 28 keratohyalin granules 5 keratolysis epidermal 483 exfoliants 481 keratolytics contact dermatitis 510 irritation 510 psoriasis 508, 509, 509–10, 511 keratoses, hydroxyacids 332 ketoconazole 117, 118 ketoprofen 287 kinetin 307 kytorphin 295, 299 labeling, sunless tanning products 141 lactic acid acne treatment 490 antiaging 483 dry skin treatment 133 psoriasis 508, 509, 509 see also sodium lactate lactic acid stinging test 23, 25 lactobionic acid 329–30, 483, 491 lamellar granules (bodies) 5 Langerhans cells 4, 6 photoaging 32 lanolin, moisturizer occlusive 126

lanugo 433 laser techniques fractionated 394–8, 399, 400–3, 404, 405–7 liposuction 459–60 non-ablative 409–16 types 409, 410, 410–15 see also carbon dioxide laser resurfacing laser-assisted hair removal 432–7 complications 436–7 concepts 433 eye protection 434 postoperative management 436 preoperative management 433–4 radiofrequency combinations 436 techniques 434–6 laser-assisted liposuction 459–60 latex, contact urticaria 58 lathering facial cleansers 97 lecithin 72 LED photomodulation 444–8 anti-inflammatory actions 446–8 clinical applications 445–6 retina protection 447 leukocytes, inflammatory process 285 levator labii superioris alequae nasi (LLSAN) 348 licochalcone A 500 lidocaine, calcium hydroxylapatite hand recontouring 474–5, 478–9 light energy device, bipolar radiofrequency 441–2 light therapy, rosacea 500 lighteners botanicals 276 vitamin C 324 lip(s) 184–6 aging 185–6 cheilitis 186 cosmetic surgery 186 dermis 185 dryness 186 histology 185 hyaluronic acid fillers 353 labial epidermis 184–5 lamina propria 185 pigmentation 186 sensitivity to environment 185 topology 185 vermillion zone 184, 185 see also lipstick lip brilliances 188 lip glosses 188 lipid(s) desquamation 8 facial moisturizer emollients 126–7 hair 238 inter-corneocyte 5 nail plate 200


Index pH effects 82 sebaceous 115 soap bar use 80 stratum corneum 82 surfactant interactions 105 synthesis 8 topically applied 11 UV damage protection 338 lipid peroxidation 281–2 lipid-free cleansers 104 alpha-lipoic acid 485, 486 liporeceptors 9 liposomes 271 moisturizers 504–5 penetration enhancement 65 liposuction 450–60 advantages 451 complications 451–2, 458–9 disadvantages 451–2 endpoint determination 457 equipment 457–8 fanning 467 feathering 468 history 450 indications 452–6 informed consent 458 intraoperative phase calculations 458–9 jowls 467, 468 indications 455–6 laser-assisted 459–60 neck 463–71 indications 455–6 operating technique 457 postoperative phase complications 459 preoperative phase complications 458 skin contour 451 skin physiology 451 tumescent local anesthesia 450, 451–2 neck 466–7 technique 456–7 tunneling 468 lipstick 184, 186–8 active ingredients 188 antioxidants 187–8 formulation 186–8 oils 187 pigments 187 preservatives 187–8 texturing agents 187 liver X receptor (LXR) 9 local anaesthetics, allergic reactions 59 long pulsed alexandrite laser 435 long pulsed diode laser 435 long pulsed ruby laser 434–5 lotions 71–4 definition 71 sunless tanning product delivery 140–1 low density lipoprotein (LDL), free radical damage 282


low threshold mechanoreceptors (LTMs) 39, 41 lutein 337, 339 Lux 2940 (Palomar) resurfacing 396, 406 lycopene 337, 339 lymphoma, immunomodulator association 288 makeup history 167–9 removal facial cleanser selection 101 toners 98 shades 172 skin color 172 see also eye cosmetics; facial foundation; lipstick Malassezia 115, 117 maltobionic acid 329 skin effects 331 structure 329 wrinkle treatment 333 mandibular border redefinition 349 manicure 201–2, 202 practice 206 marginal mandibular branch of facial nerve 463–4 damage during liposuction 469–70 mascara 190–1, 191–3 application 195, 196 applicator technology 192–3, 194, 196 composition 192 masks, peel-off/wash-off 481 masseter muscle, hypertrophy 349 mast cells, skin of color 30 matrikines 295, 297, 298, 299 matrix metalloproteinases (MMPs) 19 activation 483 collagen degradation stimulation 16 inflammatory process 286 inhibition by hydroxyacids 330 LED photomodulation 444–5 skin damage 302 sunscreen regimens 127 mechanoreceptive afferents 39, 41 MedArt FrX laser resurfacing 396, 401–2 Meissner corpuscles 39, 41 meladine, hair removal 436 melanin 7–8, 27 hair cortex 224, 229, 230 laser-assisted hair removal 433 oxidative degradation 230 photoprotection in skin of color 33 postinflammatory hyperpigmentation 29 melanocortin-1 receptor (MC1R) 28 melanocytes 4, 27–8 hair follicles 229

melanocyte-stimulating hormone (MSH) 295 alpha-melanocyte-stimulating hormone (MSH) 28 melanogenesis 28, 295 melanosomes 27–8 melasma, camouflage makeup 180 Merkel disks 39, 41 mesolabial fold, hyaluronic acid fillers 353 mesotherapy, growth factor delivery 307–8 methacrylate polymers artificial nails 215–16 nail resins 208 methyl ethyl ketone (MEK) artificial nail removal 219 nail polish remover 213 methyl methacrylate monomers 220 methylacrylates 217 methylene glycol, allergy 211 metronidazole 500 mexoryl sunscreen 481, 482 microbial resistance 111–12 microdermabrasion 418–24 advantages 423–4 chemical peel comparison 422–3 complications 424 contraindications 420 dermis effects 420 disadvantages 423–4 histopathologic changes 418–19 indications 420–2 molecular effects 419 procedure 418 side-effects 424 skin physiologic changes 418 trichloracetic acid combination 421 microdermabrasion units 418, 419 microdialysis 68, 69 microemulsions 271 microneedles 67–8 microvasculature of skin 15 milk thistle 277–8 minerals, skin health 336 mists, no-rub 142 mitochondrial ATP, photodynamic therapy 447–8 mitogen-activated protein (MAP) kinase signaling pathway 302 Mixto SX Slim Evolution 396, 400–1 Mohs surgery, dermabrasion 427, 429 moisturization of skin 6–7 body washes 91–2, 93 cosmetic products 10–11 facial foundation effect measurement 173 foot 130–1 hand 130–1 sunless tanning products 142 ultrastructural effects 133

Index moisturizers 10–11 after shaving 162 allergic reactions 58 aquaporins 135–6, 137 body washes 89–91 delivery systems 503–5 dihydroxyacetone content 142 dry skin 91 eczema treatment 502–6 emulsifiers 125, 131 emulsions 504 enhanced glycerol derivatives 136–7 facial 123–8, 142 foot 130–8 formulation 131 hand 130–8 liposomes 504–5 mechanism of action 502–3 multivesicular emulsions 504, 505 nanoemulsions 504, 505 next-generation 135–7 niosomes 504, 505 nutrient effects 339 ointments 504 psoriasis 508, 509, 509–10 rosacea 497, 498 serums 504 sunscreen containing 506 technology 131 treatment 505–6 see also sunless tanning products; sunscreens monocytes, inflammatory process 285 Mosaic Lutronic eCO2 resurfacing 396, 402–3 mucilages 272 multivesicular emulsions 504, 505 mushrooms 278 myristoyl-nicotinate 323 nail(s) 197–205 acrylic extensions 200, 215–16 artificial (see nail cosmetic prostheses) brittleness 200, 201, 202, 203 buffing 203 calcium content 199 care 202–3 composition 199–200 cuticle remover 200 irritant reactions 203–4 discoloration 198, 204, 209 dyschromia 198 dystrophy 203 filing 202–3 flexibility 200, 201, 202, 203 grooming 201–2, 202–4 hardening 210–11 infections 204–5, 205 artificial nails 220

keratin granulations 204, 204 manicure 202, 202 painting 207 pedicure 202 physiology 199–200, 201, 202 plasticizers 200 signs 198 staining 209 infections 220 thickness 202 trauma 203 trimming 202–3 nail basecoats 208 nail bed 199 changes 198 nail cosmetic prostheses 215–20 adverse reactions 219–20 equipment 218 infections 220 liquid and powder systems 215–16, 217 nail damage 220 nail surface preparation 216 nail wraps 216, 217–19 rebalancing 219 removal 219 training for technicians 220 UV gels 216–17 nail cosmetics 200 allergic reactions 59, 203, 204 application 206 colored 206–12 (see also nail polish) hygiene 206 irritant reactions 203–4 procedures 204 safe use 205 nail folds 197–8 nail hardener 200, 206, 207, 210–11 nail matrix 197, 198 nail plate 197, 199 lipids 200 surface filing 203 thinnning 204 water content 200 nail polish (lacquer) 200, 206–7, 206–12 antifungal agents 209 brittle nails 203 color stabilizers 209 colorants 208–9 ingredients 206–8, 209 plasticizers 208 preservatives 209–10 solvents 208 thixotropic agents 209 UV curable 207, 212, 213 yellow staining 204 nail polish remover 200, 212–13 irritant reactions 203–4 nail resins 208

nail surface dehydrators 216 adhesion promoters 216 nail topcoats 208, 209 nail unit anatomy 197–9 breaks in integrity 204 lines 198 nail wraps 216, 217–19 nanocapsules 66 nanoemulsions 271, 504, 505 nanosomes 271 naproxen 287 nasolabial fold collagen filler injection 368 hyaluronic acid fillers 353 softening 348 natural actives 500–1 see also cosmetic actives natural moisturizing factor (NMF) 5, 6–7, 131, 133, 503 amino acids 292 composition 131 epidermal barrier 9 Nd:YAG 1064 nm laser hair removal 435 Q-switched 410, 411, 413 Nd:YAG 1320 nm laser 410, 411, 412 neck anatomy 463–4 liposuction 463–71 advanced/ancillary techniques 470–1 anesthesia 466–7 complications 468–70 consultation 463 ethical considerations 464 fat augmentation 471 French tape application 468 indications 455–6 induration 468 overresection 470 patient selection 464–5 physical examination 463 postoperative course 468 preoperative markings 466, 467, 468 procedure 466–8 standard operative techniques 467–8 submental fold development 470 tapering of lower face 470 skin retraction 468 neuropeptides 294–5, 299 neutralizers, camouflage makeup 177 Neutrogena soap bar 78–9 neutrophils, inflammatory process 285 niacinamide (nicotinamide) 321 depigmentation 323 formulation 323 mechanisms of action 322–3 structure 322 topical effects 323


Index nicotinamide 493 nicotinate esters 321 formulation 323 nicotinic acid 321 formulation 323 mechanisms of action 322–3 niosomes moisturizers 504, 505 penetration enhancement 65–6 nitrocellulose, nail resins 208 nociception 42–3 non-steroidal anti-inflammatory drugs (NSAIDs) 287–8 nuclear factor of activated T cells (NFAT) 288 nuclear factor-κB (NFκB) 283 corticosteroid mechanism of action 286, 287 microdermabrasion effects 419 skin damage 302 nutrients 335–40 appearance improvement of skin 338–9 dermatological disorder effects 339–40 moisture/elasticity of skin 339 UV-induced damage protection 335, 336, 337–8 wound healing 339–40 oat products 278 occlusion of skin 64 occlusives facial moisturizers 125, 126 moisturizers 125, 131, 132 occupational hand eczema 60 occupational safety, hair dyes 234 octopirox 117, 118 odor control 153 oils, lipsticks 187 ointments 71–4 composition 73–4 definition 71–2 elevated temperature testing 74 moisturizers 504 natural 73–4 psoriasis 509 semi-solid 63 stability 74 omega-3 fatty acids, skin health 336 onycholysis 198, 199, 203, 204 onychomycosis 203 onychorrhexis 198 onychoschizia 198, 204 opacifiers, hair permanent waving 243 optical coherence tomography (OCT) 81 optical profilometry, wrinkles 51–2, 53 oral supplements 335–40 oxidative stress, epidermal barrier 8 4-oxoretinoids 309, 315


oxygen radical absorbance capacity (ORAC) assay 282 oxytalan fibers 32 Pacinian corpuscles 39, 41 pain fibers, dorsal horn entry 44 pain primary afferents 44 pain sensation 42–3 panthenol 323–4 pantothenic acid 323 para-toluenediamine (pTD) 234 paronychia 198, 204 patch test antigens, skin of color 30 patch testing, contact dermatitis 60 patches, penetration enhancement 67 pathogens, epidermal barrier 6 Paxel (Wavelight) resurfacing 396, 406 Pears soap 78 pedicure 202 peeling agents hydroxyacids 332–3 see also chemical peels penetration enhancement 64–8 devices 66–8 vectors 65–6 penetration enhancers 65 Penfield’s somatosensory homunculus 45 peptides acylation 296 analysis 296 antiaging applications 296–7, 298, 299 antioxidant 294 biological functions 293–5 cost 296 definition 292–3 lipophilic chain attachment 295–6 mechanism of action 293–4 skin penetration 295–6 stability 296 toxicity 296 use in cosmetics 295–6 percutaneous absorption 64 percutaneous delivery of cosmetic actives 62–9 perfume lipsticks 188 see also fragrances periocular fine lines, assessment 51–2 perioral lines, Botox treatment 348 periorbital injection, Botox 346–7 peripheral nervous system 38–9, 40, 41–3 pain 42–3 pleasure sensation 43 temperature sensing 41–2 touch 38–9, 40, 41 Perlane filler 353 permanent hair dyes 59 peroxisome proliferator activator receptor (PPAR) 9

personal care products antiperspirants 150–5 blade shaving 156–62 deodorants 150–5 personal cleansers 88–94 petrolatum moisturizer occlusive 126, 506 ointments 73, 74 white 506 phagocytes 6 phenolics 272, 283 phenylalanine 293 p-phenylenediamine (PPD) 59, 234 pheomelanin 27, 229 photoaging 13–20 antioxidants in prevention 19–20 definition 13 dermis 14 epidermis 32–3 ethnic skin 18, 32–3 histopathology 32–3 hydroxyacids 332 immunosuppression 20 inherent defense mechanisms 20 mechanism 127 medium depth chemical peel 390 microdermabrasion 422 molecular mechanisms 15–16, 17 neck liposuction 465 pathophysiology 409 physiology 13–15 prevention 18–20, 127 retinoids 19, 483–4 reversal 486 skin microvasculature 15 sun protection 18–19 UV stimulation 14–16, 17 vitamin E in reversal 484 see also antiaging entries photodynamic therapy 447–8 hair removal 436 photoepilation 432–7 photography 48–51 cosmetic product evaluation 48–50 cross-polarized 50, 51 guide 51 polarized 50, 51 UV fluorescence 50–1 UV reflectance 50, 51 visible light 50 photomodulation 444–8 photoprotection botanicals 276 facial moisturizers 127 nutrients 335, 337–8 photorejuvenation 444 LED photomodulation 445–6 photosensitivity reactions, retinoids 57 phototherapy, psoriasis 510–11

Index photothermolysis, laser-assisted hair removal 433 phytokinins 307 phytosomes 271 phytosteroids 272 pigmentation 27–35 dryness of skin 30 hair 229–30 inflammation effects 29 lips 186 melanosomes 28 retinoid effects 313 see also depigmentation; dyspigmentation; hyperpigmentation; hypopigmentation pigments facial foundation 170–1 lipsticks 188 pilosebaceous unit 157 pimecrolimus 288 eczema treatment 502 pineapple 276 Pixel 2940 (Alma) resurfacing 396, 405–6 Pixel Carbon Dioxide (Alma Lasers) 396, 401 plant alkaloids 272 plant extracts, skin barrier building 103 plasticizers, nail lacquers 208 platysma muscle 463, 464 banding 463, 465, 468, 470 Botox treatment 349 platysmaplasty 470 pleasure sensation 43 polyhydroxyacids 328, 329 acne treatment 491 antiaging 483 antioxidant 329 rosacea 501 water binding 329 polylactic acid fillers 373–6, 474 advantages 373–4 anaesthetic 373 complications 375–6 cross-hatching technique 374 disadvantages 373–4 fan technique 374 formulation 373 hands 375 injection techniques 374–5 tear troughs 375 polypeptides, cleansers 480 polyphenolics 283 skin health 336 pomades 261–2 pomegranate 278 pore cleansing, toners 98 postinflammatory hyperpigmentation (PIH) 29 postinflammatory hypopigmentation 29

potassium alum 153 potassium titanyl phosphate (KTP) 532nm laser 410, 411 preservatives allergic reactions 58 cleansers 104 cleansing bars 79 eye cosmetics 195 facial moisturizers 127 lipsticks 188 nail lacquer 209–10 vitamin E 325 prick tests 60 primary sensory afferents 39, 41 procollagen induction by trans-retinoic acid 19 inhibition by UV radiation 16 pro-opiomelanocortin 295 Propionibacterium acnes 489, 492 UV fluorescence photography 50 prostaglandin analogs, eyelash growth stimulation 194 prostaglandin E2 283 NSAID mechanism of action 287–8 skin cancer association 288 protease-activated receptor-2 (PAR-2) 28 proteases desquamation 8 stratum corneum 7 protection of skin antiaging regimen 481–3 see also antiaging products; sunscreens proteins chain 293 cosmetic use 299–300 definition 293 hair 238, 239 hydrolysis 296 proteolytic enzymes 7, 299–300 inflammation 302 pseudofolliculitis barbae 162 psoriasis 507 dermatology patients 508 education 508 flares 508 genetics 507–8 Goeckerman treatment 511 hydrocortisone 508, 509, 510 keratolytics 508, 509, 509–10, 511 lactic acid 508, 509, 509 moisturizers 508, 509, 509–10 nail dystrophy 203 ointments 509 over-the-counter medications 508–9, 511 phototherapy 510–11 physiology 507–8 regimens 507–12 salicylic acid 508, 509, 509

self-treatment 508 stress factors 508 sun exposure 510 tanning beds 510–11 tar 508, 509, 510, 511 topical medication 508–9 treatment compliance 508–9 urea 508, 509, 509 UV light therapy 510–11 pulsed dye laser 410–12 pustular eruptions 57 PUVA (psoralen and UVA) 510 pycnogenol 278 pyramid of age 362–3 pyrithione zinc (PTZ) 117, 118 chemical availability optimization 119 distribution on scalp 118–19 particle size 118, 119 types 118 pyruvic acid chemical peel 378 quality of life, camouflage makeup 182 quercetin 289 radiation dermatitis, LED photomodulation 446–7 Radiesse® filler 356 hands 474–9 indications 359 see also calcium hydroxylapatite radio allergo-sorbent tests (RASTs) 60 radiofrequency bipolar 441–2 and light 441–2 and unipolar 442 and vacuum 442 monopolar 439–41 complications 440 eyelid rejuvenation 441 unipolar 442 radiofrequency devices bipolar 439, 440 monopolar 439, 440 skin tightening 439–42 radiofrequency non-ablative resurfacing devices 410, 411, 415 Raking Light Optical Profilometry (RLOP) 48 wrinkle improvement detection 51–2, 53 razors blade edge 160 blade spacing 160 cutthroat 156 development 157 double-edge 159 electric 157 geometry control 159–60 lubricating strips 160–1 safety 156


Index shaving 159–61 skin guard 161 system 159–60 reactive oxygen species (ROS) inflammation 302 photochemical generation 15 UVA-induced 14, 15–16 reactivity of skin, skin of color 30 reducing agents hair permanent waving 241–2 hair straightening 250–1 reducing sugars, sunless tanning products 140 reflectance confocal microscopy (RCM) 30 remodeling of skin 303 resorcinol, sulfur combination 491 resorcinol peel 378, 380 Restylane filler 353, 354 resurfacing carbon dioxide laser 393–408 dermabrasion 426–31 following neck liposuction 471 microdermabrasion 418–24 non-ablative 409–16 see also chemical peels; fractionated carbon dioxide laser resurfacing; peeling agents retina protection, LED photomodulation 447 retinaldehyde 319 acne treatment 491 antiaging 484 antibacterial activity 312 cosmeceuticals 314–15 depigmentation 313, 314–15 structure 320 wrinkle treatment 314, 321 retinoic acid 483, 486 irritation induction 310 all-trans-retinoic acid, structure 320 retinoic acid peel 423 retinoic acid receptors (RAR) 319, 483 retinoic X receptors (RXR) 319, 483 retinoid dermatitis 484 retinoids 309–15 acne treatment 491 antiaging 483–4 antioxidants 312–13 cosmeceutical 309, 314–15 depigmentation 313 epidermal thickening 483–4 formulation 321 free radical scavengers 313 genomic effects 310, 312 hyaluronan 313–14, 315 intracrine proligand concept 309–10, 311, 312–13 irritation 310, 321


photoaging prevention 19, 483–4 photobiology 312 photosensitivity reactions 57 pigmentation effects 313 stability 321 structures 311 therapeutical 309 topical effects 320–1 wrinkle treatment 320–1 retinol 309 acne treatment 491 antiaging 484 cosmeceuticals 313 stratum corneum protection 313 structure 320 topical 319 wrinkle treatment 320–1 see also vitamin A retinyl esters 309, 313 cosmeceuticals 314 topical 319, 321 retinyl palmitate 312, 313 acne treatment 491 structure 320 wrinkle treatment 321 retinyl propionate acne treatment 491 wrinkle treatment 320, 321 rhinophyma, dermabrasion 427 rhytidectomy 470 rosacea alpha-hydroxyacids 500–1 antibiotic therapy 499–500 azelaic acid 501 Chrysanthellum indicum 500 cleansers 497, 498 cosmetics 498–9 erythemotelangiectatic 495, 497 flare 496, 499 flushing 500 glycolic acid 501 licochalcone A 500 light therapies 500 mild cleansing 84–5, 86 moisturizers 497, 498 natural actives 500–1 ocular 495, 497 over-the-counter products 496–9 papulopustular 495, 497, 499 phymatous 495, 497 physiology 495, 496 polyhydroxyacids 501 prescription agents 499–500 regimens 495–501 subtypes 495, 497 sun protection 496, 499 sunscreens 499 topical therapy 500 vitamin C 500

ruby laser, long-pulsed 434–5 Ruffini endings 39, 41 safety eye cosmetics 195 occupational for hair dyes 234 salicylic acid 118, 328–9 acne treatment 490–1 antiaging 483 psoriasis 508, 509, 509 salicylic acid peel 378, 379, 382 salicylism 379, 491 sarcosinates, facial cleansers 97 scalp 115, 116 sebaceous lipids 115 scalp care products 118–20 scars abrasion 427 chemical reconstruction 381–2 formation with dermabrasion 431 microdermabrasion 421 postsurgical 179 SciCon ratio 124 Sciton ProFractional resurfacing 396, 403, 404, 405 scrub particles 98 scrubs acne treatment 492 facial cleansers 98 Sculptra® filler 373 sebaceous lipids, scalp 115 sebaceous oil, cleaning of excess 100 seborrheic dermatitis see dandruff secondary metabolites, herb-based products 272, 273 selenium 339 antiaging 485, 486 UV damage protection 338 selenium sulfide 117, 118 L-selenomethionine 485, 486 self-perceived sensitive skin (SPSS) 22–5 barrier functions 25 clinical features 24–5 clinical signs 22 clinical subgroups 22–3 CNS involvement 25 diagnosis 23–4 epidemiology 24 neurogenic origin 25 physiologic mechanisms 25 provocative tests 23–4 sensitive skin 57 allergy 23 clinical signs 22 clinical subgroups 22–3 crisis phases 22 diathesis factors 23 environmental factors 23 hyperreactivity 23

Index immuno-allergologic pattern 23 provocative factors 22 severe 22 somatosensory system 38–45 topical factors 23 sensitization antiperspirants 154 deodorants 154 hair dyes 233, 234 sensory axons 39, 41 serine proteases 7 serums, moisturizers 504 shampoos 115–21, 224–5 allergic reactions 58–9 attributes 118–20 chemical availability optimization 119 colored hair 234 conditioning 121, 225 conditioning aids 116 cosmetic 116 alternating with therapeutic 120 cosmetically-optimized 116, 120 effective use 120–1 formulation 115–18, 224–5 irritation prevention 119–20, 121 products 115–18 rinse-off conditioner 121 surfactants 116–17 therapeutic 116–17 advantages/disadvantages 120 benefit 121 cost 120 effective use 120–1 shaving, blade 156–62 females 156–7, 162 hair properties 158–9 irritation 158 males 156–62 moisturizer use 162 process 161–2 razors 159–61 rinsing skin 162 skin cleansing 161 technology 156 shaving creams 161 shaving gels 161 signal transduction pathway activation 15 silicone allergic reactions 60 hair conditioners 225 hair styling aids 262–3 silicone derivatives, moisturizer occlusive 126 silicone oils, facial foundation 169 skin color 172 discoloration with collagen fillers 370 hairy 38, 39, 40, 41

hyperreactivity 23 pH 96, 108 topography 158–9 type and facial cleanser selection 99, 100 skin barrier building ingredients in cleansers 103 damage in cleansing 105 see also barrier function; epidermal barrier skin benefit agents 89–90 skin cancer immunomodulator association 288 immunosuppression 20 PGE-2 288 skin contouring techniques hand recontouring with calcium hydroxylapatite 473–9 liposuction 450–60 neck 463–71 skin disease nutrient effects 339–40 psychosocial aspects 182 skin modulation techniques laser-assisted hair removal 432–7 LED photomodulation 444–8 radiofrequency devices 439–42 skin of color 27–35 aging of skin 31–2 contact dermatitis 30 dermis 31 dryness 30 epidermis 29 facial cosmetics 167 hair differences 33–4 makeup shades 172 mast cells 30 melanin photoprotection 33 melanosomes 27–8 patch test antigens 30 photoaging 18, 32–3 reactivity 30 self-perceived sensitive skin 24 stratum corneum 29 transepidermal water loss 30 UV irradiation 18 protective factors 29 see also black skin; named racial groups; white skin skin partition coefficient, cosmetic actives 64 skin problems, facial cleansing 100–1 skin tightening expectations 440 monopolar radiofrequency 439–41 patient selection 440 radiofrequency devices 439–42 skincare, growth factors 304–5 slowly adapting (SA) receptors 39

SmartXide DOT resurfacing 396, 402 smile downturned 351 Botox treatment 348, 349 gummy 348 smoking, lip pigmentation 186 soap 57, 77 acne treatment 488–9 basic 78 drying potential on skin 80 pH 81 superfatted 81 transparent 78–9 soap bars 78–9 antibacterial 79 deodorant 79 market share 79 mildness 82–4 skin condition treatment 84–5, 86 stratum corneum interaction 80 superfatted 78 sodium cocyl isethionate 505 sodium lactate, moisturizer clinical efficacy 133–4 sodium laureth sulfate (SLES) 103 sodium lauryl sulfate (SLS) 103 damage protection 323 soft tissue augmentation 361–2 allergic reactions 60 calcium hydroxylapatite 356–60 see also fillers solid lipid nanoparticles (SNP) 66 solvents cosmetic actives 65 facial cleansers 97 irritants 57 nail lacquers 208 nail polish remover 213 somatosensory cortex 44, 45 somatosensory system central projections 43–4 pain 42–3 pathways 45 pleasure sensation 43 sensitive skin 38–45 temperature 41–2 touch 38–9, 40, 41 South Asian skin, UV irradiation 18 South-East Asian skin, UV irradiation 18 soy isoflavones 338–9 spinal cord 43–4 spinal nucleus of V 44 spinothalamic tract 44 stabilizers, vitamin E 325 Staphylococcus aureus 107 Staphylococcus epidermidis 107 status cosmeticus 22 stem cell, growth factors 307


Index stinging, burning and itching (SBI) score 24 stratum basale 4 stratum corneum 3, 4, 5 barrier function assessment 127 barrier to cosmetic actives 62 calcium gradient 9 components 4 detergent bar interactions 80–2 environmental toxin protection 7 facial skin 123–4 hydration function 7 maintenance 126 hydroxyacids effects 329 integrity assessment 9–10 intercellular spaces 10 lipids 82 moisturization function 7 pH 9 proteases 7, 8 skin of color 29 soap bar interactions 80 surfactant interaction 80 topical drug penetration protection 7 ultrastructural details 10 urea 133 see also desquamation stratum corneum chymotryptic enzyme (SCCE) 124 stratum granulosum 4 stratum spinosum 4 stress, psoriasis 508 striae, microdermabrasion 422 submandibular glands, ptotic 470 submandibular region 463 submental fat 465 submental fold, development after neck liposuction 470 submicron delivery systems (SDS) 65 substrate cleansers, facial 98–9 sulfacetamide sulfur 500 sulfites hair permanent waving 243 hair straighteners 251 sulfur 118, 491 sun exposure, psoriasis 510 sun protection clothing 482–3 photoaging prevention 18–19 rosacea 496, 499 sun protection factor (SPF) 18–19, 144, 481–2 evaluation 147 sunburn, NSAID use 288 sunscreens 481–3 regulatory status 144–5 sunless tanning products 140 SunGuard 483


sunless tanning products 139–42 active ingredients 139 buffers 140 color additives 141 coloration 141–2 creams 140–1 definition 139 delivery vehicles 140–1 evaluation 142 formulation 140 gels/gelees 141 labeling 141 lotions 140–1 moisturization 142 nitrogen-containing compounds 140 no-rub mists 142 pH 140 product attributes 141–2 regulatory aspects 141 sunscreens 140 trends 142 UV protection 142 sunlight, premature aging of skin 32 sunscreens 18, 144–8, 146–7 classification 144–5 development 145–7 efficacy evaluation 147–8 efficiency 146–7 facial moisturizers 127 formulation 147 migration over face 51 moisturizers 506 rosacea 499 UVA protection 144 vehicles 147 superficial musculo-aponeurotic system (SMAS) 32 superoxide dismutase (SOD) 8, 300 supersaturation 64 surfactants body washes 89 cleansers 480 cleansing bars 77–8 facial cleansing 96, 97 groups 96 hair permanent waving 242 hair styling products 262 lipid interactions 105 low-foam cleansers 102–3 mild 103 non-foam cleansers 102–3 pH 96 shampoos 116–17 skin barrier damage 105 skin interactions 80 stratum corneum interaction 80 substrate cleansers 98 waterless cleansers 104 see also soap; syndets/syndet bars

surgical scars, dermabrasion 427 sweat glands 150, 151, 152–3 hydrophilic substance delivery 62 sweating 155 control 155 physiology 151, 153 swelling Botox 349–50 collagen fillers 370 sympathetic nerves 43 synapses, afferent nerve 43–4 syndets/syndet bars 79 acne treatment 488–9 body washes 89 eczema 505–6 mildness 82–4 pH 81 skin condition treatment 84–5, 86 stratum corneum interactions 80–2 synthetic polymers, cleansers 480 T cells, corticosteroid prolonged use 287 T4 endonuclease V 299–300 tacrolimus 288 eczema treatment 502 tactile perception, psychophysical channels 39 tactile primary afferents 43 tanning 139 see also sunless tanning products tanning beds, psoriasis treatment 510–11 tannins 272 tape stripping 68 tar, psoriasis 508, 509, 510, 511 tattooing, medical 179 tattoos, black henna 234 tea tree oil 492 tear troughs, polylactic acid fillers 375 telangiectasia, camouflage makeup 182 telogen phase of hair growth 158, 433 temperature sensing 41–2 temperature-sensitive fibers 41–2 terminal hair 33, 433 terpenes 272 texturing agents, lipsticks 187–8 thalamocortical afferents 44, 45 Thermacool device 440 Thermafrax procedure 441 thermal primary afferents 44 thermosensitive mechanoreceptors 41–2 thickeners 73 thighs, liposuction indications 453–4 thioglycolate hair straighteners 250–1 thioglycolic acid salts 241–2, 243, 245 thiol hair straightening 250–1 with heat 255 thixotropic agents, nail lacquer 209 tighteners, botanicals 276

Index Time and Extent Application (TEA), UV filters 145 tissue inhibitors of metalloproteinase (TIMP), skin damage 302 titanium dioxide 146, 481 sunscreen 482 TNS Recovery Complex 305–6 tocopherol see vitamin E d-alpha-tocopherol, topical 484 tocopherol acetate 325 toluene, nail lacquer solvent 208 para-toluenediamine (pTD) 234 toners, facial cleansers 98 topical drugs, stratum corneum protective function 7 topical factors, sensitive skin 23 topical products antioxidant protection 52–3, 54 epidermal barrier 10 tosylamide/formaldehyde resin 211–12 touch 38–9, 40, 41 touch receptors 39 transepidermal delivery, cosmetic actives 62 transepidermal water loss (TEWL) 10, 124 extremozyme protection 300 microdermabrasion 418 self-perceived sensitive skin 25 skin of color 30 soap bar use 80 stratum corneum barrier function assessment 127 transforming growth factor beta (TGF-beta), collagen production 15 transforming growth factor beta (TGF-beta)/Smad pathway 16 trans-retinoic acid (tRA) 19 trans-urocanic acid (tUCA) 8, 9 trauma, nail dystrophy 203 traumatic scars, dermabrasion 427 tretinoin peel 378, 380 see also retinoic acid triangle of youth 362–3 trichloracetic acid 378, 379 depth-controlled peel 381 medium depth peel 384–5, 389, 390, 391 microdermabrasion comparison 423 techniques 386, 388 microdermabrasion combination 421 triclocarban 491 triclosan 491 trigeminal nerve 44 tropic acid 483 tumescent local anesthesia (TLA), liposuction 450, 451–2 neck 466–7 technique 456–7 turmeric 278–9

Tyndall effect 353 tyrosinase 28 tyrosinase-related protein (TRP) 28 ubiquinone see coenzyme Q10 (CoQ10) ultrasound waves, penetration enhancement 66–7 ultraviolet A (UVA) radiation 14, 144 critical wavelength method 148 protection antiaging 481 level determination 147–8 protective factor in black skin 29 reactive oxygen species induction 14, 15–16 sunscreens 144 ultraviolet B (UVB) radiation 14–15, 144 antiaging protection 481 hydroxyacids 330 protective factor in black skin 29 sunscreens 144 ultraviolet C (UVC) radiation 14 ultraviolet (UV) filters 145 efficiency 146–7 inorganic 146 organic 146 Time and Extent Application 145 ultraviolet (UV) fluorescence photography 50–1 ultraviolet light (UV) 144 angiogenesis of skin 19 erythema induction 447 ethnic skin 18 protective factors 29 exposure 13, 14 extracellular matrix degradation effects 19 fibroblast effects 17 keratinocyte effects 17 pigmentation induction 28 nutrient protection 335, 336, 337–8 photodamage 14–16, 17 protection 481–3 protective antioxidant product 53 psoriasis therapy 510–11 retinol absorption 314 retinyl ester absorption 314 skin damage protection 11 spectrum 14–15 vitamin E protection 325 see also photoaging ultraviolet light (UV) barrier 7–8 sunless tanning products 142 ultraviolet light protection factor (UPF) 18, 483 ultraviolet (UV) reflectance photography 50, 51 urea dry skin treatment 133

moisturizers 131 clinical efficacy 133–4 psoriasis 508, 509, 509 stratum corneum 133 urticaria, contact 56, 57–8 UV gel nails 216–17 vascular cell adhesion molecules (VCAM) 285 vascular compromise, collagen fillers 371 vascular endothelial growth factor (VEGF) 15, 19 vascular malformation, camouflage makeup 181 vellus hair 33 vermillion border, collagen filler injection 368 vibrotactile stimulation 39 VISIA CR® system 49–50 vitamin(s) oral 492–3 topical 319–26 vitamin A acne treatment 493 formulation 321 irritation 321 mechanisms of action 319–20 photodegradation 312 stability 321 structure 320 topical 319–21 UV damage protection 337 see also retinol vitamin B3 321–3 depigmentation 323 forms 321 formulation 323 mechanisms of action 322–3 structure 322 topical effects 323 wrinkle treatment 323 vitamin B5 323–4 vitamin C antiaging effects 325, 484, 486 antioxidant 281, 282, 283, 324 topical formulation 284 collagen synthesis co-factor function 484 forms 324 formulation 325, 484 mechanisms of action 324–5 photodamage mitigation 20 rosacea treatment 500 topical 324–5 UV damage protection 337 with vitamin E 484–5 vitamin D skin health 336 topical 325


Index vitamin E antiaging 484, 486 antioxidant 281, 282, 283, 325 topical formulation 284 formulation 325 isomers 484 photoaging reversal 484 skin changes 339 skin diseases 339–40 topical 325 UV damage protection 337 with vitamin C 484–5 wound healing 339–40 vitamin K, topical 325 vitamin P see flavonoids vitiligo, camouflage 179, 180 warm-sensitive fibers 41, 42 water vapor flux measurement 10 waterless cleansers 104 waterpacts 169–70 waxes hair styling aids 259, 260, 262, 263 lipsticks 187


waxy pastes, lipsticks 187 wetness control 152–3 Wetness Inhibiting Performance, antiperspirants 153 white petrolatum 506 white skin dermis 31 irritant contact dermatitis 30 photoaging 33 whitening of skin 295 wound healing dermabrasion postoperative 430 granulation 303 growth factors 303–4 inflammatory phase 303 medium depth chemical peel 388, 389 nutrient effects 339–40 physiology 302–5 re-epithelialization 303 wrinkles Botulinum neurotoxin injections 299 facial foundation effect measurement of antiwrinkle performance 173 formation with photoaging 33

hydroxyacids 332, 333 improvement detection 51–2, 53 optical profilometry 51–2, 53 peptide application 298 Raking Light Optical Profilometry 51–2, 53 retinaldehyde treatment 314 retinoid treatment 320–1 skin around lips 186 topical product evaluation 48 vitamin B3 treatment 323 zeaxanthin 337, 339 zinc deficiency 340 UV damage protection 338 zinc oxide 146 microdermabrasion 418 sunscreen 481, 482 zinc sulfonate 492 Zyderm II® filler 362, 364, 365–6, 367 hands 473 Zyplast® filler 362, 364, 365–6, 367, 369 hands 473

Cosmetic Dermatology: Products and Procedures - PDF Free Download (2024)


What is the difference between dermatology and cosmetic dermatology? ›

Dermatology is an area of medicine that focuses on medical conditions affecting the skin. Cosmetic dermatology – also known as aesthetic medicine – is a subspecialty within dermatology that helps patients improve their skin, hair, and nails for cosmetic (aesthetic) purposes, rather than for health reasons.

Is becoming a cosmetic dermatologist hard? ›

Dermatology can be considered hard because it demands extensive education, training, and a commitment to continuous learning.

What is the study of skin diseases called? ›

Dermatology is the medical specialty responsible for the study of more than 4,000 diseases of skin and cutaneous adnexae, accounting for 15% to 30% of outpatient medical care in health systems, incorporating a wide arsenal of diagnostic, therapeutic, and aesthetic resources.1, 2, 3.

What to research in dermatology? ›

Research Topics
  • Atopic Dermatitis. ...
  • Alopecia Areata. ...
  • Skin of Color Research. ...
  • Scarring Alopecia and Keloids. ...
  • Vitiligo. ...
  • Psoriasis. ...
  • Melanoma and Skin Cancer and Cutaneous T-Cell Lymphoma. ...
  • Clinical Trials.

What's higher than a dermatologist? ›

A dermatopathologist is a highly trained physician who specializes in diagnosing disorders of the skin under a microscope. They are a dermatologist or pathologist with extra board certification in evaluating skin, hair and nail diseases.

What is the difference between esthetician and cosmetic dermatologist? ›

While both are skin care professionals, they have distinct expertise and offer different kinds of services. An esthetician, or skin care specialist, provides services geared toward improving the external appearance of your skin. A dermatologist specializes in the health of your skin.

What type of dermatologist makes the most money? ›

Dermatologists who specialize in cosmetic procedures, such as Botox injections and laser treatments, may earn higher salaries than those who focus on medical dermatology. This is because cosmetic procedures are often not covered by insurance and patients are willing to pay out of pocket for them.

What's the easiest doctor to become? ›

The easiest doctor to become is relative. If we're talking “easy” in terms of how long does it take to become a doctor, then the answer is a family doctor or internist, which requires a shorter residency period than other specialties.

What major is best for cosmetic dermatology? ›

Potential dermatologists first need a bachelor's degree. Although this can be achieved in a range of subjects, most pre-medical students will study a field linked to medicine, for example biology, biomedical science, chemistry, physics or social sciences.

Which skin disease is not curable? ›

However, they're incurable, and symptoms can reappear at any time. Examples of chronic skin conditions include: rosacea, which is characterized by small, pus-filled bumps on the face. psoriasis, which causes scaly, itchy, and dry plaques.

What is the most serious skin condition? ›

Melanoma – Nearly 80% of skin cancer-related deaths are caused by melanoma. People who develop melanoma often notice sores that don't heal, areas of darker pigmentation spreading out from a mole, or quickly growing or changing spots.

What organ causes skin problems? ›

Some rashes and body skin problems can be triggered by other underlying illness such as infections (viral, bacterial, fungal etc), internal organ problems (liver, lung, gut, kidney, bone marrow, connective tissue), underlying nutritional problems (deficiencies), or may be triggered by hormone imbalances (problems in ...

What do dermatologists treat the most? ›

A dermatologist is a medical doctor who specializes in conditions that affect the skin, hair, and nails. Whether it's rashes, wrinkles, psoriasis, or melanoma, no one understands your skin, hair, and nails better than a board-certified dermatologist. The skin is an incredible organ.

Why is dermatology the hardest to get into? ›

Over the years, the number of dermatology spots has increased as the demand grew for more practicing dermatologists. However, the number of students who apply is still greater than the number of spots available, which means dermatology is extremely competitive.

What are the most important topics in dermatology? ›

The important topics in dermatology in MBBS include structure of hair, basics of dermatology, level of epidermis, drug eruptions, blistering disorders, skin lesions, acne vulgaris, bacterial infections, fungal infections, mycobacterial infections, erythema multiforme, lichen planus, STDs, papulosquamous disorders, skin ...

What is a cosmetic dermatologist of the skin? ›

Cosmetic dermatology (or aesthetic medicine) is a specialised field of dermatology that focuses on improving the skin on the face and neck for cosmetic purposes rather than for treating a medical condition.

Should I see a plastic surgeon or a dermatologist? ›

However, if you are looking to improve any aspect of your appearance, you may be better off working with a plastic surgeon. Unlike dermatologists, plastic surgeons have immense training and experience in both surgical and non-surgical techniques.

Is it better to get Botox from a dermatologist or plastic surgeon? ›

Contact a Dermatologist near you

Botox should only be done by qualified healthcare professionals, such as our dermatological providers at the California Dermatological Institute, to ensure safe and effective outcomes.

Which type of dermatologist makes the most? ›

Dermatologists who specialize in cosmetic procedures, such as Botox injections and laser treatments, may earn higher salaries than those who focus on medical dermatology. This is because cosmetic procedures are often not covered by insurance and patients are willing to pay out of pocket for them.

Top Articles
Latest Posts
Article information

Author: Aron Pacocha

Last Updated:

Views: 5855

Rating: 4.8 / 5 (68 voted)

Reviews: 91% of readers found this page helpful

Author information

Name: Aron Pacocha

Birthday: 1999-08-12

Address: 3808 Moen Corner, Gorczanyport, FL 67364-2074

Phone: +393457723392

Job: Retail Consultant

Hobby: Jewelry making, Cooking, Gaming, Reading, Juggling, Cabaret, Origami

Introduction: My name is Aron Pacocha, I am a happy, tasty, innocent, proud, talented, courageous, magnificent person who loves writing and wants to share my knowledge and understanding with you.